0	To	_	_	O
1	report	_	_	O
2	the	_	_	O
3	longer	_	_	O
4	term	_	_	O
5	results	_	_	O
6	of	_	_	O
7	a	_	_	O
8	randomized	_	_	O
9	,	_	_	O
10	clinical	_	_	O
11	trial	_	_	O
12	comparing	_	_	O
13	the	_	_	O
14	350-mm2	_	_	O
15	and	_	_	O
16	the	_	_	O
17	500-mm2	_	_	O
18	Baerveldt	_	_	O
19	glaucoma	_	_	O
20	implants	_	_	O
21	.	_	_	O

22	Extended	_	_	O
23	follow-up	_	_	O
24	on	_	_	O
25	a	_	_	O
26	randomized	_	_	O
27	,	_	_	O
28	controlled	_	_	O
29	trial	_	_	O
30	.	_	_	O

31	Between	_	_	O
32	March	_	_	O
33	1991	_	_	O
34	and	_	_	O
35	April	_	_	O
36	1993	_	_	O
37	,	_	_	O
38	107	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	uncontrolled	_	_	O
42	intraocular	_	_	O
43	pressure	_	_	O
44	(	_	_	O
45	IOP	_	_	O
46	)	_	_	O
47	due	_	_	O
48	to	_	_	O
49	non-neovascular	_	_	O
50	glaucoma	_	_	O
51	associated	_	_	O
52	with	_	_	O
53	aphakia	_	_	O
54	,	_	_	O
55	pseudophakia	_	_	O
56	,	_	_	O
57	or	_	_	O
58	failed	_	_	O
59	filters	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	for	_	_	O
64	surgical	_	_	O
65	placement	_	_	O
66	of	_	_	O
67	either	_	_	O
68	the	_	_	O
69	350-mm2	_	_	O
70	or	_	_	O
71	the	_	_	O
72	500-mm2	_	_	O
73	Baerveldt	_	_	O
74	implant	_	_	O
75	at	_	_	O
76	the	_	_	O
77	Doheny	_	_	O
78	Eye	_	_	O
79	Institute	_	_	O
80	.	_	_	O

81	A	_	_	O
82	random-numbers	_	_	O
83	table	_	_	O
84	was	_	_	O
85	used	_	_	O
86	to	_	_	O
87	assign	_	_	O
88	each	_	_	O
89	patient	_	_	O
90	to	_	_	O
91	one	_	_	O
92	of	_	_	O
93	the	_	_	O
94	two	_	_	O
95	groups	_	_	O
96	.	_	_	O

97	Preoperative	_	_	O
98	IOPs	_	_	O
99	and	_	_	O
100	visual	_	_	O
101	acuities	_	_	O
102	were	_	_	O
103	recorded	_	_	O
104	.	_	_	O

105	Clinical	_	_	O
106	records	_	_	O
107	were	_	_	O
108	reviewed	_	_	O
109	to	_	_	O
110	ascertain	_	_	O
111	postoperative	_	_	O
112	IOPs	_	_	O
113	,	_	_	O
114	visual	_	_	O
115	acuities	_	_	O
116	,	_	_	O
117	number	_	_	O
118	of	_	_	O
119	medications	_	_	O
120	used	_	_	O
121	,	_	_	O
122	and	_	_	O
123	implant-related	_	_	O
124	complications	_	_	O
125	that	_	_	O
126	occurred	_	_	O
127	throughout	_	_	O
128	the	_	_	O
129	follow-up	_	_	O
130	period	_	_	O
131	.	_	_	O

132	Success	_	_	O
133	was	_	_	O
134	defined	_	_	O
135	as	_	_	O
136	IOP	_	_	O
137	of	_	_	O
138	6	_	_	O
139	mmHg	_	_	O
140	or	_	_	O
141	greater	_	_	O
142	and	_	_	O
143	of	_	_	O
144	21	_	_	O
145	mmHg	_	_	O
146	or	_	_	O
147	less	_	_	O
148	in	_	_	O
149	two	_	_	O
150	or	_	_	O
151	more	_	_	O
152	consecutive	_	_	O
153	follow-up	_	_	O
154	visits	_	_	O
155	without	_	_	O
156	further	_	_	O
157	glaucoma	_	_	O
158	surgery	_	_	O
159	or	_	_	O
160	loss	_	_	O
161	of	_	_	O
162	light	_	_	O
163	perception	_	_	O
164	attributable	_	_	O
165	to	_	_	O
166	glaucoma	_	_	O
167	.	_	_	O

168	The	_	_	B-Premise
169	overall	_	_	I-Premise
170	success	_	_	I-Premise
171	rates	_	_	I-Premise
172	were	_	_	I-Premise
173	87	_	_	I-Premise
174	%	_	_	I-Premise
175	for	_	_	I-Premise
176	the	_	_	I-Premise
177	350-mm2	_	_	I-Premise
178	group	_	_	I-Premise
179	and	_	_	I-Premise
180	70	_	_	I-Premise
181	%	_	_	I-Premise
182	for	_	_	I-Premise
183	the	_	_	I-Premise
184	500-mm2	_	_	I-Premise
185	group	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	0.05	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Average	_	_	O
193	follow-up	_	_	O
194	was	_	_	O
195	37	_	_	O
196	months	_	_	O
197	(	_	_	O
198	range	_	_	O
199	,	_	_	O
200	1-76	_	_	O
201	months	_	_	O
202	)	_	_	O
203	for	_	_	O
204	the	_	_	O
205	350-mm2	_	_	O
206	group	_	_	O
207	and	_	_	O
208	34	_	_	O
209	months	_	_	O
210	(	_	_	O
211	range	_	_	O
212	,	_	_	O
213	5-77	_	_	O
214	months	_	_	O
215	)	_	_	O
216	for	_	_	O
217	the	_	_	O
218	500-mm2	_	_	O
219	group	_	_	O
220	.	_	_	O

221	The	_	_	B-Premise
222	life-table	_	_	I-Premise
223	success	_	_	I-Premise
224	rates	_	_	I-Premise
225	declined	_	_	I-Premise
226	over	_	_	I-Premise
227	time	_	_	I-Premise
228	for	_	_	I-Premise
229	both	_	_	I-Premise
230	implant	_	_	I-Premise
231	groups	_	_	I-Premise
232	,	_	_	I-Premise
233	from	_	_	I-Premise
234	a	_	_	I-Premise
235	high	_	_	I-Premise
236	of	_	_	I-Premise
237	98	_	_	I-Premise
238	%	_	_	I-Premise
239	for	_	_	I-Premise
240	the	_	_	I-Premise
241	350-mm2	_	_	I-Premise
242	group	_	_	I-Premise
243	and	_	_	I-Premise
244	92	_	_	I-Premise
245	%	_	_	I-Premise
246	for	_	_	I-Premise
247	the	_	_	I-Premise
248	500-mm2	_	_	I-Premise
249	group	_	_	I-Premise
250	at	_	_	I-Premise
251	1	_	_	I-Premise
252	year	_	_	I-Premise
253	to	_	_	I-Premise
254	a	_	_	I-Premise
255	cumulative	_	_	I-Premise
256	success	_	_	I-Premise
257	rate	_	_	I-Premise
258	of	_	_	I-Premise
259	79	_	_	I-Premise
260	%	_	_	I-Premise
261	for	_	_	I-Premise
262	the	_	_	I-Premise
263	350-mm2	_	_	I-Premise
264	group	_	_	I-Premise
265	and	_	_	I-Premise
266	66	_	_	I-Premise
267	%	_	_	I-Premise
268	for	_	_	I-Premise
269	the	_	_	I-Premise
270	500-mm2	_	_	I-Premise
271	group	_	_	I-Premise
272	at	_	_	I-Premise
273	5	_	_	I-Premise
274	years	_	_	I-Premise
275	.	_	_	I-Premise

276	Visual	_	_	B-Premise
277	acuities	_	_	I-Premise
278	were	_	_	I-Premise
279	better	_	_	I-Premise
280	or	_	_	I-Premise
281	remained	_	_	I-Premise
282	the	_	_	I-Premise
283	same	_	_	I-Premise
284	in	_	_	I-Premise
285	50	_	_	I-Premise
286	%	_	_	I-Premise
287	of	_	_	I-Premise
288	the	_	_	I-Premise
289	patients	_	_	I-Premise
290	in	_	_	I-Premise
291	the	_	_	I-Premise
292	350-mm2	_	_	I-Premise
293	group	_	_	I-Premise
294	and	_	_	I-Premise
295	46	_	_	I-Premise
296	%	_	_	I-Premise
297	of	_	_	I-Premise
298	those	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	500-mm2	_	_	I-Premise
302	group	_	_	I-Premise
303	.	_	_	I-Premise

304	Complications	_	_	O
305	during	_	_	O
306	the	_	_	O
307	5-year	_	_	O
308	follow-up	_	_	O
309	were	_	_	O
310	also	_	_	O
311	statistically	_	_	O
312	similar	_	_	O
313	.	_	_	O

314	The	_	_	B-Claim
315	longer	_	_	I-Claim
316	term	_	_	I-Claim
317	results	_	_	I-Claim
318	show	_	_	I-Claim
319	that	_	_	I-Claim
320	the	_	_	I-Claim
321	350-mm2	_	_	I-Claim
322	Baerveldt	_	_	I-Claim
323	implant	_	_	I-Claim
324	is	_	_	I-Claim
325	more	_	_	I-Claim
326	successful	_	_	I-Claim
327	than	_	_	I-Claim
328	the	_	_	I-Claim
329	500-mm2	_	_	I-Claim
330	implant	_	_	I-Claim
331	for	_	_	I-Claim
332	overall	_	_	I-Claim
333	IOP	_	_	I-Claim
334	control	_	_	I-Claim
335	.	_	_	I-Claim

336	Interval	_	_	B-Claim
337	comparisons	_	_	I-Claim
338	indicate	_	_	I-Claim
339	a	_	_	I-Claim
340	higher	_	_	I-Claim
341	rate	_	_	I-Claim
342	of	_	_	I-Claim
343	success	_	_	I-Claim
344	for	_	_	I-Claim
345	the	_	_	I-Claim
346	350-mm2	_	_	I-Claim
347	implant	_	_	I-Claim
348	in	_	_	I-Claim
349	the	_	_	I-Claim
350	first	_	_	I-Claim
351	,	_	_	I-Claim
352	second	_	_	I-Claim
353	,	_	_	I-Claim
354	third	_	_	I-Claim
355	,	_	_	I-Claim
356	fourth	_	_	I-Claim
357	,	_	_	I-Claim
358	and	_	_	I-Claim
359	fifth	_	_	I-Claim
360	years	_	_	I-Claim
361	of	_	_	I-Claim
362	implantation	_	_	I-Claim
363	.	_	_	I-Claim

364	Visual	_	_	O
365	acuities	_	_	O
366	,	_	_	O
367	implant-related	_	_	O
368	complications	_	_	O
369	,	_	_	O
370	and	_	_	O
371	average	_	_	O
372	IOPs	_	_	O
373	were	_	_	O
374	statistically	_	_	O
375	indistinguishable	_	_	O
376	between	_	_	O
377	the	_	_	O
378	two	_	_	O
379	groups	_	_	O
380	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	success	_	_	O
5	rates	_	_	O
6	and	_	_	O
7	quality	_	_	O
8	of	_	_	O
9	life	_	_	O
10	impact	_	_	O
11	of	_	_	O
12	brimonidine	_	_	O
13	0.2	_	_	O
14	%	_	_	O
15	with	_	_	O
16	timolol	_	_	O
17	0.5	_	_	O
18	%	_	_	O
19	in	_	_	O
20	newly	_	_	O
21	diagnosed	_	_	O
22	patients	_	_	O
23	naive	_	_	O
24	to	_	_	O
25	glaucoma	_	_	O
26	therapy	_	_	O
27	.	_	_	O

28	A	_	_	O
29	prospective	_	_	O
30	,	_	_	O
31	multicenter	_	_	O
32	,	_	_	O
33	randomized	_	_	O
34	,	_	_	O
35	double-masked	_	_	O
36	,	_	_	O
37	clinical	_	_	O
38	effectiveness	_	_	O
39	trial	_	_	O
40	in	_	_	O
41	which	_	_	O
42	the	_	_	O
43	clinical	_	_	O
44	outcomes	_	_	O
45	of	_	_	O
46	twice	_	_	O
47	daily	_	_	O
48	brimonidine	_	_	O
49	tartrate	_	_	O
50	0.2	_	_	O
51	%	_	_	O
52	were	_	_	O
53	compared	_	_	O
54	with	_	_	O
55	those	_	_	O
56	of	_	_	O
57	timolol	_	_	O
58	maleate	_	_	O
59	0.5	_	_	O
60	%	_	_	O
61	in	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	glaucoma	_	_	O
65	and	_	_	O
66	ocular	_	_	O
67	hypertension	_	_	O
68	was	_	_	O
69	conducted	_	_	O
70	.	_	_	O

71	Two	_	_	O
72	hundred	_	_	O
73	nineteen	_	_	O
74	patients	_	_	O
75	were	_	_	O
76	enrolled	_	_	O
77	--	_	_	O
78	111	_	_	O
79	in	_	_	O
80	the	_	_	O
81	brimonidine	_	_	O
82	group	_	_	O
83	and	_	_	O
84	108	_	_	O
85	in	_	_	O
86	the	_	_	O
87	timolol	_	_	O
88	group	_	_	O
89	.	_	_	O

90	Patients	_	_	O
91	instilled	_	_	O
92	their	_	_	O
93	study	_	_	O
94	medications	_	_	O
95	twice	_	_	O
96	daily	_	_	O
97	for	_	_	O
98	4	_	_	O
99	months	_	_	O
100	.	_	_	O

101	Factors	_	_	O
102	for	_	_	O
103	determining	_	_	O
104	clinical	_	_	O
105	success	_	_	O
106	were	_	_	O
107	reduction	_	_	O
108	of	_	_	O
109	intraocular	_	_	O
110	pressure	_	_	O
111	(	_	_	O
112	IOP	_	_	O
113	)	_	_	O
114	,	_	_	O
115	safety	_	_	O
116	,	_	_	O
117	and	_	_	O
118	adverse	_	_	O
119	events	_	_	O
120	.	_	_	O

121	Quality	_	_	O
122	of	_	_	O
123	life	_	_	O
124	effects	_	_	O
125	were	_	_	O
126	assessed	_	_	O
127	with	_	_	O
128	the	_	_	O
129	SF-36	_	_	O
130	Health	_	_	O
131	Survey	_	_	O
132	and	_	_	O
133	Glaucoma	_	_	O
134	Disability	_	_	O
135	Index	_	_	O
136	questionnaires	_	_	O
137	.	_	_	O

138	Clinical	_	_	B-Premise
139	success	_	_	I-Premise
140	was	_	_	I-Premise
141	71	_	_	I-Premise
142	%	_	_	I-Premise
143	(	_	_	I-Premise
144	75/106	_	_	I-Premise
145	)	_	_	I-Premise
146	with	_	_	I-Premise
147	brimonidine	_	_	I-Premise
148	and	_	_	I-Premise
149	70	_	_	I-Premise
150	%	_	_	I-Premise
151	(	_	_	I-Premise
152	73/105	_	_	I-Premise
153	)	_	_	I-Premise
154	with	_	_	I-Premise
155	timolol	_	_	I-Premise
156	as	_	_	I-Premise
157	initial	_	_	I-Premise
158	treatment	_	_	I-Premise
159	.	_	_	I-Premise

160	The	_	_	B-Premise
161	overall	_	_	I-Premise
162	mean	_	_	I-Premise
163	decrease	_	_	I-Premise
164	in	_	_	I-Premise
165	IOP	_	_	I-Premise
166	was	_	_	I-Premise
167	6.5	_	_	I-Premise
168	mm	_	_	I-Premise
169	Hg	_	_	I-Premise
170	with	_	_	I-Premise
171	brimonidine	_	_	I-Premise
172	and	_	_	I-Premise
173	6.2	_	_	I-Premise
174	mm	_	_	I-Premise
175	Hg	_	_	I-Premise
176	with	_	_	I-Premise
177	timolol	_	_	I-Premise
178	.	_	_	I-Premise

179	Few	_	_	B-Premise
180	patients	_	_	I-Premise
181	reported	_	_	I-Premise
182	a	_	_	I-Premise
183	specific	_	_	I-Premise
184	adverse	_	_	I-Premise
185	event	_	_	I-Premise
186	and	_	_	O
187	,	_	_	O
188	with	_	_	B-Premise
189	the	_	_	I-Premise
190	exception	_	_	I-Premise
191	of	_	_	I-Premise
192	a	_	_	I-Premise
193	slightly	_	_	I-Premise
194	higher	_	_	I-Premise
195	rate	_	_	I-Premise
196	of	_	_	I-Premise
197	ocular	_	_	I-Premise
198	burning	_	_	I-Premise
199	and	_	_	I-Premise
200	stinging	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	brimonidine	_	_	I-Premise
204	group	_	_	I-Premise
205	,	_	_	I-Premise
206	there	_	_	I-Premise
207	were	_	_	I-Premise
208	no	_	_	I-Premise
209	significant	_	_	I-Premise
210	between-group	_	_	I-Premise
211	differences	_	_	I-Premise
212	.	_	_	I-Premise

213	No	_	_	B-Premise
214	significant	_	_	I-Premise
215	chronotropic	_	_	I-Premise
216	effects	_	_	I-Premise
217	on	_	_	I-Premise
218	the	_	_	I-Premise
219	heart	_	_	I-Premise
220	were	_	_	I-Premise
221	seen	_	_	I-Premise
222	with	_	_	I-Premise
223	brimonidine	_	_	I-Premise
224	,	_	_	O
225	while	_	_	O
226	small	_	_	B-Premise
227	but	_	_	I-Premise
228	significant	_	_	I-Premise
229	mean	_	_	I-Premise
230	decreases	_	_	I-Premise
231	in	_	_	I-Premise
232	heart	_	_	I-Premise
233	rate	_	_	I-Premise
234	were	_	_	I-Premise
235	seen	_	_	I-Premise
236	at	_	_	I-Premise
237	months	_	_	I-Premise
238	1	_	_	I-Premise
239	and	_	_	I-Premise
240	4	_	_	I-Premise
241	with	_	_	I-Premise
242	timolol	_	_	I-Premise
243	.	_	_	I-Premise

244	Mean	_	_	B-Premise
245	systolic	_	_	I-Premise
246	and	_	_	I-Premise
247	diastolic	_	_	I-Premise
248	blood	_	_	I-Premise
249	pressure	_	_	I-Premise
250	remained	_	_	I-Premise
251	relatively	_	_	I-Premise
252	stable	_	_	I-Premise
253	in	_	_	I-Premise
254	both	_	_	I-Premise
255	groups	_	_	I-Premise
256	.	_	_	I-Premise

257	Quality	_	_	B-Premise
258	of	_	_	I-Premise
259	life	_	_	I-Premise
260	remained	_	_	I-Premise
261	stable	_	_	I-Premise
262	,	_	_	I-Premise
263	with	_	_	I-Premise
264	no	_	_	I-Premise
265	significant	_	_	I-Premise
266	between-group	_	_	I-Premise
267	differences	_	_	I-Premise
268	.	_	_	I-Premise

269	As	_	_	B-Claim
270	a	_	_	I-Claim
271	first-line	_	_	I-Claim
272	agent	_	_	I-Claim
273	for	_	_	I-Claim
274	the	_	_	I-Claim
275	treatment	_	_	I-Claim
276	of	_	_	I-Claim
277	glaucoma	_	_	I-Claim
278	and	_	_	I-Claim
279	ocular	_	_	I-Claim
280	hypertension	_	_	I-Claim
281	,	_	_	I-Claim
282	brimonidine	_	_	I-Claim
283	has	_	_	I-Claim
284	clinical	_	_	I-Claim
285	effectiveness	_	_	I-Claim
286	equivalent	_	_	I-Claim
287	to	_	_	I-Claim
288	timolol	_	_	I-Claim
289	,	_	_	I-Claim
290	but	_	_	I-Claim
291	with	_	_	I-Claim
292	less	_	_	I-Claim
293	chronotropic	_	_	I-Claim
294	effect	_	_	I-Claim
295	on	_	_	I-Claim
296	the	_	_	I-Claim
297	heart	_	_	I-Claim
298	.	_	_	I-Claim

299	Brimonidine	_	_	B-Claim
300	is	_	_	I-Claim
301	a	_	_	I-Claim
302	viable	_	_	I-Claim
303	alternative	_	_	I-Claim
304	to	_	_	I-Claim
305	timolol	_	_	I-Claim
306	for	_	_	I-Claim
307	first-line	_	_	I-Claim
308	therapy	_	_	I-Claim
309	in	_	_	I-Claim
310	glaucoma	_	_	I-Claim
311	and	_	_	I-Claim
312	ocular	_	_	I-Claim
313	hypertension	_	_	I-Claim
314	.	_	_	I-Claim


0	In	_	_	B-Claim
1	phase	_	_	I-Claim
2	II	_	_	I-Claim
3	trials	_	_	I-Claim
4	,	_	_	I-Claim
5	paclitaxel	_	_	I-Claim
6	has	_	_	I-Claim
7	been	_	_	I-Claim
8	shown	_	_	I-Claim
9	to	_	_	I-Claim
10	have	_	_	I-Claim
11	antitumor	_	_	I-Claim
12	activity	_	_	I-Claim
13	in	_	_	I-Claim
14	patients	_	_	I-Claim
15	with	_	_	I-Claim
16	advanced	_	_	I-Claim
17	non-small-cell	_	_	I-Claim
18	lung	_	_	I-Claim
19	cancer	_	_	I-Claim
20	(	_	_	I-Claim
21	NSCLC	_	_	I-Claim
22	)	_	_	I-Claim
23	.	_	_	I-Claim

24	However	_	_	O
25	,	_	_	O
26	the	_	_	O
27	survival	_	_	O
28	and	_	_	O
29	quality-of-life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	benefits	_	_	O
34	of	_	_	O
35	paclitaxel	_	_	O
36	used	_	_	O
37	as	_	_	O
38	a	_	_	O
39	single	_	_	O
40	agent	_	_	O
41	compared	_	_	O
42	with	_	_	O
43	supportive	_	_	O
44	care	_	_	O
45	alone	_	_	O
46	have	_	_	O
47	not	_	_	O
48	been	_	_	O
49	assessed	_	_	O
50	in	_	_	O
51	a	_	_	O
52	randomized	_	_	O
53	clinical	_	_	O
54	trial	_	_	O
55	.	_	_	O

56	A	_	_	O
57	total	_	_	O
58	of	_	_	O
59	157	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	stage	_	_	O
63	IIIB	_	_	O
64	or	_	_	O
65	IV	_	_	O
66	NSCLC	_	_	O
67	who	_	_	O
68	had	_	_	O
69	received	_	_	O
70	no	_	_	O
71	prior	_	_	O
72	chemotherapy	_	_	O
73	were	_	_	O
74	randomly	_	_	O
75	assigned	_	_	O
76	to	_	_	O
77	receive	_	_	O
78	either	_	_	O
79	best	_	_	O
80	supportive	_	_	O
81	care	_	_	O
82	alone	_	_	O
83	(	_	_	O
84	78	_	_	O
85	patients	_	_	O
86	)	_	_	O
87	or	_	_	O
88	paclitaxel	_	_	O
89	plus	_	_	O
90	supportive	_	_	O
91	care	_	_	O
92	(	_	_	O
93	79	_	_	O
94	patients	_	_	O
95	)	_	_	O
96	.	_	_	O

97	Paclitaxel	_	_	O
98	was	_	_	O
99	administered	_	_	O
100	as	_	_	O
101	a	_	_	O
102	3-hour	_	_	O
103	intravenous	_	_	O
104	infusion	_	_	O
105	every	_	_	O
106	3	_	_	O
107	weeks	_	_	O
108	.	_	_	O

109	Supportive	_	_	O
110	care	_	_	O
111	included	_	_	O
112	palliative	_	_	O
113	radiotherapy	_	_	O
114	and	_	_	O
115	supportive	_	_	O
116	therapy	_	_	O
117	with	_	_	O
118	corticosteroids	_	_	O
119	,	_	_	O
120	antibiotics	_	_	O
121	,	_	_	O
122	analgesics	_	_	O
123	,	_	_	O
124	antiemetics	_	_	O
125	,	_	_	O
126	transfusions	_	_	O
127	,	_	_	O
128	and	_	_	O
129	other	_	_	O
130	symptomatic	_	_	O
131	therapy	_	_	O
132	as	_	_	O
133	required	_	_	O
134	.	_	_	O

135	The	_	_	O
136	primary	_	_	O
137	end	_	_	O
138	point	_	_	O
139	of	_	_	O
140	the	_	_	O
141	study	_	_	O
142	was	_	_	O
143	survival	_	_	O
144	.	_	_	O

145	Time	_	_	O
146	to	_	_	O
147	disease	_	_	O
148	progression	_	_	O
149	,	_	_	O
150	response	_	_	O
151	rate	_	_	O
152	,	_	_	O
153	adverse	_	_	O
154	events	_	_	O
155	,	_	_	O
156	and	_	_	O
157	QOL	_	_	O
158	were	_	_	O
159	secondary	_	_	O
160	end	_	_	O
161	points	_	_	O
162	.	_	_	O

163	Pretreatment	_	_	O
164	characteristics	_	_	O
165	were	_	_	O
166	evenly	_	_	O
167	distributed	_	_	O
168	between	_	_	O
169	the	_	_	O
170	two	_	_	O
171	arms	_	_	O
172	.	_	_	O

173	Survival	_	_	B-Premise
174	was	_	_	I-Premise
175	statistically	_	_	I-Premise
176	significantly	_	_	I-Premise
177	better	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	paclitaxel	_	_	I-Premise
181	plus	_	_	I-Premise
182	supportive	_	_	I-Premise
183	care	_	_	I-Premise
184	arm	_	_	I-Premise
185	than	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	supportive	_	_	I-Premise
189	care	_	_	I-Premise
190	alone	_	_	I-Premise
191	arm	_	_	I-Premise
192	(	_	_	I-Premise
193	two-sided	_	_	I-Premise
194	P	_	_	I-Premise
195	=.037	_	_	I-Premise
196	)	_	_	I-Premise
197	(	_	_	I-Premise
198	median	_	_	I-Premise
199	survival	_	_	I-Premise
200	=	_	_	I-Premise
201	6.8	_	_	I-Premise
202	months	_	_	I-Premise
203	versus	_	_	I-Premise
204	4.8	_	_	I-Premise
205	months	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Cox	_	_	B-Premise
209	multivariate	_	_	I-Premise
210	analysis	_	_	I-Premise
211	showed	_	_	I-Premise
212	paclitaxel	_	_	I-Premise
213	plus	_	_	I-Premise
214	supportive	_	_	I-Premise
215	care	_	_	I-Premise
216	to	_	_	I-Premise
217	be	_	_	I-Premise
218	statistically	_	_	I-Premise
219	significantly	_	_	I-Premise
220	associated	_	_	I-Premise
221	with	_	_	I-Premise
222	improved	_	_	I-Premise
223	survival	_	_	I-Premise
224	(	_	_	I-Premise
225	two-sided	_	_	I-Premise
226	P	_	_	I-Premise
227	=.048	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	QOL	_	_	B-Premise
231	was	_	_	I-Premise
232	similar	_	_	I-Premise
233	for	_	_	I-Premise
234	both	_	_	I-Premise
235	treatment	_	_	I-Premise
236	arms	_	_	I-Premise
237	,	_	_	I-Premise
238	except	_	_	B-Premise
239	for	_	_	I-Premise
240	the	_	_	I-Premise
241	functional	_	_	I-Premise
242	activity	_	_	I-Premise
243	score	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	Rotterdam	_	_	I-Premise
247	Symptom	_	_	I-Premise
248	Checklist	_	_	I-Premise
249	,	_	_	I-Premise
250	where	_	_	I-Premise
251	QOL	_	_	I-Premise
252	data	_	_	I-Premise
253	statistically	_	_	I-Premise
254	significantly	_	_	I-Premise
255	favored	_	_	I-Premise
256	the	_	_	I-Premise
257	paclitaxel	_	_	I-Premise
258	plus	_	_	I-Premise
259	supportive	_	_	I-Premise
260	care	_	_	I-Premise
261	arm	_	_	I-Premise
262	(	_	_	I-Premise
263	two-sided	_	_	I-Premise
264	P	_	_	I-Premise
265	=.043	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	The	_	_	B-Claim
269	addition	_	_	I-Claim
270	of	_	_	I-Claim
271	paclitaxel	_	_	I-Claim
272	to	_	_	I-Claim
273	best	_	_	I-Claim
274	supportive	_	_	I-Claim
275	care	_	_	I-Claim
276	significantly	_	_	I-Claim
277	improved	_	_	I-Claim
278	survival	_	_	I-Claim
279	and	_	_	I-Claim
280	time	_	_	I-Claim
281	to	_	_	I-Claim
282	disease	_	_	I-Claim
283	progression	_	_	I-Claim
284	compared	_	_	I-Claim
285	with	_	_	I-Claim
286	best	_	_	I-Claim
287	supportive	_	_	I-Claim
288	care	_	_	I-Claim
289	in	_	_	I-Claim
290	patients	_	_	I-Claim
291	with	_	_	I-Claim
292	advanced	_	_	I-Claim
293	NSCLC	_	_	I-Claim
294	and	_	_	I-Claim
295	may	_	_	I-Claim
296	improve	_	_	I-Claim
297	some	_	_	I-Claim
298	aspects	_	_	I-Claim
299	of	_	_	I-Claim
300	QOL	_	_	I-Claim
301	.	_	_	I-Claim


0	The	_	_	B-Claim
1	combination	_	_	I-Claim
2	of	_	_	I-Claim
3	etoposide	_	_	I-Claim
4	plus	_	_	I-Claim
5	cisplatin	_	_	I-Claim
6	(	_	_	I-Claim
7	EP	_	_	I-Claim
8	)	_	_	I-Claim
9	is	_	_	I-Claim
10	considered	_	_	I-Claim
11	to	_	_	I-Claim
12	be	_	_	I-Claim
13	standard	_	_	I-Claim
14	therapy	_	_	I-Claim
15	for	_	_	I-Claim
16	small-cell	_	_	I-Claim
17	lung	_	_	I-Claim
18	cancer	_	_	I-Claim
19	(	_	_	I-Claim
20	SCLC	_	_	I-Claim
21	)	_	_	I-Claim
22	.	_	_	I-Claim

23	To	_	_	O
24	determine	_	_	O
25	whether	_	_	O
26	drug	_	_	O
27	intensification	_	_	O
28	improves	_	_	O
29	survival	_	_	O
30	of	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	extensive	_	_	O
34	SCLC	_	_	O
35	,	_	_	O
36	we	_	_	O
37	compared	_	_	O
38	this	_	_	O
39	treatment	_	_	O
40	with	_	_	O
41	a	_	_	O
42	four-drug	_	_	O
43	regimen	_	_	O
44	containing	_	_	O
45	EP	_	_	O
46	plus	_	_	O
47	cyclophosphamide	_	_	O
48	and	_	_	O
49	4'-epidoxorubicin	_	_	O
50	(	_	_	O
51	PCDE	_	_	O
52	)	_	_	O
53	.	_	_	O

54	In	_	_	O
55	a	_	_	O
56	phase	_	_	O
57	III	_	_	O
58	clinical	_	_	O
59	trial	_	_	O
60	organized	_	_	O
61	by	_	_	O
62	the	_	_	O
63	French	_	_	O
64	Federation	_	_	O
65	of	_	_	O
66	Cancer	_	_	O
67	Institutes	_	_	O
68	,	_	_	O
69	patients	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	receive	_	_	O
75	either	_	_	O
76	EP	_	_	O
77	(	_	_	O
78	n	_	_	O
79	=	_	_	O
80	109	_	_	O
81	;	_	_	O
82	etoposide	_	_	O
83	at	_	_	O
84	a	_	_	O
85	dose	_	_	O
86	of	_	_	O
87	100	_	_	O
88	mg/m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	on	_	_	O
93	days	_	_	O
94	1-3	_	_	O
95	plus	_	_	O
96	cisplatin	_	_	O
97	at	_	_	O
98	100	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	on	_	_	O
104	day	_	_	O
105	2	_	_	O
106	)	_	_	O
107	or	_	_	O
108	PCDE	_	_	O
109	(	_	_	O
110	n	_	_	O
111	=	_	_	O
112	117	_	_	O
113	;	_	_	O
114	etoposide	_	_	O
115	and	_	_	O
116	cisplatin	_	_	O
117	given	_	_	O
118	as	_	_	O
119	in	_	_	O
120	EP	_	_	O
121	plus	_	_	O
122	cyclophosphamide	_	_	O
123	at	_	_	O
124	400	_	_	O
125	mg/m	_	_	O
126	(	_	_	O
127	2	_	_	O
128	)	_	_	O
129	on	_	_	O
130	days	_	_	O
131	1-3	_	_	O
132	and	_	_	O
133	4'-epidoxorubicin	_	_	O
134	at	_	_	O
135	40	_	_	O
136	mg/m	_	_	O
137	(	_	_	O
138	2	_	_	O
139	)	_	_	O
140	on	_	_	O
141	day	_	_	O
142	1	_	_	O
143	)	_	_	O
144	every	_	_	O
145	4	_	_	O
146	weeks	_	_	O
147	.	_	_	O

148	Both	_	_	O
149	groups	_	_	O
150	received	_	_	O
151	a	_	_	O
152	total	_	_	O
153	of	_	_	O
154	six	_	_	O
155	cycles	_	_	O
156	.	_	_	O

157	Survival	_	_	O
158	differences	_	_	O
159	were	_	_	O
160	analyzed	_	_	O
161	by	_	_	O
162	Wilcoxon	_	_	O
163	and	_	_	O
164	log-rank	_	_	O
165	tests	_	_	O
166	.	_	_	O

167	Associations	_	_	O
168	of	_	_	O
169	treatment	_	_	O
170	group	_	_	O
171	and	_	_	O
172	putative	_	_	O
173	prognostic	_	_	O
174	variables	_	_	O
175	with	_	_	O
176	survival	_	_	O
177	were	_	_	O
178	tested	_	_	O
179	in	_	_	O
180	the	_	_	O
181	Cox	_	_	O
182	proportional	_	_	O
183	hazards	_	_	O
184	model	_	_	O
185	.	_	_	O

186	Quality	_	_	O
187	of	_	_	O
188	life	_	_	O
189	was	_	_	O
190	assessed	_	_	O
191	from	_	_	O
192	the	_	_	O
193	responses	_	_	O
194	to	_	_	O
195	the	_	_	O
196	European	_	_	O
197	Organization	_	_	O
198	for	_	_	O
199	Research	_	_	O
200	and	_	_	O
201	Treatment	_	_	O
202	of	_	_	O
203	Cancer	_	_	O
204	quality-of-life	_	_	O
205	questionnaire	_	_	O
206	(	_	_	O
207	C30	_	_	O
208	,	_	_	O
209	health	_	_	O
210	status	_	_	O
211	and	_	_	O
212	lung	_	_	O
213	cancer	_	_	O
214	module	_	_	O
215	13	_	_	O
216	)	_	_	O
217	.	_	_	O

218	All	_	_	O
219	statistical	_	_	O
220	tests	_	_	O
221	were	_	_	O
222	two-sided	_	_	O
223	.	_	_	O

224	Patients	_	_	B-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	PCDE	_	_	I-Premise
228	arm	_	_	I-Premise
229	had	_	_	I-Premise
230	a	_	_	I-Premise
231	statistically	_	_	I-Premise
232	significant	_	_	I-Premise
233	higher	_	_	I-Premise
234	frequency	_	_	I-Premise
235	of	_	_	I-Premise
236	combined	_	_	I-Premise
237	complete	_	_	I-Premise
238	plus	_	_	I-Premise
239	partial	_	_	I-Premise
240	responses	_	_	I-Premise
241	compared	_	_	I-Premise
242	with	_	_	I-Premise
243	those	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	EP	_	_	I-Premise
247	arm	_	_	I-Premise
248	(	_	_	I-Premise
249	21	_	_	I-Premise
250	%	_	_	I-Premise
251	plus	_	_	I-Premise
252	55	_	_	I-Premise
253	%	_	_	I-Premise
254	versus	_	_	I-Premise
255	13	_	_	I-Premise
256	%	_	_	I-Premise
257	plus	_	_	I-Premise
258	48	_	_	I-Premise
259	%	_	_	I-Premise
260	,	_	_	I-Premise
261	respectively	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=.02	_	_	I-Premise
265	for	_	_	I-Premise
266	difference	_	_	I-Premise
267	in	_	_	I-Premise
268	combined	_	_	I-Premise
269	objective	_	_	I-Premise
270	responses	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Patients	_	_	B-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	PCDE	_	_	I-Premise
277	arm	_	_	I-Premise
278	survived	_	_	I-Premise
279	longer	_	_	I-Premise
280	than	_	_	I-Premise
281	those	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	EP	_	_	I-Premise
285	arm	_	_	I-Premise
286	(	_	_	I-Premise
287	1-year	_	_	I-Premise
288	survival	_	_	I-Premise
289	rate	_	_	I-Premise
290	:	_	_	I-Premise
291	40	_	_	I-Premise
292	%	_	_	I-Premise
293	and	_	_	I-Premise
294	29	_	_	I-Premise
295	%	_	_	I-Premise
296	,	_	_	I-Premise
297	respectively	_	_	I-Premise
298	;	_	_	I-Premise
299	median	_	_	I-Premise
300	survival	_	_	I-Premise
301	:	_	_	I-Premise
302	10.5	_	_	I-Premise
303	and	_	_	I-Premise
304	9.3	_	_	I-Premise
305	months	_	_	I-Premise
306	,	_	_	I-Premise
307	respectively	_	_	I-Premise
308	;	_	_	I-Premise
309	log-rank	_	_	I-Premise
310	P	_	_	I-Premise
311	=.0067	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	In	_	_	B-Premise
315	the	_	_	I-Premise
316	Cox	_	_	I-Premise
317	model	_	_	I-Premise
318	,	_	_	I-Premise
319	the	_	_	I-Premise
320	relative	_	_	I-Premise
321	risk	_	_	I-Premise
322	of	_	_	I-Premise
323	death	_	_	I-Premise
324	for	_	_	I-Premise
325	patients	_	_	I-Premise
326	in	_	_	I-Premise
327	the	_	_	I-Premise
328	PCDE	_	_	I-Premise
329	arm	_	_	I-Premise
330	compared	_	_	I-Premise
331	with	_	_	I-Premise
332	those	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	EP	_	_	I-Premise
336	arm	_	_	I-Premise
337	was	_	_	I-Premise
338	0.70	_	_	I-Premise
339	(	_	_	I-Premise
340	95	_	_	I-Premise
341	%	_	_	I-Premise
342	confidence	_	_	I-Premise
343	interval	_	_	I-Premise
344	=	_	_	I-Premise
345	0.51	_	_	I-Premise
346	to	_	_	I-Premise
347	0.95	_	_	I-Premise
348	)	_	_	I-Premise
349	;	_	_	I-Premise
350	the	_	_	B-Premise
351	disease	_	_	I-Premise
352	also	_	_	I-Premise
353	progressed	_	_	I-Premise
354	more	_	_	I-Premise
355	slowly	_	_	I-Premise
356	in	_	_	I-Premise
357	patients	_	_	I-Premise
358	in	_	_	I-Premise
359	the	_	_	I-Premise
360	PCDE	_	_	I-Premise
361	arm	_	_	I-Premise
362	.	_	_	I-Premise

363	Hematologic	_	_	B-Premise
364	toxicity	_	_	I-Premise
365	was	_	_	I-Premise
366	higher	_	_	I-Premise
367	in	_	_	I-Premise
368	the	_	_	I-Premise
369	PCDE	_	_	I-Premise
370	arm	_	_	I-Premise
371	(	_	_	I-Premise
372	22	_	_	I-Premise
373	%	_	_	I-Premise
374	with	_	_	I-Premise
375	documented	_	_	I-Premise
376	infections	_	_	I-Premise
377	compared	_	_	I-Premise
378	with	_	_	I-Premise
379	8	_	_	I-Premise
380	%	_	_	I-Premise
381	in	_	_	I-Premise
382	the	_	_	I-Premise
383	EP	_	_	I-Premise
384	arm	_	_	I-Premise
385	;	_	_	I-Premise
386	P	_	_	I-Premise
387	=.0038	_	_	I-Premise
388	)	_	_	I-Premise
389	,	_	_	I-Premise
390	and	_	_	O
391	the	_	_	B-Premise
392	toxicity-related	_	_	I-Premise
393	death	_	_	I-Premise
394	rate	_	_	I-Premise
395	was	_	_	I-Premise
396	9	_	_	I-Premise
397	%	_	_	I-Premise
398	in	_	_	I-Premise
399	the	_	_	I-Premise
400	PCDE	_	_	I-Premise
401	arm	_	_	I-Premise
402	versus	_	_	I-Premise
403	5.5	_	_	I-Premise
404	%	_	_	I-Premise
405	in	_	_	I-Premise
406	the	_	_	I-Premise
407	EP	_	_	I-Premise
408	arm	_	_	I-Premise
409	(	_	_	I-Premise
410	P	_	_	I-Premise
411	=.22	_	_	I-Premise
412	)	_	_	I-Premise
413	.	_	_	I-Premise

414	The	_	_	B-Claim
415	global	_	_	I-Claim
416	health	_	_	I-Claim
417	status	_	_	I-Claim
418	showed	_	_	I-Claim
419	similar	_	_	I-Claim
420	improvement	_	_	I-Claim
421	in	_	_	I-Claim
422	both	_	_	I-Claim
423	arms	_	_	I-Claim
424	during	_	_	I-Claim
425	treatment	_	_	I-Claim
426	.	_	_	I-Claim

427	Compared	_	_	B-Claim
428	with	_	_	I-Claim
429	the	_	_	I-Claim
430	EP	_	_	I-Claim
431	regimen	_	_	I-Claim
432	,	_	_	I-Claim
433	the	_	_	I-Claim
434	PCDE	_	_	I-Claim
435	regimen	_	_	I-Claim
436	yielded	_	_	I-Claim
437	higher	_	_	I-Claim
438	response	_	_	I-Claim
439	rates	_	_	I-Claim
440	and	_	_	I-Claim
441	better	_	_	I-Claim
442	survival	_	_	I-Claim
443	rates	_	_	I-Claim
444	in	_	_	I-Claim
445	patients	_	_	I-Claim
446	with	_	_	I-Claim
447	extensive	_	_	I-Claim
448	SCLC	_	_	I-Claim
449	without	_	_	I-Claim
450	affecting	_	_	I-Claim
451	the	_	_	I-Claim
452	quality	_	_	I-Claim
453	of	_	_	I-Claim
454	life	_	_	I-Claim
455	of	_	_	I-Claim
456	the	_	_	I-Claim
457	patients	_	_	I-Claim
458	during	_	_	I-Claim
459	chemotherapy	_	_	I-Claim
460	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	double-blind	_	_	O
4	,	_	_	O
5	placebo-controlled	_	_	O
6	clinical	_	_	O
7	trial	_	_	O
8	assessed	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	epoetin	_	_	O
13	alfa	_	_	O
14	on	_	_	O
15	transfusion	_	_	O
16	requirements	_	_	O
17	,	_	_	O
18	hematopoietic	_	_	O
19	parameters	_	_	O
20	,	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QOL	_	_	O
26	)	_	_	O
27	,	_	_	O
28	and	_	_	O
29	safety	_	_	O
30	in	_	_	O
31	anemic	_	_	O
32	cancer	_	_	O
33	patients	_	_	O
34	receiving	_	_	O
35	nonplatinum	_	_	O
36	chemotherapy	_	_	O
37	.	_	_	O

38	The	_	_	O
39	study	_	_	O
40	also	_	_	O
41	explored	_	_	O
42	a	_	_	O
43	possible	_	_	O
44	relationship	_	_	O
45	between	_	_	O
46	increased	_	_	O
47	hemoglobin	_	_	O
48	and	_	_	O
49	survival	_	_	O
50	.	_	_	O

51	Three	_	_	O
52	hundred	_	_	O
53	seventy-five	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	solid	_	_	O
57	or	_	_	O
58	nonmyeloid	_	_	O
59	hematologic	_	_	O
60	malignancies	_	_	O
61	and	_	_	O
62	hemoglobin	_	_	O
63	levels	_	_	O
64	<	_	_	O
65	or	_	_	O
66	=	_	_	O
67	10.5	_	_	O
68	g/dL	_	_	O
69	,	_	_	O
70	or	_	_	O
71	greater	_	_	O
72	than	_	_	O
73	10.5	_	_	O
74	g/dL	_	_	O
75	but	_	_	O
76	<	_	_	O
77	or	_	_	O
78	=	_	_	O
79	12.0	_	_	O
80	g/dL	_	_	O
81	after	_	_	O
82	a	_	_	O
83	hemoglobin	_	_	O
84	decrease	_	_	O
85	of	_	_	O
86	>	_	_	O
87	or	_	_	O
88	=	_	_	O
89	1.5	_	_	O
90	g/dL	_	_	O
91	per	_	_	O
92	cycle	_	_	O
93	since	_	_	O
94	starting	_	_	O
95	chemotherapy	_	_	O
96	,	_	_	O
97	were	_	_	O
98	randomized	_	_	O
99	2:1	_	_	O
100	to	_	_	O
101	epoetin	_	_	O
102	alfa	_	_	O
103	150	_	_	O
104	to	_	_	O
105	300	_	_	O
106	IU/kg	_	_	O
107	(	_	_	O
108	n	_	_	O
109	=	_	_	O
110	251	_	_	O
111	)	_	_	O
112	or	_	_	O
113	placebo	_	_	O
114	(	_	_	O
115	n	_	_	O
116	=	_	_	O
117	124	_	_	O
118	)	_	_	O
119	three	_	_	O
120	times	_	_	O
121	per	_	_	O
122	week	_	_	O
123	subcutaneously	_	_	O
124	for	_	_	O
125	12	_	_	O
126	to	_	_	O
127	24	_	_	O
128	weeks	_	_	O
129	.	_	_	O

130	The	_	_	O
131	primary	_	_	O
132	end	_	_	O
133	point	_	_	O
134	was	_	_	O
135	proportion	_	_	O
136	of	_	_	O
137	patients	_	_	O
138	transfused	_	_	O
139	;	_	_	O
140	secondary	_	_	O
141	end	_	_	O
142	points	_	_	O
143	were	_	_	O
144	change	_	_	O
145	in	_	_	O
146	hemoglobin	_	_	O
147	and	_	_	O
148	QOL	_	_	O
149	.	_	_	O

150	The	_	_	O
151	protocol	_	_	O
152	was	_	_	O
153	amended	_	_	O
154	before	_	_	O
155	unblinding	_	_	O
156	to	_	_	O
157	prospectively	_	_	O
158	collect	_	_	O
159	and	_	_	O
160	assess	_	_	O
161	survival	_	_	O
162	data	_	_	O
163	12	_	_	O
164	months	_	_	O
165	after	_	_	O
166	the	_	_	O
167	last	_	_	O
168	patient	_	_	O
169	completed	_	_	O
170	the	_	_	O
171	study	_	_	O
172	.	_	_	O

173	Epoetin	_	_	B-Premise
174	alfa	_	_	I-Premise
175	,	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	placebo	_	_	I-Premise
179	,	_	_	I-Premise
180	significantly	_	_	I-Premise
181	decreased	_	_	I-Premise
182	transfusion	_	_	I-Premise
183	requirements	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=.0057	_	_	I-Premise
187	)	_	_	I-Premise
188	and	_	_	I-Premise
189	increased	_	_	I-Premise
190	hemoglobin	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	<	_	_	I-Premise
194	.001	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	Improvement	_	_	B-Premise
198	of	_	_	I-Premise
199	all	_	_	I-Premise
200	primary	_	_	I-Premise
201	cancer-	_	_	I-Premise
202	and	_	_	I-Premise
203	anemia-specific	_	_	I-Premise
204	QOL	_	_	I-Premise
205	domains	_	_	I-Premise
206	,	_	_	I-Premise
207	including	_	_	I-Premise
208	energy	_	_	I-Premise
209	level	_	_	I-Premise
210	,	_	_	I-Premise
211	ability	_	_	I-Premise
212	to	_	_	I-Premise
213	do	_	_	I-Premise
214	daily	_	_	I-Premise
215	activities	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	fatigue	_	_	I-Premise
219	,	_	_	I-Premise
220	was	_	_	I-Premise
221	significantly	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	<	_	_	I-Premise
225	.01	_	_	I-Premise
226	)	_	_	I-Premise
227	greater	_	_	I-Premise
228	for	_	_	I-Premise
229	epoetin	_	_	I-Premise
230	alfa	_	_	I-Premise
231	versus	_	_	I-Premise
232	placebo	_	_	I-Premise
233	patients	_	_	I-Premise
234	.	_	_	I-Premise

235	Although	_	_	O
236	the	_	_	O
237	study	_	_	O
238	was	_	_	O
239	not	_	_	O
240	powered	_	_	O
241	for	_	_	O
242	survival	_	_	O
243	as	_	_	O
244	an	_	_	O
245	end	_	_	O
246	point	_	_	O
247	,	_	_	O
248	Kaplan-Meier	_	_	B-Premise
249	estimates	_	_	I-Premise
250	showed	_	_	I-Premise
251	a	_	_	I-Premise
252	trend	_	_	I-Premise
253	in	_	_	I-Premise
254	overall	_	_	I-Premise
255	survival	_	_	I-Premise
256	favoring	_	_	I-Premise
257	epoetin	_	_	I-Premise
258	alfa	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	=.13	_	_	I-Premise
262	,	_	_	I-Premise
263	log-rank	_	_	I-Premise
264	test	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	O
268	Cox	_	_	B-Premise
269	regression	_	_	I-Premise
270	analysis	_	_	I-Premise
271	showed	_	_	I-Premise
272	an	_	_	I-Premise
273	estimated	_	_	I-Premise
274	hazards	_	_	I-Premise
275	ratio	_	_	I-Premise
276	of	_	_	I-Premise
277	1.309	_	_	I-Premise
278	(	_	_	I-Premise
279	P	_	_	I-Premise
280	=.052	_	_	I-Premise
281	)	_	_	I-Premise
282	favoring	_	_	I-Premise
283	epoetin	_	_	I-Premise
284	alfa	_	_	I-Premise
285	.	_	_	I-Premise

286	Adverse	_	_	B-Premise
287	events	_	_	I-Premise
288	were	_	_	I-Premise
289	comparable	_	_	I-Premise
290	between	_	_	I-Premise
291	groups	_	_	I-Premise
292	.	_	_	I-Premise

293	Epoetin	_	_	B-Claim
294	alfa	_	_	I-Claim
295	safely	_	_	I-Claim
296	and	_	_	I-Claim
297	effectively	_	_	I-Claim
298	ameliorates	_	_	I-Claim
299	anemia	_	_	I-Claim
300	and	_	_	I-Claim
301	significantly	_	_	I-Claim
302	improves	_	_	I-Claim
303	QOL	_	_	I-Claim
304	in	_	_	I-Claim
305	cancer	_	_	I-Claim
306	patients	_	_	I-Claim
307	receiving	_	_	I-Claim
308	nonplatinum	_	_	I-Claim
309	chemotherapy	_	_	I-Claim
310	.	_	_	I-Claim

311	Encouraging	_	_	B-Claim
312	results	_	_	I-Claim
313	regarding	_	_	I-Claim
314	increased	_	_	I-Claim
315	survival	_	_	I-Claim
316	warrant	_	_	I-Claim
317	another	_	_	I-Claim
318	trial	_	_	I-Claim
319	designed	_	_	I-Claim
320	to	_	_	I-Claim
321	confirm	_	_	I-Claim
322	these	_	_	I-Claim
323	findings	_	_	I-Claim
324	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure-lowering	_	_	O
5	efficacy	_	_	O
6	and	_	_	O
7	safety	_	_	O
8	of	_	_	O
9	travoprost	_	_	O
10	0.0015	_	_	O
11	%	_	_	O
12	and	_	_	O
13	0.004	_	_	O
14	%	_	_	O
15	,	_	_	O
16	dosed	_	_	O
17	daily	_	_	O
18	in	_	_	O
19	the	_	_	O
20	evening	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	vehicle	_	_	O
24	,	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	,	_	_	O
34	whose	_	_	O
35	intraocular	_	_	O
36	pressure	_	_	O
37	was	_	_	O
38	not	_	_	O
39	adequately	_	_	O
40	controlled	_	_	O
41	on	_	_	O
42	timolol	_	_	O
43	0.5	_	_	O
44	%	_	_	O
45	twice	_	_	O
46	daily	_	_	O
47	(	_	_	O
48	twice	_	_	O
49	daily	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Subjects	_	_	O
53	who	_	_	O
54	qualified	_	_	O
55	at	_	_	O
56	screening	_	_	O
57	began	_	_	O
58	a	_	_	O
59	run-in	_	_	O
60	period	_	_	O
61	dosing	_	_	O
62	timolol	_	_	O
63	twice	_	_	O
64	daily	_	_	O
65	for	_	_	O
66	3	_	_	O
67	weeks	_	_	O
68	.	_	_	O

69	If	_	_	O
70	the	_	_	O
71	subjects	_	_	O
72	had	_	_	O
73	an	_	_	O
74	intraocular	_	_	O
75	pressure	_	_	O
76	of	_	_	O
77	24	_	_	O
78	to	_	_	O
79	36	_	_	O
80	mm	_	_	O
81	Hg	_	_	O
82	at	_	_	O
83	8	_	_	O
84	AM	_	_	O
85	and	_	_	O
86	21	_	_	O
87	to	_	_	O
88	36	_	_	O
89	mm	_	_	O
90	Hg	_	_	O
91	at	_	_	O
92	10	_	_	O
93	AM	_	_	O
94	and	_	_	O
95	4	_	_	O
96	pm	_	_	O
97	in	_	_	O
98	at	_	_	O
99	least	_	_	O
100	one	_	_	O
101	eye	_	_	O
102	on	_	_	O
103	timolol	_	_	O
104	,	_	_	O
105	they	_	_	O
106	were	_	_	O
107	randomized	_	_	O
108	to	_	_	O
109	one	_	_	O
110	of	_	_	O
111	two	_	_	O
112	concentrations	_	_	O
113	of	_	_	O
114	travoprost	_	_	O
115	(	_	_	O
116	0.0015	_	_	O
117	%	_	_	O
118	or	_	_	O
119	0.004	_	_	O
120	%	_	_	O
121	)	_	_	O
122	or	_	_	O
123	vehicle	_	_	O
124	solution	_	_	O
125	every	_	_	O
126	day	_	_	O
127	and	_	_	O
128	were	_	_	O
129	followed	_	_	O
130	for	_	_	O
131	6	_	_	O
132	months	_	_	O
133	.	_	_	O

134	Four	_	_	O
135	hundred	_	_	O
136	twenty-six	_	_	O
137	subjects	_	_	O
138	were	_	_	O
139	randomized	_	_	O
140	.	_	_	O

141	The	_	_	O
142	mean	_	_	O
143	intraocular	_	_	O
144	pressure	_	_	O
145	at	_	_	O
146	8	_	_	O
147	AM	_	_	O
148	,	_	_	O
149	10	_	_	O
150	AM	_	_	O
151	,	_	_	O
152	and	_	_	O
153	4	_	_	O
154	PM	_	_	O
155	in	_	_	O
156	the	_	_	O
157	patient	_	_	O
158	's	_	_	O
159	eye	_	_	O
160	with	_	_	O
161	the	_	_	O
162	higher	_	_	O
163	intraocular	_	_	O
164	pressure	_	_	O
165	was	_	_	O
166	used	_	_	O
167	for	_	_	O
168	the	_	_	O
169	analysis	_	_	O
170	.	_	_	O

171	Mean	_	_	B-Premise
172	baseline	_	_	I-Premise
173	values	_	_	I-Premise
174	(	_	_	I-Premise
175	25	_	_	I-Premise
176	mm	_	_	I-Premise
177	Hg	_	_	I-Premise
178	)	_	_	I-Premise
179	for	_	_	I-Premise
180	subjects	_	_	I-Premise
181	at	_	_	I-Premise
182	eligibility	_	_	I-Premise
183	(	_	_	I-Premise
184	while	_	_	I-Premise
185	maintained	_	_	I-Premise
186	on	_	_	I-Premise
187	timolol	_	_	I-Premise
188	)	_	_	I-Premise
189	were	_	_	I-Premise
190	not	_	_	I-Premise
191	significantly	_	_	I-Premise
192	different	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	<	_	_	I-Premise
196	.0001	_	_	I-Premise
197	)	_	_	I-Premise
198	among	_	_	I-Premise
199	the	_	_	I-Premise
200	treatment	_	_	I-Premise
201	groups	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	intraocular	_	_	I-Premise
205	pressure	_	_	I-Premise
206	was	_	_	I-Premise
207	lowered	_	_	I-Premise
208	an	_	_	I-Premise
209	additional	_	_	I-Premise
210	-5.7	_	_	I-Premise
211	to	_	_	I-Premise
212	-7.2	_	_	I-Premise
213	mm	_	_	I-Premise
214	Hg	_	_	I-Premise
215	and	_	_	I-Premise
216	-5.1	_	_	I-Premise
217	to	_	_	I-Premise
218	-6.7	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	travoprost	_	_	I-Premise
224	0.004	_	_	I-Premise
225	%	_	_	I-Premise
226	and	_	_	I-Premise
227	0.0015	_	_	I-Premise
228	%	_	_	I-Premise
229	concentrations	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	.	_	_	I-Premise

233	These	_	_	B-Premise
234	changes	_	_	I-Premise
235	were	_	_	I-Premise
236	significantly	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	<	_	_	I-Premise
240	or	_	_	I-Premise
241	=.0001	_	_	I-Premise
242	)	_	_	I-Premise
243	different	_	_	I-Premise
244	from	_	_	I-Premise
245	the	_	_	I-Premise
246	vehicle	_	_	I-Premise
247	group	_	_	I-Premise
248	(	_	_	I-Premise
249	-1.3	_	_	I-Premise
250	to	_	_	I-Premise
251	-2.8	_	_	I-Premise
252	mm	_	_	I-Premise
253	Hg	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	The	_	_	B-Premise
257	intraocular	_	_	I-Premise
258	pressure	_	_	I-Premise
259	range	_	_	I-Premise
260	on	_	_	I-Premise
261	treatment	_	_	I-Premise
262	at	_	_	I-Premise
263	all	_	_	I-Premise
264	visit	_	_	I-Premise
265	times	_	_	I-Premise
266	over	_	_	I-Premise
267	the	_	_	I-Premise
268	6-month	_	_	I-Premise
269	treatment	_	_	I-Premise
270	period	_	_	I-Premise
271	ranged	_	_	I-Premise
272	from	_	_	I-Premise
273	17.9	_	_	I-Premise
274	to	_	_	I-Premise
275	19.2	_	_	I-Premise
276	mm	_	_	I-Premise
277	Hg	_	_	I-Premise
278	for	_	_	I-Premise
279	travoprost	_	_	I-Premise
280	0.004	_	_	I-Premise
281	%	_	_	I-Premise
282	and	_	_	I-Premise
283	18.3	_	_	I-Premise
284	to	_	_	I-Premise
285	20.1	_	_	I-Premise
286	mm	_	_	I-Premise
287	Hg	_	_	I-Premise
288	for	_	_	I-Premise
289	travoprost	_	_	I-Premise
290	0.0015	_	_	I-Premise
291	%	_	_	I-Premise
292	compared	_	_	I-Premise
293	with	_	_	I-Premise
294	22.4	_	_	I-Premise
295	to	_	_	I-Premise
296	24.1	_	_	I-Premise
297	mm	_	_	I-Premise
298	Hg	_	_	I-Premise
299	for	_	_	I-Premise
300	vehicle	_	_	I-Premise
301	.	_	_	I-Premise

302	Average	_	_	B-Premise
303	hyperemia	_	_	I-Premise
304	scores	_	_	I-Premise
305	ranged	_	_	I-Premise
306	from	_	_	I-Premise
307	trace	_	_	I-Premise
308	to	_	_	I-Premise
309	mild	_	_	I-Premise
310	(	_	_	I-Premise
311	mean	_	_	I-Premise
312	0.5	_	_	I-Premise
313	on	_	_	I-Premise
314	a	_	_	I-Premise
315	scale	_	_	I-Premise
316	of	_	_	I-Premise
317	0	_	_	I-Premise
318	=	_	_	I-Premise
319	none/trace	_	_	I-Premise
320	;	_	_	I-Premise
321	1=	_	_	I-Premise
322	mild	_	_	I-Premise
323	;	_	_	I-Premise
324	2	_	_	I-Premise
325	=	_	_	I-Premise
326	moderate	_	_	I-Premise
327	;	_	_	I-Premise
328	3	_	_	I-Premise
329	=	_	_	I-Premise
330	severe	_	_	I-Premise
331	)	_	_	I-Premise
332	for	_	_	I-Premise
333	all	_	_	I-Premise
334	treatment	_	_	I-Premise
335	groups	_	_	I-Premise
336	.	_	_	I-Premise

337	No	_	_	B-Premise
338	iris	_	_	I-Premise
339	pigmentation	_	_	I-Premise
340	changes	_	_	I-Premise
341	were	_	_	I-Premise
342	observed	_	_	I-Premise
343	in	_	_	I-Premise
344	any	_	_	I-Premise
345	patient	_	_	I-Premise
346	during	_	_	I-Premise
347	this	_	_	I-Premise
348	study	_	_	I-Premise
349	.	_	_	I-Premise

350	There	_	_	B-Premise
351	were	_	_	I-Premise
352	no	_	_	I-Premise
353	clinically	_	_	I-Premise
354	or	_	_	I-Premise
355	statistically	_	_	I-Premise
356	significant	_	_	I-Premise
357	changes	_	_	I-Premise
358	from	_	_	I-Premise
359	baseline	_	_	I-Premise
360	in	_	_	I-Premise
361	visual	_	_	I-Premise
362	acuity	_	_	I-Premise
363	,	_	_	I-Premise
364	ocular	_	_	I-Premise
365	cells	_	_	I-Premise
366	and	_	_	I-Premise
367	flare	_	_	I-Premise
368	,	_	_	I-Premise
369	fundus	_	_	I-Premise
370	parameter	_	_	I-Premise
371	,	_	_	I-Premise
372	cup-to-disk	_	_	I-Premise
373	ratio	_	_	I-Premise
374	and	_	_	I-Premise
375	visual	_	_	I-Premise
376	field	_	_	I-Premise
377	between	_	_	I-Premise
378	the	_	_	I-Premise
379	treatment	_	_	I-Premise
380	groups	_	_	I-Premise
381	.	_	_	I-Premise

382	There	_	_	B-Premise
383	were	_	_	I-Premise
384	no	_	_	I-Premise
385	serious	_	_	I-Premise
386	adverse	_	_	I-Premise
387	events	_	_	I-Premise
388	reported	_	_	I-Premise
389	for	_	_	I-Premise
390	any	_	_	I-Premise
391	treatment	_	_	I-Premise
392	group	_	_	I-Premise
393	.	_	_	I-Premise

394	Travoprost	_	_	B-Claim
395	produced	_	_	I-Claim
396	clinically	_	_	I-Claim
397	relevant	_	_	I-Claim
398	and	_	_	I-Claim
399	statistically	_	_	I-Claim
400	significant	_	_	I-Claim
401	additional	_	_	I-Claim
402	intraocular	_	_	I-Claim
403	pressure	_	_	I-Claim
404	reductions	_	_	I-Claim
405	from	_	_	I-Claim
406	baseline	_	_	I-Claim
407	when	_	_	I-Claim
408	used	_	_	I-Claim
409	adjunctively	_	_	I-Claim
410	with	_	_	I-Claim
411	timolol	_	_	I-Claim
412	in	_	_	I-Claim
413	subjects	_	_	I-Claim
414	with	_	_	I-Claim
415	open-angle	_	_	I-Claim
416	glaucoma	_	_	I-Claim
417	or	_	_	I-Claim
418	ocular	_	_	I-Claim
419	hypertension	_	_	I-Claim
420	.	_	_	I-Claim


0	Cutaneous	_	_	B-Claim
1	T-cell	_	_	I-Claim
2	lymphoma	_	_	I-Claim
3	(	_	_	I-Claim
4	CTCL	_	_	I-Claim
5	)	_	_	I-Claim
6	can	_	_	I-Claim
7	be	_	_	I-Claim
8	associated	_	_	I-Claim
9	with	_	_	I-Claim
10	painful	_	_	I-Claim
11	,	_	_	I-Claim
12	pruritic	_	_	I-Claim
13	,	_	_	I-Claim
14	disfiguring	_	_	I-Claim
15	lesions	_	_	I-Claim
16	.	_	_	I-Claim

17	As	_	_	O
18	part	_	_	O
19	of	_	_	O
20	a	_	_	O
21	multicenter	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	phase	_	_	O
25	III	_	_	O
26	trial	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	heavily	_	_	O
31	pretreated	_	_	O
32	advanced	_	_	O
33	and/or	_	_	O
34	recurrent	_	_	O
35	CTCL	_	_	O
36	,	_	_	O
37	the	_	_	O
38	effects	_	_	O
39	of	_	_	O
40	an	_	_	O
41	interleukin-2	_	_	O
42	receptor-targeted	_	_	O
43	fusion	_	_	O
44	protein	_	_	O
45	,	_	_	O
46	denileukin	_	_	O
47	diftitox	_	_	O
48	(	_	_	O
49	DAB389IL-2	_	_	O
50	,	_	_	O
51	ONTAK	_	_	O
52	)	_	_	O
53	,	_	_	O
54	on	_	_	O
55	patient-rated	_	_	O
56	overall	_	_	O
57	quality	_	_	O
58	of	_	_	O
59	life	_	_	O
60	(	_	_	O
61	QOL	_	_	O
62	)	_	_	O
63	,	_	_	O
64	skin	_	_	O
65	appearance	_	_	O
66	,	_	_	O
67	and	_	_	O
68	pruritus	_	_	O
69	severity	_	_	O
70	were	_	_	O
71	evaluated	_	_	O
72	.	_	_	O

73	A	_	_	O
74	total	_	_	O
75	of	_	_	O
76	71	_	_	O
77	patients	_	_	O
78	with	_	_	O
79	stage	_	_	O
80	IB-IVA	_	_	O
81	CTCL	_	_	O
82	received	_	_	O
83	intravenous	_	_	O
84	denileukin	_	_	O
85	diftitox	_	_	O
86	9	_	_	O
87	microg/kg/day	_	_	O
88	or	_	_	O
89	18	_	_	O
90	microg/kg/day	_	_	O
91	over	_	_	O
92	15-60	_	_	O
93	minutes	_	_	O
94	for	_	_	O
95	5	_	_	O
96	consecutive	_	_	O
97	days	_	_	O
98	on	_	_	O
99	an	_	_	O
100	outpatient	_	_	O
101	basis	_	_	O
102	;	_	_	O
103	cycles	_	_	O
104	were	_	_	O
105	planned	_	_	O
106	for	_	_	O
107	every	_	_	O
108	21	_	_	O
109	days	_	_	O
110	for	_	_	O
111	a	_	_	O
112	total	_	_	O
113	of	_	_	O
114	8	_	_	O
115	cycles	_	_	O
116	over	_	_	O
117	6	_	_	O
118	months	_	_	O
119	.	_	_	O

120	Prior	_	_	O
121	to	_	_	O
122	each	_	_	O
123	treatment	_	_	O
124	cycle	_	_	O
125	,	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	evaluated	_	_	O
129	for	_	_	O
130	disease	_	_	O
131	response	_	_	O
132	and	_	_	O
133	were	_	_	O
134	asked	_	_	O
135	to	_	_	O
136	self-rate	_	_	O
137	their	_	_	O
138	overall	_	_	O
139	QOL	_	_	O
140	via	_	_	O
141	the	_	_	O
142	Functional	_	_	O
143	Assessment	_	_	O
144	of	_	_	O
145	Cancer	_	_	O
146	Therapy-General	_	_	O
147	(	_	_	O
148	FACT-G	_	_	O
149	)	_	_	O
150	questionnaire	_	_	O
151	,	_	_	O
152	skin	_	_	O
153	appearance	_	_	O
154	(	_	_	O
155	7-point	_	_	O
156	scale	_	_	O
157	)	_	_	O
158	,	_	_	O
159	and	_	_	O
160	pruritus	_	_	O
161	severity	_	_	O
162	(	_	_	O
163	10-cm	_	_	O
164	visual	_	_	O
165	analogue	_	_	O
166	scale	_	_	O
167	)	_	_	O
168	.	_	_	O

169	Composite	_	_	B-Premise
170	FACT-G	_	_	I-Premise
171	and	_	_	I-Premise
172	most	_	_	I-Premise
173	individual	_	_	I-Premise
174	subscale	_	_	I-Premise
175	scores	_	_	I-Premise
176	(	_	_	I-Premise
177	physical	_	_	I-Premise
178	,	_	_	I-Premise
179	social/family	_	_	I-Premise
180	,	_	_	I-Premise
181	emotional	_	_	I-Premise
182	,	_	_	I-Premise
183	and	_	_	I-Premise
184	functional	_	_	I-Premise
185	well	_	_	I-Premise
186	being	_	_	I-Premise
187	)	_	_	I-Premise
188	in	_	_	I-Premise
189	documented	_	_	I-Premise
190	responders	_	_	I-Premise
191	(	_	_	I-Premise
192	n	_	_	I-Premise
193	=	_	_	I-Premise
194	21	_	_	I-Premise
195	)	_	_	I-Premise
196	gradually	_	_	I-Premise
197	increased	_	_	I-Premise
198	during	_	_	I-Premise
199	the	_	_	I-Premise
200	study	_	_	I-Premise
201	period	_	_	I-Premise
202	,	_	_	I-Premise
203	generally	_	_	I-Premise
204	reaching	_	_	I-Premise
205	statistical	_	_	I-Premise
206	significance	_	_	I-Premise
207	(	_	_	I-Premise
208	P	_	_	I-Premise
209	<	_	_	I-Premise
210	0.05	_	_	I-Premise
211	)	_	_	I-Premise
212	by	_	_	I-Premise
213	cycle	_	_	I-Premise
214	3	_	_	I-Premise
215	,	_	_	I-Premise
216	and	_	_	I-Premise
217	were	_	_	I-Premise
218	significantly	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	or	_	_	I-Premise
223	=	_	_	I-Premise
224	0.041	_	_	I-Premise
225	)	_	_	I-Premise
226	higher	_	_	I-Premise
227	than	_	_	I-Premise
228	the	_	_	I-Premise
229	scores	_	_	I-Premise
230	of	_	_	I-Premise
231	nonresponders	_	_	I-Premise
232	at	_	_	I-Premise
233	endpoint	_	_	I-Premise
234	.	_	_	I-Premise

235	Additionally	_	_	B-Premise
236	for	_	_	I-Premise
237	responders	_	_	I-Premise
238	,	_	_	I-Premise
239	assessments	_	_	I-Premise
240	of	_	_	I-Premise
241	skin	_	_	I-Premise
242	severity	_	_	I-Premise
243	and	_	_	I-Premise
244	pruritus	_	_	I-Premise
245	severity	_	_	I-Premise
246	showed	_	_	I-Premise
247	significant	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	or	_	_	I-Premise
252	=	_	_	I-Premise
253	0.05	_	_	I-Premise
254	)	_	_	I-Premise
255	improvements	_	_	I-Premise
256	at	_	_	I-Premise
257	study	_	_	I-Premise
258	endpoint	_	_	I-Premise
259	compared	_	_	I-Premise
260	with	_	_	I-Premise
261	baseline	_	_	I-Premise
262	.	_	_	I-Premise

263	Adverse	_	_	B-Premise
264	transfusion-related	_	_	I-Premise
265	events	_	_	I-Premise
266	(	_	_	I-Premise
267	eg	_	_	I-Premise
268	,	_	_	I-Premise
269	hypersensitivity	_	_	I-Premise
270	reactions	_	_	I-Premise
271	,	_	_	I-Premise
272	flu-like	_	_	I-Premise
273	syndrome	_	_	I-Premise
274	)	_	_	I-Premise
275	were	_	_	I-Premise
276	common	_	_	I-Premise
277	during	_	_	I-Premise
278	cycles	_	_	I-Premise
279	1	_	_	I-Premise
280	and	_	_	I-Premise
281	2	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	vascular-leak	_	_	I-Premise
285	syndrome	_	_	I-Premise
286	occurred	_	_	I-Premise
287	in	_	_	I-Premise
288	25	_	_	I-Premise
289	%	_	_	I-Premise
290	of	_	_	I-Premise
291	patients	_	_	I-Premise
292	.	_	_	I-Premise

293	Denileukin	_	_	B-Claim
294	diftitox	_	_	I-Claim
295	was	_	_	I-Claim
296	not	_	_	I-Claim
297	associated	_	_	I-Claim
298	with	_	_	I-Claim
299	any	_	_	I-Claim
300	clinically	_	_	I-Claim
301	significant	_	_	I-Claim
302	myelosuppression	_	_	I-Claim
303	.	_	_	I-Claim

304	Heavily	_	_	B-Claim
305	pretreated	_	_	I-Claim
306	patients	_	_	I-Claim
307	with	_	_	I-Claim
308	advanced	_	_	I-Claim
309	and/or	_	_	I-Claim
310	recurrent	_	_	I-Claim
311	CTCL	_	_	I-Claim
312	who	_	_	I-Claim
313	responded	_	_	I-Claim
314	to	_	_	I-Claim
315	denileukin	_	_	I-Claim
316	diftitox	_	_	I-Claim
317	therapy	_	_	I-Claim
318	showed	_	_	I-Claim
319	significant	_	_	I-Claim
320	improvements	_	_	I-Claim
321	in	_	_	I-Claim
322	self-rated	_	_	I-Claim
323	overall	_	_	I-Claim
324	QOL	_	_	I-Claim
325	,	_	_	I-Claim
326	skin	_	_	I-Claim
327	appearance	_	_	I-Claim
328	,	_	_	I-Claim
329	and	_	_	I-Claim
330	pruritus	_	_	I-Claim
331	severity	_	_	I-Claim
332	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	recombinant	_	_	O
6	human	_	_	O
7	erythropoietin	_	_	O
8	(	_	_	O
9	epoetin	_	_	O
10	beta	_	_	O
11	)	_	_	O
12	on	_	_	O
13	anemia	_	_	O
14	,	_	_	O
15	transfusion	_	_	O
16	need	_	_	O
17	,	_	_	O
18	and	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	in	_	_	O
26	severely	_	_	O
27	anemic	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	low-grade	_	_	O
31	non-Hodgkin	_	_	O
32	's	_	_	O
33	lymphoma	_	_	O
34	(	_	_	O
35	NHL	_	_	O
36	)	_	_	O
37	,	_	_	O
38	chronic	_	_	O
39	lymphocytic	_	_	O
40	leukemia	_	_	O
41	(	_	_	O
42	CLL	_	_	O
43	)	_	_	O
44	,	_	_	O
45	or	_	_	O
46	multiple	_	_	O
47	myeloma	_	_	O
48	(	_	_	O
49	MM	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Transfusion-dependent	_	_	O
53	patients	_	_	O
54	with	_	_	O
55	NHL	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	106	_	_	O
60	)	_	_	O
61	,	_	_	O
62	CLL	_	_	O
63	(	_	_	O
64	n	_	_	O
65	=	_	_	O
66	126	_	_	O
67	)	_	_	O
68	,	_	_	O
69	or	_	_	O
70	MM	_	_	O
71	(	_	_	O
72	n	_	_	O
73	=	_	_	O
74	117	_	_	O
75	)	_	_	O
76	and	_	_	O
77	a	_	_	O
78	low	_	_	O
79	serum	_	_	O
80	erythropoietin	_	_	O
81	concentration	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	epoetin	_	_	O
87	beta	_	_	O
88	150	_	_	O
89	IU/kg	_	_	O
90	or	_	_	O
91	placebo	_	_	O
92	subcutaneously	_	_	O
93	three	_	_	O
94	times	_	_	O
95	a	_	_	O
96	week	_	_	O
97	for	_	_	O
98	16	_	_	O
99	weeks	_	_	O
100	.	_	_	O

101	Primary	_	_	O
102	efficacy	_	_	O
103	criteria	_	_	O
104	were	_	_	O
105	transfusion-free	_	_	O
106	and	_	_	O
107	transfusion-	_	_	O
108	and	_	_	O
109	severe	_	_	O
110	anemia-free	_	_	O
111	survival	_	_	O
112	(	_	_	O
113	hemoglobin	_	_	O
114	[	_	_	O
115	Hb	_	_	O
116	]	_	_	O
117	>	_	_	O
118	8.5	_	_	O
119	g/dL	_	_	O
120	)	_	_	O
121	between	_	_	O
122	weeks	_	_	O
123	5	_	_	O
124	to	_	_	O
125	16	_	_	O
126	.	_	_	O

127	Response	_	_	O
128	was	_	_	O
129	defined	_	_	O
130	as	_	_	O
131	an	_	_	O
132	increase	_	_	O
133	in	_	_	O
134	Hb	_	_	O
135	>	_	_	O
136	or	_	_	O
137	=	_	_	O
138	2	_	_	O
139	g/dL	_	_	O
140	with	_	_	O
141	elimination	_	_	O
142	of	_	_	O
143	transfusion	_	_	O
144	need	_	_	O
145	.	_	_	O

146	QOL	_	_	O
147	was	_	_	O
148	assessed	_	_	O
149	by	_	_	O
150	the	_	_	O
151	Functional	_	_	O
152	Assessment	_	_	O
153	of	_	_	O
154	Cancer	_	_	O
155	Therapy	_	_	O
156	scale	_	_	O
157	.	_	_	O

158	Transfusion-free	_	_	B-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	=.0012	_	_	I-Premise
162	)	_	_	I-Premise
163	survival	_	_	I-Premise
164	and	_	_	I-Premise
165	transfusion-	_	_	I-Premise
166	and	_	_	I-Premise
167	severe	_	_	I-Premise
168	anemia-free	_	_	I-Premise
169	survival	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=.0001	_	_	I-Premise
173	)	_	_	I-Premise
174	were	_	_	I-Premise
175	significantly	_	_	I-Premise
176	greater	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	epoetin	_	_	I-Premise
180	beta	_	_	I-Premise
181	group	_	_	I-Premise
182	versus	_	_	I-Premise
183	placebo	_	_	I-Premise
184	(	_	_	I-Premise
185	Wald	_	_	I-Premise
186	chi	_	_	I-Premise
187	(	_	_	I-Premise
188	2	_	_	I-Premise
189	)	_	_	I-Premise
190	test	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	giving	_	_	I-Premise
194	a	_	_	I-Premise
195	relative	_	_	I-Premise
196	risk	_	_	I-Premise
197	reduction	_	_	I-Premise
198	of	_	_	I-Premise
199	43	_	_	I-Premise
200	%	_	_	I-Premise
201	and	_	_	I-Premise
202	51	_	_	I-Premise
203	%	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	.	_	_	I-Premise

207	The	_	_	B-Premise
208	response	_	_	I-Premise
209	rate	_	_	I-Premise
210	was	_	_	I-Premise
211	67	_	_	I-Premise
212	%	_	_	I-Premise
213	and	_	_	I-Premise
214	27	_	_	I-Premise
215	%	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	epoetin	_	_	I-Premise
219	beta	_	_	I-Premise
220	versus	_	_	I-Premise
221	the	_	_	I-Premise
222	placebo	_	_	I-Premise
223	group	_	_	I-Premise
224	,	_	_	I-Premise
225	respectively	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	.0001	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	After	_	_	B-Premise
233	12	_	_	I-Premise
234	and	_	_	I-Premise
235	16	_	_	I-Premise
236	weeks	_	_	I-Premise
237	of	_	_	I-Premise
238	treatment	_	_	I-Premise
239	,	_	_	I-Premise
240	QOL	_	_	I-Premise
241	significantly	_	_	I-Premise
242	improved	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	epoetin	_	_	I-Premise
246	beta	_	_	I-Premise
247	group	_	_	I-Premise
248	compared	_	_	I-Premise
249	with	_	_	I-Premise
250	placebo	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.05	_	_	I-Premise
255	)	_	_	I-Premise
256	;	_	_	I-Premise
257	this	_	_	B-Premise
258	improvement	_	_	I-Premise
259	correlated	_	_	I-Premise
260	with	_	_	I-Premise
261	an	_	_	I-Premise
262	increase	_	_	I-Premise
263	in	_	_	I-Premise
264	Hb	_	_	I-Premise
265	concentration	_	_	I-Premise
266	(	_	_	I-Premise
267	>	_	_	I-Premise
268	or	_	_	I-Premise
269	=	_	_	I-Premise
270	2	_	_	I-Premise
271	g/dL	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	A	_	_	O
275	target	_	_	O
276	Hb	_	_	O
277	that	_	_	O
278	could	_	_	O
279	be	_	_	O
280	generally	_	_	O
281	recommended	_	_	O
282	could	_	_	O
283	not	_	_	O
284	be	_	_	O
285	identified	_	_	O
286	.	_	_	O

287	Many	_	_	B-Claim
288	severely	_	_	I-Claim
289	anemic	_	_	I-Claim
290	and	_	_	I-Claim
291	transfusion-dependent	_	_	I-Claim
292	patients	_	_	I-Claim
293	with	_	_	I-Claim
294	advanced	_	_	I-Claim
295	MM	_	_	I-Claim
296	,	_	_	I-Claim
297	NHL	_	_	I-Claim
298	,	_	_	I-Claim
299	and	_	_	I-Claim
300	CLL	_	_	I-Claim
301	and	_	_	I-Claim
302	a	_	_	I-Claim
303	low	_	_	I-Claim
304	performance	_	_	I-Claim
305	status	_	_	I-Claim
306	benefited	_	_	I-Claim
307	from	_	_	I-Claim
308	epoetin	_	_	I-Claim
309	therapy	_	_	I-Claim
310	,	_	_	I-Claim
311	with	_	_	I-Claim
312	elimination	_	_	I-Claim
313	of	_	_	I-Claim
314	severe	_	_	I-Claim
315	anemia	_	_	I-Claim
316	and	_	_	I-Claim
317	transfusion	_	_	I-Claim
318	need	_	_	I-Claim
319	,	_	_	I-Claim
320	and	_	_	I-Claim
321	improvement	_	_	I-Claim
322	in	_	_	I-Claim
323	QOL	_	_	I-Claim
324	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	trial	_	_	O
3	compared	_	_	O
4	three	_	_	O
5	chemotherapy	_	_	O
6	regimens	_	_	O
7	in	_	_	O
8	the	_	_	O
9	first-line	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	advanced	_	_	O
13	colorectal	_	_	O
14	cancer	_	_	O
15	,	_	_	O
16	in	_	_	O
17	terms	_	_	O
18	of	_	_	O
19	their	_	_	O
20	effect	_	_	O
21	on	_	_	O
22	overall	_	_	O
23	and	_	_	O
24	progression-free	_	_	O
25	survival	_	_	O
26	;	_	_	O
27	other	_	_	O
28	endpoints	_	_	O
29	included	_	_	O
30	toxicity	_	_	O
31	,	_	_	O
32	symptom	_	_	O
33	palliation	_	_	O
34	,	_	_	O
35	and	_	_	O
36	quality	_	_	O
37	of	_	_	O
38	life	_	_	O
39	.	_	_	O

40	905	_	_	O
41	patients	_	_	O
42	were	_	_	O
43	randomly	_	_	O
44	assigned	_	_	O
45	the	_	_	O
46	de	_	_	O
47	Gramont	_	_	O
48	regimen	_	_	O
49	(	_	_	O
50	n=303	_	_	O
51	;	_	_	O
52	folinic	_	_	O
53	acid	_	_	O
54	200	_	_	O
55	mg/m	_	_	O
56	(	_	_	O
57	2	_	_	O
58	)	_	_	O
59	,	_	_	O
60	fluorouracil	_	_	O
61	bolus	_	_	O
62	400	_	_	O
63	mg/m	_	_	O
64	(	_	_	O
65	2	_	_	O
66	)	_	_	O
67	,	_	_	O
68	and	_	_	O
69	infusion	_	_	O
70	600	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	on	_	_	O
76	days	_	_	O
77	1	_	_	O
78	and	_	_	O
79	2	_	_	O
80	,	_	_	O
81	repeated	_	_	O
82	every	_	_	O
83	14	_	_	O
84	days	_	_	O
85	)	_	_	O
86	,	_	_	O
87	the	_	_	O
88	Lokich	_	_	O
89	regimen	_	_	O
90	(	_	_	O
91	n=301	_	_	O
92	;	_	_	O
93	protracted	_	_	O
94	venous	_	_	O
95	infusion	_	_	O
96	of	_	_	O
97	fluorouracil	_	_	O
98	300	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	daily	_	_	O
104	)	_	_	O
105	,	_	_	O
106	or	_	_	O
107	raltitrexed	_	_	O
108	(	_	_	O
109	n=301	_	_	O
110	;	_	_	O
111	3	_	_	O
112	mg/m	_	_	O
113	(	_	_	O
114	2	_	_	O
115	)	_	_	O
116	intravenously	_	_	O
117	every	_	_	O
118	21	_	_	O
119	days	_	_	O
120	)	_	_	O
121	.	_	_	O

122	Analyses	_	_	O
123	were	_	_	O
124	by	_	_	O
125	intention	_	_	O
126	to	_	_	O
127	treat	_	_	O
128	.	_	_	O

129	Median	_	_	O
130	follow-up	_	_	O
131	of	_	_	O
132	survivors	_	_	O
133	was	_	_	O
134	67	_	_	O
135	weeks	_	_	O
136	.	_	_	O

137	For	_	_	B-Premise
138	the	_	_	I-Premise
139	de	_	_	I-Premise
140	Gramont	_	_	I-Premise
141	,	_	_	I-Premise
142	Lokich	_	_	I-Premise
143	,	_	_	I-Premise
144	and	_	_	I-Premise
145	raltitrexed	_	_	I-Premise
146	groups	_	_	I-Premise
147	,	_	_	I-Premise
148	respectively	_	_	I-Premise
149	,	_	_	I-Premise
150	median	_	_	I-Premise
151	survival	_	_	I-Premise
152	was	_	_	I-Premise
153	294	_	_	I-Premise
154	,	_	_	I-Premise
155	302	_	_	I-Premise
156	,	_	_	I-Premise
157	and	_	_	I-Premise
158	266	_	_	I-Premise
159	days	_	_	I-Premise
160	.	_	_	I-Premise

161	The	_	_	B-Premise
162	hazard	_	_	I-Premise
163	ratios	_	_	I-Premise
164	for	_	_	I-Premise
165	overall	_	_	I-Premise
166	survival	_	_	I-Premise
167	were	_	_	I-Premise
168	0.88	_	_	I-Premise
169	(	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	0.70-1.12	_	_	I-Premise
174	,	_	_	I-Premise
175	p=0.17	_	_	I-Premise
176	)	_	_	I-Premise
177	for	_	_	I-Premise
178	de	_	_	I-Premise
179	Gramont	_	_	I-Premise
180	versus	_	_	I-Premise
181	Lokich	_	_	I-Premise
182	,	_	_	I-Premise
183	and	_	_	I-Premise
184	0.99	_	_	I-Premise
185	(	_	_	I-Premise
186	0.79-1.25	_	_	I-Premise
187	,	_	_	I-Premise
188	p=0.94	_	_	I-Premise
189	)	_	_	I-Premise
190	for	_	_	I-Premise
191	de	_	_	I-Premise
192	Gramont	_	_	I-Premise
193	versus	_	_	I-Premise
194	raltitrexed	_	_	I-Premise
195	.	_	_	I-Premise

196	An	_	_	B-Premise
197	increase	_	_	I-Premise
198	in	_	_	I-Premise
199	treatment-related	_	_	I-Premise
200	deaths	_	_	I-Premise
201	was	_	_	I-Premise
202	seen	_	_	I-Premise
203	on	_	_	I-Premise
204	raltitrexed	_	_	I-Premise
205	(	_	_	I-Premise
206	de	_	_	I-Premise
207	Gramont	_	_	I-Premise
208	one	_	_	I-Premise
209	,	_	_	I-Premise
210	Lokich	_	_	I-Premise
211	two	_	_	I-Premise
212	,	_	_	I-Premise
213	raltitrexed	_	_	I-Premise
214	18	_	_	I-Premise
215	)	_	_	I-Premise
216	due	_	_	I-Premise
217	to	_	_	I-Premise
218	combined	_	_	I-Premise
219	gastrointestinal	_	_	I-Premise
220	and	_	_	I-Premise
221	haematological	_	_	I-Premise
222	toxicity	_	_	I-Premise
223	.	_	_	I-Premise

224	Patients	_	_	B-Premise
225	'	_	_	I-Premise
226	assessment	_	_	I-Premise
227	of	_	_	I-Premise
228	quality	_	_	I-Premise
229	of	_	_	I-Premise
230	life	_	_	I-Premise
231	showed	_	_	I-Premise
232	that	_	_	I-Premise
233	raltitrexed	_	_	I-Premise
234	was	_	_	I-Premise
235	inferior	_	_	I-Premise
236	to	_	_	I-Premise
237	the	_	_	I-Premise
238	fluorouracil-based	_	_	I-Premise
239	regimens	_	_	I-Premise
240	,	_	_	I-Premise
241	especially	_	_	I-Premise
242	in	_	_	I-Premise
243	terms	_	_	I-Premise
244	of	_	_	I-Premise
245	palliation	_	_	I-Premise
246	and	_	_	I-Premise
247	functioning	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Claim
250	deGramont	_	_	I-Claim
251	and	_	_	I-Claim
252	Lokich	_	_	I-Claim
253	regimens	_	_	I-Claim
254	were	_	_	I-Claim
255	similar	_	_	I-Claim
256	in	_	_	I-Claim
257	terms	_	_	I-Claim
258	of	_	_	I-Claim
259	survival	_	_	I-Claim
260	,	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	,	_	_	I-Claim
265	and	_	_	I-Claim
266	response	_	_	I-Claim
267	rates	_	_	I-Claim
268	.	_	_	I-Claim

269	The	_	_	B-Claim
270	Lokich	_	_	I-Claim
271	regimen	_	_	I-Claim
272	was	_	_	I-Claim
273	associated	_	_	I-Claim
274	with	_	_	I-Claim
275	more	_	_	I-Claim
276	central	_	_	I-Claim
277	line	_	_	I-Claim
278	complications	_	_	I-Claim
279	and	_	_	I-Claim
280	hand-foot	_	_	I-Claim
281	syndrome	_	_	I-Claim
282	.	_	_	I-Claim

283	Raltitrexed	_	_	B-Claim
284	showed	_	_	I-Claim
285	similar	_	_	I-Claim
286	response	_	_	I-Claim
287	rates	_	_	I-Claim
288	and	_	_	I-Claim
289	overall	_	_	I-Claim
290	survival	_	_	I-Claim
291	to	_	_	I-Claim
292	the	_	_	I-Claim
293	de	_	_	I-Claim
294	Gramont	_	_	I-Claim
295	regimen	_	_	I-Claim
296	and	_	_	I-Claim
297	was	_	_	I-Claim
298	easier	_	_	I-Claim
299	to	_	_	I-Claim
300	administer	_	_	I-Claim
301	,	_	_	I-Claim
302	but	_	_	B-Claim
303	resulted	_	_	I-Claim
304	in	_	_	I-Claim
305	greater	_	_	I-Claim
306	toxicity	_	_	I-Claim
307	and	_	_	I-Claim
308	inferior	_	_	I-Claim
309	quality	_	_	I-Claim
310	of	_	_	I-Claim
311	life	_	_	I-Claim
312	.	_	_	I-Claim


0	In	_	_	O
1	the	_	_	O
2	Asia-Pacific	_	_	O
3	region	_	_	O
4	and	_	_	O
5	elsewhere	_	_	O
6	,	_	_	O
7	almost	_	_	O
8	85	_	_	O
9	%	_	_	O
10	of	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	hepatocellular	_	_	O
14	carcinoma	_	_	O
15	(	_	_	O
16	HCC	_	_	O
17	)	_	_	O
18	are	_	_	O
19	inoperable	_	_	O
20	at	_	_	O
21	diagnosis	_	_	O
22	and	_	_	O
23	have	_	_	O
24	a	_	_	O
25	dismal	_	_	O
26	prognosis	_	_	O
27	.	_	_	O

28	Tamoxifen	_	_	B-Claim
29	(	_	_	I-Claim
30	TMX	_	_	I-Claim
31	)	_	_	I-Claim
32	is	_	_	I-Claim
33	believed	_	_	I-Claim
34	to	_	_	I-Claim
35	inhibit	_	_	I-Claim
36	HCC	_	_	I-Claim
37	positive	_	_	I-Claim
38	for	_	_	I-Claim
39	estrogen	_	_	I-Claim
40	receptor	_	_	I-Claim
41	(	_	_	I-Claim
42	ER	_	_	I-Claim
43	)	_	_	I-Claim
44	,	_	_	I-Claim
45	but	_	_	I-Claim
46	most	_	_	I-Claim
47	HCCs	_	_	I-Claim
48	are	_	_	I-Claim
49	ER	_	_	I-Claim
50	negative	_	_	I-Claim
51	.	_	_	I-Claim

52	Results	_	_	B-Claim
53	of	_	_	I-Claim
54	previous	_	_	I-Claim
55	phase	_	_	I-Claim
56	3	_	_	I-Claim
57	trials	_	_	I-Claim
58	in	_	_	I-Claim
59	inoperable	_	_	I-Claim
60	HCC	_	_	I-Claim
61	have	_	_	I-Claim
62	been	_	_	I-Claim
63	conflicting	_	_	I-Claim
64	and	_	_	I-Claim
65	inconclusive	_	_	I-Claim
66	.	_	_	I-Claim

67	At	_	_	B-Claim
68	higher	_	_	I-Claim
69	doses	_	_	I-Claim
70	,	_	_	I-Claim
71	however	_	_	I-Claim
72	,	_	_	I-Claim
73	TMX	_	_	I-Claim
74	inhibits	_	_	I-Claim
75	HCC	_	_	I-Claim
76	through	_	_	I-Claim
77	ER-independent	_	_	I-Claim
78	mechanisms	_	_	I-Claim
79	.	_	_	I-Claim

80	A	_	_	O
81	multicenter	_	_	O
82	randomized	_	_	O
83	controlled	_	_	O
84	trial	_	_	O
85	was	_	_	O
86	performed	_	_	O
87	to	_	_	O
88	assess	_	_	O
89	the	_	_	O
90	role	_	_	O
91	of	_	_	O
92	high-dose	_	_	O
93	TMX	_	_	O
94	versus	_	_	O
95	placebo	_	_	O
96	(	_	_	O
97	P	_	_	O
98	)	_	_	O
99	in	_	_	O
100	the	_	_	O
101	treatment	_	_	O
102	of	_	_	O
103	patients	_	_	O
104	with	_	_	O
105	inoperable	_	_	O
106	HCC	_	_	O
107	with	_	_	O
108	respect	_	_	O
109	to	_	_	O
110	survival	_	_	O
111	and	_	_	O
112	quality	_	_	O
113	of	_	_	O
114	life	_	_	O
115	(	_	_	O
116	QoL	_	_	O
117	)	_	_	O
118	.	_	_	O

119	A	_	_	O
120	total	_	_	O
121	of	_	_	O
122	329	_	_	O
123	patients	_	_	O
124	from	_	_	O
125	10	_	_	O
126	centers	_	_	O
127	in	_	_	O
128	9	_	_	O
129	countries	_	_	O
130	in	_	_	O
131	the	_	_	O
132	Asia-Pacific	_	_	O
133	region	_	_	O
134	enrolled	_	_	O
135	in	_	_	O
136	a	_	_	O
137	double-blind	_	_	O
138	randomized	_	_	O
139	controlled	_	_	O
140	trial	_	_	O
141	of	_	_	O
142	TMX	_	_	O
143	120	_	_	O
144	mg/d	_	_	O
145	(	_	_	O
146	TMX120	_	_	O
147	)	_	_	O
148	against	_	_	O
149	P	_	_	O
150	as	_	_	O
151	a	_	_	O
152	control	_	_	O
153	arm	_	_	O
154	with	_	_	O
155	an	_	_	O
156	intermediate	_	_	O
157	dosage	_	_	O
158	of	_	_	O
159	TMX	_	_	O
160	60	_	_	O
161	mg/d	_	_	O
162	(	_	_	O
163	TMX60	_	_	O
164	)	_	_	O
165	to	_	_	O
166	assess	_	_	O
167	possible	_	_	O
168	dose	_	_	O
169	response	_	_	O
170	.	_	_	O

171	An	_	_	O
172	independent	_	_	O
173	data	_	_	O
174	monitoring	_	_	O
175	committee	_	_	O
176	reviewed	_	_	O
177	all	_	_	O
178	aspects	_	_	O
179	of	_	_	O
180	the	_	_	O
181	trial	_	_	O
182	.	_	_	O

183	QoL	_	_	O
184	was	_	_	O
185	assessed	_	_	O
186	using	_	_	O
187	the	_	_	O
188	European	_	_	O
189	Organization	_	_	O
190	for	_	_	O
191	Research	_	_	O
192	and	_	_	O
193	Treatment	_	_	O
194	of	_	_	O
195	Cancer	_	_	O
196	QLQ-C30	_	_	O
197	questionnaire	_	_	O
198	.	_	_	O

199	Three-month	_	_	B-Premise
200	survival	_	_	I-Premise
201	rates	_	_	I-Premise
202	for	_	_	I-Premise
203	the	_	_	I-Premise
204	P	_	_	I-Premise
205	,	_	_	I-Premise
206	TMX60	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	TMX120	_	_	I-Premise
210	groups	_	_	I-Premise
211	were	_	_	I-Premise
212	44	_	_	I-Premise
213	%	_	_	I-Premise
214	,	_	_	I-Premise
215	41	_	_	I-Premise
216	%	_	_	I-Premise
217	,	_	_	I-Premise
218	and	_	_	I-Premise
219	35	_	_	I-Premise
220	%	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	,	_	_	I-Premise
224	with	_	_	I-Premise
225	a	_	_	I-Premise
226	statistically	_	_	I-Premise
227	significant	_	_	I-Premise
228	trend	_	_	I-Premise
229	difference	_	_	I-Premise
230	in	_	_	I-Premise
231	survival	_	_	I-Premise
232	across	_	_	I-Premise
233	the	_	_	I-Premise
234	3	_	_	I-Premise
235	treatment	_	_	I-Premise
236	regimens	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	=.011	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	There	_	_	B-Premise
243	was	_	_	I-Premise
244	a	_	_	I-Premise
245	significantly	_	_	I-Premise
246	higher	_	_	I-Premise
247	risk	_	_	I-Premise
248	of	_	_	I-Premise
249	death	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	TMX120	_	_	I-Premise
253	group	_	_	I-Premise
254	compared	_	_	I-Premise
255	with	_	_	I-Premise
256	the	_	_	I-Premise
257	P	_	_	I-Premise
258	group	_	_	I-Premise
259	(	_	_	I-Premise
260	hazard	_	_	I-Premise
261	ratio	_	_	I-Premise
262	,	_	_	I-Premise
263	1.39	_	_	I-Premise
264	;	_	_	I-Premise
265	95	_	_	I-Premise
266	%	_	_	I-Premise
267	confidence	_	_	I-Premise
268	interval	_	_	I-Premise
269	,	_	_	I-Premise
270	1.07-1.81	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Adverse	_	_	B-Premise
274	drug	_	_	I-Premise
275	reactions	_	_	I-Premise
276	were	_	_	I-Premise
277	reported	_	_	I-Premise
278	in	_	_	I-Premise
279	3	_	_	I-Premise
280	%	_	_	I-Premise
281	(	_	_	I-Premise
282	9	_	_	I-Premise
283	patients	_	_	I-Premise
284	)	_	_	I-Premise
285	,	_	_	I-Premise
286	and	_	_	O
287	8	_	_	B-Premise
288	patients	_	_	I-Premise
289	were	_	_	I-Premise
290	lost	_	_	I-Premise
291	to	_	_	I-Premise
292	follow-up	_	_	I-Premise
293	.	_	_	I-Premise

294	In	_	_	O
295	conclusion	_	_	O
296	,	_	_	O
297	TMX	_	_	B-Claim
298	does	_	_	I-Claim
299	not	_	_	I-Claim
300	prolong	_	_	I-Claim
301	survival	_	_	I-Claim
302	in	_	_	I-Claim
303	patients	_	_	I-Claim
304	with	_	_	I-Claim
305	inoperable	_	_	I-Claim
306	HCC	_	_	I-Claim
307	and	_	_	I-Claim
308	has	_	_	I-Claim
309	an	_	_	I-Claim
310	increasingly	_	_	I-Claim
311	negative	_	_	I-Claim
312	impact	_	_	I-Claim
313	with	_	_	I-Claim
314	increasing	_	_	I-Claim
315	dose	_	_	I-Claim
316	.	_	_	I-Claim

317	No	_	_	B-Claim
318	appreciable	_	_	I-Claim
319	advantage	_	_	I-Claim
320	to	_	_	I-Claim
321	QoL	_	_	I-Claim
322	with	_	_	I-Claim
323	TMX	_	_	I-Claim
324	was	_	_	I-Claim
325	observed	_	_	I-Claim
326	.	_	_	I-Claim


0	A	_	_	O
1	multicenter	_	_	O
2	trial	_	_	O
3	was	_	_	O
4	conducted	_	_	O
5	to	_	_	O
6	determine	_	_	O
7	the	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	toxicity	_	_	O
11	of	_	_	O
12	escalating	_	_	O
13	dosages	_	_	O
14	of	_	_	O
15	liposomal	_	_	O
16	tretinoin	_	_	O
17	(	_	_	O
18	all-trans-retinoic	_	_	O
19	acid	_	_	O
20	)	_	_	O
21	administered	_	_	O
22	once	_	_	O
23	or	_	_	O
24	three	_	_	O
25	times	_	_	O
26	weekly	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	acquired	_	_	O
31	immunodeficiency	_	_	O
32	syndrome	_	_	O
33	(	_	_	O
34	AIDS	_	_	O
35	)	_	_	O
36	-associated	_	_	O
37	Kaposi	_	_	O
38	sarcoma	_	_	O
39	.	_	_	O

40	Seventy-six	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	acquired	_	_	O
44	immunodeficiency	_	_	O
45	syndrome	_	_	O
46	(	_	_	O
47	AIDS	_	_	O
48	)	_	_	O
49	-associated	_	_	O
50	Kaposi	_	_	O
51	sarcoma	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	receive	_	_	O
56	the	_	_	O
57	study	_	_	O
58	drug	_	_	O
59	either	_	_	O
60	once	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	30	_	_	O
65	)	_	_	O
66	or	_	_	O
67	3	_	_	O
68	times	_	_	O
69	weekly	_	_	O
70	(	_	_	O
71	n	_	_	O
72	=	_	_	O
73	46	_	_	O
74	)	_	_	O
75	.	_	_	O

76	The	_	_	O
77	starting	_	_	O
78	dosage	_	_	O
79	was	_	_	O
80	60	_	_	O
81	mg/m	_	_	O
82	(	_	_	O
83	2	_	_	O
84	)	_	_	O
85	,	_	_	O
86	which	_	_	O
87	was	_	_	O
88	escalated	_	_	O
89	to	_	_	O
90	90	_	_	O
91	mg/m	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	and	_	_	O
96	then	_	_	O
97	120	_	_	O
98	mg/m	_	_	O
99	(	_	_	O
100	2	_	_	O
101	)	_	_	O
102	if	_	_	O
103	the	_	_	O
104	drug	_	_	O
105	was	_	_	O
106	well	_	_	O
107	tolerated	_	_	O
108	(	_	_	O
109	<	_	_	O
110	or=	_	_	O
111	Grade	_	_	O
112	2	_	_	O
113	toxicities	_	_	O
114	[	_	_	O
115	according	_	_	O
116	to	_	_	O
117	the	_	_	O
118	Southwest	_	_	O
119	Oncology	_	_	O
120	Group	_	_	O
121	toxicity	_	_	O
122	scale	_	_	O
123	]	_	_	O
124	)	_	_	O
125	.	_	_	O

126	Four	_	_	O
127	weeks	_	_	O
128	of	_	_	O
129	therapy	_	_	O
130	constituted	_	_	O
131	1	_	_	O
132	cycle	_	_	O
133	;	_	_	O
134	patients	_	_	O
135	could	_	_	O
136	receive	_	_	O
137	up	_	_	O
138	to	_	_	O
139	8	_	_	O
140	cycles	_	_	O
141	and	_	_	O
142	those	_	_	O
143	who	_	_	O
144	completed	_	_	O
145	8	_	_	O
146	cycles	_	_	O
147	were	_	_	O
148	given	_	_	O
149	the	_	_	O
150	option	_	_	O
151	of	_	_	O
152	receiving	_	_	O
153	extended	_	_	O
154	therapy	_	_	O
155	.	_	_	O

156	Clinical	_	_	O
157	response	_	_	O
158	was	_	_	O
159	defined	_	_	O
160	as	_	_	O
161	complete	_	_	O
162	response	_	_	O
163	(	_	_	O
164	CR	_	_	O
165	)	_	_	O
166	,	_	_	O
167	partial	_	_	O
168	response	_	_	O
169	(	_	_	O
170	PR	_	_	O
171	)	_	_	O
172	,	_	_	O
173	or	_	_	O
174	stable	_	_	O
175	disease	_	_	O
176	(	_	_	O
177	SD	_	_	O
178	)	_	_	O
179	.	_	_	O

180	Efficacy	_	_	O
181	was	_	_	O
182	assessed	_	_	O
183	after	_	_	O
184	the	_	_	O
185	completion	_	_	O
186	of	_	_	O
187	3	_	_	O
188	treatment	_	_	O
189	cycles	_	_	O
190	;	_	_	O
191	28.9	_	_	O
192	%	_	_	O
193	of	_	_	O
194	patients	_	_	O
195	(	_	_	O
196	22	_	_	O
197	of	_	_	O
198	76	_	_	O
199	patients	_	_	O
200	)	_	_	O
201	responded	_	_	O
202	(	_	_	O
203	no	_	_	O
204	CRs	_	_	O
205	,	_	_	O
206	1	_	_	O
207	PR	_	_	O
208	,	_	_	O
209	and	_	_	O
210	21	_	_	O
211	SDs	_	_	O
212	)	_	_	O
213	.	_	_	O

214	Among	_	_	B-Premise
215	the	_	_	I-Premise
216	patients	_	_	I-Premise
217	receiving	_	_	I-Premise
218	treatment	_	_	I-Premise
219	3	_	_	I-Premise
220	times	_	_	I-Premise
221	weekly	_	_	I-Premise
222	,	_	_	I-Premise
223	16	_	_	I-Premise
224	of	_	_	I-Premise
225	49	_	_	I-Premise
226	patients	_	_	I-Premise
227	(	_	_	I-Premise
228	32.7	_	_	I-Premise
229	%	_	_	I-Premise
230	)	_	_	I-Premise
231	achieved	_	_	I-Premise
232	a	_	_	I-Premise
233	clinical	_	_	I-Premise
234	response	_	_	I-Premise
235	at	_	_	I-Premise
236	the	_	_	I-Premise
237	end	_	_	I-Premise
238	of	_	_	I-Premise
239	the	_	_	I-Premise
240	third	_	_	I-Premise
241	treatment	_	_	I-Premise
242	cycle	_	_	I-Premise
243	(	_	_	I-Premise
244	no	_	_	I-Premise
245	CRs	_	_	I-Premise
246	,	_	_	I-Premise
247	1	_	_	I-Premise
248	PR	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	15	_	_	I-Premise
252	SDs	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Concomitant	_	_	B-Premise
256	or	_	_	I-Premise
257	prior	_	_	I-Premise
258	use	_	_	I-Premise
259	of	_	_	I-Premise
260	protease	_	_	I-Premise
261	inhibitors	_	_	I-Premise
262	did	_	_	I-Premise
263	not	_	_	I-Premise
264	appear	_	_	I-Premise
265	to	_	_	I-Premise
266	affect	_	_	I-Premise
267	the	_	_	I-Premise
268	patient	_	_	I-Premise
269	's	_	_	I-Premise
270	response	_	_	I-Premise
271	to	_	_	I-Premise
272	treatment	_	_	I-Premise
273	(	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	0.183	_	_	I-Premise
277	)	_	_	I-Premise
278	.	_	_	I-Premise

279	Liposomal	_	_	B-Premise
280	tretinoin	_	_	I-Premise
281	is	_	_	I-Premise
282	a	_	_	I-Premise
283	new	_	_	I-Premise
284	therapeutic	_	_	I-Premise
285	agent	_	_	I-Premise
286	that	_	_	I-Premise
287	has	_	_	I-Premise
288	been	_	_	I-Premise
289	reported	_	_	I-Premise
290	to	_	_	I-Premise
291	have	_	_	I-Premise
292	some	_	_	I-Premise
293	clinical	_	_	I-Premise
294	activity	_	_	I-Premise
295	in	_	_	I-Premise
296	patients	_	_	I-Premise
297	with	_	_	I-Premise
298	AIDS-associated	_	_	I-Premise
299	Kaposi	_	_	I-Premise
300	sarcoma	_	_	I-Premise
301	.	_	_	I-Premise

302	A	_	_	B-Claim
303	three-times-per-week	_	_	I-Claim
304	dosing	_	_	I-Claim
305	schedule	_	_	I-Claim
306	was	_	_	I-Claim
307	noted	_	_	I-Claim
308	to	_	_	I-Claim
309	be	_	_	I-Claim
310	more	_	_	I-Claim
311	effective	_	_	I-Claim
312	compared	_	_	I-Claim
313	with	_	_	I-Claim
314	a	_	_	I-Claim
315	once-a-week	_	_	I-Claim
316	schedule	_	_	I-Claim
317	without	_	_	I-Claim
318	any	_	_	I-Claim
319	significant	_	_	I-Claim
320	difference	_	_	I-Claim
321	in	_	_	I-Claim
322	toxicity	_	_	I-Claim
323	reported	_	_	I-Claim
324	.	_	_	I-Claim


0	Radiotherapy	_	_	B-Claim
1	is	_	_	I-Claim
2	an	_	_	I-Claim
3	effective	_	_	I-Claim
4	palliative	_	_	I-Claim
5	treatment	_	_	I-Claim
6	for	_	_	I-Claim
7	cancer	_	_	I-Claim
8	patients	_	_	I-Claim
9	with	_	_	I-Claim
10	painful	_	_	I-Claim
11	bone	_	_	I-Claim
12	metastases	_	_	I-Claim
13	.	_	_	I-Claim

14	Although	_	_	O
15	single-	_	_	O
16	and	_	_	O
17	multiple-fraction	_	_	O
18	radiotherapy	_	_	O
19	are	_	_	O
20	thought	_	_	O
21	to	_	_	O
22	provide	_	_	O
23	equal	_	_	O
24	palliation	_	_	O
25	,	_	_	O
26	which	_	_	O
27	treatment	_	_	O
28	schedule	_	_	O
29	provides	_	_	O
30	better	_	_	O
31	value	_	_	O
32	for	_	_	O
33	the	_	_	O
34	money	_	_	O
35	is	_	_	O
36	unknown	_	_	O
37	.	_	_	O

38	We	_	_	O
39	compared	_	_	O
40	quality-adjusted	_	_	O
41	life	_	_	O
42	expectancy	_	_	O
43	(	_	_	O
44	the	_	_	O
45	overall	_	_	O
46	valuation	_	_	O
47	of	_	_	O
48	the	_	_	O
49	health	_	_	O
50	of	_	_	O
51	the	_	_	O
52	patients	_	_	O
53	)	_	_	O
54	and	_	_	O
55	societal	_	_	O
56	costs	_	_	O
57	for	_	_	O
58	patients	_	_	O
59	receiving	_	_	O
60	either	_	_	O
61	single-	_	_	O
62	or	_	_	O
63	multiple-fraction	_	_	O
64	radiotherapy	_	_	O
65	.	_	_	O

66	A	_	_	O
67	societal	_	_	O
68	cost-utility	_	_	O
69	analysis	_	_	O
70	was	_	_	O
71	performed	_	_	O
72	on	_	_	O
73	a	_	_	O
74	Dutch	_	_	O
75	randomized	_	_	O
76	,	_	_	O
77	controlled	_	_	O
78	trial	_	_	O
79	of	_	_	O
80	1157	_	_	O
81	patients	_	_	O
82	with	_	_	O
83	painful	_	_	O
84	bone	_	_	O
85	metastases	_	_	O
86	that	_	_	O
87	compared	_	_	O
88	pain	_	_	O
89	responses	_	_	O
90	and	_	_	O
91	quality	_	_	O
92	of	_	_	O
93	life	_	_	O
94	from	_	_	O
95	a	_	_	O
96	single-fraction	_	_	O
97	treatment	_	_	O
98	schedule	_	_	O
99	of	_	_	O
100	8	_	_	O
101	Gy	_	_	O
102	with	_	_	O
103	a	_	_	O
104	treatment	_	_	O
105	schedule	_	_	O
106	of	_	_	O
107	six	_	_	O
108	fractions	_	_	O
109	of	_	_	O
110	4	_	_	O
111	Gy	_	_	O
112	each	_	_	O
113	.	_	_	O

114	The	_	_	O
115	societal	_	_	O
116	values	_	_	O
117	of	_	_	O
118	life	_	_	O
119	expectancies	_	_	O
120	were	_	_	O
121	assessed	_	_	O
122	with	_	_	O
123	the	_	_	O
124	EuroQol	_	_	O
125	classification	_	_	O
126	system	_	_	O
127	(	_	_	O
128	EQ-5D	_	_	O
129	)	_	_	O
130	questionnaire	_	_	O
131	.	_	_	O

132	A	_	_	O
133	subset	_	_	O
134	of	_	_	O
135	166	_	_	O
136	patients	_	_	O
137	also	_	_	O
138	answered	_	_	O
139	additional	_	_	O
140	questionnaires	_	_	O
141	to	_	_	O
142	estimate	_	_	O
143	nonradiotherapy	_	_	O
144	and	_	_	O
145	nonmedical	_	_	O
146	costs	_	_	O
147	.	_	_	O

148	Statistical	_	_	O
149	tests	_	_	O
150	were	_	_	O
151	two-sided	_	_	O
152	.	_	_	O

153	Comparing	_	_	B-Premise
154	the	_	_	I-Premise
155	single-	_	_	I-Premise
156	and	_	_	I-Premise
157	multiple-fraction	_	_	I-Premise
158	radiotherapy	_	_	I-Premise
159	schedules	_	_	I-Premise
160	,	_	_	I-Premise
161	no	_	_	I-Premise
162	differences	_	_	I-Premise
163	were	_	_	I-Premise
164	found	_	_	I-Premise
165	in	_	_	I-Premise
166	life	_	_	I-Premise
167	expectancy	_	_	I-Premise
168	(	_	_	I-Premise
169	43.0	_	_	I-Premise
170	versus	_	_	I-Premise
171	40.4	_	_	I-Premise
172	weeks	_	_	I-Premise
173	,	_	_	I-Premise
174	P	_	_	I-Premise
175	=.20	_	_	I-Premise
176	)	_	_	I-Premise
177	or	_	_	I-Premise
178	quality-adjusted	_	_	I-Premise
179	life	_	_	I-Premise
180	expectancy	_	_	I-Premise
181	(	_	_	I-Premise
182	17.7	_	_	I-Premise
183	versus	_	_	I-Premise
184	16.0	_	_	I-Premise
185	weeks	_	_	I-Premise
186	,	_	_	I-Premise
187	P	_	_	I-Premise
188	=.21	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	The	_	_	B-Premise
192	estimated	_	_	I-Premise
193	cost	_	_	I-Premise
194	of	_	_	I-Premise
195	radiotherapy	_	_	I-Premise
196	,	_	_	I-Premise
197	including	_	_	I-Premise
198	retreatments	_	_	I-Premise
199	and	_	_	I-Premise
200	nonmedical	_	_	I-Premise
201	costs	_	_	I-Premise
202	,	_	_	I-Premise
203	was	_	_	I-Premise
204	statistically	_	_	I-Premise
205	significantly	_	_	I-Premise
206	lower	_	_	I-Premise
207	for	_	_	I-Premise
208	the	_	_	I-Premise
209	single-fraction	_	_	I-Premise
210	schedule	_	_	I-Premise
211	than	_	_	I-Premise
212	for	_	_	I-Premise
213	the	_	_	I-Premise
214	multiple-fraction	_	_	I-Premise
215	schedule	_	_	I-Premise
216	(	_	_	I-Premise
217	$	_	_	I-Premise
218	2438	_	_	I-Premise
219	versus	_	_	I-Premise
220	$	_	_	I-Premise
221	3311	_	_	I-Premise
222	,	_	_	I-Premise
223	difference	_	_	I-Premise
224	=	_	_	I-Premise
225	$	_	_	I-Premise
226	873	_	_	I-Premise
227	,	_	_	I-Premise
228	95	_	_	I-Premise
229	%	_	_	I-Premise
230	confidence	_	_	I-Premise
231	interval	_	_	I-Premise
232	[	_	_	I-Premise
233	CI	_	_	I-Premise
234	]	_	_	I-Premise
235	on	_	_	I-Premise
236	the	_	_	I-Premise
237	difference	_	_	I-Premise
238	=	_	_	I-Premise
239	$	_	_	I-Premise
240	449	_	_	I-Premise
241	to	_	_	I-Premise
242	$	_	_	I-Premise
243	1297	_	_	I-Premise
244	;	_	_	I-Premise
245	P	_	_	I-Premise
246	<	_	_	I-Premise
247	.001	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	The	_	_	B-Premise
251	estimated	_	_	I-Premise
252	difference	_	_	I-Premise
253	in	_	_	I-Premise
254	total	_	_	I-Premise
255	societal	_	_	I-Premise
256	costs	_	_	I-Premise
257	was	_	_	I-Premise
258	larger	_	_	I-Premise
259	,	_	_	I-Premise
260	also	_	_	I-Premise
261	in	_	_	I-Premise
262	favor	_	_	I-Premise
263	of	_	_	I-Premise
264	the	_	_	I-Premise
265	single-fraction	_	_	I-Premise
266	schedule	_	_	I-Premise
267	,	_	_	I-Premise
268	but	_	_	B-Premise
269	it	_	_	I-Premise
270	was	_	_	I-Premise
271	not	_	_	I-Premise
272	statistically	_	_	I-Premise
273	significant	_	_	I-Premise
274	(	_	_	I-Premise
275	$	_	_	I-Premise
276	4700	_	_	I-Premise
277	versus	_	_	I-Premise
278	$	_	_	I-Premise
279	6453	_	_	I-Premise
280	,	_	_	I-Premise
281	difference	_	_	I-Premise
282	=	_	_	I-Premise
283	$	_	_	I-Premise
284	1753	_	_	I-Premise
285	,	_	_	I-Premise
286	95	_	_	I-Premise
287	%	_	_	I-Premise
288	CI	_	_	I-Premise
289	on	_	_	I-Premise
290	the	_	_	I-Premise
291	difference	_	_	I-Premise
292	=	_	_	I-Premise
293	-	_	_	I-Premise
294	$	_	_	I-Premise
295	99	_	_	I-Premise
296	to	_	_	I-Premise
297	$	_	_	I-Premise
298	3604	_	_	I-Premise
299	;	_	_	I-Premise
300	P	_	_	I-Premise
301	=.06	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	For	_	_	B-Premise
305	willingness-to-pay	_	_	I-Premise
306	between	_	_	I-Premise
307	$	_	_	I-Premise
308	5000	_	_	I-Premise
309	and	_	_	I-Premise
310	$	_	_	I-Premise
311	40	_	_	I-Premise
312	000	_	_	I-Premise
313	per	_	_	I-Premise
314	quality-adjusted	_	_	I-Premise
315	life	_	_	I-Premise
316	year	_	_	I-Premise
317	,	_	_	I-Premise
318	the	_	_	I-Premise
319	single-fraction	_	_	I-Premise
320	schedule	_	_	I-Premise
321	was	_	_	I-Premise
322	statistically	_	_	I-Premise
323	significantly	_	_	I-Premise
324	more	_	_	I-Premise
325	cost-effective	_	_	I-Premise
326	than	_	_	I-Premise
327	the	_	_	I-Premise
328	multiple-fraction	_	_	I-Premise
329	schedule	_	_	I-Premise
330	(	_	_	I-Premise
331	P	_	_	I-Premise
332	<	_	_	I-Premise
333	or	_	_	I-Premise
334	=.05	_	_	I-Premise
335	)	_	_	I-Premise
336	.	_	_	I-Premise

337	Compared	_	_	B-Claim
338	with	_	_	I-Claim
339	multiple-fraction	_	_	I-Claim
340	radiotherapy	_	_	I-Claim
341	,	_	_	I-Claim
342	single-fraction	_	_	I-Claim
343	radiotherapy	_	_	I-Claim
344	provides	_	_	I-Claim
345	equal	_	_	I-Claim
346	palliation	_	_	I-Claim
347	and	_	_	I-Claim
348	quality	_	_	I-Claim
349	of	_	_	I-Claim
350	life	_	_	I-Claim
351	and	_	_	I-Claim
352	has	_	_	I-Claim
353	lower	_	_	I-Claim
354	medical	_	_	I-Claim
355	and	_	_	I-Claim
356	societal	_	_	I-Claim
357	costs	_	_	I-Claim
358	,	_	_	I-Claim
359	at	_	_	I-Claim
360	least	_	_	I-Claim
361	in	_	_	I-Claim
362	The	_	_	I-Claim
363	Netherlands	_	_	I-Claim
364	.	_	_	I-Claim

365	Therefore	_	_	B-Claim
366	,	_	_	I-Claim
367	single-fraction	_	_	I-Claim
368	radiotherapy	_	_	I-Claim
369	should	_	_	I-Claim
370	be	_	_	I-Claim
371	considered	_	_	I-Claim
372	as	_	_	I-Claim
373	the	_	_	I-Claim
374	palliative	_	_	I-Claim
375	treatment	_	_	I-Claim
376	of	_	_	I-Claim
377	choice	_	_	I-Claim
378	for	_	_	I-Claim
379	cancer	_	_	I-Claim
380	patients	_	_	I-Claim
381	with	_	_	I-Claim
382	painful	_	_	I-Claim
383	bone	_	_	I-Claim
384	metastases	_	_	I-Claim
385	.	_	_	I-Claim


0	Several	_	_	O
1	multicomponent	_	_	O
2	regimens	_	_	O
3	have	_	_	O
4	been	_	_	O
5	reported	_	_	O
6	to	_	_	O
7	be	_	_	O
8	useful	_	_	O
9	in	_	_	O
10	advanced	_	_	O
11	androgen-independent	_	_	O
12	prostate	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	We	_	_	O
16	used	_	_	O
17	a	_	_	O
18	randomized	_	_	O
19	phase	_	_	O
20	II	_	_	O
21	design	_	_	O
22	to	_	_	O
23	evaluate	_	_	O
24	and	_	_	O
25	compare	_	_	O
26	two	_	_	O
27	such	_	_	O
28	regimens	_	_	O
29	.	_	_	O

30	Patients	_	_	O
31	were	_	_	O
32	accrued	_	_	O
33	primarily	_	_	O
34	in	_	_	O
35	the	_	_	O
36	community	_	_	O
37	setting	_	_	O
38	.	_	_	O

39	Patients	_	_	O
40	with	_	_	O
41	progressive	_	_	O
42	,	_	_	O
43	androgen-independent	_	_	O
44	prostate	_	_	O
45	cancer	_	_	O
46	were	_	_	O
47	randomly	_	_	O
48	assigned	_	_	O
49	to	_	_	O
50	one	_	_	O
51	of	_	_	O
52	two	_	_	O
53	treatments	_	_	O
54	:	_	_	O
55	either	_	_	O
56	ketoconazole/doxorubicin	_	_	O
57	alternating	_	_	O
58	with	_	_	O
59	vinblastine/estramustine	_	_	O
60	(	_	_	O
61	KA/VE	_	_	O
62	)	_	_	O
63	or	_	_	O
64	paclitaxel	_	_	O
65	,	_	_	O
66	estramustine	_	_	O
67	,	_	_	O
68	and	_	_	O
69	oral	_	_	O
70	etoposide	_	_	O
71	(	_	_	O
72	TEE	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Patients	_	_	O
76	were	_	_	O
77	prospectively	_	_	O
78	stratified	_	_	O
79	on	_	_	O
80	the	_	_	O
81	basis	_	_	O
82	of	_	_	O
83	disease	_	_	O
84	volume	_	_	O
85	.	_	_	O

86	The	_	_	O
87	primary	_	_	O
88	end	_	_	O
89	points	_	_	O
90	were	_	_	O
91	response	_	_	O
92	and	_	_	O
93	overall	_	_	O
94	survival	_	_	O
95	time	_	_	O
96	.	_	_	O

97	A	_	_	O
98	total	_	_	O
99	of	_	_	O
100	75	_	_	O
101	patients	_	_	O
102	were	_	_	O
103	registered	_	_	O
104	;	_	_	O
105	71	_	_	O
106	are	_	_	O
107	included	_	_	O
108	in	_	_	O
109	the	_	_	O
110	analysis	_	_	O
111	.	_	_	O

112	By	_	_	O
113	the	_	_	O
114	criterion	_	_	O
115	of	_	_	O
116	an	_	_	O
117	80	_	_	O
118	%	_	_	O
119	prostate-specific	_	_	O
120	antigen	_	_	O
121	reduction	_	_	O
122	maintained	_	_	O
123	for	_	_	O
124	at	_	_	O
125	least	_	_	O
126	8	_	_	O
127	weeks	_	_	O
128	,	_	_	O
129	11	_	_	O
130	(	_	_	O
131	30	_	_	O
132	%	_	_	O
133	)	_	_	O
134	of	_	_	O
135	37	_	_	O
136	patients	_	_	O
137	in	_	_	O
138	the	_	_	O
139	TEE	_	_	O
140	arm	_	_	O
141	responded	_	_	O
142	,	_	_	O
143	whereas	_	_	O
144	11	_	_	O
145	(	_	_	O
146	32	_	_	O
147	%	_	_	O
148	)	_	_	O
149	of	_	_	O
150	34	_	_	O
151	assigned	_	_	O
152	to	_	_	O
153	KA/VE	_	_	O
154	responded	_	_	O
155	.	_	_	O

156	Median	_	_	B-Premise
157	survival	_	_	I-Premise
158	was	_	_	I-Premise
159	16.9	_	_	I-Premise
160	months	_	_	I-Premise
161	(	_	_	I-Premise
162	95	_	_	I-Premise
163	%	_	_	I-Premise
164	confidence	_	_	I-Premise
165	interval	_	_	I-Premise
166	[	_	_	I-Premise
167	CI	_	_	I-Premise
168	]	_	_	I-Premise
169	,	_	_	I-Premise
170	10.5	_	_	I-Premise
171	to	_	_	I-Premise
172	21.2	_	_	I-Premise
173	months	_	_	I-Premise
174	)	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	TEE	_	_	I-Premise
178	arm	_	_	I-Premise
179	and	_	_	I-Premise
180	23.4	_	_	I-Premise
181	months	_	_	I-Premise
182	(	_	_	I-Premise
183	95	_	_	I-Premise
184	%	_	_	I-Premise
185	CI	_	_	I-Premise
186	,	_	_	I-Premise
187	12.9	_	_	I-Premise
188	to	_	_	I-Premise
189	30.6	_	_	I-Premise
190	months	_	_	I-Premise
191	)	_	_	I-Premise
192	for	_	_	I-Premise
193	patients	_	_	I-Premise
194	treated	_	_	I-Premise
195	with	_	_	I-Premise
196	KA/VE	_	_	I-Premise
197	.	_	_	I-Premise

198	Many	_	_	B-Premise
199	patients	_	_	I-Premise
200	(	_	_	I-Premise
201	24	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	failed	_	_	I-Premise
205	to	_	_	I-Premise
206	complete	_	_	I-Premise
207	at	_	_	I-Premise
208	least	_	_	I-Premise
209	6	_	_	I-Premise
210	weeks	_	_	I-Premise
211	of	_	_	I-Premise
212	therapy	_	_	I-Premise
213	,	_	_	I-Premise
214	including	_	_	I-Premise
215	five	_	_	I-Premise
216	(	_	_	I-Premise
217	8	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	treatment-related	_	_	I-Premise
221	early	_	_	I-Premise
222	deaths	_	_	I-Premise
223	.	_	_	I-Premise

224	Each	_	_	B-Claim
225	of	_	_	I-Claim
226	these	_	_	I-Claim
227	regimens	_	_	I-Claim
228	produced	_	_	I-Claim
229	clinically	_	_	I-Claim
230	significant	_	_	I-Claim
231	responses	_	_	I-Claim
232	,	_	_	I-Claim
233	and	_	_	O
234	the	_	_	B-Claim
235	observed	_	_	I-Claim
236	median	_	_	I-Claim
237	survival	_	_	I-Claim
238	(	_	_	I-Claim
239	18.9	_	_	I-Claim
240	months	_	_	I-Claim
241	for	_	_	I-Claim
242	all	_	_	I-Claim
243	71	_	_	I-Claim
244	patients	_	_	I-Claim
245	)	_	_	I-Claim
246	compares	_	_	I-Claim
247	favorably	_	_	I-Claim
248	with	_	_	I-Claim
249	previously	_	_	I-Claim
250	published	_	_	I-Claim
251	results	_	_	I-Claim
252	,	_	_	I-Claim
253	especially	_	_	I-Claim
254	in	_	_	I-Claim
255	the	_	_	I-Claim
256	community	_	_	I-Claim
257	setting	_	_	I-Claim
258	.	_	_	I-Claim

259	Nonetheless	_	_	B-Claim
260	,	_	_	I-Claim
261	it	_	_	I-Claim
262	is	_	_	I-Claim
263	apparent	_	_	I-Claim
264	that	_	_	I-Claim
265	these	_	_	I-Claim
266	first-generation	_	_	I-Claim
267	regimens	_	_	I-Claim
268	must	_	_	I-Claim
269	be	_	_	I-Claim
270	applied	_	_	I-Claim
271	judiciously	_	_	I-Claim
272	,	_	_	I-Claim
273	and	_	_	O
274	thus	_	_	B-Claim
275	we	_	_	I-Claim
276	view	_	_	I-Claim
277	efforts	_	_	I-Claim
278	at	_	_	I-Claim
279	better	_	_	I-Claim
280	patient	_	_	I-Claim
281	selection	_	_	I-Claim
282	and	_	_	I-Claim
283	the	_	_	I-Claim
284	development	_	_	I-Claim
285	of	_	_	I-Claim
286	more	_	_	I-Claim
287	tolerable	_	_	I-Claim
288	therapies	_	_	I-Claim
289	as	_	_	I-Claim
290	higher	_	_	I-Claim
291	priorities	_	_	I-Claim
292	than	_	_	I-Claim
293	carrying	_	_	I-Claim
294	either	_	_	I-Claim
295	of	_	_	I-Claim
296	these	_	_	I-Claim
297	regimens	_	_	I-Claim
298	to	_	_	I-Claim
299	phase	_	_	I-Claim
300	III	_	_	I-Claim
301	evaluation	_	_	I-Claim
302	in	_	_	I-Claim
303	the	_	_	I-Claim
304	cooperative	_	_	I-Claim
305	group	_	_	I-Claim
306	setting	_	_	I-Claim
307	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	treatment	_	_	O
4	with	_	_	O
5	betaxolol	_	_	O
6	can	_	_	O
7	delay	_	_	O
8	or	_	_	O
9	prevent	_	_	O
10	the	_	_	O
11	conversion	_	_	O
12	from	_	_	O
13	ocular	_	_	O
14	hypertension	_	_	O
15	to	_	_	O
16	early	_	_	O
17	glaucoma	_	_	O
18	on	_	_	O
19	the	_	_	O
20	basis	_	_	O
21	of	_	_	O
22	visual	_	_	O
23	field	_	_	O
24	criteria	_	_	O
25	,	_	_	O
26	by	_	_	O
27	means	_	_	O
28	of	_	_	O
29	a	_	_	O
30	prospective	_	_	O
31	,	_	_	O
32	randomised	_	_	O
33	,	_	_	O
34	placebo-controlled	_	_	O
35	trial	_	_	O
36	.	_	_	O

37	Three	_	_	O
38	hundred	_	_	O
39	and	_	_	O
40	fifty-six	_	_	O
41	ocular	_	_	O
42	hypertensives	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	to	_	_	O
46	treatment	_	_	O
47	with	_	_	O
48	either	_	_	O
49	betaxolol	_	_	O
50	drops	_	_	O
51	or	_	_	O
52	placebo	_	_	O
53	drops	_	_	O
54	during	_	_	O
55	the	_	_	O
56	period	_	_	O
57	1992-1996	_	_	O
58	.	_	_	O

59	Each	_	_	O
60	patient	_	_	O
61	was	_	_	O
62	followed	_	_	O
63	prospectively	_	_	O
64	with	_	_	O
65	4-monthly	_	_	O
66	visits	_	_	O
67	.	_	_	O

68	Examination	_	_	O
69	at	_	_	O
70	each	_	_	O
71	visit	_	_	O
72	included	_	_	O
73	visual	_	_	O
74	field	_	_	O
75	testing	_	_	O
76	,	_	_	O
77	intra-ocular	_	_	O
78	pressure	_	_	O
79	(	_	_	O
80	IOP	_	_	O
81	)	_	_	O
82	measurement	_	_	O
83	and	_	_	O
84	optic	_	_	O
85	disc	_	_	O
86	imaging	_	_	O
87	.	_	_	O

88	Conversion	_	_	O
89	to	_	_	O
90	early	_	_	O
91	glaucoma	_	_	O
92	was	_	_	O
93	defined	_	_	O
94	on	_	_	O
95	the	_	_	O
96	basis	_	_	O
97	of	_	_	O
98	visual	_	_	O
99	field	_	_	O
100	change	_	_	O
101	by	_	_	O
102	AGIS	_	_	O
103	criteria	_	_	O
104	.	_	_	O

105	An	_	_	O
106	intent-to-treat	_	_	O
107	analysis	_	_	O
108	compared	_	_	O
109	visual	_	_	O
110	field	_	_	O
111	conversion	_	_	O
112	after	_	_	O
113	3	_	_	O
114	years	_	_	O
115	in	_	_	O
116	the	_	_	O
117	treatment	_	_	O
118	and	_	_	O
119	placebo	_	_	O
120	arms	_	_	O
121	.	_	_	O

122	Normal	_	_	O
123	visual	_	_	O
124	field	_	_	O
125	survival	_	_	O
126	analysis	_	_	O
127	was	_	_	O
128	also	_	_	O
129	performed	_	_	O
130	.	_	_	O

131	The	_	_	O
132	IOP	_	_	O
133	characteristics	_	_	O
134	of	_	_	O
135	the	_	_	O
136	two	_	_	O
137	treatment	_	_	O
138	groups	_	_	O
139	were	_	_	O
140	compared	_	_	O
141	.	_	_	O

142	Two	_	_	O
143	hundred	_	_	O
144	and	_	_	O
145	fifty-five	_	_	O
146	patients	_	_	O
147	completed	_	_	O
148	the	_	_	O
149	study	_	_	O
150	,	_	_	O
151	which	_	_	O
152	ended	_	_	O
153	in	_	_	O
154	1998	_	_	O
155	,	_	_	O
156	with	_	_	O
157	a	_	_	O
158	range	_	_	O
159	of	_	_	O
160	follow-up	_	_	O
161	of	_	_	O
162	2-6	_	_	O
163	years	_	_	O
164	.	_	_	O

165	Sixteen	_	_	B-Premise
166	(	_	_	I-Premise
167	13.2	_	_	I-Premise
168	%	_	_	I-Premise
169	)	_	_	I-Premise
170	of	_	_	I-Premise
171	121	_	_	I-Premise
172	patients	_	_	I-Premise
173	in	_	_	I-Premise
174	the	_	_	I-Premise
175	placebo	_	_	I-Premise
176	group	_	_	I-Premise
177	converted	_	_	I-Premise
178	to	_	_	I-Premise
179	glaucoma	_	_	I-Premise
180	,	_	_	I-Premise
181	compared	_	_	I-Premise
182	with	_	_	I-Premise
183	12	_	_	I-Premise
184	(	_	_	I-Premise
185	9.0	_	_	I-Premise
186	%	_	_	I-Premise
187	)	_	_	I-Premise
188	of	_	_	I-Premise
189	134	_	_	I-Premise
190	patients	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	betaxolol	_	_	I-Premise
194	group	_	_	I-Premise
195	.	_	_	I-Premise

196	The	_	_	B-Premise
197	intent-to-treat	_	_	I-Premise
198	analysis	_	_	I-Premise
199	demonstrated	_	_	I-Premise
200	no	_	_	I-Premise
201	evidence	_	_	I-Premise
202	of	_	_	I-Premise
203	any	_	_	I-Premise
204	difference	_	_	I-Premise
205	in	_	_	I-Premise
206	conversion	_	_	I-Premise
207	rates	_	_	I-Premise
208	between	_	_	I-Premise
209	the	_	_	I-Premise
210	betaxolol	_	_	I-Premise
211	and	_	_	I-Premise
212	placebo	_	_	I-Premise
213	groups	_	_	I-Premise
214	after	_	_	I-Premise
215	3	_	_	I-Premise
216	years	_	_	I-Premise
217	.	_	_	I-Premise

218	Visual	_	_	B-Premise
219	field	_	_	I-Premise
220	survival	_	_	I-Premise
221	analysis	_	_	I-Premise
222	demonstrated	_	_	I-Premise
223	no	_	_	I-Premise
224	significant	_	_	I-Premise
225	difference	_	_	I-Premise
226	between	_	_	I-Premise
227	the	_	_	I-Premise
228	betaxolol	_	_	I-Premise
229	and	_	_	I-Premise
230	placebo	_	_	I-Premise
231	groups	_	_	I-Premise
232	.	_	_	I-Premise

233	The	_	_	B-Premise
234	betaxolol-treated	_	_	I-Premise
235	group	_	_	I-Premise
236	had	_	_	I-Premise
237	significantly	_	_	I-Premise
238	lower	_	_	I-Premise
239	post-treatment	_	_	I-Premise
240	IOP	_	_	I-Premise
241	values	_	_	I-Premise
242	.	_	_	I-Premise

243	Converters	_	_	B-Premise
244	had	_	_	I-Premise
245	significantly	_	_	I-Premise
246	higher	_	_	I-Premise
247	pre-	_	_	I-Premise
248	and	_	_	I-Premise
249	post-treatment	_	_	I-Premise
250	IOP	_	_	I-Premise
251	values	_	_	I-Premise
252	than	_	_	I-Premise
253	non-converters	_	_	I-Premise
254	.	_	_	I-Premise

255	Betaxolol	_	_	B-Premise
256	significantly	_	_	I-Premise
257	lowered	_	_	I-Premise
258	the	_	_	I-Premise
259	IOP	_	_	I-Premise
260	level	_	_	I-Premise
261	compared	_	_	I-Premise
262	with	_	_	I-Premise
263	placebo	_	_	I-Premise
264	.	_	_	I-Premise

265	Conversion	_	_	B-Premise
266	to	_	_	I-Premise
267	glaucoma	_	_	I-Premise
268	was	_	_	I-Premise
269	found	_	_	I-Premise
270	to	_	_	I-Premise
271	be	_	_	I-Premise
272	related	_	_	I-Premise
273	to	_	_	I-Premise
274	both	_	_	I-Premise
275	the	_	_	I-Premise
276	baseline	_	_	I-Premise
277	and	_	_	I-Premise
278	post-treatment	_	_	I-Premise
279	IOP	_	_	I-Premise
280	levels	_	_	I-Premise
281	.	_	_	I-Premise

282	However	_	_	O
283	the	_	_	B-Claim
284	intent-to-treat	_	_	I-Claim
285	analysis	_	_	I-Claim
286	did	_	_	I-Claim
287	not	_	_	I-Claim
288	demonstrate	_	_	I-Claim
289	a	_	_	I-Claim
290	statistically	_	_	I-Claim
291	significant	_	_	I-Claim
292	reduction	_	_	I-Claim
293	in	_	_	I-Claim
294	the	_	_	I-Claim
295	conversion	_	_	I-Claim
296	rate	_	_	I-Claim
297	in	_	_	I-Claim
298	the	_	_	I-Claim
299	betaxolol-treated	_	_	I-Claim
300	group	_	_	I-Claim
301	.	_	_	I-Claim


0	Carteolol	_	_	O
1	is	_	_	O
2	a	_	_	O
3	beta-adrenoceptor	_	_	O
4	antagonist	_	_	O
5	with	_	_	O
6	intrinsic	_	_	O
7	sympathomimetic	_	_	O
8	activity	_	_	O
9	.	_	_	O

10	Used	_	_	O
11	topically	_	_	O
12	to	_	_	O
13	reduce	_	_	O
14	intraocular	_	_	O
15	pressure	_	_	O
16	,	_	_	O
17	it	_	_	O
18	is	_	_	O
19	typically	_	_	O
20	applied	_	_	O
21	twice	_	_	O
22	daily	_	_	O
23	.	_	_	O

24	In	_	_	O
25	an	_	_	O
26	effort	_	_	O
27	to	_	_	O
28	provide	_	_	O
29	a	_	_	O
30	once-daily	_	_	O
31	dosing	_	_	O
32	regimen	_	_	O
33	,	_	_	O
34	carteolol	_	_	O
35	was	_	_	O
36	formulated	_	_	O
37	with	_	_	O
38	1	_	_	O
39	%	_	_	O
40	alginic	_	_	O
41	acid	_	_	O
42	.	_	_	O

43	Sodium	_	_	O
44	alginate	_	_	O
45	is	_	_	O
46	a	_	_	O
47	natural	_	_	O
48	polymer	_	_	O
49	product	_	_	O
50	with	_	_	O
51	bioadhesive	_	_	O
52	properties	_	_	O
53	providing	_	_	O
54	increased	_	_	O
55	corneal	_	_	O
56	contact	_	_	O
57	time	_	_	O
58	and	_	_	O
59	a	_	_	O
60	better	_	_	O
61	carteolol	_	_	O
62	penetration	_	_	O
63	through	_	_	O
64	the	_	_	O
65	cornea	_	_	O
66	.	_	_	O

67	The	_	_	O
68	objective	_	_	O
69	of	_	_	O
70	this	_	_	O
71	study	_	_	O
72	was	_	_	O
73	to	_	_	O
74	evaluate	_	_	O
75	the	_	_	O
76	efficacy	_	_	O
77	and	_	_	O
78	safety	_	_	O
79	of	_	_	O
80	long-acting	_	_	O
81	1	_	_	O
82	%	_	_	O
83	carteolol	_	_	O
84	alginate	_	_	O
85	solution	_	_	O
86	compared	_	_	O
87	to	_	_	O
88	standard	_	_	O
89	1	_	_	O
90	%	_	_	O
91	carteolol	_	_	O
92	solution	_	_	O
93	.	_	_	O

94	This	_	_	O
95	was	_	_	O
96	a	_	_	O
97	double-masked	_	_	O
98	,	_	_	O
99	parallel	_	_	O
100	group	_	_	O
101	,	_	_	O
102	multicentre	_	_	O
103	study	_	_	O
104	.	_	_	O

105	Patients	_	_	O
106	with	_	_	O
107	ocular	_	_	O
108	hypertension	_	_	O
109	or	_	_	O
110	open	_	_	O
111	angle	_	_	O
112	glaucoma	_	_	O
113	(	_	_	O
114	n=151	_	_	O
115	)	_	_	O
116	were	_	_	O
117	randomly	_	_	O
118	assigned	_	_	O
119	to	_	_	O
120	receive	_	_	O
121	either	_	_	O
122	1	_	_	O
123	%	_	_	O
124	carteolol	_	_	O
125	alginate	_	_	O
126	once	_	_	O
127	daily	_	_	O
128	(	_	_	O
129	AM	_	_	O
130	)	_	_	O
131	or	_	_	O
132	standard	_	_	O
133	1	_	_	O
134	%	_	_	O
135	carteolol	_	_	O
136	solution	_	_	O
137	twice	_	_	O
138	daily	_	_	O
139	for	_	_	O
140	2	_	_	O
141	months	_	_	O
142	.	_	_	O

143	The	_	_	O
144	masking	_	_	O
145	was	_	_	O
146	maintained	_	_	O
147	through	_	_	O
148	the	_	_	O
149	use	_	_	O
150	of	_	_	O
151	a	_	_	O
152	placebo	_	_	O
153	in	_	_	O
154	the	_	_	O
155	evening	_	_	O
156	for	_	_	O
157	the	_	_	O
158	alginate	_	_	O
159	group	_	_	O
160	.	_	_	O

161	Entry	_	_	O
162	into	_	_	O
163	the	_	_	O
164	study	_	_	O
165	required	_	_	O
166	unmedicated	_	_	O
167	intraocular	_	_	O
168	pressure	_	_	O
169	(	_	_	O
170	IOP	_	_	O
171	)	_	_	O
172	between	_	_	O
173	23	_	_	O
174	mmHg	_	_	O
175	and	_	_	O
176	32	_	_	O
177	mmHg	_	_	O
178	at	_	_	O
179	9	_	_	O
180	AM	_	_	O
181	and	_	_	O
182	11	_	_	O
183	AM	_	_	O
184	.	_	_	O

185	Patients	_	_	O
186	using	_	_	O
187	ocular	_	_	O
188	hypotensive	_	_	O
189	medication	_	_	O
190	were	_	_	O
191	required	_	_	O
192	to	_	_	O
193	undergo	_	_	O
194	a	_	_	O
195	washout	_	_	O
196	.	_	_	O

197	All	_	_	O
198	patients	_	_	O
199	provided	_	_	O
200	written	_	_	O
201	informed	_	_	O
202	consent	_	_	O
203	.	_	_	O

204	Excluded	_	_	O
205	from	_	_	O
206	the	_	_	O
207	study	_	_	O
208	were	_	_	O
209	patients	_	_	O
210	with	_	_	O
211	angle	_	_	O
212	closure	_	_	O
213	,	_	_	O
214	congenital	_	_	O
215	,	_	_	O
216	secondary	_	_	O
217	glaucoma	_	_	O
218	or	_	_	O
219	advanced	_	_	O
220	glaucoma	_	_	O
221	;	_	_	O
222	any	_	_	O
223	intraocular	_	_	O
224	infection	_	_	O
225	or	_	_	O
226	inflammation	_	_	O
227	,	_	_	O
228	ocular	_	_	O
229	trauma	_	_	O
230	,	_	_	O
231	ocular	_	_	O
232	surgery	_	_	O
233	or	_	_	O
234	laser	_	_	O
235	trabeculoplasty	_	_	O
236	within	_	_	O
237	the	_	_	O
238	previous	_	_	O
239	3	_	_	O
240	months	_	_	O
241	;	_	_	O
242	contraindications	_	_	O
243	to	_	_	O
244	the	_	_	O
245	use	_	_	O
246	of	_	_	O
247	beta	_	_	O
248	adrenoceptor	_	_	O
249	antagonists	_	_	O
250	;	_	_	O
251	systemic	_	_	O
252	medications	_	_	O
253	likely	_	_	O
254	to	_	_	O
255	modify	_	_	O
256	IOP	_	_	O
257	prescribed	_	_	O
258	or	_	_	O
259	modified	_	_	O
260	during	_	_	O
261	the	_	_	O
262	previous	_	_	O
263	3	_	_	O
264	months	_	_	O
265	;	_	_	O
266	ocular	_	_	O
267	steroid	_	_	O
268	use	_	_	O
269	;	_	_	O
270	contact	_	_	O
271	lens	_	_	O
272	wear	_	_	O
273	;	_	_	O
274	and	_	_	O
275	pregnant	_	_	O
276	and	_	_	O
277	lactating	_	_	O
278	women	_	_	O
279	.	_	_	O

280	Patients	_	_	O
281	were	_	_	O
282	evaluated	_	_	O
283	at	_	_	O
284	baseline	_	_	O
285	,	_	_	O
286	15	_	_	O
287	and	_	_	O
288	60	_	_	O
289	days	_	_	O
290	,	_	_	O
291	with	_	_	O
292	IOP	_	_	O
293	measurements	_	_	O
294	at	_	_	O
295	9	_	_	O
296	AM	_	_	O
297	and	_	_	O
298	11	_	_	O
299	AM	_	_	O
300	.	_	_	O

301	At	_	_	O
302	day	_	_	O
303	15	_	_	O
304	and	_	_	O
305	day	_	_	O
306	60	_	_	O
307	,	_	_	O
308	IOP	_	_	O
309	was	_	_	O
310	measured	_	_	O
311	just	_	_	O
312	before	_	_	O
313	instillation	_	_	O
314	of	_	_	O
315	medication	_	_	O
316	(	_	_	O
317	9	_	_	O
318	AM	_	_	O
319	)	_	_	O
320	and	_	_	O
321	2	_	_	O
322	hours	_	_	O
323	after	_	_	O
324	(	_	_	O
325	11	_	_	O
326	AM	_	_	O
327	)	_	_	O
328	.	_	_	O

329	Slit	_	_	O
330	lamp	_	_	O
331	examinations	_	_	O
332	were	_	_	O
333	performed	_	_	O
334	at	_	_	O
335	each	_	_	O
336	follow-up	_	_	O
337	examination	_	_	O
338	,	_	_	O
339	together	_	_	O
340	with	_	_	O
341	measurement	_	_	O
342	of	_	_	O
343	heart	_	_	O
344	rate	_	_	O
345	and	_	_	O
346	blood	_	_	O
347	pressure	_	_	O
348	(	_	_	O
349	10	_	_	O
350	AM	_	_	O
351	)	_	_	O
352	and	_	_	O
353	ocular	_	_	O
354	tolerance	_	_	O
355	after	_	_	O
356	medication	_	_	O
357	(	_	_	O
358	11	_	_	O
359	AM	_	_	O
360	)	_	_	O
361	.	_	_	O

362	The	_	_	O
363	primary	_	_	O
364	efficacy	_	_	O
365	criterion	_	_	O
366	was	_	_	O
367	the	_	_	O
368	decrease	_	_	O
369	in	_	_	O
370	IOP	_	_	O
371	from	_	_	O
372	baseline	_	_	O
373	at	_	_	O
374	day	_	_	O
375	60	_	_	O
376	for	_	_	O
377	each	_	_	O
378	measurement	_	_	O
379	at	_	_	O
380	9	_	_	O
381	AM	_	_	O
382	and	_	_	O
383	11	_	_	O
384	AM	_	_	O
385	.	_	_	O

386	The	_	_	O
387	study	_	_	O
388	eye	_	_	O
389	was	_	_	O
390	the	_	_	O
391	eye	_	_	O
392	with	_	_	O
393	the	_	_	O
394	higher	_	_	O
395	IOP	_	_	O
396	at	_	_	O
397	day	_	_	O
398	0	_	_	O
399	or	_	_	O
400	,	_	_	O
401	if	_	_	O
402	equal	_	_	O
403	,	_	_	O
404	the	_	_	O
405	right	_	_	O
406	eye	_	_	O
407	.	_	_	O

408	Efficacy-of	_	_	O
409	the	_	_	O
410	151	_	_	O
411	patients	_	_	O
412	included	_	_	O
413	in	_	_	O
414	the	_	_	O
415	study	_	_	O
416	,	_	_	O
417	149	_	_	O
418	were	_	_	O
419	evaluated	_	_	O
420	(	_	_	O
421	two	_	_	O
422	patients	_	_	O
423	were	_	_	O
424	lost	_	_	O
425	to	_	_	O
426	follow-up	_	_	O
427	after	_	_	O
428	day	_	_	O
429	0	_	_	O
430	)	_	_	O
431	:	_	_	O
432	74	_	_	O
433	in	_	_	O
434	the	_	_	O
435	alginate	_	_	O
436	group	_	_	O
437	and	_	_	O
438	75	_	_	O
439	in	_	_	O
440	the	_	_	O
441	standard	_	_	O
442	group	_	_	O
443	.	_	_	O

444	Both	_	_	O
445	treatment	_	_	O
446	groups	_	_	O
447	were	_	_	O
448	comparable	_	_	O
449	at	_	_	O
450	day	_	_	O
451	0	_	_	O
452	except	_	_	O
453	for	_	_	O
454	sex	_	_	O
455	,	_	_	O
456	diastolic	_	_	O
457	blood	_	_	O
458	pressure	_	_	O
459	,	_	_	O
460	and	_	_	O
461	IOP	_	_	O
462	in	_	_	O
463	the	_	_	O
464	fellow	_	_	O
465	eye	_	_	O
466	.	_	_	O

467	At	_	_	B-Premise
468	09.00	_	_	I-Premise
469	hours	_	_	I-Premise
470	(	_	_	I-Premise
471	presumed	_	_	I-Premise
472	trough	_	_	I-Premise
473	)	_	_	I-Premise
474	on	_	_	I-Premise
475	day	_	_	I-Premise
476	60	_	_	I-Premise
477	,	_	_	I-Premise
478	mean	_	_	I-Premise
479	reductions	_	_	I-Premise
480	from	_	_	I-Premise
481	baseline	_	_	I-Premise
482	in	_	_	I-Premise
483	intraocular	_	_	I-Premise
484	pressure	_	_	I-Premise
485	were	_	_	I-Premise
486	6.32+/-2.87	_	_	I-Premise
487	and	_	_	I-Premise
488	5.67+/-3.30	_	_	I-Premise
489	mmHg	_	_	I-Premise
490	for	_	_	I-Premise
491	the	_	_	I-Premise
492	alginate	_	_	I-Premise
493	carteolol	_	_	I-Premise
494	and	_	_	I-Premise
495	standard	_	_	I-Premise
496	groups	_	_	I-Premise
497	,	_	_	I-Premise
498	respectively	_	_	I-Premise
499	.	_	_	I-Premise

500	At	_	_	B-Premise
501	11.00	_	_	I-Premise
502	hours	_	_	I-Premise
503	(	_	_	I-Premise
504	presumed	_	_	I-Premise
505	peak	_	_	I-Premise
506	)	_	_	I-Premise
507	,	_	_	I-Premise
508	mean	_	_	I-Premise
509	reductions	_	_	I-Premise
510	were	_	_	I-Premise
511	6.70+/-2.81	_	_	I-Premise
512	and	_	_	I-Premise
513	6.55+/-3.35	_	_	I-Premise
514	mmHg	_	_	I-Premise
515	,	_	_	I-Premise
516	respectively	_	_	I-Premise
517	.	_	_	I-Premise

518	At	_	_	B-Premise
519	each	_	_	I-Premise
520	evaluation	_	_	I-Premise
521	time	_	_	I-Premise
522	,	_	_	I-Premise
523	the	_	_	I-Premise
524	two	_	_	I-Premise
525	unilateral	_	_	I-Premise
526	t	_	_	I-Premise
527	tests	_	_	I-Premise
528	were	_	_	I-Premise
529	highly	_	_	I-Premise
530	significant	_	_	I-Premise
531	(	_	_	I-Premise
532	p	_	_	I-Premise
533	<	_	_	I-Premise
534	0.005	_	_	I-Premise
535	)	_	_	I-Premise
536	,	_	_	I-Premise
537	confirming	_	_	O
538	the	_	_	O
539	equivalence	_	_	O
540	of	_	_	O
541	both	_	_	O
542	treatments	_	_	O
543	.	_	_	O

544	Conclusions	_	_	O
545	were	_	_	O
546	not	_	_	O
547	modified	_	_	O
548	taking	_	_	O
549	into	_	_	O
550	account	_	_	O
551	sex	_	_	O
552	and	_	_	O
553	diastolic	_	_	O
554	blood	_	_	O
555	pressure	_	_	O
556	.	_	_	O

557	Safety-	_	_	B-Premise
558	Slight	_	_	I-Premise
559	decreases	_	_	I-Premise
560	in	_	_	I-Premise
561	heart	_	_	I-Premise
562	rate	_	_	I-Premise
563	and	_	_	I-Premise
564	blood	_	_	I-Premise
565	pressure	_	_	I-Premise
566	means	_	_	I-Premise
567	were	_	_	I-Premise
568	observed	_	_	I-Premise
569	in	_	_	I-Premise
570	both	_	_	I-Premise
571	groups	_	_	I-Premise
572	at	_	_	I-Premise
573	follow-up	_	_	I-Premise
574	visits	_	_	I-Premise
575	with	_	_	I-Premise
576	no	_	_	I-Premise
577	significant	_	_	I-Premise
578	difference	_	_	I-Premise
579	between	_	_	I-Premise
580	groups	_	_	I-Premise
581	.	_	_	I-Premise

582	Subjective	_	_	B-Premise
583	tolerance	_	_	I-Premise
584	upon	_	_	I-Premise
585	instillation	_	_	I-Premise
586	was	_	_	I-Premise
587	judged	_	_	I-Premise
588	good	_	_	I-Premise
589	or	_	_	I-Premise
590	very	_	_	I-Premise
591	good	_	_	I-Premise
592	at	_	_	I-Premise
593	day	_	_	I-Premise
594	60	_	_	I-Premise
595	by	_	_	I-Premise
596	100	_	_	I-Premise
597	%	_	_	I-Premise
598	of	_	_	I-Premise
599	alginate	_	_	I-Premise
600	patients	_	_	I-Premise
601	and	_	_	I-Premise
602	by	_	_	I-Premise
603	98.7	_	_	I-Premise
604	%	_	_	I-Premise
605	of	_	_	I-Premise
606	standard	_	_	I-Premise
607	patients	_	_	I-Premise
608	.	_	_	I-Premise

609	Transient	_	_	B-Premise
610	discomfort	_	_	I-Premise
611	(	_	_	I-Premise
612	mainly	_	_	I-Premise
613	stinging	_	_	I-Premise
614	or	_	_	I-Premise
615	burning	_	_	I-Premise
616	sensation	_	_	I-Premise
617	)	_	_	I-Premise
618	was	_	_	I-Premise
619	reported	_	_	I-Premise
620	by	_	_	I-Premise
621	approximately	_	_	I-Premise
622	4	_	_	I-Premise
623	%	_	_	I-Premise
624	-	_	_	I-Premise
625	6	_	_	I-Premise
626	%	_	_	I-Premise
627	of	_	_	I-Premise
628	patients	_	_	I-Premise
629	in	_	_	I-Premise
630	each	_	_	I-Premise
631	treatment	_	_	I-Premise
632	group	_	_	I-Premise
633	at	_	_	I-Premise
634	each	_	_	I-Premise
635	visit	_	_	I-Premise
636	.	_	_	I-Premise

637	A	_	_	B-Premise
638	blurred	_	_	I-Premise
639	vision	_	_	I-Premise
640	sensation	_	_	I-Premise
641	was	_	_	I-Premise
642	reported	_	_	I-Premise
643	by	_	_	I-Premise
644	2	_	_	I-Premise
645	out	_	_	I-Premise
646	of	_	_	I-Premise
647	74	_	_	I-Premise
648	patients	_	_	I-Premise
649	of	_	_	I-Premise
650	the	_	_	I-Premise
651	alginate	_	_	I-Premise
652	group	_	_	I-Premise
653	.	_	_	I-Premise

654	Among	_	_	B-Premise
655	the	_	_	I-Premise
656	17	_	_	I-Premise
657	reported	_	_	I-Premise
658	adverse	_	_	I-Premise
659	events	_	_	I-Premise
660	,	_	_	I-Premise
661	three	_	_	I-Premise
662	were	_	_	I-Premise
663	assessed	_	_	I-Premise
664	as	_	_	I-Premise
665	drug-related	_	_	I-Premise
666	:	_	_	I-Premise
667	one	_	_	I-Premise
668	vertigo	_	_	I-Premise
669	,	_	_	I-Premise
670	one	_	_	I-Premise
671	superficial	_	_	I-Premise
672	punctate	_	_	I-Premise
673	keratitis	_	_	I-Premise
674	in	_	_	I-Premise
675	the	_	_	I-Premise
676	alginate	_	_	I-Premise
677	group	_	_	I-Premise
678	and	_	_	I-Premise
679	one	_	_	I-Premise
680	decrease	_	_	I-Premise
681	in	_	_	I-Premise
682	blood	_	_	I-Premise
683	pressure	_	_	I-Premise
684	in	_	_	I-Premise
685	the	_	_	I-Premise
686	standard	_	_	I-Premise
687	group	_	_	I-Premise
688	.	_	_	I-Premise

689	No	_	_	B-Premise
690	serious	_	_	I-Premise
691	adverse	_	_	I-Premise
692	events	_	_	I-Premise
693	were	_	_	I-Premise
694	reported	_	_	I-Premise
695	.	_	_	I-Premise

696	The	_	_	B-Claim
697	new	_	_	I-Claim
698	alginate	_	_	I-Claim
699	formulation	_	_	I-Claim
700	of	_	_	I-Claim
701	long-acting	_	_	I-Claim
702	carteolol	_	_	I-Claim
703	1	_	_	I-Claim
704	%	_	_	I-Claim
705	given	_	_	I-Claim
706	once	_	_	I-Claim
707	daily	_	_	I-Claim
708	is	_	_	I-Claim
709	as	_	_	I-Claim
710	effective	_	_	I-Claim
711	as	_	_	I-Claim
712	standard	_	_	I-Claim
713	1	_	_	I-Claim
714	%	_	_	I-Claim
715	carteolol	_	_	I-Claim
716	given	_	_	I-Claim
717	twice	_	_	I-Claim
718	daily	_	_	I-Claim
719	,	_	_	I-Claim
720	with	_	_	I-Claim
721	no	_	_	I-Claim
722	meaningful	_	_	I-Claim
723	differences	_	_	I-Claim
724	regarding	_	_	I-Claim
725	safety	_	_	I-Claim
726	.	_	_	I-Claim

727	This	_	_	O
728	efficacy	_	_	O
729	wasy	_	_	O
730	was	_	_	O
731	verified	_	_	O
732	at	_	_	O
733	9	_	_	O
734	AM	_	_	O
735	(	_	_	O
736	24	_	_	O
737	hours	_	_	O
738	after	_	_	O
739	the	_	_	O
740	last	_	_	O
741	drop	_	_	O
742	of	_	_	O
743	long-acting	_	_	O
744	carteolol	_	_	O
745	or	_	_	O
746	12	_	_	O
747	hours	_	_	O
748	after	_	_	O
749	that	_	_	O
750	of	_	_	O
751	standard	_	_	O
752	carteolol	_	_	O
753	)	_	_	O
754	and	_	_	O
755	at	_	_	O
756	11	_	_	O
757	AM	_	_	O
758	(	_	_	O
759	2	_	_	O
760	hours	_	_	O
761	after	_	_	O
762	the	_	_	O
763	morning	_	_	O
764	drop	_	_	O
765	)	_	_	O
766	.	_	_	O

767	The	_	_	B-Claim
768	new	_	_	I-Claim
769	alginate	_	_	I-Claim
770	formulation	_	_	I-Claim
771	of	_	_	I-Claim
772	long-acting	_	_	I-Claim
773	carteolol	_	_	I-Claim
774	1	_	_	I-Claim
775	%	_	_	I-Claim
776	given	_	_	I-Claim
777	once	_	_	I-Claim
778	a	_	_	I-Claim
779	day	_	_	I-Claim
780	is	_	_	I-Claim
781	effective	_	_	I-Claim
782	and	_	_	I-Claim
783	well	_	_	I-Claim
784	tolerated	_	_	I-Claim
785	by	_	_	I-Claim
786	glaucoma	_	_	I-Claim
787	patients	_	_	I-Claim
788	who	_	_	I-Claim
789	require	_	_	I-Claim
790	chronic	_	_	I-Claim
791	treatment	_	_	I-Claim
792	.	_	_	I-Claim


0	We	_	_	O
1	previously	_	_	O
2	reported	_	_	O
3	that	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	patients	_	_	O
7	with	_	_	O
8	symptomatic	_	_	O
9	advanced	_	_	O
10	non-small	_	_	O
11	cell	_	_	O
12	lung	_	_	O
13	cancer	_	_	O
14	with	_	_	O
15	single	_	_	O
16	agent	_	_	O
17	Gemcitabine	_	_	O
18	(	_	_	O
19	GEM	_	_	O
20	)	_	_	O
21	resulted	_	_	O
22	in	_	_	O
23	a	_	_	O
24	superior	_	_	O
25	clinical-benefit	_	_	O
26	response	_	_	O
27	rate	_	_	O
28	(	_	_	O
29	RR	_	_	O
30	)	_	_	O
31	compared	_	_	O
32	to	_	_	O
33	cisplatin-based	_	_	O
34	combination	_	_	O
35	chemotherapy	_	_	O
36	.	_	_	O

37	We	_	_	O
38	now	_	_	O
39	report	_	_	O
40	the	_	_	O
41	detailed	_	_	O
42	individual	_	_	O
43	symptom	_	_	O
44	control	_	_	O
45	analysis	_	_	O
46	,	_	_	O
47	and	_	_	O
48	the	_	_	O
49	influence	_	_	O
50	of	_	_	O
51	cisplatin-use	_	_	O
52	,	_	_	O
53	age	_	_	O
54	,	_	_	O
55	performance	_	_	O
56	status	_	_	O
57	(	_	_	O
58	PS	_	_	O
59	)	_	_	O
60	and	_	_	O
61	duration	_	_	O
62	of	_	_	O
63	treatment	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	received	_	_	O
67	either	_	_	O
68	GEM	_	_	O
69	(	_	_	O
70	1000	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	,	_	_	O
76	days	_	_	O
77	1	_	_	O
78	,	_	_	O
79	8	_	_	O
80	and	_	_	O
81	15	_	_	O
82	)	_	_	O
83	or	_	_	O
84	cisplatin	_	_	O
85	(	_	_	O
86	100	_	_	O
87	mg/m	_	_	O
88	(	_	_	O
89	2	_	_	O
90	)	_	_	O
91	,	_	_	O
92	day	_	_	O
93	1	_	_	O
94	)	_	_	O
95	plus	_	_	O
96	Vindesine	_	_	O
97	(	_	_	O
98	3	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	,	_	_	O
104	days	_	_	O
105	1	_	_	O
106	and	_	_	O
107	15	_	_	O
108	)	_	_	O
109	(	_	_	O
110	PV	_	_	O
111	)	_	_	O
112	,	_	_	O
113	both	_	_	O
114	every	_	_	O
115	4	_	_	O
116	weeks	_	_	O
117	.	_	_	O

118	Scores	_	_	O
119	of	_	_	O
120	9	_	_	O
121	symptoms	_	_	O
122	were	_	_	O
123	listed	_	_	O
124	weekly	_	_	O
125	by	_	_	O
126	the	_	_	O
127	patient	_	_	O
128	on	_	_	O
129	visual	_	_	O
130	analogue	_	_	O
131	scales	_	_	O
132	.	_	_	O

133	Improvement	_	_	O
134	of	_	_	O
135	a	_	_	O
136	symptom	_	_	O
137	was	_	_	O
138	defined	_	_	O
139	as	_	_	O
140	2	_	_	O
141	consecutive	_	_	O
142	cycles	_	_	O
143	of	_	_	O
144	improvement	_	_	O
145	over	_	_	O
146	baseline	_	_	O
147	.	_	_	O

148	Baseline	_	_	O
149	symptoms	_	_	O
150	in	_	_	O
151	the	_	_	O
152	169	_	_	O
153	patients	_	_	O
154	were	_	_	O
155	well	_	_	O
156	balanced	_	_	O
157	between	_	_	O
158	the	_	_	O
159	2	_	_	O
160	arms	_	_	O
161	(	_	_	O
162	84	_	_	O
163	GEM	_	_	O
164	,	_	_	O
165	85	_	_	O
166	PV	_	_	O
167	)	_	_	O
168	.	_	_	O

169	Both	_	_	B-Premise
170	patients	_	_	I-Premise
171	with	_	_	I-Premise
172	objective	_	_	I-Premise
173	response	_	_	I-Premise
174	and	_	_	I-Premise
175	disease	_	_	I-Premise
176	stabilisation	_	_	I-Premise
177	had	_	_	I-Premise
178	clearly	_	_	I-Premise
179	better	_	_	I-Premise
180	symptom	_	_	I-Premise
181	control	_	_	I-Premise
182	than	_	_	I-Premise
183	those	_	_	I-Premise
184	with	_	_	I-Premise
185	disease	_	_	I-Premise
186	progression	_	_	I-Premise
187	.	_	_	I-Premise

188	Symptom	_	_	B-Premise
189	control	_	_	I-Premise
190	in	_	_	I-Premise
191	both	_	_	I-Premise
192	arms	_	_	I-Premise
193	was	_	_	I-Premise
194	similar	_	_	I-Premise
195	for	_	_	I-Premise
196	'disease-specific	_	_	I-Premise
197	'	_	_	I-Premise
198	symptoms	_	_	I-Premise
199	such	_	_	I-Premise
200	as	_	_	I-Premise
201	cough	_	_	I-Premise
202	,	_	_	I-Premise
203	dyspnea	_	_	I-Premise
204	,	_	_	I-Premise
205	pain	_	_	I-Premise
206	or	_	_	I-Premise
207	haemoptysis	_	_	I-Premise
208	.	_	_	I-Premise

209	Compared	_	_	B-Premise
210	to	_	_	I-Premise
211	PV	_	_	I-Premise
212	,	_	_	I-Premise
213	a	_	_	I-Premise
214	significantly	_	_	I-Premise
215	larger	_	_	I-Premise
216	number	_	_	I-Premise
217	of	_	_	I-Premise
218	GEM-patients	_	_	I-Premise
219	had	_	_	I-Premise
220	better	_	_	I-Premise
221	scores	_	_	I-Premise
222	for	_	_	I-Premise
223	'constitutional	_	_	I-Premise
224	'	_	_	I-Premise
225	items	_	_	I-Premise
226	such	_	_	I-Premise
227	as	_	_	I-Premise
228	anorexia	_	_	I-Premise
229	(	_	_	I-Premise
230	P=0.007	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	ability	_	_	I-Premise
234	to	_	_	I-Premise
235	carry	_	_	I-Premise
236	on	_	_	I-Premise
237	with	_	_	I-Premise
238	daily	_	_	I-Premise
239	activities	_	_	I-Premise
240	(	_	_	I-Premise
241	P=0.04	_	_	I-Premise
242	)	_	_	I-Premise
243	and	_	_	I-Premise
244	overall	_	_	I-Premise
245	impression	_	_	I-Premise
246	of	_	_	I-Premise
247	quality-of-life	_	_	I-Premise
248	(	_	_	I-Premise
249	P=0.008	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Symptom	_	_	B-Premise
253	control	_	_	I-Premise
254	was	_	_	I-Premise
255	very	_	_	I-Premise
256	similar	_	_	I-Premise
257	in	_	_	I-Premise
258	younger	_	_	I-Premise
259	(	_	_	I-Premise
260	<	_	_	I-Premise
261	65	_	_	I-Premise
262	years	_	_	I-Premise
263	)	_	_	I-Premise
264	versus	_	_	I-Premise
265	older	_	_	I-Premise
266	(	_	_	I-Premise
267	>	_	_	I-Premise
268	/=65	_	_	I-Premise
269	years	_	_	I-Premise
270	)	_	_	I-Premise
271	patients	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	I-Premise
274	only	_	_	I-Premise
275	slightly	_	_	I-Premise
276	better	_	_	I-Premise
277	in	_	_	I-Premise
278	those	_	_	I-Premise
279	with	_	_	I-Premise
280	a	_	_	I-Premise
281	Karnofsky	_	_	I-Premise
282	PS	_	_	I-Premise
283	>	_	_	I-Premise
284	/=80	_	_	I-Premise
285	%	_	_	I-Premise
286	compared	_	_	I-Premise
287	to	_	_	I-Premise
288	those	_	_	I-Premise
289	<	_	_	I-Premise
290	80	_	_	I-Premise
291	%	_	_	I-Premise
292	.	_	_	I-Premise

293	Most	_	_	B-Premise
294	of	_	_	I-Premise
295	the	_	_	I-Premise
296	symptom	_	_	I-Premise
297	improvement	_	_	I-Premise
298	occurred	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	first	_	_	I-Premise
302	3	_	_	I-Premise
303	cycles	_	_	I-Premise
304	,	_	_	I-Premise
305	with	_	_	I-Premise
306	some	_	_	I-Premise
307	further	_	_	I-Premise
308	symptom	_	_	I-Premise
309	improvement	_	_	I-Premise
310	in	_	_	I-Premise
311	the	_	_	I-Premise
312	following	_	_	I-Premise
313	cycles	_	_	I-Premise
314	in	_	_	I-Premise
315	the	_	_	I-Premise
316	GEM-arm	_	_	I-Premise
317	only	_	_	I-Premise
318	.	_	_	I-Premise

319	Both	_	_	B-Claim
320	GEM	_	_	I-Claim
321	and	_	_	I-Claim
322	PV	_	_	I-Claim
323	yield	_	_	I-Claim
324	a	_	_	I-Claim
325	symptom	_	_	I-Claim
326	control	_	_	I-Claim
327	rate	_	_	I-Claim
328	much	_	_	I-Claim
329	higher	_	_	I-Claim
330	than	_	_	I-Claim
331	expected	_	_	I-Claim
332	by	_	_	I-Claim
333	the	_	_	I-Claim
334	objective	_	_	I-Claim
335	tumour	_	_	I-Claim
336	RR	_	_	I-Claim
337	.	_	_	I-Claim

338	GEM	_	_	B-Claim
339	is	_	_	I-Claim
340	equally	_	_	I-Claim
341	effective	_	_	I-Claim
342	in	_	_	I-Claim
343	controlling	_	_	I-Claim
344	'disease-specific	_	_	I-Claim
345	'	_	_	I-Claim
346	symptoms	_	_	I-Claim
347	,	_	_	I-Claim
348	but	_	_	I-Claim
349	superior	_	_	I-Claim
350	in	_	_	I-Claim
351	controlling	_	_	I-Claim
352	'constitutional	_	_	I-Claim
353	'	_	_	I-Claim
354	symptoms	_	_	I-Claim
355	.	_	_	I-Claim

356	Most	_	_	B-Premise
357	of	_	_	I-Premise
358	the	_	_	I-Premise
359	symptom	_	_	I-Premise
360	control	_	_	I-Premise
361	was	_	_	I-Premise
362	achieved	_	_	I-Premise
363	during	_	_	I-Premise
364	the	_	_	I-Premise
365	first	_	_	I-Premise
366	3	_	_	I-Premise
367	cycles	_	_	I-Premise
368	of	_	_	I-Premise
369	treatment	_	_	I-Premise
370	,	_	_	I-Premise
371	with	_	_	I-Premise
372	some	_	_	I-Premise
373	further	_	_	I-Premise
374	improvement	_	_	I-Premise
375	thereafter	_	_	I-Premise
376	in	_	_	I-Premise
377	the	_	_	I-Premise
378	GEM-arm	_	_	I-Premise
379	only	_	_	I-Premise
380	.	_	_	I-Premise


0	Brimonidine	_	_	O
1	is	_	_	O
2	a	_	_	O
3	highly	_	_	O
4	selective	_	_	O
5	alpha-2	_	_	O
6	adrenergic	_	_	O
7	receptor	_	_	O
8	agonist	_	_	O
9	with	_	_	O
10	intraocular	_	_	O
11	pressure	_	_	O
12	(	_	_	O
13	IOP	_	_	O
14	)	_	_	O
15	reducing	_	_	O
16	effect	_	_	O
17	.	_	_	O

18	We	_	_	O
19	conducted	_	_	O
20	this	_	_	O
21	study	_	_	O
22	in	_	_	O
23	Taiwan	_	_	O
24	to	_	_	O
25	compare	_	_	O
26	the	_	_	O
27	safety	_	_	O
28	and	_	_	O
29	efficacy	_	_	O
30	of	_	_	O
31	brimonidine	_	_	O
32	0.2	_	_	O
33	%	_	_	O
34	with	_	_	O
35	timolol	_	_	O
36	0.5	_	_	O
37	%	_	_	O
38	for	_	_	O
39	the	_	_	O
40	treatment	_	_	O
41	of	_	_	O
42	glaucoma	_	_	O
43	.	_	_	O

44	A	_	_	O
45	prospective	_	_	O
46	,	_	_	O
47	randomized	_	_	O
48	,	_	_	O
49	single-masked	_	_	O
50	,	_	_	O
51	1-month	_	_	O
52	clinical	_	_	O
53	efficacy	_	_	O
54	and	_	_	O
55	safety	_	_	O
56	trial	_	_	O
57	was	_	_	O
58	conducted	_	_	O
59	from	_	_	O
60	March	_	_	O
61	to	_	_	O
62	September	_	_	O
63	2000	_	_	O
64	.	_	_	O

65	Forty	_	_	O
66	glaucoma	_	_	O
67	patients	_	_	O
68	were	_	_	O
69	enrolled	_	_	O
70	--	_	_	O
71	29	_	_	O
72	in	_	_	O
73	the	_	_	O
74	brimonidine	_	_	O
75	group	_	_	O
76	and	_	_	O
77	11	_	_	O
78	in	_	_	O
79	the	_	_	O
80	timolol	_	_	O
81	group	_	_	O
82	.	_	_	O

83	Patients	_	_	O
84	instilled	_	_	O
85	their	_	_	O
86	study	_	_	O
87	medications	_	_	O
88	twice	_	_	O
89	daily	_	_	O
90	for	_	_	O
91	4	_	_	O
92	weeks	_	_	O
93	,	_	_	O
94	and	_	_	O
95	were	_	_	O
96	followed	_	_	O
97	at	_	_	O
98	baseline	_	_	O
99	visit	_	_	O
100	,	_	_	O
101	weeks	_	_	O
102	2	_	_	O
103	and	_	_	O
104	4	_	_	O
105	.	_	_	O

106	Demographic	_	_	O
107	data	_	_	O
108	,	_	_	O
109	reduction	_	_	O
110	of	_	_	O
111	IOP	_	_	O
112	,	_	_	O
113	safety	_	_	O
114	and	_	_	O
115	adverse	_	_	O
116	events	_	_	O
117	were	_	_	O
118	obtained	_	_	O
119	and	_	_	O
120	analyzed	_	_	O
121	.	_	_	O

122	Both	_	_	O
123	drugs	_	_	O
124	showed	_	_	O
125	sustained	_	_	O
126	ocular	_	_	O
127	hypotensive	_	_	O
128	efficacy	_	_	O
129	in	_	_	O
130	the	_	_	O
131	study	_	_	O
132	period	_	_	O
133	.	_	_	O

134	At	_	_	B-Premise
135	baseline	_	_	I-Premise
136	,	_	_	I-Premise
137	the	_	_	I-Premise
138	mean	_	_	I-Premise
139	IOP	_	_	I-Premise
140	was	_	_	I-Premise
141	24.48	_	_	I-Premise
142	+/-	_	_	I-Premise
143	2.29	_	_	I-Premise
144	mmHg	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	brimonidine	_	_	I-Premise
148	group	_	_	I-Premise
149	and	_	_	I-Premise
150	23.32	_	_	I-Premise
151	+/-	_	_	I-Premise
152	0.82	_	_	I-Premise
153	mmHg	_	_	I-Premise
154	in	_	_	I-Premise
155	the	_	_	I-Premise
156	timolol	_	_	I-Premise
157	group	_	_	I-Premise
158	.	_	_	I-Premise

159	The	_	_	B-Premise
160	IOP	_	_	I-Premise
161	readings	_	_	I-Premise
162	after	_	_	I-Premise
163	treatment	_	_	I-Premise
164	were	_	_	I-Premise
165	significantly	_	_	I-Premise
166	lower	_	_	I-Premise
167	than	_	_	I-Premise
168	their	_	_	I-Premise
169	baseline	_	_	I-Premise
170	levels	_	_	I-Premise
171	in	_	_	I-Premise
172	both	_	_	I-Premise
173	groups	_	_	I-Premise
174	at	_	_	I-Premise
175	all	_	_	I-Premise
176	visits	_	_	I-Premise
177	(	_	_	I-Premise
178	p	_	_	I-Premise
179	<	_	_	I-Premise
180	0.001	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	At	_	_	B-Premise
184	peak	_	_	I-Premise
185	,	_	_	I-Premise
186	the	_	_	I-Premise
187	mean	_	_	I-Premise
188	decreases	_	_	I-Premise
189	from	_	_	I-Premise
190	the	_	_	I-Premise
191	baseline	_	_	I-Premise
192	IOP	_	_	I-Premise
193	ranged	_	_	I-Premise
194	from	_	_	I-Premise
195	5.22	_	_	I-Premise
196	+/-	_	_	I-Premise
197	0.30	_	_	I-Premise
198	mmHg	_	_	I-Premise
199	to	_	_	I-Premise
200	6.96	_	_	I-Premise
201	+/-	_	_	I-Premise
202	0.33	_	_	I-Premise
203	mmHg	_	_	I-Premise
204	for	_	_	I-Premise
205	brimonidine	_	_	I-Premise
206	and	_	_	I-Premise
207	from	_	_	I-Premise
208	4.55	_	_	I-Premise
209	+/-	_	_	I-Premise
210	0.49	_	_	I-Premise
211	mmHg	_	_	I-Premise
212	to	_	_	I-Premise
213	6.64	_	_	I-Premise
214	+/-	_	_	I-Premise
215	0.53	_	_	I-Premise
216	mmHg	_	_	I-Premise
217	for	_	_	I-Premise
218	timolol	_	_	I-Premise
219	.	_	_	I-Premise

220	At	_	_	B-Premise
221	trough	_	_	I-Premise
222	,	_	_	I-Premise
223	the	_	_	I-Premise
224	mean	_	_	I-Premise
225	decreases	_	_	I-Premise
226	from	_	_	I-Premise
227	baseline	_	_	I-Premise
228	ranged	_	_	I-Premise
229	from	_	_	I-Premise
230	3.72	_	_	I-Premise
231	+/-	_	_	I-Premise
232	0.32	_	_	I-Premise
233	mmHg	_	_	I-Premise
234	to	_	_	I-Premise
235	4.55	_	_	I-Premise
236	+/-	_	_	I-Premise
237	0.32	_	_	I-Premise
238	mmHg	_	_	I-Premise
239	for	_	_	I-Premise
240	brimonidine	_	_	I-Premise
241	and	_	_	I-Premise
242	3.82	_	_	I-Premise
243	+/-	_	_	I-Premise
244	0.52	_	_	I-Premise
245	mmHg	_	_	I-Premise
246	to	_	_	I-Premise
247	4.27	_	_	I-Premise
248	+/-	_	_	I-Premise
249	0.51	_	_	I-Premise
250	mmHg	_	_	I-Premise
251	for	_	_	I-Premise
252	timolol	_	_	I-Premise
253	.	_	_	I-Premise

254	No	_	_	O
255	significant	_	_	O
256	between-group	_	_	O
257	differences	_	_	O
258	were	_	_	O
259	seen	_	_	O
260	at	_	_	O
261	peak	_	_	O
262	or	_	_	O
263	trough	_	_	O
264	at	_	_	O
265	all	_	_	O
266	visits	_	_	O
267	.	_	_	O

268	The	_	_	B-Premise
269	clinical	_	_	I-Premise
270	success	_	_	I-Premise
271	rate	_	_	I-Premise
272	was	_	_	I-Premise
273	86.2	_	_	I-Premise
274	%	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	brimonidine	_	_	I-Premise
278	group	_	_	I-Premise
279	and	_	_	I-Premise
280	81.8	_	_	I-Premise
281	%	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	timolol	_	_	I-Premise
285	group	_	_	I-Premise
286	,	_	_	I-Premise
287	making	_	_	I-Premise
288	no	_	_	I-Premise
289	statistically	_	_	I-Premise
290	significant	_	_	I-Premise
291	difference	_	_	I-Premise
292	between	_	_	I-Premise
293	them	_	_	I-Premise
294	(	_	_	I-Premise
295	p	_	_	I-Premise
296	=	_	_	I-Premise
297	0.817	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	17.2	_	_	B-Premise
301	%	_	_	I-Premise
302	of	_	_	I-Premise
303	patients	_	_	I-Premise
304	in	_	_	I-Premise
305	brimonidine	_	_	I-Premise
306	group	_	_	I-Premise
307	and	_	_	I-Premise
308	9.0	_	_	I-Premise
309	%	_	_	I-Premise
310	patients	_	_	I-Premise
311	in	_	_	I-Premise
312	timolol	_	_	I-Premise
313	group	_	_	I-Premise
314	reported	_	_	I-Premise
315	mild	_	_	I-Premise
316	adverse	_	_	I-Premise
317	events	_	_	I-Premise
318	.	_	_	I-Premise

319	Ocular	_	_	B-Premise
320	allergy	_	_	I-Premise
321	occurred	_	_	I-Premise
322	in	_	_	I-Premise
323	10.3	_	_	I-Premise
324	%	_	_	I-Premise
325	of	_	_	I-Premise
326	patients	_	_	I-Premise
327	in	_	_	I-Premise
328	brimonidine	_	_	I-Premise
329	group	_	_	I-Premise
330	.	_	_	I-Premise

331	No	_	_	B-Premise
332	significant	_	_	I-Premise
333	changes	_	_	I-Premise
334	in	_	_	I-Premise
335	visual	_	_	I-Premise
336	acuity	_	_	I-Premise
337	,	_	_	I-Premise
338	biomicroscopy	_	_	I-Premise
339	or	_	_	I-Premise
340	ophthalmoscopy	_	_	I-Premise
341	were	_	_	I-Premise
342	observed	_	_	I-Premise
343	in	_	_	I-Premise
344	both	_	_	I-Premise
345	groups	_	_	I-Premise
346	.	_	_	I-Premise

347	Mean	_	_	B-Premise
348	systolic	_	_	I-Premise
349	and	_	_	I-Premise
350	diastolic	_	_	I-Premise
351	blood	_	_	I-Premise
352	pressure	_	_	I-Premise
353	remained	_	_	I-Premise
354	relatively	_	_	I-Premise
355	stable	_	_	I-Premise
356	in	_	_	I-Premise
357	both	_	_	I-Premise
358	groups	_	_	I-Premise
359	except	_	_	B-Premise
360	in	_	_	I-Premise
361	week	_	_	I-Premise
362	2	_	_	I-Premise
363	(	_	_	I-Premise
364	p	_	_	I-Premise
365	=	_	_	I-Premise
366	0.016	_	_	I-Premise
367	)	_	_	I-Premise
368	when	_	_	I-Premise
369	brimonidine	_	_	I-Premise
370	had	_	_	I-Premise
371	lower	_	_	I-Premise
372	systolic	_	_	I-Premise
373	blood	_	_	I-Premise
374	pressure	_	_	I-Premise
375	.	_	_	I-Premise

376	However	_	_	O
377	,	_	_	O
378	brimonidine	_	_	O
379	showed	_	_	O
380	no	_	_	O
381	significant	_	_	O
382	difference	_	_	O
383	in	_	_	O
384	week	_	_	O
385	4	_	_	O
386	from	_	_	O
387	baseline	_	_	O
388	.	_	_	O

389	The	_	_	B-Premise
390	mean	_	_	I-Premise
391	heart	_	_	I-Premise
392	rate	_	_	I-Premise
393	in	_	_	I-Premise
394	the	_	_	I-Premise
395	brimonidine	_	_	I-Premise
396	group	_	_	I-Premise
397	was	_	_	I-Premise
398	relatively	_	_	I-Premise
399	unchanged	_	_	I-Premise
400	over	_	_	I-Premise
401	the	_	_	I-Premise
402	study	_	_	I-Premise
403	period	_	_	I-Premise
404	.	_	_	I-Premise

405	Patients	_	_	B-Premise
406	receiving	_	_	I-Premise
407	timolol	_	_	I-Premise
408	experienced	_	_	I-Premise
409	statistically	_	_	I-Premise
410	significant	_	_	I-Premise
411	mean	_	_	I-Premise
412	heart	_	_	I-Premise
413	rate	_	_	I-Premise
414	decreases	_	_	I-Premise
415	from	_	_	I-Premise
416	baseline	_	_	I-Premise
417	(	_	_	I-Premise
418	p	_	_	I-Premise
419	=	_	_	I-Premise
420	0.020	_	_	I-Premise
421	)	_	_	I-Premise
422	in	_	_	I-Premise
423	week	_	_	I-Premise
424	4	_	_	I-Premise
425	.	_	_	I-Premise

426	Topically	_	_	B-Claim
427	applied	_	_	I-Claim
428	twice	_	_	I-Claim
429	daily	_	_	I-Claim
430	for	_	_	I-Claim
431	one	_	_	I-Claim
432	month	_	_	I-Claim
433	,	_	_	I-Claim
434	brimonidine	_	_	I-Claim
435	tartrate	_	_	I-Claim
436	0.2	_	_	I-Claim
437	%	_	_	I-Claim
438	has	_	_	I-Claim
439	clinical	_	_	I-Claim
440	effectiveness	_	_	I-Claim
441	equivalent	_	_	I-Claim
442	to	_	_	I-Claim
443	timolol	_	_	I-Claim
444	0.5	_	_	I-Claim
445	%	_	_	I-Claim
446	in	_	_	I-Claim
447	Taiwanese	_	_	I-Claim
448	patients	_	_	I-Claim
449	with	_	_	I-Claim
450	glaucoma	_	_	I-Claim
451	.	_	_	I-Claim

452	It	_	_	B-Claim
453	has	_	_	I-Claim
454	a	_	_	I-Claim
455	safe	_	_	I-Claim
456	systemic	_	_	I-Claim
457	profile	_	_	I-Claim
458	with	_	_	I-Claim
459	minimum	_	_	I-Claim
460	effect	_	_	I-Claim
461	on	_	_	I-Claim
462	the	_	_	I-Claim
463	heart	_	_	I-Claim
464	.	_	_	I-Claim


0	This	_	_	O
1	trial	_	_	O
2	was	_	_	O
3	conducted	_	_	O
4	to	_	_	O
5	determine	_	_	O
6	whether	_	_	O
7	high-dose	_	_	O
8	fluorouracil	_	_	O
9	(	_	_	O
10	FU	_	_	O
11	)	_	_	O
12	given	_	_	O
13	as	_	_	O
14	a	_	_	O
15	weekly	_	_	O
16	24-hour	_	_	O
17	infusion	_	_	O
18	is	_	_	O
19	more	_	_	O
20	active	_	_	O
21	than	_	_	O
22	bolus	_	_	O
23	FU	_	_	O
24	+	_	_	O
25	leucovorin	_	_	O
26	(	_	_	O
27	LV	_	_	O
28	)	_	_	O
29	,	_	_	O
30	and	_	_	O
31	whether	_	_	O
32	high-dose	_	_	O
33	infusional	_	_	O
34	FU	_	_	O
35	can	_	_	O
36	be	_	_	O
37	modulated	_	_	O
38	by	_	_	O
39	LV	_	_	O
40	.	_	_	O

41	A	_	_	O
42	total	_	_	O
43	of	_	_	O
44	497	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	previously	_	_	O
48	untreated	_	_	O
49	metastatic	_	_	O
50	colorectal	_	_	O
51	cancer	_	_	O
52	were	_	_	O
53	randomly	_	_	O
54	assigned	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	bolus	_	_	O
58	FU	_	_	O
59	425	_	_	O
60	mg/m2	_	_	O
61	intravenously	_	_	O
62	+	_	_	O
63	LV	_	_	O
64	20	_	_	O
65	mg/m2	_	_	O
66	on	_	_	O
67	days	_	_	O
68	1	_	_	O
69	to	_	_	O
70	5	_	_	O
71	and	_	_	O
72	repeated	_	_	O
73	on	_	_	O
74	day	_	_	O
75	28	_	_	O
76	(	_	_	O
77	FU	_	_	O
78	+	_	_	O
79	LV	_	_	O
80	)	_	_	O
81	,	_	_	O
82	or	_	_	O
83	FU	_	_	O
84	2600	_	_	O
85	mg/m2	_	_	O
86	as	_	_	O
87	a	_	_	O
88	24-hour	_	_	O
89	infusion	_	_	O
90	alone	_	_	O
91	(	_	_	O
92	FU24h	_	_	O
93	)	_	_	O
94	or	_	_	O
95	in	_	_	O
96	combination	_	_	O
97	with	_	_	O
98	500	_	_	O
99	mg/m2	_	_	O
100	LV	_	_	O
101	(	_	_	O
102	FU24h	_	_	O
103	+	_	_	O
104	LV	_	_	O
105	)	_	_	O
106	-all	_	_	O
107	given	_	_	O
108	weekly	_	_	O
109	x6	_	_	O
110	followed	_	_	O
111	by	_	_	O
112	a	_	_	O
113	2-week	_	_	O
114	rest	_	_	O
115	period	_	_	O
116	.	_	_	O

117	Survival	_	_	O
118	was	_	_	O
119	the	_	_	O
120	major	_	_	O
121	study	_	_	O
122	end	_	_	O
123	point	_	_	O
124	.	_	_	O

125	With	_	_	B-Premise
126	a	_	_	I-Premise
127	median	_	_	I-Premise
128	follow-up	_	_	I-Premise
129	of	_	_	I-Premise
130	more	_	_	I-Premise
131	than	_	_	I-Premise
132	3	_	_	I-Premise
133	years	_	_	I-Premise
134	,	_	_	I-Premise
135	survival	_	_	I-Premise
136	did	_	_	I-Premise
137	not	_	_	I-Premise
138	differ	_	_	I-Premise
139	among	_	_	I-Premise
140	the	_	_	I-Premise
141	treatment	_	_	I-Premise
142	groups	_	_	I-Premise
143	(	_	_	I-Premise
144	median	_	_	I-Premise
145	FU	_	_	I-Premise
146	+	_	_	I-Premise
147	LV	_	_	I-Premise
148	,	_	_	I-Premise
149	11.1	_	_	I-Premise
150	months	_	_	I-Premise
151	[	_	_	I-Premise
152	95	_	_	I-Premise
153	%	_	_	I-Premise
154	CI	_	_	I-Premise
155	,	_	_	I-Premise
156	10.2	_	_	I-Premise
157	to	_	_	I-Premise
158	15.0	_	_	I-Premise
159	months	_	_	I-Premise
160	]	_	_	I-Premise
161	;	_	_	I-Premise
162	FU24h	_	_	I-Premise
163	,	_	_	I-Premise
164	13.0	_	_	I-Premise
165	months	_	_	I-Premise
166	[	_	_	I-Premise
167	95	_	_	I-Premise
168	%	_	_	I-Premise
169	CI	_	_	I-Premise
170	,	_	_	I-Premise
171	10.4	_	_	I-Premise
172	to	_	_	I-Premise
173	15.4	_	_	I-Premise
174	months	_	_	I-Premise
175	]	_	_	I-Premise
176	;	_	_	I-Premise
177	FU24h	_	_	I-Premise
178	+	_	_	I-Premise
179	LV	_	_	I-Premise
180	,	_	_	I-Premise
181	13.7	_	_	I-Premise
182	months	_	_	I-Premise
183	[	_	_	I-Premise
184	95	_	_	I-Premise
185	%	_	_	I-Premise
186	CI	_	_	I-Premise
187	,	_	_	I-Premise
188	12.0	_	_	I-Premise
189	to	_	_	I-Premise
190	16.4	_	_	I-Premise
191	months	_	_	I-Premise
192	]	_	_	I-Premise
193	;	_	_	I-Premise
194	P	_	_	I-Premise
195	=.724	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	Progression-free	_	_	B-Premise
199	survival	_	_	I-Premise
200	(	_	_	I-Premise
201	PFS	_	_	I-Premise
202	)	_	_	I-Premise
203	was	_	_	I-Premise
204	significantly	_	_	I-Premise
205	longer	_	_	I-Premise
206	for	_	_	I-Premise
207	FU24h	_	_	I-Premise
208	+	_	_	I-Premise
209	LV	_	_	I-Premise
210	(	_	_	I-Premise
211	median	_	_	I-Premise
212	FU	_	_	I-Premise
213	+	_	_	I-Premise
214	LV	_	_	I-Premise
215	,	_	_	I-Premise
216	4.0	_	_	I-Premise
217	months	_	_	I-Premise
218	[	_	_	I-Premise
219	95	_	_	I-Premise
220	%	_	_	I-Premise
221	CI	_	_	I-Premise
222	,	_	_	I-Premise
223	3.4	_	_	I-Premise
224	to	_	_	I-Premise
225	4.9	_	_	I-Premise
226	]	_	_	I-Premise
227	;	_	_	I-Premise
228	FU24h	_	_	I-Premise
229	,	_	_	I-Premise
230	4.1	_	_	I-Premise
231	months	_	_	I-Premise
232	[	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	,	_	_	I-Premise
237	3.4	_	_	I-Premise
238	to	_	_	I-Premise
239	5.0	_	_	I-Premise
240	]	_	_	I-Premise
241	;	_	_	I-Premise
242	FU24h	_	_	I-Premise
243	+	_	_	I-Premise
244	LV	_	_	I-Premise
245	5.6	_	_	I-Premise
246	months	_	_	I-Premise
247	[	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	,	_	_	I-Premise
252	4.4	_	_	I-Premise
253	to	_	_	I-Premise
254	6.7	_	_	I-Premise
255	]	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=.029	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	The	_	_	B-Premise
262	response	_	_	I-Premise
263	rates	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	subgroup	_	_	I-Premise
267	of	_	_	I-Premise
268	patients	_	_	I-Premise
269	with	_	_	I-Premise
270	measurable	_	_	I-Premise
271	disease	_	_	I-Premise
272	were	_	_	I-Premise
273	12	_	_	I-Premise
274	%	_	_	I-Premise
275	,	_	_	I-Premise
276	10	_	_	I-Premise
277	%	_	_	I-Premise
278	,	_	_	I-Premise
279	and	_	_	I-Premise
280	17	_	_	I-Premise
281	%	_	_	I-Premise
282	for	_	_	I-Premise
283	FU	_	_	I-Premise
284	+	_	_	I-Premise
285	LV	_	_	I-Premise
286	,	_	_	I-Premise
287	FU24h	_	_	I-Premise
288	,	_	_	I-Premise
289	and	_	_	I-Premise
290	FU24h	_	_	I-Premise
291	+	_	_	I-Premise
292	LV	_	_	I-Premise
293	,	_	_	I-Premise
294	respectively	_	_	I-Premise
295	(	_	_	I-Premise
296	not	_	_	I-Premise
297	significant	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Occurrence	_	_	B-Premise
301	of	_	_	I-Premise
302	grade	_	_	I-Premise
303	3	_	_	I-Premise
304	and	_	_	I-Premise
305	4	_	_	I-Premise
306	diarrhea	_	_	I-Premise
307	was	_	_	I-Premise
308	higher	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	FU24h	_	_	I-Premise
312	+	_	_	I-Premise
313	LV	_	_	I-Premise
314	arm	_	_	I-Premise
315	(	_	_	I-Premise
316	22	_	_	I-Premise
317	%	_	_	I-Premise
318	)	_	_	I-Premise
319	compared	_	_	I-Premise
320	with	_	_	I-Premise
321	the	_	_	I-Premise
322	FU24h	_	_	I-Premise
323	(	_	_	I-Premise
324	6	_	_	I-Premise
325	%	_	_	I-Premise
326	)	_	_	I-Premise
327	or	_	_	I-Premise
328	FU	_	_	I-Premise
329	+	_	_	I-Premise
330	LV	_	_	I-Premise
331	(	_	_	I-Premise
332	9	_	_	I-Premise
333	%	_	_	I-Premise
334	)	_	_	I-Premise
335	arms	_	_	I-Premise
336	;	_	_	I-Premise
337	however	_	_	B-Premise
338	,	_	_	I-Premise
339	stomatitis	_	_	I-Premise
340	(	_	_	I-Premise
341	11	_	_	I-Premise
342	%	_	_	I-Premise
343	in	_	_	I-Premise
344	FU	_	_	I-Premise
345	+	_	_	I-Premise
346	LV	_	_	I-Premise
347	v	_	_	I-Premise
348	3	_	_	I-Premise
349	%	_	_	I-Premise
350	in	_	_	I-Premise
351	FU24h	_	_	I-Premise
352	v	_	_	I-Premise
353	5	_	_	I-Premise
354	%	_	_	I-Premise
355	in	_	_	I-Premise
356	FU24h	_	_	I-Premise
357	+	_	_	I-Premise
358	LV	_	_	I-Premise
359	arms	_	_	I-Premise
360	)	_	_	I-Premise
361	and	_	_	I-Premise
362	hematologic	_	_	I-Premise
363	toxicity	_	_	I-Premise
364	were	_	_	I-Premise
365	higher	_	_	I-Premise
366	in	_	_	I-Premise
367	the	_	_	I-Premise
368	bolus	_	_	I-Premise
369	FU	_	_	I-Premise
370	+	_	_	I-Premise
371	LV	_	_	I-Premise
372	arm	_	_	I-Premise
373	.	_	_	I-Premise

374	Global	_	_	B-Claim
375	quality	_	_	I-Claim
376	of	_	_	I-Claim
377	life	_	_	I-Claim
378	did	_	_	I-Claim
379	not	_	_	I-Claim
380	differ	_	_	I-Claim
381	within	_	_	I-Claim
382	the	_	_	I-Claim
383	three	_	_	I-Claim
384	arms	_	_	I-Claim
385	.	_	_	I-Claim

386	Neither	_	_	B-Claim
387	FU24h	_	_	I-Claim
388	+	_	_	I-Claim
389	LV	_	_	I-Claim
390	nor	_	_	I-Claim
391	FU24h	_	_	I-Claim
392	prolong	_	_	I-Claim
393	survival	_	_	I-Claim
394	,	_	_	I-Claim
395	relative	_	_	I-Claim
396	to	_	_	I-Claim
397	bolus	_	_	I-Claim
398	FU	_	_	I-Claim
399	+	_	_	I-Claim
400	LV	_	_	I-Claim
401	.	_	_	I-Claim

402	Leucovorin	_	_	B-Claim
403	increases	_	_	I-Claim
404	PFS	_	_	I-Claim
405	if	_	_	I-Claim
406	added	_	_	I-Claim
407	to	_	_	I-Claim
408	FU24h	_	_	I-Claim
409	,	_	_	I-Claim
410	but	_	_	I-Claim
411	increases	_	_	I-Claim
412	toxicity	_	_	I-Claim
413	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	topical	_	_	O
8	bimatoprost	_	_	O
9	(	_	_	O
10	LUMIGAN	_	_	O
11	;	_	_	O
12	Allergan	_	_	O
13	,	_	_	O
14	Inc.	_	_	O
15	,	_	_	O
16	Irvine	_	_	O
17	,	_	_	O
18	CA	_	_	O
19	)	_	_	O
20	once	_	_	O
21	daily	_	_	O
22	with	_	_	O
23	that	_	_	O
24	of	_	_	O
25	topical	_	_	O
26	combined	_	_	O
27	timolol	_	_	O
28	and	_	_	O
29	dorzolamide	_	_	O
30	(	_	_	O
31	Cosopt	_	_	O
32	;	_	_	O
33	Merck	_	_	O
34	and	_	_	O
35	Co	_	_	O
36	,	_	_	O
37	Inc.	_	_	O
38	,	_	_	O
39	Whitehouse	_	_	O
40	Station	_	_	O
41	,	_	_	O
42	NJ	_	_	O
43	)	_	_	O
44	twice	_	_	O
45	daily	_	_	O
46	.	_	_	O

47	Prospective	_	_	O
48	,	_	_	O
49	randomized	_	_	O
50	,	_	_	O
51	double-masked	_	_	O
52	,	_	_	O
53	multicenter	_	_	O
54	clinical	_	_	O
55	trial	_	_	O
56	.	_	_	O

57	One	_	_	O
58	hundred	_	_	O
59	seventy-seven	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	a	_	_	O
63	diagnosis	_	_	O
64	of	_	_	O
65	glaucoma	_	_	O
66	or	_	_	O
67	ocular	_	_	O
68	hypertension	_	_	O
69	and	_	_	O
70	inadequate	_	_	O
71	control	_	_	O
72	of	_	_	O
73	intraocular	_	_	O
74	pressure	_	_	O
75	(	_	_	O
76	IOP	_	_	O
77	)	_	_	O
78	after	_	_	O
79	at	_	_	O
80	least	_	_	O
81	2	_	_	O
82	weeks	_	_	O
83	of	_	_	O
84	topical	_	_	O
85	timolol	_	_	O
86	maleate	_	_	O
87	0.5	_	_	O
88	%	_	_	O
89	monotherapy	_	_	O
90	.	_	_	O

91	Patients	_	_	O
92	were	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	receive	_	_	O
96	bimatoprost	_	_	O
97	0.03	_	_	O
98	%	_	_	O
99	once	_	_	O
100	daily	_	_	O
101	(	_	_	O
102	n	_	_	O
103	=	_	_	O
104	90	_	_	O
105	)	_	_	O
106	or	_	_	O
107	combined	_	_	O
108	timolol	_	_	O
109	0.5	_	_	O
110	%	_	_	O
111	and	_	_	O
112	dorzolamide	_	_	O
113	2	_	_	O
114	%	_	_	O
115	twice	_	_	O
116	daily	_	_	O
117	(	_	_	O
118	n	_	_	O
119	=	_	_	O
120	87	_	_	O
121	)	_	_	O
122	over	_	_	O
123	a	_	_	O
124	3-month	_	_	O
125	period	_	_	O
126	.	_	_	O

127	Intraocular	_	_	O
128	pressure	_	_	O
129	,	_	_	O
130	the	_	_	O
131	primary	_	_	O
132	end	_	_	O
133	point	_	_	O
134	,	_	_	O
135	was	_	_	O
136	measured	_	_	O
137	at	_	_	O
138	8	_	_	O
139	AM	_	_	O
140	and	_	_	O
141	10	_	_	O
142	AM	_	_	O
143	at	_	_	O
144	baseline	_	_	O
145	,	_	_	O
146	week	_	_	O
147	1	_	_	O
148	,	_	_	O
149	and	_	_	O
150	months	_	_	O
151	1	_	_	O
152	,	_	_	O
153	2	_	_	O
154	,	_	_	O
155	and	_	_	O
156	3	_	_	O
157	,	_	_	O
158	and	_	_	O
159	also	_	_	O
160	at	_	_	O
161	4	_	_	O
162	PM	_	_	O
163	and	_	_	O
164	8	_	_	O
165	PM	_	_	O
166	at	_	_	O
167	baseline	_	_	O
168	and	_	_	O
169	month	_	_	O
170	3	_	_	O
171	.	_	_	O

172	Bimatoprost	_	_	B-Premise
173	provided	_	_	I-Premise
174	significantly	_	_	I-Premise
175	greater	_	_	I-Premise
176	IOP	_	_	I-Premise
177	lowering	_	_	I-Premise
178	compared	_	_	I-Premise
179	with	_	_	I-Premise
180	combined	_	_	I-Premise
181	timolol	_	_	I-Premise
182	and	_	_	I-Premise
183	dorzolamide	_	_	I-Premise
184	.	_	_	I-Premise

185	At	_	_	B-Premise
186	the	_	_	I-Premise
187	8	_	_	I-Premise
188	AM	_	_	I-Premise
189	measurements	_	_	I-Premise
190	,	_	_	I-Premise
191	bimatoprost	_	_	I-Premise
192	lowered	_	_	I-Premise
193	mean	_	_	I-Premise
194	IOP	_	_	I-Premise
195	6.8	_	_	I-Premise
196	mmHg	_	_	I-Premise
197	to	_	_	I-Premise
198	7.6	_	_	I-Premise
199	mmHg	_	_	I-Premise
200	from	_	_	I-Premise
201	baseline	_	_	I-Premise
202	,	_	_	I-Premise
203	whereas	_	_	I-Premise
204	combined	_	_	I-Premise
205	timolol	_	_	I-Premise
206	and	_	_	I-Premise
207	dorzolamide	_	_	I-Premise
208	lowered	_	_	I-Premise
209	mean	_	_	I-Premise
210	IOP	_	_	I-Premise
211	4.4	_	_	I-Premise
212	to	_	_	I-Premise
213	5.0	_	_	I-Premise
214	mmHg	_	_	I-Premise
215	from	_	_	I-Premise
216	baseline	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	<	_	_	I-Premise
220	0.001	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	At	_	_	B-Premise
224	the	_	_	I-Premise
225	last	_	_	I-Premise
226	follow-up	_	_	I-Premise
227	,	_	_	I-Premise
228	patients	_	_	I-Premise
229	had	_	_	I-Premise
230	better	_	_	I-Premise
231	diurnal	_	_	I-Premise
232	IOP	_	_	I-Premise
233	control	_	_	I-Premise
234	with	_	_	I-Premise
235	bimatoprost	_	_	I-Premise
236	than	_	_	I-Premise
237	combined	_	_	I-Premise
238	timolol	_	_	I-Premise
239	and	_	_	I-Premise
240	dorzolamide	_	_	I-Premise
241	.	_	_	I-Premise

242	At	_	_	B-Premise
243	8	_	_	I-Premise
244	AM	_	_	I-Premise
245	at	_	_	I-Premise
246	the	_	_	I-Premise
247	3-month	_	_	I-Premise
248	visit	_	_	I-Premise
249	,	_	_	I-Premise
250	the	_	_	I-Premise
251	percentages	_	_	I-Premise
252	of	_	_	I-Premise
253	patients	_	_	I-Premise
254	achieving	_	_	I-Premise
255	IOPs	_	_	I-Premise
256	of	_	_	I-Premise
257	<	_	_	I-Premise
258	or	_	_	I-Premise
259	=13	_	_	I-Premise
260	mmHg	_	_	I-Premise
261	,	_	_	I-Premise
262	<	_	_	I-Premise
263	or	_	_	I-Premise
264	=14	_	_	I-Premise
265	mmHg	_	_	I-Premise
266	,	_	_	I-Premise
267	<	_	_	I-Premise
268	or	_	_	I-Premise
269	=15	_	_	I-Premise
270	mmHg	_	_	I-Premise
271	,	_	_	I-Premise
272	or	_	_	I-Premise
273	<	_	_	I-Premise
274	or	_	_	I-Premise
275	=16	_	_	I-Premise
276	mmHg	_	_	I-Premise
277	were	_	_	I-Premise
278	more	_	_	I-Premise
279	than	_	_	I-Premise
280	twice	_	_	I-Premise
281	as	_	_	I-Premise
282	high	_	_	I-Premise
283	for	_	_	I-Premise
284	bimatoprost	_	_	I-Premise
285	than	_	_	I-Premise
286	for	_	_	I-Premise
287	combined	_	_	I-Premise
288	timolol	_	_	I-Premise
289	and	_	_	I-Premise
290	dorzolamide	_	_	I-Premise
291	(	_	_	I-Premise
292	all	_	_	I-Premise
293	P	_	_	I-Premise
294	<	_	_	I-Premise
295	or	_	_	I-Premise
296	=0.008	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Taste	_	_	B-Premise
300	perversion	_	_	I-Premise
301	,	_	_	I-Premise
302	ocular	_	_	I-Premise
303	burning	_	_	I-Premise
304	,	_	_	I-Premise
305	and	_	_	I-Premise
306	stinging	_	_	I-Premise
307	with	_	_	I-Premise
308	instillation	_	_	I-Premise
309	were	_	_	I-Premise
310	more	_	_	I-Premise
311	common	_	_	I-Premise
312	with	_	_	I-Premise
313	combined	_	_	I-Premise
314	timolol	_	_	I-Premise
315	and	_	_	I-Premise
316	dorzolamide	_	_	I-Premise
317	,	_	_	I-Premise
318	whereas	_	_	I-Premise
319	conjunctival	_	_	I-Premise
320	hyperemia	_	_	I-Premise
321	was	_	_	I-Premise
322	more	_	_	I-Premise
323	common	_	_	I-Premise
324	with	_	_	I-Premise
325	bimatoprost	_	_	I-Premise
326	.	_	_	I-Premise

327	In	_	_	B-Claim
328	individuals	_	_	I-Claim
329	with	_	_	I-Claim
330	glaucoma	_	_	I-Claim
331	or	_	_	I-Claim
332	ocular	_	_	I-Claim
333	hypertension	_	_	I-Claim
334	,	_	_	I-Claim
335	uncontrolled	_	_	I-Claim
336	on	_	_	I-Claim
337	a	_	_	I-Claim
338	topical	_	_	I-Claim
339	beta-blocker	_	_	I-Claim
340	alone	_	_	I-Claim
341	,	_	_	I-Claim
342	bimatoprost	_	_	I-Claim
343	lowered	_	_	I-Claim
344	IOP	_	_	I-Claim
345	more	_	_	I-Claim
346	consistently	_	_	I-Claim
347	than	_	_	I-Claim
348	did	_	_	I-Claim
349	combined	_	_	I-Claim
350	timolol	_	_	I-Claim
351	and	_	_	I-Claim
352	dorzolamide	_	_	I-Claim
353	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	health-related	_	_	O
3	quality	_	_	O
4	of	_	_	O
5	life	_	_	O
6	(	_	_	O
7	HRQOL	_	_	O
8	)	_	_	O
9	in	_	_	O
10	patients	_	_	O
11	with	_	_	O
12	metastatic	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	receiving	_	_	O
16	the	_	_	O
17	combination	_	_	O
18	of	_	_	O
19	doxorubicin	_	_	O
20	and	_	_	O
21	paclitaxel	_	_	O
22	(	_	_	O
23	AT	_	_	O
24	)	_	_	O
25	or	_	_	O
26	doxorubicin	_	_	O
27	and	_	_	O
28	cyclophosphamide	_	_	O
29	(	_	_	O
30	AC	_	_	O
31	)	_	_	O
32	as	_	_	O
33	first-line	_	_	O
34	chemotherapy	_	_	O
35	treatment	_	_	O
36	.	_	_	O

37	Eligible	_	_	O
38	patients	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	275	_	_	O
43	)	_	_	O
44	with	_	_	O
45	anthracycline-naive	_	_	O
46	measurable	_	_	O
47	metastatic	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	were	_	_	O
51	randomly	_	_	O
52	assigned	_	_	O
53	to	_	_	O
54	AT	_	_	O
55	(	_	_	O
56	doxorubicin	_	_	O
57	60	_	_	O
58	mg/m	_	_	O
59	(	_	_	O
60	2	_	_	O
61	)	_	_	O
62	as	_	_	O
63	an	_	_	O
64	intravenous	_	_	O
65	bolus	_	_	O
66	plus	_	_	O
67	paclitaxel	_	_	O
68	175	_	_	O
69	mg/m	_	_	O
70	(	_	_	O
71	2	_	_	O
72	)	_	_	O
73	as	_	_	O
74	a	_	_	O
75	3-hour	_	_	O
76	infusion	_	_	O
77	)	_	_	O
78	or	_	_	O
79	AC	_	_	O
80	(	_	_	O
81	doxorubicin	_	_	O
82	60	_	_	O
83	mg/m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	plus	_	_	O
88	cyclophosphamide	_	_	O
89	600	_	_	O
90	mg/m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	)	_	_	O
95	every	_	_	O
96	3	_	_	O
97	weeks	_	_	O
98	for	_	_	O
99	a	_	_	O
100	maximum	_	_	O
101	of	_	_	O
102	six	_	_	O
103	cycles	_	_	O
104	.	_	_	O

105	Dose	_	_	O
106	escalation	_	_	O
107	of	_	_	O
108	paclitaxel	_	_	O
109	(	_	_	O
110	200	_	_	O
111	mg/m	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	)	_	_	O
116	and	_	_	O
117	cyclophosphamide	_	_	O
118	(	_	_	O
119	750	_	_	O
120	mg/m	_	_	O
121	(	_	_	O
122	2	_	_	O
123	)	_	_	O
124	)	_	_	O
125	was	_	_	O
126	planned	_	_	O
127	at	_	_	O
128	cycle	_	_	O
129	2	_	_	O
130	to	_	_	O
131	reach	_	_	O
132	equivalent	_	_	O
133	myelosuppression	_	_	O
134	in	_	_	O
135	the	_	_	O
136	two	_	_	O
137	groups	_	_	O
138	.	_	_	O

139	HRQOL	_	_	O
140	was	_	_	O
141	assessed	_	_	O
142	with	_	_	O
143	the	_	_	O
144	European	_	_	O
145	Organization	_	_	O
146	for	_	_	O
147	Research	_	_	O
148	and	_	_	O
149	Treatment	_	_	O
150	of	_	_	O
151	Cancer	_	_	O
152	(	_	_	O
153	EORTC	_	_	O
154	)	_	_	O
155	Quality	_	_	O
156	of	_	_	O
157	Life	_	_	O
158	Questionnaire	_	_	O
159	C30	_	_	O
160	and	_	_	O
161	the	_	_	O
162	EORTC	_	_	O
163	Breast	_	_	O
164	Module	_	_	O
165	at	_	_	O
166	baseline	_	_	O
167	and	_	_	O
168	the	_	_	O
169	start	_	_	O
170	of	_	_	O
171	cycles	_	_	O
172	2	_	_	O
173	,	_	_	O
174	4	_	_	O
175	,	_	_	O
176	and	_	_	O
177	6	_	_	O
178	,	_	_	O
179	and	_	_	O
180	3	_	_	O
181	months	_	_	O
182	after	_	_	O
183	the	_	_	O
184	last	_	_	O
185	cycle	_	_	O
186	.	_	_	O

187	Seventy-nine	_	_	O
188	percent	_	_	O
189	of	_	_	O
190	the	_	_	O
191	patients	_	_	O
192	(	_	_	O
193	n	_	_	O
194	=	_	_	O
195	219	_	_	O
196	)	_	_	O
197	completed	_	_	O
198	a	_	_	O
199	baseline	_	_	O
200	measure	_	_	O
201	.	_	_	O

202	However	_	_	O
203	,	_	_	O
204	there	_	_	B-Premise
205	were	_	_	I-Premise
206	no	_	_	I-Premise
207	statistically	_	_	I-Premise
208	significant	_	_	I-Premise
209	differences	_	_	I-Premise
210	in	_	_	I-Premise
211	HRQOL	_	_	I-Premise
212	between	_	_	I-Premise
213	the	_	_	I-Premise
214	two	_	_	I-Premise
215	treatment	_	_	I-Premise
216	groups	_	_	I-Premise
217	.	_	_	I-Premise

218	In	_	_	B-Premise
219	both	_	_	I-Premise
220	groups	_	_	I-Premise
221	,	_	_	I-Premise
222	selected	_	_	I-Premise
223	aspects	_	_	I-Premise
224	of	_	_	I-Premise
225	HRQOL	_	_	I-Premise
226	were	_	_	I-Premise
227	impaired	_	_	I-Premise
228	over	_	_	I-Premise
229	time	_	_	I-Premise
230	,	_	_	I-Premise
231	with	_	_	I-Premise
232	increased	_	_	I-Premise
233	fatigue	_	_	I-Premise
234	,	_	_	I-Premise
235	although	_	_	B-Premise
236	some	_	_	I-Premise
237	clinically	_	_	I-Premise
238	significant	_	_	I-Premise
239	improvements	_	_	I-Premise
240	in	_	_	I-Premise
241	emotional	_	_	I-Premise
242	functioning	_	_	I-Premise
243	were	_	_	I-Premise
244	seen	_	_	I-Premise
245	,	_	_	I-Premise
246	as	_	_	I-Premise
247	well	_	_	I-Premise
248	as	_	_	I-Premise
249	a	_	_	I-Premise
250	reduction	_	_	I-Premise
251	in	_	_	I-Premise
252	pain	_	_	I-Premise
253	over	_	_	I-Premise
254	time	_	_	I-Premise
255	.	_	_	I-Premise

256	Overall	_	_	B-Claim
257	,	_	_	I-Claim
258	global	_	_	I-Claim
259	quality	_	_	I-Claim
260	of	_	_	I-Claim
261	life	_	_	I-Claim
262	was	_	_	I-Claim
263	maintained	_	_	I-Claim
264	in	_	_	I-Claim
265	both	_	_	I-Claim
266	treatment	_	_	I-Claim
267	groups	_	_	I-Claim
268	.	_	_	I-Claim

269	This	_	_	B-Claim
270	information	_	_	I-Claim
271	is	_	_	I-Claim
272	important	_	_	I-Claim
273	when	_	_	I-Claim
274	advising	_	_	I-Claim
275	women	_	_	I-Claim
276	patients	_	_	I-Claim
277	of	_	_	I-Claim
278	the	_	_	I-Claim
279	expected	_	_	I-Claim
280	HRQOL	_	_	I-Claim
281	consequences	_	_	I-Claim
282	of	_	_	I-Claim
283	treatment	_	_	I-Claim
284	regimens	_	_	I-Claim
285	and	_	_	I-Claim
286	should	_	_	I-Claim
287	help	_	_	I-Claim
288	clinicians	_	_	I-Claim
289	and	_	_	I-Claim
290	their	_	_	I-Claim
291	patients	_	_	I-Claim
292	make	_	_	I-Claim
293	informed	_	_	I-Claim
294	treatment	_	_	I-Claim
295	decisions	_	_	I-Claim
296	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	incidence	_	_	O
4	and	_	_	O
5	temporal	_	_	O
6	resolution	_	_	O
7	of	_	_	O
8	dysuria	_	_	O
9	after	_	_	O
10	permanent	_	_	O
11	prostate	_	_	O
12	brachytherapy	_	_	O
13	,	_	_	O
14	and	_	_	O
15	to	_	_	O
16	identify	_	_	O
17	predictors	_	_	O
18	of	_	_	O
19	brachytherapy-related	_	_	O
20	dysuria	_	_	O
21	.	_	_	O

22	The	_	_	O
23	study	_	_	O
24	included	_	_	O
25	130	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	no	_	_	O
29	history	_	_	O
30	of	_	_	O
31	transurethral	_	_	O
32	resection	_	_	O
33	of	_	_	O
34	the	_	_	O
35	prostate	_	_	O
36	before	_	_	O
37	treatment	_	_	O
38	,	_	_	O
39	who	_	_	O
40	had	_	_	O
41	brachytherapy	_	_	O
42	on	_	_	O
43	one	_	_	O
44	of	_	_	O
45	two	_	_	O
46	prospective	_	_	O
47	randomized	_	_	O
48	trials	_	_	O
49	,	_	_	O
50	with	_	_	O
51	explicitly	_	_	O
52	planned	_	_	O
53	and	_	_	O
54	executed	_	_	O
55	urethral-sparing	_	_	O
56	techniques	_	_	O
57	(	_	_	O
58	100-150	_	_	O
59	%	_	_	O
60	minimum	_	_	O
61	peripheral	_	_	O
62	dose	_	_	O
63	)	_	_	O
64	using	_	_	O
65	either	_	_	O
66	103Pd	_	_	O
67	or	_	_	O
68	125I	_	_	O
69	for	_	_	O
70	clinical	_	_	O
71	T1c-T2c	_	_	O
72	prostate	_	_	O
73	cancer	_	_	O
74	.	_	_	O

75	The	_	_	O
76	median	_	_	O
77	follow-up	_	_	O
78	was	_	_	O
79	22.6	_	_	O
80	months	_	_	O
81	.	_	_	O

82	An	_	_	O
83	alpha-blocker	_	_	O
84	was	_	_	O
85	initiated	_	_	O
86	either	_	_	O
87	prophylactically	_	_	O
88	2	_	_	O
89	weeks	_	_	O
90	before	_	_	O
91	implantation	_	_	O
92	and	_	_	O
93	continued	_	_	O
94	at	_	_	O
95	least	_	_	O
96	until	_	_	O
97	the	_	_	O
98	International	_	_	O
99	Prostate	_	_	O
100	Symptom	_	_	O
101	Score	_	_	O
102	(	_	_	O
103	IPSS	_	_	O
104	)	_	_	O
105	returned	_	_	O
106	to	_	_	O
107	normal	_	_	O
108	,	_	_	O
109	or	_	_	O
110	withheld	_	_	O
111	until	_	_	O
112	the	_	_	O
113	onset	_	_	O
114	of	_	_	O
115	significant	_	_	O
116	brachytherapy-related	_	_	O
117	urinary	_	_	O
118	morbidity	_	_	O
119	.	_	_	O

120	Dysuria	_	_	O
121	was	_	_	O
122	evaluated	_	_	O
123	on	_	_	O
124	a	_	_	O
125	0-10	_	_	O
126	scale	_	_	O
127	,	_	_	O
128	before	_	_	O
129	brachytherapy	_	_	O
130	and	_	_	O
131	then	_	_	O
132	at	_	_	O
133	1	_	_	O
134	,	_	_	O
135	3	_	_	O
136	,	_	_	O
137	6	_	_	O
138	and	_	_	O
139	12	_	_	O
140	months	_	_	O
141	afterward	_	_	O
142	,	_	_	O
143	with	_	_	O
144	a	_	_	O
145	median	_	_	O
146	of	_	_	O
147	four	_	_	O
148	dysuria	_	_	O
149	questionnaires	_	_	O
150	per	_	_	O
151	patient	_	_	O
152	.	_	_	O

153	Clinical	_	_	O
154	,	_	_	O
155	treatment	_	_	O
156	and	_	_	O
157	dosimetric	_	_	O
158	variables	_	_	O
159	evaluated	_	_	O
160	included	_	_	O
161	alpha-blocker	_	_	O
162	,	_	_	O
163	age	_	_	O
164	,	_	_	O
165	IPSS	_	_	O
166	before	_	_	O
167	and	_	_	O
168	the	_	_	O
169	maximum	_	_	O
170	after	_	_	O
171	treatment	_	_	O
172	,	_	_	O
173	prostate	_	_	O
174	volume	_	_	O
175	on	_	_	O
176	ultrasonography	_	_	O
177	,	_	_	O
178	hormonal	_	_	O
179	status	_	_	O
180	,	_	_	O
181	supplemental	_	_	O
182	radiotherapy	_	_	O
183	,	_	_	O
184	isotope	_	_	O
185	,	_	_	O
186	urethral	_	_	O
187	dose	_	_	O
188	,	_	_	O
189	V	_	_	O
190	(	_	_	O
191	100/200	_	_	O
192	)	_	_	O
193	,	_	_	O
194	D90	_	_	O
195	,	_	_	O
196	and	_	_	O
197	time	_	_	O
198	to	_	_	O
199	obtaining	_	_	O
200	a	_	_	O
201	normal	_	_	O
202	IPSS	_	_	O
203	.	_	_	O

204	The	_	_	O
205	maximum	_	_	O
206	incidence	_	_	O
207	of	_	_	O
208	dysuria	_	_	O
209	was	_	_	O
210	85	_	_	O
211	%	_	_	O
212	at	_	_	O
213	1	_	_	O
214	month	_	_	O
215	after	_	_	O
216	brachytherapy	_	_	O
217	,	_	_	O
218	with	_	_	O
219	subsequent	_	_	O
220	resolution	_	_	O
221	over	_	_	O
222	time	_	_	O
223	.	_	_	O

224	The	_	_	B-Premise
225	use	_	_	I-Premise
226	of	_	_	I-Premise
227	prophylactic	_	_	I-Premise
228	tamsulosin	_	_	I-Premise
229	resulted	_	_	I-Premise
230	in	_	_	I-Premise
231	a	_	_	I-Premise
232	statistically	_	_	I-Premise
233	lower	_	_	I-Premise
234	dysuria	_	_	I-Premise
235	severity	_	_	I-Premise
236	score	_	_	I-Premise
237	(	_	_	I-Premise
238	difference	_	_	I-Premise
239	of	_	_	I-Premise
240	2.7	_	_	I-Premise
241	vs	_	_	I-Premise
242	4.2	_	_	I-Premise
243	,	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	0.005	_	_	I-Premise
247	)	_	_	I-Premise
248	at	_	_	I-Premise
249	1	_	_	I-Premise
250	month	_	_	I-Premise
251	,	_	_	I-Premise
252	with	_	_	I-Premise
253	no	_	_	I-Premise
254	discernible	_	_	I-Premise
255	differences	_	_	I-Premise
256	at	_	_	I-Premise
257	3	_	_	I-Premise
258	,	_	_	I-Premise
259	6	_	_	I-Premise
260	,	_	_	I-Premise
261	12	_	_	I-Premise
262	and	_	_	I-Premise
263	18	_	_	I-Premise
264	months	_	_	I-Premise
265	.	_	_	I-Premise

266	Patients	_	_	B-Premise
267	with	_	_	I-Premise
268	dysuria	_	_	I-Premise
269	had	_	_	I-Premise
270	a	_	_	I-Premise
271	statistically	_	_	I-Premise
272	higher	_	_	I-Premise
273	IPSS	_	_	I-Premise
274	.	_	_	I-Premise

275	The	_	_	B-Premise
276	dysuria	_	_	I-Premise
277	resolved	_	_	I-Premise
278	faster	_	_	I-Premise
279	in	_	_	I-Premise
280	patients	_	_	I-Premise
281	implanted	_	_	I-Premise
282	with	_	_	I-Premise
283	103Pd	_	_	I-Premise
284	but	_	_	B-Premise
285	was	_	_	I-Premise
286	unaffected	_	_	I-Premise
287	by	_	_	I-Premise
288	the	_	_	I-Premise
289	use	_	_	I-Premise
290	of	_	_	I-Premise
291	supplemental	_	_	I-Premise
292	radiotherapy	_	_	I-Premise
293	and/or	_	_	I-Premise
294	androgen	_	_	I-Premise
295	deprivation	_	_	I-Premise
296	therapy	_	_	I-Premise
297	.	_	_	I-Premise

298	In	_	_	B-Premise
299	multivariate	_	_	I-Premise
300	analysis	_	_	I-Premise
301	,	_	_	I-Premise
302	prophylactic	_	_	I-Premise
303	alpha-blockers	_	_	I-Premise
304	resulted	_	_	I-Premise
305	in	_	_	I-Premise
306	statistically	_	_	I-Premise
307	lower	_	_	I-Premise
308	maximum	_	_	I-Premise
309	dysuria	_	_	I-Premise
310	scores	_	_	I-Premise
311	,	_	_	I-Premise
312	while	_	_	B-Premise
313	the	_	_	I-Premise
314	maximum	_	_	I-Premise
315	IPSS	_	_	I-Premise
316	after	_	_	I-Premise
317	implantation	_	_	I-Premise
318	and	_	_	I-Premise
319	isotope	_	_	I-Premise
320	type	_	_	I-Premise
321	(	_	_	I-Premise
322	but	_	_	I-Premise
323	only	_	_	I-Premise
324	at	_	_	I-Premise
325	6	_	_	I-Premise
326	months	_	_	I-Premise
327	)	_	_	I-Premise
328	were	_	_	I-Premise
329	the	_	_	I-Premise
330	best	_	_	I-Premise
331	predictors	_	_	I-Premise
332	of	_	_	I-Premise
333	the	_	_	I-Premise
334	resolution	_	_	I-Premise
335	of	_	_	I-Premise
336	dysuria	_	_	I-Premise
337	.	_	_	I-Premise

338	Dysuria	_	_	B-Claim
339	is	_	_	I-Claim
340	common	_	_	I-Claim
341	after	_	_	I-Claim
342	brachytherapy	_	_	I-Claim
343	but	_	_	I-Claim
344	is	_	_	I-Claim
345	typically	_	_	I-Claim
346	mild	_	_	I-Claim
347	.	_	_	I-Claim

348	Prophylactic	_	_	B-Claim
349	alpha-blockers	_	_	I-Claim
350	gave	_	_	I-Claim
351	significantly	_	_	I-Claim
352	lower	_	_	I-Claim
353	maximum	_	_	I-Claim
354	dysuria	_	_	I-Claim
355	scores	_	_	I-Claim
356	but	_	_	B-Claim
357	did	_	_	I-Claim
358	not	_	_	I-Claim
359	affect	_	_	I-Claim
360	the	_	_	I-Claim
361	time	_	_	I-Claim
362	to	_	_	I-Claim
363	the	_	_	I-Claim
364	resolution	_	_	I-Claim
365	of	_	_	I-Claim
366	dysuria	_	_	I-Claim
367	.	_	_	I-Claim

368	The	_	_	B-Claim
369	maximum	_	_	I-Claim
370	IPSS	_	_	I-Claim
371	after	_	_	I-Claim
372	the	_	_	I-Claim
373	implant	_	_	I-Claim
374	was	_	_	I-Claim
375	the	_	_	I-Claim
376	best	_	_	I-Claim
377	predictor	_	_	I-Claim
378	of	_	_	I-Claim
379	the	_	_	I-Claim
380	resolution	_	_	I-Claim
381	of	_	_	I-Claim
382	dysuria	_	_	I-Claim
383	.	_	_	I-Claim


0	Many	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	advanced	_	_	O
4	ovarian	_	_	O
5	cancer	_	_	O
6	will	_	_	O
7	develop	_	_	O
8	recurrent	_	_	O
9	disease	_	_	O
10	.	_	_	O

11	For	_	_	B-Premise
12	those	_	_	I-Premise
13	patients	_	_	I-Premise
14	who	_	_	I-Premise
15	have	_	_	I-Premise
16	recurrence	_	_	I-Premise
17	of	_	_	I-Premise
18	disease	_	_	I-Premise
19	at	_	_	I-Premise
20	least	_	_	I-Premise
21	6	_	_	I-Premise
22	months	_	_	I-Premise
23	after	_	_	I-Premise
24	initial	_	_	I-Premise
25	therapy	_	_	I-Premise
26	,	_	_	I-Premise
27	the	_	_	I-Premise
28	paclitaxel-platinum	_	_	I-Premise
29	combination	_	_	I-Premise
30	has	_	_	I-Premise
31	been	_	_	I-Premise
32	shown	_	_	I-Premise
33	to	_	_	I-Premise
34	be	_	_	I-Premise
35	a	_	_	I-Premise
36	superior	_	_	I-Premise
37	treatment	_	_	I-Premise
38	to	_	_	I-Premise
39	platinum	_	_	I-Premise
40	monotherapy	_	_	I-Premise
41	.	_	_	I-Premise

42	However	_	_	B-Claim
43	,	_	_	I-Claim
44	many	_	_	I-Claim
45	patients	_	_	I-Claim
46	develop	_	_	I-Claim
47	clinically	_	_	I-Claim
48	relevant	_	_	I-Claim
49	neurotoxicity	_	_	I-Claim
50	,	_	_	I-Claim
51	frequently	_	_	I-Claim
52	resulting	_	_	I-Claim
53	in	_	_	I-Claim
54	treatment	_	_	I-Claim
55	discontinuation	_	_	I-Claim
56	.	_	_	I-Claim

57	The	_	_	O
58	efficacy	_	_	O
59	and	_	_	O
60	safety	_	_	O
61	of	_	_	O
62	an	_	_	O
63	alternative	_	_	O
64	regimen	_	_	O
65	that	_	_	O
66	does	_	_	O
67	not	_	_	O
68	show	_	_	O
69	significant	_	_	O
70	neurotoxicity	_	_	O
71	were	_	_	O
72	evaluated	_	_	O
73	by	_	_	O
74	comparing	_	_	O
75	gemcitabine-carboplatin	_	_	O
76	with	_	_	O
77	carboplatin	_	_	O
78	in	_	_	O
79	platinum-sensitive	_	_	O
80	recurrent	_	_	O
81	ovarian	_	_	O
82	cancer	_	_	O
83	patients	_	_	O
84	in	_	_	O
85	a	_	_	O
86	Gynecologic	_	_	O
87	Cancer	_	_	O
88	InterGroup	_	_	O
89	trial	_	_	O
90	of	_	_	O
91	the	_	_	O
92	Arbeitsgemeinschaft	_	_	O
93	Gynakologische	_	_	O
94	Onkologie	_	_	O
95	Ovarian	_	_	O
96	Cancer	_	_	O
97	Study	_	_	O
98	Group	_	_	O
99	,	_	_	O
100	the	_	_	O
101	National	_	_	O
102	Cancer	_	_	O
103	Institute	_	_	O
104	of	_	_	O
105	Canada	_	_	O
106	Clinical	_	_	O
107	Trials	_	_	O
108	Group	_	_	O
109	,	_	_	O
110	and	_	_	O
111	the	_	_	O
112	European	_	_	O
113	Organisation	_	_	O
114	for	_	_	O
115	Research	_	_	O
116	and	_	_	O
117	Treatment	_	_	O
118	of	_	_	O
119	Cancer	_	_	O
120	Gynaecological	_	_	O
121	Cancer	_	_	O
122	Group	_	_	O
123	.	_	_	O

124	Participants	_	_	O
125	with	_	_	O
126	recurrent	_	_	O
127	platinum-sensitive	_	_	O
128	ovarian	_	_	O
129	cancer	_	_	O
130	were	_	_	O
131	randomly	_	_	O
132	assigned	_	_	O
133	to	_	_	O
134	receive	_	_	O
135	either	_	_	O
136	gemcitabine-carboplatin	_	_	O
137	or	_	_	O
138	carboplatin	_	_	O
139	every	_	_	O
140	21	_	_	O
141	days	_	_	O
142	.	_	_	O

143	The	_	_	O
144	primary	_	_	O
145	objective	_	_	O
146	was	_	_	O
147	to	_	_	O
148	compare	_	_	O
149	progression-free	_	_	O
150	survival	_	_	O
151	(	_	_	O
152	PFS	_	_	O
153	)	_	_	O
154	between	_	_	O
155	the	_	_	O
156	groups	_	_	O
157	.	_	_	O

158	From	_	_	O
159	September	_	_	O
160	1999	_	_	O
161	to	_	_	O
162	April	_	_	O
163	2002	_	_	O
164	,	_	_	O
165	356	_	_	O
166	patients	_	_	O
167	(	_	_	O
168	178	_	_	O
169	participants	_	_	O
170	received	_	_	O
171	gemcitabine-carboplatin	_	_	O
172	,	_	_	O
173	178	_	_	O
174	received	_	_	O
175	carboplatin	_	_	O
176	only	_	_	O
177	)	_	_	O
178	were	_	_	O
179	randomized	_	_	O
180	to	_	_	O
181	treatment	_	_	O
182	.	_	_	O

183	Patients	_	_	O
184	received	_	_	O
185	six	_	_	O
186	cycles	_	_	O
187	of	_	_	O
188	either	_	_	O
189	gemcitabine-carboplatin	_	_	O
190	or	_	_	O
191	carboplatin	_	_	O
192	.	_	_	O

193	With	_	_	B-Premise
194	a	_	_	I-Premise
195	median	_	_	I-Premise
196	follow-up	_	_	I-Premise
197	of	_	_	I-Premise
198	17	_	_	I-Premise
199	months	_	_	I-Premise
200	,	_	_	I-Premise
201	median	_	_	I-Premise
202	PFS	_	_	I-Premise
203	was	_	_	I-Premise
204	8.6	_	_	I-Premise
205	months	_	_	I-Premise
206	for	_	_	I-Premise
207	gemcitabine-carboplatin	_	_	I-Premise
208	(	_	_	I-Premise
209	95	_	_	I-Premise
210	%	_	_	I-Premise
211	confidence	_	_	I-Premise
212	interval	_	_	I-Premise
213	[	_	_	I-Premise
214	CI	_	_	I-Premise
215	]	_	_	I-Premise
216	7.9-9.7	_	_	I-Premise
217	months	_	_	I-Premise
218	)	_	_	I-Premise
219	and	_	_	I-Premise
220	5.8	_	_	I-Premise
221	months	_	_	I-Premise
222	for	_	_	I-Premise
223	carboplatin	_	_	I-Premise
224	(	_	_	I-Premise
225	95	_	_	I-Premise
226	%	_	_	I-Premise
227	CI	_	_	I-Premise
228	5.2-7.1	_	_	I-Premise
229	months	_	_	I-Premise
230	;	_	_	I-Premise
231	hazard	_	_	I-Premise
232	ratio	_	_	I-Premise
233	[	_	_	I-Premise
234	HR	_	_	I-Premise
235	]	_	_	I-Premise
236	0.72	_	_	I-Premise
237	[	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	CI	_	_	I-Premise
241	0.58-0.90	_	_	I-Premise
242	;	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	0.0032	_	_	I-Premise
246	]	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	response	_	_	I-Premise
251	rate	_	_	I-Premise
252	for	_	_	I-Premise
253	the	_	_	I-Premise
254	gemcitabine-carboplatin	_	_	I-Premise
255	group	_	_	I-Premise
256	was	_	_	I-Premise
257	47.2	_	_	I-Premise
258	%	_	_	I-Premise
259	(	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	CI	_	_	I-Premise
263	39.9-54.5	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	and	_	_	I-Premise
267	30.9	_	_	I-Premise
268	%	_	_	I-Premise
269	for	_	_	I-Premise
270	carboplatin	_	_	I-Premise
271	group	_	_	I-Premise
272	(	_	_	I-Premise
273	95	_	_	I-Premise
274	%	_	_	I-Premise
275	CI	_	_	I-Premise
276	24.1-37.7	_	_	I-Premise
277	%	_	_	I-Premise
278	;	_	_	I-Premise
279	P	_	_	I-Premise
280	=	_	_	I-Premise
281	0.0016	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	The	_	_	B-Premise
285	HR	_	_	I-Premise
286	for	_	_	I-Premise
287	overall	_	_	I-Premise
288	survival	_	_	I-Premise
289	was	_	_	I-Premise
290	0.96	_	_	I-Premise
291	(	_	_	I-Premise
292	95	_	_	I-Premise
293	%	_	_	I-Premise
294	CI	_	_	I-Premise
295	0.75-1.23	_	_	I-Premise
296	;	_	_	I-Premise
297	P	_	_	I-Premise
298	=	_	_	I-Premise
299	0.7349	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	Patients	_	_	B-Premise
303	treated	_	_	I-Premise
304	with	_	_	I-Premise
305	gemcitabine-carboplatin	_	_	I-Premise
306	reported	_	_	I-Premise
307	significantly	_	_	I-Premise
308	faster	_	_	I-Premise
309	palliation	_	_	I-Premise
310	of	_	_	I-Premise
311	abdominal	_	_	I-Premise
312	symptoms	_	_	I-Premise
313	and	_	_	I-Premise
314	a	_	_	I-Premise
315	significantly	_	_	I-Premise
316	improved	_	_	I-Premise
317	global	_	_	I-Premise
318	quality	_	_	I-Premise
319	of	_	_	I-Premise
320	life	_	_	I-Premise
321	.	_	_	I-Premise

322	Gemcitabine-carboplatin	_	_	B-Claim
323	treatment	_	_	I-Claim
324	significantly	_	_	I-Claim
325	improves	_	_	I-Claim
326	the	_	_	I-Claim
327	PFS	_	_	I-Claim
328	of	_	_	I-Claim
329	patients	_	_	I-Claim
330	with	_	_	I-Claim
331	platinum-sensitive	_	_	I-Claim
332	recurrent	_	_	I-Claim
333	ovarian	_	_	I-Claim
334	cancer	_	_	I-Claim
335	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	impact	_	_	O
4	of	_	_	O
5	letrozole	_	_	O
6	compared	_	_	O
7	with	_	_	O
8	placebo	_	_	O
9	after	_	_	O
10	adjuvant	_	_	O
11	tamoxifen	_	_	O
12	on	_	_	O
13	quality	_	_	O
14	of	_	_	O
15	life	_	_	O
16	(	_	_	O
17	QOL	_	_	O
18	)	_	_	O
19	in	_	_	O
20	the	_	_	O
21	MA.17	_	_	O
22	trial	_	_	O
23	.	_	_	O

24	Patients	_	_	O
25	completed	_	_	O
26	the	_	_	O
27	Short	_	_	O
28	Form	_	_	O
29	36-item	_	_	O
30	Health	_	_	O
31	Survey	_	_	O
32	(	_	_	O
33	SF-36	_	_	O
34	)	_	_	O
35	and	_	_	O
36	the	_	_	O
37	Menopause	_	_	O
38	Specific	_	_	O
39	Quality	_	_	O
40	of	_	_	O
41	Life	_	_	O
42	Questionnaire	_	_	O
43	(	_	_	O
44	MENQOL	_	_	O
45	)	_	_	O
46	at	_	_	O
47	baseline	_	_	O
48	,	_	_	O
49	6	_	_	O
50	months	_	_	O
51	,	_	_	O
52	and	_	_	O
53	annually	_	_	O
54	.	_	_	O

55	Mean	_	_	O
56	change	_	_	O
57	scores	_	_	O
58	from	_	_	O
59	baseline	_	_	O
60	were	_	_	O
61	compared	_	_	O
62	between	_	_	O
63	groups	_	_	O
64	for	_	_	O
65	summary	_	_	O
66	measures	_	_	O
67	and	_	_	O
68	domains	_	_	O
69	.	_	_	O

70	A	_	_	O
71	response	_	_	O
72	analysis	_	_	O
73	compared	_	_	O
74	the	_	_	O
75	proportion	_	_	O
76	of	_	_	O
77	patients	_	_	O
78	who	_	_	O
79	demonstrated	_	_	O
80	an	_	_	O
81	important	_	_	O
82	change	_	_	O
83	in	_	_	O
84	QOL	_	_	O
85	.	_	_	O

86	Of	_	_	O
87	5,187	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	women	_	_	O
91	in	_	_	O
92	the	_	_	O
93	trial	_	_	O
94	,	_	_	O
95	3,612	_	_	O
96	(	_	_	O
97	69.9	_	_	O
98	%	_	_	O
99	)	_	_	O
100	participated	_	_	O
101	in	_	_	O
102	the	_	_	O
103	QOL	_	_	O
104	substudy	_	_	O
105	:	_	_	O
106	1,799	_	_	O
107	were	_	_	O
108	allocated	_	_	O
109	to	_	_	O
110	placebo	_	_	O
111	and	_	_	O
112	1,813	_	_	O
113	were	_	_	O
114	allocated	_	_	O
115	to	_	_	O
116	letrozole	_	_	O
117	.	_	_	O

118	No	_	_	B-Premise
119	differences	_	_	I-Premise
120	were	_	_	I-Premise
121	seen	_	_	I-Premise
122	between	_	_	I-Premise
123	groups	_	_	I-Premise
124	in	_	_	I-Premise
125	mean	_	_	I-Premise
126	change	_	_	I-Premise
127	scores	_	_	I-Premise
128	from	_	_	I-Premise
129	baseline	_	_	I-Premise
130	for	_	_	I-Premise
131	the	_	_	I-Premise
132	SF-36	_	_	I-Premise
133	physical	_	_	I-Premise
134	and	_	_	I-Premise
135	mental	_	_	I-Premise
136	component	_	_	I-Premise
137	summary	_	_	I-Premise
138	scores	_	_	I-Premise
139	at	_	_	I-Premise
140	6	_	_	I-Premise
141	,	_	_	I-Premise
142	12	_	_	I-Premise
143	,	_	_	I-Premise
144	24	_	_	I-Premise
145	,	_	_	I-Premise
146	and	_	_	I-Premise
147	36	_	_	I-Premise
148	months	_	_	I-Premise
149	.	_	_	I-Premise

150	Small	_	_	B-Premise
151	(	_	_	I-Premise
152	<	_	_	I-Premise
153	0.2	_	_	I-Premise
154	standard	_	_	I-Premise
155	deviations	_	_	I-Premise
156	)	_	_	I-Premise
157	but	_	_	I-Premise
158	statistically	_	_	I-Premise
159	significant	_	_	I-Premise
160	differences	_	_	I-Premise
161	in	_	_	I-Premise
162	mean	_	_	I-Premise
163	change	_	_	I-Premise
164	scores	_	_	I-Premise
165	from	_	_	I-Premise
166	baseline	_	_	I-Premise
167	were	_	_	I-Premise
168	seen	_	_	I-Premise
169	for	_	_	I-Premise
170	the	_	_	I-Premise
171	SF-36	_	_	I-Premise
172	domains	_	_	I-Premise
173	of	_	_	I-Premise
174	physical	_	_	I-Premise
175	functioning	_	_	I-Premise
176	(	_	_	I-Premise
177	12	_	_	I-Premise
178	months	_	_	I-Premise
179	)	_	_	I-Premise
180	,	_	_	I-Premise
181	bodily	_	_	I-Premise
182	pain	_	_	I-Premise
183	(	_	_	I-Premise
184	6	_	_	I-Premise
185	months	_	_	I-Premise
186	)	_	_	I-Premise
187	and	_	_	I-Premise
188	vitality	_	_	I-Premise
189	(	_	_	I-Premise
190	6	_	_	I-Premise
191	and	_	_	I-Premise
192	12	_	_	I-Premise
193	months	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	and	_	_	I-Premise
197	the	_	_	I-Premise
198	MENQOL	_	_	I-Premise
199	vasomotor	_	_	I-Premise
200	(	_	_	I-Premise
201	6	_	_	I-Premise
202	,	_	_	I-Premise
203	12	_	_	I-Premise
204	,	_	_	I-Premise
205	and	_	_	I-Premise
206	24	_	_	I-Premise
207	months	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	sexual	_	_	I-Premise
211	domains	_	_	I-Premise
212	(	_	_	I-Premise
213	12	_	_	I-Premise
214	and	_	_	I-Premise
215	24	_	_	I-Premise
216	months	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	On	_	_	B-Premise
220	the	_	_	I-Premise
221	response	_	_	I-Premise
222	analysis	_	_	I-Premise
223	,	_	_	I-Premise
224	a	_	_	I-Premise
225	significant	_	_	I-Premise
226	difference	_	_	I-Premise
227	was	_	_	I-Premise
228	seen	_	_	I-Premise
229	between	_	_	I-Premise
230	groups	_	_	I-Premise
231	for	_	_	I-Premise
232	the	_	_	I-Premise
233	bodily	_	_	I-Premise
234	pain	_	_	I-Premise
235	domain	_	_	I-Premise
236	(	_	_	I-Premise
237	percentage	_	_	I-Premise
238	of	_	_	I-Premise
239	patients	_	_	I-Premise
240	reporting	_	_	I-Premise
241	a	_	_	I-Premise
242	worsening	_	_	I-Premise
243	of	_	_	I-Premise
244	QOL	_	_	I-Premise
245	,	_	_	I-Premise
246	47	_	_	I-Premise
247	%	_	_	I-Premise
248	placebo	_	_	I-Premise
249	v	_	_	I-Premise
250	51	_	_	I-Premise
251	%	_	_	I-Premise
252	letrozole	_	_	I-Premise
253	;	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.009	_	_	I-Premise
257	)	_	_	I-Premise
258	and	_	_	I-Premise
259	the	_	_	I-Premise
260	vasomotor	_	_	I-Premise
261	domain	_	_	I-Premise
262	(	_	_	I-Premise
263	22	_	_	I-Premise
264	%	_	_	I-Premise
265	placebo	_	_	I-Premise
266	v	_	_	I-Premise
267	29	_	_	I-Premise
268	%	_	_	I-Premise
269	letrozole	_	_	I-Premise
270	;	_	_	I-Premise
271	P	_	_	I-Premise
272	=	_	_	I-Premise
273	.001	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Letrozole	_	_	B-Claim
277	did	_	_	I-Claim
278	not	_	_	I-Claim
279	have	_	_	I-Claim
280	an	_	_	I-Claim
281	adverse	_	_	I-Claim
282	impact	_	_	I-Claim
283	on	_	_	I-Claim
284	overall	_	_	I-Claim
285	QOL	_	_	I-Claim
286	.	_	_	I-Claim

287	Small	_	_	B-Claim
288	effects	_	_	I-Claim
289	were	_	_	I-Claim
290	seen	_	_	I-Claim
291	in	_	_	I-Claim
292	some	_	_	I-Claim
293	domains	_	_	I-Claim
294	consistent	_	_	I-Claim
295	with	_	_	I-Claim
296	a	_	_	I-Claim
297	minority	_	_	I-Claim
298	of	_	_	I-Claim
299	patients	_	_	I-Claim
300	experiencing	_	_	I-Claim
301	changes	_	_	I-Claim
302	in	_	_	I-Claim
303	QOL	_	_	I-Claim
304	compatible	_	_	I-Claim
305	with	_	_	I-Claim
306	a	_	_	I-Claim
307	reduction	_	_	I-Claim
308	in	_	_	I-Claim
309	estrogen	_	_	I-Claim
310	synthesis	_	_	I-Claim
311	.	_	_	I-Claim


0	On	_	_	O
1	March	_	_	O
2	15	_	_	O
3	,	_	_	O
4	2005	_	_	O
5	,	_	_	O
6	the	_	_	O
7	US	_	_	O
8	Food	_	_	O
9	and	_	_	O
10	Drug	_	_	O
11	Administration	_	_	O
12	approved	_	_	O
13	temozolomide	_	_	O
14	(	_	_	O
15	Temodar	_	_	O
16	capsules	_	_	O
17	,	_	_	O
18	Schering-Plough	_	_	O
19	Research	_	_	O
20	Institute	_	_	O
21	)	_	_	O
22	for	_	_	O
23	the	_	_	O
24	treatment	_	_	O
25	of	_	_	O
26	adult	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	newly	_	_	O
30	diagnosed	_	_	O
31	glioblastoma	_	_	O
32	multiforme	_	_	O
33	concomitantly	_	_	O
34	with	_	_	O
35	radiotherapy	_	_	O
36	and	_	_	O
37	then	_	_	O
38	as	_	_	O
39	maintenance	_	_	O
40	treatment	_	_	O
41	.	_	_	O

42	Five	_	_	O
43	hundred	_	_	O
44	seventy-three	_	_	O
45	glioblastoma	_	_	O
46	multiforme	_	_	O
47	patients	_	_	O
48	were	_	_	O
49	randomized	_	_	O
50	to	_	_	O
51	receive	_	_	O
52	either	_	_	O
53	temozolomide	_	_	O
54	+	_	_	O
55	radiotherapy	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	287	_	_	O
60	)	_	_	O
61	or	_	_	O
62	radiotherapy	_	_	O
63	alone	_	_	O
64	(	_	_	O
65	n	_	_	O
66	=	_	_	O
67	286	_	_	O
68	)	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	in	_	_	O
72	the	_	_	O
73	temozolomide	_	_	O
74	+	_	_	O
75	radiotherapy	_	_	O
76	arm	_	_	O
77	received	_	_	O
78	concomitant	_	_	O
79	temozolomide	_	_	O
80	(	_	_	O
81	75	_	_	O
82	mg/m2	_	_	O
83	)	_	_	O
84	once	_	_	O
85	daily	_	_	O
86	for	_	_	O
87	the	_	_	O
88	duration	_	_	O
89	of	_	_	O
90	radiation	_	_	O
91	therapy	_	_	O
92	(	_	_	O
93	42-49	_	_	O
94	days	_	_	O
95	)	_	_	O
96	.	_	_	O

97	This	_	_	O
98	was	_	_	O
99	followed	_	_	O
100	,	_	_	O
101	4	_	_	O
102	weeks	_	_	O
103	later	_	_	O
104	,	_	_	O
105	by	_	_	O
106	six	_	_	O
107	cycles	_	_	O
108	of	_	_	O
109	temozolomide	_	_	O
110	,	_	_	O
111	150	_	_	O
112	or	_	_	O
113	200	_	_	O
114	mg/m2	_	_	O
115	daily	_	_	O
116	for	_	_	O
117	5	_	_	O
118	days	_	_	O
119	,	_	_	O
120	every	_	_	O
121	4	_	_	O
122	weeks	_	_	O
123	.	_	_	O

124	Patients	_	_	O
125	in	_	_	O
126	the	_	_	O
127	control	_	_	O
128	arm	_	_	O
129	received	_	_	O
130	radiotherapy	_	_	O
131	only	_	_	O
132	.	_	_	O

133	In	_	_	O
134	both	_	_	O
135	arms	_	_	O
136	,	_	_	O
137	radiotherapy	_	_	O
138	was	_	_	O
139	delivered	_	_	O
140	as	_	_	O
141	60	_	_	O
142	Gy/30	_	_	O
143	fractions	_	_	O
144	to	_	_	O
145	the	_	_	O
146	tumor	_	_	O
147	site	_	_	O
148	with	_	_	O
149	a	_	_	O
150	2	_	_	O
151	to	_	_	O
152	3	_	_	O
153	cm	_	_	O
154	margin	_	_	O
155	.	_	_	O

156	Pneumocystis	_	_	O
157	carinii	_	_	O
158	pneumonia	_	_	O
159	prophylaxis	_	_	O
160	was	_	_	O
161	required	_	_	O
162	during	_	_	O
163	temozolomide	_	_	O
164	+	_	_	O
165	radiotherapy	_	_	O
166	treatment	_	_	O
167	and	_	_	O
168	was	_	_	O
169	continued	_	_	O
170	until	_	_	O
171	recovery	_	_	O
172	of	_	_	O
173	lymphocytopenia	_	_	O
174	(	_	_	O
175	Common	_	_	O
176	Toxicity	_	_	O
177	Criteria	_	_	O
178	grade	_	_	O
179	<	_	_	O
180	1	_	_	O
181	)	_	_	O
182	.	_	_	O

183	At	_	_	O
184	disease	_	_	O
185	progression	_	_	O
186	,	_	_	O
187	temozolomide	_	_	O
188	salvage	_	_	O
189	treatment	_	_	O
190	was	_	_	O
191	given	_	_	O
192	to	_	_	O
193	161	_	_	O
194	of	_	_	O
195	282	_	_	O
196	patients	_	_	O
197	(	_	_	O
198	57	_	_	O
199	%	_	_	O
200	)	_	_	O
201	in	_	_	O
202	the	_	_	O
203	radiotherapy	_	_	O
204	alone	_	_	O
205	arm	_	_	O
206	,	_	_	O
207	and	_	_	O
208	to	_	_	O
209	62	_	_	O
210	of	_	_	O
211	277	_	_	O
212	patients	_	_	O
213	(	_	_	O
214	22	_	_	O
215	%	_	_	O
216	)	_	_	O
217	in	_	_	O
218	the	_	_	O
219	temozolomide	_	_	O
220	+	_	_	O
221	radiotherapy	_	_	O
222	arm	_	_	O
223	.	_	_	O

224	Patients	_	_	B-Claim
225	receiving	_	_	I-Claim
226	concomitant	_	_	I-Claim
227	and	_	_	I-Claim
228	maintenance	_	_	I-Claim
229	temozolomide	_	_	I-Claim
230	+	_	_	I-Claim
231	radiotherapy	_	_	I-Claim
232	had	_	_	I-Claim
233	significantly	_	_	I-Claim
234	improved	_	_	I-Claim
235	overall	_	_	I-Claim
236	survival	_	_	I-Claim
237	.	_	_	I-Claim

238	The	_	_	B-Premise
239	hazard	_	_	I-Premise
240	ratio	_	_	I-Premise
241	was	_	_	I-Premise
242	0.63	_	_	I-Premise
243	(	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	confidence	_	_	I-Premise
247	interval	_	_	I-Premise
248	,	_	_	I-Premise
249	0.52-0.75	_	_	I-Premise
250	;	_	_	I-Premise
251	log-rank	_	_	I-Premise
252	,	_	_	I-Premise
253	P	_	_	I-Premise
254	<	_	_	I-Premise
255	0.0001	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	Median	_	_	B-Premise
259	survival	_	_	I-Premise
260	was	_	_	I-Premise
261	14.6	_	_	I-Premise
262	months	_	_	I-Premise
263	(	_	_	I-Premise
264	temozolomide	_	_	I-Premise
265	+	_	_	I-Premise
266	radiotherapy	_	_	I-Premise
267	)	_	_	I-Premise
268	versus	_	_	I-Premise
269	12.1	_	_	I-Premise
270	months	_	_	I-Premise
271	(	_	_	I-Premise
272	radiotherapy	_	_	I-Premise
273	alone	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Adverse	_	_	B-Claim
277	events	_	_	I-Claim
278	during	_	_	I-Claim
279	temozolomide	_	_	I-Claim
280	treatment	_	_	I-Claim
281	included	_	_	I-Claim
282	thrombocytopenia	_	_	I-Claim
283	,	_	_	I-Claim
284	nausea	_	_	I-Claim
285	,	_	_	I-Claim
286	vomiting	_	_	I-Claim
287	,	_	_	I-Claim
288	anorexia	_	_	I-Claim
289	,	_	_	I-Claim
290	constipation	_	_	I-Claim
291	,	_	_	I-Claim
292	alopecia	_	_	I-Claim
293	,	_	_	I-Claim
294	headache	_	_	I-Claim
295	,	_	_	I-Claim
296	fatigue	_	_	I-Claim
297	,	_	_	I-Claim
298	and	_	_	I-Claim
299	convulsions	_	_	I-Claim
300	.	_	_	I-Claim


0	Chemotherapy	_	_	B-Claim
1	can	_	_	I-Claim
2	profoundly	_	_	I-Claim
3	affect	_	_	I-Claim
4	patients	_	_	I-Claim
5	'	_	_	I-Claim
6	quality	_	_	I-Claim
7	of	_	_	I-Claim
8	life	_	_	I-Claim
9	(	_	_	I-Claim
10	QOL	_	_	I-Claim
11	)	_	_	I-Claim
12	,	_	_	I-Claim
13	yet	_	_	O
14	few	_	_	O
15	clinical	_	_	O
16	trials	_	_	O
17	in	_	_	O
18	advanced	_	_	O
19	cervical	_	_	O
20	cancer	_	_	O
21	have	_	_	O
22	included	_	_	O
23	QOL	_	_	O
24	outcomes	_	_	O
25	.	_	_	O

26	Our	_	_	O
27	purpose	_	_	O
28	was	_	_	O
29	to	_	_	O
30	assess	_	_	O
31	the	_	_	O
32	impact	_	_	O
33	of	_	_	O
34	cisplatin	_	_	O
35	(	_	_	O
36	C	_	_	O
37	)	_	_	O
38	versus	_	_	O
39	cisplatin	_	_	O
40	plus	_	_	O
41	paclitaxel	_	_	O
42	(	_	_	O
43	CP	_	_	O
44	)	_	_	O
45	on	_	_	O
46	overall	_	_	O
47	QOL	_	_	O
48	and	_	_	O
49	pain	_	_	O
50	in	_	_	O
51	cervical	_	_	O
52	cancer	_	_	O
53	patients	_	_	O
54	.	_	_	O

55	QOL	_	_	O
56	was	_	_	O
57	assessed	_	_	O
58	using	_	_	O
59	FACT-Cx	_	_	O
60	,	_	_	O
61	consisting	_	_	O
62	of	_	_	O
63	the	_	_	O
64	Functional	_	_	O
65	Assessment	_	_	O
66	of	_	_	O
67	Cancer	_	_	O
68	Therapy	_	_	O
69	(	_	_	O
70	FACT-G	_	_	O
71	)	_	_	O
72	plus	_	_	O
73	a	_	_	O
74	cervix	_	_	O
75	cancer-specific	_	_	O
76	subscale	_	_	O
77	,	_	_	O
78	the	_	_	O
79	Brief	_	_	O
80	Pain	_	_	O
81	Inventory-Short	_	_	O
82	Form	_	_	O
83	(	_	_	O
84	BPI-SF	_	_	O
85	)	_	_	O
86	,	_	_	O
87	and	_	_	O
88	a	_	_	O
89	neurotoxicity	_	_	O
90	subscale	_	_	O
91	.	_	_	O

92	Time	_	_	O
93	points	_	_	O
94	were	_	_	O
95	:	_	_	O
96	baseline	_	_	O
97	(	_	_	O
98	prior	_	_	O
99	to	_	_	O
100	randomization	_	_	O
101	)	_	_	O
102	and	_	_	O
103	prior	_	_	O
104	to	_	_	O
105	chemotherapy	_	_	O
106	cycles	_	_	O
107	2	_	_	O
108	,	_	_	O
109	3	_	_	O
110	,	_	_	O
111	and	_	_	O
112	4	_	_	O
113	.	_	_	O

114	Overall	_	_	B-Premise
115	(	_	_	I-Premise
116	FACT-G	_	_	I-Premise
117	)	_	_	I-Premise
118	scores	_	_	I-Premise
119	did	_	_	I-Premise
120	not	_	_	I-Premise
121	differ	_	_	I-Premise
122	significantly	_	_	I-Premise
123	between	_	_	I-Premise
124	arms	_	_	I-Premise
125	at	_	_	I-Premise
126	the	_	_	I-Premise
127	fourth	_	_	I-Premise
128	assessment	_	_	I-Premise
129	(	_	_	I-Premise
130	C	_	_	I-Premise
131	=	_	_	I-Premise
132	70.3	_	_	I-Premise
133	(	_	_	I-Premise
134	19.6	_	_	I-Premise
135	)	_	_	I-Premise
136	;	_	_	I-Premise
137	CP	_	_	I-Premise
138	=	_	_	I-Premise
139	72.8	_	_	I-Premise
140	(	_	_	I-Premise
141	17.4	_	_	I-Premise
142	)	_	_	I-Premise
143	)	_	_	I-Premise
144	.	_	_	I-Premise

145	Scores	_	_	B-Premise
146	were	_	_	I-Premise
147	stable	_	_	I-Premise
148	over	_	_	I-Premise
149	time	_	_	I-Premise
150	and	_	_	I-Premise
151	considerably	_	_	I-Premise
152	lower	_	_	I-Premise
153	than	_	_	I-Premise
154	the	_	_	I-Premise
155	general	_	_	I-Premise
156	population	_	_	I-Premise
157	norms	_	_	I-Premise
158	.	_	_	I-Premise

159	The	_	_	B-Premise
160	BPI-SF	_	_	I-Premise
161	revealed	_	_	I-Premise
162	a	_	_	I-Premise
163	decline	_	_	I-Premise
164	in	_	_	I-Premise
165	pain	_	_	I-Premise
166	scores	_	_	I-Premise
167	in	_	_	I-Premise
168	both	_	_	I-Premise
169	arms	_	_	I-Premise
170	from	_	_	I-Premise
171	the	_	_	I-Premise
172	first	_	_	I-Premise
173	to	_	_	I-Premise
174	fourth	_	_	I-Premise
175	assessments	_	_	I-Premise
176	.	_	_	I-Premise

177	The	_	_	B-Premise
178	CP	_	_	I-Premise
179	arm	_	_	I-Premise
180	produced	_	_	I-Premise
181	a	_	_	I-Premise
182	significantly	_	_	I-Premise
183	higher	_	_	I-Premise
184	response	_	_	I-Premise
185	rate	_	_	I-Premise
186	and	_	_	I-Premise
187	progression-free	_	_	I-Premise
188	survival	_	_	I-Premise
189	(	_	_	I-Premise
190	PFS	_	_	I-Premise
191	)	_	_	I-Premise
192	but	_	_	B-Premise
193	not	_	_	I-Premise
194	overall	_	_	I-Premise
195	survival	_	_	I-Premise
196	(	_	_	I-Premise
197	OS	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Greater	_	_	B-Premise
201	myelosuppression	_	_	I-Premise
202	was	_	_	I-Premise
203	reported	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	combination	_	_	I-Premise
207	arm	_	_	I-Premise
208	.	_	_	I-Premise

209	The	_	_	B-Premise
210	rate	_	_	I-Premise
211	of	_	_	I-Premise
212	QOL	_	_	I-Premise
213	drop-out	_	_	I-Premise
214	for	_	_	I-Premise
215	any	_	_	I-Premise
216	reason	_	_	I-Premise
217	was	_	_	I-Premise
218	higher	_	_	I-Premise
219	for	_	_	I-Premise
220	C	_	_	I-Premise
221	(	_	_	I-Premise
222	53	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	compared	_	_	I-Premise
226	to	_	_	I-Premise
227	CP	_	_	I-Premise
228	(	_	_	I-Premise
229	38	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	<	_	_	I-Premise
235	0.05	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	At	_	_	O
239	the	_	_	O
240	fourth	_	_	O
241	time	_	_	O
242	point	_	_	O
243	,	_	_	O
244	60	_	_	O
245	%	_	_	O
246	of	_	_	O
247	living	_	_	O
248	patients	_	_	O
249	in	_	_	O
250	both	_	_	O
251	arms	_	_	O
252	completed	_	_	O
253	a	_	_	O
254	QOL	_	_	O
255	assessment	_	_	O
256	.	_	_	O

257	There	_	_	B-Claim
258	was	_	_	I-Claim
259	no	_	_	I-Claim
260	significant	_	_	I-Claim
261	difference	_	_	I-Claim
262	in	_	_	I-Claim
263	overall	_	_	I-Claim
264	QOL	_	_	I-Claim
265	scores	_	_	I-Claim
266	between	_	_	I-Claim
267	treatment	_	_	I-Claim
268	arms	_	_	I-Claim
269	or	_	_	I-Claim
270	serially	_	_	I-Claim
271	.	_	_	I-Claim

272	Combined	_	_	B-Claim
273	with	_	_	I-Claim
274	QOL	_	_	I-Claim
275	results	_	_	I-Claim
276	,	_	_	I-Claim
277	the	_	_	I-Claim
278	significant	_	_	I-Claim
279	increase	_	_	I-Claim
280	in	_	_	I-Claim
281	response	_	_	I-Claim
282	and	_	_	I-Claim
283	PFS	_	_	I-Claim
284	in	_	_	I-Claim
285	the	_	_	I-Claim
286	CP	_	_	I-Claim
287	arm	_	_	I-Claim
288	and	_	_	I-Claim
289	the	_	_	I-Claim
290	higher	_	_	I-Claim
291	drop-out	_	_	I-Claim
292	rate	_	_	I-Claim
293	in	_	_	I-Claim
294	the	_	_	I-Claim
295	C	_	_	I-Claim
296	arm	_	_	I-Claim
297	suggest	_	_	I-Claim
298	a	_	_	I-Claim
299	better	_	_	I-Claim
300	outcome	_	_	I-Claim
301	for	_	_	I-Claim
302	the	_	_	I-Claim
303	combination	_	_	I-Claim
304	regimen	_	_	I-Claim
305	despite	_	_	I-Claim
306	its	_	_	I-Claim
307	increased	_	_	I-Claim
308	myelosuppression	_	_	I-Claim
309	.	_	_	I-Claim


0	Recent	_	_	B-Claim
1	studies	_	_	I-Claim
2	have	_	_	I-Claim
3	shown	_	_	I-Claim
4	that	_	_	I-Claim
5	administering	_	_	I-Claim
6	the	_	_	I-Claim
7	aromatase	_	_	I-Claim
8	inhibitor	_	_	I-Claim
9	exemestane	_	_	I-Claim
10	after	_	_	I-Claim
11	2-3	_	_	I-Claim
12	years	_	_	I-Claim
13	of	_	_	I-Claim
14	tamoxifen	_	_	I-Claim
15	therapy	_	_	I-Claim
16	significantly	_	_	I-Claim
17	improves	_	_	I-Claim
18	disease-free	_	_	I-Claim
19	survival	_	_	I-Claim
20	in	_	_	I-Claim
21	postmenopausal	_	_	I-Claim
22	women	_	_	I-Claim
23	with	_	_	I-Claim
24	primary	_	_	I-Claim
25	breast	_	_	I-Claim
26	cancer	_	_	I-Claim
27	in	_	_	I-Claim
28	comparison	_	_	I-Claim
29	with	_	_	I-Claim
30	standard	_	_	I-Claim
31	5-year	_	_	I-Claim
32	tamoxifen	_	_	I-Claim
33	treatment	_	_	I-Claim
34	.	_	_	I-Claim

35	Although	_	_	O
36	many	_	_	O
37	of	_	_	O
38	the	_	_	O
39	adverse	_	_	O
40	effects	_	_	O
41	associated	_	_	O
42	with	_	_	O
43	exemestane	_	_	O
44	and	_	_	O
45	tamoxifen	_	_	O
46	have	_	_	O
47	been	_	_	O
48	analysed	_	_	O
49	,	_	_	O
50	there	_	_	O
51	are	_	_	O
52	no	_	_	O
53	comparative	_	_	O
54	data	_	_	O
55	concerning	_	_	O
56	body	_	_	O
57	weight	_	_	O
58	and	_	_	O
59	body	_	_	O
60	composition	_	_	O
61	.	_	_	O

62	The	_	_	O
63	aim	_	_	O
64	of	_	_	O
65	this	_	_	O
66	randomised	_	_	O
67	study	_	_	O
68	was	_	_	O
69	to	_	_	O
70	evaluate	_	_	O
71	the	_	_	O
72	longitudinal	_	_	O
73	changes	_	_	O
74	in	_	_	O
75	body	_	_	O
76	composition	_	_	O
77	and	_	_	O
78	lipid	_	_	O
79	profiles	_	_	O
80	in	_	_	O
81	postmenopausal	_	_	O
82	women	_	_	O
83	switched	_	_	O
84	from	_	_	O
85	tamoxifen	_	_	O
86	to	_	_	O
87	exemestane	_	_	O
88	.	_	_	O

89	In	_	_	O
90	total	_	_	O
91	,	_	_	O
92	60	_	_	O
93	overweight	_	_	O
94	or	_	_	O
95	obese	_	_	O
96	postmenopausal	_	_	O
97	patients	_	_	O
98	were	_	_	O
99	enrolled	_	_	O
100	.	_	_	O

101	Their	_	_	O
102	anthropometric	_	_	O
103	data	_	_	O
104	,	_	_	O
105	body	_	_	O
106	composition	_	_	O
107	,	_	_	O
108	including	_	_	O
109	fat	_	_	O
110	mass	_	_	O
111	(	_	_	O
112	FM	_	_	O
113	)	_	_	O
114	and	_	_	O
115	fat-free	_	_	O
116	mass	_	_	O
117	(	_	_	O
118	FFM	_	_	O
119	)	_	_	O
120	,	_	_	O
121	and	_	_	O
122	lipid	_	_	O
123	profiles	_	_	O
124	,	_	_	O
125	caloric	_	_	O
126	intake	_	_	O
127	and	_	_	O
128	physical	_	_	O
129	activity	_	_	O
130	were	_	_	O
131	assessed	_	_	O
132	1	_	_	O
133	week	_	_	O
134	before	_	_	O
135	randomisation	_	_	O
136	,	_	_	O
137	and	_	_	O
138	6	_	_	O
139	and	_	_	O
140	12	_	_	O
141	months	_	_	O
142	later	_	_	O
143	.	_	_	O

144	In	_	_	O
145	all	_	_	O
146	,	_	_	O
147	55	_	_	O
148	patients	_	_	O
149	(	_	_	O
150	27	_	_	O
151	on	_	_	O
152	tamoxifen	_	_	O
153	and	_	_	O
154	28	_	_	O
155	on	_	_	O
156	exemestane	_	_	O
157	)	_	_	O
158	completed	_	_	O
159	the	_	_	O
160	1-year	_	_	O
161	study	_	_	O
162	period	_	_	O
163	.	_	_	O

164	Fat	_	_	B-Premise
165	mass	_	_	I-Premise
166	had	_	_	I-Premise
167	significantly	_	_	I-Premise
168	decreased	_	_	I-Premise
169	by	_	_	I-Premise
170	month	_	_	I-Premise
171	12	_	_	I-Premise
172	in	_	_	I-Premise
173	the	_	_	I-Premise
174	exemestane	_	_	I-Premise
175	,	_	_	I-Premise
176	but	_	_	I-Premise
177	not	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	tamoxifen	_	_	I-Premise
181	group	_	_	I-Premise
182	;	_	_	I-Premise
183	the	_	_	B-Premise
184	between-group	_	_	I-Premise
185	difference	_	_	I-Premise
186	was	_	_	I-Premise
187	statistically	_	_	I-Premise
188	significant	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	<	_	_	I-Premise
192	0.01	_	_	I-Premise
193	)	_	_	I-Premise
194	.	_	_	I-Premise

195	The	_	_	B-Premise
196	FFM/FM	_	_	I-Premise
197	ratio	_	_	I-Premise
198	had	_	_	I-Premise
199	significantly	_	_	I-Premise
200	increased	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	exemestane	_	_	I-Premise
204	group	_	_	I-Premise
205	,	_	_	I-Premise
206	but	_	_	I-Premise
207	not	_	_	I-Premise
208	the	_	_	I-Premise
209	tamoxifen	_	_	I-Premise
210	group	_	_	I-Premise
211	;	_	_	I-Premise
212	the	_	_	B-Premise
213	between-group	_	_	I-Premise
214	difference	_	_	I-Premise
215	was	_	_	I-Premise
216	statistically	_	_	I-Premise
217	significant	_	_	I-Premise
218	(	_	_	I-Premise
219	P	_	_	I-Premise
220	<	_	_	I-Premise
221	0.05	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	Triglycerides	_	_	B-Premise
225	and	_	_	I-Premise
226	high-density	_	_	I-Premise
227	lipoprotein	_	_	I-Premise
228	cholesterol	_	_	I-Premise
229	significantly	_	_	I-Premise
230	decreased	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	0.01	_	_	I-Premise
235	;	_	_	I-Premise
236	P	_	_	I-Premise
237	<	_	_	I-Premise
238	0.05	_	_	I-Premise
239	)	_	_	I-Premise
240	,	_	_	I-Premise
241	and	_	_	O
242	low-density	_	_	B-Premise
243	lipoprotein	_	_	I-Premise
244	cholesterol	_	_	I-Premise
245	significantly	_	_	I-Premise
246	increased	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	<	_	_	I-Premise
250	0.01	_	_	I-Premise
251	)	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	exemestane	_	_	I-Premise
255	group	_	_	I-Premise
256	at	_	_	I-Premise
257	the	_	_	I-Premise
258	end	_	_	I-Premise
259	of	_	_	I-Premise
260	the	_	_	I-Premise
261	1-year	_	_	I-Premise
262	study	_	_	I-Premise
263	period	_	_	I-Premise
264	.	_	_	I-Premise

265	Our	_	_	B-Claim
266	findings	_	_	I-Claim
267	suggest	_	_	I-Claim
268	that	_	_	I-Claim
269	switching	_	_	I-Claim
270	patients	_	_	I-Claim
271	to	_	_	I-Claim
272	adjuvant	_	_	I-Claim
273	exemestane	_	_	I-Claim
274	treatment	_	_	I-Claim
275	after	_	_	I-Claim
276	at	_	_	I-Claim
277	least	_	_	I-Claim
278	2	_	_	I-Claim
279	years	_	_	I-Claim
280	of	_	_	I-Claim
281	tamoxifen	_	_	I-Claim
282	therapy	_	_	I-Claim
283	may	_	_	I-Claim
284	be	_	_	I-Claim
285	associated	_	_	I-Claim
286	with	_	_	I-Claim
287	an	_	_	I-Claim
288	advantage	_	_	I-Claim
289	over	_	_	I-Claim
290	continuing	_	_	I-Claim
291	adjuvant	_	_	I-Claim
292	tamoxifen	_	_	I-Claim
293	treatment	_	_	I-Claim
294	in	_	_	I-Claim
295	terms	_	_	I-Claim
296	of	_	_	I-Claim
297	body	_	_	I-Claim
298	composition	_	_	I-Claim
299	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	gemcitabine	_	_	O
8	plus	_	_	O
9	cisplatin	_	_	O
10	with	_	_	O
11	single-agent	_	_	O
12	gemcitabine	_	_	O
13	as	_	_	O
14	first-line	_	_	O
15	chemotherapy	_	_	O
16	for	_	_	O
17	locally	_	_	O
18	advanced	_	_	O
19	or	_	_	O
20	metastatic	_	_	O
21	pancreatic	_	_	O
22	cancer	_	_	O
23	.	_	_	O

24	Patients	_	_	O
25	with	_	_	O
26	advanced	_	_	O
27	adenocarcinoma	_	_	O
28	of	_	_	O
29	the	_	_	O
30	pancreas	_	_	O
31	were	_	_	O
32	randomly	_	_	O
33	assigned	_	_	O
34	to	_	_	O
35	receive	_	_	O
36	either	_	_	O
37	gemcitabine	_	_	O
38	1,000	_	_	O
39	mg/m2	_	_	O
40	and	_	_	O
41	cisplatin	_	_	O
42	50	_	_	O
43	mg/m2	_	_	O
44	given	_	_	O
45	on	_	_	O
46	days	_	_	O
47	1	_	_	O
48	and	_	_	O
49	15	_	_	O
50	of	_	_	O
51	a	_	_	O
52	4-week	_	_	O
53	cycle	_	_	O
54	(	_	_	O
55	GemCis	_	_	O
56	arm	_	_	O
57	)	_	_	O
58	or	_	_	O
59	gemcitabine	_	_	O
60	alone	_	_	O
61	at	_	_	O
62	a	_	_	O
63	dose	_	_	O
64	of	_	_	O
65	1,000	_	_	O
66	mg/m2	_	_	O
67	on	_	_	O
68	days	_	_	O
69	1	_	_	O
70	,	_	_	O
71	8	_	_	O
72	,	_	_	O
73	and	_	_	O
74	15	_	_	O
75	of	_	_	O
76	a	_	_	O
77	4-week	_	_	O
78	regimen	_	_	O
79	(	_	_	O
80	Gem	_	_	O
81	arm	_	_	O
82	)	_	_	O
83	.	_	_	O

84	The	_	_	O
85	primary	_	_	O
86	end	_	_	O
87	point	_	_	O
88	was	_	_	O
89	overall	_	_	O
90	survival	_	_	O
91	;	_	_	O
92	secondary	_	_	O
93	end	_	_	O
94	points	_	_	O
95	were	_	_	O
96	progression-free	_	_	O
97	survival	_	_	O
98	,	_	_	O
99	response	_	_	O
100	rate	_	_	O
101	,	_	_	O
102	safety	_	_	O
103	,	_	_	O
104	and	_	_	O
105	quality	_	_	O
106	of	_	_	O
107	life	_	_	O
108	.	_	_	O

109	One	_	_	O
110	hundred	_	_	O
111	ninety-five	_	_	O
112	patients	_	_	O
113	were	_	_	O
114	enrolled	_	_	O
115	and	_	_	O
116	showed	_	_	O
117	baseline	_	_	O
118	characteristics	_	_	O
119	well	_	_	O
120	balanced	_	_	O
121	between	_	_	O
122	treatment	_	_	O
123	arms	_	_	O
124	.	_	_	O

125	Combination	_	_	B-Premise
126	treatment	_	_	I-Premise
127	in	_	_	I-Premise
128	the	_	_	I-Premise
129	GemCis	_	_	I-Premise
130	arm	_	_	I-Premise
131	was	_	_	I-Premise
132	associated	_	_	I-Premise
133	with	_	_	I-Premise
134	a	_	_	I-Premise
135	prolonged	_	_	I-Premise
136	median	_	_	I-Premise
137	progression-free	_	_	I-Premise
138	survival	_	_	I-Premise
139	(	_	_	I-Premise
140	5.3	_	_	I-Premise
141	months	_	_	I-Premise
142	v	_	_	I-Premise
143	3.1	_	_	I-Premise
144	months	_	_	I-Premise
145	;	_	_	I-Premise
146	hazard	_	_	I-Premise
147	ratio	_	_	I-Premise
148	[	_	_	I-Premise
149	HR	_	_	I-Premise
150	]	_	_	I-Premise
151	=	_	_	I-Premise
152	0.75	_	_	I-Premise
153	;	_	_	I-Premise
154	P	_	_	I-Premise
155	=	_	_	I-Premise
156	.053	_	_	I-Premise
157	)	_	_	I-Premise
158	.	_	_	I-Premise

159	Also	_	_	B-Premise
160	,	_	_	I-Premise
161	median	_	_	I-Premise
162	overall	_	_	I-Premise
163	survival	_	_	I-Premise
164	was	_	_	I-Premise
165	superior	_	_	I-Premise
166	for	_	_	I-Premise
167	patients	_	_	I-Premise
168	treated	_	_	I-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	GemCis	_	_	I-Premise
172	arm	_	_	I-Premise
173	as	_	_	I-Premise
174	compared	_	_	I-Premise
175	with	_	_	I-Premise
176	the	_	_	I-Premise
177	Gem	_	_	I-Premise
178	arm	_	_	I-Premise
179	(	_	_	I-Premise
180	7.5	_	_	I-Premise
181	v	_	_	I-Premise
182	6.0	_	_	I-Premise
183	months	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	an	_	_	B-Premise
187	advantage	_	_	I-Premise
188	which	_	_	I-Premise
189	did	_	_	I-Premise
190	not	_	_	I-Premise
191	,	_	_	I-Premise
192	however	_	_	I-Premise
193	,	_	_	I-Premise
194	reach	_	_	I-Premise
195	statistical	_	_	I-Premise
196	significance	_	_	I-Premise
197	(	_	_	I-Premise
198	HR	_	_	I-Premise
199	=	_	_	I-Premise
200	0.80	_	_	I-Premise
201	;	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	.15	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Tumor	_	_	B-Premise
208	response	_	_	I-Premise
209	rates	_	_	I-Premise
210	were	_	_	I-Premise
211	comparable	_	_	I-Premise
212	between	_	_	I-Premise
213	treatment	_	_	I-Premise
214	arms	_	_	I-Premise
215	(	_	_	I-Premise
216	10.2	_	_	I-Premise
217	%	_	_	I-Premise
218	v	_	_	I-Premise
219	8.2	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	The	_	_	B-Premise
224	rate	_	_	I-Premise
225	of	_	_	I-Premise
226	stable	_	_	I-Premise
227	disease	_	_	I-Premise
228	was	_	_	I-Premise
229	,	_	_	I-Premise
230	however	_	_	I-Premise
231	,	_	_	I-Premise
232	greater	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	combination	_	_	I-Premise
236	arm	_	_	I-Premise
237	(	_	_	I-Premise
238	60.2	_	_	I-Premise
239	%	_	_	I-Premise
240	v	_	_	I-Premise
241	40.2	_	_	I-Premise
242	%	_	_	I-Premise
243	;	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	.001	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	O

249	Grade	_	_	B-Premise
250	3	_	_	I-Premise
251	to	_	_	I-Premise
252	4	_	_	I-Premise
253	hematologic	_	_	I-Premise
254	toxicity	_	_	I-Premise
255	did	_	_	I-Premise
256	not	_	_	I-Premise
257	exceed	_	_	I-Premise
258	15	_	_	I-Premise
259	%	_	_	I-Premise
260	in	_	_	I-Premise
261	both	_	_	I-Premise
262	treatment	_	_	I-Premise
263	arms	_	_	I-Premise
264	.	_	_	I-Premise

265	These	_	_	B-Claim
266	results	_	_	I-Claim
267	support	_	_	I-Claim
268	the	_	_	I-Claim
269	efficacy	_	_	I-Claim
270	and	_	_	I-Claim
271	safety	_	_	I-Claim
272	of	_	_	I-Claim
273	an	_	_	I-Claim
274	every-2-weeks	_	_	I-Claim
275	treatment	_	_	I-Claim
276	with	_	_	I-Claim
277	gemcitabine	_	_	I-Claim
278	plus	_	_	I-Claim
279	cisplatin	_	_	I-Claim
280	.	_	_	I-Claim

281	Median	_	_	B-Claim
282	overall	_	_	I-Claim
283	survival	_	_	I-Claim
284	and	_	_	I-Claim
285	progression-free	_	_	I-Claim
286	survival	_	_	I-Claim
287	were	_	_	I-Claim
288	more	_	_	I-Claim
289	favorable	_	_	I-Claim
290	in	_	_	I-Claim
291	the	_	_	I-Claim
292	combination	_	_	I-Claim
293	arm	_	_	I-Claim
294	as	_	_	I-Claim
295	compared	_	_	I-Claim
296	with	_	_	I-Claim
297	gemcitabine	_	_	I-Claim
298	alone	_	_	I-Claim
299	,	_	_	I-Claim
300	although	_	_	B-Premise
301	the	_	_	I-Premise
302	difference	_	_	I-Premise
303	did	_	_	I-Premise
304	not	_	_	I-Premise
305	attain	_	_	I-Premise
306	statistical	_	_	I-Premise
307	significance	_	_	I-Premise
308	.	_	_	I-Premise


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	impact	_	_	O
5	of	_	_	O
6	laying	_	_	O
7	on	_	_	O
8	of	_	_	O
9	hands	_	_	O
10	on	_	_	O
11	the	_	_	O
12	well-being	_	_	O
13	of	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	advanced	_	_	O
17	cancer	_	_	O
18	is	_	_	O
19	more	_	_	O
20	efficient	_	_	O
21	when	_	_	O
22	performed	_	_	O
23	by	_	_	O
24	a	_	_	O
25	person	_	_	O
26	with	_	_	O
27	self-declared	_	_	O
28	healing	_	_	O
29	powers	_	_	O
30	as	_	_	O
31	compared	_	_	O
32	to	_	_	O
33	an	_	_	O
34	actor	_	_	O
35	mimicking	_	_	O
36	the	_	_	O
37	healer	_	_	O
38	in	_	_	O
39	close	_	_	O
40	detail	_	_	O
41	.	_	_	O

42	A	_	_	O
43	total	_	_	O
44	of	_	_	O
45	80	_	_	O
46	patients	_	_	O
47	were	_	_	O
48	registered	_	_	O
49	to	_	_	O
50	participate	_	_	O
51	in	_	_	O
52	a	_	_	O
53	randomized	_	_	O
54	,	_	_	O
55	single-blind	_	_	O
56	phase	_	_	O
57	III	_	_	O
58	trial	_	_	O
59	to	_	_	O
60	evaluate	_	_	O
61	the	_	_	O
62	difference	_	_	O
63	in	_	_	O
64	efficacy	_	_	O
65	of	_	_	O
66	laying	_	_	O
67	on	_	_	O
68	of	_	_	O
69	hands	_	_	O
70	by	_	_	O
71	either	_	_	O
72	a	_	_	O
73	healer	_	_	O
74	or	_	_	O
75	an	_	_	O
76	actor	_	_	O
77	.	_	_	O

78	Each	_	_	O
79	group	_	_	O
80	consisted	_	_	O
81	of	_	_	O
82	40	_	_	O
83	patients	_	_	O
84	,	_	_	O
85	scheduled	_	_	O
86	to	_	_	O
87	receive	_	_	O
88	treatment	_	_	O
89	for	_	_	O
90	5	_	_	O
91	min	_	_	O
92	,	_	_	O
93	three	_	_	O
94	times	_	_	O
95	a	_	_	O
96	week	_	_	O
97	.	_	_	O

98	The	_	_	O
99	effect	_	_	O
100	of	_	_	O
101	treatment	_	_	O
102	was	_	_	O
103	measured	_	_	O
104	using	_	_	O
105	a	_	_	O
106	Well-Being	_	_	O
107	scale	_	_	O
108	,	_	_	O
109	with	_	_	O
110	the	_	_	O
111	difference	_	_	O
112	of	_	_	O
113	the	_	_	O
114	average	_	_	O
115	score	_	_	O
116	of	_	_	O
117	the	_	_	O
118	Well-Being	_	_	O
119	scale	_	_	O
120	on	_	_	O
121	day	_	_	O
122	10	_	_	O
123	being	_	_	O
124	defined	_	_	O
125	as	_	_	O
126	primary	_	_	O
127	and	_	_	O
128	that	_	_	O
129	on	_	_	O
130	day	_	_	O
131	5	_	_	O
132	as	_	_	O
133	secondary	_	_	O
134	endpoint	_	_	O
135	.	_	_	O

136	There	_	_	B-Premise
137	was	_	_	I-Premise
138	no	_	_	I-Premise
139	significant	_	_	I-Premise
140	difference	_	_	I-Premise
141	in	_	_	I-Premise
142	average	_	_	I-Premise
143	score	_	_	I-Premise
144	values	_	_	I-Premise
145	between	_	_	I-Premise
146	the	_	_	I-Premise
147	healer	_	_	O
148	and	_	_	O
149	the	_	_	O
150	actor	_	_	O
151	with	_	_	O
152	regard	_	_	I-Premise
153	to	_	_	I-Premise
154	the	_	_	I-Premise
155	primary	_	_	I-Premise
156	(	_	_	I-Premise
157	p	_	_	I-Premise
158	=	_	_	I-Premise
159	0.34	_	_	I-Premise
160	)	_	_	I-Premise
161	or	_	_	I-Premise
162	the	_	_	I-Premise
163	secondary	_	_	I-Premise
164	endpoint	_	_	I-Premise
165	(	_	_	I-Premise
166	p	_	_	I-Premise
167	=	_	_	I-Premise
168	0.94	_	_	I-Premise
169	)	_	_	I-Premise
170	,	_	_	I-Premise
171	but	_	_	B-Premise
172	the	_	_	I-Premise
173	comparison	_	_	I-Premise
174	was	_	_	I-Premise
175	limited	_	_	I-Premise
176	due	_	_	I-Premise
177	to	_	_	I-Premise
178	major	_	_	I-Premise
179	protocol	_	_	I-Premise
180	violations	_	_	I-Premise
181	by	_	_	I-Premise
182	the	_	_	I-Premise
183	healer	_	_	O
184	who	_	_	I-Premise
185	unblinded	_	_	I-Premise
186	his	_	_	I-Premise
187	status	_	_	I-Premise
188	after	_	_	I-Premise
189	the	_	_	I-Premise
190	first	_	_	I-Premise
191	run	_	_	I-Premise
192	and	_	_	I-Premise
193	quit	_	_	I-Premise
194	the	_	_	I-Premise
195	study	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	O
198	study	_	_	O
199	was	_	_	O
200	completed	_	_	O
201	by	_	_	O
202	the	_	_	O
203	actor	_	_	O
204	as	_	_	O
205	a	_	_	O
206	descriptive	_	_	O
207	,	_	_	O
208	explorative	_	_	O
209	study	_	_	O
210	on	_	_	O
211	the	_	_	O
212	impact	_	_	O
213	of	_	_	O
214	laying	_	_	O
215	on	_	_	O
216	of	_	_	O
217	hands	_	_	O
218	.	_	_	O

219	A	_	_	O
220	significant	_	_	I-Premise
221	improvement	_	_	I-Premise
222	in	_	_	I-Premise
223	symptoms	_	_	I-Premise
224	after	_	_	I-Premise
225	treatment	_	_	I-Premise
226	was	_	_	I-Premise
227	found	_	_	I-Premise
228	on	_	_	I-Premise
229	day	_	_	I-Premise
230	5	_	_	I-Premise
231	(	_	_	I-Premise
232	p	_	_	I-Premise
233	<	_	_	I-Premise
234	0.001	_	_	I-Premise
235	)	_	_	I-Premise
236	and	_	_	I-Premise
237	on	_	_	I-Premise
238	day	_	_	I-Premise
239	10	_	_	I-Premise
240	(	_	_	I-Premise
241	p	_	_	I-Premise
242	=	_	_	I-Premise
243	0.0002	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	Laying	_	_	I-Claim
247	on	_	_	I-Claim
248	of	_	_	I-Claim
249	hands	_	_	I-Claim
250	resulted	_	_	I-Claim
251	in	_	_	I-Claim
252	a	_	_	I-Claim
253	significant	_	_	I-Claim
254	improvement	_	_	I-Claim
255	of	_	_	I-Claim
256	cancer-	_	_	I-Claim
257	or	_	_	I-Claim
258	cancer-therapy-associated	_	_	I-Claim
259	symptoms	_	_	I-Claim
260	.	_	_	I-Claim

261	The	_	_	B-Claim
262	magnitude	_	_	I-Claim
263	of	_	_	I-Claim
264	improvement	_	_	I-Claim
265	obtained	_	_	I-Claim
266	was	_	_	I-Claim
267	similar	_	_	I-Claim
268	whether	_	_	I-Claim
269	on	_	_	I-Claim
270	a	_	_	I-Claim
271	self-declared-healer-	_	_	I-Claim
272	or	_	_	I-Claim
273	an	_	_	I-Claim
274	actor-provided	_	_	I-Claim
275	treatment	_	_	O
276	.	_	_	O


0	The	_	_	B-Claim
1	efficacy	_	_	I-Claim
2	and	_	_	I-Claim
3	safety	_	_	I-Claim
4	of	_	_	I-Claim
5	uterine-artery	_	_	I-Claim
6	embolization	_	_	I-Claim
7	,	_	_	I-Claim
8	as	_	_	I-Claim
9	compared	_	_	I-Claim
10	with	_	_	I-Claim
11	standard	_	_	I-Claim
12	surgical	_	_	I-Claim
13	methods	_	_	I-Claim
14	,	_	_	I-Claim
15	for	_	_	I-Claim
16	the	_	_	I-Claim
17	treatment	_	_	I-Claim
18	of	_	_	I-Claim
19	symptomatic	_	_	I-Claim
20	uterine	_	_	I-Claim
21	fibroids	_	_	I-Claim
22	remain	_	_	I-Claim
23	uncertain	_	_	I-Claim
24	.	_	_	I-Claim

25	We	_	_	O
26	conducted	_	_	O
27	a	_	_	O
28	randomized	_	_	O
29	trial	_	_	O
30	comparing	_	_	O
31	uterine-artery	_	_	O
32	embolization	_	_	O
33	and	_	_	O
34	surgery	_	_	O
35	in	_	_	O
36	women	_	_	O
37	with	_	_	O
38	symptomatic	_	_	O
39	uterine	_	_	O
40	fibroids	_	_	O
41	.	_	_	O

42	The	_	_	O
43	primary	_	_	O
44	outcome	_	_	O
45	was	_	_	O
46	quality	_	_	O
47	of	_	_	O
48	life	_	_	O
49	at	_	_	O
50	1	_	_	O
51	year	_	_	O
52	of	_	_	O
53	follow-up	_	_	O
54	,	_	_	O
55	as	_	_	O
56	measured	_	_	O
57	by	_	_	O
58	the	_	_	O
59	Medical	_	_	O
60	Outcomes	_	_	O
61	Study	_	_	O
62	36-Item	_	_	O
63	Short-Form	_	_	O
64	General	_	_	O
65	Health	_	_	O
66	Survey	_	_	O
67	(	_	_	O
68	SF-36	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Patients	_	_	O
72	were	_	_	O
73	randomly	_	_	O
74	assigned	_	_	O
75	in	_	_	O
76	a	_	_	O
77	2:1	_	_	O
78	ratio	_	_	O
79	to	_	_	O
80	undergo	_	_	O
81	either	_	_	O
82	uterine-artery	_	_	O
83	embolization	_	_	O
84	or	_	_	O
85	surgery	_	_	O
86	,	_	_	O
87	with	_	_	O
88	106	_	_	O
89	patients	_	_	O
90	undergoing	_	_	O
91	embolization	_	_	O
92	and	_	_	O
93	51	_	_	O
94	undergoing	_	_	O
95	surgery	_	_	O
96	(	_	_	O
97	43	_	_	O
98	hysterectomies	_	_	O
99	and	_	_	O
100	8	_	_	O
101	myomectomies	_	_	O
102	)	_	_	O
103	.	_	_	O

104	There	_	_	B-Premise
105	were	_	_	I-Premise
106	no	_	_	I-Premise
107	significant	_	_	I-Premise
108	differences	_	_	I-Premise
109	between	_	_	I-Premise
110	groups	_	_	I-Premise
111	in	_	_	I-Premise
112	any	_	_	I-Premise
113	of	_	_	I-Premise
114	the	_	_	I-Premise
115	eight	_	_	I-Premise
116	components	_	_	I-Premise
117	of	_	_	I-Premise
118	the	_	_	I-Premise
119	SF-36	_	_	I-Premise
120	scores	_	_	I-Premise
121	at	_	_	I-Premise
122	1	_	_	I-Premise
123	year	_	_	I-Premise
124	.	_	_	I-Premise

125	The	_	_	B-Premise
126	embolization	_	_	I-Premise
127	group	_	_	I-Premise
128	had	_	_	I-Premise
129	a	_	_	I-Premise
130	shorter	_	_	I-Premise
131	median	_	_	I-Premise
132	duration	_	_	I-Premise
133	of	_	_	I-Premise
134	hospitalization	_	_	I-Premise
135	than	_	_	I-Premise
136	the	_	_	I-Premise
137	surgical	_	_	I-Premise
138	group	_	_	I-Premise
139	(	_	_	I-Premise
140	1	_	_	I-Premise
141	day	_	_	I-Premise
142	vs.	_	_	I-Premise
143	5	_	_	I-Premise
144	days	_	_	I-Premise
145	,	_	_	I-Premise
146	P	_	_	I-Premise
147	<	_	_	I-Premise
148	0.001	_	_	I-Premise
149	)	_	_	I-Premise
150	and	_	_	I-Premise
151	a	_	_	I-Premise
152	shorter	_	_	I-Premise
153	time	_	_	I-Premise
154	before	_	_	I-Premise
155	returning	_	_	I-Premise
156	to	_	_	I-Premise
157	work	_	_	I-Premise
158	(	_	_	I-Premise
159	P	_	_	I-Premise
160	<	_	_	I-Premise
161	0.001	_	_	I-Premise
162	)	_	_	I-Premise
163	.	_	_	I-Premise

164	At	_	_	B-Premise
165	1	_	_	I-Premise
166	year	_	_	I-Premise
167	,	_	_	I-Premise
168	symptom	_	_	I-Premise
169	scores	_	_	I-Premise
170	were	_	_	I-Premise
171	better	_	_	I-Premise
172	in	_	_	I-Premise
173	the	_	_	I-Premise
174	surgical	_	_	I-Premise
175	group	_	_	I-Premise
176	(	_	_	I-Premise
177	P=0.03	_	_	I-Premise
178	)	_	_	I-Premise
179	.	_	_	I-Premise

180	During	_	_	B-Premise
181	the	_	_	I-Premise
182	first	_	_	I-Premise
183	year	_	_	I-Premise
184	of	_	_	I-Premise
185	follow-up	_	_	I-Premise
186	,	_	_	I-Premise
187	there	_	_	I-Premise
188	were	_	_	I-Premise
189	13	_	_	I-Premise
190	major	_	_	I-Premise
191	adverse	_	_	I-Premise
192	events	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	embolization	_	_	I-Premise
196	group	_	_	I-Premise
197	(	_	_	I-Premise
198	12	_	_	I-Premise
199	%	_	_	I-Premise
200	)	_	_	I-Premise
201	and	_	_	I-Premise
202	10	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	surgical	_	_	I-Premise
206	group	_	_	I-Premise
207	(	_	_	I-Premise
208	20	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	(	_	_	I-Premise
212	P=0.22	_	_	I-Premise
213	)	_	_	I-Premise
214	,	_	_	I-Premise
215	mostly	_	_	I-Premise
216	related	_	_	I-Premise
217	to	_	_	I-Premise
218	the	_	_	I-Premise
219	intervention	_	_	I-Premise
220	.	_	_	I-Premise

221	Ten	_	_	B-Premise
222	patients	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	embolization	_	_	I-Premise
226	group	_	_	I-Premise
227	(	_	_	I-Premise
228	9	_	_	I-Premise
229	%	_	_	I-Premise
230	)	_	_	I-Premise
231	required	_	_	I-Premise
232	repeated	_	_	I-Premise
233	embolization	_	_	I-Premise
234	or	_	_	I-Premise
235	hysterectomy	_	_	I-Premise
236	for	_	_	I-Premise
237	inadequate	_	_	I-Premise
238	symptom	_	_	I-Premise
239	control	_	_	I-Premise
240	.	_	_	I-Premise

241	After	_	_	B-Premise
242	the	_	_	I-Premise
243	first	_	_	I-Premise
244	year	_	_	I-Premise
245	of	_	_	I-Premise
246	follow-up	_	_	I-Premise
247	,	_	_	I-Premise
248	14	_	_	I-Premise
249	women	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	embolization	_	_	I-Premise
253	group	_	_	I-Premise
254	(	_	_	I-Premise
255	13	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	required	_	_	I-Premise
259	hospitalization	_	_	I-Premise
260	,	_	_	I-Premise
261	3	_	_	I-Premise
262	of	_	_	I-Premise
263	them	_	_	I-Premise
264	for	_	_	I-Premise
265	major	_	_	I-Premise
266	adverse	_	_	I-Premise
267	events	_	_	I-Premise
268	and	_	_	I-Premise
269	11	_	_	I-Premise
270	for	_	_	I-Premise
271	reintervention	_	_	I-Premise
272	for	_	_	I-Premise
273	treatment	_	_	I-Premise
274	failure	_	_	I-Premise
275	.	_	_	I-Premise

276	In	_	_	B-Claim
277	women	_	_	I-Claim
278	with	_	_	I-Claim
279	symptomatic	_	_	I-Claim
280	fibroids	_	_	I-Claim
281	,	_	_	I-Claim
282	the	_	_	I-Claim
283	faster	_	_	I-Claim
284	recovery	_	_	I-Claim
285	after	_	_	I-Claim
286	embolization	_	_	I-Claim
287	must	_	_	I-Claim
288	be	_	_	I-Claim
289	weighed	_	_	I-Claim
290	against	_	_	I-Claim
291	the	_	_	I-Claim
292	need	_	_	I-Claim
293	for	_	_	I-Claim
294	further	_	_	I-Claim
295	treatment	_	_	I-Claim
296	in	_	_	I-Claim
297	a	_	_	I-Claim
298	minority	_	_	I-Claim
299	of	_	_	I-Claim
300	patients	_	_	I-Claim
301	.	_	_	I-Claim


0	The	_	_	O
1	impact	_	_	O
2	of	_	_	O
3	psychotherapeutic	_	_	O
4	support	_	_	O
5	on	_	_	O
6	survival	_	_	O
7	for	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	gastrointestinal	_	_	O
11	cancer	_	_	O
12	undergoing	_	_	O
13	surgery	_	_	O
14	was	_	_	O
15	studied	_	_	O
16	.	_	_	O

17	A	_	_	O
18	randomized	_	_	O
19	controlled	_	_	O
20	trial	_	_	O
21	was	_	_	O
22	conducted	_	_	O
23	in	_	_	O
24	cooperation	_	_	O
25	with	_	_	O
26	the	_	_	O
27	Departments	_	_	O
28	of	_	_	O
29	General	_	_	O
30	Surgery	_	_	O
31	and	_	_	O
32	Medical	_	_	O
33	Psychology	_	_	O
34	,	_	_	O
35	University	_	_	O
36	Hospital	_	_	O
37	of	_	_	O
38	Hamburg	_	_	O
39	,	_	_	O
40	Germany	_	_	O
41	,	_	_	O
42	from	_	_	O
43	January	_	_	O
44	1991	_	_	O
45	to	_	_	O
46	January	_	_	O
47	1993	_	_	O
48	.	_	_	O

49	Consenting	_	_	O
50	patients	_	_	O
51	(	_	_	O
52	N	_	_	O
53	=	_	_	O
54	271	_	_	O
55	)	_	_	O
56	with	_	_	O
57	a	_	_	O
58	preliminary	_	_	O
59	diagnosis	_	_	O
60	of	_	_	O
61	cancer	_	_	O
62	of	_	_	O
63	the	_	_	O
64	esophagus	_	_	O
65	,	_	_	O
66	stomach	_	_	O
67	,	_	_	O
68	liver/gallbladder	_	_	O
69	,	_	_	O
70	pancreas	_	_	O
71	,	_	_	O
72	or	_	_	O
73	colon/rectum	_	_	O
74	were	_	_	O
75	stratified	_	_	O
76	by	_	_	O
77	sex	_	_	O
78	and	_	_	O
79	randomly	_	_	O
80	assigned	_	_	O
81	to	_	_	O
82	a	_	_	O
83	control	_	_	O
84	group	_	_	O
85	that	_	_	O
86	received	_	_	O
87	standard	_	_	O
88	care	_	_	O
89	as	_	_	O
90	provided	_	_	O
91	on	_	_	O
92	the	_	_	O
93	surgical	_	_	O
94	wards	_	_	O
95	,	_	_	O
96	or	_	_	O
97	to	_	_	O
98	an	_	_	O
99	experimental	_	_	O
100	group	_	_	O
101	that	_	_	O
102	received	_	_	O
103	formal	_	_	O
104	psychotherapeutic	_	_	O
105	support	_	_	O
106	in	_	_	O
107	addition	_	_	O
108	to	_	_	O
109	routine	_	_	O
110	care	_	_	O
111	during	_	_	O
112	the	_	_	O
113	hospital	_	_	O
114	stay	_	_	O
115	.	_	_	O

116	From	_	_	O
117	June	_	_	O
118	2003	_	_	O
119	to	_	_	O
120	December	_	_	O
121	2003	_	_	O
122	,	_	_	O
123	the	_	_	O
124	10-year	_	_	O
125	follow-up	_	_	O
126	was	_	_	O
127	conducted	_	_	O
128	.	_	_	O

129	Survival	_	_	O
130	status	_	_	O
131	for	_	_	O
132	all	_	_	O
133	patients	_	_	O
134	was	_	_	O
135	determined	_	_	O
136	from	_	_	O
137	our	_	_	O
138	own	_	_	O
139	records	_	_	O
140	and	_	_	O
141	from	_	_	O
142	three	_	_	O
143	external	_	_	O
144	sources	_	_	O
145	:	_	_	O
146	the	_	_	O
147	Hamburg	_	_	O
148	cancer	_	_	O
149	registry	_	_	O
150	,	_	_	O
151	family	_	_	O
152	doctors	_	_	O
153	,	_	_	O
154	and	_	_	O
155	the	_	_	O
156	general	_	_	O
157	citizen	_	_	O
158	registration	_	_	O
159	offices	_	_	O
160	.	_	_	O

161	Kaplan-Meier	_	_	B-Premise
162	survival	_	_	I-Premise
163	curves	_	_	I-Premise
164	demonstrated	_	_	I-Premise
165	better	_	_	I-Premise
166	survival	_	_	I-Premise
167	for	_	_	I-Premise
168	the	_	_	I-Premise
169	experimental	_	_	I-Premise
170	group	_	_	I-Premise
171	than	_	_	I-Premise
172	the	_	_	I-Premise
173	control	_	_	I-Premise
174	group	_	_	I-Premise
175	.	_	_	I-Premise

176	The	_	_	B-Premise
177	unadjusted	_	_	I-Premise
178	significance	_	_	I-Premise
179	level	_	_	I-Premise
180	for	_	_	I-Premise
181	group	_	_	I-Premise
182	differences	_	_	I-Premise
183	was	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.0006	_	_	I-Premise
187	for	_	_	I-Premise
188	survival	_	_	I-Premise
189	to	_	_	I-Premise
190	10	_	_	I-Premise
191	years	_	_	I-Premise
192	.	_	_	I-Premise

193	Cox	_	_	B-Premise
194	regression	_	_	I-Premise
195	models	_	_	I-Premise
196	that	_	_	I-Premise
197	took	_	_	I-Premise
198	TNM	_	_	I-Premise
199	staging	_	_	I-Premise
200	or	_	_	I-Premise
201	the	_	_	I-Premise
202	residual	_	_	I-Premise
203	tumor	_	_	I-Premise
204	classification	_	_	I-Premise
205	and	_	_	I-Premise
206	tumor	_	_	I-Premise
207	site	_	_	I-Premise
208	into	_	_	I-Premise
209	account	_	_	I-Premise
210	also	_	_	I-Premise
211	found	_	_	I-Premise
212	significant	_	_	I-Premise
213	differences	_	_	I-Premise
214	at	_	_	I-Premise
215	10	_	_	I-Premise
216	years	_	_	I-Premise
217	.	_	_	I-Premise

218	Secondary	_	_	B-Premise
219	analyses	_	_	I-Premise
220	found	_	_	I-Premise
221	that	_	_	I-Premise
222	differences	_	_	I-Premise
223	in	_	_	I-Premise
224	favor	_	_	I-Premise
225	of	_	_	I-Premise
226	the	_	_	I-Premise
227	experimental	_	_	I-Premise
228	group	_	_	I-Premise
229	occurred	_	_	I-Premise
230	in	_	_	I-Premise
231	patients	_	_	I-Premise
232	with	_	_	I-Premise
233	stomach	_	_	I-Premise
234	,	_	_	I-Premise
235	pancreatic	_	_	I-Premise
236	,	_	_	I-Premise
237	primary	_	_	I-Premise
238	liver	_	_	I-Premise
239	,	_	_	I-Premise
240	or	_	_	I-Premise
241	colorectal	_	_	I-Premise
242	cancer	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Claim
245	results	_	_	I-Claim
246	of	_	_	I-Claim
247	this	_	_	I-Claim
248	study	_	_	I-Claim
249	indicate	_	_	I-Claim
250	that	_	_	I-Claim
251	patients	_	_	I-Claim
252	with	_	_	I-Claim
253	gastrointestinal	_	_	I-Claim
254	cancer	_	_	I-Claim
255	,	_	_	I-Claim
256	who	_	_	I-Claim
257	undergo	_	_	I-Claim
258	surgery	_	_	I-Claim
259	for	_	_	I-Claim
260	stomach	_	_	I-Claim
261	,	_	_	I-Claim
262	pancreatic	_	_	I-Claim
263	,	_	_	I-Claim
264	primary	_	_	I-Claim
265	liver	_	_	I-Claim
266	,	_	_	I-Claim
267	or	_	_	I-Claim
268	colorectal	_	_	I-Claim
269	cancer	_	_	I-Claim
270	,	_	_	I-Claim
271	benefit	_	_	I-Claim
272	from	_	_	I-Claim
273	a	_	_	I-Claim
274	formal	_	_	I-Claim
275	program	_	_	I-Claim
276	of	_	_	I-Claim
277	psychotherapeutic	_	_	I-Claim
278	support	_	_	I-Claim
279	during	_	_	I-Claim
280	the	_	_	I-Claim
281	inpatient	_	_	I-Claim
282	hospital	_	_	I-Claim
283	stay	_	_	I-Claim
284	in	_	_	I-Claim
285	terms	_	_	I-Claim
286	of	_	_	I-Claim
287	long-term	_	_	I-Claim
288	survival	_	_	I-Claim
289	.	_	_	I-Claim


0	Therapy	_	_	B-Claim
1	of	_	_	I-Claim
2	patients	_	_	I-Claim
3	with	_	_	I-Claim
4	advanced	_	_	I-Claim
5	gastric	_	_	I-Claim
6	or	_	_	I-Claim
7	gastroesophageal	_	_	I-Claim
8	junction	_	_	I-Claim
9	cancer	_	_	I-Claim
10	should	_	_	I-Claim
11	provide	_	_	I-Claim
12	symptom	_	_	I-Claim
13	relief	_	_	I-Claim
14	and	_	_	I-Claim
15	improve	_	_	I-Claim
16	quality	_	_	I-Claim
17	of	_	_	I-Claim
18	life	_	_	I-Claim
19	(	_	_	I-Claim
20	QOL	_	_	I-Claim
21	)	_	_	I-Claim
22	because	_	_	I-Claim
23	most	_	_	I-Claim
24	patients	_	_	I-Claim
25	are	_	_	I-Claim
26	symptomatic	_	_	I-Claim
27	at	_	_	I-Claim
28	baseline	_	_	I-Claim
29	.	_	_	I-Claim

30	Using	_	_	O
31	validated	_	_	O
32	instruments	_	_	O
33	,	_	_	O
34	we	_	_	O
35	prospectively	_	_	O
36	assessed	_	_	O
37	QOL	_	_	O
38	(	_	_	O
39	even	_	_	O
40	after	_	_	O
41	completion	_	_	O
42	of	_	_	O
43	protocol	_	_	O
44	treatment	_	_	O
45	)	_	_	O
46	as	_	_	O
47	one	_	_	O
48	of	_	_	O
49	the	_	_	O
50	secondary	_	_	O
51	end	_	_	O
52	points	_	_	O
53	of	_	_	O
54	the	_	_	O
55	V325	_	_	O
56	phase	_	_	O
57	III	_	_	O
58	trial	_	_	O
59	.	_	_	O

60	Four	_	_	O
61	hundred	_	_	O
62	forty-five	_	_	O
63	patients	_	_	O
64	randomly	_	_	O
65	received	_	_	O
66	either	_	_	O
67	docetaxel	_	_	O
68	75	_	_	O
69	mg/m	_	_	O
70	(	_	_	O
71	2	_	_	O
72	)	_	_	O
73	and	_	_	O
74	cisplatin	_	_	O
75	75	_	_	O
76	mg/m	_	_	O
77	(	_	_	O
78	2	_	_	O
79	)	_	_	O
80	each	_	_	O
81	on	_	_	O
82	day	_	_	O
83	1	_	_	O
84	plus	_	_	O
85	fluorouracil	_	_	O
86	750	_	_	O
87	mg/m	_	_	O
88	(	_	_	O
89	2	_	_	O
90	)	_	_	O
91	/d	_	_	O
92	continuous	_	_	O
93	infusion	_	_	O
94	on	_	_	O
95	days	_	_	O
96	1	_	_	O
97	to	_	_	O
98	5	_	_	O
99	every	_	_	O
100	3	_	_	O
101	weeks	_	_	O
102	(	_	_	O
103	DCF	_	_	O
104	)	_	_	O
105	or	_	_	O
106	cisplatin	_	_	O
107	100	_	_	O
108	mg/m	_	_	O
109	(	_	_	O
110	2	_	_	O
111	)	_	_	O
112	on	_	_	O
113	day	_	_	O
114	1	_	_	O
115	plus	_	_	O
116	fluorouracil	_	_	O
117	1,000	_	_	O
118	mg/m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	/d	_	_	O
123	continuous	_	_	O
124	infusion	_	_	O
125	on	_	_	O
126	days	_	_	O
127	1	_	_	O
128	to	_	_	O
129	5	_	_	O
130	every	_	_	O
131	4	_	_	O
132	weeks	_	_	O
133	(	_	_	O
134	CF	_	_	O
135	)	_	_	O
136	.	_	_	O

137	The	_	_	O
138	European	_	_	O
139	Organisation	_	_	O
140	for	_	_	O
141	Research	_	_	O
142	and	_	_	O
143	Treatment	_	_	O
144	of	_	_	O
145	Cancer	_	_	O
146	Quality	_	_	O
147	of	_	_	O
148	Life	_	_	O
149	Questionnaire	_	_	O
150	C30	_	_	O
151	(	_	_	O
152	EORTC	_	_	O
153	QLQ-C30	_	_	O
154	)	_	_	O
155	and	_	_	O
156	,	_	_	O
157	where	_	_	O
158	available	_	_	O
159	,	_	_	O
160	the	_	_	O
161	EuroQOL	_	_	O
162	EQ-5D	_	_	O
163	questionnaire	_	_	O
164	were	_	_	O
165	administered	_	_	O
166	every	_	_	O
167	8	_	_	O
168	weeks	_	_	O
169	from	_	_	O
170	baseline	_	_	O
171	until	_	_	O
172	progression	_	_	O
173	and	_	_	O
174	then	_	_	O
175	every	_	_	O
176	3	_	_	O
177	months	_	_	O
178	.	_	_	O

179	Time	_	_	O
180	to	_	_	O
181	definitive	_	_	O
182	deterioration	_	_	O
183	of	_	_	O
184	QOL	_	_	O
185	parameters	_	_	O
186	was	_	_	O
187	analyzed	_	_	O
188	.	_	_	O

189	The	_	_	O
190	proportions	_	_	O
191	of	_	_	O
192	patients	_	_	O
193	having	_	_	O
194	assessable	_	_	O
195	EORTC	_	_	O
196	QLQ-C30	_	_	O
197	and	_	_	O
198	EQ-5D	_	_	O
199	questionnaires	_	_	O
200	at	_	_	O
201	baseline	_	_	O
202	were	_	_	O
203	86.0	_	_	O
204	%	_	_	O
205	and	_	_	O
206	78.7	_	_	O
207	%	_	_	O
208	with	_	_	O
209	DCF	_	_	O
210	,	_	_	O
211	respectively	_	_	O
212	,	_	_	O
213	and	_	_	O
214	89.7	_	_	O
215	%	_	_	O
216	and	_	_	O
217	92.8	_	_	O
218	%	_	_	O
219	with	_	_	O
220	CF	_	_	O
221	,	_	_	O
222	respectively	_	_	O
223	.	_	_	O

224	Time	_	_	B-Premise
225	to	_	_	I-Premise
226	5	_	_	I-Premise
227	%	_	_	I-Premise
228	deterioration	_	_	I-Premise
229	of	_	_	I-Premise
230	global	_	_	I-Premise
231	health	_	_	I-Premise
232	status	_	_	I-Premise
233	(	_	_	I-Premise
234	primary	_	_	I-Premise
235	end	_	_	I-Premise
236	point	_	_	I-Premise
237	)	_	_	I-Premise
238	significantly	_	_	I-Premise
239	favored	_	_	I-Premise
240	DCF	_	_	I-Premise
241	over	_	_	I-Premise
242	CF	_	_	I-Premise
243	(	_	_	I-Premise
244	log-rank	_	_	I-Premise
245	test	_	_	I-Premise
246	,	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	.01	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	QOL	_	_	B-Premise
253	was	_	_	I-Premise
254	preserved	_	_	I-Premise
255	longer	_	_	I-Premise
256	for	_	_	I-Premise
257	patients	_	_	I-Premise
258	on	_	_	I-Premise
259	DCF	_	_	I-Premise
260	than	_	_	I-Premise
261	those	_	_	I-Premise
262	on	_	_	I-Premise
263	CF	_	_	I-Premise
264	for	_	_	I-Premise
265	all	_	_	I-Premise
266	time	_	_	I-Premise
267	to	_	_	I-Premise
268	deterioration	_	_	I-Premise
269	analyses	_	_	I-Premise
270	,	_	_	I-Premise
271	demonstrating	_	_	I-Premise
272	the	_	_	I-Premise
273	statistical	_	_	I-Premise
274	superiority	_	_	I-Premise
275	of	_	_	I-Premise
276	DCF	_	_	I-Premise
277	compared	_	_	I-Premise
278	with	_	_	I-Premise
279	CF	_	_	I-Premise
280	.	_	_	I-Premise

281	V325	_	_	O
282	represents	_	_	O
283	the	_	_	O
284	largest	_	_	O
285	trial	_	_	O
286	with	_	_	O
287	the	_	_	O
288	longest	_	_	O
289	prospectively	_	_	O
290	controlled	_	_	O
291	evaluations	_	_	O
292	of	_	_	O
293	QOL	_	_	O
294	during	_	_	O
295	protocol	_	_	O
296	chemotherapy	_	_	O
297	and	_	_	O
298	follow-up	_	_	O
299	in	_	_	O
300	patients	_	_	O
301	with	_	_	O
302	advanced	_	_	O
303	gastric	_	_	O
304	or	_	_	O
305	gastroesophageal	_	_	O
306	junction	_	_	O
307	cancer	_	_	O
308	.	_	_	O

309	In	_	_	B-Claim
310	V325	_	_	I-Claim
311	,	_	_	I-Claim
312	advanced	_	_	I-Claim
313	gastric	_	_	I-Claim
314	or	_	_	I-Claim
315	gastroesophageal	_	_	I-Claim
316	junction	_	_	I-Claim
317	cancer	_	_	I-Claim
318	patients	_	_	I-Claim
319	receiving	_	_	I-Claim
320	DCF	_	_	I-Claim
321	not	_	_	I-Claim
322	only	_	_	I-Claim
323	had	_	_	I-Claim
324	statistically	_	_	I-Claim
325	improved	_	_	I-Claim
326	overall	_	_	I-Claim
327	survival	_	_	I-Claim
328	and	_	_	I-Claim
329	time	_	_	I-Claim
330	to	_	_	I-Claim
331	tumor-progression	_	_	I-Claim
332	,	_	_	I-Claim
333	but	_	_	I-Claim
334	they	_	_	I-Claim
335	also	_	_	I-Claim
336	had	_	_	I-Claim
337	better	_	_	I-Claim
338	preservation	_	_	I-Claim
339	of	_	_	I-Claim
340	QOL	_	_	I-Claim
341	compared	_	_	I-Claim
342	with	_	_	I-Claim
343	patients	_	_	I-Claim
344	receiving	_	_	I-Claim
345	CF	_	_	I-Claim
346	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	if	_	_	O
3	raising	_	_	O
4	baseline	_	_	O
5	and	_	_	O
6	maintaining	_	_	O
7	hemoglobin	_	_	O
8	(	_	_	O
9	Hb	_	_	O
10	)	_	_	O
11	levels	_	_	O
12	with	_	_	O
13	red	_	_	O
14	blood	_	_	O
15	cell	_	_	O
16	(	_	_	O
17	RBC	_	_	O
18	)	_	_	O
19	transfusion	_	_	O
20	could	_	_	O
21	improve	_	_	O
22	the	_	_	O
23	outcomes	_	_	O
24	of	_	_	O
25	chemotherapy	_	_	O
26	for	_	_	O
27	advanced	_	_	O
28	gastric	_	_	O
29	cancer	_	_	O
30	(	_	_	O
31	AGC	_	_	O
32	)	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	were	_	_	O
36	randomized	_	_	O
37	to	_	_	O
38	receive	_	_	O
39	RBC	_	_	O
40	transfusion	_	_	O
41	to	_	_	O
42	maintain	_	_	O
43	their	_	_	O
44	Hb	_	_	O
45	levels	_	_	O
46	>	_	_	O
47	or=10	_	_	O
48	g/dl	_	_	O
49	(	_	_	O
50	arm	_	_	O
51	1	_	_	O
52	)	_	_	O
53	or	_	_	O
54	>	_	_	O
55	or=12	_	_	O
56	(	_	_	O
57	arm	_	_	O
58	2	_	_	O
59	)	_	_	O
60	before	_	_	O
61	the	_	_	O
62	start	_	_	O
63	of	_	_	O
64	their	_	_	O
65	5-fluorouracil-based	_	_	O
66	first-line	_	_	O
67	chemotherapy	_	_	O
68	.	_	_	O

69	Objective	_	_	O
70	response	_	_	O
71	,	_	_	O
72	KPS	_	_	O
73	and	_	_	O
74	quality	_	_	O
75	of	_	_	O
76	life	_	_	O
77	(	_	_	O
78	QOL	_	_	O
79	)	_	_	O
80	data	_	_	O
81	were	_	_	O
82	measured	_	_	O
83	.	_	_	O

84	For	_	_	O
85	87	_	_	O
86	patients	_	_	O
87	enrolled	_	_	O
88	,	_	_	O
89	mean	_	_	O
90	baseline	_	_	O
91	Hb	_	_	O
92	was	_	_	O
93	10.1	_	_	O
94	g/dl	_	_	O
95	,	_	_	O
96	and	_	_	O
97	54	_	_	O
98	patients	_	_	O
99	received	_	_	O
100	RBC	_	_	O
101	prior	_	_	O
102	to	_	_	O
103	chemotherapy	_	_	O
104	initiation	_	_	O
105	.	_	_	O

106	Despite	_	_	O
107	transfusion	_	_	O
108	,	_	_	O
109	we	_	_	O
110	failed	_	_	O
111	to	_	_	O
112	maintain	_	_	O
113	the	_	_	O
114	Hb	_	_	O
115	level	_	_	O
116	above	_	_	O
117	the	_	_	O
118	predefined	_	_	O
119	target	_	_	O
120	range	_	_	O
121	.	_	_	O

122	Eighteen	_	_	B-Premise
123	patients	_	_	I-Premise
124	experienced	_	_	I-Premise
125	brief	_	_	I-Premise
126	and	_	_	I-Premise
127	reversible	_	_	I-Premise
128	adverse	_	_	I-Premise
129	events	_	_	I-Premise
130	during	_	_	I-Premise
131	transfusion	_	_	I-Premise
132	,	_	_	I-Premise
133	including	_	_	I-Premise
134	two	_	_	I-Premise
135	patients	_	_	I-Premise
136	with	_	_	I-Premise
137	acute	_	_	I-Premise
138	pulmonary	_	_	I-Premise
139	edema	_	_	I-Premise
140	.	_	_	I-Premise

141	KPS	_	_	B-Premise
142	was	_	_	I-Premise
143	improved	_	_	I-Premise
144	from	_	_	I-Premise
145	baseline	_	_	I-Premise
146	to	_	_	I-Premise
147	post-chemotherapy	_	_	I-Premise
148	in	_	_	I-Premise
149	both	_	_	I-Premise
150	arms	_	_	I-Premise
151	.	_	_	I-Premise

152	QOL	_	_	B-Premise
153	data	_	_	I-Premise
154	showed	_	_	I-Premise
155	improvement	_	_	I-Premise
156	in	_	_	I-Premise
157	some	_	_	I-Premise
158	symptom	_	_	I-Premise
159	scores	_	_	I-Premise
160	,	_	_	I-Premise
161	but	_	_	B-Premise
162	there	_	_	I-Premise
163	was	_	_	I-Premise
164	no	_	_	I-Premise
165	difference	_	_	I-Premise
166	in	_	_	I-Premise
167	the	_	_	I-Premise
168	QOL	_	_	I-Premise
169	scores	_	_	I-Premise
170	between	_	_	I-Premise
171	the	_	_	I-Premise
172	two	_	_	I-Premise
173	arms	_	_	I-Premise
174	at	_	_	I-Premise
175	baseline	_	_	I-Premise
176	and	_	_	I-Premise
177	all	_	_	I-Premise
178	four	_	_	I-Premise
179	cycles	_	_	I-Premise
180	of	_	_	I-Premise
181	treatment	_	_	I-Premise
182	.	_	_	I-Premise

183	Similar	_	_	B-Premise
184	response	_	_	I-Premise
185	rates	_	_	I-Premise
186	were	_	_	I-Premise
187	observed	_	_	I-Premise
188	in	_	_	I-Premise
189	both	_	_	I-Premise
190	arms	_	_	I-Premise
191	(	_	_	I-Premise
192	arm	_	_	I-Premise
193	1	_	_	I-Premise
194	,	_	_	I-Premise
195	30	_	_	I-Premise
196	%	_	_	I-Premise
197	;	_	_	I-Premise
198	arm	_	_	I-Premise
199	2	_	_	I-Premise
200	,	_	_	I-Premise
201	35	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Both	_	_	B-Premise
206	arms	_	_	I-Premise
207	showed	_	_	I-Premise
208	similar	_	_	I-Premise
209	chemotherapy	_	_	I-Premise
210	duration	_	_	I-Premise
211	(	_	_	I-Premise
212	3.8	_	_	I-Premise
213	and	_	_	I-Premise
214	4.1	_	_	I-Premise
215	months	_	_	I-Premise
216	,	_	_	I-Premise
217	respectively	_	_	I-Premise
218	)	_	_	I-Premise
219	,	_	_	I-Premise
220	progression-free	_	_	I-Premise
221	survival	_	_	I-Premise
222	(	_	_	I-Premise
223	4.0	_	_	I-Premise
224	and	_	_	I-Premise
225	4.1	_	_	I-Premise
226	months	_	_	I-Premise
227	)	_	_	I-Premise
228	and	_	_	I-Premise
229	overall	_	_	I-Premise
230	survival	_	_	I-Premise
231	(	_	_	I-Premise
232	9.9	_	_	I-Premise
233	and	_	_	I-Premise
234	9.3	_	_	I-Premise
235	months	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Red	_	_	B-Claim
239	blood	_	_	I-Claim
240	cell	_	_	I-Claim
241	transfusion	_	_	I-Claim
242	achieving	_	_	I-Claim
243	Hb	_	_	I-Claim
244	level	_	_	I-Claim
245	above	_	_	I-Claim
246	10	_	_	I-Claim
247	g/dl	_	_	I-Claim
248	might	_	_	I-Claim
249	contribute	_	_	I-Claim
250	to	_	_	I-Claim
251	the	_	_	I-Claim
252	improvement	_	_	I-Claim
253	of	_	_	I-Claim
254	the	_	_	I-Claim
255	KPS	_	_	I-Claim
256	and	_	_	I-Claim
257	QOL	_	_	I-Claim
258	seen	_	_	I-Claim
259	in	_	_	I-Claim
260	patients	_	_	I-Claim
261	with	_	_	I-Claim
262	AGC	_	_	I-Claim
263	.	_	_	I-Claim

264	The	_	_	B-Claim
265	observation	_	_	I-Claim
266	of	_	_	I-Claim
267	equivalent	_	_	I-Claim
268	outcomes	_	_	I-Claim
269	at	_	_	I-Claim
270	the	_	_	I-Claim
271	two	_	_	I-Claim
272	target	_	_	I-Claim
273	Hb	_	_	I-Claim
274	levels	_	_	I-Claim
275	supports	_	_	I-Claim
276	the	_	_	I-Claim
277	feasibility	_	_	I-Claim
278	of	_	_	I-Claim
279	anemia	_	_	I-Claim
280	correction	_	_	I-Claim
281	to	_	_	I-Claim
282	Hb	_	_	I-Claim
283	10	_	_	I-Claim
284	g/dl	_	_	I-Claim
285	,	_	_	I-Claim
286	which	_	_	I-Claim
287	merits	_	_	I-Claim
288	further	_	_	I-Claim
289	evaluation	_	_	I-Claim
290	.	_	_	O


0	Cancer-related	_	_	B-Claim
1	fatigue	_	_	I-Claim
2	is	_	_	I-Claim
3	the	_	_	I-Claim
4	most	_	_	I-Claim
5	disabling	_	_	I-Claim
6	symptom	_	_	I-Claim
7	experienced	_	_	I-Claim
8	by	_	_	I-Claim
9	breast	_	_	I-Claim
10	cancer	_	_	I-Claim
11	patients	_	_	I-Claim
12	following	_	_	I-Claim
13	the	_	_	I-Claim
14	cancer	_	_	I-Claim
15	treatment	_	_	I-Claim
16	.	_	_	I-Claim

17	The	_	_	B-Premise
18	positive	_	_	I-Premise
19	effects	_	_	I-Premise
20	of	_	_	I-Premise
21	physical	_	_	I-Premise
22	activity	_	_	I-Premise
23	in	_	_	I-Premise
24	the	_	_	I-Premise
25	rehabilitation	_	_	I-Premise
26	of	_	_	I-Premise
27	breast	_	_	I-Premise
28	cancer	_	_	I-Premise
29	patients	_	_	I-Premise
30	are	_	_	I-Premise
31	documented	_	_	I-Premise
32	in	_	_	I-Premise
33	several	_	_	I-Premise
34	studies	_	_	I-Premise
35	.	_	_	I-Premise

36	In	_	_	O
37	a	_	_	O
38	randomized	_	_	O
39	controlled	_	_	O
40	study	_	_	O
41	the	_	_	O
42	effects	_	_	O
43	of	_	_	O
44	a	_	_	O
45	structured	_	_	O
46	physical	_	_	O
47	training	_	_	O
48	program	_	_	O
49	on	_	_	O
50	fatigue	_	_	O
51	and	_	_	O
52	health-related	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	were	_	_	O
57	evaluated	_	_	O
58	.	_	_	O

59	63	_	_	O
60	breast	_	_	O
61	cancer	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	cancer-related	_	_	O
65	chronic	_	_	O
66	fatigue	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	at	_	_	O
70	the	_	_	O
71	beginning	_	_	O
72	of	_	_	O
73	the	_	_	O
74	inpatient	_	_	O
75	rehabilitation	_	_	O
76	.	_	_	O

77	The	_	_	O
78	control	_	_	O
79	group	_	_	O
80	received	_	_	O
81	the	_	_	O
82	standard	_	_	O
83	complex	_	_	O
84	rehabilitation	_	_	O
85	program	_	_	O
86	,	_	_	O
87	the	_	_	O
88	intervention	_	_	O
89	group	_	_	O
90	a	_	_	O
91	structured	_	_	O
92	physical	_	_	O
93	training	_	_	O
94	program	_	_	O
95	and	_	_	O
96	additional	_	_	O
97	muscle	_	_	O
98	strength	_	_	O
99	and	_	_	O
100	aerobic	_	_	O
101	exercises	_	_	O
102	.	_	_	O

103	The	_	_	O
104	effects	_	_	O
105	of	_	_	O
106	the	_	_	O
107	treatment	_	_	O
108	were	_	_	O
109	evaluated	_	_	O
110	by	_	_	O
111	questionnaires	_	_	O
112	at	_	_	O
113	the	_	_	O
114	start	_	_	O
115	of	_	_	O
116	rehabilitation	_	_	O
117	(	_	_	O
118	t1	_	_	O
119	)	_	_	O
120	,	_	_	O
121	end	_	_	O
122	of	_	_	O
123	rehabilitation	_	_	O
124	(	_	_	O
125	t2	_	_	O
126	)	_	_	O
127	,	_	_	O
128	and	_	_	O
129	3	_	_	O
130	months	_	_	O
131	after	_	_	O
132	t2	_	_	O
133	(	_	_	O
134	t3	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Isometric	_	_	O
138	muscle	_	_	O
139	strength	_	_	O
140	and	_	_	O
141	aerobic	_	_	O
142	capacity	_	_	O
143	were	_	_	O
144	evaluated	_	_	O
145	at	_	_	O
146	t1	_	_	O
147	and	_	_	O
148	t2	_	_	O
149	.	_	_	O

150	There	_	_	B-Premise
151	was	_	_	I-Premise
152	an	_	_	I-Premise
153	improvement	_	_	I-Premise
154	of	_	_	I-Premise
155	muscle	_	_	I-Premise
156	strength	_	_	I-Premise
157	at	_	_	I-Premise
158	the	_	_	I-Premise
159	end	_	_	I-Premise
160	of	_	_	I-Premise
161	rehabilitation	_	_	I-Premise
162	for	_	_	I-Premise
163	both	_	_	I-Premise
164	groups	_	_	I-Premise
165	.	_	_	I-Premise

166	The	_	_	B-Premise
167	increase	_	_	I-Premise
168	from	_	_	I-Premise
169	t1	_	_	I-Premise
170	to	_	_	I-Premise
171	t2	_	_	I-Premise
172	was	_	_	I-Premise
173	significantly	_	_	I-Premise
174	higher	_	_	I-Premise
175	for	_	_	I-Premise
176	the	_	_	I-Premise
177	training	_	_	I-Premise
178	group	_	_	I-Premise
179	.	_	_	I-Premise

180	The	_	_	B-Premise
181	scores	_	_	I-Premise
182	for	_	_	I-Premise
183	global	_	_	I-Premise
184	quality	_	_	I-Premise
185	of	_	_	I-Premise
186	life	_	_	I-Premise
187	,	_	_	I-Premise
188	physical	_	_	I-Premise
189	well-being	_	_	I-Premise
190	,	_	_	I-Premise
191	and	_	_	I-Premise
192	functionality	_	_	I-Premise
193	increased	_	_	I-Premise
194	from	_	_	I-Premise
195	t1	_	_	I-Premise
196	to	_	_	I-Premise
197	t2	_	_	I-Premise
198	,	_	_	I-Premise
199	but	_	_	B-Premise
200	further	_	_	I-Premise
201	improvement	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	follow-up	_	_	I-Premise
205	(	_	_	I-Premise
206	t3	_	_	I-Premise
207	)	_	_	I-Premise
208	was	_	_	I-Premise
209	only	_	_	I-Premise
210	observed	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	training	_	_	I-Premise
214	group	_	_	I-Premise
215	.	_	_	I-Premise

216	The	_	_	B-Premise
217	cancer-related	_	_	I-Premise
218	fatigue	_	_	I-Premise
219	was	_	_	I-Premise
220	significantly	_	_	I-Premise
221	reduced	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	training	_	_	I-Premise
225	group	_	_	I-Premise
226	from	_	_	I-Premise
227	t1	_	_	I-Premise
228	to	_	_	I-Premise
229	t3	_	_	I-Premise
230	,	_	_	I-Premise
231	however	_	_	I-Premise
232	,	_	_	I-Premise
233	not	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	control	_	_	I-Premise
237	group	_	_	I-Premise
238	.	_	_	I-Premise

239	Structured	_	_	B-Claim
240	physical	_	_	I-Claim
241	training	_	_	I-Claim
242	programs	_	_	I-Claim
243	initiated	_	_	I-Claim
244	during	_	_	I-Claim
245	inpatient	_	_	I-Claim
246	rehabilitation	_	_	I-Claim
247	and	_	_	I-Claim
248	continuously	_	_	I-Claim
249	practiced	_	_	I-Claim
250	in	_	_	I-Claim
251	the	_	_	I-Claim
252	time	_	_	I-Claim
253	thereafter	_	_	I-Claim
254	can	_	_	I-Claim
255	improve	_	_	I-Claim
256	symptoms	_	_	I-Claim
257	of	_	_	I-Claim
258	chronic	_	_	I-Claim
259	fatigue	_	_	I-Claim
260	and	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	in	_	_	I-Claim
265	breast	_	_	I-Claim
266	cancer	_	_	I-Claim
267	patients	_	_	I-Claim
268	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	sought	_	_	O
3	to	_	_	O
4	continue	_	_	O
5	research	_	_	O
6	on	_	_	O
7	psychosocial	_	_	O
8	interventions	_	_	O
9	for	_	_	O
10	patients	_	_	O
11	being	_	_	O
12	treated	_	_	O
13	with	_	_	O
14	radiation	_	_	O
15	therapy	_	_	O
16	across	_	_	O
17	multiple	_	_	O
18	centers	_	_	O
19	and	_	_	O
20	to	_	_	O
21	replicate	_	_	O
22	positive	_	_	O
23	findings	_	_	O
24	of	_	_	O
25	a	_	_	O
26	single-center	_	_	O
27	study	_	_	O
28	of	_	_	O
29	patients	_	_	O
30	being	_	_	O
31	treated	_	_	O
32	with	_	_	O
33	chemotherapy	_	_	O
34	.	_	_	O

35	The	_	_	O
36	primary	_	_	O
37	objective	_	_	O
38	of	_	_	O
39	this	_	_	O
40	study	_	_	O
41	was	_	_	O
42	to	_	_	O
43	determine	_	_	O
44	if	_	_	O
45	a	_	_	O
46	stress	_	_	O
47	management	_	_	O
48	intervention	_	_	O
49	was	_	_	O
50	effective	_	_	O
51	in	_	_	O
52	improving	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	and	_	_	O
57	decreasing	_	_	O
58	psychological	_	_	O
59	distress	_	_	O
60	in	_	_	O
61	patients	_	_	O
62	undergoing	_	_	O
63	radiotherapy	_	_	O
64	for	_	_	O
65	cancer	_	_	O
66	.	_	_	O

67	A	_	_	O
68	total	_	_	O
69	of	_	_	O
70	310	_	_	O
71	patients	_	_	O
72	about	_	_	O
73	to	_	_	O
74	begin	_	_	O
75	radiotherapy	_	_	O
76	treatment	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	receive	_	_	O
82	usual	_	_	O
83	care	_	_	O
84	only	_	_	O
85	or	_	_	O
86	self-administered	_	_	O
87	stress	_	_	O
88	management	_	_	O
89	training	_	_	O
90	.	_	_	O

91	Quality-of-life	_	_	O
92	assessments	_	_	O
93	occurred	_	_	O
94	at	_	_	O
95	baseline	_	_	O
96	and	_	_	O
97	for	_	_	O
98	3	_	_	O
99	weeks	_	_	O
100	after	_	_	O
101	the	_	_	O
102	beginning	_	_	O
103	of	_	_	O
104	radiotherapy	_	_	O
105	treatment	_	_	O
106	.	_	_	O

107	Overall	_	_	B-Premise
108	,	_	_	I-Premise
109	patients	_	_	I-Premise
110	assigned	_	_	I-Premise
111	to	_	_	I-Premise
112	receive	_	_	I-Premise
113	stress	_	_	I-Premise
114	management	_	_	I-Premise
115	training	_	_	I-Premise
116	did	_	_	I-Premise
117	not	_	_	I-Premise
118	report	_	_	I-Premise
119	significantly	_	_	I-Premise
120	less	_	_	I-Premise
121	psychological	_	_	I-Premise
122	distress	_	_	I-Premise
123	on	_	_	I-Premise
124	the	_	_	I-Premise
125	Medical	_	_	I-Premise
126	Outcomes	_	_	I-Premise
127	Study	_	_	I-Premise
128	36-Item	_	_	I-Premise
129	Short	_	_	I-Premise
130	Form	_	_	I-Premise
131	(	_	_	I-Premise
132	SF-36	_	_	I-Premise
133	)	_	_	I-Premise
134	Mental	_	_	I-Premise
135	Component	_	_	I-Premise
136	Summary	_	_	I-Premise
137	Scale	_	_	I-Premise
138	than	_	_	I-Premise
139	did	_	_	I-Premise
140	those	_	_	I-Premise
141	assigned	_	_	I-Premise
142	to	_	_	I-Premise
143	usual	_	_	I-Premise
144	care	_	_	I-Premise
145	.	_	_	I-Premise

146	When	_	_	O
147	divided	_	_	O
148	into	_	_	O
149	subgroups	_	_	O
150	based	_	_	O
151	on	_	_	O
152	the	_	_	O
153	SF-36	_	_	O
154	Mental	_	_	O
155	Component	_	_	O
156	Summary	_	_	O
157	Scale	_	_	O
158	scores	_	_	O
159	immediately	_	_	O
160	after	_	_	O
161	their	_	_	O
162	first	_	_	O
163	radiotherapy	_	_	O
164	treatment	_	_	O
165	,	_	_	O
166	patients	_	_	B-Premise
167	with	_	_	I-Premise
168	above-average	_	_	I-Premise
169	levels	_	_	I-Premise
170	of	_	_	I-Premise
171	psychological	_	_	I-Premise
172	distress	_	_	I-Premise
173	(	_	_	I-Premise
174	scores	_	_	I-Premise
175	<	_	_	I-Premise
176	or	_	_	I-Premise
177	=	_	_	I-Premise
178	50	_	_	I-Premise
179	)	_	_	I-Premise
180	who	_	_	I-Premise
181	were	_	_	I-Premise
182	randomly	_	_	I-Premise
183	assigned	_	_	I-Premise
184	to	_	_	I-Premise
185	the	_	_	I-Premise
186	intervention	_	_	I-Premise
187	condition	_	_	I-Premise
188	reported	_	_	I-Premise
189	significant	_	_	I-Premise
190	improvement	_	_	I-Premise
191	in	_	_	I-Premise
192	their	_	_	I-Premise
193	distress	_	_	I-Premise
194	compared	_	_	I-Premise
195	with	_	_	I-Premise
196	those	_	_	I-Premise
197	assigned	_	_	I-Premise
198	to	_	_	I-Premise
199	usual	_	_	I-Premise
200	care	_	_	I-Premise
201	only	_	_	I-Premise
202	on	_	_	I-Premise
203	the	_	_	I-Premise
204	SF-36	_	_	I-Premise
205	Mental	_	_	I-Premise
206	Health	_	_	I-Premise
207	Subscale	_	_	I-Premise
208	and	_	_	I-Premise
209	the	_	_	I-Premise
210	Center	_	_	I-Premise
211	for	_	_	I-Premise
212	Epidemiologic	_	_	I-Premise
213	Studies	_	_	I-Premise
214	Depression	_	_	I-Premise
215	Scale	_	_	I-Premise
216	.	_	_	I-Premise

217	This	_	_	B-Claim
218	study	_	_	I-Claim
219	found	_	_	I-Claim
220	that	_	_	I-Claim
221	self-administered	_	_	I-Claim
222	stress	_	_	I-Claim
223	management	_	_	I-Claim
224	training	_	_	I-Claim
225	is	_	_	I-Claim
226	effective	_	_	I-Claim
227	only	_	_	I-Claim
228	in	_	_	I-Claim
229	those	_	_	I-Claim
230	radiotherapy	_	_	I-Claim
231	patients	_	_	I-Claim
232	with	_	_	I-Claim
233	initially	_	_	I-Claim
234	higher	_	_	I-Claim
235	levels	_	_	I-Claim
236	of	_	_	I-Claim
237	psychological	_	_	I-Claim
238	distress	_	_	I-Claim
239	.	_	_	I-Claim

240	Additional	_	_	B-Claim
241	research	_	_	I-Claim
242	should	_	_	I-Claim
243	examine	_	_	I-Claim
244	the	_	_	I-Claim
245	benefits	_	_	I-Claim
246	of	_	_	I-Claim
247	stress	_	_	I-Claim
248	management	_	_	I-Claim
249	training	_	_	I-Claim
250	targeted	_	_	I-Claim
251	specifically	_	_	I-Claim
252	to	_	_	I-Claim
253	patients	_	_	I-Claim
254	experiencing	_	_	I-Claim
255	heightened	_	_	I-Claim
256	distress	_	_	I-Claim
257	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	intraocular	_	_	O
5	pressure	_	_	O
6	(	_	_	O
7	IOP	_	_	O
8	)	_	_	O
9	control	_	_	O
10	of	_	_	O
11	trabeculectomy	_	_	O
12	and	_	_	O
13	triple	_	_	O
14	procedure	_	_	O
15	(	_	_	O
16	cataract	_	_	O
17	extraction	_	_	O
18	by	_	_	O
19	phacoemulsification	_	_	O
20	,	_	_	O
21	intraocular	_	_	O
22	lens	_	_	O
23	implantation	_	_	O
24	and	_	_	O
25	trabeculectomy	_	_	O
26	)	_	_	O
27	,	_	_	O
28	1,542	_	_	O
29	eyes	_	_	O
30	of	_	_	O
31	900	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	primary	_	_	O
35	open	_	_	O
36	angle	_	_	O
37	glaucoma	_	_	O
38	(	_	_	O
39	POAG	_	_	O
40	)	_	_	O
41	or	_	_	O
42	chronic	_	_	O
43	primary	_	_	O
44	angle	_	_	O
45	closure	_	_	O
46	glaucoma	_	_	O
47	(	_	_	O
48	CPACG	_	_	O
49	)	_	_	O
50	were	_	_	O
51	included	_	_	O
52	.	_	_	O

53	When	_	_	O
54	success	_	_	O
55	was	_	_	O
56	defined	_	_	O
57	as	_	_	O
58	an	_	_	O
59	IOP	_	_	O
60	reduction	_	_	O
61	of	_	_	O
62	at	_	_	O
63	least	_	_	O
64	30	_	_	O
65	%	_	_	O
66	from	_	_	O
67	baseline	_	_	O
68	,	_	_	O
69	with	_	_	O
70	or	_	_	O
71	without	_	_	O
72	antiglaucoma	_	_	O
73	medications	_	_	O
74	,	_	_	O
75	the	_	_	B-Premise
76	overall	_	_	I-Premise
77	probability	_	_	I-Premise
78	of	_	_	I-Premise
79	success	_	_	I-Premise
80	of	_	_	I-Premise
81	trabeculectomy	_	_	I-Premise
82	and	_	_	I-Premise
83	triple	_	_	I-Premise
84	procedure	_	_	I-Premise
85	was	_	_	I-Premise
86	0.613	_	_	I-Premise
87	and	_	_	I-Premise
88	0.733	_	_	I-Premise
89	at	_	_	I-Premise
90	15	_	_	I-Premise
91	years	_	_	I-Premise
92	,	_	_	I-Premise
93	respectively	_	_	I-Premise
94	.	_	_	I-Premise

95	The	_	_	B-Premise
96	success	_	_	I-Premise
97	probability	_	_	I-Premise
98	of	_	_	I-Premise
99	trabeculectomy	_	_	I-Premise
100	and	_	_	I-Premise
101	triple	_	_	I-Premise
102	procedure	_	_	I-Premise
103	in	_	_	I-Premise
104	reducing	_	_	I-Premise
105	IOP	_	_	I-Premise
106	below	_	_	I-Premise
107	18	_	_	I-Premise
108	mm	_	_	I-Premise
109	Hg	_	_	I-Premise
110	was	_	_	I-Premise
111	0.748	_	_	I-Premise
112	and	_	_	I-Premise
113	0.825	_	_	I-Premise
114	at	_	_	I-Premise
115	15	_	_	I-Premise
116	years	_	_	I-Premise
117	,	_	_	I-Premise
118	respectively	_	_	I-Premise
119	.	_	_	I-Premise

120	In	_	_	B-Claim
121	POAG	_	_	I-Claim
122	and	_	_	I-Claim
123	CPACG	_	_	I-Claim
124	patients	_	_	I-Claim
125	,	_	_	I-Claim
126	trabeculectomy	_	_	I-Claim
127	and	_	_	I-Claim
128	triple	_	_	I-Claim
129	procedure	_	_	I-Claim
130	were	_	_	I-Claim
131	effective	_	_	I-Claim
132	in	_	_	I-Claim
133	reducing	_	_	I-Claim
134	IOP	_	_	I-Claim
135	for	_	_	I-Claim
136	up	_	_	I-Claim
137	to	_	_	I-Claim
138	15	_	_	I-Claim
139	years	_	_	I-Claim
140	after	_	_	I-Claim
141	surgery	_	_	I-Claim
142	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	immediate	_	_	O
4	and	_	_	O
5	long-term	_	_	O
6	effects	_	_	O
7	of	_	_	O
8	true	_	_	O
9	acupuncture	_	_	O
10	versus	_	_	O
11	sham	_	_	O
12	acupuncture	_	_	O
13	on	_	_	O
14	hot	_	_	O
15	flash	_	_	O
16	frequency	_	_	O
17	in	_	_	O
18	women	_	_	O
19	with	_	_	O
20	breast	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	Seventy-two	_	_	O
24	women	_	_	O
25	with	_	_	O
26	breast	_	_	O
27	cancer	_	_	O
28	experiencing	_	_	O
29	three	_	_	O
30	or	_	_	O
31	more	_	_	O
32	hot	_	_	O
33	flashes	_	_	O
34	per	_	_	O
35	day	_	_	O
36	were	_	_	O
37	randomly	_	_	O
38	assigned	_	_	O
39	to	_	_	O
40	receive	_	_	O
41	either	_	_	O
42	true	_	_	O
43	or	_	_	O
44	sham	_	_	O
45	acupuncture	_	_	O
46	.	_	_	O

47	Interventions	_	_	O
48	were	_	_	O
49	given	_	_	O
50	twice	_	_	O
51	weekly	_	_	O
52	for	_	_	O
53	4	_	_	O
54	consecutive	_	_	O
55	weeks	_	_	O
56	.	_	_	O

57	Hot	_	_	O
58	flash	_	_	O
59	frequency	_	_	O
60	was	_	_	O
61	evaluated	_	_	O
62	at	_	_	O
63	baseline	_	_	O
64	,	_	_	O
65	at	_	_	O
66	6	_	_	O
67	weeks	_	_	O
68	,	_	_	O
69	and	_	_	O
70	at	_	_	O
71	6	_	_	O
72	months	_	_	O
73	after	_	_	O
74	initiation	_	_	O
75	of	_	_	O
76	treatment	_	_	O
77	.	_	_	O

78	Patients	_	_	O
79	initially	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	the	_	_	O
84	sham	_	_	O
85	group	_	_	O
86	were	_	_	O
87	crossed	_	_	O
88	over	_	_	O
89	to	_	_	O
90	true	_	_	O
91	acupuncture	_	_	O
92	starting	_	_	O
93	at	_	_	O
94	week	_	_	O
95	7	_	_	O
96	.	_	_	O

97	The	_	_	O
98	mean	_	_	O
99	number	_	_	O
100	of	_	_	O
101	hot	_	_	O
102	flashes	_	_	O
103	per	_	_	O
104	day	_	_	O
105	was	_	_	O
106	reduced	_	_	O
107	from	_	_	O
108	8.7	_	_	O
109	(	_	_	O
110	standard	_	_	O
111	deviation	_	_	O
112	[	_	_	O
113	SD	_	_	O
114	]	_	_	O
115	,	_	_	O
116	3.9	_	_	O
117	)	_	_	O
118	to	_	_	O
119	6.2	_	_	O
120	(	_	_	O
121	SD	_	_	O
122	,	_	_	O
123	4.2	_	_	O
124	)	_	_	O
125	in	_	_	O
126	the	_	_	O
127	true	_	_	O
128	acupuncture	_	_	O
129	group	_	_	O
130	and	_	_	O
131	from	_	_	O
132	10.0	_	_	O
133	(	_	_	O
134	SD	_	_	O
135	,	_	_	O
136	6.1	_	_	O
137	)	_	_	O
138	to	_	_	O
139	7.6	_	_	O
140	(	_	_	O
141	SD	_	_	O
142	,	_	_	O
143	5.7	_	_	O
144	)	_	_	O
145	in	_	_	O
146	the	_	_	O
147	sham	_	_	O
148	group	_	_	O
149	.	_	_	O

150	True	_	_	B-Premise
151	acupuncture	_	_	I-Premise
152	was	_	_	I-Premise
153	associated	_	_	I-Premise
154	with	_	_	I-Premise
155	0.8	_	_	I-Premise
156	fewer	_	_	I-Premise
157	hot	_	_	I-Premise
158	flashes	_	_	I-Premise
159	per	_	_	I-Premise
160	day	_	_	I-Premise
161	than	_	_	I-Premise
162	sham	_	_	I-Premise
163	at	_	_	I-Premise
164	6	_	_	I-Premise
165	weeks	_	_	I-Premise
166	,	_	_	O
167	but	_	_	B-Premise
168	the	_	_	I-Premise
169	difference	_	_	I-Premise
170	did	_	_	I-Premise
171	not	_	_	I-Premise
172	reach	_	_	I-Premise
173	statistical	_	_	I-Premise
174	significance	_	_	I-Premise
175	(	_	_	I-Premise
176	95	_	_	I-Premise
177	%	_	_	I-Premise
178	CI	_	_	I-Premise
179	,	_	_	I-Premise
180	-0.7	_	_	I-Premise
181	to	_	_	I-Premise
182	2.4	_	_	I-Premise
183	;	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.3	_	_	I-Premise
187	)	_	_	I-Premise
188	.	_	_	I-Premise

189	When	_	_	B-Premise
190	participants	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	sham	_	_	I-Premise
194	acupuncture	_	_	I-Premise
195	group	_	_	I-Premise
196	were	_	_	I-Premise
197	crossed	_	_	I-Premise
198	over	_	_	I-Premise
199	to	_	_	I-Premise
200	true	_	_	I-Premise
201	acupuncture	_	_	I-Premise
202	,	_	_	I-Premise
203	a	_	_	I-Premise
204	further	_	_	I-Premise
205	reduction	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	frequency	_	_	I-Premise
209	of	_	_	I-Premise
210	hot	_	_	I-Premise
211	flashes	_	_	I-Premise
212	was	_	_	I-Premise
213	seen	_	_	I-Premise
214	.	_	_	I-Premise

215	This	_	_	O
216	reduction	_	_	O
217	in	_	_	O
218	hot	_	_	O
219	flash	_	_	O
220	frequency	_	_	O
221	persisted	_	_	O
222	for	_	_	O
223	up	_	_	O
224	to	_	_	O
225	6	_	_	O
226	months	_	_	O
227	after	_	_	O
228	the	_	_	O
229	completion	_	_	O
230	of	_	_	O
231	treatment	_	_	O
232	.	_	_	O

233	Hot	_	_	B-Claim
234	flash	_	_	I-Claim
235	frequency	_	_	I-Claim
236	in	_	_	I-Claim
237	breast	_	_	I-Claim
238	cancer	_	_	I-Claim
239	patients	_	_	I-Claim
240	was	_	_	I-Claim
241	reduced	_	_	I-Claim
242	following	_	_	I-Claim
243	acupuncture	_	_	I-Claim
244	.	_	_	I-Claim

245	However	_	_	O
246	,	_	_	O
247	when	_	_	B-Premise
248	compared	_	_	I-Premise
249	with	_	_	I-Premise
250	sham	_	_	I-Premise
251	acupuncture	_	_	I-Premise
252	,	_	_	I-Premise
253	the	_	_	I-Premise
254	reduction	_	_	I-Premise
255	by	_	_	I-Premise
256	the	_	_	I-Premise
257	acupuncture	_	_	I-Premise
258	regimen	_	_	I-Premise
259	as	_	_	I-Premise
260	provided	_	_	I-Premise
261	in	_	_	I-Premise
262	the	_	_	I-Premise
263	current	_	_	I-Premise
264	study	_	_	I-Premise
265	did	_	_	I-Premise
266	not	_	_	I-Premise
267	reach	_	_	I-Premise
268	statistical	_	_	I-Premise
269	significance	_	_	I-Premise
270	.	_	_	I-Premise

271	We	_	_	B-Claim
272	can	_	_	I-Claim
273	not	_	_	I-Claim
274	exclude	_	_	I-Claim
275	the	_	_	I-Claim
276	possibility	_	_	I-Claim
277	that	_	_	I-Claim
278	a	_	_	I-Claim
279	longer	_	_	I-Claim
280	and	_	_	I-Claim
281	more	_	_	I-Claim
282	intense	_	_	I-Claim
283	acupuncture	_	_	I-Claim
284	intervention	_	_	I-Claim
285	could	_	_	I-Claim
286	produce	_	_	I-Claim
287	a	_	_	I-Claim
288	larger	_	_	I-Claim
289	reduction	_	_	I-Claim
290	of	_	_	I-Claim
291	these	_	_	I-Claim
292	symptoms	_	_	I-Claim
293	.	_	_	I-Claim


0	To	_	_	O
1	prospectively	_	_	O
2	evaluate	_	_	O
3	health-related	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	HRQOL	_	_	O
9	)	_	_	O
10	outcomes	_	_	O
11	for	_	_	O
12	uterine	_	_	O
13	artery	_	_	O
14	embolization	_	_	O
15	(	_	_	O
16	UAE	_	_	O
17	)	_	_	O
18	and	_	_	O
19	hysterectomy	_	_	O
20	up	_	_	O
21	to	_	_	O
22	24	_	_	O
23	months	_	_	O
24	after	_	_	O
25	the	_	_	O
26	intervention	_	_	O
27	in	_	_	O
28	terms	_	_	O
29	of	_	_	O
30	mental	_	_	O
31	and	_	_	O
32	physical	_	_	O
33	health	_	_	O
34	,	_	_	O
35	urinary	_	_	O
36	and	_	_	O
37	defecatory	_	_	O
38	function	_	_	O
39	,	_	_	O
40	and	_	_	O
41	overall	_	_	O
42	patient	_	_	O
43	satisfaction	_	_	O
44	.	_	_	O

45	Ethics	_	_	O
46	committee	_	_	O
47	approval	_	_	O
48	and	_	_	O
49	informed	_	_	O
50	consent	_	_	O
51	were	_	_	O
52	obtained	_	_	O
53	for	_	_	O
54	the	_	_	O
55	Embolisation	_	_	O
56	versus	_	_	O
57	Hysterectomy	_	_	O
58	Trial	_	_	O
59	.	_	_	O

60	Women	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	177	_	_	O
65	)	_	_	O
66	with	_	_	O
67	uterine	_	_	O
68	fibroids	_	_	O
69	and	_	_	O
70	heavy	_	_	O
71	menstrual	_	_	O
72	bleeding	_	_	O
73	who	_	_	O
74	were	_	_	O
75	scheduled	_	_	O
76	to	_	_	O
77	undergo	_	_	O
78	hysterectomy	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	undergo	_	_	O
84	UAE	_	_	O
85	(	_	_	O
86	n	_	_	O
87	=	_	_	O
88	88	_	_	O
89	)	_	_	O
90	or	_	_	O
91	hysterectomy	_	_	O
92	(	_	_	O
93	n	_	_	O
94	=	_	_	O
95	89	_	_	O
96	)	_	_	O
97	.	_	_	O

98	HRQOL	_	_	O
99	was	_	_	O
100	measured	_	_	O
101	six	_	_	O
102	times	_	_	O
103	during	_	_	O
104	a	_	_	O
105	24-month	_	_	O
106	follow-up	_	_	O
107	period	_	_	O
108	with	_	_	O
109	the	_	_	O
110	following	_	_	O
111	validated	_	_	O
112	questionnaires	_	_	O
113	:	_	_	O
114	Medical	_	_	O
115	Outcome	_	_	O
116	Study	_	_	O
117	Short	_	_	O
118	Form	_	_	O
119	36	_	_	O
120	(	_	_	O
121	SF-36	_	_	O
122	)	_	_	O
123	mental	_	_	O
124	component	_	_	O
125	summary	_	_	O
126	(	_	_	O
127	MCS	_	_	O
128	)	_	_	O
129	and	_	_	O
130	physical	_	_	O
131	component	_	_	O
132	summary	_	_	O
133	(	_	_	O
134	PCS	_	_	O
135	)	_	_	O
136	,	_	_	O
137	Health	_	_	O
138	Utilities	_	_	O
139	Index	_	_	O
140	Mark	_	_	O
141	3	_	_	O
142	,	_	_	O
143	EuroQol	_	_	O
144	5D	_	_	O
145	,	_	_	O
146	urogenital	_	_	O
147	distress	_	_	O
148	inventory	_	_	O
149	(	_	_	O
150	UDI	_	_	O
151	)	_	_	O
152	,	_	_	O
153	incontinence	_	_	O
154	impact	_	_	O
155	questionnaire	_	_	O
156	,	_	_	O
157	and	_	_	O
158	defecation	_	_	O
159	distress	_	_	O
160	inventory	_	_	O
161	(	_	_	O
162	DDI	_	_	O
163	)	_	_	O
164	.	_	_	O

165	Satisfaction	_	_	O
166	was	_	_	O
167	assessed	_	_	O
168	with	_	_	O
169	a	_	_	O
170	seven-point	_	_	O
171	Likert	_	_	O
172	scale	_	_	O
173	.	_	_	O

174	Repeated	_	_	O
175	measurement	_	_	O
176	analysis	_	_	O
177	was	_	_	O
178	performed	_	_	O
179	for	_	_	O
180	between-group	_	_	O
181	analysis	_	_	O
182	.	_	_	O

183	Paired	_	_	O
184	t	_	_	O
185	tests	_	_	O
186	were	_	_	O
187	performed	_	_	O
188	for	_	_	O
189	within-group	_	_	O
190	analysis	_	_	O
191	.	_	_	O

192	Satisfaction	_	_	O
193	was	_	_	O
194	analyzed	_	_	O
195	with	_	_	O
196	the	_	_	O
197	Fisher	_	_	O
198	exact	_	_	O
199	test	_	_	O
200	.	_	_	O

201	The	_	_	B-Premise
202	SF-36	_	_	I-Premise
203	MCS	_	_	I-Premise
204	and	_	_	I-Premise
205	PCS	_	_	I-Premise
206	,	_	_	I-Premise
207	Health	_	_	I-Premise
208	Utilities	_	_	I-Premise
209	Index	_	_	I-Premise
210	Mark	_	_	I-Premise
211	3	_	_	I-Premise
212	,	_	_	I-Premise
213	EuroQol	_	_	I-Premise
214	5D	_	_	I-Premise
215	,	_	_	I-Premise
216	and	_	_	I-Premise
217	UDI	_	_	I-Premise
218	scores	_	_	I-Premise
219	were	_	_	I-Premise
220	improved	_	_	I-Premise
221	significantly	_	_	I-Premise
222	in	_	_	I-Premise
223	both	_	_	I-Premise
224	groups	_	_	I-Premise
225	at	_	_	I-Premise
226	6	_	_	I-Premise
227	months	_	_	I-Premise
228	and	_	_	I-Premise
229	afterward	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	.05	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	O
237	DDI	_	_	O
238	score	_	_	O
239	was	_	_	O
240	improved	_	_	O
241	significantly	_	_	O
242	in	_	_	O
243	only	_	_	O
244	the	_	_	O
245	UAE	_	_	O
246	group	_	_	O
247	at	_	_	O
248	6	_	_	O
249	months	_	_	O
250	and	_	_	O
251	afterward	_	_	O
252	(	_	_	O
253	P	_	_	O
254	<	_	_	O
255	.05	_	_	O
256	)	_	_	O
257	.	_	_	O

258	No	_	_	O
259	differences	_	_	O
260	between	_	_	O
261	groups	_	_	O
262	were	_	_	O
263	observed	_	_	O
264	,	_	_	O
265	with	_	_	O
266	the	_	_	O
267	exception	_	_	O
268	of	_	_	O
269	PCS	_	_	O
270	scores	_	_	O
271	at	_	_	O
272	6-week	_	_	O
273	follow-up	_	_	O
274	:	_	_	O
275	Patients	_	_	O
276	in	_	_	O
277	the	_	_	O
278	UAE	_	_	O
279	group	_	_	O
280	had	_	_	O
281	significantly	_	_	O
282	better	_	_	O
283	scores	_	_	O
284	than	_	_	O
285	did	_	_	O
286	patients	_	_	O
287	in	_	_	O
288	the	_	_	O
289	hysterectomy	_	_	O
290	group	_	_	O
291	(	_	_	O
292	P	_	_	O
293	<	_	_	O
294	.001	_	_	O
295	)	_	_	O
296	.	_	_	O

297	Improvement	_	_	O
298	in	_	_	O
299	PCS	_	_	O
300	score	_	_	O
301	at	_	_	O
302	24-month	_	_	O
303	follow-up	_	_	O
304	was	_	_	O
305	significantly	_	_	O
306	higher	_	_	O
307	for	_	_	O
308	patients	_	_	O
309	who	_	_	O
310	were	_	_	O
311	employed	_	_	O
312	at	_	_	O
313	baseline	_	_	O
314	(	_	_	O
315	P	_	_	O
316	=	_	_	O
317	.035	_	_	O
318	)	_	_	O
319	.	_	_	O

320	At	_	_	B-Premise
321	24-month	_	_	I-Premise
322	follow-up	_	_	I-Premise
323	,	_	_	I-Premise
324	patients	_	_	I-Premise
325	in	_	_	I-Premise
326	the	_	_	I-Premise
327	hysterectomy	_	_	I-Premise
328	group	_	_	I-Premise
329	were	_	_	I-Premise
330	significantly	_	_	I-Premise
331	more	_	_	I-Premise
332	satisfied	_	_	I-Premise
333	than	_	_	I-Premise
334	those	_	_	I-Premise
335	in	_	_	I-Premise
336	the	_	_	I-Premise
337	UAE	_	_	I-Premise
338	group	_	_	I-Premise
339	(	_	_	I-Premise
340	P	_	_	I-Premise
341	=	_	_	I-Premise
342	.02	_	_	I-Premise
343	)	_	_	I-Premise
344	.	_	_	I-Premise

345	Both	_	_	B-Claim
346	UAE	_	_	I-Claim
347	and	_	_	I-Claim
348	hysterectomy	_	_	I-Claim
349	improved	_	_	I-Claim
350	HRQOL	_	_	I-Claim
351	.	_	_	I-Claim

352	No	_	_	B-Claim
353	differences	_	_	I-Claim
354	were	_	_	I-Claim
355	observed	_	_	I-Claim
356	between	_	_	I-Claim
357	groups	_	_	I-Claim
358	regarding	_	_	I-Claim
359	HRQOL	_	_	I-Claim
360	at	_	_	I-Claim
361	24-month	_	_	I-Claim
362	follow-up	_	_	I-Claim
363	.	_	_	I-Claim

364	On	_	_	B-Claim
365	the	_	_	I-Claim
366	basis	_	_	I-Claim
367	of	_	_	I-Claim
368	HRQOL	_	_	I-Claim
369	results	_	_	I-Claim
370	,	_	_	I-Claim
371	the	_	_	I-Claim
372	authors	_	_	I-Claim
373	determined	_	_	I-Claim
374	that	_	_	I-Claim
375	UAE	_	_	I-Claim
376	is	_	_	I-Claim
377	a	_	_	I-Claim
378	good	_	_	I-Claim
379	alternative	_	_	I-Claim
380	to	_	_	I-Claim
381	hysterectomy	_	_	I-Claim
382	.	_	_	I-Claim


0	Debilitating	_	_	B-Claim
1	hot	_	_	I-Claim
2	flushes	_	_	I-Claim
3	and	_	_	I-Claim
4	sleep	_	_	I-Claim
5	dysfunction	_	_	I-Claim
6	often	_	_	I-Claim
7	affect	_	_	I-Claim
8	survivors	_	_	I-Claim
9	of	_	_	I-Claim
10	breast	_	_	I-Claim
11	cancer	_	_	I-Claim
12	,	_	_	I-Claim
13	most	_	_	I-Claim
14	notably	_	_	I-Claim
15	in	_	_	I-Claim
16	those	_	_	I-Claim
17	taking	_	_	I-Claim
18	anti-oestrogen	_	_	I-Claim
19	medications	_	_	I-Claim
20	.	_	_	I-Claim

21	Conventional	_	_	B-Claim
22	treatments	_	_	I-Claim
23	have	_	_	I-Claim
24	been	_	_	I-Claim
25	only	_	_	I-Claim
26	partially	_	_	I-Claim
27	effective	_	_	I-Claim
28	in	_	_	I-Claim
29	diminishing	_	_	I-Claim
30	these	_	_	I-Claim
31	issues	_	_	I-Claim
32	,	_	_	I-Claim
33	and	_	_	I-Claim
34	some	_	_	I-Claim
35	have	_	_	I-Claim
36	serious	_	_	I-Claim
37	risks	_	_	I-Claim
38	.	_	_	I-Claim

39	We	_	_	O
40	did	_	_	O
41	a	_	_	O
42	pilot	_	_	O
43	study	_	_	O
44	to	_	_	O
45	investigate	_	_	O
46	our	_	_	O
47	hypothesis	_	_	O
48	that	_	_	O
49	stellate-ganglion	_	_	O
50	block	_	_	O
51	can	_	_	O
52	be	_	_	O
53	a	_	_	O
54	safe	_	_	O
55	and	_	_	O
56	effective	_	_	O
57	treatment	_	_	O
58	for	_	_	O
59	hot	_	_	O
60	flushes	_	_	O
61	and	_	_	O
62	sleep	_	_	O
63	dysfunction	_	_	O
64	in	_	_	O
65	this	_	_	O
66	patient	_	_	O
67	population	_	_	O
68	.	_	_	O

69	13	_	_	O
70	survivors	_	_	O
71	of	_	_	O
72	breast	_	_	O
73	cancer	_	_	O
74	(	_	_	O
75	in	_	_	O
76	remission	_	_	O
77	)	_	_	O
78	with	_	_	O
79	severe	_	_	O
80	hot	_	_	O
81	flushes	_	_	O
82	and	_	_	O
83	night	_	_	O
84	awakenings	_	_	O
85	were	_	_	O
86	treated	_	_	O
87	with	_	_	O
88	stellate-ganglion	_	_	O
89	block	_	_	O
90	at	_	_	O
91	the	_	_	O
92	anterolateral	_	_	O
93	aspect	_	_	O
94	of	_	_	O
95	the	_	_	O
96	C6	_	_	O
97	vertebra	_	_	O
98	on	_	_	O
99	the	_	_	O
100	right	_	_	O
101	side	_	_	O
102	under	_	_	O
103	fluoroscopy	_	_	O
104	.	_	_	O

105	Patients	_	_	O
106	recorded	_	_	O
107	hot	_	_	O
108	flushes	_	_	O
109	in	_	_	O
110	a	_	_	O
111	daily	_	_	O
112	diary	_	_	O
113	by	_	_	O
114	use	_	_	O
115	of	_	_	O
116	the	_	_	O
117	Hot-Flash	_	_	O
118	Score	_	_	O
119	,	_	_	O
120	devised	_	_	O
121	by	_	_	O
122	Sloan	_	_	O
123	and	_	_	O
124	colleagues	_	_	O
125	,	_	_	O
126	and	_	_	O
127	night	_	_	O
128	awakenings	_	_	O
129	by	_	_	O
130	use	_	_	O
131	of	_	_	O
132	the	_	_	O
133	Pittsburgh	_	_	O
134	Sleep	_	_	O
135	Quality	_	_	O
136	Index	_	_	O
137	.	_	_	O

138	Both	_	_	O
139	instruments	_	_	O
140	were	_	_	O
141	used	_	_	O
142	1	_	_	O
143	week	_	_	O
144	before	_	_	O
145	the	_	_	O
146	procedure	_	_	O
147	[	_	_	O
148	A40	_	_	O
149	]	_	_	O
150	and	_	_	O
151	then	_	_	O
152	weekly	_	_	O
153	after	_	_	O
154	the	_	_	O
155	procedure	_	_	O
156	for	_	_	O
157	12	_	_	O
158	weeks	_	_	O
159	.	_	_	O

160	We	_	_	O
161	used	_	_	O
162	the	_	_	O
163	generalised-estimating-equations	_	_	O
164	method	_	_	O
165	to	_	_	O
166	analyse	_	_	O
167	the	_	_	O
168	longitudinal	_	_	O
169	measurements	_	_	O
170	of	_	_	O
171	the	_	_	O
172	number	_	_	O
173	of	_	_	O
174	hot	_	_	O
175	flushes	_	_	O
176	and	_	_	O
177	night	_	_	O
178	awakenings	_	_	O
179	over	_	_	O
180	time	_	_	O
181	.	_	_	O

182	This	_	_	O
183	method	_	_	O
184	is	_	_	O
185	a	_	_	O
186	popular	_	_	O
187	approach	_	_	O
188	to	_	_	O
189	analysing	_	_	O
190	datasets	_	_	O
191	that	_	_	O
192	have	_	_	O
193	repeated	_	_	O
194	measures	_	_	O
195	from	_	_	O
196	the	_	_	O
197	same	_	_	O
198	person	_	_	O
199	,	_	_	O
200	and	_	_	O
201	is	_	_	O
202	robust	_	_	O
203	because	_	_	O
204	it	_	_	O
205	does	_	_	O
206	not	_	_	O
207	need	_	_	O
208	the	_	_	O
209	complete	_	_	O
210	distribution	_	_	O
211	of	_	_	O
212	the	_	_	O
213	outcomes	_	_	O
214	to	_	_	O
215	be	_	_	O
216	specified	_	_	O
217	.	_	_	O

218	This	_	_	O
219	trial	_	_	O
220	is	_	_	O
221	registered	_	_	O
222	on	_	_	O
223	the	_	_	O
224	International	_	_	O
225	Standard	_	_	O
226	Randomised	_	_	O
227	Controlled	_	_	O
228	Trial	_	_	O
229	Number	_	_	O
230	register	_	_	O
231	(	_	_	O
232	ISRCTN14318565	_	_	O
233	)	_	_	O
234	.	_	_	O

235	There	_	_	O
236	were	_	_	O
237	no	_	_	O
238	adverse	_	_	O
239	events	_	_	O
240	resulting	_	_	O
241	from	_	_	O
242	the	_	_	O
243	stellate-ganglion	_	_	O
244	block	_	_	O
245	,	_	_	O
246	although	_	_	O
247	patients	_	_	O
248	had	_	_	O
249	temporary	_	_	O
250	Horner	_	_	O
251	's	_	_	O
252	syndrome	_	_	O
253	indicating	_	_	O
254	the	_	_	O
255	effectiveness	_	_	O
256	of	_	_	O
257	the	_	_	O
258	block	_	_	O
259	.	_	_	O

260	Five	_	_	O
261	patients	_	_	O
262	had	_	_	O
263	only	_	_	O
264	one	_	_	O
265	stellate-ganglion	_	_	O
266	block	_	_	O
267	and	_	_	O
268	eight	_	_	O
269	had	_	_	O
270	two	_	_	O
271	stellate-ganglion	_	_	O
272	blocks	_	_	O
273	.	_	_	O

274	The	_	_	B-Premise
275	total	_	_	I-Premise
276	number	_	_	I-Premise
277	of	_	_	I-Premise
278	hot	_	_	I-Premise
279	flushes	_	_	I-Premise
280	decreased	_	_	I-Premise
281	from	_	_	I-Premise
282	a	_	_	I-Premise
283	mean	_	_	I-Premise
284	of	_	_	I-Premise
285	79.4	_	_	I-Premise
286	(	_	_	I-Premise
287	SD	_	_	I-Premise
288	37.4	_	_	I-Premise
289	)	_	_	I-Premise
290	per	_	_	I-Premise
291	week	_	_	I-Premise
292	before	_	_	I-Premise
293	the	_	_	I-Premise
294	procedure	_	_	I-Premise
295	to	_	_	I-Premise
296	a	_	_	I-Premise
297	mean	_	_	I-Premise
298	of	_	_	I-Premise
299	49.9	_	_	I-Premise
300	(	_	_	I-Premise
301	SD	_	_	I-Premise
302	39.9	_	_	I-Premise
303	)	_	_	I-Premise
304	per	_	_	I-Premise
305	week	_	_	I-Premise
306	during	_	_	I-Premise
307	the	_	_	I-Premise
308	first	_	_	I-Premise
309	2	_	_	I-Premise
310	weeks	_	_	I-Premise
311	after	_	_	I-Premise
312	the	_	_	I-Premise
313	procedure	_	_	I-Premise
314	(	_	_	I-Premise
315	p=0.0002	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	The	_	_	B-Premise
319	total	_	_	I-Premise
320	number	_	_	I-Premise
321	of	_	_	I-Premise
322	hot	_	_	I-Premise
323	flushes	_	_	I-Premise
324	continued	_	_	I-Premise
325	to	_	_	I-Premise
326	decrease	_	_	I-Premise
327	over	_	_	I-Premise
328	the	_	_	I-Premise
329	remaining	_	_	I-Premise
330	follow-up	_	_	I-Premise
331	period	_	_	I-Premise
332	(	_	_	I-Premise
333	weeks	_	_	I-Premise
334	3-12	_	_	I-Premise
335	)	_	_	I-Premise
336	,	_	_	I-Premise
337	and	_	_	I-Premise
338	stabilised	_	_	I-Premise
339	at	_	_	I-Premise
340	a	_	_	I-Premise
341	mean	_	_	I-Premise
342	of	_	_	I-Premise
343	8.1	_	_	I-Premise
344	(	_	_	I-Premise
345	SD	_	_	I-Premise
346	5.6	_	_	I-Premise
347	)	_	_	I-Premise
348	per	_	_	I-Premise
349	week	_	_	I-Premise
350	(	_	_	I-Premise
351	p	_	_	I-Premise
352	<	_	_	I-Premise
353	0.0001	_	_	I-Premise
354	)	_	_	I-Premise
355	.	_	_	I-Premise

356	The	_	_	B-Premise
357	number	_	_	I-Premise
358	of	_	_	I-Premise
359	very	_	_	I-Premise
360	severe	_	_	I-Premise
361	hot	_	_	I-Premise
362	flushes	_	_	I-Premise
363	was	_	_	I-Premise
364	decreased	_	_	I-Premise
365	to	_	_	I-Premise
366	near	_	_	I-Premise
367	zero	_	_	I-Premise
368	by	_	_	I-Premise
369	the	_	_	I-Premise
370	end	_	_	I-Premise
371	of	_	_	I-Premise
372	the	_	_	I-Premise
373	follow-up	_	_	I-Premise
374	period	_	_	I-Premise
375	(	_	_	I-Premise
376	week	_	_	I-Premise
377	12	_	_	I-Premise
378	;	_	_	I-Premise
379	p	_	_	I-Premise
380	<	_	_	I-Premise
381	0.0001	_	_	I-Premise
382	)	_	_	I-Premise
383	.	_	_	I-Premise

384	Night	_	_	B-Premise
385	awakenings	_	_	I-Premise
386	decreased	_	_	I-Premise
387	from	_	_	I-Premise
388	a	_	_	I-Premise
389	mean	_	_	I-Premise
390	of	_	_	I-Premise
391	19.5	_	_	I-Premise
392	(	_	_	I-Premise
393	SD	_	_	I-Premise
394	14.8	_	_	I-Premise
395	)	_	_	I-Premise
396	per	_	_	I-Premise
397	week	_	_	I-Premise
398	before	_	_	I-Premise
399	the	_	_	I-Premise
400	procedure	_	_	I-Premise
401	to	_	_	I-Premise
402	a	_	_	I-Premise
403	mean	_	_	I-Premise
404	of	_	_	I-Premise
405	7.3	_	_	I-Premise
406	(	_	_	I-Premise
407	SD	_	_	I-Premise
408	7.1	_	_	I-Premise
409	)	_	_	I-Premise
410	per	_	_	I-Premise
411	week	_	_	I-Premise
412	during	_	_	I-Premise
413	the	_	_	I-Premise
414	first	_	_	I-Premise
415	2	_	_	I-Premise
416	weeks	_	_	I-Premise
417	after	_	_	I-Premise
418	the	_	_	I-Premise
419	procedure	_	_	I-Premise
420	(	_	_	I-Premise
421	p	_	_	I-Premise
422	<	_	_	I-Premise
423	0.0001	_	_	I-Premise
424	)	_	_	I-Premise
425	.	_	_	I-Premise

426	The	_	_	B-Premise
427	total	_	_	I-Premise
428	number	_	_	I-Premise
429	of	_	_	I-Premise
430	night	_	_	I-Premise
431	awakenings	_	_	I-Premise
432	continued	_	_	I-Premise
433	to	_	_	I-Premise
434	decrease	_	_	I-Premise
435	over	_	_	I-Premise
436	the	_	_	I-Premise
437	remaining	_	_	I-Premise
438	follow-up	_	_	I-Premise
439	period	_	_	I-Premise
440	(	_	_	I-Premise
441	weeks	_	_	I-Premise
442	3-12	_	_	I-Premise
443	)	_	_	I-Premise
444	and	_	_	I-Premise
445	stabilised	_	_	I-Premise
446	at	_	_	I-Premise
447	a	_	_	I-Premise
448	mean	_	_	I-Premise
449	of	_	_	I-Premise
450	1.4	_	_	I-Premise
451	(	_	_	I-Premise
452	SD	_	_	I-Premise
453	1.2	_	_	I-Premise
454	)	_	_	I-Premise
455	per	_	_	I-Premise
456	week	_	_	I-Premise
457	(	_	_	I-Premise
458	p	_	_	I-Premise
459	<	_	_	I-Premise
460	0.0001	_	_	I-Premise
461	)	_	_	I-Premise
462	.	_	_	I-Premise

463	The	_	_	B-Claim
464	findings	_	_	I-Claim
465	of	_	_	I-Claim
466	this	_	_	I-Claim
467	study	_	_	I-Claim
468	suggest	_	_	I-Claim
469	that	_	_	I-Claim
470	stellate-ganglion	_	_	I-Claim
471	block	_	_	I-Claim
472	can	_	_	I-Claim
473	provide	_	_	I-Claim
474	survivors	_	_	I-Claim
475	of	_	_	I-Claim
476	breast	_	_	I-Claim
477	cancer	_	_	I-Claim
478	with	_	_	I-Claim
479	relief	_	_	I-Claim
480	from	_	_	I-Claim
481	hot	_	_	I-Claim
482	flushes	_	_	I-Claim
483	and	_	_	I-Claim
484	sleep	_	_	I-Claim
485	dysfunction	_	_	I-Claim
486	with	_	_	I-Claim
487	few	_	_	I-Claim
488	or	_	_	I-Claim
489	no	_	_	I-Claim
490	side-effects	_	_	I-Claim
491	.	_	_	I-Claim

492	Long-term	_	_	B-Claim
493	relief	_	_	I-Claim
494	of	_	_	I-Claim
495	symptoms	_	_	I-Claim
496	has	_	_	I-Claim
497	the	_	_	I-Claim
498	potential	_	_	I-Claim
499	to	_	_	I-Claim
500	improve	_	_	I-Claim
501	overall	_	_	I-Claim
502	quality	_	_	I-Claim
503	of	_	_	I-Claim
504	life	_	_	I-Claim
505	and	_	_	I-Claim
506	increase	_	_	I-Claim
507	compliance	_	_	I-Claim
508	with	_	_	I-Claim
509	anti-oestrogen	_	_	I-Claim
510	medications	_	_	I-Claim
511	for	_	_	I-Claim
512	breast	_	_	I-Claim
513	cancer	_	_	I-Claim
514	.	_	_	I-Claim


0	Performance	_	_	O
1	status	_	_	O
2	(	_	_	O
3	PS	_	_	O
4	)	_	_	O
5	2	_	_	O
6	patients	_	_	O
7	with	_	_	O
8	non-small	_	_	O
9	cell	_	_	O
10	lung	_	_	O
11	cancer	_	_	O
12	(	_	_	O
13	NSCLC	_	_	O
14	)	_	_	O
15	experience	_	_	O
16	more	_	_	O
17	toxicity	_	_	O
18	,	_	_	O
19	lower	_	_	O
20	response	_	_	O
21	rates	_	_	O
22	,	_	_	O
23	and	_	_	O
24	shorter	_	_	O
25	survival	_	_	O
26	times	_	_	O
27	than	_	_	O
28	healthier	_	_	O
29	patients	_	_	O
30	treated	_	_	O
31	with	_	_	O
32	standard	_	_	O
33	chemotherapy	_	_	O
34	.	_	_	O

35	Paclitaxel	_	_	O
36	poliglumex	_	_	O
37	(	_	_	O
38	PPX	_	_	O
39	)	_	_	O
40	,	_	_	O
41	a	_	_	O
42	macromolecule	_	_	O
43	drug	_	_	O
44	conjugate	_	_	O
45	of	_	_	O
46	paclitaxel	_	_	O
47	and	_	_	O
48	polyglutamic	_	_	O
49	acid	_	_	O
50	,	_	_	O
51	reduces	_	_	O
52	systemic	_	_	O
53	exposure	_	_	O
54	to	_	_	O
55	peak	_	_	O
56	concentrations	_	_	O
57	of	_	_	O
58	free	_	_	O
59	paclitaxel	_	_	O
60	and	_	_	O
61	may	_	_	O
62	lead	_	_	O
63	to	_	_	O
64	increased	_	_	O
65	concentrations	_	_	O
66	in	_	_	O
67	tumors	_	_	O
68	due	_	_	O
69	to	_	_	O
70	enhanced	_	_	O
71	vascular	_	_	O
72	permeability	_	_	O
73	.	_	_	O

74	Chemotherapy-naive	_	_	O
75	PS	_	_	O
76	2	_	_	O
77	patients	_	_	O
78	with	_	_	O
79	advanced	_	_	O
80	NSCLC	_	_	O
81	were	_	_	O
82	randomized	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	carboplatin	_	_	O
86	(	_	_	O
87	area	_	_	O
88	under	_	_	O
89	the	_	_	O
90	curve	_	_	O
91	=	_	_	O
92	6	_	_	O
93	)	_	_	O
94	and	_	_	O
95	either	_	_	O
96	PPX	_	_	O
97	(	_	_	O
98	210	_	_	O
99	mg/m/10	_	_	O
100	min	_	_	O
101	without	_	_	O
102	routine	_	_	O
103	steroid	_	_	O
104	premedication	_	_	O
105	)	_	_	O
106	or	_	_	O
107	paclitaxel	_	_	O
108	(	_	_	O
109	225	_	_	O
110	mg/m/3	_	_	O
111	h	_	_	O
112	with	_	_	O
113	standard	_	_	O
114	premedication	_	_	O
115	)	_	_	O
116	every	_	_	O
117	3	_	_	O
118	weeks	_	_	O
119	.	_	_	O

120	The	_	_	O
121	primary	_	_	O
122	end	_	_	O
123	point	_	_	O
124	was	_	_	O
125	overall	_	_	O
126	survival	_	_	O
127	.	_	_	O

128	A	_	_	O
129	total	_	_	O
130	of	_	_	O
131	400	_	_	O
132	patients	_	_	O
133	were	_	_	O
134	enrolled	_	_	O
135	.	_	_	O

136	Alopecia	_	_	B-Premise
137	,	_	_	I-Premise
138	arthralgias/myalgias	_	_	I-Premise
139	,	_	_	I-Premise
140	and	_	_	I-Premise
141	cardiac	_	_	I-Premise
142	events	_	_	I-Premise
143	were	_	_	I-Premise
144	significantly	_	_	I-Premise
145	less	_	_	I-Premise
146	frequent	_	_	I-Premise
147	with	_	_	I-Premise
148	PPX/carboplatin	_	_	I-Premise
149	,	_	_	I-Premise
150	whereas	_	_	I-Premise
151	grade	_	_	I-Premise
152	>	_	_	I-Premise
153	or	_	_	I-Premise
154	=3	_	_	I-Premise
155	neutropenia	_	_	I-Premise
156	and	_	_	I-Premise
157	grade	_	_	I-Premise
158	3	_	_	I-Premise
159	neuropathy	_	_	I-Premise
160	showed	_	_	I-Premise
161	a	_	_	I-Premise
162	trend	_	_	I-Premise
163	of	_	_	I-Premise
164	worsening	_	_	I-Premise
165	.	_	_	I-Premise

166	There	_	_	B-Premise
167	was	_	_	I-Premise
168	no	_	_	I-Premise
169	significant	_	_	I-Premise
170	difference	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	incidence	_	_	I-Premise
174	of	_	_	I-Premise
175	hypersensitivity	_	_	I-Premise
176	reactions	_	_	I-Premise
177	despite	_	_	I-Premise
178	the	_	_	I-Premise
179	absence	_	_	I-Premise
180	of	_	_	I-Premise
181	routine	_	_	I-Premise
182	premedication	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	PPX	_	_	I-Premise
186	arm	_	_	I-Premise
187	.	_	_	I-Premise

188	Overall	_	_	B-Premise
189	survival	_	_	I-Premise
190	was	_	_	I-Premise
191	similar	_	_	I-Premise
192	between	_	_	I-Premise
193	treatment	_	_	I-Premise
194	arms	_	_	I-Premise
195	(	_	_	I-Premise
196	hazard	_	_	I-Premise
197	ratio	_	_	I-Premise
198	,	_	_	I-Premise
199	0.97	_	_	I-Premise
200	;	_	_	I-Premise
201	log	_	_	I-Premise
202	rank	_	_	I-Premise
203	p	_	_	I-Premise
204	=	_	_	I-Premise
205	0.769	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Median	_	_	B-Premise
209	and	_	_	I-Premise
210	1-year	_	_	I-Premise
211	survival	_	_	I-Premise
212	rates	_	_	I-Premise
213	were	_	_	I-Premise
214	7.9	_	_	I-Premise
215	months	_	_	I-Premise
216	and	_	_	I-Premise
217	31	_	_	I-Premise
218	%	_	_	I-Premise
219	,	_	_	I-Premise
220	for	_	_	I-Premise
221	PPX	_	_	I-Premise
222	versus	_	_	I-Premise
223	8	_	_	I-Premise
224	months	_	_	I-Premise
225	and	_	_	I-Premise
226	31	_	_	I-Premise
227	%	_	_	I-Premise
228	for	_	_	I-Premise
229	paclitaxel	_	_	I-Premise
230	.	_	_	I-Premise

231	Disease	_	_	O
232	control	_	_	O
233	rates	_	_	O
234	were	_	_	O
235	64	_	_	O
236	%	_	_	O
237	and	_	_	O
238	69	_	_	O
239	%	_	_	O
240	for	_	_	O
241	PPX	_	_	O
242	and	_	_	O
243	paclitaxel	_	_	O
244	,	_	_	O
245	respectively	_	_	O
246	.	_	_	O

247	Time	_	_	O
248	to	_	_	O
249	progression	_	_	O
250	was	_	_	O
251	similar	_	_	O
252	:	_	_	O
253	3.9	_	_	O
254	months	_	_	O
255	for	_	_	O
256	PPX/carboplatin	_	_	O
257	versus	_	_	O
258	4.6	_	_	O
259	months	_	_	O
260	for	_	_	O
261	paclitaxel/carboplatin	_	_	O
262	(	_	_	O
263	p	_	_	O
264	=	_	_	O
265	0.210	_	_	O
266	)	_	_	O
267	.	_	_	O

268	PPX/carboplatin	_	_	B-Claim
269	failed	_	_	I-Claim
270	to	_	_	I-Claim
271	provide	_	_	I-Claim
272	superior	_	_	I-Claim
273	survival	_	_	I-Claim
274	compared	_	_	I-Claim
275	with	_	_	I-Claim
276	paclitaxel/carboplatin	_	_	I-Claim
277	in	_	_	I-Claim
278	the	_	_	I-Claim
279	first-line	_	_	I-Claim
280	treatment	_	_	I-Claim
281	of	_	_	I-Claim
282	PS	_	_	I-Claim
283	2	_	_	I-Claim
284	patients	_	_	I-Claim
285	with	_	_	I-Claim
286	NSCLC	_	_	I-Claim
287	,	_	_	I-Claim
288	but	_	_	B-Claim
289	the	_	_	I-Claim
290	results	_	_	I-Claim
291	with	_	_	I-Claim
292	respect	_	_	I-Claim
293	to	_	_	I-Claim
294	progression-free	_	_	I-Claim
295	survival	_	_	I-Claim
296	and	_	_	I-Claim
297	overall	_	_	I-Claim
298	survival	_	_	I-Claim
299	were	_	_	I-Claim
300	comparable	_	_	I-Claim
301	and	_	_	I-Claim
302	the	_	_	I-Claim
303	PPX	_	_	I-Claim
304	regimen	_	_	I-Claim
305	was	_	_	I-Claim
306	more	_	_	I-Claim
307	convenient	_	_	I-Claim
308	.	_	_	I-Claim


0	Trabeculectomy	_	_	O
1	is	_	_	O
2	a	_	_	O
3	commonly	_	_	O
4	used	_	_	O
5	surgical	_	_	O
6	treatment	_	_	O
7	for	_	_	O
8	glaucoma	_	_	O
9	.	_	_	O

10	To	_	_	O
11	evaluate	_	_	O
12	the	_	_	O
13	effectiveness	_	_	O
14	of	_	_	O
15	combination	_	_	O
16	of	_	_	O
17	permanent	_	_	O
18	and	_	_	O
19	releasable	_	_	O
20	scleral	_	_	O
21	flap	_	_	O
22	sutures	_	_	O
23	to	_	_	O
24	minimize	_	_	O
25	the	_	_	O
26	immediate	_	_	O
27	postoperative	_	_	O
28	complications	_	_	O
29	of	_	_	O
30	trabeculectomy	_	_	O
31	.	_	_	O

32	This	_	_	O
33	study	_	_	O
34	was	_	_	O
35	carried	_	_	O
36	out	_	_	O
37	in	_	_	O
38	Department	_	_	O
39	of	_	_	O
40	Ophthalmology	_	_	O
41	,	_	_	O
42	B	_	_	O
43	P	_	_	O
44	Koirala	_	_	O
45	Institute	_	_	O
46	of	_	_	O
47	Health	_	_	O
48	Sciences	_	_	O
49	,	_	_	O
50	Dharan	_	_	O
51	,	_	_	O
52	Nepal	_	_	O
53	.	_	_	O

54	Forty	_	_	O
55	one	_	_	O
56	eyes	_	_	O
57	of	_	_	O
58	34	_	_	O
59	patients	_	_	O
60	undergoing	_	_	O
61	trabeculectomy	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	undergo	_	_	O
66	either	_	_	O
67	conventional	_	_	O
68	trabeculectomy	_	_	O
69	(	_	_	O
70	Group	_	_	O
71	A=	_	_	O
72	20	_	_	O
73	eyes	_	_	O
74	)	_	_	O
75	or	_	_	O
76	trabeculectomy	_	_	O
77	with	_	_	O
78	combination	_	_	O
79	of	_	_	O
80	permanent	_	_	O
81	and	_	_	O
82	releasable	_	_	O
83	scleral	_	_	O
84	flap	_	_	O
85	sutures	_	_	O
86	(	_	_	O
87	Group	_	_	O
88	B	_	_	O
89	=21	_	_	O
90	eyes	_	_	O
91	)	_	_	O
92	.	_	_	O

93	The	_	_	O
94	parameters	_	_	O
95	studied	_	_	O
96	were	_	_	O
97	intraocular	_	_	O
98	pressure	_	_	O
99	(	_	_	O
100	IOP	_	_	O
101	)	_	_	O
102	,	_	_	O
103	anterior	_	_	O
104	chamber	_	_	O
105	depth	_	_	O
106	(	_	_	O
107	ACD	_	_	O
108	)	_	_	O
109	and	_	_	O
110	surgical	_	_	O
111	complications	_	_	O
112	over	_	_	O
113	a	_	_	O
114	period	_	_	O
115	of	_	_	O
116	6	_	_	O
117	weeks	_	_	O
118	.	_	_	O

119	Significantly	_	_	B-Premise
120	higher	_	_	I-Premise
121	number	_	_	I-Premise
122	of	_	_	I-Premise
123	eyes	_	_	I-Premise
124	belonging	_	_	I-Premise
125	to	_	_	I-Premise
126	group	_	_	I-Premise
127	A	_	_	I-Premise
128	(	_	_	I-Premise
129	14	_	_	I-Premise
130	eyes	_	_	I-Premise
131	)	_	_	I-Premise
132	had	_	_	I-Premise
133	shallower	_	_	I-Premise
134	anterior	_	_	I-Premise
135	chamber	_	_	I-Premise
136	than	_	_	I-Premise
137	group	_	_	I-Premise
138	B	_	_	I-Premise
139	(	_	_	I-Premise
140	7	_	_	I-Premise
141	eyes	_	_	I-Premise
142	)	_	_	I-Premise
143	on	_	_	I-Premise
144	first	_	_	I-Premise
145	post	_	_	I-Premise
146	operative	_	_	I-Premise
147	day	_	_	I-Premise
148	(	_	_	I-Premise
149	p=0.042	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	Six	_	_	B-Premise
153	eyes	_	_	I-Premise
154	(	_	_	I-Premise
155	30	_	_	I-Premise
156	%	_	_	I-Premise
157	)	_	_	I-Premise
158	in	_	_	I-Premise
159	group	_	_	I-Premise
160	A	_	_	I-Premise
161	had	_	_	I-Premise
162	peripheral	_	_	I-Premise
163	or	_	_	I-Premise
164	central	_	_	I-Premise
165	irido-corneal	_	_	I-Premise
166	touch	_	_	I-Premise
167	in	_	_	I-Premise
168	early	_	_	I-Premise
169	postoperative	_	_	I-Premise
170	period	_	_	I-Premise
171	as	_	_	I-Premise
172	compared	_	_	I-Premise
173	to	_	_	I-Premise
174	only	_	_	I-Premise
175	one	_	_	I-Premise
176	in	_	_	I-Premise
177	Group	_	_	I-Premise
178	B.	_	_	I-Premise
179	Hypotony	_	_	B-Premise
180	was	_	_	I-Premise
181	noted	_	_	I-Premise
182	in	_	_	I-Premise
183	3	_	_	I-Premise
184	eyes	_	_	I-Premise
185	in	_	_	I-Premise
186	each	_	_	I-Premise
187	group	_	_	I-Premise
188	.	_	_	I-Premise

189	Two	_	_	O
190	patients	_	_	O
191	in	_	_	O
192	group	_	_	O
193	A	_	_	O
194	required	_	_	O
195	reformation	_	_	O
196	of	_	_	O
197	anterior	_	_	O
198	chamber	_	_	O
199	.	_	_	O

200	Other	_	_	O
201	surgical	_	_	O
202	complications	_	_	O
203	in	_	_	O
204	the	_	_	O
205	two	_	_	O
206	groups	_	_	O
207	were	_	_	O
208	similar	_	_	O
209	.	_	_	O

210	Both	_	_	B-Claim
211	the	_	_	I-Claim
212	groups	_	_	I-Claim
213	had	_	_	I-Claim
214	a	_	_	I-Claim
215	significant	_	_	I-Claim
216	drop	_	_	I-Claim
217	in	_	_	I-Claim
218	IOP	_	_	I-Claim
219	following	_	_	I-Claim
220	surgery	_	_	I-Claim
221	.	_	_	O

222	However	_	_	O
223	,	_	_	O
224	there	_	_	B-Premise
225	was	_	_	I-Premise
226	no	_	_	I-Premise
227	significant	_	_	I-Premise
228	difference	_	_	I-Premise
229	in	_	_	I-Premise
230	the	_	_	I-Premise
231	IOP	_	_	I-Premise
232	between	_	_	I-Premise
233	the	_	_	I-Premise
234	two	_	_	I-Premise
235	groups	_	_	I-Premise
236	after	_	_	I-Premise
237	6	_	_	I-Premise
238	weeks	_	_	I-Premise
239	(	_	_	I-Premise
240	Group	_	_	I-Premise
241	A	_	_	I-Premise
242	:	_	_	I-Premise
243	10.95	_	_	I-Premise
244	+/-	_	_	I-Premise
245	3.03	_	_	I-Premise
246	mmHg	_	_	I-Premise
247	vs.	_	_	I-Premise
248	Group	_	_	I-Premise
249	B	_	_	I-Premise
250	:	_	_	I-Premise
251	12.29	_	_	I-Premise
252	+/-	_	_	I-Premise
253	4.67	_	_	I-Premise
254	mmHg	_	_	I-Premise
255	;	_	_	I-Premise
256	p=0.87	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	There	_	_	B-Premise
260	was	_	_	I-Premise
261	a	_	_	I-Premise
262	significant	_	_	I-Premise
263	drop	_	_	I-Premise
264	in	_	_	I-Premise
265	IOP	_	_	I-Premise
266	following	_	_	I-Premise
267	removal	_	_	I-Premise
268	of	_	_	I-Premise
269	sutures	_	_	I-Premise
270	(	_	_	I-Premise
271	15.19	_	_	I-Premise
272	+/-	_	_	I-Premise
273	6.15	_	_	I-Premise
274	mmHg	_	_	I-Premise
275	to	_	_	I-Premise
276	13.19	_	_	I-Premise
277	+/-	_	_	I-Premise
278	6.13	_	_	I-Premise
279	mmHg	_	_	I-Premise
280	;	_	_	I-Premise
281	p=006	_	_	I-Premise
282	)	_	_	I-Premise
283	in	_	_	I-Premise
284	group	_	_	I-Premise
285	B	_	_	I-Premise
286	.	_	_	I-Premise

287	Use	_	_	B-Claim
288	of	_	_	I-Claim
289	combination	_	_	I-Claim
290	of	_	_	I-Claim
291	permanent	_	_	I-Claim
292	and	_	_	I-Claim
293	releasable	_	_	I-Claim
294	scleral	_	_	I-Claim
295	flap	_	_	I-Claim
296	sutures	_	_	I-Claim
297	is	_	_	I-Claim
298	a	_	_	I-Claim
299	safe	_	_	I-Claim
300	technique	_	_	I-Claim
301	that	_	_	I-Claim
302	significantly	_	_	I-Claim
303	reduces	_	_	I-Claim
304	the	_	_	I-Claim
305	incidence	_	_	I-Claim
306	of	_	_	I-Claim
307	immediate	_	_	I-Claim
308	postoperative	_	_	I-Claim
309	shallow	_	_	I-Claim
310	anterior	_	_	I-Claim
311	chamber	_	_	I-Claim
312	after	_	_	I-Claim
313	trabeculectomy	_	_	I-Claim
314	.	_	_	I-Claim


0	The	_	_	O
1	combination	_	_	O
2	of	_	_	O
3	cisplatin	_	_	O
4	and	_	_	O
5	etoposide	_	_	O
6	(	_	_	O
7	PE	_	_	O
8	)	_	_	O
9	has	_	_	O
10	been	_	_	O
11	a	_	_	O
12	standard	_	_	O
13	treatment	_	_	O
14	for	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	poor-prognosis	_	_	O
18	small	_	_	O
19	cell	_	_	O
20	lung	_	_	O
21	cancer	_	_	O
22	(	_	_	O
23	SCLC	_	_	O
24	)	_	_	O
25	.	_	_	O

26	This	_	_	O
27	non-inferiority	_	_	O
28	design	_	_	O
29	trial	_	_	O
30	aimed	_	_	O
31	to	_	_	O
32	determine	_	_	O
33	whether	_	_	O
34	the	_	_	O
35	combination	_	_	O
36	of	_	_	O
37	gemcitabine	_	_	O
38	and	_	_	O
39	carboplatin	_	_	O
40	(	_	_	O
41	GC	_	_	O
42	)	_	_	O
43	results	_	_	O
44	in	_	_	O
45	similar	_	_	O
46	survival	_	_	O
47	but	_	_	O
48	is	_	_	O
49	less	_	_	O
50	toxic	_	_	O
51	with	_	_	O
52	better	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	.	_	_	O

57	Previously	_	_	O
58	untreated	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	SCLC	_	_	O
62	with	_	_	O
63	extensive	_	_	O
64	disease	_	_	O
65	or	_	_	O
66	limited	_	_	O
67	stage	_	_	O
68	with	_	_	O
69	poor	_	_	O
70	prognostic	_	_	O
71	factors	_	_	O
72	were	_	_	O
73	randomly	_	_	O
74	assigned	_	_	O
75	to	_	_	O
76	six	_	_	O
77	3-weekly	_	_	O
78	cycles	_	_	O
79	of	_	_	O
80	GC	_	_	O
81	or	_	_	O
82	PE	_	_	O
83	.	_	_	O

84	241	_	_	O
85	patients	_	_	O
86	(	_	_	O
87	121	_	_	O
88	GC	_	_	O
89	,	_	_	O
90	120	_	_	O
91	PE	_	_	O
92	)	_	_	O
93	were	_	_	O
94	recruited	_	_	O
95	,	_	_	O
96	of	_	_	O
97	which	_	_	O
98	216	_	_	O
99	(	_	_	O
100	90	_	_	O
101	%	_	_	O
102	)	_	_	O
103	had	_	_	O
104	died	_	_	O
105	.	_	_	O

106	There	_	_	B-Premise
107	was	_	_	I-Premise
108	no	_	_	I-Premise
109	difference	_	_	I-Premise
110	in	_	_	I-Premise
111	overall	_	_	I-Premise
112	survival	_	_	I-Premise
113	(	_	_	I-Premise
114	HR	_	_	I-Premise
115	1.01	_	_	I-Premise
116	,	_	_	I-Premise
117	95	_	_	I-Premise
118	%	_	_	I-Premise
119	CI	_	_	I-Premise
120	0.77	_	_	I-Premise
121	to	_	_	I-Premise
122	1.32	_	_	I-Premise
123	)	_	_	I-Premise
124	.	_	_	I-Premise

125	Median	_	_	B-Premise
126	survival	_	_	I-Premise
127	with	_	_	I-Premise
128	GC	_	_	I-Premise
129	and	_	_	I-Premise
130	PE	_	_	I-Premise
131	was	_	_	I-Premise
132	8.0	_	_	I-Premise
133	and	_	_	I-Premise
134	8.1	_	_	I-Premise
135	months	_	_	I-Premise
136	,	_	_	I-Premise
137	respectively	_	_	I-Premise
138	.	_	_	I-Premise

139	Median	_	_	B-Premise
140	progression-free	_	_	I-Premise
141	survival	_	_	I-Premise
142	was	_	_	I-Premise
143	5.9	_	_	I-Premise
144	months	_	_	I-Premise
145	with	_	_	I-Premise
146	GC	_	_	I-Premise
147	and	_	_	I-Premise
148	6.3	_	_	I-Premise
149	months	_	_	I-Premise
150	with	_	_	I-Premise
151	PE	_	_	I-Premise
152	.	_	_	I-Premise

153	Grade	_	_	B-Premise
154	3	_	_	I-Premise
155	or	_	_	I-Premise
156	4	_	_	I-Premise
157	myelosuppressions	_	_	I-Premise
158	were	_	_	I-Premise
159	more	_	_	I-Premise
160	frequent	_	_	I-Premise
161	with	_	_	I-Premise
162	GC	_	_	I-Premise
163	(	_	_	I-Premise
164	anaemia	_	_	I-Premise
165	:	_	_	I-Premise
166	14	_	_	I-Premise
167	%	_	_	I-Premise
168	GC	_	_	I-Premise
169	vs	_	_	I-Premise
170	2	_	_	I-Premise
171	%	_	_	I-Premise
172	PE	_	_	I-Premise
173	;	_	_	I-Premise
174	leucopenia	_	_	I-Premise
175	:	_	_	I-Premise
176	32	_	_	I-Premise
177	%	_	_	I-Premise
178	GC	_	_	I-Premise
179	vs	_	_	I-Premise
180	13	_	_	I-Premise
181	%	_	_	I-Premise
182	PE	_	_	I-Premise
183	;	_	_	I-Premise
184	thrombocytopenia	_	_	I-Premise
185	:	_	_	I-Premise
186	22	_	_	I-Premise
187	%	_	_	I-Premise
188	GC	_	_	I-Premise
189	vs	_	_	I-Premise
190	4	_	_	I-Premise
191	%	_	_	I-Premise
192	PE	_	_	I-Premise
193	)	_	_	I-Premise
194	,	_	_	I-Premise
195	but	_	_	B-Premise
196	these	_	_	I-Premise
197	were	_	_	I-Premise
198	not	_	_	I-Premise
199	associated	_	_	I-Premise
200	with	_	_	I-Premise
201	increased	_	_	I-Premise
202	hospital	_	_	I-Premise
203	admissions	_	_	I-Premise
204	,	_	_	I-Premise
205	infections	_	_	I-Premise
206	or	_	_	I-Premise
207	fatalities	_	_	I-Premise
208	.	_	_	I-Premise

209	Grade	_	_	B-Premise
210	2-3	_	_	I-Premise
211	alopecia	_	_	I-Premise
212	(	_	_	I-Premise
213	68	_	_	I-Premise
214	%	_	_	I-Premise
215	PE	_	_	I-Premise
216	vs	_	_	I-Premise
217	17	_	_	I-Premise
218	%	_	_	I-Premise
219	GC	_	_	I-Premise
220	)	_	_	I-Premise
221	and	_	_	I-Premise
222	nausea	_	_	I-Premise
223	(	_	_	I-Premise
224	43	_	_	I-Premise
225	%	_	_	I-Premise
226	PE	_	_	I-Premise
227	vs	_	_	I-Premise
228	26	_	_	I-Premise
229	%	_	_	I-Premise
230	GC	_	_	I-Premise
231	)	_	_	I-Premise
232	were	_	_	I-Premise
233	more	_	_	I-Premise
234	frequent	_	_	I-Premise
235	with	_	_	I-Premise
236	PE	_	_	I-Premise
237	.	_	_	I-Premise

238	Patients	_	_	O
239	given	_	_	O
240	GC	_	_	O
241	received	_	_	O
242	more	_	_	O
243	chemotherapy	_	_	O
244	as	_	_	O
245	outpatients	_	_	O
246	(	_	_	O
247	89	_	_	O
248	%	_	_	O
249	GC	_	_	O
250	vs	_	_	O
251	66	_	_	O
252	%	_	_	O
253	PE	_	_	O
254	of	_	_	O
255	treatment	_	_	O
256	cycles	_	_	O
257	)	_	_	O
258	.	_	_	O

259	In	_	_	B-Premise
260	QoL	_	_	I-Premise
261	questionnaires	_	_	I-Premise
262	,	_	_	I-Premise
263	more	_	_	I-Premise
264	patients	_	_	I-Premise
265	receiving	_	_	I-Premise
266	PE	_	_	I-Premise
267	reported	_	_	I-Premise
268	being	_	_	I-Premise
269	upset	_	_	I-Premise
270	by	_	_	I-Premise
271	hair	_	_	I-Premise
272	loss	_	_	I-Premise
273	(	_	_	I-Premise
274	p	_	_	I-Premise
275	=	_	_	I-Premise
276	0.004	_	_	I-Premise
277	)	_	_	I-Premise
278	and	_	_	I-Premise
279	impaired	_	_	I-Premise
280	cognitive	_	_	I-Premise
281	functioning	_	_	I-Premise
282	(	_	_	I-Premise
283	p	_	_	I-Premise
284	=	_	_	I-Premise
285	0.04	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	GC	_	_	B-Claim
289	is	_	_	I-Claim
290	as	_	_	I-Claim
291	effective	_	_	I-Claim
292	as	_	_	I-Claim
293	PE	_	_	I-Claim
294	in	_	_	I-Claim
295	terms	_	_	I-Claim
296	of	_	_	I-Claim
297	overall	_	_	I-Claim
298	survival	_	_	I-Claim
299	and	_	_	I-Claim
300	progression-free	_	_	I-Claim
301	survival	_	_	I-Claim
302	and	_	_	I-Claim
303	has	_	_	I-Claim
304	a	_	_	I-Claim
305	toxicity	_	_	I-Claim
306	profile	_	_	I-Claim
307	more	_	_	I-Claim
308	acceptable	_	_	I-Claim
309	to	_	_	I-Claim
310	patients	_	_	I-Claim
311	.	_	_	I-Claim


0	The	_	_	O
1	physiological	_	_	O
2	and	_	_	O
3	psychological	_	_	O
4	stress	_	_	O
5	that	_	_	O
6	brain	_	_	O
7	tumor	_	_	O
8	patients	_	_	O
9	undergo	_	_	O
10	during	_	_	O
11	the	_	_	O
12	entire	_	_	O
13	surgical	_	_	O
14	experience	_	_	O
15	can	_	_	O
16	considerably	_	_	O
17	affect	_	_	O
18	several	_	_	O
19	aspects	_	_	O
20	of	_	_	O
21	their	_	_	O
22	hospitalization	_	_	O
23	.	_	_	O

24	The	_	_	O
25	purpose	_	_	O
26	of	_	_	O
27	this	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	examine	_	_	O
32	the	_	_	O
33	effects	_	_	O
34	of	_	_	O
35	live	_	_	O
36	music	_	_	O
37	therapy	_	_	O
38	on	_	_	O
39	quality	_	_	O
40	of	_	_	O
41	life	_	_	O
42	indicators	_	_	O
43	,	_	_	O
44	amount	_	_	O
45	of	_	_	O
46	medications	_	_	O
47	administered	_	_	O
48	and	_	_	O
49	length	_	_	O
50	of	_	_	O
51	stay	_	_	O
52	for	_	_	O
53	persons	_	_	O
54	receiving	_	_	O
55	elective	_	_	O
56	surgical	_	_	O
57	procedures	_	_	O
58	of	_	_	O
59	the	_	_	O
60	brain	_	_	O
61	.	_	_	O

62	Subjects	_	_	O
63	(	_	_	O
64	N	_	_	O
65	=	_	_	O
66	27	_	_	O
67	)	_	_	O
68	were	_	_	O
69	patients	_	_	O
70	admitted	_	_	O
71	for	_	_	O
72	some	_	_	O
73	type	_	_	O
74	of	_	_	O
75	surgical	_	_	O
76	procedure	_	_	O
77	of	_	_	O
78	the	_	_	O
79	brain	_	_	O
80	.	_	_	O

81	Subjects	_	_	O
82	were	_	_	O
83	randomly	_	_	O
84	assigned	_	_	O
85	to	_	_	O
86	either	_	_	O
87	the	_	_	O
88	control	_	_	O
89	group	_	_	O
90	receiving	_	_	O
91	no	_	_	O
92	music	_	_	O
93	intervention	_	_	O
94	(	_	_	O
95	n	_	_	O
96	=	_	_	O
97	13	_	_	O
98	)	_	_	O
99	or	_	_	O
100	the	_	_	O
101	experimental	_	_	O
102	group	_	_	O
103	receiving	_	_	O
104	pre	_	_	O
105	and	_	_	O
106	postoperative	_	_	O
107	live	_	_	O
108	music	_	_	O
109	therapy	_	_	O
110	sessions	_	_	O
111	(	_	_	O
112	n	_	_	O
113	=	_	_	O
114	14	_	_	O
115	)	_	_	O
116	.	_	_	O

117	Anxiety	_	_	O
118	,	_	_	O
119	mood	_	_	O
120	,	_	_	O
121	pain	_	_	O
122	,	_	_	O
123	perception	_	_	O
124	of	_	_	O
125	hospitalization	_	_	O
126	or	_	_	O
127	procedure	_	_	O
128	,	_	_	O
129	relaxation	_	_	O
130	,	_	_	O
131	and	_	_	O
132	stress	_	_	O
133	were	_	_	O
134	measured	_	_	O
135	using	_	_	O
136	a	_	_	O
137	self-report	_	_	O
138	Visual	_	_	O
139	Analog	_	_	O
140	Scale	_	_	O
141	(	_	_	O
142	VAS	_	_	O
143	)	_	_	O
144	for	_	_	O
145	each	_	_	O
146	of	_	_	O
147	the	_	_	O
148	variables	_	_	O
149	.	_	_	O

150	The	_	_	O
151	documented	_	_	O
152	administration	_	_	O
153	of	_	_	O
154	postoperative	_	_	O
155	pain	_	_	O
156	medications	_	_	O
157	;	_	_	O
158	the	_	_	O
159	frequency	_	_	O
160	,	_	_	O
161	dosage	_	_	O
162	,	_	_	O
163	type	_	_	O
164	,	_	_	O
165	and	_	_	O
166	how	_	_	O
167	it	_	_	O
168	was	_	_	O
169	given	_	_	O
170	was	_	_	O
171	also	_	_	O
172	compared	_	_	O
173	between	_	_	O
174	groups	_	_	O
175	.	_	_	O

176	Experimental	_	_	O
177	subjects	_	_	O
178	live	_	_	O
179	and	_	_	O
180	interactive	_	_	O
181	music	_	_	O
182	therapy	_	_	O
183	sessions	_	_	O
184	,	_	_	O
185	including	_	_	O
186	a	_	_	O
187	pre-operative	_	_	O
188	session	_	_	O
189	and	_	_	O
190	continuing	_	_	O
191	with	_	_	O
192	daily	_	_	O
193	sessions	_	_	O
194	until	_	_	O
195	the	_	_	O
196	patient	_	_	O
197	was	_	_	O
198	discharged	_	_	O
199	home	_	_	O
200	.	_	_	O

201	Control	_	_	O
202	subjects	_	_	O
203	received	_	_	O
204	routine	_	_	O
205	hospital	_	_	O
206	care	_	_	O
207	without	_	_	O
208	any	_	_	O
209	music	_	_	O
210	therapy	_	_	O
211	intervention	_	_	O
212	.	_	_	O

213	Differences	_	_	O
214	in	_	_	O
215	experimental	_	_	O
216	pretest	_	_	O
217	and	_	_	O
218	posttest	_	_	O
219	scores	_	_	O
220	were	_	_	O
221	analyzed	_	_	O
222	using	_	_	O
223	a	_	_	O
224	Wilcoxon	_	_	O
225	Matched-Pairs	_	_	O
226	Signed-Rank	_	_	O
227	test	_	_	O
228	.	_	_	O

229	Results	_	_	B-Premise
230	indicated	_	_	I-Premise
231	statistically	_	_	I-Premise
232	significant	_	_	I-Premise
233	differences	_	_	I-Premise
234	for	_	_	I-Premise
235	4	_	_	I-Premise
236	of	_	_	I-Premise
237	the	_	_	I-Premise
238	6	_	_	I-Premise
239	quality	_	_	I-Premise
240	of	_	_	I-Premise
241	life	_	_	I-Premise
242	measures	_	_	I-Premise
243	:	_	_	I-Premise
244	anxiety	_	_	I-Premise
245	(	_	_	I-Premise
246	p	_	_	I-Premise
247	=	_	_	I-Premise
248	.03	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	perception	_	_	I-Premise
252	of	_	_	I-Premise
253	hospitalization	_	_	I-Premise
254	(	_	_	I-Premise
255	p	_	_	I-Premise
256	=	_	_	I-Premise
257	.03	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	relaxation	_	_	I-Premise
261	(	_	_	I-Premise
262	p	_	_	I-Premise
263	=	_	_	I-Premise
264	.001	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	stress	_	_	I-Premise
269	(	_	_	I-Premise
270	p	_	_	I-Premise
271	=	_	_	I-Premise
272	.001	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	No	_	_	B-Premise
276	statistically	_	_	I-Premise
277	significant	_	_	I-Premise
278	differences	_	_	I-Premise
279	were	_	_	I-Premise
280	found	_	_	I-Premise
281	for	_	_	I-Premise
282	mood	_	_	I-Premise
283	(	_	_	I-Premise
284	p	_	_	I-Premise
285	>	_	_	I-Premise
286	.05	_	_	I-Premise
287	)	_	_	I-Premise
288	or	_	_	I-Premise
289	pain	_	_	I-Premise
290	(	_	_	I-Premise
291	p	_	_	I-Premise
292	>	_	_	I-Premise
293	.05	_	_	I-Premise
294	)	_	_	I-Premise
295	levels	_	_	I-Premise
296	.	_	_	I-Premise

297	Administration	_	_	O
298	amounts	_	_	O
299	of	_	_	O
300	nausea	_	_	O
301	and	_	_	O
302	pain	_	_	O
303	medications	_	_	O
304	were	_	_	O
305	compared	_	_	O
306	with	_	_	O
307	a	_	_	O
308	Two-Way	_	_	O
309	ANOVA	_	_	O
310	with	_	_	O
311	One	_	_	O
312	Repeated	_	_	O
313	Measure	_	_	O
314	resulting	_	_	O
315	in	_	_	O
316	no	_	_	O
317	significant	_	_	O
318	differences	_	_	O
319	between	_	_	O
320	groups	_	_	O
321	and	_	_	O
322	medications	_	_	O
323	,	_	_	O
324	F	_	_	O
325	(	_	_	O
326	1	_	_	O
327	,	_	_	O
328	51	_	_	O
329	)	_	_	O
330	=	_	_	O
331	0.03	_	_	O
332	;	_	_	O
333	p	_	_	O
334	>	_	_	O
335	.05	_	_	O
336	.	_	_	O

337	Results	_	_	O
338	indicate	_	_	O
339	no	_	_	O
340	significant	_	_	O
341	differences	_	_	O
342	between	_	_	O
343	groups	_	_	O
344	for	_	_	O
345	length	_	_	O
346	of	_	_	O
347	stay	_	_	O
348	(	_	_	O
349	t	_	_	O
350	=	_	_	O
351	.97	_	_	O
352	,	_	_	O
353	df	_	_	O
354	=	_	_	O
355	25	_	_	O
356	,	_	_	O
357	p	_	_	O
358	>	_	_	O
359	.05	_	_	O
360	)	_	_	O
361	.	_	_	O

362	This	_	_	B-Claim
363	research	_	_	I-Claim
364	study	_	_	I-Claim
365	indicates	_	_	I-Claim
366	that	_	_	I-Claim
367	live	_	_	I-Claim
368	music	_	_	I-Claim
369	therapy	_	_	I-Claim
370	using	_	_	I-Claim
371	patient-preferred	_	_	I-Claim
372	music	_	_	I-Claim
373	can	_	_	I-Claim
374	be	_	_	I-Claim
375	beneficial	_	_	I-Claim
376	in	_	_	I-Claim
377	improving	_	_	I-Claim
378	quality	_	_	I-Claim
379	of	_	_	I-Claim
380	life	_	_	I-Claim
381	indicators	_	_	I-Claim
382	such	_	_	I-Claim
383	as	_	_	I-Claim
384	anxiety	_	_	I-Claim
385	,	_	_	I-Claim
386	perception	_	_	I-Claim
387	of	_	_	I-Claim
388	the	_	_	I-Claim
389	hospitalization	_	_	I-Claim
390	or	_	_	I-Claim
391	procedure	_	_	I-Claim
392	,	_	_	I-Claim
393	relaxation	_	_	I-Claim
394	,	_	_	I-Claim
395	and	_	_	I-Claim
396	stress	_	_	I-Claim
397	in	_	_	I-Claim
398	patients	_	_	I-Claim
399	undergoing	_	_	I-Claim
400	surgical	_	_	I-Claim
401	procedures	_	_	I-Claim
402	of	_	_	I-Claim
403	the	_	_	I-Claim
404	brain	_	_	I-Claim
405	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	toxicities	_	_	O
4	,	_	_	O
5	tumor	_	_	O
6	control	_	_	O
7	,	_	_	O
8	survival	_	_	O
9	,	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	of	_	_	O
15	nasopharyngeal	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	NPC	_	_	O
19	)	_	_	O
20	patients	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	sequential	_	_	O
24	neoadjuvant	_	_	O
25	chemotherapy	_	_	O
26	followed	_	_	O
27	by	_	_	O
28	concurrent	_	_	O
29	cisplatin-radiotherapy	_	_	O
30	(	_	_	O
31	CRT	_	_	O
32	)	_	_	O
33	or	_	_	O
34	CRT	_	_	O
35	alone	_	_	O
36	.	_	_	O

37	Previously	_	_	O
38	untreated	_	_	O
39	stage	_	_	O
40	III	_	_	O
41	to	_	_	O
42	IVB	_	_	O
43	NPC	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	(	_	_	O
49	1	_	_	O
50	)	_	_	O
51	neoadjuvant	_	_	O
52	docetaxel	_	_	O
53	75	_	_	O
54	mg/m	_	_	O
55	(	_	_	O
56	2	_	_	O
57	)	_	_	O
58	and	_	_	O
59	cisplatin	_	_	O
60	75	_	_	O
61	mg/m	_	_	O
62	(	_	_	O
63	2	_	_	O
64	)	_	_	O
65	every	_	_	O
66	3	_	_	O
67	weeks	_	_	O
68	for	_	_	O
69	two	_	_	O
70	cycles	_	_	O
71	,	_	_	O
72	followed	_	_	O
73	by	_	_	O
74	cisplatin	_	_	O
75	40	_	_	O
76	mg/m	_	_	O
77	(	_	_	O
78	2	_	_	O
79	)	_	_	O
80	/wk	_	_	O
81	concurrent	_	_	O
82	with	_	_	O
83	radiotherapy	_	_	O
84	,	_	_	O
85	or	_	_	O
86	(	_	_	O
87	2	_	_	O
88	)	_	_	O
89	CRT	_	_	O
90	alone	_	_	O
91	.	_	_	O

92	Planned	_	_	O
93	accrual	_	_	O
94	was	_	_	O
95	30	_	_	O
96	patients	_	_	O
97	per	_	_	O
98	arm	_	_	O
99	to	_	_	O
100	detect	_	_	O
101	20	_	_	O
102	%	_	_	O
103	difference	_	_	O
104	of	_	_	O
105	toxicities	_	_	O
106	based	_	_	O
107	on	_	_	O
108	95	_	_	O
109	%	_	_	O
110	CIs	_	_	O
111	.	_	_	O

112	From	_	_	O
113	November	_	_	O
114	2002	_	_	O
115	to	_	_	O
116	November	_	_	O
117	2004	_	_	O
118	,	_	_	O
119	65	_	_	O
120	eligible	_	_	O
121	patients	_	_	O
122	were	_	_	O
123	randomly	_	_	O
124	assigned	_	_	O
125	to	_	_	O
126	neoadjuvant	_	_	O
127	chemotherapy	_	_	O
128	followed	_	_	O
129	by	_	_	O
130	CRT	_	_	O
131	(	_	_	O
132	n	_	_	O
133	=	_	_	O
134	34	_	_	O
135	)	_	_	O
136	or	_	_	O
137	CRT	_	_	O
138	alone	_	_	O
139	(	_	_	O
140	n	_	_	O
141	=	_	_	O
142	31	_	_	O
143	)	_	_	O
144	.	_	_	O

145	There	_	_	B-Premise
146	was	_	_	I-Premise
147	a	_	_	I-Premise
148	high	_	_	I-Premise
149	rate	_	_	I-Premise
150	of	_	_	I-Premise
151	grade	_	_	I-Premise
152	3/4	_	_	I-Premise
153	neutropenia	_	_	I-Premise
154	(	_	_	I-Premise
155	97	_	_	I-Premise
156	%	_	_	I-Premise
157	)	_	_	I-Premise
158	but	_	_	I-Premise
159	not	_	_	I-Premise
160	neutropenic	_	_	I-Premise
161	fever	_	_	I-Premise
162	(	_	_	I-Premise
163	12	_	_	I-Premise
164	%	_	_	I-Premise
165	)	_	_	I-Premise
166	during	_	_	I-Premise
167	neoadjuvant	_	_	I-Premise
168	chemotherapy	_	_	I-Premise
169	.	_	_	I-Premise

170	No	_	_	B-Premise
171	significant	_	_	I-Premise
172	differences	_	_	I-Premise
173	in	_	_	I-Premise
174	rates	_	_	I-Premise
175	of	_	_	I-Premise
176	acute	_	_	I-Premise
177	toxicities	_	_	I-Premise
178	were	_	_	I-Premise
179	observed	_	_	I-Premise
180	between	_	_	I-Premise
181	the	_	_	I-Premise
182	two	_	_	I-Premise
183	arms	_	_	I-Premise
184	during	_	_	I-Premise
185	CRT	_	_	I-Premise
186	.	_	_	I-Premise

187	Dose	_	_	B-Premise
188	intensities	_	_	I-Premise
189	of	_	_	I-Premise
190	concurrent	_	_	I-Premise
191	cisplatin	_	_	I-Premise
192	,	_	_	I-Premise
193	late	_	_	I-Premise
194	RT	_	_	I-Premise
195	toxicities	_	_	I-Premise
196	and	_	_	I-Premise
197	quality	_	_	I-Premise
198	of	_	_	I-Premise
199	life	_	_	I-Premise
200	scores	_	_	I-Premise
201	were	_	_	I-Premise
202	comparable	_	_	I-Premise
203	in	_	_	I-Premise
204	both	_	_	I-Premise
205	arms	_	_	I-Premise
206	.	_	_	I-Premise

207	The	_	_	B-Premise
208	3-year	_	_	I-Premise
209	progression-free	_	_	I-Premise
210	survival	_	_	I-Premise
211	for	_	_	I-Premise
212	neoadjuvant	_	_	I-Premise
213	versus	_	_	I-Premise
214	control	_	_	I-Premise
215	arm	_	_	I-Premise
216	was	_	_	I-Premise
217	88.2	_	_	I-Premise
218	%	_	_	I-Premise
219	and	_	_	I-Premise
220	59.5	_	_	I-Premise
221	%	_	_	I-Premise
222	(	_	_	I-Premise
223	hazard	_	_	I-Premise
224	ratio	_	_	I-Premise
225	=	_	_	I-Premise
226	0.49	_	_	I-Premise
227	;	_	_	I-Premise
228	95	_	_	I-Premise
229	%	_	_	I-Premise
230	CI	_	_	I-Premise
231	,	_	_	I-Premise
232	0.20	_	_	I-Premise
233	to	_	_	I-Premise
234	1.19	_	_	I-Premise
235	;	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	.12	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	The	_	_	B-Premise
242	3-year	_	_	I-Premise
243	overall	_	_	I-Premise
244	survival	_	_	I-Premise
245	for	_	_	I-Premise
246	neoadjuvant	_	_	I-Premise
247	versus	_	_	I-Premise
248	control	_	_	I-Premise
249	arm	_	_	I-Premise
250	was	_	_	I-Premise
251	94.1	_	_	I-Premise
252	%	_	_	I-Premise
253	and	_	_	I-Premise
254	67.7	_	_	I-Premise
255	%	_	_	I-Premise
256	(	_	_	I-Premise
257	hazard	_	_	I-Premise
258	ratio	_	_	I-Premise
259	=	_	_	I-Premise
260	0.24	_	_	I-Premise
261	;	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	CI	_	_	I-Premise
265	,	_	_	I-Premise
266	0.078	_	_	I-Premise
267	to	_	_	I-Premise
268	0.73	_	_	I-Premise
269	;	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	.012	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	Neoadjuvant	_	_	B-Claim
276	docetaxel-cisplatin	_	_	I-Claim
277	followed	_	_	I-Claim
278	by	_	_	I-Claim
279	CRT	_	_	I-Claim
280	was	_	_	I-Claim
281	well	_	_	I-Claim
282	tolerated	_	_	I-Claim
283	with	_	_	I-Claim
284	a	_	_	I-Claim
285	manageable	_	_	I-Claim
286	toxicity	_	_	I-Claim
287	profile	_	_	I-Claim
288	that	_	_	I-Claim
289	allowed	_	_	I-Claim
290	subsequent	_	_	I-Claim
291	delivery	_	_	I-Claim
292	of	_	_	I-Claim
293	full-dose	_	_	I-Claim
294	CRT	_	_	I-Claim
295	.	_	_	I-Claim

296	Preliminary	_	_	B-Claim
297	results	_	_	I-Claim
298	suggested	_	_	I-Claim
299	a	_	_	I-Claim
300	positive	_	_	I-Claim
301	impact	_	_	I-Claim
302	on	_	_	I-Claim
303	survival	_	_	I-Claim
304	.	_	_	I-Claim

305	A	_	_	O
306	phase	_	_	O
307	III	_	_	O
308	study	_	_	O
309	to	_	_	O
310	definitively	_	_	O
311	test	_	_	O
312	this	_	_	O
313	neoadjuvant-concurrent	_	_	O
314	strategy	_	_	O
315	is	_	_	O
316	warranted	_	_	O
317	.	_	_	O


0	Androgen	_	_	O
1	treatment	_	_	O
2	for	_	_	O
3	prostate	_	_	O
4	cancer	_	_	O
5	can	_	_	O
6	adversely	_	_	O
7	affect	_	_	O
8	functional	_	_	O
9	domains	_	_	O
10	of	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	.	_	_	O

15	We	_	_	O
16	aimed	_	_	O
17	to	_	_	O
18	assess	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	in	_	_	O
23	men	_	_	O
24	with	_	_	O
25	locally	_	_	O
26	advanced	_	_	O
27	prostate	_	_	O
28	cancer	_	_	O
29	in	_	_	O
30	an	_	_	O
31	open-label	_	_	O
32	phase	_	_	O
33	III	_	_	O
34	randomised	_	_	O
35	comparison	_	_	O
36	between	_	_	O
37	lifelong	_	_	O
38	endocrine	_	_	O
39	treatment	_	_	O
40	with	_	_	O
41	and	_	_	O
42	without	_	_	O
43	radiotherapy	_	_	O
44	.	_	_	O

45	We	_	_	O
46	obtained	_	_	O
47	quality-of-life	_	_	O
48	information	_	_	O
49	from	_	_	O
50	872	_	_	O
51	(	_	_	O
52	99	_	_	O
53	%	_	_	O
54	)	_	_	O
55	of	_	_	O
56	875	_	_	O
57	eligible	_	_	O
58	men	_	_	O
59	with	_	_	O
60	locally	_	_	O
61	advanced	_	_	O
62	prostate	_	_	O
63	cancer	_	_	O
64	(	_	_	O
65	T3	_	_	O
66	;	_	_	O
67	78	_	_	O
68	%	_	_	O
69	)	_	_	O
70	who	_	_	O
71	were	_	_	O
72	randomly	_	_	O
73	assigned	_	_	O
74	,	_	_	O
75	between	_	_	O
76	1996	_	_	O
77	and	_	_	O
78	2002	_	_	O
79	,	_	_	O
80	to	_	_	O
81	3	_	_	O
82	months	_	_	O
83	of	_	_	O
84	total	_	_	O
85	androgen	_	_	O
86	blockade	_	_	O
87	followed	_	_	O
88	by	_	_	O
89	continuous	_	_	O
90	endocrine	_	_	O
91	treatment	_	_	O
92	(	_	_	O
93	439	_	_	O
94	patients	_	_	O
95	)	_	_	O
96	or	_	_	O
97	the	_	_	O
98	same	_	_	O
99	hormonal	_	_	O
100	treatment	_	_	O
101	with	_	_	O
102	radiotherapy	_	_	O
103	3	_	_	O
104	months	_	_	O
105	after	_	_	O
106	randomisation	_	_	O
107	(	_	_	O
108	436	_	_	O
109	patients	_	_	O
110	)	_	_	O
111	.	_	_	O

112	Prospective	_	_	O
113	outcomes	_	_	O
114	included	_	_	O
115	patient-reported	_	_	O
116	symptoms	_	_	O
117	and	_	_	O
118	quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	assessed	_	_	O
122	with	_	_	O
123	questionnaires	_	_	O
124	from	_	_	O
125	baseline	_	_	O
126	to	_	_	O
127	4	_	_	O
128	years	_	_	O
129	after	_	_	O
130	randomisation	_	_	O
131	.	_	_	O

132	Analysis	_	_	O
133	was	_	_	O
134	by	_	_	O
135	intention	_	_	O
136	to	_	_	O
137	treat	_	_	O
138	.	_	_	O

139	This	_	_	O
140	study	_	_	O
141	is	_	_	O
142	registered	_	_	O
143	as	_	_	O
144	an	_	_	O
145	international	_	_	O
146	standard	_	_	O
147	randomised	_	_	O
148	controlled	_	_	O
149	trial	_	_	O
150	,	_	_	O
151	number	_	_	O
152	ISRCTN01534787	_	_	O
153	.	_	_	O

154	438	_	_	O
155	of	_	_	O
156	439	_	_	O
157	men	_	_	O
158	assigned	_	_	O
159	endocrine	_	_	O
160	treatment	_	_	O
161	and	_	_	O
162	434	_	_	O
163	of	_	_	O
164	436	_	_	O
165	assigned	_	_	O
166	endocrine	_	_	O
167	plus	_	_	O
168	radiotherapy	_	_	O
169	completed	_	_	O
170	at	_	_	O
171	least	_	_	O
172	one	_	_	O
173	questionnaire	_	_	O
174	.	_	_	O

175	Missing	_	_	O
176	data	_	_	O
177	at	_	_	O
178	baseline	_	_	O
179	and	_	_	O
180	during	_	_	O
181	follow-up	_	_	O
182	was	_	_	O
183	equally	_	_	O
184	distributed	_	_	O
185	between	_	_	O
186	groups	_	_	O
187	.	_	_	O

188	At	_	_	B-Premise
189	4	_	_	I-Premise
190	years	_	_	I-Premise
191	,	_	_	I-Premise
192	64	_	_	I-Premise
193	(	_	_	I-Premise
194	18	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	of	_	_	I-Premise
198	353	_	_	I-Premise
199	patients	_	_	I-Premise
200	on	_	_	I-Premise
201	combined	_	_	I-Premise
202	therapy	_	_	I-Premise
203	and	_	_	I-Premise
204	39	_	_	I-Premise
205	(	_	_	I-Premise
206	12	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	of	_	_	I-Premise
210	337	_	_	I-Premise
211	on	_	_	I-Premise
212	endocrine-alone	_	_	I-Premise
213	therapy	_	_	I-Premise
214	had	_	_	I-Premise
215	moderate	_	_	I-Premise
216	to	_	_	I-Premise
217	severe	_	_	I-Premise
218	urinary	_	_	I-Premise
219	bother	_	_	I-Premise
220	(	_	_	I-Premise
221	p=0.005	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	and	_	_	I-Premise
225	16	_	_	I-Premise
226	(	_	_	I-Premise
227	4	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	of	_	_	I-Premise
231	355	_	_	I-Premise
232	on	_	_	I-Premise
233	combined	_	_	I-Premise
234	therapy	_	_	I-Premise
235	and	_	_	I-Premise
236	five	_	_	I-Premise
237	(	_	_	I-Premise
238	2	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	of	_	_	I-Premise
242	338	_	_	I-Premise
243	on	_	_	I-Premise
244	endocrine	_	_	I-Premise
245	treatment	_	_	I-Premise
246	alone	_	_	I-Premise
247	had	_	_	I-Premise
248	pain	_	_	I-Premise
249	while	_	_	I-Premise
250	urinating	_	_	I-Premise
251	(	_	_	I-Premise
252	p=0.024	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	37	_	_	B-Premise
256	(	_	_	I-Premise
257	11	_	_	I-Premise
258	%	_	_	I-Premise
259	)	_	_	I-Premise
260	of	_	_	I-Premise
261	350	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	combined	_	_	I-Premise
265	group	_	_	I-Premise
266	and	_	_	I-Premise
267	23	_	_	I-Premise
268	(	_	_	I-Premise
269	7	_	_	I-Premise
270	%	_	_	I-Premise
271	)	_	_	I-Premise
272	of	_	_	I-Premise
273	35	_	_	I-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	endocrine-only	_	_	I-Premise
277	group	_	_	I-Premise
278	had	_	_	I-Premise
279	overall	_	_	I-Premise
280	bother	_	_	I-Premise
281	from	_	_	I-Premise
282	all	_	_	I-Premise
283	bowel	_	_	I-Premise
284	symptoms	_	_	I-Premise
285	(	_	_	I-Premise
286	p=0.022	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	281	_	_	B-Premise
290	(	_	_	I-Premise
291	85	_	_	I-Premise
292	%	_	_	I-Premise
293	)	_	_	I-Premise
294	of	_	_	I-Premise
295	332	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	combined-treatment	_	_	I-Premise
299	group	_	_	I-Premise
300	and	_	_	I-Premise
301	227	_	_	I-Premise
302	(	_	_	I-Premise
303	72	_	_	I-Premise
304	%	_	_	I-Premise
305	)	_	_	I-Premise
306	of	_	_	I-Premise
307	313	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	endocrine-only	_	_	I-Premise
311	group	_	_	I-Premise
312	had	_	_	I-Premise
313	erectile	_	_	I-Premise
314	dysfunction	_	_	I-Premise
315	(	_	_	I-Premise
316	p=0.0002	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	Quality	_	_	B-Premise
320	of	_	_	I-Premise
321	life	_	_	I-Premise
322	at	_	_	I-Premise
323	4	_	_	I-Premise
324	years	_	_	I-Premise
325	was	_	_	I-Premise
326	similar	_	_	I-Premise
327	,	_	_	I-Premise
328	with	_	_	I-Premise
329	the	_	_	I-Premise
330	exception	_	_	I-Premise
331	of	_	_	I-Premise
332	decreased	_	_	I-Premise
333	social	_	_	I-Premise
334	function	_	_	I-Premise
335	in	_	_	I-Premise
336	patients	_	_	I-Premise
337	receiving	_	_	I-Premise
338	endocrine	_	_	I-Premise
339	treatment	_	_	I-Premise
340	plus	_	_	I-Premise
341	radiotherapy	_	_	I-Premise
342	.	_	_	I-Premise

343	Although	_	_	B-Claim
344	addition	_	_	I-Claim
345	of	_	_	I-Claim
346	radiotherapy	_	_	I-Claim
347	to	_	_	I-Claim
348	endocrine	_	_	I-Claim
349	treatment	_	_	I-Claim
350	significantly	_	_	I-Claim
351	increased	_	_	I-Claim
352	some	_	_	I-Claim
353	treatment-related	_	_	I-Claim
354	symptoms	_	_	I-Claim
355	,	_	_	I-Claim
356	none	_	_	I-Claim
357	were	_	_	I-Claim
358	serious	_	_	I-Claim
359	.	_	_	I-Claim

360	Given	_	_	O
361	the	_	_	O
362	substantial	_	_	O
363	survival	_	_	O
364	benefit	_	_	O
365	of	_	_	O
366	combined	_	_	O
367	treatment	_	_	O
368	,	_	_	O
369	the	_	_	B-Claim
370	increase	_	_	I-Claim
371	of	_	_	I-Claim
372	symptoms	_	_	I-Claim
373	seems	_	_	I-Claim
374	acceptable	_	_	I-Claim
375	and	_	_	I-Claim
376	has	_	_	I-Claim
377	little	_	_	I-Claim
378	extra	_	_	I-Claim
379	effect	_	_	I-Claim
380	on	_	_	I-Claim
381	quality	_	_	I-Claim
382	of	_	_	I-Claim
383	life	_	_	I-Claim
384	after	_	_	I-Claim
385	4	_	_	I-Claim
386	years	_	_	I-Claim
387	compared	_	_	I-Claim
388	with	_	_	I-Claim
389	endocrine	_	_	I-Claim
390	treatment	_	_	I-Claim
391	alone	_	_	I-Claim
392	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	efficacy	_	_	O
5	and	_	_	O
6	safety	_	_	O
7	of	_	_	O
8	combined	_	_	O
9	trabeculectomy	_	_	O
10	and	_	_	O
11	cataract	_	_	O
12	extraction	_	_	O
13	versus	_	_	O
14	trabeculectomy	_	_	O
15	alone	_	_	O
16	in	_	_	O
17	primary	_	_	O
18	angle-closure	_	_	O
19	glaucoma	_	_	O
20	(	_	_	O
21	PACG	_	_	O
22	)	_	_	O
23	.	_	_	O

24	Hospital	_	_	O
25	files	_	_	O
26	were	_	_	O
27	retrospectively	_	_	O
28	examined	_	_	O
29	for	_	_	O
30	99	_	_	O
31	Chinese	_	_	O
32	PACG	_	_	O
33	patients	_	_	O
34	;	_	_	O
35	75	_	_	O
36	patients	_	_	O
37	underwent	_	_	O
38	combined	_	_	O
39	surgery	_	_	O
40	and	_	_	O
41	24	_	_	O
42	underwent	_	_	O
43	trabeculectomy	_	_	O
44	alone	_	_	O
45	.	_	_	O

46	Success	_	_	O
47	rates	_	_	O
48	were	_	_	O
49	assessed	_	_	O
50	with	_	_	O
51	the	_	_	O
52	Kaplan-Meier	_	_	O
53	survival	_	_	O
54	analysis	_	_	O
55	.	_	_	O

56	The	_	_	O
57	main	_	_	O
58	outcome	_	_	O
59	was	_	_	O
60	the	_	_	O
61	complete	_	_	O
62	success	_	_	O
63	rate	_	_	O
64	defined	_	_	O
65	as	_	_	O
66	either	_	_	O
67	a	_	_	O
68	>	_	_	O
69	20	_	_	O
70	%	_	_	O
71	reduction	_	_	O
72	in	_	_	O
73	intraocular	_	_	O
74	pressure	_	_	O
75	(	_	_	O
76	IOP	_	_	O
77	)	_	_	O
78	or	_	_	O
79	an	_	_	O
80	IOP	_	_	O
81	that	_	_	O
82	remained	_	_	O
83	below	_	_	O
84	15	_	_	O
85	mm	_	_	O
86	Hg	_	_	O
87	,	_	_	O
88	with	_	_	O
89	no	_	_	O
90	medications	_	_	O
91	required	_	_	O
92	.	_	_	O

93	Patients	_	_	O
94	in	_	_	O
95	the	_	_	O
96	combined	_	_	O
97	group	_	_	O
98	and	_	_	O
99	trabeculectomy	_	_	O
100	group	_	_	O
101	had	_	_	O
102	a	_	_	O
103	mean	_	_	O
104	follow-up	_	_	O
105	period	_	_	O
106	of	_	_	O
107	25.8	_	_	O
108	(	_	_	O
109	SD	_	_	O
110	10.8	_	_	O
111	)	_	_	O
112	months	_	_	O
113	and	_	_	O
114	31.4	_	_	O
115	(	_	_	O
116	8.9	_	_	O
117	)	_	_	O
118	months	_	_	O
119	,	_	_	O
120	respectively	_	_	O
121	.	_	_	O

122	Survival	_	_	O
123	analysis	_	_	O
124	showed	_	_	O
125	that	_	_	O
126	the	_	_	O
127	complete	_	_	O
128	success	_	_	O
129	rate	_	_	O
130	at	_	_	O
131	3	_	_	O
132	years	_	_	O
133	was	_	_	O
134	56	_	_	O
135	%	_	_	O
136	in	_	_	O
137	the	_	_	O
138	combined	_	_	O
139	group	_	_	O
140	and	_	_	O
141	54	_	_	O
142	%	_	_	O
143	in	_	_	O
144	the	_	_	O
145	trabeculectomy	_	_	O
146	group	_	_	O
147	(	_	_	O
148	p	_	_	O
149	=	_	_	O
150	0.903	_	_	O
151	)	_	_	O
152	.	_	_	O

153	There	_	_	O
154	were	_	_	O
155	no	_	_	O
156	significant	_	_	O
157	differences	_	_	O
158	between	_	_	O
159	groups	_	_	O
160	in	_	_	O
161	either	_	_	O
162	IOP	_	_	O
163	or	_	_	O
164	the	_	_	O
165	number	_	_	O
166	of	_	_	O
167	glaucoma	_	_	O
168	medications	_	_	O
169	throughout	_	_	O
170	the	_	_	O
171	3-year	_	_	O
172	follow-up	_	_	O
173	.	_	_	O

174	The	_	_	B-Premise
175	incidences	_	_	I-Premise
176	of	_	_	I-Premise
177	postoperative	_	_	I-Premise
178	complications	_	_	I-Premise
179	were	_	_	I-Premise
180	similar	_	_	I-Premise
181	between	_	_	I-Premise
182	groups	_	_	I-Premise
183	(	_	_	I-Premise
184	p	_	_	I-Premise
185	=	_	_	I-Premise
186	0.232	_	_	I-Premise
187	)	_	_	I-Premise
188	.	_	_	I-Premise

189	No	_	_	B-Premise
190	additional	_	_	I-Premise
191	IOP-lowering	_	_	I-Premise
192	surgical	_	_	I-Premise
193	procedures	_	_	I-Premise
194	were	_	_	I-Premise
195	required	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	combined	_	_	I-Premise
199	group	_	_	I-Premise
200	,	_	_	I-Premise
201	while	_	_	I-Premise
202	13	_	_	I-Premise
203	(	_	_	I-Premise
204	54	_	_	I-Premise
205	%	_	_	I-Premise
206	)	_	_	I-Premise
207	eyes	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	trabeculectomy	_	_	I-Premise
211	group	_	_	I-Premise
212	required	_	_	I-Premise
213	either	_	_	I-Premise
214	cataract	_	_	I-Premise
215	extraction	_	_	I-Premise
216	or	_	_	I-Premise
217	further	_	_	I-Premise
218	IOP-lowering	_	_	I-Premise
219	surgical	_	_	I-Premise
220	procedures	_	_	I-Premise
221	(	_	_	I-Premise
222	p	_	_	I-Premise
223	<	_	_	I-Premise
224	0.001	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	In	_	_	B-Claim
228	patients	_	_	I-Claim
229	with	_	_	I-Claim
230	PACG	_	_	I-Claim
231	,	_	_	I-Claim
232	the	_	_	I-Claim
233	long-term	_	_	I-Claim
234	IOP-lowering	_	_	I-Claim
235	effect	_	_	I-Claim
236	and	_	_	I-Claim
237	surgical	_	_	I-Claim
238	complications	_	_	I-Claim
239	of	_	_	I-Claim
240	combined	_	_	I-Claim
241	trabeculectomy	_	_	I-Claim
242	and	_	_	I-Claim
243	cataract	_	_	I-Claim
244	extraction	_	_	I-Claim
245	are	_	_	I-Claim
246	comparable	_	_	I-Claim
247	with	_	_	I-Claim
248	those	_	_	I-Claim
249	of	_	_	I-Claim
250	trabeculectomy	_	_	I-Claim
251	alone	_	_	I-Claim
252	.	_	_	I-Claim

253	However	_	_	B-Claim
254	,	_	_	I-Claim
255	the	_	_	I-Claim
256	combined	_	_	I-Claim
257	surgery	_	_	I-Claim
258	incurred	_	_	I-Claim
259	fewer	_	_	I-Claim
260	subsequent	_	_	I-Claim
261	surgical	_	_	I-Claim
262	interventions	_	_	I-Claim
263	.	_	_	I-Claim


0	Studies	_	_	O
1	on	_	_	O
2	quality	_	_	O
3	of	_	_	O
4	life	_	_	O
5	(	_	_	O
6	QOL	_	_	O
7	)	_	_	O
8	among	_	_	O
9	women	_	_	O
10	with	_	_	O
11	endometrial	_	_	O
12	cancer	_	_	O
13	have	_	_	O
14	shown	_	_	O
15	that	_	_	O
16	patients	_	_	O
17	who	_	_	O
18	undergo	_	_	O
19	pelvic	_	_	O
20	radiotherapy	_	_	O
21	report	_	_	O
22	lower	_	_	O
23	role	_	_	O
24	functioning	_	_	O
25	and	_	_	O
26	more	_	_	O
27	diarrhea	_	_	O
28	and	_	_	O
29	fatigue	_	_	O
30	.	_	_	O

31	In	_	_	O
32	the	_	_	O
33	Post	_	_	O
34	Operative	_	_	O
35	Radiation	_	_	O
36	Therapy	_	_	O
37	in	_	_	O
38	Endometrial	_	_	O
39	Cancer	_	_	O
40	(	_	_	O
41	PORTEC	_	_	O
42	)	_	_	O
43	trial	_	_	O
44	,	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	endometrial	_	_	O
48	carcinoma	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	external-beam	_	_	O
55	radiotherapy	_	_	O
56	(	_	_	O
57	EBRT	_	_	O
58	)	_	_	O
59	or	_	_	O
60	vaginal	_	_	O
61	brachytherapy	_	_	O
62	(	_	_	O
63	VBT	_	_	O
64	)	_	_	O
65	.	_	_	O

66	QOL	_	_	O
67	was	_	_	O
68	evaluated	_	_	O
69	by	_	_	O
70	using	_	_	O
71	the	_	_	O
72	European	_	_	O
73	Organisation	_	_	O
74	for	_	_	O
75	Research	_	_	O
76	and	_	_	O
77	Treatment	_	_	O
78	of	_	_	O
79	Cancer	_	_	O
80	Quality	_	_	O
81	of	_	_	O
82	Life	_	_	O
83	Questionnaire	_	_	O
84	C30	_	_	O
85	and	_	_	O
86	subscales	_	_	O
87	from	_	_	O
88	the	_	_	O
89	prostate	_	_	O
90	cancer	_	_	O
91	module	_	_	O
92	,	_	_	O
93	PR-25	_	_	O
94	,	_	_	O
95	and	_	_	O
96	the	_	_	O
97	ovarian	_	_	O
98	cancer	_	_	O
99	module	_	_	O
100	,	_	_	O
101	OV-28	_	_	O
102	.	_	_	O

103	PORTEC-2	_	_	O
104	accrued	_	_	O
105	427	_	_	O
106	patients	_	_	O
107	between	_	_	O
108	2002	_	_	O
109	and	_	_	O
110	2006	_	_	O
111	,	_	_	O
112	of	_	_	O
113	whom	_	_	O
114	214	_	_	O
115	were	_	_	O
116	randomly	_	_	O
117	assigned	_	_	O
118	to	_	_	O
119	EBRT	_	_	O
120	,	_	_	O
121	and	_	_	O
122	213	_	_	O
123	were	_	_	O
124	randomly	_	_	O
125	assigned	_	_	O
126	to	_	_	O
127	VBT	_	_	O
128	.	_	_	O

129	Three-hundred	_	_	O
130	forty-eight	_	_	O
131	patients	_	_	O
132	(	_	_	O
133	81	_	_	O
134	%	_	_	O
135	)	_	_	O
136	were	_	_	O
137	evaluable	_	_	O
138	for	_	_	O
139	QOL	_	_	O
140	.	_	_	O

141	QOL	_	_	O
142	outcomes	_	_	O
143	were	_	_	O
144	analyzed	_	_	O
145	at	_	_	O
146	a	_	_	O
147	median	_	_	O
148	follow-up	_	_	O
149	of	_	_	O
150	2	_	_	O
151	years	_	_	O
152	.	_	_	O

153	At	_	_	O
154	baseline	_	_	O
155	after	_	_	O
156	surgery	_	_	O
157	,	_	_	O
158	patient	_	_	O
159	functioning	_	_	O
160	was	_	_	O
161	at	_	_	O
162	the	_	_	O
163	lowest	_	_	O
164	level	_	_	O
165	,	_	_	O
166	and	_	_	O
167	it	_	_	O
168	increased	_	_	O
169	during	_	_	O
170	and	_	_	O
171	after	_	_	O
172	radiotherapy	_	_	O
173	to	_	_	O
174	reach	_	_	O
175	a	_	_	O
176	plateau	_	_	O
177	after	_	_	O
178	12	_	_	O
179	months	_	_	O
180	.	_	_	O

181	Patients	_	_	B-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	VBT	_	_	I-Premise
185	group	_	_	I-Premise
186	reported	_	_	I-Premise
187	better	_	_	I-Premise
188	social	_	_	I-Premise
189	functioning	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	<	_	_	I-Premise
193	.002	_	_	I-Premise
194	)	_	_	I-Premise
195	and	_	_	I-Premise
196	lower	_	_	I-Premise
197	symptom	_	_	I-Premise
198	scores	_	_	I-Premise
199	for	_	_	I-Premise
200	diarrhea	_	_	I-Premise
201	,	_	_	I-Premise
202	fecal	_	_	I-Premise
203	leakage	_	_	I-Premise
204	,	_	_	I-Premise
205	the	_	_	I-Premise
206	need	_	_	I-Premise
207	to	_	_	I-Premise
208	stay	_	_	I-Premise
209	close	_	_	I-Premise
210	to	_	_	I-Premise
211	the	_	_	I-Premise
212	toilet	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	limitation	_	_	I-Premise
216	in	_	_	I-Premise
217	daily	_	_	I-Premise
218	activities	_	_	I-Premise
219	because	_	_	I-Premise
220	of	_	_	I-Premise
221	bowel	_	_	I-Premise
222	symptoms	_	_	I-Premise
223	(	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	.001	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	At	_	_	O
230	baseline	_	_	O
231	,	_	_	O
232	15	_	_	O
233	%	_	_	O
234	of	_	_	O
235	patients	_	_	O
236	were	_	_	O
237	sexually	_	_	O
238	active	_	_	O
239	;	_	_	O
240	this	_	_	O
241	increased	_	_	O
242	significantly	_	_	O
243	to	_	_	O
244	39	_	_	O
245	%	_	_	O
246	during	_	_	O
247	the	_	_	O
248	first	_	_	O
249	year	_	_	O
250	(	_	_	O
251	P	_	_	O
252	<	_	_	O
253	.001	_	_	O
254	)	_	_	O
255	.	_	_	O

256	Sexual	_	_	B-Premise
257	functioning	_	_	I-Premise
258	and	_	_	I-Premise
259	symptoms	_	_	I-Premise
260	did	_	_	I-Premise
261	not	_	_	I-Premise
262	differ	_	_	I-Premise
263	between	_	_	I-Premise
264	the	_	_	I-Premise
265	treatment	_	_	I-Premise
266	groups	_	_	I-Premise
267	.	_	_	I-Premise

268	Patients	_	_	B-Premise
269	who	_	_	I-Premise
270	received	_	_	I-Premise
271	EBRT	_	_	I-Premise
272	reported	_	_	I-Premise
273	significantly	_	_	I-Premise
274	higher	_	_	I-Premise
275	levels	_	_	I-Premise
276	of	_	_	I-Premise
277	diarrhea	_	_	I-Premise
278	and	_	_	I-Premise
279	bowel	_	_	I-Premise
280	symptoms	_	_	I-Premise
281	.	_	_	I-Premise

282	This	_	_	O
283	resulted	_	_	O
284	in	_	_	O
285	a	_	_	O
286	higher	_	_	O
287	need	_	_	O
288	to	_	_	O
289	remain	_	_	O
290	close	_	_	O
291	to	_	_	O
292	a	_	_	O
293	toilet	_	_	O
294	and	_	_	O
295	,	_	_	O
296	as	_	_	O
297	a	_	_	O
298	consequence	_	_	O
299	,	_	_	O
300	more	_	_	O
301	limitation	_	_	O
302	of	_	_	O
303	daily	_	_	O
304	activities	_	_	O
305	because	_	_	O
306	of	_	_	O
307	bowel	_	_	O
308	symptoms	_	_	O
309	and	_	_	O
310	decreased	_	_	O
311	social	_	_	O
312	functioning	_	_	O
313	.	_	_	O

314	Vaginal	_	_	B-Claim
315	brachytherapy	_	_	I-Claim
316	provides	_	_	I-Claim
317	a	_	_	I-Claim
318	better	_	_	I-Claim
319	QOL	_	_	I-Claim
320	,	_	_	I-Claim
321	and	_	_	I-Claim
322	should	_	_	I-Claim
323	be	_	_	I-Claim
324	the	_	_	I-Claim
325	preferred	_	_	I-Claim
326	treatment	_	_	I-Claim
327	from	_	_	I-Claim
328	a	_	_	I-Claim
329	QOL	_	_	I-Claim
330	perspective	_	_	I-Claim
331	.	_	_	I-Claim


0	Transthoracic	_	_	O
1	and	_	_	O
2	transhiatal	_	_	O
3	esophagectomy	_	_	O
4	are	_	_	O
5	two	_	_	O
6	common	_	_	O
7	procedures	_	_	O
8	for	_	_	O
9	esophageal	_	_	O
10	cancer	_	_	O
11	resection	_	_	O
12	.	_	_	O

13	Prospective	_	_	O
14	studies	_	_	O
15	comparing	_	_	O
16	the	_	_	O
17	two	_	_	O
18	methods	_	_	O
19	in	_	_	O
20	Asian	_	_	O
21	people	_	_	O
22	are	_	_	O
23	few	_	_	O
24	.	_	_	O

25	In	_	_	O
26	addition	_	_	O
27	,	_	_	O
28	the	_	_	O
29	data	_	_	O
30	comparing	_	_	O
31	their	_	_	O
32	effects	_	_	O
33	on	_	_	O
34	the	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	are	_	_	O
39	lacking	_	_	O
40	.	_	_	O

41	A	_	_	O
42	prospective	_	_	O
43	randomized	_	_	O
44	study	_	_	O
45	was	_	_	O
46	conducted	_	_	O
47	from	_	_	O
48	January	_	_	O
49	2003	_	_	O
50	.	_	_	O

51	Patients	_	_	O
52	of	_	_	O
53	resectable	_	_	O
54	esophageal	_	_	O
55	cancer	_	_	O
56	of	_	_	O
57	comparable	_	_	O
58	stage	_	_	O
59	were	_	_	O
60	allocated	_	_	O
61	to	_	_	O
62	undergo	_	_	O
63	the	_	_	O
64	transthoracic	_	_	O
65	or	_	_	O
66	transhiatal	_	_	O
67	procedure	_	_	O
68	in	_	_	O
69	turn	_	_	O
70	.	_	_	O

71	They	_	_	O
72	were	_	_	O
73	all	_	_	O
74	reconstructed	_	_	O
75	with	_	_	O
76	stomach	_	_	O
77	interposition	_	_	O
78	through	_	_	O
79	the	_	_	O
80	retrosternal	_	_	O
81	route	_	_	O
82	.	_	_	O

83	Discharged	_	_	O
84	patients	_	_	O
85	were	_	_	O
86	followed-up	_	_	O
87	in	_	_	O
88	the	_	_	O
89	outpatient	_	_	O
90	clinic	_	_	O
91	.	_	_	O

92	They	_	_	O
93	were	_	_	O
94	questioned	_	_	O
95	on	_	_	O
96	the	_	_	O
97	topics	_	_	O
98	of	_	_	O
99	(	_	_	O
100	i	_	_	O
101	)	_	_	O
102	severity	_	_	O
103	of	_	_	O
104	pain	_	_	O
105	,	_	_	O
106	(	_	_	O
107	ii	_	_	O
108	)	_	_	O
109	ease	_	_	O
110	of	_	_	O
111	swallowing	_	_	O
112	,	_	_	O
113	(	_	_	O
114	iii	_	_	O
115	)	_	_	O
116	satisfaction	_	_	O
117	of	_	_	O
118	daily	_	_	O
119	activities	_	_	O
120	,	_	_	O
121	(	_	_	O
122	iv	_	_	O
123	)	_	_	O
124	dependence	_	_	O
125	on	_	_	O
126	medications	_	_	O
127	,	_	_	O
128	(	_	_	O
129	v	_	_	O
130	)	_	_	O
131	working	_	_	O
132	ability	_	_	O
133	,	_	_	O
134	(	_	_	O
135	vi	_	_	O
136	)	_	_	O
137	fatigue	_	_	O
138	,	_	_	O
139	(	_	_	O
140	vii	_	_	O
141	)	_	_	O
142	appetite	_	_	O
143	,	_	_	O
144	(	_	_	O
145	viii	_	_	O
146	)	_	_	O
147	sociality	_	_	O
148	,	_	_	O
149	(	_	_	O
150	ix	_	_	O
151	)	_	_	O
152	happiness	_	_	O
153	and	_	_	O
154	(	_	_	O
155	x	_	_	O
156	)	_	_	O
157	self	_	_	O
158	respect	_	_	O
159	,	_	_	O
160	in	_	_	O
161	the	_	_	O
162	third	_	_	O
163	,	_	_	O
164	sixth	_	_	O
165	and	_	_	O
166	twelfth	_	_	O
167	month	_	_	O
168	.	_	_	O

169	Also	_	_	O
170	the	_	_	O
171	demographic	_	_	O
172	data	_	_	O
173	,	_	_	O
174	operative	_	_	O
175	results	_	_	O
176	and	_	_	O
177	survival	_	_	O
178	were	_	_	O
179	recorded	_	_	O
180	.	_	_	O

181	Up	_	_	O
182	to	_	_	O
183	December	_	_	O
184	2006	_	_	O
185	,	_	_	O
186	eighty-seven	_	_	O
187	patients	_	_	O
188	of	_	_	O
189	stage	_	_	O
190	II	_	_	O
191	and	_	_	O
192	III	_	_	O
193	,	_	_	O
194	including	_	_	O
195	71	_	_	O
196	patients	_	_	O
197	of	_	_	O
198	middle	_	_	O
199	third	_	_	O
200	lesions	_	_	O
201	and	_	_	O
202	16	_	_	O
203	lower	_	_	O
204	third	_	_	O
205	lesions	_	_	O
206	were	_	_	O
207	enrolled	_	_	O
208	.	_	_	O

209	The	_	_	B-Premise
210	operation	_	_	I-Premise
211	time	_	_	I-Premise
212	was	_	_	I-Premise
213	significantly	_	_	I-Premise
214	longer	_	_	I-Premise
215	,	_	_	I-Premise
216	and	_	_	I-Premise
217	the	_	_	I-Premise
218	leakage	_	_	I-Premise
219	rate	_	_	I-Premise
220	was	_	_	I-Premise
221	higher	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	transthoracic	_	_	I-Premise
225	group	_	_	I-Premise
226	(	_	_	I-Premise
227	Student	_	_	I-Premise
228	's	_	_	I-Premise
229	t-test	_	_	I-Premise
230	and	_	_	I-Premise
231	Fischer	_	_	I-Premise
232	's	_	_	I-Premise
233	exact	_	_	I-Premise
234	test	_	_	I-Premise
235	,	_	_	I-Premise
236	respectively	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	However	_	_	O
240	,	_	_	O
241	intraoperative	_	_	B-Premise
242	blood	_	_	I-Premise
243	loss	_	_	I-Premise
244	and	_	_	I-Premise
245	postoperative	_	_	I-Premise
246	hospital	_	_	I-Premise
247	stay	_	_	I-Premise
248	were	_	_	I-Premise
249	not	_	_	I-Premise
250	significantly	_	_	I-Premise
251	different	_	_	I-Premise
252	(	_	_	I-Premise
253	Student	_	_	I-Premise
254	t-test	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Also	_	_	O
258	,	_	_	O
259	the	_	_	B-Premise
260	Kaplan-Meier	_	_	I-Premise
261	survival	_	_	I-Premise
262	curves	_	_	I-Premise
263	of	_	_	I-Premise
264	these	_	_	I-Premise
265	two	_	_	I-Premise
266	groups	_	_	I-Premise
267	were	_	_	I-Premise
268	not	_	_	I-Premise
269	significantly	_	_	I-Premise
270	different	_	_	I-Premise
271	by	_	_	I-Premise
272	log-rank	_	_	I-Premise
273	test	_	_	I-Premise
274	(	_	_	I-Premise
275	p=0.286	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	The	_	_	B-Premise
279	score	_	_	I-Premise
280	on	_	_	I-Premise
281	the	_	_	I-Premise
282	quality	_	_	I-Premise
283	of	_	_	I-Premise
284	life	_	_	I-Premise
285	of	_	_	I-Premise
286	transhiatal	_	_	I-Premise
287	patients	_	_	I-Premise
288	was	_	_	I-Premise
289	significantly	_	_	I-Premise
290	higher	_	_	I-Premise
291	than	_	_	I-Premise
292	that	_	_	I-Premise
293	of	_	_	I-Premise
294	transthoracic	_	_	I-Premise
295	patients	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	third	_	_	I-Premise
299	,	_	_	I-Premise
300	sixth	_	_	I-Premise
301	and	_	_	I-Premise
302	twelfth	_	_	I-Premise
303	month	_	_	I-Premise
304	.	_	_	I-Premise

305	Transhiatal	_	_	B-Claim
306	esophagectomy	_	_	I-Claim
307	is	_	_	I-Claim
308	a	_	_	I-Claim
309	safe	_	_	I-Claim
310	and	_	_	I-Claim
311	fast	_	_	I-Claim
312	procedure	_	_	I-Claim
313	.	_	_	I-Claim

314	The	_	_	B-Claim
315	survival	_	_	I-Claim
316	was	_	_	I-Claim
317	similar	_	_	I-Claim
318	to	_	_	I-Claim
319	that	_	_	I-Claim
320	of	_	_	I-Claim
321	transthoracic	_	_	I-Claim
322	approach	_	_	I-Claim
323	.	_	_	I-Claim

324	Its	_	_	B-Claim
325	leakage	_	_	I-Claim
326	rate	_	_	I-Claim
327	was	_	_	I-Claim
328	lower	_	_	I-Claim
329	and	_	_	I-Claim
330	quality	_	_	I-Claim
331	of	_	_	I-Claim
332	life	_	_	I-Claim
333	was	_	_	I-Claim
334	better	_	_	I-Claim
335	.	_	_	I-Claim


0	Lymphoma	_	_	O
1	patients	_	_	O
2	commonly	_	_	O
3	experience	_	_	O
4	declines	_	_	O
5	in	_	_	O
6	physical	_	_	O
7	functioning	_	_	O
8	and	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QoL	_	_	O
14	)	_	_	O
15	that	_	_	O
16	may	_	_	O
17	be	_	_	O
18	reversed	_	_	O
19	with	_	_	O
20	exercise	_	_	O
21	training	_	_	O
22	.	_	_	O

23	We	_	_	O
24	conducted	_	_	O
25	a	_	_	O
26	randomized	_	_	O
27	controlled	_	_	O
28	trial	_	_	O
29	in	_	_	O
30	Edmonton	_	_	O
31	,	_	_	O
32	Alberta	_	_	O
33	,	_	_	O
34	Canada	_	_	O
35	,	_	_	O
36	between	_	_	O
37	2005	_	_	O
38	and	_	_	O
39	2008	_	_	O
40	that	_	_	O
41	stratified	_	_	O
42	122	_	_	O
43	lymphoma	_	_	O
44	patients	_	_	O
45	by	_	_	O
46	major	_	_	O
47	disease	_	_	O
48	type	_	_	O
49	and	_	_	O
50	current	_	_	O
51	treatment	_	_	O
52	status	_	_	O
53	and	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	them	_	_	O
57	to	_	_	O
58	usual	_	_	O
59	care	_	_	O
60	(	_	_	O
61	UC	_	_	O
62	;	_	_	O
63	n	_	_	O
64	=	_	_	O
65	62	_	_	O
66	)	_	_	O
67	or	_	_	O
68	12	_	_	O
69	weeks	_	_	O
70	of	_	_	O
71	supervised	_	_	O
72	aerobic	_	_	O
73	exercise	_	_	O
74	training	_	_	O
75	(	_	_	O
76	AET	_	_	O
77	;	_	_	O
78	n	_	_	O
79	=	_	_	O
80	60	_	_	O
81	)	_	_	O
82	.	_	_	O

83	Our	_	_	O
84	primary	_	_	O
85	end	_	_	O
86	point	_	_	O
87	was	_	_	O
88	patient-rated	_	_	O
89	physical	_	_	O
90	functioning	_	_	O
91	assessed	_	_	O
92	by	_	_	O
93	the	_	_	O
94	Trial	_	_	O
95	Outcome	_	_	O
96	Index-Anemia	_	_	O
97	.	_	_	O

98	Secondary	_	_	O
99	end	_	_	O
100	points	_	_	O
101	were	_	_	O
102	overall	_	_	O
103	QoL	_	_	O
104	,	_	_	O
105	psychosocial	_	_	O
106	functioning	_	_	O
107	,	_	_	O
108	cardiovascular	_	_	O
109	fitness	_	_	O
110	,	_	_	O
111	and	_	_	O
112	body	_	_	O
113	composition	_	_	O
114	.	_	_	O

115	Follow-up	_	_	O
116	assessment	_	_	O
117	for	_	_	O
118	our	_	_	O
119	primary	_	_	O
120	end	_	_	O
121	point	_	_	O
122	was	_	_	O
123	96	_	_	O
124	%	_	_	O
125	(	_	_	O
126	117	_	_	O
127	of	_	_	O
128	122	_	_	O
129	)	_	_	O
130	at	_	_	O
131	postintervention	_	_	O
132	and	_	_	O
133	90	_	_	O
134	%	_	_	O
135	(	_	_	O
136	110	_	_	O
137	of	_	_	O
138	122	_	_	O
139	)	_	_	O
140	at	_	_	O
141	6-month	_	_	O
142	follow-up	_	_	O
143	.	_	_	O

144	Median	_	_	O
145	adherence	_	_	O
146	to	_	_	O
147	the	_	_	O
148	supervised	_	_	O
149	exercise	_	_	O
150	program	_	_	O
151	was	_	_	O
152	92	_	_	O
153	%	_	_	O
154	.	_	_	O

155	At	_	_	B-Premise
156	postintervention	_	_	I-Premise
157	,	_	_	I-Premise
158	AET	_	_	I-Premise
159	was	_	_	I-Premise
160	superior	_	_	I-Premise
161	to	_	_	I-Premise
162	UC	_	_	I-Premise
163	for	_	_	I-Premise
164	patient-rated	_	_	I-Premise
165	physical	_	_	I-Premise
166	functioning	_	_	I-Premise
167	(	_	_	I-Premise
168	mean	_	_	I-Premise
169	group	_	_	I-Premise
170	difference	_	_	I-Premise
171	,	_	_	I-Premise
172	+9.0	_	_	I-Premise
173	;	_	_	I-Premise
174	95	_	_	I-Premise
175	%	_	_	I-Premise
176	CI	_	_	I-Premise
177	,	_	_	I-Premise
178	2.0	_	_	I-Premise
179	to	_	_	I-Premise
180	16.0	_	_	I-Premise
181	;	_	_	I-Premise
182	P	_	_	I-Premise
183	=	_	_	I-Premise
184	.012	_	_	I-Premise
185	)	_	_	I-Premise
186	,	_	_	I-Premise
187	overall	_	_	I-Premise
188	QoL	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	=	_	_	I-Premise
192	.021	_	_	I-Premise
193	)	_	_	I-Premise
194	,	_	_	I-Premise
195	fatigue	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.013	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	happiness	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	.004	_	_	I-Premise
207	)	_	_	I-Premise
208	,	_	_	I-Premise
209	depression	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	.005	_	_	I-Premise
214	)	_	_	I-Premise
215	,	_	_	I-Premise
216	general	_	_	I-Premise
217	health	_	_	I-Premise
218	(	_	_	I-Premise
219	P	_	_	I-Premise
220	<	_	_	I-Premise
221	.001	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	cardiovascular	_	_	I-Premise
225	fitness	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	.001	_	_	I-Premise
230	)	_	_	I-Premise
231	,	_	_	I-Premise
232	and	_	_	I-Premise
233	lean	_	_	I-Premise
234	body	_	_	I-Premise
235	mass	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	=	_	_	I-Premise
239	.008	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Change	_	_	O
243	in	_	_	O
244	peak	_	_	O
245	cardiovascular	_	_	O
246	fitness	_	_	O
247	mediated	_	_	O
248	the	_	_	O
249	change	_	_	O
250	in	_	_	O
251	patient-rated	_	_	O
252	physical	_	_	O
253	functioning	_	_	O
254	.	_	_	O

255	AET	_	_	B-Premise
256	did	_	_	I-Premise
257	not	_	_	I-Premise
258	interfere	_	_	I-Premise
259	with	_	_	I-Premise
260	chemotherapy	_	_	I-Premise
261	completion	_	_	I-Premise
262	rate	_	_	I-Premise
263	or	_	_	I-Premise
264	treatment	_	_	I-Premise
265	response	_	_	I-Premise
266	.	_	_	I-Premise

267	At	_	_	B-Premise
268	6-month	_	_	I-Premise
269	follow-up	_	_	I-Premise
270	,	_	_	I-Premise
271	AET	_	_	I-Premise
272	was	_	_	I-Premise
273	still	_	_	I-Premise
274	borderline	_	_	I-Premise
275	or	_	_	I-Premise
276	significantly	_	_	I-Premise
277	superior	_	_	I-Premise
278	to	_	_	I-Premise
279	UC	_	_	I-Premise
280	for	_	_	I-Premise
281	overall	_	_	I-Premise
282	QoL	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	.054	_	_	I-Premise
287	)	_	_	I-Premise
288	,	_	_	I-Premise
289	happiness	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	.034	_	_	I-Premise
294	)	_	_	I-Premise
295	,	_	_	I-Premise
296	and	_	_	I-Premise
297	depression	_	_	I-Premise
298	(	_	_	I-Premise
299	P	_	_	I-Premise
300	=	_	_	I-Premise
301	.009	_	_	I-Premise
302	)	_	_	I-Premise
303	without	_	_	I-Premise
304	an	_	_	I-Premise
305	increased	_	_	I-Premise
306	risk	_	_	I-Premise
307	of	_	_	I-Premise
308	disease	_	_	I-Premise
309	recurrence/progression	_	_	I-Premise
310	.	_	_	I-Premise

311	AET	_	_	B-Claim
312	significantly	_	_	I-Claim
313	improved	_	_	I-Claim
314	important	_	_	I-Claim
315	patient-rated	_	_	I-Claim
316	outcomes	_	_	I-Claim
317	and	_	_	I-Claim
318	objective	_	_	I-Claim
319	physical	_	_	I-Claim
320	functioning	_	_	I-Claim
321	in	_	_	I-Claim
322	lymphoma	_	_	I-Claim
323	patients	_	_	I-Claim
324	without	_	_	I-Claim
325	interfering	_	_	I-Claim
326	with	_	_	I-Claim
327	medical	_	_	I-Claim
328	treatments	_	_	I-Claim
329	or	_	_	I-Claim
330	response	_	_	I-Claim
331	.	_	_	I-Claim

332	Exercise	_	_	B-Claim
333	training	_	_	I-Claim
334	to	_	_	I-Claim
335	improve	_	_	I-Claim
336	cardiovascular	_	_	I-Claim
337	fitness	_	_	I-Claim
338	should	_	_	I-Claim
339	be	_	_	I-Claim
340	considered	_	_	I-Claim
341	in	_	_	I-Claim
342	the	_	_	I-Claim
343	management	_	_	I-Claim
344	of	_	_	I-Claim
345	lymphoma	_	_	I-Claim
346	patients	_	_	I-Claim
347	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	a	_	_	O
6	multimodal	_	_	O
7	group	_	_	O
8	exercise	_	_	O
9	intervention	_	_	O
10	,	_	_	O
11	as	_	_	O
12	an	_	_	O
13	adjunct	_	_	O
14	to	_	_	O
15	conventional	_	_	O
16	care	_	_	O
17	,	_	_	O
18	on	_	_	O
19	fatigue	_	_	O
20	,	_	_	O
21	physical	_	_	O
22	capacity	_	_	O
23	,	_	_	O
24	general	_	_	O
25	wellbeing	_	_	O
26	,	_	_	O
27	physical	_	_	O
28	activity	_	_	O
29	,	_	_	O
30	and	_	_	O
31	quality	_	_	O
32	of	_	_	O
33	life	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	cancer	_	_	O
38	who	_	_	O
39	were	_	_	O
40	undergoing	_	_	O
41	adjuvant	_	_	O
42	chemotherapy	_	_	O
43	or	_	_	O
44	treatment	_	_	O
45	for	_	_	O
46	advanced	_	_	O
47	disease	_	_	O
48	.	_	_	O

49	Randomised	_	_	O
50	controlled	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	Two	_	_	O
54	university	_	_	O
55	hospitals	_	_	O
56	in	_	_	O
57	Copenhagen	_	_	O
58	,	_	_	O
59	Denmark	_	_	O
60	.	_	_	O

61	269	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	cancer	_	_	O
65	;	_	_	O
66	73	_	_	O
67	men	_	_	O
68	,	_	_	O
69	196	_	_	O
70	women	_	_	O
71	,	_	_	O
72	mean	_	_	O
73	age	_	_	O
74	47	_	_	O
75	years	_	_	O
76	(	_	_	O
77	range	_	_	O
78	20-65	_	_	O
79	)	_	_	O
80	representing	_	_	O
81	21	_	_	O
82	diagnoses	_	_	O
83	.	_	_	O

84	Main	_	_	O
85	exclusion	_	_	O
86	criteria	_	_	O
87	were	_	_	O
88	brain	_	_	O
89	or	_	_	O
90	bone	_	_	O
91	metastases	_	_	O
92	.	_	_	O

93	235	_	_	O
94	patients	_	_	O
95	completed	_	_	O
96	follow-up	_	_	O
97	.	_	_	O

98	Supervised	_	_	O
99	exercise	_	_	O
100	comprising	_	_	O
101	high	_	_	O
102	intensity	_	_	O
103	cardiovascular	_	_	O
104	and	_	_	O
105	resistance	_	_	O
106	training	_	_	O
107	,	_	_	O
108	relaxation	_	_	O
109	and	_	_	O
110	body	_	_	O
111	awareness	_	_	O
112	training	_	_	O
113	,	_	_	O
114	massage	_	_	O
115	,	_	_	O
116	nine	_	_	O
117	hours	_	_	O
118	weekly	_	_	O
119	for	_	_	O
120	six	_	_	O
121	weeks	_	_	O
122	in	_	_	O
123	addition	_	_	O
124	to	_	_	O
125	conventional	_	_	O
126	care	_	_	O
127	,	_	_	O
128	compared	_	_	O
129	with	_	_	O
130	conventional	_	_	O
131	care	_	_	O
132	.	_	_	O

133	The	_	_	O
134	general	_	_	O
135	linear	_	_	O
136	model	_	_	O
137	was	_	_	O
138	used	_	_	O
139	for	_	_	O
140	continuous	_	_	O
141	outcome	_	_	O
142	while	_	_	O
143	analysis	_	_	O
144	of	_	_	O
145	associates	_	_	O
146	between	_	_	O
147	categorical	_	_	O
148	outcomes	_	_	O
149	was	_	_	O
150	performed	_	_	O
151	as	_	_	O
152	analysis	_	_	O
153	of	_	_	O
154	marginal	_	_	O
155	homogeneity	_	_	O
156	in	_	_	O
157	contingency	_	_	O
158	tables	_	_	O
159	.	_	_	O

160	Adjusted	_	_	B-Premise
161	for	_	_	I-Premise
162	baseline	_	_	I-Premise
163	score	_	_	I-Premise
164	,	_	_	I-Premise
165	disease	_	_	I-Premise
166	,	_	_	I-Premise
167	and	_	_	I-Premise
168	demographic	_	_	I-Premise
169	covariates	_	_	I-Premise
170	,	_	_	I-Premise
171	the	_	_	I-Premise
172	intervention	_	_	I-Premise
173	group	_	_	I-Premise
174	showed	_	_	I-Premise
175	an	_	_	I-Premise
176	estimated	_	_	I-Premise
177	improvement	_	_	I-Premise
178	at	_	_	I-Premise
179	six	_	_	I-Premise
180	weeks	_	_	I-Premise
181	for	_	_	I-Premise
182	the	_	_	I-Premise
183	primary	_	_	I-Premise
184	outcome	_	_	I-Premise
185	,	_	_	I-Premise
186	fatigue	_	_	I-Premise
187	,	_	_	I-Premise
188	of	_	_	I-Premise
189	-6.6	_	_	I-Premise
190	points	_	_	I-Premise
191	(	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	confidence	_	_	I-Premise
195	interval	_	_	I-Premise
196	-12.3	_	_	I-Premise
197	to	_	_	I-Premise
198	-0.9	_	_	I-Premise
199	,	_	_	I-Premise
200	P=0.02	_	_	I-Premise
201	;	_	_	I-Premise
202	effect	_	_	I-Premise
203	size=0.33	_	_	I-Premise
204	,	_	_	I-Premise
205	0.04	_	_	I-Premise
206	to	_	_	I-Premise
207	0.61	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	Significant	_	_	B-Premise
211	effects	_	_	I-Premise
212	were	_	_	I-Premise
213	seen	_	_	I-Premise
214	on	_	_	I-Premise
215	vitality	_	_	I-Premise
216	(	_	_	I-Premise
217	effect	_	_	I-Premise
218	size	_	_	I-Premise
219	0.55	_	_	I-Premise
220	,	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	CI	_	_	I-Premise
224	0.27	_	_	I-Premise
225	to	_	_	I-Premise
226	0.82	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	physical	_	_	I-Premise
230	functioning	_	_	I-Premise
231	(	_	_	I-Premise
232	0.37	_	_	I-Premise
233	,	_	_	I-Premise
234	0.09	_	_	I-Premise
235	to	_	_	I-Premise
236	0.65	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	role	_	_	I-Premise
240	physical	_	_	I-Premise
241	(	_	_	I-Premise
242	0.37	_	_	I-Premise
243	,	_	_	I-Premise
244	0.10	_	_	I-Premise
245	to	_	_	I-Premise
246	0.64	_	_	I-Premise
247	)	_	_	I-Premise
248	,	_	_	I-Premise
249	role	_	_	I-Premise
250	emotional	_	_	I-Premise
251	(	_	_	I-Premise
252	0.32	_	_	I-Premise
253	,	_	_	I-Premise
254	0.05	_	_	I-Premise
255	to	_	_	I-Premise
256	0.59	_	_	I-Premise
257	)	_	_	I-Premise
258	,	_	_	I-Premise
259	and	_	_	I-Premise
260	mental	_	_	I-Premise
261	health	_	_	I-Premise
262	(	_	_	I-Premise
263	0.28	_	_	I-Premise
264	,	_	_	I-Premise
265	0.02	_	_	I-Premise
266	to	_	_	I-Premise
267	0.56	_	_	I-Premise
268	)	_	_	I-Premise
269	scores	_	_	I-Premise
270	.	_	_	I-Premise

271	Improvement	_	_	B-Premise
272	was	_	_	I-Premise
273	noted	_	_	I-Premise
274	in	_	_	I-Premise
275	physical	_	_	I-Premise
276	capacity	_	_	I-Premise
277	:	_	_	I-Premise
278	estimated	_	_	I-Premise
279	mean	_	_	I-Premise
280	difference	_	_	I-Premise
281	between	_	_	I-Premise
282	groups	_	_	I-Premise
283	for	_	_	I-Premise
284	maximum	_	_	I-Premise
285	oxygen	_	_	I-Premise
286	consumption	_	_	I-Premise
287	was	_	_	I-Premise
288	0.16	_	_	I-Premise
289	l/min	_	_	I-Premise
290	(	_	_	I-Premise
291	95	_	_	I-Premise
292	%	_	_	I-Premise
293	CI	_	_	I-Premise
294	0.1	_	_	I-Premise
295	to	_	_	I-Premise
296	0.2	_	_	I-Premise
297	,	_	_	I-Premise
298	P	_	_	I-Premise
299	<	_	_	I-Premise
300	0.0001	_	_	I-Premise
301	)	_	_	I-Premise
302	and	_	_	I-Premise
303	for	_	_	I-Premise
304	muscular	_	_	I-Premise
305	strength	_	_	I-Premise
306	(	_	_	I-Premise
307	leg	_	_	I-Premise
308	press	_	_	I-Premise
309	)	_	_	I-Premise
310	was	_	_	I-Premise
311	29.7	_	_	I-Premise
312	kg	_	_	I-Premise
313	(	_	_	I-Premise
314	23.4	_	_	I-Premise
315	to	_	_	I-Premise
316	34.9	_	_	I-Premise
317	,	_	_	I-Premise
318	P	_	_	I-Premise
319	<	_	_	I-Premise
320	0.0001	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	No	_	_	B-Premise
324	significant	_	_	I-Premise
325	effect	_	_	I-Premise
326	was	_	_	I-Premise
327	seen	_	_	I-Premise
328	on	_	_	I-Premise
329	global	_	_	I-Premise
330	health	_	_	I-Premise
331	status/quality	_	_	I-Premise
332	of	_	_	I-Premise
333	life	_	_	I-Premise
334	.	_	_	I-Premise

335	A	_	_	B-Claim
336	supervised	_	_	I-Claim
337	multimodal	_	_	I-Claim
338	exercise	_	_	I-Claim
339	intervention	_	_	I-Claim
340	including	_	_	I-Claim
341	high	_	_	I-Claim
342	and	_	_	I-Claim
343	low	_	_	I-Claim
344	intensity	_	_	I-Claim
345	components	_	_	I-Claim
346	was	_	_	I-Claim
347	feasible	_	_	I-Claim
348	and	_	_	I-Claim
349	could	_	_	I-Claim
350	safely	_	_	I-Claim
351	be	_	_	I-Claim
352	used	_	_	I-Claim
353	in	_	_	I-Claim
354	patients	_	_	I-Claim
355	with	_	_	I-Claim
356	various	_	_	I-Claim
357	cancers	_	_	I-Claim
358	who	_	_	I-Claim
359	were	_	_	I-Claim
360	receiving	_	_	I-Claim
361	adjuvant	_	_	I-Claim
362	chemotherapy	_	_	I-Claim
363	or	_	_	I-Claim
364	treatment	_	_	I-Claim
365	for	_	_	I-Claim
366	advanced	_	_	I-Claim
367	disease	_	_	I-Claim
368	.	_	_	I-Claim

369	The	_	_	B-Claim
370	intervention	_	_	I-Claim
371	reduced	_	_	I-Claim
372	fatigue	_	_	I-Claim
373	and	_	_	I-Claim
374	improved	_	_	I-Claim
375	vitality	_	_	I-Claim
376	,	_	_	I-Claim
377	aerobic	_	_	I-Claim
378	capacity	_	_	I-Claim
379	,	_	_	I-Claim
380	muscular	_	_	I-Claim
381	strength	_	_	I-Claim
382	,	_	_	I-Claim
383	and	_	_	I-Claim
384	physical	_	_	I-Claim
385	and	_	_	I-Claim
386	functional	_	_	I-Claim
387	activity	_	_	I-Claim
388	,	_	_	I-Claim
389	and	_	_	I-Claim
390	emotional	_	_	I-Claim
391	wellbeing	_	_	I-Claim
392	,	_	_	I-Claim
393	but	_	_	B-Claim
394	not	_	_	I-Claim
395	quality	_	_	I-Claim
396	of	_	_	I-Claim
397	life	_	_	I-Claim
398	.	_	_	I-Claim


0	Both	_	_	O
1	gemcitabine	_	_	O
2	(	_	_	O
3	GEM	_	_	O
4	)	_	_	O
5	and	_	_	O
6	fluoropyrimidines	_	_	O
7	are	_	_	O
8	valuable	_	_	O
9	treatment	_	_	O
10	for	_	_	O
11	advanced	_	_	O
12	pancreatic	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	This	_	_	O
16	open-label	_	_	O
17	study	_	_	O
18	was	_	_	O
19	designed	_	_	O
20	to	_	_	O
21	compare	_	_	O
22	the	_	_	O
23	overall	_	_	O
24	survival	_	_	O
25	(	_	_	O
26	OS	_	_	O
27	)	_	_	O
28	of	_	_	O
29	patients	_	_	O
30	randomly	_	_	O
31	assigned	_	_	O
32	to	_	_	O
33	GEM	_	_	O
34	alone	_	_	O
35	or	_	_	O
36	GEM	_	_	O
37	plus	_	_	O
38	capecitabine	_	_	O
39	(	_	_	O
40	GEM-CAP	_	_	O
41	)	_	_	O
42	.	_	_	O

43	Patients	_	_	O
44	with	_	_	O
45	previously	_	_	O
46	untreated	_	_	O
47	histologically	_	_	O
48	or	_	_	O
49	cytologically	_	_	O
50	proven	_	_	O
51	locally	_	_	O
52	advanced	_	_	O
53	or	_	_	O
54	metastatic	_	_	O
55	carcinoma	_	_	O
56	of	_	_	O
57	the	_	_	O
58	pancreas	_	_	O
59	with	_	_	O
60	a	_	_	O
61	performance	_	_	O
62	status	_	_	O
63	<	_	_	O
64	or=	_	_	O
65	2	_	_	O
66	were	_	_	O
67	recruited	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	GEM	_	_	O
75	or	_	_	O
76	GEM-CAP	_	_	O
77	.	_	_	O

78	The	_	_	O
79	primary	_	_	O
80	outcome	_	_	O
81	measure	_	_	O
82	was	_	_	O
83	survival	_	_	O
84	.	_	_	O

85	Meta-analysis	_	_	O
86	of	_	_	O
87	published	_	_	O
88	studies	_	_	O
89	was	_	_	O
90	also	_	_	O
91	conducted	_	_	O
92	.	_	_	O

93	Between	_	_	O
94	May	_	_	O
95	2002	_	_	O
96	and	_	_	O
97	January	_	_	O
98	2005	_	_	O
99	,	_	_	O
100	533	_	_	O
101	patients	_	_	O
102	were	_	_	O
103	randomly	_	_	O
104	assigned	_	_	O
105	to	_	_	O
106	GEM	_	_	O
107	(	_	_	O
108	n	_	_	O
109	=	_	_	O
110	266	_	_	O
111	)	_	_	O
112	and	_	_	O
113	GEM-CAP	_	_	O
114	(	_	_	O
115	n	_	_	O
116	=	_	_	O
117	267	_	_	O
118	)	_	_	O
119	arms	_	_	O
120	.	_	_	O

121	GEM-CAP	_	_	B-Premise
122	significantly	_	_	I-Premise
123	improved	_	_	I-Premise
124	objective	_	_	I-Premise
125	response	_	_	I-Premise
126	rate	_	_	I-Premise
127	(	_	_	I-Premise
128	19.1	_	_	I-Premise
129	%	_	_	I-Premise
130	v	_	_	I-Premise
131	12.4	_	_	I-Premise
132	%	_	_	I-Premise
133	;	_	_	I-Premise
134	P	_	_	I-Premise
135	=	_	_	I-Premise
136	.034	_	_	I-Premise
137	)	_	_	I-Premise
138	and	_	_	I-Premise
139	progression-free	_	_	I-Premise
140	survival	_	_	I-Premise
141	(	_	_	I-Premise
142	hazard	_	_	I-Premise
143	ratio	_	_	I-Premise
144	[	_	_	I-Premise
145	HR	_	_	I-Premise
146	]	_	_	I-Premise
147	,	_	_	I-Premise
148	0.78	_	_	I-Premise
149	;	_	_	I-Premise
150	95	_	_	I-Premise
151	%	_	_	I-Premise
152	CI	_	_	I-Premise
153	,	_	_	I-Premise
154	0.66	_	_	I-Premise
155	to	_	_	I-Premise
156	0.93	_	_	I-Premise
157	;	_	_	I-Premise
158	P	_	_	I-Premise
159	=	_	_	I-Premise
160	.004	_	_	I-Premise
161	)	_	_	I-Premise
162	and	_	_	I-Premise
163	was	_	_	I-Premise
164	associated	_	_	I-Premise
165	with	_	_	I-Premise
166	a	_	_	I-Premise
167	trend	_	_	I-Premise
168	toward	_	_	I-Premise
169	improved	_	_	I-Premise
170	OS	_	_	I-Premise
171	(	_	_	I-Premise
172	HR	_	_	I-Premise
173	,	_	_	I-Premise
174	0.86	_	_	I-Premise
175	;	_	_	I-Premise
176	95	_	_	I-Premise
177	%	_	_	I-Premise
178	CI	_	_	I-Premise
179	,	_	_	I-Premise
180	0.72	_	_	I-Premise
181	to	_	_	I-Premise
182	1.02	_	_	I-Premise
183	;	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.08	_	_	I-Premise
187	)	_	_	I-Premise
188	compared	_	_	I-Premise
189	with	_	_	I-Premise
190	GEM	_	_	I-Premise
191	alone	_	_	I-Premise
192	.	_	_	I-Premise

193	This	_	_	B-Premise
194	trend	_	_	I-Premise
195	for	_	_	I-Premise
196	OS	_	_	I-Premise
197	benefit	_	_	I-Premise
198	for	_	_	I-Premise
199	GEM-CAP	_	_	I-Premise
200	was	_	_	I-Premise
201	consistent	_	_	I-Premise
202	across	_	_	I-Premise
203	different	_	_	I-Premise
204	prognostic	_	_	I-Premise
205	subgroups	_	_	I-Premise
206	according	_	_	I-Premise
207	to	_	_	I-Premise
208	baseline	_	_	I-Premise
209	stratification	_	_	I-Premise
210	factors	_	_	I-Premise
211	(	_	_	I-Premise
212	stage	_	_	I-Premise
213	and	_	_	I-Premise
214	performance	_	_	I-Premise
215	status	_	_	I-Premise
216	)	_	_	I-Premise
217	and	_	_	I-Premise
218	remained	_	_	I-Premise
219	after	_	_	I-Premise
220	adjusting	_	_	I-Premise
221	for	_	_	I-Premise
222	these	_	_	I-Premise
223	stratification	_	_	I-Premise
224	factors	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.077	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	Moreover	_	_	O
232	,	_	_	O
233	the	_	_	B-Premise
234	meta-analysis	_	_	I-Premise
235	of	_	_	I-Premise
236	two	_	_	I-Premise
237	additional	_	_	I-Premise
238	studies	_	_	I-Premise
239	involving	_	_	I-Premise
240	935	_	_	I-Premise
241	patients	_	_	I-Premise
242	showed	_	_	I-Premise
243	a	_	_	I-Premise
244	significant	_	_	I-Premise
245	survival	_	_	I-Premise
246	benefit	_	_	I-Premise
247	in	_	_	I-Premise
248	favor	_	_	I-Premise
249	of	_	_	I-Premise
250	GEM-CAP	_	_	I-Premise
251	(	_	_	I-Premise
252	HR	_	_	I-Premise
253	,	_	_	I-Premise
254	0.86	_	_	I-Premise
255	;	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.75	_	_	I-Premise
261	to	_	_	I-Premise
262	0.98	_	_	I-Premise
263	;	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.02	_	_	I-Premise
267	)	_	_	I-Premise
268	with	_	_	I-Premise
269	no	_	_	I-Premise
270	intertrial	_	_	I-Premise
271	heterogeneity	_	_	I-Premise
272	.	_	_	I-Premise

273	On	_	_	B-Claim
274	the	_	_	I-Claim
275	basis	_	_	I-Claim
276	of	_	_	I-Claim
277	our	_	_	I-Claim
278	trial	_	_	I-Claim
279	and	_	_	I-Claim
280	the	_	_	I-Claim
281	meta-analysis	_	_	I-Claim
282	,	_	_	I-Claim
283	GEM-CAP	_	_	I-Claim
284	should	_	_	I-Claim
285	be	_	_	I-Claim
286	considered	_	_	I-Claim
287	as	_	_	I-Claim
288	one	_	_	I-Claim
289	of	_	_	I-Claim
290	the	_	_	I-Claim
291	standard	_	_	I-Claim
292	first-line	_	_	I-Claim
293	options	_	_	I-Claim
294	in	_	_	I-Claim
295	locally	_	_	I-Claim
296	advanced	_	_	I-Claim
297	and	_	_	I-Claim
298	metastatic	_	_	I-Claim
299	pancreatic	_	_	I-Claim
300	cancer	_	_	I-Claim
301	.	_	_	I-Claim


0	Bimatoprost	_	_	O
1	and	_	_	O
2	the	_	_	O
3	fixed	_	_	O
4	combination	_	_	O
5	of	_	_	O
6	latanoprost	_	_	O
7	with	_	_	O
8	timolol	_	_	O
9	maleate	_	_	O
10	are	_	_	O
11	2	_	_	O
12	medications	_	_	O
13	widely	_	_	O
14	used	_	_	O
15	to	_	_	O
16	treat	_	_	O
17	glaucoma	_	_	O
18	and	_	_	O
19	ocular	_	_	O
20	hypertension	_	_	O
21	(	_	_	O
22	OHT	_	_	O
23	)	_	_	O
24	.	_	_	O

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	the	_	_	O
29	study	_	_	O
30	is	_	_	O
31	to	_	_	O
32	compare	_	_	O
33	the	_	_	O
34	efficacy	_	_	O
35	of	_	_	O
36	these	_	_	O
37	2	_	_	O
38	drugs	_	_	O
39	in	_	_	O
40	reducing	_	_	O
41	intraocular	_	_	O
42	pressure	_	_	O
43	(	_	_	O
44	IOP	_	_	O
45	)	_	_	O
46	after	_	_	O
47	8	_	_	O
48	weeks	_	_	O
49	of	_	_	O
50	treatment	_	_	O
51	in	_	_	O
52	patients	_	_	O
53	with	_	_	O
54	primary	_	_	O
55	open	_	_	O
56	angle	_	_	O
57	glaucoma	_	_	O
58	(	_	_	O
59	POAG	_	_	O
60	)	_	_	O
61	or	_	_	O
62	OHT	_	_	O
63	.	_	_	O

64	In	_	_	O
65	this	_	_	O
66	randomized	_	_	O
67	,	_	_	O
68	open-label	_	_	O
69	trial	_	_	O
70	,	_	_	O
71	44	_	_	O
72	patients	_	_	O
73	with	_	_	O
74	POAG	_	_	O
75	or	_	_	O
76	OHT	_	_	O
77	were	_	_	O
78	allocated	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	either	_	_	O
82	bimatoprost	_	_	O
83	(	_	_	O
84	1	_	_	O
85	drop	_	_	O
86	QD	_	_	O
87	)	_	_	O
88	or	_	_	O
89	latanoprost/timolol	_	_	O
90	(	_	_	O
91	1	_	_	O
92	drop	_	_	O
93	QD	_	_	O
94	)	_	_	O
95	.	_	_	O

96	Primary	_	_	O
97	outcome	_	_	O
98	was	_	_	O
99	the	_	_	O
100	mean	_	_	O
101	diurnal	_	_	O
102	IOP	_	_	O
103	measurement	_	_	O
104	at	_	_	O
105	the	_	_	O
106	8th	_	_	O
107	week	_	_	O
108	,	_	_	O
109	calculated	_	_	O
110	as	_	_	O
111	the	_	_	O
112	mean	_	_	O
113	IOP	_	_	O
114	measurements	_	_	O
115	taken	_	_	O
116	at	_	_	O
117	8:00	_	_	O
118	am	_	_	O
119	,	_	_	O
120	10:00	_	_	O
121	am	_	_	O
122	,	_	_	O
123	and	_	_	O
124	12:00	_	_	O
125	pm	_	_	O
126	Secondary	_	_	O
127	outcomes	_	_	O
128	included	_	_	O
129	the	_	_	O
130	baseline	_	_	O
131	change	_	_	O
132	in	_	_	O
133	IOP	_	_	O
134	measured	_	_	O
135	3	_	_	O
136	times	_	_	O
137	a	_	_	O
138	day	_	_	O
139	,	_	_	O
140	after	_	_	O
141	the	_	_	O
142	water-drinking	_	_	O
143	test	_	_	O
144	(	_	_	O
145	performed	_	_	O
146	after	_	_	O
147	the	_	_	O
148	last	_	_	O
149	IOP	_	_	O
150	measurement	_	_	O
151	)	_	_	O
152	,	_	_	O
153	and	_	_	O
154	the	_	_	O
155	assessment	_	_	O
156	of	_	_	O
157	side	_	_	O
158	effects	_	_	O
159	of	_	_	O
160	each	_	_	O
161	therapy	_	_	O
162	.	_	_	O

163	The	_	_	B-Premise
164	mean	_	_	I-Premise
165	IOP	_	_	I-Premise
166	levels	_	_	I-Premise
167	of	_	_	I-Premise
168	latanoprost/timolol	_	_	I-Premise
169	(	_	_	I-Premise
170	13.83	_	_	I-Premise
171	,	_	_	I-Premise
172	SD	_	_	I-Premise
173	=	_	_	I-Premise
174	2.54	_	_	I-Premise
175	)	_	_	I-Premise
176	was	_	_	I-Premise
177	significantly	_	_	I-Premise
178	lower	_	_	I-Premise
179	than	_	_	I-Premise
180	of	_	_	I-Premise
181	bimatoprost	_	_	I-Premise
182	(	_	_	I-Premise
183	16.16	_	_	I-Premise
184	,	_	_	I-Premise
185	SD	_	_	I-Premise
186	=	_	_	I-Premise
187	3.28	_	_	I-Premise
188	;	_	_	I-Premise
189	P	_	_	I-Premise
190	<	_	_	I-Premise
191	0.0001	_	_	I-Premise
192	)	_	_	I-Premise
193	at	_	_	I-Premise
194	week	_	_	I-Premise
195	8	_	_	I-Premise
196	.	_	_	I-Premise

197	Also	_	_	O
198	,	_	_	O
199	the	_	_	B-Premise
200	change	_	_	I-Premise
201	in	_	_	I-Premise
202	mean	_	_	I-Premise
203	IOP	_	_	I-Premise
204	values	_	_	I-Premise
205	was	_	_	I-Premise
206	significantly	_	_	I-Premise
207	higher	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	latanoprost/timolol	_	_	I-Premise
211	group	_	_	I-Premise
212	at	_	_	I-Premise
213	10:00	_	_	I-Premise
214	am	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	0.013	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	12:00	_	_	I-Premise
222	pm	_	_	I-Premise
223	(	_	_	I-Premise
224	P	_	_	I-Premise
225	=	_	_	I-Premise
226	0.01	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	but	_	_	I-Premise
230	not	_	_	I-Premise
231	at	_	_	I-Premise
232	8:00	_	_	I-Premise
233	am	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	ns	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	During	_	_	O
241	the	_	_	O
242	water-drinking	_	_	O
243	test	_	_	O
244	,	_	_	O
245	there	_	_	O
246	was	_	_	O
247	no	_	_	O
248	significant	_	_	O
249	difference	_	_	O
250	in	_	_	O
251	IOP	_	_	O
252	increase	_	_	O
253	(	_	_	O
254	absolute	_	_	O
255	and	_	_	O
256	percentage	_	_	O
257	)	_	_	O
258	between	_	_	O
259	groups	_	_	O
260	;	_	_	O
261	however	_	_	O
262	,	_	_	O
263	there	_	_	B-Premise
264	was	_	_	I-Premise
265	a	_	_	I-Premise
266	significant	_	_	I-Premise
267	decrease	_	_	I-Premise
268	in	_	_	I-Premise
269	mean	_	_	I-Premise
270	heart	_	_	I-Premise
271	rate	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	latanoprost/timolol	_	_	I-Premise
275	group	_	_	I-Premise
276	.	_	_	O

277	Finally	_	_	O
278	,	_	_	O
279	no	_	_	B-Premise
280	significant	_	_	I-Premise
281	changes	_	_	I-Premise
282	in	_	_	I-Premise
283	blood	_	_	I-Premise
284	pressure	_	_	I-Premise
285	and	_	_	I-Premise
286	lung	_	_	I-Premise
287	spirometry	_	_	I-Premise
288	were	_	_	I-Premise
289	observed	_	_	I-Premise
290	in	_	_	I-Premise
291	either	_	_	I-Premise
292	groups	_	_	I-Premise
293	.	_	_	I-Premise

294	The	_	_	B-Claim
295	fixed	_	_	I-Claim
296	combination	_	_	I-Claim
297	of	_	_	I-Claim
298	latanoprost/timolol	_	_	I-Claim
299	was	_	_	I-Claim
300	significantly	_	_	I-Claim
301	superior	_	_	I-Claim
302	to	_	_	I-Claim
303	bimatoprost	_	_	I-Claim
304	alone	_	_	I-Claim
305	in	_	_	I-Claim
306	reducing	_	_	I-Claim
307	IOP	_	_	I-Claim
308	in	_	_	I-Claim
309	patients	_	_	I-Claim
310	with	_	_	I-Claim
311	POAG	_	_	I-Claim
312	or	_	_	I-Claim
313	OHT	_	_	I-Claim
314	.	_	_	I-Claim

315	Further	_	_	B-Claim
316	studies	_	_	I-Claim
317	with	_	_	I-Claim
318	large	_	_	I-Claim
319	sample	_	_	I-Claim
320	sizes	_	_	I-Claim
321	should	_	_	I-Claim
322	be	_	_	I-Claim
323	taken	_	_	I-Claim
324	to	_	_	I-Claim
325	support	_	_	I-Claim
326	the	_	_	I-Claim
327	superior	_	_	I-Claim
328	efficacy	_	_	I-Claim
329	of	_	_	I-Claim
330	latanoprost/timolol	_	_	I-Claim
331	,	_	_	I-Claim
332	as	_	_	I-Claim
333	well	_	_	I-Claim
334	as	_	_	I-Claim
335	to	_	_	I-Claim
336	better	_	_	I-Claim
337	assess	_	_	I-Claim
338	its	_	_	I-Claim
339	profile	_	_	I-Claim
340	of	_	_	I-Claim
341	side	_	_	I-Claim
342	effects	_	_	I-Claim
343	.	_	_	I-Claim


0	Gastrojejunostomy	_	_	O
1	(	_	_	O
2	GJJ	_	_	O
3	)	_	_	O
4	and	_	_	O
5	stent	_	_	O
6	placement	_	_	O
7	are	_	_	O
8	the	_	_	O
9	most	_	_	O
10	commonly	_	_	O
11	used	_	_	O
12	palliative	_	_	O
13	treatments	_	_	O
14	for	_	_	O
15	malignant	_	_	O
16	gastric	_	_	O
17	outlet	_	_	O
18	obstruction	_	_	O
19	(	_	_	O
20	GOO	_	_	O
21	)	_	_	O
22	.	_	_	O

23	In	_	_	O
24	a	_	_	O
25	recent	_	_	O
26	randomized	_	_	O
27	trial	_	_	O
28	,	_	_	O
29	stent	_	_	O
30	placement	_	_	O
31	was	_	_	O
32	preferred	_	_	O
33	in	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	a	_	_	O
37	relatively	_	_	O
38	short	_	_	O
39	survival	_	_	O
40	and	_	_	O
41	GJJ	_	_	O
42	in	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	a	_	_	O
46	longer	_	_	O
47	survival	_	_	O
48	.	_	_	O

49	As	_	_	O
50	health	_	_	O
51	economic	_	_	O
52	aspects	_	_	O
53	have	_	_	O
54	only	_	_	O
55	been	_	_	O
56	studied	_	_	O
57	in	_	_	O
58	general	_	_	O
59	terms	_	_	O
60	,	_	_	O
61	we	_	_	O
62	estimated	_	_	O
63	the	_	_	O
64	cost	_	_	O
65	of	_	_	O
66	GJJ	_	_	O
67	and	_	_	O
68	that	_	_	O
69	of	_	_	O
70	stent	_	_	O
71	placement	_	_	O
72	in	_	_	O
73	such	_	_	O
74	patients	_	_	O
75	.	_	_	O

76	In	_	_	O
77	the	_	_	O
78	SUSTENT	_	_	O
79	study	_	_	O
80	,	_	_	O
81	patients	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	GJJ	_	_	O
86	(	_	_	O
87	n	_	_	O
88	=	_	_	O
89	18	_	_	O
90	)	_	_	O
91	or	_	_	O
92	stent	_	_	O
93	placement	_	_	O
94	(	_	_	O
95	n	_	_	O
96	=	_	_	O
97	21	_	_	O
98	)	_	_	O
99	.	_	_	O

100	Pancreatic	_	_	O
101	cancer	_	_	O
102	was	_	_	O
103	the	_	_	O
104	most	_	_	O
105	common	_	_	O
106	cause	_	_	O
107	of	_	_	O
108	GOO	_	_	O
109	.	_	_	O

110	We	_	_	O
111	compared	_	_	O
112	initial	_	_	O
113	costs	_	_	O
114	and	_	_	O
115	costs	_	_	O
116	during	_	_	O
117	follow-up	_	_	O
118	.	_	_	O

119	For	_	_	O
120	cost-effectiveness	_	_	O
121	,	_	_	O
122	the	_	_	O
123	incremental	_	_	O
124	cost-effectiveness	_	_	O
125	ratio	_	_	O
126	was	_	_	O
127	calculated	_	_	O
128	.	_	_	O

129	Food	_	_	B-Premise
130	intake	_	_	I-Premise
131	improved	_	_	I-Premise
132	more	_	_	I-Premise
133	rapidly	_	_	I-Premise
134	after	_	_	I-Premise
135	stent	_	_	I-Premise
136	placement	_	_	I-Premise
137	than	_	_	I-Premise
138	after	_	_	I-Premise
139	GJJ	_	_	I-Premise
140	,	_	_	I-Premise
141	but	_	_	B-Premise
142	long-term	_	_	I-Premise
143	relief	_	_	I-Premise
144	of	_	_	I-Premise
145	obstructive	_	_	I-Premise
146	symptoms	_	_	I-Premise
147	was	_	_	I-Premise
148	better	_	_	I-Premise
149	after	_	_	I-Premise
150	GJJ	_	_	I-Premise
151	.	_	_	I-Premise

152	More	_	_	B-Premise
153	major	_	_	I-Premise
154	complications	_	_	I-Premise
155	(	_	_	I-Premise
156	P	_	_	I-Premise
157	=	_	_	I-Premise
158	0.02	_	_	I-Premise
159	)	_	_	I-Premise
160	occurred	_	_	I-Premise
161	and	_	_	I-Premise
162	more	_	_	I-Premise
163	reinterventions	_	_	I-Premise
164	were	_	_	I-Premise
165	performed	_	_	I-Premise
166	(	_	_	I-Premise
167	P	_	_	I-Premise
168	<	_	_	I-Premise
169	0.01	_	_	I-Premise
170	)	_	_	I-Premise
171	after	_	_	I-Premise
172	stent	_	_	I-Premise
173	placement	_	_	I-Premise
174	than	_	_	I-Premise
175	after	_	_	I-Premise
176	GJJ	_	_	I-Premise
177	.	_	_	I-Premise

178	Initial	_	_	B-Premise
179	costs	_	_	I-Premise
180	were	_	_	I-Premise
181	higher	_	_	I-Premise
182	for	_	_	I-Premise
183	GJJ	_	_	I-Premise
184	compared	_	_	I-Premise
185	to	_	_	I-Premise
186	stent	_	_	I-Premise
187	placement	_	_	I-Premise
188	(	_	_	I-Premise
189	euro8315	_	_	I-Premise
190	vs.	_	_	I-Premise
191	euro4820	_	_	I-Premise
192	,	_	_	I-Premise
193	P	_	_	I-Premise
194	<	_	_	I-Premise
195	0.001	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	We	_	_	B-Premise
199	found	_	_	I-Premise
200	no	_	_	I-Premise
201	difference	_	_	I-Premise
202	in	_	_	I-Premise
203	follow-up	_	_	I-Premise
204	costs	_	_	I-Premise
205	.	_	_	I-Premise

206	Total	_	_	B-Premise
207	costs	_	_	I-Premise
208	per	_	_	I-Premise
209	patient	_	_	I-Premise
210	were	_	_	I-Premise
211	higher	_	_	I-Premise
212	for	_	_	I-Premise
213	GJJ	_	_	I-Premise
214	compared	_	_	I-Premise
215	to	_	_	I-Premise
216	stent	_	_	I-Premise
217	placement	_	_	I-Premise
218	(	_	_	I-Premise
219	euro12433	_	_	I-Premise
220	vs.	_	_	I-Premise
221	euro8819	_	_	I-Premise
222	,	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	0.049	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	The	_	_	B-Premise
229	incremental	_	_	I-Premise
230	cost-effectiveness	_	_	I-Premise
231	ratio	_	_	I-Premise
232	of	_	_	I-Premise
233	GJJ	_	_	I-Premise
234	compared	_	_	I-Premise
235	to	_	_	I-Premise
236	stent	_	_	I-Premise
237	placement	_	_	I-Premise
238	was	_	_	I-Premise
239	euro164	_	_	I-Premise
240	per	_	_	I-Premise
241	extra	_	_	I-Premise
242	day	_	_	I-Premise
243	with	_	_	I-Premise
244	a	_	_	I-Premise
245	gastric	_	_	I-Premise
246	outlet	_	_	I-Premise
247	obstruction	_	_	I-Premise
248	scoring	_	_	I-Premise
249	system	_	_	I-Premise
250	(	_	_	I-Premise
251	GOOSS	_	_	I-Premise
252	)	_	_	I-Premise
253	>	_	_	I-Premise
254	or=2	_	_	I-Premise
255	adjusted	_	_	I-Premise
256	for	_	_	I-Premise
257	survival	_	_	I-Premise
258	.	_	_	I-Premise

259	Medical	_	_	B-Claim
260	effects	_	_	I-Claim
261	were	_	_	I-Claim
262	better	_	_	I-Claim
263	after	_	_	I-Claim
264	GJJ	_	_	I-Claim
265	,	_	_	O
266	although	_	_	B-Claim
267	GJJ	_	_	I-Claim
268	had	_	_	I-Claim
269	higher	_	_	I-Claim
270	total	_	_	I-Claim
271	costs	_	_	I-Claim
272	.	_	_	I-Claim

273	Since	_	_	B-Claim
274	the	_	_	I-Claim
275	cost	_	_	I-Claim
276	difference	_	_	I-Claim
277	between	_	_	I-Claim
278	the	_	_	I-Claim
279	two	_	_	I-Claim
280	treatments	_	_	I-Claim
281	was	_	_	I-Claim
282	only	_	_	I-Claim
283	small	_	_	I-Claim
284	,	_	_	I-Claim
285	cost	_	_	B-Claim
286	should	_	_	I-Claim
287	not	_	_	I-Claim
288	play	_	_	I-Claim
289	a	_	_	I-Claim
290	predominant	_	_	I-Claim
291	role	_	_	I-Claim
292	when	_	_	I-Claim
293	deciding	_	_	I-Claim
294	on	_	_	I-Claim
295	the	_	_	I-Claim
296	type	_	_	I-Claim
297	of	_	_	I-Claim
298	treatment	_	_	I-Claim
299	assigned	_	_	I-Claim
300	to	_	_	I-Claim
301	patients	_	_	I-Claim
302	with	_	_	I-Claim
303	malignant	_	_	I-Claim
304	GOO	_	_	I-Claim
305	.	_	_	I-Claim


0	A	_	_	O
1	significant	_	_	O
2	proportion	_	_	O
3	of	_	_	O
4	patients	_	_	O
5	develop	_	_	O
6	urinary	_	_	O
7	incontinence	_	_	O
8	early	_	_	O
9	after	_	_	O
10	radical	_	_	O
11	prostatectomy	_	_	O
12	.	_	_	O

13	Posterior	_	_	O
14	reconstruction	_	_	O
15	of	_	_	O
16	supporting	_	_	O
17	tissues	_	_	O
18	has	_	_	O
19	been	_	_	O
20	found	_	_	O
21	to	_	_	O
22	reduce	_	_	O
23	incontinence	_	_	O
24	in	_	_	O
25	open	_	_	O
26	and	_	_	O
27	conventional	_	_	O
28	laparoscopic	_	_	O
29	prostatectomy	_	_	O
30	series	_	_	O
31	.	_	_	O

32	To	_	_	O
33	investigate	_	_	O
34	whether	_	_	O
35	our	_	_	O
36	version	_	_	O
37	of	_	_	O
38	a	_	_	O
39	posterior	_	_	O
40	musculofascial	_	_	O
41	reconstruction	_	_	O
42	will	_	_	O
43	reduce	_	_	O
44	early	_	_	O
45	incontinence	_	_	O
46	and	_	_	O
47	have	_	_	O
48	a	_	_	O
49	beneficial	_	_	O
50	effect	_	_	O
51	on	_	_	O
52	patients	_	_	O
53	'	_	_	O
54	quality	_	_	O
55	of	_	_	O
56	life	_	_	O
57	(	_	_	O
58	QoL	_	_	O
59	)	_	_	O
60	.	_	_	O

61	One	_	_	O
62	hundred	_	_	O
63	seven	_	_	O
64	consecutive	_	_	O
65	patients	_	_	O
66	undergoing	_	_	O
67	primary	_	_	O
68	robot-assisted	_	_	O
69	radical	_	_	O
70	laparoscopic	_	_	O
71	prostatectomy	_	_	O
72	(	_	_	O
73	RALP	_	_	O
74	)	_	_	O
75	performed	_	_	O
76	by	_	_	O
77	a	_	_	O
78	single	_	_	O
79	surgeon	_	_	O
80	at	_	_	O
81	one	_	_	O
82	tertiary	_	_	O
83	referral	_	_	O
84	oncology	_	_	O
85	institution	_	_	O
86	were	_	_	O
87	alternately	_	_	O
88	assigned	_	_	O
89	(	_	_	O
90	not	_	_	O
91	randomised	_	_	O
92	)	_	_	O
93	to	_	_	O
94	intervention	_	_	O
95	(	_	_	O
96	n=53	_	_	O
97	)	_	_	O
98	or	_	_	O
99	control	_	_	O
100	groups	_	_	O
101	(	_	_	O
102	n=54	_	_	O
103	)	_	_	O
104	.	_	_	O

105	RALP	_	_	O
106	with	_	_	O
107	median	_	_	O
108	fibrous	_	_	O
109	raphe	_	_	O
110	reconstruction	_	_	O
111	(	_	_	O
112	MFRR	_	_	O
113	)	_	_	O
114	followed	_	_	O
115	by	_	_	O
116	formation	_	_	O
117	of	_	_	O
118	the	_	_	O
119	urethrovesical	_	_	O
120	anastomosis	_	_	O
121	(	_	_	O
122	intervention	_	_	O
123	group	_	_	O
124	)	_	_	O
125	versus	_	_	O
126	standard	_	_	O
127	anastomosis	_	_	O
128	without	_	_	O
129	posterior	_	_	O
130	reconstruction	_	_	O
131	(	_	_	O
132	control	_	_	O
133	group	_	_	O
134	)	_	_	O
135	.	_	_	O

136	Measurements	_	_	O
137	included	_	_	O
138	incontinence	_	_	O
139	at	_	_	O
140	baseline	_	_	O
141	and	_	_	O
142	3-mo	_	_	O
143	intervals	_	_	O
144	;	_	_	O
145	QoL	_	_	O
146	as	_	_	O
147	measured	_	_	O
148	by	_	_	O
149	a	_	_	O
150	simple	_	_	O
151	questionnaire	_	_	O
152	,	_	_	O
153	the	_	_	O
154	European	_	_	O
155	Organisation	_	_	O
156	for	_	_	O
157	Research	_	_	O
158	and	_	_	O
159	Treatment	_	_	O
160	of	_	_	O
161	Cancer	_	_	O
162	(	_	_	O
163	EORTC	_	_	O
164	)	_	_	O
165	Quality	_	_	O
166	of	_	_	O
167	Life-Core	_	_	O
168	30	_	_	O
169	(	_	_	O
170	QLQ-C30	_	_	O
171	)	_	_	O
172	,	_	_	O
173	and	_	_	O
174	Prostate	_	_	O
175	Cancer	_	_	O
176	Module	_	_	O
177	(	_	_	O
178	PR25	_	_	O
179	)	_	_	O
180	questionnaires	_	_	O
181	preoperatively	_	_	O
182	and	_	_	O
183	at	_	_	O
184	6	_	_	O
185	mo	_	_	O
186	postprocedure	_	_	O
187	;	_	_	O
188	tumour	_	_	O
189	characteristics	_	_	O
190	;	_	_	O
191	operative	_	_	O
192	time	_	_	O
193	;	_	_	O
194	fascial	_	_	O
195	preservation	_	_	O
196	score	_	_	O
197	;	_	_	O
198	duration	_	_	O
199	of	_	_	O
200	catheterisation	_	_	O
201	;	_	_	O
202	and	_	_	O
203	anastomotic	_	_	O
204	leakage	_	_	O
205	on	_	_	O
206	cystogram	_	_	O
207	.	_	_	O

208	For	_	_	B-Premise
209	intervention	_	_	I-Premise
210	and	_	_	I-Premise
211	control	_	_	I-Premise
212	groups	_	_	I-Premise
213	respectively	_	_	I-Premise
214	,	_	_	I-Premise
215	mean	_	_	I-Premise
216	catheter	_	_	I-Premise
217	duration	_	_	I-Premise
218	was	_	_	I-Premise
219	11.74	_	_	I-Premise
220	d	_	_	I-Premise
221	and	_	_	I-Premise
222	12.74	_	_	I-Premise
223	d	_	_	I-Premise
224	(	_	_	I-Premise
225	p=0.451	_	_	I-Premise
226	)	_	_	I-Premise
227	;	_	_	I-Premise
228	leakage	_	_	I-Premise
229	on	_	_	I-Premise
230	cystogram	_	_	I-Premise
231	was	_	_	I-Premise
232	present	_	_	I-Premise
233	in	_	_	I-Premise
234	six	_	_	I-Premise
235	and	_	_	I-Premise
236	eight	_	_	I-Premise
237	cases	_	_	I-Premise
238	(	_	_	I-Premise
239	p=0.28	_	_	I-Premise
240	)	_	_	I-Premise
241	;	_	_	I-Premise
242	and	_	_	I-Premise
243	incontinence	_	_	I-Premise
244	(	_	_	I-Premise
245	any	_	_	I-Premise
246	involuntary	_	_	I-Premise
247	urine	_	_	I-Premise
248	loss	_	_	I-Premise
249	)	_	_	I-Premise
250	at	_	_	I-Premise
251	3	_	_	I-Premise
252	mo	_	_	I-Premise
253	was	_	_	I-Premise
254	75	_	_	I-Premise
255	%	_	_	I-Premise
256	and	_	_	I-Premise
257	69	_	_	I-Premise
258	%	_	_	I-Premise
259	(	_	_	I-Premise
260	p=0.391	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	at	_	_	I-Premise
264	6	_	_	I-Premise
265	mo	_	_	I-Premise
266	was	_	_	I-Premise
267	51	_	_	I-Premise
268	%	_	_	I-Premise
269	and	_	_	I-Premise
270	43	_	_	I-Premise
271	%	_	_	I-Premise
272	(	_	_	I-Premise
273	p=0.686	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Urinary	_	_	B-Premise
277	retention	_	_	I-Premise
278	occurred	_	_	I-Premise
279	only	_	_	I-Premise
280	in	_	_	I-Premise
281	one	_	_	I-Premise
282	case	_	_	I-Premise
283	(	_	_	I-Premise
284	control	_	_	I-Premise
285	group	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	The	_	_	B-Premise
289	percentage	_	_	I-Premise
290	of	_	_	I-Premise
291	cases	_	_	I-Premise
292	returning	_	_	I-Premise
293	to	_	_	I-Premise
294	baseline	_	_	I-Premise
295	in	_	_	I-Premise
296	all	_	_	I-Premise
297	QoL	_	_	I-Premise
298	domains	_	_	I-Premise
299	(	_	_	I-Premise
300	except	_	_	I-Premise
301	insomnia	_	_	I-Premise
302	)	_	_	I-Premise
303	was	_	_	I-Premise
304	similar	_	_	I-Premise
305	at	_	_	I-Premise
306	6	_	_	I-Premise
307	mo	_	_	I-Premise
308	between	_	_	I-Premise
309	the	_	_	I-Premise
310	two	_	_	I-Premise
311	groups	_	_	I-Premise
312	.	_	_	I-Premise

313	Short	_	_	B-Premise
314	follow-up	_	_	I-Premise
315	,	_	_	I-Premise
316	lack	_	_	I-Premise
317	of	_	_	I-Premise
318	blinding	_	_	I-Premise
319	,	_	_	I-Premise
320	and	_	_	I-Premise
321	probable	_	_	I-Premise
322	small	_	_	I-Premise
323	differences	_	_	I-Premise
324	in	_	_	I-Premise
325	our	_	_	I-Premise
326	method	_	_	I-Premise
327	of	_	_	I-Premise
328	MFRR	_	_	I-Premise
329	performed	_	_	I-Premise
330	compared	_	_	I-Premise
331	with	_	_	I-Premise
332	other	_	_	I-Premise
333	studies	_	_	I-Premise
334	were	_	_	I-Premise
335	identified	_	_	I-Premise
336	as	_	_	I-Premise
337	significant	_	_	I-Premise
338	limitations	_	_	I-Premise
339	.	_	_	I-Premise

340	No	_	_	B-Premise
341	significant	_	_	I-Premise
342	difference	_	_	I-Premise
343	in	_	_	I-Premise
344	any	_	_	I-Premise
345	of	_	_	I-Premise
346	the	_	_	I-Premise
347	analysed	_	_	I-Premise
348	outcome	_	_	I-Premise
349	measures	_	_	I-Premise
350	was	_	_	I-Premise
351	observed	_	_	I-Premise
352	.	_	_	I-Premise

353	Posterior	_	_	B-Claim
354	reconstruction	_	_	I-Claim
355	of	_	_	I-Claim
356	the	_	_	I-Claim
357	musculofascial	_	_	I-Claim
358	complex	_	_	I-Claim
359	does	_	_	I-Claim
360	not	_	_	I-Claim
361	appear	_	_	I-Claim
362	to	_	_	I-Claim
363	improve	_	_	I-Claim
364	early	_	_	I-Claim
365	urinary	_	_	I-Claim
366	incontinence	_	_	I-Claim
367	after	_	_	I-Claim
368	RALP	_	_	I-Claim
369	.	_	_	I-Claim


0	The	_	_	O
1	objective	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	long-term	_	_	O
10	efficacy	_	_	O
11	and	_	_	O
12	safety	_	_	O
13	of	_	_	O
14	tafluprost	_	_	O
15	0.0015	_	_	O
16	%	_	_	O
17	with	_	_	O
18	latanoprost	_	_	O
19	0.005	_	_	O
20	%	_	_	O
21	eye	_	_	O
22	drops	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	open-angle	_	_	O
27	glaucoma	_	_	O
28	or	_	_	O
29	ocular	_	_	O
30	hypertension	_	_	O
31	.	_	_	O

32	This	_	_	O
33	double-masked	_	_	O
34	,	_	_	O
35	active-controlled	_	_	O
36	,	_	_	O
37	parallel-group	_	_	O
38	,	_	_	O
39	multinational	_	_	O
40	,	_	_	O
41	multicentre	_	_	O
42	,	_	_	O
43	phase	_	_	O
44	III	_	_	O
45	study	_	_	O
46	was	_	_	O
47	conducted	_	_	O
48	at	_	_	O
49	49	_	_	O
50	centres	_	_	O
51	in	_	_	O
52	8	_	_	O
53	countries	_	_	O
54	.	_	_	O

55	Eligible	_	_	O
56	patients	_	_	O
57	were	_	_	O
58	assigned	_	_	O
59	to	_	_	O
60	treatment	_	_	O
61	administered	_	_	O
62	once	_	_	O
63	daily	_	_	O
64	at	_	_	O
65	20:00	_	_	O
66	hrs	_	_	O
67	for	_	_	O
68	up	_	_	O
69	to	_	_	O
70	24	_	_	O
71	months	_	_	O
72	.	_	_	O

73	Change	_	_	O
74	from	_	_	O
75	baseline	_	_	O
76	intraocular	_	_	O
77	pressure	_	_	O
78	(	_	_	O
79	IOP	_	_	O
80	)	_	_	O
81	was	_	_	O
82	the	_	_	O
83	primary	_	_	O
84	efficacy	_	_	O
85	variable	_	_	O
86	.	_	_	O

87	Adverse	_	_	O
88	events	_	_	O
89	were	_	_	O
90	recorded	_	_	O
91	and	_	_	O
92	ocular	_	_	O
93	safety	_	_	O
94	was	_	_	O
95	evaluated	_	_	O
96	.	_	_	O

97	Both	_	_	O
98	tafluprost	_	_	O
99	and	_	_	O
100	latanoprost	_	_	O
101	were	_	_	O
102	preserved	_	_	O
103	with	_	_	O
104	benzalkonium	_	_	O
105	chloride	_	_	O
106	.	_	_	O

107	From	_	_	O
108	533	_	_	O
109	patients	_	_	O
110	randomized	_	_	O
111	,	_	_	O
112	402	_	_	O
113	patients	_	_	O
114	completed	_	_	O
115	24	_	_	O
116	months	_	_	O
117	of	_	_	O
118	therapy	_	_	O
119	.	_	_	O

120	Both	_	_	B-Premise
121	treatments	_	_	I-Premise
122	had	_	_	I-Premise
123	a	_	_	I-Premise
124	substantial	_	_	I-Premise
125	IOP-lowering	_	_	I-Premise
126	effect	_	_	I-Premise
127	which	_	_	I-Premise
128	persisted	_	_	I-Premise
129	throughout	_	_	I-Premise
130	the	_	_	I-Premise
131	study	_	_	I-Premise
132	(	_	_	I-Premise
133	-7.1	_	_	I-Premise
134	mmHg	_	_	I-Premise
135	for	_	_	I-Premise
136	tafluprost	_	_	I-Premise
137	and	_	_	I-Premise
138	-7.7	_	_	I-Premise
139	mmHg	_	_	I-Premise
140	for	_	_	I-Premise
141	latanoprost	_	_	I-Premise
142	at	_	_	I-Premise
143	24	_	_	I-Premise
144	months	_	_	I-Premise
145	)	_	_	I-Premise
146	.	_	_	I-Premise

147	Although	_	_	O
148	the	_	_	B-Claim
149	IOP-lowering	_	_	I-Claim
150	effect	_	_	I-Claim
151	during	_	_	I-Claim
152	the	_	_	I-Claim
153	study	_	_	I-Claim
154	was	_	_	I-Claim
155	slightly	_	_	I-Claim
156	larger	_	_	I-Claim
157	with	_	_	I-Claim
158	latanoprost	_	_	I-Claim
159	,	_	_	I-Claim
160	this	_	_	B-Premise
161	difference	_	_	I-Premise
162	was	_	_	I-Premise
163	clinically	_	_	I-Premise
164	small	_	_	I-Premise
165	and	_	_	I-Premise
166	the	_	_	I-Premise
167	noninferiority	_	_	I-Premise
168	of	_	_	I-Premise
169	tafluprost	_	_	I-Premise
170	to	_	_	I-Premise
171	latanoprost	_	_	I-Premise
172	over	_	_	I-Premise
173	all	_	_	I-Premise
174	diurnal	_	_	I-Premise
175	IOP	_	_	I-Premise
176	measurements	_	_	I-Premise
177	was	_	_	I-Premise
178	shown	_	_	I-Premise
179	with	_	_	I-Premise
180	anova	_	_	I-Premise
181	and	_	_	I-Premise
182	almost	_	_	I-Premise
183	reached	_	_	I-Premise
184	with	_	_	I-Premise
185	ancova	_	_	I-Premise
186	(	_	_	I-Premise
187	upper	_	_	I-Premise
188	limits	_	_	I-Premise
189	of	_	_	I-Premise
190	the	_	_	I-Premise
191	95	_	_	I-Premise
192	%	_	_	I-Premise
193	confidence	_	_	I-Premise
194	intervals	_	_	I-Premise
195	1.38	_	_	I-Premise
196	and	_	_	I-Premise
197	1.52	_	_	I-Premise
198	for	_	_	I-Premise
199	the	_	_	I-Premise
200	overall	_	_	I-Premise
201	period	_	_	I-Premise
202	,	_	_	I-Premise
203	respectively	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	The	_	_	O
207	noninferiority	_	_	O
208	limit	_	_	O
209	was	_	_	O
210	1.5	_	_	O
211	mmHg	_	_	O
212	.	_	_	O

213	Tafluprost	_	_	B-Claim
214	is	_	_	I-Claim
215	a	_	_	I-Claim
216	new	_	_	I-Claim
217	effective	_	_	I-Claim
218	and	_	_	I-Claim
219	well-tolerated	_	_	I-Claim
220	treatment	_	_	I-Claim
221	for	_	_	I-Claim
222	glaucoma	_	_	I-Claim
223	and	_	_	I-Claim
224	ocular	_	_	I-Claim
225	hypertension	_	_	I-Claim
226	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	0.0015	_	_	O
8	%	_	_	O
9	tafluprost	_	_	O
10	ophthalmic	_	_	O
11	solution	_	_	O
12	(	_	_	O
13	Tafluprost	_	_	O
14	)	_	_	O
15	with	_	_	O
16	Placebo	_	_	O
17	ophthalmic	_	_	O
18	solution	_	_	O
19	(	_	_	O
20	Placebo	_	_	O
21	)	_	_	O
22	in	_	_	O
23	normal	_	_	O
24	tension	_	_	O
25	glaucoma	_	_	O
26	(	_	_	O
27	NTG	_	_	O
28	)	_	_	O
29	.	_	_	O

30	Total	_	_	O
31	of	_	_	O
32	94	_	_	O
33	patients	_	_	O
34	enrolled	_	_	O
35	in	_	_	O
36	a	_	_	O
37	randomized	_	_	O
38	,	_	_	O
39	double-blind	_	_	O
40	,	_	_	O
41	parallel-group	_	_	O
42	and	_	_	O
43	multicenter	_	_	O
44	study	_	_	O
45	.	_	_	O

46	Patients	_	_	O
47	with	_	_	O
48	NTG	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	to	_	_	O
53	either	_	_	O
54	Tafluprost	_	_	O
55	or	_	_	O
56	Placebo	_	_	O
57	.	_	_	O

58	Both	_	_	O
59	ophthalmic	_	_	O
60	solutions	_	_	O
61	were	_	_	O
62	instilled	_	_	O
63	once	_	_	O
64	a	_	_	O
65	day	_	_	O
66	in	_	_	O
67	the	_	_	O
68	morning	_	_	O
69	for	_	_	O
70	4	_	_	O
71	weeks	_	_	O
72	.	_	_	O

73	Mean	_	_	B-Premise
74	intraocular	_	_	I-Premise
75	pressure	_	_	I-Premise
76	(	_	_	I-Premise
77	IOP	_	_	I-Premise
78	)	_	_	I-Premise
79	changes	_	_	I-Premise
80	from	_	_	I-Premise
81	baseline	_	_	I-Premise
82	were	_	_	I-Premise
83	-4.0	_	_	I-Premise
84	+/-	_	_	I-Premise
85	1.7	_	_	I-Premise
86	mmHg	_	_	I-Premise
87	in	_	_	I-Premise
88	Tafluprost	_	_	I-Premise
89	administered	_	_	I-Premise
90	patients	_	_	I-Premise
91	and	_	_	I-Premise
92	-1.4	_	_	I-Premise
93	+/-	_	_	I-Premise
94	1.8	_	_	I-Premise
95	mmHg	_	_	I-Premise
96	in	_	_	I-Premise
97	Placebo	_	_	I-Premise
98	administered	_	_	I-Premise
99	patients	_	_	I-Premise
100	at	_	_	I-Premise
101	4	_	_	I-Premise
102	weeks	_	_	I-Premise
103	,	_	_	I-Premise
104	with	_	_	I-Premise
105	a	_	_	I-Premise
106	statistically	_	_	I-Premise
107	significant	_	_	I-Premise
108	difference	_	_	I-Premise
109	(	_	_	I-Premise
110	p	_	_	I-Premise
111	<	_	_	I-Premise
112	0.001	_	_	I-Premise
113	)	_	_	I-Premise
114	.	_	_	I-Premise

115	IOP	_	_	B-Premise
116	change	_	_	I-Premise
117	at	_	_	I-Premise
118	4	_	_	I-Premise
119	weeks	_	_	I-Premise
120	,	_	_	I-Premise
121	%	_	_	I-Premise
122	IOP	_	_	I-Premise
123	reduction	_	_	I-Premise
124	at	_	_	I-Premise
125	2	_	_	I-Premise
126	and	_	_	I-Premise
127	4	_	_	I-Premise
128	weeks	_	_	I-Premise
129	were	_	_	I-Premise
130	also	_	_	I-Premise
131	significantly	_	_	I-Premise
132	greater	_	_	I-Premise
133	in	_	_	I-Premise
134	Tafluprost	_	_	I-Premise
135	than	_	_	I-Premise
136	in	_	_	I-Premise
137	Placebo	_	_	I-Premise
138	.	_	_	I-Premise

139	A	_	_	B-Premise
140	total	_	_	I-Premise
141	of	_	_	I-Premise
142	51.0	_	_	I-Premise
143	%	_	_	I-Premise
144	in	_	_	I-Premise
145	Tafluprost	_	_	I-Premise
146	treated	_	_	I-Premise
147	group	_	_	I-Premise
148	and	_	_	I-Premise
149	8.9	_	_	I-Premise
150	%	_	_	I-Premise
151	in	_	_	I-Premise
152	Placebo	_	_	I-Premise
153	treated	_	_	I-Premise
154	group	_	_	I-Premise
155	reported	_	_	I-Premise
156	adverse	_	_	I-Premise
157	drug	_	_	I-Premise
158	reactions	_	_	I-Premise
159	.	_	_	I-Premise

160	These	_	_	B-Claim
161	results	_	_	I-Claim
162	indicate	_	_	I-Claim
163	that	_	_	I-Claim
164	Tafluprost	_	_	I-Claim
165	is	_	_	I-Claim
166	clinically	_	_	I-Claim
167	useful	_	_	I-Claim
168	in	_	_	I-Claim
169	the	_	_	I-Claim
170	treatment	_	_	I-Claim
171	of	_	_	I-Claim
172	NTG	_	_	I-Claim
173	.	_	_	I-Claim


0	Paclitaxel	_	_	O
1	and	_	_	O
2	pegylated	_	_	O
3	liposomal	_	_	O
4	doxorubicin	_	_	O
5	(	_	_	O
6	PLD	_	_	O
7	)	_	_	O
8	are	_	_	O
9	active	_	_	O
10	cytotoxic	_	_	O
11	agents	_	_	O
12	for	_	_	O
13	the	_	_	O
14	treatment	_	_	O
15	of	_	_	O
16	human	_	_	O
17	immunodeficiency	_	_	O
18	virus	_	_	O
19	(	_	_	O
20	HIV	_	_	O
21	)	_	_	O
22	-associated	_	_	O
23	Kaposi	_	_	O
24	sarcoma	_	_	O
25	(	_	_	O
26	KS	_	_	O
27	)	_	_	O
28	.	_	_	O

29	A	_	_	O
30	randomized	_	_	O
31	trial	_	_	O
32	comparing	_	_	O
33	the	_	_	O
34	efficacy	_	_	O
35	and	_	_	O
36	toxicity	_	_	O
37	of	_	_	O
38	paclitaxel	_	_	O
39	and	_	_	O
40	PLD	_	_	O
41	was	_	_	O
42	performed	_	_	O
43	,	_	_	O
44	and	_	_	O
45	the	_	_	O
46	effects	_	_	O
47	of	_	_	O
48	therapy	_	_	O
49	on	_	_	O
50	symptom	_	_	O
51	palliation	_	_	O
52	and	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	were	_	_	O
57	determined	_	_	O
58	.	_	_	O

59	Patients	_	_	O
60	with	_	_	O
61	advanced	_	_	O
62	HIV-associated	_	_	O
63	KS	_	_	O
64	were	_	_	O
65	randomly	_	_	O
66	assigned	_	_	O
67	to	_	_	O
68	receive	_	_	O
69	paclitaxel	_	_	O
70	at	_	_	O
71	a	_	_	O
72	dose	_	_	O
73	of	_	_	O
74	100	_	_	O
75	mg/m2	_	_	O
76	intravenously	_	_	O
77	(	_	_	O
78	iv	_	_	O
79	)	_	_	O
80	every	_	_	O
81	2	_	_	O
82	weeks	_	_	O
83	or	_	_	O
84	PLD	_	_	O
85	at	_	_	O
86	a	_	_	O
87	dose	_	_	O
88	of	_	_	O
89	20	_	_	O
90	mg/m2	_	_	O
91	iv	_	_	O
92	every	_	_	O
93	3	_	_	O
94	weeks	_	_	O
95	.	_	_	O

96	The	_	_	O
97	KS	_	_	O
98	Functional	_	_	O
99	Assessment	_	_	O
100	of	_	_	O
101	HIV	_	_	O
102	(	_	_	O
103	FAHI	_	_	O
104	)	_	_	O
105	quality	_	_	O
106	of	_	_	O
107	life	_	_	O
108	instrument	_	_	O
109	was	_	_	O
110	used	_	_	O
111	before	_	_	O
112	and	_	_	O
113	after	_	_	O
114	every	_	_	O
115	other	_	_	O
116	treatment	_	_	O
117	cycle	_	_	O
118	.	_	_	O

119	The	_	_	O
120	study	_	_	O
121	included	_	_	O
122	73	_	_	O
123	analyzable	_	_	O
124	patients	_	_	O
125	enrolled	_	_	O
126	between	_	_	O
127	1998	_	_	O
128	and	_	_	O
129	2002	_	_	O
130	,	_	_	O
131	including	_	_	O
132	36	_	_	O
133	in	_	_	O
134	the	_	_	O
135	paclitaxel	_	_	O
136	arm	_	_	O
137	and	_	_	O
138	37	_	_	O
139	in	_	_	O
140	the	_	_	O
141	PLD	_	_	O
142	arm	_	_	O
143	;	_	_	O
144	73	_	_	O
145	%	_	_	O
146	of	_	_	O
147	patients	_	_	O
148	received	_	_	O
149	highly	_	_	O
150	active	_	_	O
151	antiretroviral	_	_	O
152	therapy	_	_	O
153	(	_	_	O
154	HAART	_	_	O
155	)	_	_	O
156	and	_	_	O
157	32	_	_	O
158	%	_	_	O
159	had	_	_	O
160	an	_	_	O
161	undetectable	_	_	O
162	viral	_	_	O
163	load	_	_	O
164	(	_	_	O
165	<	_	_	O
166	400	_	_	O
167	copies/mL	_	_	O
168	)	_	_	O
169	.	_	_	O

170	Treatment	_	_	B-Premise
171	was	_	_	I-Premise
172	associated	_	_	I-Premise
173	with	_	_	I-Premise
174	significant	_	_	I-Premise
175	improvements	_	_	I-Premise
176	in	_	_	I-Premise
177	pain	_	_	I-Premise
178	(	_	_	I-Premise
179	P=.024	_	_	I-Premise
180	)	_	_	I-Premise
181	and	_	_	I-Premise
182	swelling	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	<	_	_	I-Premise
186	.001	_	_	I-Premise
187	)	_	_	I-Premise
188	.	_	_	I-Premise

189	Of	_	_	B-Premise
190	the	_	_	I-Premise
191	36	_	_	I-Premise
192	patients	_	_	I-Premise
193	who	_	_	I-Premise
194	reported	_	_	I-Premise
195	that	_	_	I-Premise
196	pain	_	_	I-Premise
197	interfered	_	_	I-Premise
198	with	_	_	I-Premise
199	their	_	_	I-Premise
200	normal	_	_	I-Premise
201	work	_	_	I-Premise
202	or	_	_	I-Premise
203	activities	_	_	I-Premise
204	at	_	_	I-Premise
205	baseline	_	_	I-Premise
206	,	_	_	I-Premise
207	25	_	_	I-Premise
208	(	_	_	I-Premise
209	69	_	_	I-Premise
210	%	_	_	I-Premise
211	)	_	_	I-Premise
212	improved	_	_	I-Premise
213	.	_	_	I-Premise

214	Of	_	_	B-Premise
215	the	_	_	I-Premise
216	41	_	_	I-Premise
217	patients	_	_	I-Premise
218	who	_	_	I-Premise
219	reported	_	_	I-Premise
220	swelling	_	_	I-Premise
221	at	_	_	I-Premise
222	baseline	_	_	I-Premise
223	,	_	_	I-Premise
224	38	_	_	I-Premise
225	(	_	_	I-Premise
226	93	_	_	I-Premise
227	%	_	_	I-Premise
228	)	_	_	I-Premise
229	improved	_	_	I-Premise
230	.	_	_	I-Premise

231	Comparing	_	_	B-Premise
232	the	_	_	I-Premise
233	paclitaxel	_	_	I-Premise
234	and	_	_	I-Premise
235	PLD	_	_	I-Premise
236	arms	_	_	I-Premise
237	revealed	_	_	I-Premise
238	comparable	_	_	I-Premise
239	response	_	_	I-Premise
240	rates	_	_	I-Premise
241	(	_	_	I-Premise
242	56	_	_	I-Premise
243	%	_	_	I-Premise
244	vs	_	_	I-Premise
245	46	_	_	I-Premise
246	%	_	_	I-Premise
247	;	_	_	I-Premise
248	P=.49	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	median	_	_	I-Premise
252	progression-free	_	_	I-Premise
253	survival	_	_	I-Premise
254	(	_	_	I-Premise
255	17.5	_	_	I-Premise
256	months	_	_	I-Premise
257	vs	_	_	I-Premise
258	12.2	_	_	I-Premise
259	months	_	_	I-Premise
260	;	_	_	I-Premise
261	P=.66	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	2-year	_	_	I-Premise
266	survival	_	_	I-Premise
267	rates	_	_	I-Premise
268	(	_	_	I-Premise
269	79	_	_	I-Premise
270	%	_	_	I-Premise
271	vs	_	_	I-Premise
272	78	_	_	I-Premise
273	%	_	_	I-Premise
274	;	_	_	I-Premise
275	P=.75	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	but	_	_	B-Premise
279	somewhat	_	_	I-Premise
280	more	_	_	I-Premise
281	grade	_	_	I-Premise
282	3	_	_	I-Premise
283	to	_	_	I-Premise
284	5	_	_	I-Premise
285	toxicity	_	_	I-Premise
286	for	_	_	I-Premise
287	paclitaxel	_	_	I-Premise
288	(	_	_	I-Premise
289	84	_	_	I-Premise
290	%	_	_	I-Premise
291	vs	_	_	I-Premise
292	66	_	_	I-Premise
293	%	_	_	I-Premise
294	;	_	_	I-Premise
295	P=.077	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Treatment	_	_	B-Claim
299	with	_	_	I-Claim
300	either	_	_	I-Claim
301	paclitaxel	_	_	I-Claim
302	or	_	_	I-Claim
303	PLD	_	_	I-Claim
304	appears	_	_	I-Claim
305	to	_	_	I-Claim
306	produce	_	_	I-Claim
307	significant	_	_	I-Claim
308	improvements	_	_	I-Claim
309	in	_	_	I-Claim
310	pain	_	_	I-Claim
311	and	_	_	I-Claim
312	swelling	_	_	I-Claim
313	in	_	_	I-Claim
314	patients	_	_	I-Claim
315	with	_	_	I-Claim
316	advanced	_	_	I-Claim
317	,	_	_	I-Claim
318	symptomatic	_	_	I-Claim
319	,	_	_	I-Claim
320	HIV-associated	_	_	I-Claim
321	KS	_	_	I-Claim
322	treated	_	_	I-Claim
323	in	_	_	I-Claim
324	the	_	_	I-Claim
325	HAART	_	_	I-Claim
326	era	_	_	I-Claim
327	.	_	_	I-Claim


0	Sentinel	_	_	O
1	lymph	_	_	O
2	node	_	_	O
3	resection	_	_	O
4	(	_	_	O
5	SNR	_	_	O
6	)	_	_	O
7	may	_	_	O
8	reduce	_	_	O
9	morbidity	_	_	O
10	while	_	_	O
11	providing	_	_	O
12	the	_	_	O
13	same	_	_	O
14	clinical	_	_	O
15	utility	_	_	O
16	as	_	_	O
17	conventional	_	_	O
18	axillary	_	_	O
19	dissection	_	_	O
20	(	_	_	O
21	AD	_	_	O
22	)	_	_	O
23	.	_	_	O

24	National	_	_	O
25	Surgical	_	_	O
26	Adjuvant	_	_	O
27	Breast	_	_	O
28	and	_	_	O
29	Bowel	_	_	O
30	Project	_	_	O
31	(	_	_	O
32	NSABP	_	_	O
33	)	_	_	O
34	B-32	_	_	O
35	is	_	_	O
36	a	_	_	O
37	randomized	_	_	O
38	phase	_	_	O
39	III	_	_	O
40	trial	_	_	O
41	comparing	_	_	O
42	SNR	_	_	O
43	immediately	_	_	O
44	followed	_	_	O
45	by	_	_	O
46	AD	_	_	O
47	(	_	_	O
48	SNAD	_	_	O
49	)	_	_	O
50	to	_	_	O
51	SNR	_	_	O
52	and	_	_	O
53	subsequent	_	_	O
54	AD	_	_	O
55	if	_	_	O
56	SN	_	_	O
57	is	_	_	O
58	positive	_	_	O
59	.	_	_	O

60	We	_	_	O
61	report	_	_	O
62	the	_	_	O
63	definitive	_	_	O
64	patient-reported	_	_	O
65	outcomes	_	_	O
66	(	_	_	O
67	PRO	_	_	O
68	)	_	_	O
69	comparisons	_	_	O
70	.	_	_	O

71	Eligible	_	_	O
72	patients	_	_	O
73	had	_	_	O
74	clinically	_	_	O
75	node-negative	_	_	O
76	,	_	_	O
77	operable	_	_	O
78	invasive	_	_	O
79	breast	_	_	O
80	cancer	_	_	O
81	.	_	_	O

82	The	_	_	O
83	PRO	_	_	O
84	substudy	_	_	O
85	included	_	_	O
86	all	_	_	O
87	SN-negative	_	_	O
88	participants	_	_	O
89	enrolled	_	_	O
90	May	_	_	O
91	2001	_	_	O
92	to	_	_	O
93	February	_	_	O
94	2004	_	_	O
95	at	_	_	O
96	community	_	_	O
97	institutions	_	_	O
98	in	_	_	O
99	the	_	_	O
100	United	_	_	O
101	States	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	749	_	_	O
106	;	_	_	O
107	78	_	_	O
108	%	_	_	O
109	age	_	_	O
110	>	_	_	O
111	or	_	_	O
112	=	_	_	O
113	50	_	_	O
114	;	_	_	O
115	87	_	_	O
116	%	_	_	O
117	clinical	_	_	O
118	tumor	_	_	O
119	size	_	_	O
120	<	_	_	O
121	or	_	_	O
122	=	_	_	O
123	2.0	_	_	O
124	cm	_	_	O
125	;	_	_	O
126	84	_	_	O
127	%	_	_	O
128	lumpectomy	_	_	O
129	;	_	_	O
130	87	_	_	O
131	%	_	_	O
132	white	_	_	O
133	)	_	_	O
134	.	_	_	O

135	They	_	_	O
136	completed	_	_	O
137	questionnaires	_	_	O
138	presurgery	_	_	O
139	,	_	_	O
140	1	_	_	O
141	and	_	_	O
142	2	_	_	O
143	to	_	_	O
144	3	_	_	O
145	weeks	_	_	O
146	postoperatively	_	_	O
147	,	_	_	O
148	and	_	_	O
149	every	_	_	O
150	6	_	_	O
151	months	_	_	O
152	through	_	_	O
153	year	_	_	O
154	3	_	_	O
155	.	_	_	O

156	Arm	_	_	O
157	symptoms	_	_	O
158	,	_	_	O
159	arm	_	_	O
160	use	_	_	O
161	avoidance	_	_	O
162	,	_	_	O
163	activity	_	_	O
164	limitations	_	_	O
165	,	_	_	O
166	and	_	_	O
167	quality	_	_	O
168	of	_	_	O
169	life	_	_	O
170	(	_	_	O
171	QOL	_	_	O
172	)	_	_	O
173	were	_	_	O
174	compared	_	_	O
175	with	_	_	O
176	intent-to-treat	_	_	O
177	two-sample	_	_	O
178	t-tests	_	_	O
179	and	_	_	O
180	repeated	_	_	O
181	measures	_	_	O
182	analyses	_	_	O
183	.	_	_	O

184	Arm	_	_	B-Premise
185	symptoms	_	_	I-Premise
186	were	_	_	I-Premise
187	significantly	_	_	I-Premise
188	more	_	_	I-Premise
189	bothersome	_	_	I-Premise
190	for	_	_	I-Premise
191	SNAD	_	_	I-Premise
192	compared	_	_	I-Premise
193	with	_	_	I-Premise
194	SNR	_	_	I-Premise
195	patients	_	_	I-Premise
196	at	_	_	I-Premise
197	6	_	_	I-Premise
198	months	_	_	I-Premise
199	(	_	_	I-Premise
200	mean	_	_	I-Premise
201	,	_	_	I-Premise
202	4.8	_	_	I-Premise
203	v	_	_	I-Premise
204	3.0	_	_	I-Premise
205	;	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.001	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	at	_	_	I-Premise
212	12	_	_	I-Premise
213	months	_	_	I-Premise
214	(	_	_	I-Premise
215	3.6	_	_	I-Premise
216	v	_	_	I-Premise
217	2.5	_	_	I-Premise
218	;	_	_	I-Premise
219	P	_	_	I-Premise
220	=	_	_	I-Premise
221	.006	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	Longitudinally	_	_	B-Premise
225	,	_	_	I-Premise
226	SNAD	_	_	I-Premise
227	patients	_	_	I-Premise
228	were	_	_	I-Premise
229	more	_	_	I-Premise
230	likely	_	_	I-Premise
231	to	_	_	I-Premise
232	experience	_	_	I-Premise
233	ipsilateral	_	_	I-Premise
234	arm	_	_	I-Premise
235	and	_	_	I-Premise
236	breast	_	_	I-Premise
237	symptoms	_	_	I-Premise
238	,	_	_	I-Premise
239	restricted	_	_	I-Premise
240	work	_	_	I-Premise
241	and	_	_	I-Premise
242	social	_	_	I-Premise
243	activity	_	_	I-Premise
244	,	_	_	I-Premise
245	and	_	_	I-Premise
246	impaired	_	_	I-Premise
247	QOL	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	or	_	_	I-Premise
252	=	_	_	I-Premise
253	.002	_	_	I-Premise
254	all	_	_	I-Premise
255	items	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	From	_	_	B-Premise
259	12	_	_	I-Premise
260	to	_	_	I-Premise
261	36	_	_	I-Premise
262	months	_	_	I-Premise
263	,	_	_	I-Premise
264	fewer	_	_	I-Premise
265	than	_	_	I-Premise
266	15	_	_	I-Premise
267	%	_	_	I-Premise
268	of	_	_	I-Premise
269	either	_	_	I-Premise
270	SNAD	_	_	I-Premise
271	or	_	_	I-Premise
272	SNR	_	_	I-Premise
273	patients	_	_	I-Premise
274	reported	_	_	I-Premise
275	moderate	_	_	I-Premise
276	or	_	_	I-Premise
277	greater	_	_	I-Premise
278	severity	_	_	I-Premise
279	of	_	_	I-Premise
280	any	_	_	I-Premise
281	given	_	_	I-Premise
282	symptom	_	_	I-Premise
283	or	_	_	I-Premise
284	activity	_	_	I-Premise
285	limitation	_	_	I-Premise
286	.	_	_	I-Premise

287	Arm	_	_	B-Claim
288	morbidity	_	_	I-Claim
289	was	_	_	I-Claim
290	greater	_	_	I-Claim
291	with	_	_	I-Claim
292	SNAD	_	_	I-Claim
293	than	_	_	I-Claim
294	with	_	_	I-Claim
295	SNR	_	_	I-Claim
296	.	_	_	I-Claim

297	Despite	_	_	O
298	considerable	_	_	O
299	fears	_	_	O
300	about	_	_	O
301	complications	_	_	O
302	from	_	_	O
303	AD	_	_	O
304	for	_	_	O
305	breast	_	_	O
306	cancer	_	_	O
307	,	_	_	O
308	this	_	_	B-Claim
309	study	_	_	I-Claim
310	demonstrates	_	_	I-Claim
311	that	_	_	I-Claim
312	initial	_	_	I-Claim
313	problems	_	_	I-Claim
314	with	_	_	I-Claim
315	either	_	_	I-Claim
316	surgery	_	_	I-Claim
317	resolve	_	_	I-Claim
318	over	_	_	I-Claim
319	time	_	_	I-Claim
320	.	_	_	I-Claim


0	The	_	_	O
1	EORTC	_	_	O
2	24971/TAX	_	_	O
3	323	_	_	O
4	,	_	_	O
5	a	_	_	O
6	phase	_	_	O
7	III	_	_	O
8	study	_	_	O
9	of	_	_	O
10	358	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	unresectable	_	_	O
14	locoregionally	_	_	O
15	advanced	_	_	O
16	squamous	_	_	O
17	cell	_	_	O
18	carcinoma	_	_	O
19	of	_	_	O
20	the	_	_	O
21	head	_	_	O
22	and	_	_	O
23	neck	_	_	O
24	,	_	_	O
25	showed	_	_	O
26	an	_	_	O
27	improved	_	_	O
28	progression-free	_	_	O
29	and	_	_	O
30	overall	_	_	O
31	survival	_	_	O
32	(	_	_	O
33	OS	_	_	O
34	)	_	_	O
35	with	_	_	O
36	less	_	_	O
37	toxicity	_	_	O
38	when	_	_	O
39	docetaxel	_	_	O
40	(	_	_	O
41	T	_	_	O
42	)	_	_	O
43	was	_	_	O
44	added	_	_	O
45	to	_	_	O
46	cisplatin	_	_	O
47	and	_	_	O
48	5-fluorouracil	_	_	O
49	(	_	_	O
50	PF	_	_	O
51	)	_	_	O
52	for	_	_	O
53	induction	_	_	O
54	and	_	_	O
55	given	_	_	O
56	before	_	_	O
57	radiotherapy	_	_	O
58	(	_	_	O
59	RT	_	_	O
60	)	_	_	O
61	.	_	_	O

62	The	_	_	O
63	impact	_	_	O
64	of	_	_	O
65	the	_	_	O
66	addition	_	_	O
67	of	_	_	O
68	docetaxel	_	_	O
69	on	_	_	O
70	patients	_	_	O
71	'	_	_	O
72	health-related	_	_	O
73	quality	_	_	O
74	of	_	_	O
75	life	_	_	O
76	(	_	_	O
77	HRQOL	_	_	O
78	)	_	_	O
79	and	_	_	O
80	symptoms	_	_	O
81	was	_	_	O
82	investigated	_	_	O
83	.	_	_	O

84	HRQOL	_	_	O
85	was	_	_	O
86	assessed	_	_	O
87	at	_	_	O
88	baseline	_	_	O
89	,	_	_	O
90	at	_	_	O
91	end	_	_	O
92	of	_	_	O
93	cycle	_	_	O
94	2	_	_	O
95	,	_	_	O
96	and	_	_	O
97	4	_	_	O
98	,	_	_	O
99	6	_	_	O
100	,	_	_	O
101	and	_	_	O
102	9	_	_	O
103	months	_	_	O
104	after	_	_	O
105	completion	_	_	O
106	of	_	_	O
107	RT	_	_	O
108	using	_	_	O
109	the	_	_	O
110	European	_	_	O
111	Organisation	_	_	O
112	for	_	_	O
113	Research	_	_	O
114	and	_	_	O
115	Treatment	_	_	O
116	of	_	_	O
117	Cancer	_	_	O
118	(	_	_	O
119	EORTC	_	_	O
120	)	_	_	O
121	Quality	_	_	O
122	of	_	_	O
123	Life	_	_	O
124	Questionnaire	_	_	O
125	C30	_	_	O
126	(	_	_	O
127	QLQ-C30	_	_	O
128	)	_	_	O
129	and	_	_	O
130	the	_	_	O
131	EORTC	_	_	O
132	QLQ	_	_	O
133	Head	_	_	O
134	and	_	_	O
135	Neck	_	_	O
136	Cancer-Specific	_	_	O
137	Module	_	_	O
138	(	_	_	O
139	EORTC	_	_	O
140	QLQ-H	_	_	O
141	&	_	_	O
142	amp	_	_	O
143	;	_	_	O
144	N35	_	_	O
145	)	_	_	O
146	.	_	_	O

147	The	_	_	O
148	primary	_	_	O
149	HRQOL	_	_	O
150	scale	_	_	O
151	was	_	_	O
152	global	_	_	O
153	HRQOL	_	_	O
154	per	_	_	O
155	protocol	_	_	O
156	.	_	_	O

157	Compliance	_	_	O
158	to	_	_	O
159	HRQOL	_	_	O
160	assessments	_	_	O
161	was	_	_	O
162	97	_	_	O
163	%	_	_	O
164	at	_	_	O
165	baseline	_	_	O
166	,	_	_	O
167	but	_	_	O
168	dropped	_	_	O
169	to	_	_	O
170	54	_	_	O
171	%	_	_	O
172	by	_	_	O
173	6	_	_	O
174	months	_	_	O
175	.	_	_	O

176	Data	_	_	O
177	were	_	_	O
178	analysed	_	_	O
179	up	_	_	O
180	to	_	_	O
181	6	_	_	O
182	months	_	_	O
183	.	_	_	O

184	There	_	_	B-Premise
185	was	_	_	I-Premise
186	a	_	_	I-Premise
187	trend	_	_	I-Premise
188	towards	_	_	I-Premise
189	improved	_	_	I-Premise
190	global	_	_	I-Premise
191	HRQOL	_	_	I-Premise
192	during	_	_	I-Premise
193	the	_	_	I-Premise
194	treatment	_	_	I-Premise
195	period	_	_	I-Premise
196	.	_	_	I-Premise

197	At	_	_	B-Premise
198	6	_	_	I-Premise
199	months	_	_	I-Premise
200	after	_	_	I-Premise
201	the	_	_	I-Premise
202	end	_	_	I-Premise
203	of	_	_	I-Premise
204	RT	_	_	I-Premise
205	,	_	_	I-Premise
206	global	_	_	I-Premise
207	HRQOL	_	_	I-Premise
208	was	_	_	I-Premise
209	higher	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	TPF	_	_	I-Premise
213	arm	_	_	I-Premise
214	than	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	PF	_	_	I-Premise
218	arm	_	_	I-Premise
219	,	_	_	I-Premise
220	but	_	_	B-Premise
221	the	_	_	I-Premise
222	low	_	_	I-Premise
223	compliance	_	_	I-Premise
224	does	_	_	I-Premise
225	not	_	_	I-Premise
226	allow	_	_	I-Premise
227	to	_	_	I-Premise
228	draw	_	_	I-Premise
229	definitive	_	_	I-Premise
230	conclusions	_	_	I-Premise
231	.	_	_	I-Premise

232	Swallowing	_	_	B-Premise
233	and	_	_	I-Premise
234	coughing	_	_	I-Premise
235	problems	_	_	I-Premise
236	decreased	_	_	I-Premise
237	more	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	TPF	_	_	I-Premise
241	arm	_	_	I-Premise
242	than	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	PF	_	_	I-Premise
246	arm	_	_	I-Premise
247	at	_	_	I-Premise
248	the	_	_	I-Premise
249	end	_	_	I-Premise
250	of	_	_	I-Premise
251	cycle	_	_	I-Premise
252	2	_	_	I-Premise
253	,	_	_	I-Premise
254	but	_	_	B-Premise
255	to	_	_	I-Premise
256	a	_	_	I-Premise
257	limited	_	_	I-Premise
258	extent	_	_	I-Premise
259	.	_	_	I-Premise

260	Induction	_	_	B-Claim
261	chemotherapy	_	_	I-Claim
262	with	_	_	I-Claim
263	TPF	_	_	I-Claim
264	before	_	_	I-Claim
265	RT	_	_	I-Claim
266	not	_	_	I-Claim
267	only	_	_	I-Claim
268	improves	_	_	I-Claim
269	survival	_	_	I-Claim
270	and	_	_	I-Claim
271	reduces	_	_	I-Claim
272	toxicity	_	_	I-Claim
273	compared	_	_	I-Claim
274	with	_	_	I-Claim
275	PF	_	_	I-Claim
276	but	_	_	I-Claim
277	also	_	_	I-Claim
278	seems	_	_	I-Claim
279	to	_	_	I-Claim
280	improve	_	_	I-Claim
281	global	_	_	I-Claim
282	HRQOL	_	_	I-Claim
283	in	_	_	I-Claim
284	a	_	_	I-Claim
285	more	_	_	I-Claim
286	sustainable	_	_	I-Claim
287	manner	_	_	I-Claim
288	.	_	_	I-Claim


0	Compared	_	_	O
1	with	_	_	O
2	placebo	_	_	O
3	,	_	_	O
4	prophylactic	_	_	O
5	treatment	_	_	O
6	with	_	_	O
7	bisphosphonates	_	_	O
8	reduces	_	_	O
9	risk	_	_	O
10	of	_	_	O
11	skeletal	_	_	O
12	events	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	multiple	_	_	O
17	myeloma	_	_	O
18	.	_	_	O

19	However	_	_	O
20	,	_	_	O
21	because	_	_	O
22	of	_	_	O
23	toxicity	_	_	O
24	associated	_	_	O
25	with	_	_	O
26	long-term	_	_	O
27	bisphosphonate	_	_	O
28	treatment	_	_	O
29	,	_	_	O
30	establishing	_	_	O
31	the	_	_	O
32	lowest	_	_	O
33	effective	_	_	O
34	dose	_	_	O
35	is	_	_	O
36	important	_	_	O
37	.	_	_	O

38	This	_	_	O
39	study	_	_	O
40	compared	_	_	O
41	the	_	_	O
42	effect	_	_	O
43	of	_	_	O
44	two	_	_	O
45	doses	_	_	O
46	of	_	_	O
47	pamidronate	_	_	O
48	on	_	_	O
49	health-related	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	and	_	_	O
54	skeletal	_	_	O
55	morbidity	_	_	O
56	in	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	newly	_	_	O
60	diagnosed	_	_	O
61	multiple	_	_	O
62	myeloma	_	_	O
63	.	_	_	O

64	This	_	_	O
65	double-blind	_	_	O
66	,	_	_	O
67	randomised	_	_	O
68	,	_	_	O
69	phase	_	_	O
70	3	_	_	O
71	trial	_	_	O
72	was	_	_	O
73	undertaken	_	_	O
74	at	_	_	O
75	37	_	_	O
76	clinics	_	_	O
77	in	_	_	O
78	Denmark	_	_	O
79	,	_	_	O
80	Norway	_	_	O
81	,	_	_	O
82	and	_	_	O
83	Sweden	_	_	O
84	.	_	_	O

85	Patients	_	_	O
86	with	_	_	O
87	multiple	_	_	O
88	myeloma	_	_	O
89	who	_	_	O
90	were	_	_	O
91	starting	_	_	O
92	antimyeloma	_	_	O
93	treatment	_	_	O
94	were	_	_	O
95	randomly	_	_	O
96	assigned	_	_	O
97	in	_	_	O
98	a	_	_	O
99	1:1	_	_	O
100	ratio	_	_	O
101	to	_	_	O
102	receive	_	_	O
103	one	_	_	O
104	of	_	_	O
105	two	_	_	O
106	doses	_	_	O
107	of	_	_	O
108	pamidronate	_	_	O
109	(	_	_	O
110	30	_	_	O
111	mg	_	_	O
112	or	_	_	O
113	90	_	_	O
114	mg	_	_	O
115	)	_	_	O
116	given	_	_	O
117	by	_	_	O
118	intravenous	_	_	O
119	infusion	_	_	O
120	once	_	_	O
121	a	_	_	O
122	month	_	_	O
123	for	_	_	O
124	at	_	_	O
125	least	_	_	O
126	3	_	_	O
127	years	_	_	O
128	.	_	_	O

129	Randomisation	_	_	O
130	was	_	_	O
131	done	_	_	O
132	by	_	_	O
133	use	_	_	O
134	of	_	_	O
135	a	_	_	O
136	central	_	_	O
137	,	_	_	O
138	computerised	_	_	O
139	minimisation	_	_	O
140	system	_	_	O
141	.	_	_	O

142	Primary	_	_	O
143	outcome	_	_	O
144	was	_	_	O
145	physical	_	_	O
146	function	_	_	O
147	after	_	_	O
148	12	_	_	O
149	months	_	_	O
150	estimated	_	_	O
151	by	_	_	O
152	the	_	_	O
153	European	_	_	O
154	Organisation	_	_	O
155	for	_	_	O
156	Research	_	_	O
157	and	_	_	O
158	Treatment	_	_	O
159	of	_	_	O
160	Cancer	_	_	O
161	(	_	_	O
162	EORTC	_	_	O
163	)	_	_	O
164	QLQ-C30	_	_	O
165	questionnaire	_	_	O
166	(	_	_	O
167	scale	_	_	O
168	0-100	_	_	O
169	)	_	_	O
170	.	_	_	O

171	All	_	_	O
172	patients	_	_	O
173	who	_	_	O
174	returned	_	_	O
175	questionnaires	_	_	O
176	at	_	_	O
177	12	_	_	O
178	months	_	_	O
179	and	_	_	O
180	were	_	_	O
181	still	_	_	O
182	on	_	_	O
183	study	_	_	O
184	treatment	_	_	O
185	were	_	_	O
186	included	_	_	O
187	in	_	_	O
188	the	_	_	O
189	analysis	_	_	O
190	of	_	_	O
191	the	_	_	O
192	primary	_	_	O
193	endpoint	_	_	O
194	.	_	_	O

195	From	_	_	O
196	January	_	_	O
197	,	_	_	O
198	2001	_	_	O
199	,	_	_	O
200	until	_	_	O
201	August	_	_	O
202	,	_	_	O
203	2005	_	_	O
204	,	_	_	O
205	504	_	_	O
206	patients	_	_	O
207	were	_	_	O
208	randomly	_	_	O
209	assigned	_	_	O
210	to	_	_	O
211	pamidronate	_	_	O
212	30	_	_	O
213	mg	_	_	O
214	or	_	_	O
215	90	_	_	O
216	mg	_	_	O
217	(	_	_	O
218	252	_	_	O
219	in	_	_	O
220	each	_	_	O
221	group	_	_	O
222	)	_	_	O
223	.	_	_	O

224	157	_	_	O
225	patients	_	_	O
226	in	_	_	O
227	the	_	_	O
228	90	_	_	O
229	mg	_	_	O
230	group	_	_	O
231	and	_	_	O
232	156	_	_	O
233	in	_	_	O
234	the	_	_	O
235	30	_	_	O
236	mg	_	_	O
237	group	_	_	O
238	were	_	_	O
239	included	_	_	O
240	in	_	_	O
241	the	_	_	O
242	primary	_	_	O
243	analysis	_	_	O
244	.	_	_	O

245	Mean	_	_	B-Premise
246	physical	_	_	I-Premise
247	function	_	_	I-Premise
248	at	_	_	I-Premise
249	12	_	_	I-Premise
250	months	_	_	I-Premise
251	was	_	_	I-Premise
252	66	_	_	I-Premise
253	points	_	_	I-Premise
254	(	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	629-700	_	_	I-Premise
259	)	_	_	I-Premise
260	in	_	_	I-Premise
261	the	_	_	I-Premise
262	90	_	_	I-Premise
263	mg	_	_	I-Premise
264	group	_	_	I-Premise
265	and	_	_	I-Premise
266	68	_	_	I-Premise
267	points	_	_	I-Premise
268	(	_	_	I-Premise
269	646-714	_	_	I-Premise
270	)	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	30	_	_	I-Premise
274	mg	_	_	I-Premise
275	group	_	_	I-Premise
276	(	_	_	I-Premise
277	95	_	_	I-Premise
278	%	_	_	I-Premise
279	CI	_	_	I-Premise
280	of	_	_	I-Premise
281	difference	_	_	I-Premise
282	-66	_	_	I-Premise
283	to	_	_	I-Premise
284	33	_	_	I-Premise
285	;	_	_	I-Premise
286	p=052	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	Median	_	_	B-Premise
290	time	_	_	I-Premise
291	to	_	_	I-Premise
292	first	_	_	I-Premise
293	skeletal-related	_	_	I-Premise
294	event	_	_	I-Premise
295	in	_	_	I-Premise
296	patients	_	_	I-Premise
297	who	_	_	I-Premise
298	had	_	_	I-Premise
299	such	_	_	I-Premise
300	an	_	_	I-Premise
301	event	_	_	I-Premise
302	was	_	_	I-Premise
303	92	_	_	I-Premise
304	months	_	_	I-Premise
305	(	_	_	I-Premise
306	81-107	_	_	I-Premise
307	)	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	90	_	_	I-Premise
311	mg	_	_	I-Premise
312	group	_	_	I-Premise
313	and	_	_	I-Premise
314	102	_	_	I-Premise
315	months	_	_	I-Premise
316	(	_	_	I-Premise
317	73-140	_	_	I-Premise
318	)	_	_	I-Premise
319	in	_	_	I-Premise
320	the	_	_	I-Premise
321	30	_	_	I-Premise
322	mg	_	_	I-Premise
323	group	_	_	I-Premise
324	(	_	_	I-Premise
325	p=063	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	In	_	_	O
329	a	_	_	O
330	retrospective	_	_	O
331	analysis	_	_	O
332	,	_	_	O
333	eight	_	_	B-Premise
334	patients	_	_	I-Premise
335	in	_	_	I-Premise
336	the	_	_	I-Premise
337	pamidronate	_	_	I-Premise
338	90	_	_	I-Premise
339	mg	_	_	I-Premise
340	group	_	_	I-Premise
341	developed	_	_	I-Premise
342	osteonecrosis	_	_	I-Premise
343	of	_	_	I-Premise
344	the	_	_	I-Premise
345	jaw	_	_	I-Premise
346	compared	_	_	I-Premise
347	with	_	_	I-Premise
348	two	_	_	I-Premise
349	patients	_	_	I-Premise
350	in	_	_	I-Premise
351	the	_	_	I-Premise
352	30	_	_	I-Premise
353	mg	_	_	I-Premise
354	group	_	_	I-Premise
355	.	_	_	I-Premise

356	Monthly	_	_	B-Claim
357	infusion	_	_	I-Claim
358	of	_	_	I-Claim
359	pamidronate	_	_	I-Claim
360	30	_	_	I-Claim
361	mg	_	_	I-Claim
362	should	_	_	I-Claim
363	be	_	_	I-Claim
364	the	_	_	I-Claim
365	recommended	_	_	I-Claim
366	dose	_	_	I-Claim
367	for	_	_	I-Claim
368	prevention	_	_	I-Claim
369	of	_	_	I-Claim
370	bone	_	_	I-Claim
371	disease	_	_	I-Claim
372	in	_	_	I-Claim
373	patients	_	_	I-Claim
374	with	_	_	I-Claim
375	multiple	_	_	I-Claim
376	myeloma	_	_	I-Claim
377	.	_	_	I-Claim


0	Chemotherapy-induced	_	_	O
1	anemia	_	_	O
2	(	_	_	O
3	CIA	_	_	O
4	)	_	_	O
5	is	_	_	O
6	responsive	_	_	O
7	to	_	_	O
8	treatment	_	_	O
9	with	_	_	O
10	erythropoiesis-stimulating	_	_	O
11	agents	_	_	O
12	(	_	_	O
13	ESAs	_	_	O
14	)	_	_	O
15	such	_	_	O
16	as	_	_	O
17	darbepoetin	_	_	O
18	alfa	_	_	O
19	.	_	_	O

20	Administration	_	_	O
21	of	_	_	O
22	ESAs	_	_	O
23	on	_	_	O
24	a	_	_	O
25	synchronous	_	_	O
26	schedule	_	_	O
27	with	_	_	O
28	chemotherapy	_	_	O
29	administration	_	_	O
30	could	_	_	O
31	benefit	_	_	O
32	patients	_	_	O
33	by	_	_	O
34	reducing	_	_	O
35	clinic	_	_	O
36	visits	_	_	O
37	and	_	_	O
38	potentially	_	_	O
39	enhancing	_	_	O
40	on-time	_	_	O
41	chemotherapy	_	_	O
42	delivery	_	_	O
43	.	_	_	O

44	This	_	_	O
45	phase	_	_	O
46	2	_	_	O
47	,	_	_	O
48	25-week	_	_	O
49	,	_	_	O
50	open-label	_	_	O
51	study	_	_	O
52	evaluated	_	_	O
53	the	_	_	O
54	noninferiority	_	_	O
55	of	_	_	O
56	darbepoetin	_	_	O
57	alfa	_	_	O
58	administered	_	_	O
59	weekly	_	_	O
60	vs.	_	_	O
61	as	_	_	O
62	an	_	_	O
63	extended	_	_	O
64	dosing	_	_	O
65	schedule	_	_	O
66	(	_	_	O
67	every	_	_	O
68	2	_	_	O
69	or	_	_	O
70	3	_	_	O
71	weeks	_	_	O
72	)	_	_	O
73	in	_	_	O
74	patients	_	_	O
75	with	_	_	O
76	CIA	_	_	O
77	.	_	_	O

78	Patients	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	1:1	_	_	O
82	to	_	_	O
83	an	_	_	O
84	extended	_	_	O
85	dosing	_	_	O
86	schedule	_	_	O
87	(	_	_	O
88	EDS	_	_	O
89	:	_	_	O
90	darbepoetin	_	_	O
91	alfa	_	_	O
92	300	_	_	O
93	g	_	_	O
94	Q2W	_	_	O
95	if	_	_	O
96	chemotherapy	_	_	O
97	was	_	_	O
98	QW	_	_	O
99	,	_	_	O
100	Q2W	_	_	O
101	,	_	_	O
102	or	_	_	O
103	Q4W	_	_	O
104	or	_	_	O
105	darbepoetin	_	_	O
106	alfa	_	_	O
107	500	_	_	O
108	g	_	_	O
109	Q3W	_	_	O
110	if	_	_	O
111	chemotherapy	_	_	O
112	was	_	_	O
113	Q3W	_	_	O
114	)	_	_	O
115	or	_	_	O
116	weekly	_	_	O
117	(	_	_	O
118	150	_	_	O
119	g	_	_	O
120	QW	_	_	O
121	regardless	_	_	O
122	of	_	_	O
123	chemotherapy	_	_	O
124	schedule	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Stratification	_	_	O
128	factors	_	_	O
129	included	_	_	O
130	chemotherapy	_	_	O
131	cycle	_	_	O
132	length	_	_	O
133	,	_	_	O
134	screening	_	_	O
135	hemoglobin	_	_	O
136	(	_	_	O
137	<	_	_	O
138	10	_	_	O
139	g/dL	_	_	O
140	vs.	_	_	O
141	10	_	_	O
142	g/dL	_	_	O
143	)	_	_	O
144	,	_	_	O
145	and	_	_	O
146	tumor	_	_	O
147	type	_	_	O
148	(	_	_	O
149	lung/gynecological	_	_	O
150	vs.	_	_	O
151	other	_	_	O
152	nonmyeloid	_	_	O
153	malignancies	_	_	O
154	)	_	_	O
155	.	_	_	O

156	The	_	_	O
157	primary	_	_	O
158	endpoint	_	_	O
159	was	_	_	O
160	change	_	_	O
161	in	_	_	O
162	hemoglobin	_	_	O
163	from	_	_	O
164	baseline	_	_	O
165	to	_	_	O
166	Week	_	_	O
167	13	_	_	O
168	.	_	_	O

169	Seven	_	_	O
170	hundred	_	_	O
171	fifty-two	_	_	O
172	patients	_	_	O
173	(	_	_	O
174	374	_	_	O
175	QW	_	_	O
176	patients	_	_	O
177	;	_	_	O
178	378	_	_	O
179	EDS	_	_	O
180	patients	_	_	O
181	)	_	_	O
182	received	_	_	O
183	1	_	_	O
184	dose	_	_	O
185	of	_	_	O
186	darbepoetin	_	_	O
187	alfa	_	_	O
188	and	_	_	O
189	were	_	_	O
190	included	_	_	O
191	in	_	_	O
192	the	_	_	O
193	analysis	_	_	O
194	.	_	_	O

195	Demographics	_	_	O
196	and	_	_	O
197	disease	_	_	O
198	state	_	_	O
199	were	_	_	O
200	similar	_	_	O
201	between	_	_	O
202	groups	_	_	O
203	.	_	_	O

204	Seventy-one	_	_	B-Premise
205	percent	_	_	I-Premise
206	of	_	_	I-Premise
207	patients	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	EDS	_	_	I-Premise
211	group	_	_	I-Premise
212	and	_	_	I-Premise
213	76	_	_	I-Premise
214	%	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	QW	_	_	I-Premise
218	group	_	_	I-Premise
219	achieved	_	_	I-Premise
220	the	_	_	I-Premise
221	target	_	_	I-Premise
222	hemoglobin	_	_	I-Premise
223	of	_	_	I-Premise
224	11.0	_	_	I-Premise
225	g/dL	_	_	I-Premise
226	.	_	_	I-Premise

227	There	_	_	O
228	was	_	_	O
229	a	_	_	O
230	minimal	_	_	O
231	difference	_	_	O
232	in	_	_	O
233	the	_	_	O
234	primary	_	_	O
235	endpoint	_	_	O
236	of	_	_	O
237	mean	_	_	O
238	change	_	_	O
239	in	_	_	O
240	hemoglobin	_	_	O
241	(	_	_	O
242	baseline	_	_	O
243	to	_	_	O
244	Week	_	_	O
245	13	_	_	O
246	)	_	_	O
247	between	_	_	O
248	the	_	_	O
249	QW	_	_	O
250	and	_	_	O
251	the	_	_	O
252	EDS	_	_	O
253	groups	_	_	O
254	(	_	_	O
255	-0.04	_	_	O
256	g/dL	_	_	O
257	;	_	_	O
258	95	_	_	O
259	%	_	_	O
260	confidence	_	_	O
261	interval	_	_	O
262	:	_	_	O
263	-0.26	_	_	O
264	,	_	_	O
265	0.17	_	_	O
266	g/dL	_	_	O
267	)	_	_	O
268	.	_	_	O

269	The	_	_	O
270	upper	_	_	O
271	limit	_	_	O
272	of	_	_	O
273	the	_	_	O
274	95	_	_	O
275	%	_	_	O
276	confidence	_	_	O
277	interval	_	_	O
278	was	_	_	O
279	less	_	_	O
280	than	_	_	O
281	the	_	_	O
282	prespecified	_	_	O
283	limit	_	_	O
284	of	_	_	O
285	<	_	_	O
286	0.75	_	_	O
287	g/dL	_	_	O
288	,	_	_	O
289	supporting	_	_	O
290	noninferiority	_	_	O
291	of	_	_	O
292	the	_	_	O
293	EDS	_	_	O
294	dosing	_	_	O
295	schedule	_	_	O
296	.	_	_	O

297	Reported	_	_	B-Premise
298	adverse	_	_	I-Premise
299	events	_	_	I-Premise
300	were	_	_	I-Premise
301	similar	_	_	I-Premise
302	between	_	_	I-Premise
303	groups	_	_	I-Premise
304	.	_	_	I-Premise

305	A	_	_	B-Premise
306	slight	_	_	I-Premise
307	increase	_	_	I-Premise
308	in	_	_	I-Premise
309	transfusions	_	_	I-Premise
310	was	_	_	I-Premise
311	reported	_	_	I-Premise
312	in	_	_	I-Premise
313	the	_	_	I-Premise
314	QW	_	_	I-Premise
315	group	_	_	I-Premise
316	.	_	_	I-Premise

317	Darbepoetin	_	_	B-Claim
318	alfa	_	_	I-Claim
319	,	_	_	I-Claim
320	when	_	_	I-Claim
321	administered	_	_	I-Claim
322	synchronously	_	_	I-Claim
323	with	_	_	I-Claim
324	chemotherapy	_	_	I-Claim
325	,	_	_	I-Claim
326	on	_	_	I-Claim
327	an	_	_	I-Claim
328	EDS	_	_	I-Claim
329	appears	_	_	I-Claim
330	to	_	_	I-Claim
331	be	_	_	I-Claim
332	similarly	_	_	I-Claim
333	efficacious	_	_	I-Claim
334	to	_	_	I-Claim
335	darbepoetin	_	_	I-Claim
336	alfa	_	_	I-Claim
337	weekly	_	_	I-Claim
338	dosing	_	_	I-Claim
339	with	_	_	I-Claim
340	no	_	_	I-Claim
341	unexpected	_	_	I-Claim
342	adverse	_	_	I-Claim
343	events	_	_	I-Claim
344	.	_	_	I-Claim

345	This	_	_	O
346	study	_	_	O
347	provides	_	_	O
348	prospective	_	_	O
349	data	_	_	O
350	on	_	_	O
351	how	_	_	O
352	multiple	_	_	O
353	dosing	_	_	O
354	regimens	_	_	O
355	available	_	_	O
356	with	_	_	O
357	darbepoetin	_	_	O
358	alfa	_	_	O
359	can	_	_	O
360	be	_	_	O
361	synchronized	_	_	O
362	with	_	_	O
363	chemotherapy	_	_	O
364	administered	_	_	O
365	across	_	_	O
366	a	_	_	O
367	range	_	_	O
368	of	_	_	O
369	dosing	_	_	O
370	schedules	_	_	O
371	.	_	_	O


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	2-year	_	_	O
10	functional	_	_	O
11	performance	_	_	O
12	and	_	_	O
13	quality	_	_	O
14	of	_	_	O
15	life	_	_	O
16	in	_	_	O
17	patients	_	_	O
18	with	_	_	O
19	operable	_	_	O
20	squamous	_	_	O
21	cell	_	_	O
22	carcinoma	_	_	O
23	of	_	_	O
24	the	_	_	O
25	esophagus	_	_	O
26	,	_	_	O
27	who	_	_	O
28	have	_	_	O
29	received	_	_	O
30	either	_	_	O
31	surgery	_	_	O
32	or	_	_	O
33	definitive	_	_	O
34	chemoradiation	_	_	O
35	(	_	_	O
36	CRT	_	_	O
37	)	_	_	O
38	.	_	_	O

39	The	_	_	O
40	functional	_	_	O
41	outcomes	_	_	O
42	and	_	_	O
43	quality	_	_	O
44	of	_	_	O
45	life	_	_	O
46	in	_	_	O
47	patients	_	_	O
48	receiving	_	_	O
49	esophagectomy	_	_	O
50	or	_	_	O
51	definitive	_	_	O
52	CRT	_	_	O
53	is	_	_	O
54	uncertain	_	_	O
55	.	_	_	O

56	Data	_	_	O
57	were	_	_	O
58	extracted	_	_	O
59	from	_	_	O
60	the	_	_	O
61	database	_	_	O
62	of	_	_	O
63	a	_	_	O
64	prospective	_	_	O
65	randomized	_	_	O
66	controlled	_	_	O
67	trial	_	_	O
68	that	_	_	O
69	included	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	resectable	_	_	O
73	mid	_	_	O
74	or	_	_	O
75	lower	_	_	O
76	thoracic	_	_	O
77	esophageal	_	_	O
78	cancers	_	_	O
79	.	_	_	O

80	The	_	_	O
81	patients	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	either	_	_	O
86	standard	_	_	O
87	esophagectomy	_	_	O
88	or	_	_	O
89	definitive	_	_	O
90	CRT	_	_	O
91	.	_	_	O

92	Quality	_	_	O
93	of	_	_	O
94	life	_	_	O
95	assessments	_	_	O
96	were	_	_	O
97	performed	_	_	O
98	using	_	_	O
99	the	_	_	O
100	EORTC	_	_	O
101	QLQ-C30	_	_	O
102	and	_	_	O
103	QLQ-OES24	_	_	O
104	modules	_	_	O
105	.	_	_	O

106	Other	_	_	O
107	functional	_	_	O
108	assessments	_	_	O
109	included	_	_	O
110	pulmonary	_	_	O
111	and	_	_	O
112	eating	_	_	O
113	functions	_	_	O
114	.	_	_	O

115	From	_	_	O
116	July	_	_	O
117	2000	_	_	O
118	to	_	_	O
119	December	_	_	O
120	2004	_	_	O
121	,	_	_	O
122	a	_	_	O
123	total	_	_	O
124	of	_	_	O
125	81	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	enrolled	_	_	O
129	into	_	_	O
130	the	_	_	O
131	study	_	_	O
132	.	_	_	O

133	No	_	_	B-Premise
134	significant	_	_	I-Premise
135	longitudinal	_	_	I-Premise
136	changes	_	_	I-Premise
137	were	_	_	I-Premise
138	detected	_	_	I-Premise
139	in	_	_	I-Premise
140	the	_	_	I-Premise
141	global	_	_	I-Premise
142	health	_	_	I-Premise
143	status	_	_	I-Premise
144	in	_	_	I-Premise
145	both	_	_	I-Premise
146	groups	_	_	I-Premise
147	upon	_	_	I-Premise
148	available	_	_	I-Premise
149	follow-up	_	_	I-Premise
150	.	_	_	I-Premise

151	Surgery	_	_	B-Premise
152	was	_	_	I-Premise
153	associated	_	_	I-Premise
154	with	_	_	I-Premise
155	worsened	_	_	I-Premise
156	physical	_	_	I-Premise
157	functioning	_	_	I-Premise
158	and	_	_	I-Premise
159	fatigue	_	_	I-Premise
160	symptoms	_	_	I-Premise
161	up	_	_	I-Premise
162	to	_	_	I-Premise
163	6	_	_	I-Premise
164	months	_	_	I-Premise
165	after	_	_	I-Premise
166	treatment	_	_	I-Premise
167	(	_	_	I-Premise
168	P	_	_	I-Premise
169	<	_	_	I-Premise
170	0.001	_	_	I-Premise
171	and	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	0.021	_	_	I-Premise
175	,	_	_	I-Premise
176	respectively	_	_	I-Premise
177	)	_	_	I-Premise
178	and	_	_	I-Premise
179	these	_	_	I-Premise
180	scales	_	_	I-Premise
181	improved	_	_	I-Premise
182	at	_	_	I-Premise
183	2	_	_	I-Premise
184	years	_	_	I-Premise
185	.	_	_	I-Premise

186	In	_	_	B-Premise
187	terms	_	_	I-Premise
188	of	_	_	I-Premise
189	pulmonary	_	_	I-Premise
190	function	_	_	I-Premise
191	,	_	_	I-Premise
192	dyspnoic	_	_	I-Premise
193	and	_	_	I-Premise
194	coughing	_	_	I-Premise
195	symptoms	_	_	I-Premise
196	were	_	_	I-Premise
197	significantly	_	_	I-Premise
198	worsened	_	_	I-Premise
199	3	_	_	I-Premise
200	months	_	_	I-Premise
201	after	_	_	I-Premise
202	surgery	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.024	_	_	I-Premise
207	and	_	_	I-Premise
208	P	_	_	I-Premise
209	=	_	_	I-Premise
210	0.036	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	)	_	_	I-Premise
214	whereas	_	_	I-Premise
215	symptoms	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	CRT	_	_	I-Premise
219	group	_	_	I-Premise
220	progressively	_	_	I-Premise
221	deteriorated	_	_	I-Premise
222	over	_	_	I-Premise
223	time	_	_	I-Premise
224	.	_	_	I-Premise

225	Concerning	_	_	B-Premise
226	the	_	_	I-Premise
227	eating	_	_	I-Premise
228	function	_	_	I-Premise
229	,	_	_	I-Premise
230	both	_	_	I-Premise
231	groups	_	_	I-Premise
232	had	_	_	I-Premise
233	improvements	_	_	I-Premise
234	in	_	_	I-Premise
235	dysphagia	_	_	I-Premise
236	but	_	_	I-Premise
237	there	_	_	I-Premise
238	were	_	_	I-Premise
239	frequent	_	_	I-Premise
240	need	_	_	I-Premise
241	for	_	_	I-Premise
242	endoscopic	_	_	I-Premise
243	intervention	_	_	I-Premise
244	.	_	_	I-Premise

245	Neither	_	_	B-Premise
246	surgery	_	_	I-Premise
247	nor	_	_	I-Premise
248	definitive	_	_	I-Premise
249	CRT	_	_	I-Premise
250	significantly	_	_	I-Premise
251	impaired	_	_	I-Premise
252	the	_	_	I-Premise
253	global	_	_	I-Premise
254	health	_	_	I-Premise
255	status	_	_	I-Premise
256	of	_	_	I-Premise
257	patients	_	_	I-Premise
258	.	_	_	I-Premise

259	Surgery	_	_	B-Claim
260	was	_	_	I-Claim
261	associated	_	_	I-Claim
262	with	_	_	I-Claim
263	a	_	_	I-Claim
264	short-term	_	_	I-Claim
265	negative	_	_	I-Claim
266	impact	_	_	I-Claim
267	in	_	_	I-Claim
268	some	_	_	I-Claim
269	aspects	_	_	I-Claim
270	of	_	_	I-Claim
271	health	_	_	I-Claim
272	related	_	_	I-Claim
273	quality	_	_	I-Claim
274	of	_	_	I-Claim
275	life	_	_	I-Claim
276	assessments	_	_	I-Claim
277	but	_	_	B-Claim
278	these	_	_	I-Claim
279	changes	_	_	I-Claim
280	became	_	_	I-Claim
281	insignificant	_	_	I-Claim
282	2	_	_	I-Claim
283	years	_	_	I-Claim
284	after	_	_	I-Claim
285	treatment	_	_	I-Claim
286	.	_	_	I-Claim

287	However	_	_	O
288	,	_	_	O
289	CRT	_	_	B-Claim
290	was	_	_	I-Claim
291	associated	_	_	I-Claim
292	with	_	_	I-Claim
293	progressive	_	_	I-Claim
294	deteriorations	_	_	I-Claim
295	in	_	_	I-Claim
296	pulmonary	_	_	I-Claim
297	function	_	_	I-Claim
298	in	_	_	I-Claim
299	the	_	_	I-Claim
300	longer	_	_	I-Claim
301	term	_	_	I-Claim
302	.	_	_	I-Claim


0	Anti-aromatase	_	_	B-Claim
1	therapy	_	_	I-Claim
2	is	_	_	I-Claim
3	important	_	_	I-Claim
4	in	_	_	I-Claim
5	the	_	_	I-Claim
6	treatment	_	_	I-Claim
7	of	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	in	_	_	I-Claim
11	postmenopausal	_	_	I-Claim
12	women	_	_	I-Claim
13	but	_	_	O
14	they	_	_	O
15	have	_	_	O
16	effects	_	_	O
17	on	_	_	O
18	the	_	_	O
19	bone	_	_	O
20	mineral	_	_	O
21	density	_	_	O
22	(	_	_	O
23	BMD	_	_	O
24	)	_	_	O
25	and	_	_	O
26	osteoporosis	_	_	O
27	.	_	_	O

28	Cyclooxygenase-2	_	_	B-Claim
29	(	_	_	I-Claim
30	COX-2	_	_	I-Claim
31	)	_	_	I-Claim
32	inhibitors	_	_	I-Claim
33	have	_	_	I-Claim
34	been	_	_	I-Claim
35	shown	_	_	I-Claim
36	to	_	_	I-Claim
37	be	_	_	I-Claim
38	effective	_	_	I-Claim
39	in	_	_	I-Claim
40	chemoprevention	_	_	I-Claim
41	in	_	_	I-Claim
42	animal	_	_	I-Claim
43	and	_	_	I-Claim
44	clinical	_	_	I-Claim
45	studies	_	_	I-Claim
46	.	_	_	I-Claim

47	A	_	_	O
48	proof	_	_	O
49	of	_	_	O
50	principle	_	_	O
51	study	_	_	O
52	was	_	_	O
53	performed	_	_	O
54	to	_	_	O
55	investigate	_	_	O
56	the	_	_	O
57	efficacy	_	_	O
58	of	_	_	O
59	combing	_	_	O
60	anti-aromatase	_	_	O
61	therapy	_	_	O
62	(	_	_	O
63	exemestane	_	_	O
64	)	_	_	O
65	and	_	_	O
66	COX-2	_	_	O
67	inhibitors	_	_	O
68	neoadjuvantly	_	_	O
69	.	_	_	O

70	The	_	_	O
71	changes	_	_	O
72	in	_	_	O
73	the	_	_	O
74	BMD	_	_	O
75	,	_	_	O
76	bone	_	_	O
77	turnover	_	_	O
78	proteins	_	_	O
79	and	_	_	O
80	quality-of-life	_	_	O
81	(	_	_	O
82	QoL	_	_	O
83	)	_	_	O
84	were	_	_	O
85	analyzed	_	_	O
86	and	_	_	O
87	presented	_	_	O
88	here	_	_	O
89	.	_	_	O

90	82	_	_	O
91	postmenopausal	_	_	O
92	patients	_	_	O
93	with	_	_	O
94	histologically	_	_	O
95	confirmed	_	_	O
96	invasive	_	_	O
97	hormone-sensitive	_	_	O
98	breast	_	_	O
99	cancers	_	_	O
100	were	_	_	O
101	included	_	_	O
102	for	_	_	O
103	the	_	_	O
104	neoadjuvant	_	_	O
105	therapy	_	_	O
106	(	_	_	O
107	NHT	_	_	O
108	)	_	_	O
109	.	_	_	O

110	30	_	_	O
111	patients	_	_	O
112	received	_	_	O
113	exemestane	_	_	O
114	(	_	_	O
115	EXE	_	_	O
116	)	_	_	O
117	25	_	_	O
118	mg	_	_	O
119	daily	_	_	O
120	and	_	_	O
121	celecoxib	_	_	O
122	(	_	_	O
123	CXB	_	_	O
124	)	_	_	O
125	400	_	_	O
126	mg	_	_	O
127	twice	_	_	O
128	daily	_	_	O
129	(	_	_	O
130	group	_	_	O
131	A	_	_	O
132	)	_	_	O
133	,	_	_	O
134	24	_	_	O
135	patients	_	_	O
136	received	_	_	O
137	EXE	_	_	O
138	25	_	_	O
139	mg	_	_	O
140	daily	_	_	O
141	(	_	_	O
142	group	_	_	O
143	B	_	_	O
144	)	_	_	O
145	and	_	_	O
146	28	_	_	O
147	patients	_	_	O
148	received	_	_	O
149	letrozole	_	_	O
150	(	_	_	O
151	LET	_	_	O
152	)	_	_	O
153	2.5	_	_	O
154	mg	_	_	O
155	daily	_	_	O
156	(	_	_	O
157	group	_	_	O
158	C	_	_	O
159	)	_	_	O
160	.	_	_	O

161	The	_	_	O
162	same	_	_	O
163	assigned	_	_	O
164	treatment	_	_	O
165	was	_	_	O
166	intended	_	_	O
167	to	_	_	O
168	continue	_	_	O
169	for	_	_	O
170	2	_	_	O
171	years	_	_	O
172	to	_	_	O
173	study	_	_	O
174	the	_	_	O
175	changes	_	_	O
176	in	_	_	O
177	the	_	_	O
178	bone	_	_	O
179	metabolism	_	_	O
180	.	_	_	O

181	BMD	_	_	O
182	of	_	_	O
183	48	_	_	O
184	patients	_	_	O
185	were	_	_	O
186	analyzed	_	_	O
187	;	_	_	O
188	23	_	_	O
189	belongs	_	_	O
190	to	_	_	O
191	group	_	_	O
192	A	_	_	O
193	,	_	_	O
194	10	_	_	O
195	to	_	_	O
196	group	_	_	O
197	B	_	_	O
198	and	_	_	O
199	15	_	_	O
200	to	_	_	O
201	group	_	_	O
202	C.	_	_	O
203	The	_	_	O
204	serum	_	_	O
205	bone	_	_	O
206	turnover	_	_	O
207	proteins	_	_	O
208	bone-specific	_	_	O
209	alkaline	_	_	O
210	phosphatase	_	_	O
211	(	_	_	O
212	BAP	_	_	O
213	)	_	_	O
214	and	_	_	O
215	carboxyterminal	_	_	O
216	crosslinked	_	_	O
217	telopeptide	_	_	O
218	of	_	_	O
219	type	_	_	O
220	I	_	_	O
221	collagen	_	_	O
222	(	_	_	O
223	ICTP	_	_	O
224	)	_	_	O
225	,	_	_	O
226	were	_	_	O
227	measured	_	_	O
228	with	_	_	O
229	commercially	_	_	O
230	available	_	_	O
231	test	_	_	O
232	kits	_	_	O
233	before	_	_	O
234	treatment	_	_	O
235	,	_	_	O
236	3	_	_	O
237	months	_	_	O
238	and	_	_	O
239	15	_	_	O
240	months	_	_	O
241	after	_	_	O
242	treatment	_	_	O
243	.	_	_	O

244	Functional	_	_	O
245	Assessment	_	_	O
246	of	_	_	O
247	Cancer	_	_	O
248	Therapy	_	_	O
249	core	_	_	O
250	questionnaire	_	_	O
251	(	_	_	O
252	FACT-G	_	_	O
253	)	_	_	O
254	with	_	_	O
255	its	_	_	O
256	additional	_	_	O
257	breast	_	_	O
258	cancer	_	_	O
259	subscale	_	_	O
260	were	_	_	O
261	performed	_	_	O
262	at	_	_	O
263	baseline	_	_	O
264	,	_	_	O
265	4	_	_	O
266	,	_	_	O
267	8	_	_	O
268	,	_	_	O
269	and	_	_	O
270	12	_	_	O
271	weeks	_	_	O
272	after	_	_	O
273	NHT	_	_	O
274	.	_	_	O

275	Difference	_	_	B-Premise
276	between	_	_	I-Premise
277	groups	_	_	I-Premise
278	(	_	_	I-Premise
279	p=0.007	_	_	I-Premise
280	)	_	_	I-Premise
281	for	_	_	I-Premise
282	BMD	_	_	I-Premise
283	at	_	_	I-Premise
284	femur	_	_	I-Premise
285	was	_	_	I-Premise
286	significant	_	_	I-Premise
287	.	_	_	I-Premise

288	The	_	_	B-Premise
289	changes	_	_	I-Premise
290	of	_	_	I-Premise
291	BMD	_	_	I-Premise
292	in	_	_	I-Premise
293	group	_	_	I-Premise
294	B	_	_	I-Premise
295	patients	_	_	I-Premise
296	were	_	_	I-Premise
297	significantly	_	_	I-Premise
298	greater	_	_	I-Premise
299	than	_	_	I-Premise
300	patients	_	_	I-Premise
301	in	_	_	I-Premise
302	group	_	_	I-Premise
303	A	_	_	I-Premise
304	(	_	_	I-Premise
305	p=0.011	_	_	I-Premise
306	,	_	_	I-Premise
307	CI=0.063-0.437	_	_	I-Premise
308	)	_	_	I-Premise
309	,	_	_	I-Premise
310	and	_	_	I-Premise
311	group	_	_	I-Premise
312	C	_	_	I-Premise
313	(	_	_	I-Premise
314	p=0.003	_	_	I-Premise
315	,	_	_	I-Premise
316	CI=0.146-0.620	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	The	_	_	B-Premise
320	mean	_	_	I-Premise
321	BAP	_	_	I-Premise
322	increased	_	_	I-Premise
323	from	_	_	I-Premise
324	baseline	_	_	I-Premise
325	in	_	_	I-Premise
326	group	_	_	I-Premise
327	B	_	_	I-Premise
328	patients	_	_	I-Premise
329	but	_	_	I-Premise
330	decreased	_	_	I-Premise
331	from	_	_	I-Premise
332	baseline	_	_	I-Premise
333	in	_	_	I-Premise
334	group	_	_	I-Premise
335	C	_	_	I-Premise
336	patients	_	_	I-Premise
337	at	_	_	I-Premise
338	3	_	_	I-Premise
339	months	_	_	I-Premise
340	and	_	_	I-Premise
341	15	_	_	I-Premise
342	months	_	_	I-Premise
343	.	_	_	I-Premise

344	No	_	_	B-Premise
345	statistical	_	_	I-Premise
346	significance	_	_	I-Premise
347	was	_	_	I-Premise
348	found	_	_	I-Premise
349	in	_	_	I-Premise
350	the	_	_	I-Premise
351	FACT-G	_	_	I-Premise
352	scores	_	_	I-Premise
353	and	_	_	I-Premise
354	FACT-B	_	_	I-Premise
355	scores	_	_	I-Premise
356	among	_	_	I-Premise
357	different	_	_	I-Premise
358	groups	_	_	I-Premise
359	at	_	_	I-Premise
360	baseline	_	_	I-Premise
361	,	_	_	I-Premise
362	week	_	_	I-Premise
363	4	_	_	I-Premise
364	,	_	_	I-Premise
365	week	_	_	I-Premise
366	8	_	_	I-Premise
367	and	_	_	I-Premise
368	week	_	_	I-Premise
369	12	_	_	I-Premise
370	after	_	_	I-Premise
371	NHT	_	_	I-Premise
372	.	_	_	I-Premise

373	The	_	_	B-Premise
374	Breast	_	_	I-Premise
375	Cancer	_	_	I-Premise
376	Subscale	_	_	I-Premise
377	scores	_	_	I-Premise
378	in	_	_	I-Premise
379	group	_	_	I-Premise
380	A	_	_	I-Premise
381	patients	_	_	I-Premise
382	were	_	_	I-Premise
383	significantly	_	_	I-Premise
384	higher	_	_	I-Premise
385	than	_	_	I-Premise
386	that	_	_	I-Premise
387	of	_	_	I-Premise
388	group	_	_	I-Premise
389	C	_	_	I-Premise
390	patients	_	_	I-Premise
391	(	_	_	I-Premise
392	p=0.021	_	_	I-Premise
393	)	_	_	I-Premise
394	.	_	_	I-Premise

395	After	_	_	B-Premise
396	4	_	_	I-Premise
397	weeks	_	_	I-Premise
398	of	_	_	I-Premise
399	NHT	_	_	I-Premise
400	,	_	_	I-Premise
401	negative	_	_	I-Premise
402	changes	_	_	I-Premise
403	of	_	_	I-Premise
404	FACT-B	_	_	I-Premise
405	and	_	_	I-Premise
406	FACT-G	_	_	I-Premise
407	scores	_	_	I-Premise
408	were	_	_	I-Premise
409	found	_	_	I-Premise
410	in	_	_	I-Premise
411	group	_	_	I-Premise
412	B	_	_	I-Premise
413	and	_	_	I-Premise
414	C	_	_	I-Premise
415	patients	_	_	I-Premise
416	,	_	_	I-Premise
417	but	_	_	B-Premise
418	there	_	_	I-Premise
419	were	_	_	I-Premise
420	positive	_	_	I-Premise
421	changes	_	_	I-Premise
422	in	_	_	I-Premise
423	group	_	_	I-Premise
424	A	_	_	I-Premise
425	patients	_	_	I-Premise
426	.	_	_	I-Premise

427	Significant	_	_	B-Premise
428	differences	_	_	I-Premise
429	of	_	_	I-Premise
430	FACT-B	_	_	I-Premise
431	score	_	_	I-Premise
432	(	_	_	I-Premise
433	p=0.008	_	_	I-Premise
434	)	_	_	I-Premise
435	and	_	_	I-Premise
436	FACT-G	_	_	I-Premise
437	score	_	_	I-Premise
438	(	_	_	I-Premise
439	p=0.019	_	_	I-Premise
440	)	_	_	I-Premise
441	were	_	_	I-Premise
442	observed	_	_	I-Premise
443	at	_	_	I-Premise
444	that	_	_	I-Premise
445	time	_	_	I-Premise
446	point	_	_	I-Premise
447	.	_	_	I-Premise

448	Article	_	_	O
449	from	_	_	O
450	the	_	_	O
451	Special	_	_	O
452	issue	_	_	O
453	on	_	_	O
454	Targeted	_	_	O
455	Inhibitors	_	_	O
456	.	_	_	O


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	frequent	_	_	O
4	hospital	_	_	O
5	follow-up	_	_	O
6	in	_	_	O
7	the	_	_	O
8	first	_	_	O
9	year	_	_	O
10	after	_	_	O
11	breast	_	_	O
12	cancer	_	_	O
13	treatment	_	_	O
14	might	_	_	O
15	partly	_	_	O
16	be	_	_	O
17	replaced	_	_	O
18	by	_	_	O
19	nurse-led	_	_	O
20	telephone	_	_	O
21	follow-up	_	_	O
22	without	_	_	O
23	deteriorating	_	_	O
24	health-related	_	_	O
25	quality	_	_	O
26	of	_	_	O
27	life	_	_	O
28	(	_	_	O
29	HRQoL	_	_	O
30	)	_	_	O
31	,	_	_	O
32	and	_	_	O
33	whether	_	_	O
34	a	_	_	O
35	short	_	_	O
36	educational	_	_	O
37	group	_	_	O
38	programme	_	_	O
39	(	_	_	O
40	EGP	_	_	O
41	)	_	_	O
42	would	_	_	O
43	enhance	_	_	O
44	HRQoL	_	_	O
45	.	_	_	O

46	A	_	_	O
47	multicentre	_	_	O
48	pragmatic	_	_	O
49	randomised	_	_	O
50	controlled	_	_	O
51	trial	_	_	O
52	(	_	_	O
53	RCT	_	_	O
54	)	_	_	O
55	with	_	_	O
56	a	_	_	O
57	22	_	_	O
58	factorial	_	_	O
59	design	_	_	O
60	was	_	_	O
61	performed	_	_	O
62	among	_	_	O
63	320	_	_	O
64	breast	_	_	O
65	cancer	_	_	O
66	patients	_	_	O
67	who	_	_	O
68	were	_	_	O
69	treated	_	_	O
70	with	_	_	O
71	curative	_	_	O
72	intent	_	_	O
73	.	_	_	O

74	Participants	_	_	O
75	were	_	_	O
76	randomised	_	_	O
77	to	_	_	O
78	follow-up	_	_	O
79	care	_	_	O
80	as	_	_	O
81	usual	_	_	O
82	(	_	_	O
83	3-monthly	_	_	O
84	outpatient	_	_	O
85	clinic	_	_	O
86	visits	_	_	O
87	)	_	_	O
88	,	_	_	O
89	nurse-led	_	_	O
90	telephone	_	_	O
91	follow-up	_	_	O
92	,	_	_	O
93	or	_	_	O
94	the	_	_	O
95	former	_	_	O
96	strategies	_	_	O
97	combined	_	_	O
98	with	_	_	O
99	an	_	_	O
100	educational	_	_	O
101	group	_	_	O
102	programme	_	_	O
103	.	_	_	O

104	The	_	_	O
105	primary	_	_	O
106	outcome	_	_	O
107	for	_	_	O
108	both	_	_	O
109	interventions	_	_	O
110	was	_	_	O
111	HRQoL	_	_	O
112	,	_	_	O
113	measured	_	_	O
114	by	_	_	O
115	EORTC	_	_	O
116	QLQ-C30	_	_	O
117	.	_	_	O

118	Secondary	_	_	O
119	outcomes	_	_	O
120	were	_	_	O
121	role	_	_	O
122	and	_	_	O
123	emotional	_	_	O
124	functioning	_	_	O
125	and	_	_	O
126	feelings	_	_	O
127	of	_	_	O
128	control	_	_	O
129	and	_	_	O
130	anxiety	_	_	O
131	.	_	_	O

132	Data	_	_	O
133	of	_	_	O
134	299	_	_	O
135	patients	_	_	O
136	were	_	_	O
137	available	_	_	O
138	for	_	_	O
139	evaluation	_	_	O
140	.	_	_	O

141	There	_	_	B-Premise
142	was	_	_	I-Premise
143	no	_	_	I-Premise
144	significant	_	_	I-Premise
145	difference	_	_	I-Premise
146	in	_	_	I-Premise
147	HRQoL	_	_	I-Premise
148	between	_	_	I-Premise
149	nurse-led	_	_	I-Premise
150	telephone	_	_	I-Premise
151	and	_	_	I-Premise
152	hospital	_	_	I-Premise
153	follow-up	_	_	I-Premise
154	at	_	_	I-Premise
155	12	_	_	I-Premise
156	months	_	_	I-Premise
157	after	_	_	I-Premise
158	treatment	_	_	I-Premise
159	(	_	_	I-Premise
160	p	_	_	I-Premise
161	=	_	_	I-Premise
162	0.42	_	_	I-Premise
163	;	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	confidence	_	_	I-Premise
167	interval	_	_	I-Premise
168	(	_	_	I-Premise
169	CI	_	_	I-Premise
170	)	_	_	I-Premise
171	for	_	_	I-Premise
172	difference	_	_	I-Premise
173	:	_	_	I-Premise
174	-1.93-4.64	_	_	I-Premise
175	)	_	_	I-Premise
176	and	_	_	I-Premise
177	neither	_	_	I-Premise
178	between	_	_	I-Premise
179	follow-up	_	_	I-Premise
180	with	_	_	I-Premise
181	or	_	_	I-Premise
182	without	_	_	I-Premise
183	EGP	_	_	I-Premise
184	(	_	_	I-Premise
185	p	_	_	I-Premise
186	=	_	_	I-Premise
187	0.86	_	_	I-Premise
188	;	_	_	I-Premise
189	95	_	_	I-Premise
190	%	_	_	I-Premise
191	CI	_	_	I-Premise
192	for	_	_	I-Premise
193	difference	_	_	I-Premise
194	:	_	_	I-Premise
195	-3.59-3.00	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	Furthermore	_	_	O
199	,	_	_	O
200	no	_	_	B-Premise
201	differences	_	_	I-Premise
202	between	_	_	I-Premise
203	the	_	_	I-Premise
204	intervention	_	_	I-Premise
205	groups	_	_	I-Premise
206	and	_	_	I-Premise
207	their	_	_	I-Premise
208	corresponding	_	_	I-Premise
209	control	_	_	I-Premise
210	groups	_	_	I-Premise
211	were	_	_	I-Premise
212	found	_	_	I-Premise
213	in	_	_	I-Premise
214	role	_	_	I-Premise
215	and	_	_	I-Premise
216	emotional	_	_	I-Premise
217	functioning	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	feelings	_	_	I-Premise
221	of	_	_	I-Premise
222	control	_	_	I-Premise
223	and	_	_	I-Premise
224	anxiety	_	_	I-Premise
225	(	_	_	I-Premise
226	all	_	_	I-Premise
227	p-values	_	_	I-Premise
228	>	_	_	I-Premise
229	0.05	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Replacement	_	_	B-Claim
233	of	_	_	I-Claim
234	most	_	_	I-Claim
235	hospital	_	_	I-Claim
236	follow-up	_	_	I-Claim
237	visits	_	_	I-Claim
238	in	_	_	I-Claim
239	the	_	_	I-Claim
240	first	_	_	I-Claim
241	year	_	_	I-Claim
242	after	_	_	I-Claim
243	breast	_	_	I-Claim
244	cancer	_	_	I-Claim
245	treatment	_	_	I-Claim
246	by	_	_	I-Claim
247	nurse-led	_	_	I-Claim
248	telephone	_	_	I-Claim
249	follow-up	_	_	I-Claim
250	does	_	_	I-Claim
251	not	_	_	I-Claim
252	impede	_	_	I-Claim
253	patient	_	_	I-Claim
254	outcomes	_	_	I-Claim
255	.	_	_	I-Claim

256	Hence	_	_	O
257	,	_	_	O
258	nurse-led	_	_	B-Claim
259	telephone	_	_	I-Claim
260	follow-up	_	_	I-Claim
261	seems	_	_	I-Claim
262	an	_	_	I-Claim
263	appropriate	_	_	I-Claim
264	way	_	_	I-Claim
265	to	_	_	I-Claim
266	reduce	_	_	I-Claim
267	clinic	_	_	I-Claim
268	visits	_	_	I-Claim
269	and	_	_	I-Claim
270	represents	_	_	I-Claim
271	an	_	_	I-Claim
272	accepted	_	_	I-Claim
273	alternative	_	_	I-Claim
274	strategy	_	_	I-Claim
275	.	_	_	I-Claim

276	An	_	_	O
277	EGP	_	_	O
278	does	_	_	O
279	not	_	_	O
280	unequivocally	_	_	O
281	affect	_	_	O
282	positive	_	_	O
283	HRQoL	_	_	O
284	outcomes	_	_	O
285	.	_	_	O


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	outcome	_	_	O
5	and	_	_	O
6	health-related	_	_	O
7	quality	_	_	O
8	of	_	_	O
9	life	_	_	O
10	(	_	_	O
11	HRQL	_	_	O
12	)	_	_	O
13	of	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	endometrial	_	_	O
17	carcinoma	_	_	O
18	(	_	_	O
19	EC	_	_	O
20	)	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	or	_	_	O
24	without	_	_	O
25	pelvic	_	_	O
26	radiotherapy	_	_	O
27	in	_	_	O
28	the	_	_	O
29	Post	_	_	O
30	Operative	_	_	O
31	Radiation	_	_	O
32	Therapy	_	_	O
33	in	_	_	O
34	Endometrial	_	_	O
35	Carcinoma	_	_	O
36	1	_	_	O
37	(	_	_	O
38	PORTEC-1	_	_	O
39	)	_	_	O
40	trial	_	_	O
41	.	_	_	O

42	Between	_	_	O
43	1990	_	_	O
44	and	_	_	O
45	1997	_	_	O
46	,	_	_	O
47	714	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	stage	_	_	O
51	IC	_	_	O
52	grade	_	_	O
53	1	_	_	O
54	to	_	_	O
55	2	_	_	O
56	or	_	_	O
57	IB	_	_	O
58	grade	_	_	O
59	2	_	_	O
60	to	_	_	O
61	3	_	_	O
62	EC	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	allocated	_	_	O
66	to	_	_	O
67	pelvic	_	_	O
68	external-beam	_	_	O
69	radiotherapy	_	_	O
70	(	_	_	O
71	EBRT	_	_	O
72	)	_	_	O
73	or	_	_	O
74	no	_	_	O
75	additional	_	_	O
76	treatment	_	_	O
77	(	_	_	O
78	NAT	_	_	O
79	)	_	_	O
80	.	_	_	O

81	HRQL	_	_	O
82	was	_	_	O
83	evaluated	_	_	O
84	with	_	_	O
85	the	_	_	O
86	Short	_	_	O
87	Form	_	_	O
88	36-Item	_	_	O
89	(	_	_	O
90	SF-36	_	_	O
91	)	_	_	O
92	questionnaire	_	_	O
93	;	_	_	O
94	subscales	_	_	O
95	from	_	_	O
96	the	_	_	O
97	European	_	_	O
98	Organisation	_	_	O
99	for	_	_	O
100	Research	_	_	O
101	and	_	_	O
102	Treatment	_	_	O
103	of	_	_	O
104	Cancer	_	_	O
105	(	_	_	O
106	EORTC	_	_	O
107	)	_	_	O
108	PR25	_	_	O
109	module	_	_	O
110	for	_	_	O
111	bowel	_	_	O
112	and	_	_	O
113	bladder	_	_	O
114	symptoms	_	_	O
115	and	_	_	O
116	the	_	_	O
117	OV28	_	_	O
118	and	_	_	O
119	CX24	_	_	O
120	modules	_	_	O
121	for	_	_	O
122	sexual	_	_	O
123	symptoms	_	_	O
124	;	_	_	O
125	and	_	_	O
126	demographic	_	_	O
127	questions	_	_	O
128	.	_	_	O

129	Analysis	_	_	O
130	was	_	_	O
131	by	_	_	O
132	intention-to-treat	_	_	O
133	.	_	_	O

134	Median	_	_	O
135	follow-up	_	_	O
136	was	_	_	O
137	13.3	_	_	O
138	years	_	_	O
139	.	_	_	O

140	The	_	_	B-Premise
141	15-year	_	_	I-Premise
142	actuarial	_	_	I-Premise
143	locoregional	_	_	I-Premise
144	recurrence	_	_	I-Premise
145	rates	_	_	I-Premise
146	were	_	_	I-Premise
147	5.8	_	_	I-Premise
148	%	_	_	I-Premise
149	for	_	_	I-Premise
150	EBRT	_	_	I-Premise
151	versus	_	_	I-Premise
152	15.5	_	_	I-Premise
153	%	_	_	I-Premise
154	for	_	_	I-Premise
155	NAT	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	<	_	_	I-Premise
159	.001	_	_	I-Premise
160	)	_	_	I-Premise
161	,	_	_	I-Premise
162	and	_	_	I-Premise
163	15-year	_	_	I-Premise
164	overall	_	_	I-Premise
165	survival	_	_	I-Premise
166	was	_	_	I-Premise
167	52	_	_	I-Premise
168	%	_	_	I-Premise
169	versus	_	_	I-Premise
170	60	_	_	I-Premise
171	%	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.14	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Of	_	_	O
179	the	_	_	O
180	351	_	_	O
181	patients	_	_	O
182	confirmed	_	_	O
183	to	_	_	O
184	be	_	_	O
185	alive	_	_	O
186	with	_	_	O
187	correct	_	_	O
188	address	_	_	O
189	,	_	_	O
190	246	_	_	O
191	(	_	_	O
192	70	_	_	O
193	%	_	_	O
194	)	_	_	O
195	returned	_	_	O
196	the	_	_	O
197	questionnaire	_	_	O
198	.	_	_	O

199	Patients	_	_	B-Premise
200	treated	_	_	I-Premise
201	with	_	_	I-Premise
202	EBRT	_	_	I-Premise
203	reported	_	_	I-Premise
204	significant	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.01	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	clinically	_	_	I-Premise
212	relevant	_	_	I-Premise
213	higher	_	_	I-Premise
214	rates	_	_	I-Premise
215	of	_	_	I-Premise
216	urinary	_	_	I-Premise
217	incontinence	_	_	I-Premise
218	,	_	_	I-Premise
219	diarrhea	_	_	I-Premise
220	,	_	_	I-Premise
221	and	_	_	I-Premise
222	fecal	_	_	I-Premise
223	leakage	_	_	I-Premise
224	leading	_	_	I-Premise
225	to	_	_	I-Premise
226	more	_	_	I-Premise
227	limitations	_	_	I-Premise
228	in	_	_	I-Premise
229	daily	_	_	I-Premise
230	activities	_	_	I-Premise
231	.	_	_	I-Premise

232	Increased	_	_	B-Premise
233	symptoms	_	_	I-Premise
234	were	_	_	I-Premise
235	reflected	_	_	I-Premise
236	by	_	_	I-Premise
237	the	_	_	I-Premise
238	frequent	_	_	I-Premise
239	use	_	_	I-Premise
240	of	_	_	I-Premise
241	incontinence	_	_	I-Premise
242	materials	_	_	I-Premise
243	after	_	_	I-Premise
244	EBRT	_	_	I-Premise
245	(	_	_	I-Premise
246	day	_	_	I-Premise
247	and	_	_	I-Premise
248	night	_	_	I-Premise
249	use	_	_	I-Premise
250	,	_	_	I-Premise
251	42.9	_	_	I-Premise
252	%	_	_	I-Premise
253	v	_	_	I-Premise
254	15.2	_	_	I-Premise
255	%	_	_	I-Premise
256	for	_	_	I-Premise
257	NAT	_	_	I-Premise
258	;	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	.001	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Patients	_	_	B-Premise
265	treated	_	_	I-Premise
266	with	_	_	I-Premise
267	EBRT	_	_	I-Premise
268	reported	_	_	I-Premise
269	lower	_	_	I-Premise
270	scores	_	_	I-Premise
271	on	_	_	I-Premise
272	the	_	_	I-Premise
273	SF-36	_	_	I-Premise
274	scales	_	_	I-Premise
275	physical	_	_	I-Premise
276	functioning	_	_	I-Premise
277	(	_	_	O
278	P	_	_	O
279	=	_	_	I-Premise
280	.004	_	_	I-Premise
281	)	_	_	I-Premise
282	and	_	_	I-Premise
283	role-physical	_	_	I-Premise
284	(	_	_	O
285	P	_	_	O
286	=	_	_	I-Premise
287	.003	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	EBRT	_	_	B-Claim
291	for	_	_	I-Claim
292	endometrial	_	_	I-Claim
293	cancer	_	_	I-Claim
294	is	_	_	I-Claim
295	associated	_	_	I-Claim
296	with	_	_	I-Claim
297	long-term	_	_	I-Claim
298	urinary	_	_	I-Claim
299	and	_	_	I-Claim
300	bowel	_	_	I-Claim
301	symptoms	_	_	I-Claim
302	and	_	_	I-Claim
303	lower	_	_	I-Claim
304	physical	_	_	I-Claim
305	and	_	_	I-Claim
306	role-physical	_	_	I-Claim
307	functioning	_	_	I-Claim
308	,	_	_	I-Claim
309	even	_	_	I-Claim
310	15	_	_	I-Claim
311	years	_	_	I-Claim
312	after	_	_	I-Claim
313	treatment	_	_	I-Claim
314	.	_	_	I-Claim

315	Despite	_	_	B-Claim
316	its	_	_	I-Claim
317	efficacy	_	_	I-Claim
318	in	_	_	I-Claim
319	reducing	_	_	I-Claim
320	locoregional	_	_	I-Claim
321	recurrence	_	_	I-Claim
322	,	_	_	I-Claim
323	EBRT	_	_	I-Claim
324	should	_	_	I-Claim
325	be	_	_	I-Claim
326	avoided	_	_	I-Claim
327	in	_	_	I-Claim
328	patients	_	_	I-Claim
329	with	_	_	I-Claim
330	low-	_	_	I-Claim
331	and	_	_	I-Claim
332	intermediate-risk	_	_	I-Claim
333	EC	_	_	I-Claim
334	.	_	_	I-Claim


0	A	_	_	O
1	randomised	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	(	_	_	O
5	RCT	_	_	O
6	)	_	_	O
7	demonstrated	_	_	O
8	that	_	_	O
9	cognitive	_	_	O
10	behaviour	_	_	O
11	therapy	_	_	O
12	(	_	_	O
13	CBT	_	_	O
14	)	_	_	O
15	for	_	_	O
16	fatigue	_	_	O
17	during	_	_	O
18	curative	_	_	O
19	cancer	_	_	O
20	treatment	_	_	O
21	was	_	_	O
22	effective	_	_	O
23	shortly	_	_	O
24	after	_	_	O
25	cancer	_	_	O
26	treatment	_	_	O
27	.	_	_	O

28	This	_	_	O
29	study	_	_	O
30	aimed	_	_	O
31	to	_	_	O
32	identify	_	_	O
33	which	_	_	O
34	patient	_	_	O
35	characteristics	_	_	O
36	predict	_	_	O
37	fatigue	_	_	O
38	improvement	_	_	O
39	after	_	_	O
40	CBT	_	_	O
41	.	_	_	O

42	In	_	_	O
43	addition	_	_	O
44	,	_	_	O
45	the	_	_	O
46	long-term	_	_	O
47	effectiveness	_	_	O
48	was	_	_	O
49	investigated	_	_	O
50	.	_	_	O

51	Patients	_	_	O
52	with	_	_	O
53	various	_	_	O
54	malignancies	_	_	O
55	participated	_	_	O
56	in	_	_	O
57	the	_	_	O
58	RCT	_	_	O
59	(	_	_	O
60	n	_	_	O
61	=	_	_	O
62	210	_	_	O
63	)	_	_	O
64	.	_	_	O

65	Participants	_	_	O
66	were	_	_	O
67	assessed	_	_	O
68	before	_	_	O
69	cancer	_	_	O
70	treatment	_	_	O
71	(	_	_	O
72	T1	_	_	O
73	)	_	_	O
74	,	_	_	O
75	postintervention	_	_	O
76	(	_	_	O
77	T2	_	_	O
78	)	_	_	O
79	,	_	_	O
80	which	_	_	O
81	was	_	_	O
82	at	_	_	O
83	least	_	_	O
84	2	_	_	O
85	months	_	_	O
86	after	_	_	O
87	cancer	_	_	O
88	treatment	_	_	O
89	,	_	_	O
90	and	_	_	O
91	after	_	_	O
92	1-year	_	_	O
93	follow-up	_	_	O
94	(	_	_	O
95	T3	_	_	O
96	)	_	_	O
97	.	_	_	O

98	Monthly	_	_	O
99	fatigue	_	_	O
100	assessments	_	_	O
101	were	_	_	O
102	completed	_	_	O
103	between	_	_	O
104	T2	_	_	O
105	and	_	_	O
106	T3	_	_	O
107	.	_	_	O

108	A	_	_	O
109	regression	_	_	O
110	analysis	_	_	O
111	with	_	_	O
112	interactions	_	_	O
113	was	_	_	O
114	performed	_	_	O
115	to	_	_	O
116	determine	_	_	O
117	if	_	_	O
118	domains	_	_	O
119	of	_	_	O
120	quality	_	_	O
121	of	_	_	O
122	life	_	_	O
123	(	_	_	O
124	EORTC-QLQ-C30	_	_	O
125	)	_	_	O
126	functioning	_	_	O
127	(	_	_	O
128	Health	_	_	O
129	Survey	_	_	O
130	Short	_	_	O
131	Form-36	_	_	O
132	)	_	_	O
133	or	_	_	O
134	psychological	_	_	O
135	distress	_	_	O
136	(	_	_	O
137	Symptom	_	_	O
138	Checklist-90	_	_	O
139	)	_	_	O
140	moderated	_	_	O
141	the	_	_	O
142	effect	_	_	O
143	of	_	_	O
144	CBT	_	_	O
145	on	_	_	O
146	fatigue	_	_	O
147	.	_	_	O

148	Analyses	_	_	O
149	of	_	_	O
150	covariance	_	_	O
151	were	_	_	O
152	used	_	_	O
153	to	_	_	O
154	study	_	_	O
155	the	_	_	O
156	long-term	_	_	O
157	effectiveness	_	_	O
158	of	_	_	O
159	CBT	_	_	O
160	.	_	_	O

161	Fatigue	_	_	B-Premise
162	at	_	_	I-Premise
163	T2	_	_	I-Premise
164	was	_	_	I-Premise
165	predicted	_	_	I-Premise
166	by	_	_	I-Premise
167	a	_	_	I-Premise
168	significant	_	_	I-Premise
169	interaction	_	_	I-Premise
170	between	_	_	I-Premise
171	self-reported	_	_	I-Premise
172	cognitive	_	_	I-Premise
173	functioning	_	_	I-Premise
174	and	_	_	I-Premise
175	CBT	_	_	I-Premise
176	.	_	_	I-Premise

177	No	_	_	B-Premise
178	interactions	_	_	I-Premise
179	were	_	_	I-Premise
180	found	_	_	I-Premise
181	between	_	_	I-Premise
182	other	_	_	I-Premise
183	domains	_	_	I-Premise
184	of	_	_	I-Premise
185	quality	_	_	I-Premise
186	of	_	_	I-Premise
187	life	_	_	I-Premise
188	,	_	_	I-Premise
189	functioning	_	_	I-Premise
190	,	_	_	I-Premise
191	psychological	_	_	I-Premise
192	distress	_	_	I-Premise
193	and	_	_	I-Premise
194	CBT	_	_	I-Premise
195	.	_	_	I-Premise

196	At	_	_	B-Premise
197	T3	_	_	I-Premise
198	,	_	_	I-Premise
199	no	_	_	I-Premise
200	significant	_	_	I-Premise
201	difference	_	_	I-Premise
202	on	_	_	I-Premise
203	fatigue	_	_	I-Premise
204	was	_	_	I-Premise
205	found	_	_	I-Premise
206	between	_	_	I-Premise
207	CBT	_	_	I-Premise
208	and	_	_	I-Premise
209	usual	_	_	I-Premise
210	care	_	_	I-Premise
211	.	_	_	I-Premise

212	Exploratory	_	_	B-Premise
213	analyses	_	_	I-Premise
214	showed	_	_	I-Premise
215	that	_	_	I-Premise
216	the	_	_	I-Premise
217	difference	_	_	I-Premise
218	nearly	_	_	I-Premise
219	reached	_	_	I-Premise
220	significance	_	_	I-Premise
221	until	_	_	I-Premise
222	7	_	_	I-Premise
223	months	_	_	I-Premise
224	postintervention	_	_	I-Premise
225	.	_	_	I-Premise

226	Patients	_	_	B-Premise
227	who	_	_	I-Premise
228	experienced	_	_	I-Premise
229	more	_	_	I-Premise
230	concentration	_	_	I-Premise
231	and	_	_	I-Premise
232	memory	_	_	I-Premise
233	problems	_	_	I-Premise
234	at	_	_	I-Premise
235	T1	_	_	I-Premise
236	benefited	_	_	I-Premise
237	more	_	_	I-Premise
238	from	_	_	I-Premise
239	CBT	_	_	I-Premise
240	for	_	_	I-Premise
241	fatigue	_	_	I-Premise
242	and	_	_	I-Premise
243	are	_	_	I-Premise
244	indicators	_	_	I-Premise
245	.	_	_	I-Premise

246	After	_	_	B-Premise
247	a	_	_	I-Premise
248	year	_	_	I-Premise
249	of	_	_	I-Premise
250	follow-up	_	_	I-Premise
251	,	_	_	I-Premise
252	the	_	_	I-Premise
253	effect	_	_	I-Premise
254	of	_	_	I-Premise
255	CBT	_	_	I-Premise
256	for	_	_	I-Premise
257	fatigue	_	_	I-Premise
258	was	_	_	I-Premise
259	no	_	_	I-Premise
260	longer	_	_	I-Premise
261	observed	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	the	_	_	I-Premise
265	effect	_	_	I-Premise
266	on	_	_	I-Premise
267	fatigue	_	_	I-Premise
268	seemed	_	_	I-Premise
269	to	_	_	I-Premise
270	be	_	_	I-Premise
271	diminished	_	_	I-Premise
272	7	_	_	I-Premise
273	months	_	_	I-Premise
274	postintervention	_	_	I-Premise
275	.	_	_	I-Premise

276	The	_	_	B-Claim
277	implication	_	_	I-Claim
278	is	_	_	I-Claim
279	that	_	_	I-Claim
280	CBT	_	_	I-Claim
281	for	_	_	I-Claim
282	fatigue	_	_	I-Claim
283	should	_	_	I-Claim
284	be	_	_	I-Claim
285	offered	_	_	I-Claim
286	to	_	_	I-Claim
287	patients	_	_	I-Claim
288	with	_	_	I-Claim
289	cancer	_	_	I-Claim
290	with	_	_	I-Claim
291	the	_	_	I-Claim
292	highest	_	_	I-Claim
293	chance	_	_	I-Claim
294	to	_	_	I-Claim
295	benefit	_	_	I-Claim
296	.	_	_	I-Claim


0		_	_	O
1	The	_	_	O
2	aim	_	_	O
3	of	_	_	O
4	this	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	the	_	_	O
10	efficacy	_	_	O
11	of	_	_	O
12	augmenting	_	_	O
13	trabeculectomy	_	_	O
14	with	_	_	O
15	subconjunctival	_	_	O
16	mitomycin	_	_	O
17	C	_	_	O
18	(	_	_	O
19	TMMC	_	_	O
20	)	_	_	O
21	versus	_	_	O
22	5-fluorouracil	_	_	O
23	(	_	_	O
24	T5-FU	_	_	O
25	)	_	_	O
26	in	_	_	O
27	lowering	_	_	O
28	intraocular	_	_	O
29	pressure	_	_	O
30	(	_	_	O
31	IOP	_	_	O
32	)	_	_	O
33	.	_	_	O

34	Forty	_	_	O
35	eyes	_	_	O
36	from	_	_	O
37	40	_	_	O
38	patients	_	_	O
39	referred	_	_	O
40	to	_	_	O
41	the	_	_	O
42	Nikoukari	_	_	O
43	Ophthalmology	_	_	O
44	University	_	_	O
45	Hospital	_	_	O
46	,	_	_	O
47	Tabriz	_	_	O
48	University	_	_	O
49	of	_	_	O
50	Medical	_	_	O
51	Sciences	_	_	O
52	,	_	_	O
53	Tabriz	_	_	O
54	,	_	_	O
55	Iran	_	_	O
56	,	_	_	O
57	were	_	_	O
58	enrolled	_	_	O
59	in	_	_	O
60	a	_	_	O
61	randomized	_	_	O
62	clinical	_	_	O
63	trial	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	with	_	_	O
67	high-risk	_	_	O
68	open	_	_	O
69	angle	_	_	O
70	glaucoma	_	_	O
71	were	_	_	O
72	allocated	_	_	O
73	to	_	_	O
74	receive	_	_	O
75	either	_	_	O
76	subconjunctival	_	_	O
77	TMMC	_	_	O
78	or	_	_	O
79	T5-FU	_	_	O
80	.	_	_	O

81	Mean	_	_	O
82	overall	_	_	O
83	preoperative	_	_	O
84	IOP	_	_	O
85	was	_	_	O
86	30.8	_	_	O
87	mmHg	_	_	O
88	.	_	_	O

89	Mean	_	_	B-Premise
90	preoperative	_	_	I-Premise
91	IOPs	_	_	I-Premise
92	in	_	_	I-Premise
93	the	_	_	I-Premise
94	TMMC	_	_	I-Premise
95	and	_	_	I-Premise
96	T5-FU	_	_	I-Premise
97	groups	_	_	I-Premise
98	were	_	_	I-Premise
99	31.2	_	_	I-Premise
100		_	_	I-Premise
101	9.8	_	_	I-Premise
102	and	_	_	I-Premise
103	30.6	_	_	I-Premise
104		_	_	I-Premise
105	9.9	_	_	I-Premise
106	mmHg	_	_	I-Premise
107	,	_	_	I-Premise
108	respectively	_	_	I-Premise
109	.	_	_	I-Premise

110	Postoperatively	_	_	I-Premise
111	,	_	_	I-Premise
112	mean	_	_	I-Premise
113	IOPs	_	_	I-Premise
114	were	_	_	I-Premise
115	11.4	_	_	I-Premise
116		_	_	I-Premise
117	4.9	_	_	I-Premise
118	and	_	_	I-Premise
119	13.6	_	_	I-Premise
120		_	_	I-Premise
121	3.9	_	_	I-Premise
122	mmHg	_	_	I-Premise
123	,	_	_	I-Premise
124	respectively	_	_	I-Premise
125	for	_	_	I-Premise
126	TMMC	_	_	I-Premise
127	and	_	_	I-Premise
128	T5-FU	_	_	I-Premise
129	groups	_	_	I-Premise
130	after	_	_	I-Premise
131	6	_	_	I-Premise
132	months	_	_	I-Premise
133	.	_	_	I-Premise

134	In	_	_	O
135	spite	_	_	O
136	of	_	_	O
137	some	_	_	O
138	existing	_	_	O
139	descriptive	_	_	O
140	differences	_	_	O
141	in	_	_	O
142	IOP	_	_	O
143	between	_	_	O
144	the	_	_	O
145	groups	_	_	O
146	,	_	_	O
147	statistical	_	_	B-Premise
148	tests	_	_	I-Premise
149	showed	_	_	I-Premise
150	no	_	_	I-Premise
151	difference	_	_	I-Premise
152	in	_	_	I-Premise
153	mean	_	_	I-Premise
154	and	_	_	I-Premise
155	median	_	_	I-Premise
156	IOP	_	_	I-Premise
157	.	_	_	I-Premise

158	Three	_	_	B-Premise
159	cases	_	_	I-Premise
160	of	_	_	I-Premise
161	hypotonia	_	_	I-Premise
162	(	_	_	I-Premise
163	IOP	_	_	I-Premise
164	<	_	_	I-Premise
165	6	_	_	I-Premise
166	mmHg	_	_	I-Premise
167	)	_	_	I-Premise
168	and	_	_	I-Premise
169	1	_	_	I-Premise
170	case	_	_	I-Premise
171	of	_	_	I-Premise
172	epithelial	_	_	I-Premise
173	keratitis	_	_	I-Premise
174	were	_	_	I-Premise
175	detected	_	_	I-Premise
176	.	_	_	I-Premise

177	TMMC	_	_	B-Claim
178	and	_	_	I-Claim
179	T5-FU	_	_	I-Claim
180	appeared	_	_	I-Claim
181	to	_	_	I-Claim
182	have	_	_	I-Claim
183	similar	_	_	I-Claim
184	efficacy	_	_	I-Claim
185	in	_	_	I-Claim
186	lowering	_	_	I-Claim
187	IOP	_	_	I-Claim
188	.	_	_	I-Claim


0	Anemia	_	_	B-Claim
1	is	_	_	I-Claim
2	an	_	_	I-Claim
3	expected	_	_	I-Claim
4	consequence	_	_	I-Claim
5	of	_	_	I-Claim
6	intensive	_	_	I-Claim
7	chemotherapy	_	_	I-Claim
8	regimens	_	_	I-Claim
9	administered	_	_	I-Claim
10	to	_	_	I-Claim
11	patients	_	_	I-Claim
12	with	_	_	I-Claim
13	acute	_	_	I-Claim
14	leukemia	_	_	I-Claim
15	.	_	_	I-Claim

16	This	_	_	O
17	study	_	_	O
18	was	_	_	O
19	designed	_	_	O
20	to	_	_	O
21	determine	_	_	O
22	whether	_	_	O
23	epoetin	_	_	O
24	alpha	_	_	O
25	would	_	_	O
26	decrease	_	_	O
27	the	_	_	O
28	number	_	_	O
29	of	_	_	O
30	transfusion	_	_	O
31	events	_	_	O
32	and	_	_	O
33	units	_	_	O
34	of	_	_	O
35	packed	_	_	O
36	erythrocytes	_	_	O
37	(	_	_	O
38	PRBCs	_	_	O
39	)	_	_	O
40	transfused	_	_	O
41	,	_	_	O
42	and	_	_	O
43	the	_	_	O
44	secondary	_	_	O
45	objective	_	_	O
46	was	_	_	O
47	to	_	_	O
48	study	_	_	O
49	the	_	_	O
50	effects	_	_	O
51	of	_	_	O
52	epoetin	_	_	O
53	alpha	_	_	O
54	on	_	_	O
55	quality	_	_	O
56	of	_	_	O
57	life	_	_	O
58	(	_	_	O
59	QOL	_	_	O
60	)	_	_	O
61	and	_	_	O
62	complete	_	_	O
63	remission	_	_	O
64	(	_	_	O
65	CR	_	_	O
66	)	_	_	O
67	rates	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	with	_	_	O
71	acute	_	_	O
72	lymphoblastic	_	_	O
73	leukemia	_	_	O
74	(	_	_	O
75	ALL	_	_	O
76	)	_	_	O
77	,	_	_	O
78	lymphoblastic	_	_	O
79	lymphoma	_	_	O
80	(	_	_	O
81	LL	_	_	O
82	)	_	_	O
83	,	_	_	O
84	or	_	_	O
85	Burkitt	_	_	O
86	lymphoma	_	_	O
87	(	_	_	O
88	BL	_	_	O
89	)	_	_	O
90	who	_	_	O
91	were	_	_	O
92	receiving	_	_	O
93	frontline	_	_	O
94	myelosuppressive	_	_	O
95	chemotherapy	_	_	O
96	were	_	_	O
97	randomized	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	epoetin	_	_	O
101	alpha	_	_	O
102	or	_	_	O
103	no	_	_	O
104	epoetin	_	_	O
105	during	_	_	O
106	the	_	_	O
107	first	_	_	O
108	6	_	_	O
109	cycles	_	_	O
110	of	_	_	O
111	their	_	_	O
112	planned	_	_	O
113	chemotherapy	_	_	O
114	.	_	_	O

115	QOL	_	_	O
116	was	_	_	O
117	assessed	_	_	O
118	by	_	_	O
119	using	_	_	O
120	the	_	_	O
121	Edmonton	_	_	O
122	Symptom	_	_	O
123	Assessment	_	_	O
124	Scale	_	_	O
125	(	_	_	O
126	ESAS	_	_	O
127	)	_	_	O
128	and	_	_	O
129	the	_	_	O
130	Functional	_	_	O
131	Assessment	_	_	O
132	of	_	_	O
133	Cancer	_	_	O
134	Therapy	_	_	O
135	(	_	_	O
136	FACT	_	_	O
137	)	_	_	O
138	-Anemia	_	_	O
139	questionnaires	_	_	O
140	.	_	_	O

141	Fifty-five	_	_	O
142	patients	_	_	O
143	were	_	_	O
144	randomized	_	_	O
145	to	_	_	O
146	receive	_	_	O
147	epoetin	_	_	O
148	alpha	_	_	O
149	,	_	_	O
150	and	_	_	O
151	54	_	_	O
152	patients	_	_	O
153	received	_	_	O
154	no	_	_	O
155	epoetin	_	_	O
156	.	_	_	O

157	Transfusion	_	_	O
158	data	_	_	O
159	were	_	_	O
160	available	_	_	O
161	for	_	_	O
162	79	_	_	O
163	of	_	_	O
164	81	_	_	O
165	evaluable	_	_	O
166	patients	_	_	O
167	(	_	_	O
168	98	_	_	O
169	%	_	_	O
170	)	_	_	O
171	who	_	_	O
172	completed	_	_	O
173	the	_	_	O
174	treatment/observation	_	_	O
175	period	_	_	O
176	.	_	_	O

177	The	_	_	B-Premise
178	trial	_	_	I-Premise
179	was	_	_	I-Premise
180	stopped	_	_	I-Premise
181	early	_	_	I-Premise
182	because	_	_	I-Premise
183	of	_	_	I-Premise
184	poor	_	_	I-Premise
185	accrual	_	_	I-Premise
186	before	_	_	I-Premise
187	the	_	_	I-Premise
188	target	_	_	I-Premise
189	of	_	_	I-Premise
190	123	_	_	I-Premise
191	evaluable	_	_	I-Premise
192	patients	_	_	I-Premise
193	was	_	_	I-Premise
194	met	_	_	I-Premise
195	.	_	_	I-Premise

196	A	_	_	B-Premise
197	mean	_	_	I-Premise
198	of	_	_	I-Premise
199	10.6	_	_	I-Premise
200	units	_	_	I-Premise
201	of	_	_	I-Premise
202	PRBCs	_	_	I-Premise
203	over	_	_	I-Premise
204	5	_	_	I-Premise
205	months	_	_	I-Premise
206	were	_	_	I-Premise
207	administered	_	_	I-Premise
208	to	_	_	I-Premise
209	those	_	_	I-Premise
210	who	_	_	I-Premise
211	received	_	_	I-Premise
212	epoetin	_	_	I-Premise
213	alpha	_	_	I-Premise
214	compared	_	_	I-Premise
215	with	_	_	I-Premise
216	13	_	_	I-Premise
217	units	_	_	I-Premise
218	for	_	_	I-Premise
219	those	_	_	I-Premise
220	who	_	_	I-Premise
221	did	_	_	I-Premise
222	not	_	_	I-Premise
223	receive	_	_	I-Premise
224	epoetin	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.04	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	There	_	_	B-Premise
232	was	_	_	I-Premise
233	no	_	_	I-Premise
234	significant	_	_	I-Premise
235	difference	_	_	I-Premise
236	in	_	_	I-Premise
237	QOL	_	_	I-Premise
238	as	_	_	I-Premise
239	assessed	_	_	I-Premise
240	by	_	_	I-Premise
241	the	_	_	I-Premise
242	FACT-Anemia	_	_	I-Premise
243	or	_	_	I-Premise
244	ESAS	_	_	I-Premise
245	instruments	_	_	I-Premise
246	.	_	_	I-Premise

247	The	_	_	B-Premise
248	CR	_	_	I-Premise
249	rate	_	_	I-Premise
250	and	_	_	I-Premise
251	the	_	_	I-Premise
252	3-year	_	_	I-Premise
253	CR	_	_	I-Premise
254	duration	_	_	I-Premise
255	were	_	_	I-Premise
256	not	_	_	I-Premise
257	affected	_	_	I-Premise
258	adversely	_	_	I-Premise
259	by	_	_	I-Premise
260	use	_	_	I-Premise
261	of	_	_	I-Premise
262	epoetin	_	_	I-Premise
263	alpha	_	_	I-Premise
264	.	_	_	I-Premise

265	Epoetin	_	_	B-Claim
266	alpha	_	_	I-Claim
267	decreased	_	_	I-Claim
268	the	_	_	I-Claim
269	number	_	_	I-Claim
270	of	_	_	I-Claim
271	PRBC	_	_	I-Claim
272	transfusions	_	_	I-Claim
273	and	_	_	I-Claim
274	did	_	_	I-Claim
275	not	_	_	I-Claim
276	appear	_	_	I-Claim
277	to	_	_	I-Claim
278	have	_	_	I-Claim
279	a	_	_	I-Claim
280	negative	_	_	I-Claim
281	impact	_	_	I-Claim
282	on	_	_	I-Claim
283	remission	_	_	I-Claim
284	duration	_	_	I-Claim
285	.	_	_	I-Claim

286	No	_	_	B-Claim
287	difference	_	_	I-Claim
288	in	_	_	I-Claim
289	QOL	_	_	I-Claim
290	was	_	_	I-Claim
291	observed	_	_	I-Claim
292	.	_	_	I-Claim


0	For	_	_	B-Claim
1	men	_	_	I-Claim
2	with	_	_	I-Claim
3	localised	_	_	I-Claim
4	prostate	_	_	I-Claim
5	cancer	_	_	I-Claim
6	,	_	_	I-Claim
7	surgery	_	_	I-Claim
8	provides	_	_	I-Claim
9	a	_	_	I-Claim
10	survival	_	_	I-Claim
11	benefit	_	_	I-Claim
12	compared	_	_	I-Claim
13	with	_	_	I-Claim
14	watchful	_	_	I-Claim
15	waiting	_	_	I-Claim
16	.	_	_	I-Claim

17	Treatments	_	_	O
18	are	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	morbidity	_	_	O
22	.	_	_	O

23	Results	_	_	O
24	for	_	_	O
25	functional	_	_	O
26	outcome	_	_	O
27	and	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	are	_	_	O
32	rarely	_	_	O
33	reported	_	_	O
34	beyond	_	_	O
35	10	_	_	O
36	years	_	_	O
37	and	_	_	O
38	are	_	_	O
39	lacking	_	_	O
40	from	_	_	O
41	randomised	_	_	O
42	settings	_	_	O
43	.	_	_	O

44	We	_	_	O
45	report	_	_	O
46	results	_	_	O
47	for	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	for	_	_	O
52	men	_	_	O
53	in	_	_	O
54	the	_	_	O
55	Scandinavian	_	_	O
56	Prostate	_	_	O
57	Cancer	_	_	O
58	Group	_	_	O
59	Study	_	_	O
60	Number	_	_	O
61	4	_	_	O
62	(	_	_	O
63	SPCG-4	_	_	O
64	)	_	_	O
65	after	_	_	O
66	a	_	_	O
67	median	_	_	O
68	follow-up	_	_	O
69	of	_	_	O
70	more	_	_	O
71	than	_	_	O
72	12	_	_	O
73	years	_	_	O
74	.	_	_	O

75	All	_	_	O
76	living	_	_	O
77	Swedish	_	_	O
78	and	_	_	O
79	Finnish	_	_	O
80	men	_	_	O
81	(	_	_	O
82	400	_	_	O
83	of	_	_	O
84	695	_	_	O
85	)	_	_	O
86	randomly	_	_	O
87	assigned	_	_	O
88	to	_	_	O
89	radical	_	_	O
90	prostatectomy	_	_	O
91	or	_	_	O
92	watchful	_	_	O
93	waiting	_	_	O
94	in	_	_	O
95	SPCG-4	_	_	O
96	from	_	_	O
97	1989	_	_	O
98	to	_	_	O
99	1999	_	_	O
100	were	_	_	O
101	included	_	_	O
102	in	_	_	O
103	our	_	_	O
104	analysis	_	_	O
105	.	_	_	O

106	An	_	_	O
107	additional	_	_	O
108	281	_	_	O
109	men	_	_	O
110	were	_	_	O
111	included	_	_	O
112	in	_	_	O
113	a	_	_	O
114	population-based	_	_	O
115	control	_	_	O
116	group	_	_	O
117	matched	_	_	O
118	for	_	_	O
119	region	_	_	O
120	and	_	_	O
121	age	_	_	O
122	.	_	_	O

123	Physical	_	_	O
124	symptoms	_	_	O
125	,	_	_	O
126	symptom-induced	_	_	O
127	stress	_	_	O
128	,	_	_	O
129	and	_	_	O
130	self-assessed	_	_	O
131	quality	_	_	O
132	of	_	_	O
133	life	_	_	O
134	were	_	_	O
135	evaluated	_	_	O
136	with	_	_	O
137	a	_	_	O
138	study-specific	_	_	O
139	questionnaire	_	_	O
140	.	_	_	O

141	Longitudinal	_	_	O
142	data	_	_	O
143	were	_	_	O
144	available	_	_	O
145	for	_	_	O
146	166	_	_	O
147	Swedish	_	_	O
148	men	_	_	O
149	who	_	_	O
150	had	_	_	O
151	answered	_	_	O
152	quality-of-life	_	_	O
153	questionnaires	_	_	O
154	at	_	_	O
155	an	_	_	O
156	earlier	_	_	O
157	timepoint	_	_	O
158	.	_	_	O

159	182	_	_	O
160	(	_	_	O
161	88	_	_	O
162	%	_	_	O
163	)	_	_	O
164	of	_	_	O
165	208	_	_	O
166	men	_	_	O
167	in	_	_	O
168	the	_	_	O
169	radical	_	_	O
170	prostatectomy	_	_	O
171	group	_	_	O
172	,	_	_	O
173	167	_	_	O
174	(	_	_	O
175	87	_	_	O
176	%	_	_	O
177	)	_	_	O
178	of	_	_	O
179	192	_	_	O
180	men	_	_	O
181	in	_	_	O
182	the	_	_	O
183	watchful-waiting	_	_	O
184	group	_	_	O
185	,	_	_	O
186	and	_	_	O
187	214	_	_	O
188	(	_	_	O
189	76	_	_	O
190	%	_	_	O
191	)	_	_	O
192	of	_	_	O
193	281	_	_	O
194	men	_	_	O
195	in	_	_	O
196	the	_	_	O
197	population-based	_	_	O
198	control	_	_	O
199	group	_	_	O
200	answered	_	_	O
201	the	_	_	O
202	questionnaire	_	_	O
203	.	_	_	O

204	Men	_	_	O
205	in	_	_	O
206	SPCG-4	_	_	O
207	had	_	_	O
208	a	_	_	O
209	median	_	_	O
210	follow-up	_	_	O
211	of	_	_	O
212	122	_	_	O
213	years	_	_	O
214	(	_	_	O
215	range	_	_	O
216	7-17	_	_	O
217	)	_	_	O
218	and	_	_	O
219	a	_	_	O
220	median	_	_	O
221	age	_	_	O
222	of	_	_	O
223	770	_	_	O
224	years	_	_	O
225	(	_	_	O
226	range	_	_	O
227	61-88	_	_	O
228	)	_	_	O
229	.	_	_	O

230	High	_	_	B-Premise
231	self-assessed	_	_	I-Premise
232	quality	_	_	I-Premise
233	of	_	_	I-Premise
234	life	_	_	I-Premise
235	was	_	_	I-Premise
236	reported	_	_	I-Premise
237	by	_	_	I-Premise
238	62	_	_	I-Premise
239	(	_	_	I-Premise
240	35	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	of	_	_	I-Premise
244	179	_	_	I-Premise
245	men	_	_	I-Premise
246	allocated	_	_	I-Premise
247	radical	_	_	I-Premise
248	prostatectomy	_	_	I-Premise
249	,	_	_	I-Premise
250	55	_	_	I-Premise
251	(	_	_	I-Premise
252	34	_	_	I-Premise
253	%	_	_	I-Premise
254	)	_	_	I-Premise
255	of	_	_	I-Premise
256	160	_	_	I-Premise
257	men	_	_	I-Premise
258	assigned	_	_	I-Premise
259	to	_	_	I-Premise
260	watchful	_	_	I-Premise
261	waiting	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	93	_	_	I-Premise
265	(	_	_	I-Premise
266	45	_	_	I-Premise
267	%	_	_	I-Premise
268	)	_	_	I-Premise
269	of	_	_	I-Premise
270	208	_	_	I-Premise
271	men	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	control	_	_	I-Premise
275	group	_	_	I-Premise
276	.	_	_	I-Premise

277	Anxiety	_	_	B-Premise
278	was	_	_	I-Premise
279	higher	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	SPCG-4	_	_	I-Premise
283	groups	_	_	I-Premise
284	(	_	_	I-Premise
285	77	_	_	I-Premise
286	[	_	_	I-Premise
287	43	_	_	I-Premise
288	%	_	_	I-Premise
289	]	_	_	I-Premise
290	of	_	_	I-Premise
291	178	_	_	I-Premise
292	and	_	_	I-Premise
293	69	_	_	I-Premise
294	[	_	_	I-Premise
295	43	_	_	I-Premise
296	%	_	_	I-Premise
297	]	_	_	I-Premise
298	of	_	_	I-Premise
299	161	_	_	I-Premise
300	men	_	_	I-Premise
301	)	_	_	I-Premise
302	than	_	_	I-Premise
303	in	_	_	I-Premise
304	the	_	_	I-Premise
305	control	_	_	I-Premise
306	group	_	_	I-Premise
307	(	_	_	I-Premise
308	68	_	_	I-Premise
309	[	_	_	I-Premise
310	33	_	_	I-Premise
311	%	_	_	I-Premise
312	]	_	_	I-Premise
313	of	_	_	I-Premise
314	208	_	_	I-Premise
315	men	_	_	I-Premise
316	;	_	_	I-Premise
317	relative	_	_	I-Premise
318	risk	_	_	I-Premise
319	142	_	_	I-Premise
320	,	_	_	I-Premise
321	95	_	_	I-Premise
322	%	_	_	I-Premise
323	CI	_	_	I-Premise
324	107-188	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	Prevalence	_	_	B-Premise
328	of	_	_	I-Premise
329	erectile	_	_	I-Premise
330	dysfunction	_	_	I-Premise
331	was	_	_	I-Premise
332	84	_	_	I-Premise
333	%	_	_	I-Premise
334	(	_	_	I-Premise
335	146	_	_	I-Premise
336	of	_	_	I-Premise
337	173	_	_	I-Premise
338	men	_	_	I-Premise
339	)	_	_	I-Premise
340	in	_	_	I-Premise
341	the	_	_	I-Premise
342	radical	_	_	I-Premise
343	prostatectomy	_	_	I-Premise
344	group	_	_	I-Premise
345	,	_	_	I-Premise
346	80	_	_	I-Premise
347	%	_	_	I-Premise
348	(	_	_	I-Premise
349	122	_	_	I-Premise
350	of	_	_	I-Premise
351	153	_	_	I-Premise
352	)	_	_	I-Premise
353	in	_	_	I-Premise
354	the	_	_	I-Premise
355	watchful-waiting	_	_	I-Premise
356	group	_	_	I-Premise
357	,	_	_	I-Premise
358	and	_	_	I-Premise
359	46	_	_	I-Premise
360	%	_	_	I-Premise
361	(	_	_	I-Premise
362	95	_	_	I-Premise
363	of	_	_	I-Premise
364	208	_	_	I-Premise
365	)	_	_	I-Premise
366	in	_	_	I-Premise
367	the	_	_	I-Premise
368	control	_	_	I-Premise
369	group	_	_	I-Premise
370	and	_	_	I-Premise
371	prevalence	_	_	I-Premise
372	of	_	_	I-Premise
373	urinary	_	_	I-Premise
374	leakage	_	_	I-Premise
375	was	_	_	I-Premise
376	41	_	_	I-Premise
377	%	_	_	I-Premise
378	(	_	_	I-Premise
379	71	_	_	I-Premise
380	of	_	_	I-Premise
381	173	_	_	I-Premise
382	)	_	_	I-Premise
383	,	_	_	I-Premise
384	11	_	_	I-Premise
385	%	_	_	I-Premise
386	(	_	_	I-Premise
387	18	_	_	I-Premise
388	of	_	_	I-Premise
389	164	_	_	I-Premise
390	)	_	_	I-Premise
391	,	_	_	I-Premise
392	and	_	_	I-Premise
393	3	_	_	I-Premise
394	%	_	_	I-Premise
395	(	_	_	I-Premise
396	six	_	_	I-Premise
397	of	_	_	I-Premise
398	209	_	_	I-Premise
399	)	_	_	I-Premise
400	,	_	_	I-Premise
401	respectively	_	_	I-Premise
402	.	_	_	I-Premise

403	Distress	_	_	B-Premise
404	caused	_	_	I-Premise
405	by	_	_	I-Premise
406	these	_	_	I-Premise
407	symptoms	_	_	I-Premise
408	was	_	_	I-Premise
409	reported	_	_	I-Premise
410	significantly	_	_	I-Premise
411	more	_	_	I-Premise
412	often	_	_	I-Premise
413	by	_	_	I-Premise
414	men	_	_	I-Premise
415	allocated	_	_	I-Premise
416	radical	_	_	I-Premise
417	prostatectomy	_	_	I-Premise
418	than	_	_	I-Premise
419	by	_	_	I-Premise
420	men	_	_	I-Premise
421	assigned	_	_	I-Premise
422	to	_	_	I-Premise
423	watchful	_	_	I-Premise
424	waiting	_	_	I-Premise
425	.	_	_	I-Premise

426	In	_	_	B-Premise
427	a	_	_	I-Premise
428	longitudinal	_	_	I-Premise
429	analysis	_	_	I-Premise
430	of	_	_	I-Premise
431	men	_	_	I-Premise
432	in	_	_	I-Premise
433	SPCG-4	_	_	I-Premise
434	who	_	_	I-Premise
435	provided	_	_	I-Premise
436	information	_	_	I-Premise
437	at	_	_	I-Premise
438	two	_	_	I-Premise
439	follow-up	_	_	I-Premise
440	points	_	_	I-Premise
441	9	_	_	I-Premise
442	years	_	_	I-Premise
443	apart	_	_	I-Premise
444	,	_	_	I-Premise
445	38	_	_	I-Premise
446	(	_	_	I-Premise
447	45	_	_	I-Premise
448	%	_	_	I-Premise
449	)	_	_	I-Premise
450	of	_	_	I-Premise
451	85	_	_	I-Premise
452	men	_	_	I-Premise
453	allocated	_	_	I-Premise
454	radical	_	_	I-Premise
455	prostatectomy	_	_	I-Premise
456	and	_	_	I-Premise
457	48	_	_	I-Premise
458	(	_	_	I-Premise
459	60	_	_	I-Premise
460	%	_	_	I-Premise
461	)	_	_	I-Premise
462	of	_	_	I-Premise
463	80	_	_	I-Premise
464	men	_	_	I-Premise
465	allocated	_	_	I-Premise
466	watchful	_	_	I-Premise
467	waiting	_	_	I-Premise
468	reported	_	_	I-Premise
469	an	_	_	I-Premise
470	increase	_	_	I-Premise
471	in	_	_	I-Premise
472	number	_	_	I-Premise
473	of	_	_	I-Premise
474	physical	_	_	I-Premise
475	symptoms	_	_	I-Premise
476	;	_	_	I-Premise
477	50	_	_	I-Premise
478	(	_	_	I-Premise
479	61	_	_	I-Premise
480	%	_	_	I-Premise
481	)	_	_	I-Premise
482	of	_	_	I-Premise
483	82	_	_	I-Premise
484	and	_	_	I-Premise
485	47	_	_	I-Premise
486	(	_	_	I-Premise
487	64	_	_	I-Premise
488	%	_	_	I-Premise
489	)	_	_	I-Premise
490	of	_	_	I-Premise
491	74	_	_	I-Premise
492	men	_	_	I-Premise
493	,	_	_	I-Premise
494	respectively	_	_	I-Premise
495	,	_	_	I-Premise
496	reported	_	_	I-Premise
497	a	_	_	I-Premise
498	reduction	_	_	I-Premise
499	in	_	_	I-Premise
500	quality	_	_	I-Premise
501	of	_	_	I-Premise
502	life	_	_	I-Premise
503	.	_	_	I-Premise

504	For	_	_	B-Premise
505	men	_	_	I-Premise
506	in	_	_	I-Premise
507	SPCG-4	_	_	I-Premise
508	,	_	_	I-Premise
509	negative	_	_	I-Premise
510	side-effects	_	_	I-Premise
511	were	_	_	I-Premise
512	common	_	_	I-Premise
513	and	_	_	I-Premise
514	added	_	_	I-Premise
515	more	_	_	I-Premise
516	stress	_	_	I-Premise
517	than	_	_	I-Premise
518	was	_	_	I-Premise
519	reported	_	_	I-Premise
520	in	_	_	I-Premise
521	the	_	_	I-Premise
522	control	_	_	I-Premise
523	population	_	_	I-Premise
524	.	_	_	I-Premise

525	In	_	_	B-Claim
526	the	_	_	I-Claim
527	radical	_	_	I-Claim
528	prostatectomy	_	_	I-Claim
529	group	_	_	I-Claim
530	,	_	_	I-Claim
531	erectile	_	_	I-Claim
532	dysfunction	_	_	I-Claim
533	and	_	_	I-Claim
534	urinary	_	_	I-Claim
535	leakage	_	_	I-Claim
536	were	_	_	I-Claim
537	often	_	_	I-Claim
538	consequences	_	_	I-Claim
539	of	_	_	I-Claim
540	surgery	_	_	I-Claim
541	.	_	_	I-Claim

542	In	_	_	B-Claim
543	the	_	_	I-Claim
544	watchful-waiting	_	_	I-Claim
545	group	_	_	I-Claim
546	,	_	_	I-Claim
547	side-effects	_	_	I-Claim
548	can	_	_	I-Claim
549	be	_	_	I-Claim
550	caused	_	_	I-Claim
551	by	_	_	I-Claim
552	tumour	_	_	I-Claim
553	progression	_	_	I-Claim
554	.	_	_	I-Claim

555	The	_	_	B-Claim
556	number	_	_	I-Claim
557	and	_	_	I-Claim
558	severity	_	_	I-Claim
559	of	_	_	I-Claim
560	side-effects	_	_	I-Claim
561	changes	_	_	I-Claim
562	over	_	_	I-Claim
563	time	_	_	I-Claim
564	at	_	_	I-Claim
565	a	_	_	I-Claim
566	higher	_	_	I-Claim
567	rate	_	_	I-Claim
568	than	_	_	I-Claim
569	is	_	_	I-Claim
570	caused	_	_	I-Claim
571	by	_	_	I-Claim
572	normal	_	_	I-Claim
573	ageing	_	_	I-Claim
574	and	_	_	I-Claim
575	a	_	_	I-Claim
576	loss	_	_	I-Claim
577	of	_	_	I-Claim
578	sexual	_	_	I-Claim
579	ability	_	_	I-Claim
580	is	_	_	I-Claim
581	a	_	_	I-Claim
582	persistent	_	_	I-Claim
583	psychological	_	_	I-Claim
584	problem	_	_	I-Claim
585	for	_	_	I-Claim
586	both	_	_	I-Claim
587	interventions	_	_	I-Claim
588	.	_	_	I-Claim

589	An	_	_	O
590	understanding	_	_	O
591	of	_	_	O
592	the	_	_	O
593	patterns	_	_	O
594	of	_	_	O
595	side-effects	_	_	O
596	and	_	_	O
597	time	_	_	O
598	dimension	_	_	O
599	of	_	_	O
600	their	_	_	O
601	occurrence	_	_	O
602	for	_	_	O
603	each	_	_	O
604	treatment	_	_	O
605	is	_	_	O
606	important	_	_	O
607	for	_	_	O
608	full	_	_	O
609	patient	_	_	O
610	information	_	_	O
611	.	_	_	O


0	Both	_	_	O
1	Billroth	_	_	O
2	I	_	_	O
3	(	_	_	O
4	B-I	_	_	O
5	)	_	_	O
6	and	_	_	O
7	Roux-en-Y	_	_	O
8	(	_	_	O
9	R-Y	_	_	O
10	)	_	_	O
11	reconstructions	_	_	O
12	are	_	_	O
13	commonly	_	_	O
14	performed	_	_	O
15	as	_	_	O
16	standard	_	_	O
17	procedures	_	_	O
18	,	_	_	O
19	but	_	_	O
20	it	_	_	O
21	has	_	_	O
22	yet	_	_	O
23	to	_	_	O
24	be	_	_	O
25	determined	_	_	O
26	which	_	_	O
27	reconstruction	_	_	O
28	is	_	_	O
29	better	_	_	O
30	for	_	_	O
31	patients	_	_	O
32	.	_	_	O

33	A	_	_	O
34	randomized	_	_	O
35	prospective	_	_	O
36	phase	_	_	O
37	II	_	_	O
38	trial	_	_	O
39	with	_	_	O
40	body	_	_	O
41	weight	_	_	O
42	loss	_	_	O
43	at	_	_	O
44	1	_	_	O
45	year	_	_	O
46	after	_	_	O
47	surgery	_	_	O
48	as	_	_	O
49	a	_	_	O
50	primary	_	_	O
51	endpoint	_	_	O
52	was	_	_	O
53	performed	_	_	O
54	to	_	_	O
55	address	_	_	O
56	this	_	_	O
57	issue	_	_	O
58	.	_	_	O

59	The	_	_	O
60	current	_	_	O
61	report	_	_	O
62	delivers	_	_	O
63	data	_	_	O
64	on	_	_	O
65	the	_	_	O
66	quality	_	_	O
67	of	_	_	O
68	life	_	_	O
69	and	_	_	O
70	degree	_	_	O
71	of	_	_	O
72	postoperative	_	_	O
73	dysfunction	_	_	O
74	,	_	_	O
75	which	_	_	O
76	were	_	_	O
77	the	_	_	O
78	secondary	_	_	O
79	endpoints	_	_	O
80	of	_	_	O
81	this	_	_	O
82	study	_	_	O
83	.	_	_	O

84	Gastric	_	_	O
85	cancer	_	_	O
86	patients	_	_	O
87	who	_	_	O
88	underwent	_	_	O
89	distal	_	_	O
90	gastrectomy	_	_	O
91	were	_	_	O
92	intraoperatively	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	B-I	_	_	O
96	or	_	_	O
97	R-Y	_	_	O
98	.	_	_	O

99	Postsurgical	_	_	O
100	QOL	_	_	O
101	was	_	_	O
102	evaluated	_	_	O
103	using	_	_	O
104	the	_	_	O
105	EORTC	_	_	O
106	QLQ-C30	_	_	O
107	and	_	_	O
108	DAUGS	_	_	O
109	20	_	_	O
110	.	_	_	O

111	Between	_	_	O
112	August	_	_	O
113	2005	_	_	O
114	and	_	_	O
115	December	_	_	O
116	2008	_	_	O
117	,	_	_	O
118	332	_	_	O
119	patients	_	_	O
120	were	_	_	O
121	enrolled	_	_	O
122	in	_	_	O
123	a	_	_	O
124	randomized	_	_	O
125	trial	_	_	O
126	comparing	_	_	O
127	B-I	_	_	O
128	versus	_	_	O
129	R-Y	_	_	O
130	.	_	_	O

131	A	_	_	O
132	mail	_	_	O
133	survey	_	_	O
134	questionnaire	_	_	O
135	sent	_	_	O
136	to	_	_	O
137	327	_	_	O
138	patients	_	_	O
139	was	_	_	O
140	completed	_	_	O
141	by	_	_	O
142	268	_	_	O
143	(	_	_	O
144	86.2	_	_	O
145	%	_	_	O
146	)	_	_	O
147	of	_	_	O
148	them	_	_	O
149	.	_	_	O

150	EORTC	_	_	O
151	QLQ-C30	_	_	O
152	scores	_	_	O
153	were	_	_	O
154	as	_	_	O
155	follows	_	_	O
156	:	_	_	O
157	global	_	_	O
158	health	_	_	O
159	status	_	_	O
160	was	_	_	O
161	similar	_	_	O
162	in	_	_	O
163	each	_	_	O
164	group	_	_	O
165	(	_	_	O
166	B-I	_	_	O
167	73.5	_	_	O
168		_	_	O
169	18.8	_	_	O
170	,	_	_	O
171	R-Y	_	_	O
172	73.2	_	_	O
173		_	_	O
174	20.2	_	_	O
175	,	_	_	O
176	p	_	_	O
177	=	_	_	O
178	0.87	_	_	O
179	)	_	_	O
180	.	_	_	O

181	Scores	_	_	O
182	of	_	_	O
183	five	_	_	O
184	functional	_	_	O
185	scales	_	_	O
186	were	_	_	O
187	also	_	_	O
188	similar	_	_	O
189	.	_	_	O

190	Only	_	_	B-Premise
191	the	_	_	I-Premise
192	dyspnea	_	_	I-Premise
193	symptom	_	_	I-Premise
194	scale	_	_	I-Premise
195	showed	_	_	I-Premise
196	superior	_	_	I-Premise
197	results	_	_	I-Premise
198	for	_	_	I-Premise
199	R-Y	_	_	I-Premise
200	than	_	_	I-Premise
201	for	_	_	I-Premise
202	B-I	_	_	I-Premise
203	(	_	_	I-Premise
204	B-I	_	_	I-Premise
205	13.6	_	_	I-Premise
206		_	_	I-Premise
207	17.9	_	_	I-Premise
208	,	_	_	I-Premise
209	R-Y	_	_	I-Premise
210	8.6	_	_	I-Premise
211		_	_	I-Premise
212	16.3	_	_	I-Premise
213	,	_	_	I-Premise
214	p	_	_	I-Premise
215	=	_	_	I-Premise
216	0.02	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	With	_	_	B-Premise
220	respect	_	_	I-Premise
221	to	_	_	I-Premise
222	DAUGS	_	_	I-Premise
223	20	_	_	I-Premise
224	,	_	_	I-Premise
225	the	_	_	I-Premise
226	total	_	_	I-Premise
227	score	_	_	I-Premise
228	did	_	_	I-Premise
229	not	_	_	I-Premise
230	differ	_	_	I-Premise
231	significantly	_	_	I-Premise
232	between	_	_	I-Premise
233	the	_	_	I-Premise
234	R-Y	_	_	I-Premise
235	and	_	_	I-Premise
236	B-I	_	_	I-Premise
237	groups	_	_	I-Premise
238	(	_	_	I-Premise
239	24.8	_	_	I-Premise
240	vs.	_	_	I-Premise
241	23.6	_	_	I-Premise
242	,	_	_	I-Premise
243	p	_	_	I-Premise
244	=	_	_	I-Premise
245	0.41	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Only	_	_	B-Premise
249	reflux	_	_	I-Premise
250	symptoms	_	_	I-Premise
251	were	_	_	I-Premise
252	significantly	_	_	I-Premise
253	worse	_	_	I-Premise
254	for	_	_	I-Premise
255	B-I	_	_	I-Premise
256	than	_	_	I-Premise
257	for	_	_	I-Premise
258	R-Y	_	_	I-Premise
259	(	_	_	I-Premise
260	0.7	_	_	I-Premise
261		_	_	I-Premise
262	0.6	_	_	I-Premise
263	vs.	_	_	I-Premise
264	0.5	_	_	I-Premise
265		_	_	I-Premise
266	0.6	_	_	I-Premise
267	,	_	_	I-Premise
268	p	_	_	I-Premise
269	=	_	_	I-Premise
270	0.01	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Claim
274	B-I	_	_	I-Claim
275	and	_	_	I-Claim
276	R-Y	_	_	I-Claim
277	techniques	_	_	I-Claim
278	were	_	_	I-Claim
279	generally	_	_	I-Claim
280	equivalent	_	_	I-Claim
281	in	_	_	I-Claim
282	terms	_	_	I-Claim
283	of	_	_	I-Claim
284	postoperative	_	_	I-Claim
285	QOL	_	_	I-Claim
286	and	_	_	I-Claim
287	dysfunction	_	_	I-Claim
288	.	_	_	I-Claim

289	Both	_	_	B-Claim
290	procedures	_	_	I-Claim
291	seem	_	_	I-Claim
292	acceptable	_	_	I-Claim
293	as	_	_	I-Claim
294	standard	_	_	I-Claim
295	reconstructions	_	_	I-Claim
296	after	_	_	I-Claim
297	distal	_	_	I-Claim
298	gastrectomy	_	_	I-Claim
299	with	_	_	I-Claim
300	regard	_	_	I-Claim
301	to	_	_	I-Claim
302	postoperative	_	_	I-Claim
303	QOL	_	_	I-Claim
304	and	_	_	I-Claim
305	dysfunction	_	_	I-Claim
306	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	Chinese	_	_	O
6	medicine	_	_	O
7	(	_	_	O
8	CM	_	_	O
9	)	_	_	O
10	comprehensive	_	_	O
11	regimen	_	_	O
12	as	_	_	O
13	the	_	_	O
14	maintenance	_	_	O
15	therapy	_	_	O
16	(	_	_	O
17	MT	_	_	O
18	)	_	_	O
19	on	_	_	O
20	time	_	_	O
21	to	_	_	O
22	progression	_	_	O
23	(	_	_	O
24	TTP	_	_	O
25	)	_	_	O
26	and	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	of	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	advanced	_	_	O
37	non-small-cell	_	_	O
38	lung	_	_	O
39	cancer	_	_	O
40	(	_	_	O
41	NSCLC	_	_	O
42	)	_	_	O
43	.	_	_	O

44	The	_	_	O
45	study	_	_	O
46	was	_	_	O
47	a	_	_	O
48	prospective	_	_	O
49	,	_	_	O
50	randomized	_	_	O
51	and	_	_	O
52	controlled	_	_	O
53	clinical	_	_	O
54	trial	_	_	O
55	.	_	_	O

56	Fifty	_	_	O
57	non-progressive	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	advanced	_	_	O
61	NSCLC	_	_	O
62	who	_	_	O
63	responded	_	_	O
64	to	_	_	O
65	first-line	_	_	O
66	therapy	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	into	_	_	O
70	the	_	_	O
71	test	_	_	O
72	group	_	_	O
73	(	_	_	O
74	25	_	_	O
75	cases	_	_	O
76	,	_	_	O
77	treated	_	_	O
78	with	_	_	O
79	CM	_	_	O
80	comprehensive	_	_	O
81	regimen	_	_	O
82	:	_	_	O
83	intravenous	_	_	O
84	dripping	_	_	O
85	of	_	_	O
86	Chinese	_	_	O
87	herbal	_	_	O
88	preparation	_	_	O
89	,	_	_	O
90	oral	_	_	O
91	administration	_	_	O
92	of	_	_	O
93	Chinese	_	_	O
94	herbal	_	_	O
95	decoction	_	_	O
96	,	_	_	O
97	and	_	_	O
98	point	_	_	O
99	application	_	_	O
100	)	_	_	O
101	and	_	_	O
102	the	_	_	O
103	control	_	_	O
104	group	_	_	O
105	[	_	_	O
106	25	_	_	O
107	cases	_	_	O
108	,	_	_	O
109	treated	_	_	O
110	with	_	_	O
111	one	_	_	O
112	of	_	_	O
113	three	_	_	O
114	single-agent	_	_	O
115	maintenance	_	_	O
116	chemotherapy	_	_	O
117	regimens	_	_	O
118	:	_	_	O
119	pemetrexed	_	_	O
120	(	_	_	O
121	500	_	_	O
122	mg/m2	_	_	O
123	,	_	_	O
124	day	_	_	O
125	1	_	_	O
126	)	_	_	O
127	,	_	_	O
128	docetaxel	_	_	O
129	(	_	_	O
130	75	_	_	O
131	mg/m2	_	_	O
132	,	_	_	O
133	day	_	_	O
134	1	_	_	O
135	)	_	_	O
136	,	_	_	O
137	and	_	_	O
138	gemcitabine	_	_	O
139	(	_	_	O
140	1000	_	_	O
141	mg/mi	_	_	O
142	,	_	_	O
143	day	_	_	O
144	1	_	_	O
145	and	_	_	O
146	day	_	_	O
147	8	_	_	O
148	)	_	_	O
149	in	_	_	O
150	the	_	_	O
151	ratio	_	_	O
152	of	_	_	O
153	1:1	_	_	O
154	]	_	_	O
155	.	_	_	O

156	Each	_	_	O
157	cycle	_	_	O
158	consisted	_	_	O
159	of	_	_	O
160	21	_	_	O
161	days	_	_	O
162	.	_	_	O

163	Cycles	_	_	O
164	were	_	_	O
165	repeated	_	_	O
166	until	_	_	O
167	the	_	_	O
168	disease	_	_	O
169	progressed	_	_	O
170	,	_	_	O
171	or	_	_	O
172	intolerable	_	_	O
173	toxic	_	_	O
174	or	_	_	O
175	adverse	_	_	O
176	reaction	_	_	O
177	occurred	_	_	O
178	,	_	_	O
179	or	_	_	O
180	patients	_	_	O
181	refused	_	_	O
182	to	_	_	O
183	continue	_	_	O
184	the	_	_	O
185	treatment	_	_	O
186	.	_	_	O

187	The	_	_	O
188	primary	_	_	O
189	end	_	_	O
190	point	_	_	O
191	was	_	_	O
192	TTP	_	_	O
193	and	_	_	O
194	the	_	_	O
195	secondary	_	_	O
196	end	_	_	O
197	point	_	_	O
198	was	_	_	O
199	QOL	_	_	O
200	.	_	_	O

201	QOL	_	_	O
202	was	_	_	O
203	evaluated	_	_	O
204	using	_	_	O
205	the	_	_	O
206	European	_	_	O
207	Organization	_	_	O
208	for	_	_	O
209	Research	_	_	O
210	and	_	_	O
211	Treatment	_	_	O
212	of	_	_	O
213	Cancer	_	_	O
214	quality-of-life	_	_	O
215	questionnaire	_	_	O
216	QLQ-LC43	_	_	O
217	(	_	_	O
218	EORTC	_	_	O
219	QLQ-LC43	_	_	O
220	)	_	_	O
221	.	_	_	O

222	TTP	_	_	O
223	of	_	_	O
224	fifty	_	_	O
225	patients	_	_	O
226	and	_	_	O
227	QOL	_	_	O
228	of	_	_	O
229	43	_	_	O
230	patients	_	_	O
231	had	_	_	O
232	been	_	_	O
233	statistically	_	_	O
234	analyzed	_	_	O
235	.	_	_	O

236	(	_	_	O
237	1	_	_	O
238	)	_	_	O
239	The	_	_	B-Premise
240	TTP	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	test	_	_	I-Premise
244	group	_	_	I-Premise
245	was	_	_	I-Premise
246	prolonged	_	_	I-Premise
247	for	_	_	I-Premise
248	23	_	_	I-Premise
249	days	_	_	I-Premise
250	when	_	_	I-Premise
251	compared	_	_	I-Premise
252	with	_	_	I-Premise
253	that	_	_	I-Premise
254	of	_	_	I-Premise
255	the	_	_	I-Premise
256	control	_	_	I-Premise
257	group	_	_	I-Premise
258	,	_	_	I-Premise
259	with	_	_	I-Premise
260	insignificant	_	_	I-Premise
261	difference	_	_	I-Premise
262	(	_	_	I-Premise
263	87	_	_	I-Premise
264	days	_	_	I-Premise
265	vs	_	_	I-Premise
266	64	_	_	I-Premise
267	days	_	_	I-Premise
268	,	_	_	I-Premise
269	P=0.063	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	(	_	_	O
273	2	_	_	O
274	)	_	_	O
275	The	_	_	B-Premise
276	scores	_	_	I-Premise
277	of	_	_	I-Premise
278	domains	_	_	I-Premise
279	in	_	_	I-Premise
280	EORTC	_	_	I-Premise
281	QLQ-LC43	_	_	I-Premise
282	were	_	_	I-Premise
283	statistically	_	_	I-Premise
284	significantly	_	_	I-Premise
285	better	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	test	_	_	I-Premise
289	group	_	_	I-Premise
290	than	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	control	_	_	I-Premise
294	group	_	_	I-Premise
295	(	_	_	I-Premise
296	P	_	_	I-Premise
297	<	_	_	I-Premise
298	0.05	_	_	I-Premise
299	)	_	_	I-Premise
300	except	_	_	B-Premise
301	cognitive	_	_	I-Premise
302	and	_	_	I-Premise
303	social	_	_	I-Premise
304	functions	_	_	I-Premise
305	,	_	_	I-Premise
306	the	_	_	I-Premise
307	symptoms	_	_	I-Premise
308	of	_	_	I-Premise
309	dysphagia	_	_	I-Premise
310	and	_	_	I-Premise
311	pain	_	_	I-Premise
312	in	_	_	I-Premise
313	other	_	_	I-Premise
314	parts	_	_	I-Premise
315	.	_	_	I-Premise

316	(	_	_	O
317	1	_	_	O
318	)	_	_	O
319	The	_	_	B-Claim
320	CM	_	_	I-Claim
321	comprehensive	_	_	I-Claim
322	regimen	_	_	I-Claim
323	as	_	_	I-Claim
324	MT	_	_	I-Claim
325	had	_	_	I-Claim
326	equivalent	_	_	I-Claim
327	efficacy	_	_	I-Claim
328	on	_	_	I-Claim
329	TTP	_	_	I-Claim
330	when	_	_	I-Claim
331	compared	_	_	I-Claim
332	with	_	_	I-Claim
333	single-agent	_	_	I-Claim
334	maintenance	_	_	I-Claim
335	chemotherapy	_	_	I-Claim
336	regimen	_	_	I-Claim
337	.	_	_	I-Claim

338	It	_	_	B-Claim
339	was	_	_	I-Claim
340	advantageous	_	_	I-Claim
341	over	_	_	I-Claim
342	improving	_	_	I-Claim
343	the	_	_	I-Claim
344	QOL	_	_	I-Claim
345	.	_	_	I-Claim

346	(	_	_	O
347	2	_	_	O
348	)	_	_	O
349	It	_	_	B-Claim
350	is	_	_	I-Claim
351	necessary	_	_	I-Claim
352	to	_	_	I-Claim
353	enlarge	_	_	I-Claim
354	the	_	_	I-Claim
355	sample	_	_	I-Claim
356	size	_	_	I-Claim
357	to	_	_	I-Claim
358	further	_	_	I-Claim
359	confirm	_	_	I-Claim
360	the	_	_	I-Claim
361	therapeutic	_	_	I-Claim
362	efficacy	_	_	I-Claim
363	of	_	_	I-Claim
364	CM	_	_	I-Claim
365	comprehensive	_	_	I-Claim
366	regimen	_	_	I-Claim
367	as	_	_	I-Claim
368	MT	_	_	I-Claim
369	in	_	_	I-Claim
370	treatment	_	_	I-Claim
371	of	_	_	I-Claim
372	patients	_	_	I-Claim
373	with	_	_	I-Claim
374	advanced	_	_	I-Claim
375	NSCLC	_	_	I-Claim
376	.	_	_	I-Claim


0	Gynecological	_	_	O
1	neoplastic	_	_	O
2	disease	_	_	O
3	progression	_	_	O
4	is	_	_	O
5	characterized	_	_	O
6	by	_	_	O
7	specific	_	_	O
8	energy	_	_	O
9	metabolism	_	_	O
10	alterations	_	_	O
11	and	_	_	O
12	by	_	_	O
13	symptoms	_	_	O
14	including	_	_	O
15	fatigue	_	_	O
16	,	_	_	O
17	anorexia	_	_	O
18	,	_	_	O
19	nausea	_	_	O
20	,	_	_	O
21	anemia	_	_	O
22	,	_	_	O
23	and	_	_	O
24	immunodepression	_	_	O
25	,	_	_	O
26	which	_	_	O
27	result	_	_	O
28	in	_	_	O
29	a	_	_	O
30	cachexia	_	_	O
31	syndrome	_	_	O
32	and	_	_	O
33	a	_	_	O
34	marked	_	_	O
35	decrease	_	_	O
36	in	_	_	O
37	patient	_	_	O
38	quality	_	_	O
39	of	_	_	O
40	life	_	_	O
41	(	_	_	O
42	QoL	_	_	O
43	)	_	_	O
44	.	_	_	O

45	Therapeutic	_	_	O
46	protocols	_	_	O
47	associated	_	_	O
48	with	_	_	O
49	appropriate	_	_	O
50	and	_	_	O
51	effective	_	_	O
52	psychological	_	_	O
53	and	_	_	O
54	social	_	_	O
55	support	_	_	O
56	systems	_	_	O
57	are	_	_	O
58	essential	_	_	O
59	to	_	_	O
60	counteract	_	_	O
61	the	_	_	O
62	symptoms	_	_	O
63	of	_	_	O
64	neoplastic	_	_	O
65	disease	_	_	O
66	in	_	_	O
67	incurable	_	_	O
68	patients	_	_	O
69	.	_	_	O

70	A	_	_	O
71	phase	_	_	O
72	III	_	_	O
73	randomized	_	_	O
74	study	_	_	O
75	was	_	_	O
76	performed	_	_	O
77	to	_	_	O
78	establish	_	_	O
79	the	_	_	O
80	most	_	_	O
81	effective	_	_	O
82	and	_	_	O
83	safest	_	_	O
84	treatment	_	_	O
85	to	_	_	O
86	improve	_	_	O
87	the	_	_	O
88	key	_	_	O
89	symptoms	_	_	O
90	in	_	_	O
91	advanced	_	_	O
92	gynecological	_	_	O
93	cancer	_	_	O
94	patients	_	_	O
95	,	_	_	O
96	i.e.	_	_	O
97	,	_	_	O
98	lean	_	_	O
99	body	_	_	O
100	mass	_	_	O
101	(	_	_	O
102	LBM	_	_	O
103	)	_	_	O
104	,	_	_	O
105	resting	_	_	O
106	energy	_	_	O
107	expenditure	_	_	O
108	(	_	_	O
109	REE	_	_	O
110	)	_	_	O
111	,	_	_	O
112	fatigue	_	_	O
113	,	_	_	O
114	and	_	_	O
115	QoL	_	_	O
116	.	_	_	O

117	In	_	_	O
118	addition	_	_	O
119	,	_	_	O
120	the	_	_	O
121	impact	_	_	O
122	of	_	_	O
123	the	_	_	O
124	treatment	_	_	O
125	arms	_	_	O
126	on	_	_	O
127	the	_	_	O
128	main	_	_	O
129	metabolic	_	_	O
130	and	_	_	O
131	inflammatory	_	_	O
132	parameters	_	_	O
133	,	_	_	O
134	including	_	_	O
135	C-reactive	_	_	O
136	protein	_	_	O
137	(	_	_	O
138	CRP	_	_	O
139	)	_	_	O
140	,	_	_	O
141	interleukin	_	_	O
142	(	_	_	O
143	IL	_	_	O
144	)	_	_	O
145	-6	_	_	O
146	,	_	_	O
147	tumor	_	_	O
148	necrosis	_	_	O
149	factor	_	_	O
150	(	_	_	O
151	TNF	_	_	O
152	)	_	_	O
153	-	_	_	O
154	,	_	_	O
155	leptin	_	_	O
156	,	_	_	O
157	reactive	_	_	O
158	oxygen	_	_	O
159	species	_	_	O
160	(	_	_	O
161	ROS	_	_	O
162	)	_	_	O
163	,	_	_	O
164	and	_	_	O
165	glutathione	_	_	O
166	peroxidase	_	_	O
167	,	_	_	O
168	was	_	_	O
169	evaluated	_	_	O
170	.	_	_	O

171	The	_	_	O
172	change	_	_	O
173	in	_	_	O
174	the	_	_	O
175	Glasgow	_	_	O
176	Prognostic	_	_	O
177	Score	_	_	O
178	(	_	_	O
179	GPS	_	_	O
180	)	_	_	O
181	during	_	_	O
182	treatment	_	_	O
183	was	_	_	O
184	also	_	_	O
185	assessed	_	_	O
186	.	_	_	O

187	A	_	_	O
188	total	_	_	O
189	of	_	_	O
190	104	_	_	O
191	advanced-stage	_	_	O
192	gynecological	_	_	O
193	cancer	_	_	O
194	patients	_	_	O
195	were	_	_	O
196	enrolled	_	_	O
197	and	_	_	O
198	randomly	_	_	O
199	assigned	_	_	O
200	to	_	_	O
201	receive	_	_	O
202	either	_	_	O
203	megestrol	_	_	O
204	acetate	_	_	O
205	(	_	_	O
206	MA	_	_	O
207	)	_	_	O
208	plus	_	_	O
209	l-carnitine	_	_	O
210	,	_	_	O
211	celecoxib	_	_	O
212	,	_	_	O
213	and	_	_	O
214	antioxidants	_	_	O
215	(	_	_	O
216	arm	_	_	O
217	1	_	_	O
218	)	_	_	O
219	or	_	_	O
220	MA	_	_	O
221	alone	_	_	O
222	(	_	_	O
223	arm	_	_	O
224	2	_	_	O
225	)	_	_	O
226	.	_	_	O

227	The	_	_	O
228	treatment	_	_	O
229	duration	_	_	O
230	was	_	_	O
231	4	_	_	O
232	months	_	_	O
233	.	_	_	O

234	The	_	_	B-Premise
235	combination	_	_	I-Premise
236	arm	_	_	I-Premise
237	was	_	_	I-Premise
238	more	_	_	I-Premise
239	effective	_	_	I-Premise
240	than	_	_	I-Premise
241	arm	_	_	I-Premise
242	2	_	_	I-Premise
243	with	_	_	I-Premise
244	respect	_	_	I-Premise
245	to	_	_	I-Premise
246	LBM	_	_	I-Premise
247	,	_	_	I-Premise
248	REE	_	_	I-Premise
249	,	_	_	I-Premise
250	fatigue	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	global	_	_	I-Premise
254	QoL	_	_	I-Premise
255	.	_	_	I-Premise

256	As	_	_	B-Premise
257	for	_	_	I-Premise
258	the	_	_	I-Premise
259	secondary	_	_	I-Premise
260	efficacy	_	_	I-Premise
261	endpoints	_	_	I-Premise
262	,	_	_	I-Premise
263	patient	_	_	I-Premise
264	appetite	_	_	I-Premise
265	increased	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	ECOG	_	_	I-Premise
269	PS	_	_	I-Premise
270	decreased	_	_	I-Premise
271	significantly	_	_	I-Premise
272	in	_	_	I-Premise
273	both	_	_	I-Premise
274	arms	_	_	I-Premise
275	.	_	_	I-Premise

276	The	_	_	B-Premise
277	inflammation	_	_	I-Premise
278	and	_	_	I-Premise
279	oxidative	_	_	I-Premise
280	stress	_	_	I-Premise
281	parameters	_	_	I-Premise
282	IL-6	_	_	I-Premise
283	,	_	_	I-Premise
284	TNF-	_	_	I-Premise
285	,	_	_	I-Premise
286	CRP	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	ROS	_	_	I-Premise
290	decreased	_	_	I-Premise
291	significantly	_	_	I-Premise
292	in	_	_	I-Premise
293	arm	_	_	I-Premise
294	1	_	_	I-Premise
295	,	_	_	I-Premise
296	while	_	_	I-Premise
297	no	_	_	I-Premise
298	significant	_	_	I-Premise
299	change	_	_	I-Premise
300	was	_	_	I-Premise
301	observed	_	_	I-Premise
302	in	_	_	I-Premise
303	arm	_	_	I-Premise
304	2	_	_	I-Premise
305	.	_	_	I-Premise

306	The	_	_	B-Claim
307	combined	_	_	I-Claim
308	treatment	_	_	I-Claim
309	improved	_	_	I-Claim
310	both	_	_	I-Claim
311	immunometabolic	_	_	I-Claim
312	alterations	_	_	I-Claim
313	and	_	_	I-Claim
314	patient	_	_	I-Claim
315	QoL	_	_	I-Claim
316	.	_	_	I-Claim

317	Multimodality	_	_	B-Claim
318	therapies	_	_	I-Claim
319	for	_	_	I-Claim
320	cachexia	_	_	I-Claim
321	ideally	_	_	I-Claim
322	should	_	_	I-Claim
323	be	_	_	I-Claim
324	introduced	_	_	I-Claim
325	within	_	_	I-Claim
326	a	_	_	I-Claim
327	context	_	_	I-Claim
328	of	_	_	I-Claim
329	best	_	_	I-Claim
330	supportive	_	_	I-Claim
331	care	_	_	I-Claim
332	that	_	_	I-Claim
333	includes	_	_	I-Claim
334	optimal	_	_	I-Claim
335	symptom	_	_	I-Claim
336	management	_	_	I-Claim
337	and	_	_	I-Claim
338	careful	_	_	I-Claim
339	psychosocial	_	_	I-Claim
340	counseling	_	_	I-Claim
341	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aims	_	_	O
3	to	_	_	O
4	examine	_	_	O
5	the	_	_	O
6	effectiveness	_	_	O
7	of	_	_	O
8	a	_	_	O
9	self-management	_	_	O
10	multimodal	_	_	O
11	comprehensive	_	_	O
12	coping	_	_	O
13	strategy	_	_	O
14	program	_	_	O
15	(	_	_	O
16	CCSP	_	_	O
17	)	_	_	O
18	on	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	among	_	_	O
26	breast	_	_	O
27	cancer	_	_	O
28	patients	_	_	O
29	1	_	_	O
30	year	_	_	O
31	after	_	_	O
32	treatment	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	(	_	_	O
36	n	_	_	O
37	=	_	_	O
38	110	_	_	O
39	)	_	_	O
40	with	_	_	O
41	stage	_	_	O
42	II	_	_	O
43	,	_	_	O
44	III	_	_	O
45	,	_	_	O
46	or	_	_	O
47	IV	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	scheduled	_	_	O
51	to	_	_	O
52	receive	_	_	O
53	high	_	_	O
54	dose	_	_	O
55	chemotherapy	_	_	O
56	and	_	_	O
57	autologous	_	_	O
58	hematopoietic	_	_	O
59	stem	_	_	O
60	cell	_	_	O
61	transplantation	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	either	_	_	O
66	CCSP	_	_	O
67	treatment	_	_	O
68	or	_	_	O
69	control	_	_	O
70	group	_	_	O
71	.	_	_	O

72	The	_	_	O
73	CCSP	_	_	O
74	intervention	_	_	O
75	was	_	_	O
76	taught	_	_	O
77	2	_	_	O
78	week	_	_	O
79	before	_	_	O
80	hospital	_	_	O
81	admission	_	_	O
82	with	_	_	O
83	reinforcement	_	_	O
84	at	_	_	O
85	specified	_	_	O
86	times	_	_	O
87	during	_	_	O
88	treatment	_	_	O
89	and	_	_	O
90	3	_	_	O
91	months	_	_	O
92	after	_	_	O
93	discharge	_	_	O
94	.	_	_	O

95	The	_	_	O
96	CCSP	_	_	O
97	components	_	_	O
98	included	_	_	O
99	educational	_	_	O
100	information	_	_	O
101	,	_	_	O
102	cognitive	_	_	O
103	restructuring	_	_	O
104	,	_	_	O
105	coping	_	_	O
106	skills	_	_	O
107	enhancement	_	_	O
108	,	_	_	O
109	and	_	_	O
110	relaxation	_	_	O
111	with	_	_	O
112	guided	_	_	O
113	imagery	_	_	O
114	.	_	_	O

115	Instruments	_	_	O
116	administered	_	_	O
117	at	_	_	O
118	baseline	_	_	O
119	included	_	_	O
120	the	_	_	O
121	following	_	_	O
122	:	_	_	O
123	Quality	_	_	O
124	of	_	_	O
125	Life	_	_	O
126	Index-Cancer	_	_	O
127	Version	_	_	O
128	(	_	_	O
129	QOLI-CV	_	_	O
130	)	_	_	O
131	,	_	_	O
132	State-Trait	_	_	O
133	Anxiety	_	_	O
134	Inventory	_	_	O
135	,	_	_	O
136	Beck	_	_	O
137	Depression	_	_	O
138	Inventory	_	_	O
139	,	_	_	O
140	and	_	_	O
141	Coping	_	_	O
142	Strategies	_	_	O
143	Questionnaire	_	_	O
144	.	_	_	O

145	At	_	_	O
146	1-year	_	_	O
147	follow-up	_	_	O
148	,	_	_	O
149	patients	_	_	O
150	(	_	_	O
151	n	_	_	O
152	=	_	_	O
153	73	_	_	O
154	)	_	_	O
155	completed	_	_	O
156	and	_	_	O
157	returned	_	_	O
158	the	_	_	O
159	follow-up	_	_	O
160	QOLI-CV	_	_	O
161	.	_	_	O

162	Patients	_	_	O
163	were	_	_	O
164	mainly	_	_	O
165		_	_	O
166	40	_	_	O
167	years	_	_	O
168	of	_	_	O
169	age	_	_	O
170	,	_	_	O
171	married	_	_	O
172	,	_	_	O
173	Caucasian	_	_	O
174	,	_	_	O
175	and	_	_	O
176	diagnosed	_	_	O
177	with	_	_	O
178	advanced	_	_	O
179	breast	_	_	O
180	cancer	_	_	O
181	.	_	_	O

182	A	_	_	B-Premise
183	model	_	_	I-Premise
184	measuring	_	_	I-Premise
185	effectiveness	_	_	I-Premise
186	of	_	_	I-Premise
187	CCSP	_	_	I-Premise
188	on	_	_	I-Premise
189	QOL	_	_	I-Premise
190	(	_	_	I-Premise
191	total	_	_	I-Premise
192	and	_	_	I-Premise
193	subscale	_	_	I-Premise
194	)	_	_	I-Premise
195	at	_	_	I-Premise
196	1-year	_	_	I-Premise
197	follow-up	_	_	I-Premise
198	showed	_	_	I-Premise
199	that	_	_	I-Premise
200	the	_	_	I-Premise
201	CCSP	_	_	I-Premise
202	group	_	_	I-Premise
203	(	_	_	I-Premise
204	n	_	_	I-Premise
205	=	_	_	I-Premise
206	38	_	_	I-Premise
207	)	_	_	I-Premise
208	had	_	_	I-Premise
209	significant	_	_	I-Premise
210	improvement	_	_	I-Premise
211	in	_	_	I-Premise
212	overall	_	_	I-Premise
213	QOL	_	_	I-Premise
214	(	_	_	I-Premise
215	p	_	_	I-Premise
216	<	_	_	I-Premise
217	0.01	_	_	I-Premise
218	)	_	_	I-Premise
219	,	_	_	I-Premise
220	health	_	_	I-Premise
221	and	_	_	I-Premise
222	functioning	_	_	I-Premise
223	(	_	_	I-Premise
224	p	_	_	I-Premise
225	<	_	_	I-Premise
226	0.05	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	and	_	_	I-Premise
230	socioeconomic	_	_	I-Premise
231	(	_	_	I-Premise
232	p	_	_	I-Premise
233	<	_	_	I-Premise
234	0.05	_	_	I-Premise
235	)	_	_	I-Premise
236	and	_	_	I-Premise
237	psychological/spiritual	_	_	I-Premise
238	well-being	_	_	I-Premise
239	(	_	_	I-Premise
240	p	_	_	I-Premise
241	<	_	_	I-Premise
242	0.01	_	_	I-Premise
243	)	_	_	I-Premise
244	compared	_	_	I-Premise
245	with	_	_	I-Premise
246	the	_	_	I-Premise
247	control	_	_	I-Premise
248	group	_	_	I-Premise
249	(	_	_	I-Premise
250	n	_	_	I-Premise
251	=	_	_	I-Premise
252	35	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Premise
256	CCSP	_	_	I-Premise
257	patients	_	_	I-Premise
258	frequently	_	_	I-Premise
259	used	_	_	I-Premise
260	the	_	_	I-Premise
261	CCSP	_	_	I-Premise
262	to	_	_	I-Premise
263	manage	_	_	I-Premise
264	psychological	_	_	I-Premise
265	(	_	_	I-Premise
266	51	_	_	I-Premise
267	%	_	_	I-Premise
268	)	_	_	I-Premise
269	and	_	_	I-Premise
270	sleep	_	_	I-Premise
271	problems	_	_	I-Premise
272	(	_	_	I-Premise
273	60	_	_	I-Premise
274	%	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	The	_	_	B-Premise
278	CCSP	_	_	I-Premise
279	improved	_	_	I-Premise
280	QOL	_	_	I-Premise
281	for	_	_	I-Premise
282	patients	_	_	I-Premise
283	at	_	_	I-Premise
284	1-year	_	_	I-Premise
285	follow-up	_	_	I-Premise
286	.	_	_	I-Premise

287	Patients	_	_	B-Premise
288	overwhelmingly	_	_	I-Premise
289	reported	_	_	I-Premise
290	that	_	_	I-Premise
291	CCSP	_	_	I-Premise
292	was	_	_	I-Premise
293	beneficial	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Claim
296	CCSP	_	_	I-Claim
297	as	_	_	I-Claim
298	an	_	_	I-Claim
299	effective	_	_	I-Claim
300	coping	_	_	I-Claim
301	intervention	_	_	I-Claim
302	has	_	_	I-Claim
303	potential	_	_	I-Claim
304	as	_	_	I-Claim
305	a	_	_	I-Claim
306	self-management	_	_	I-Claim
307	program	_	_	I-Claim
308	for	_	_	I-Claim
309	breast	_	_	I-Claim
310	cancer	_	_	I-Claim
311	survivors	_	_	I-Claim
312	.	_	_	I-Claim


0	As	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	pancreas	_	_	O
4	and	_	_	O
5	periampullary	_	_	O
6	cancer	_	_	O
7	(	_	_	O
8	PPC	_	_	O
9	)	_	_	O
10	experience	_	_	O
11	improved	_	_	O
12	survival	_	_	O
13	rates	_	_	O
14	and	_	_	O
15	longevity	_	_	O
16	,	_	_	O
17	the	_	_	O
18	focus	_	_	O
19	shifts	_	_	O
20	toward	_	_	O
21	living	_	_	O
22	life	_	_	O
23	while	_	_	O
24	surviving	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	Fatigue	_	_	O
28	is	_	_	O
29	the	_	_	O
30	most	_	_	O
31	commonly	_	_	O
32	reported	_	_	O
33	symptom	_	_	O
34	in	_	_	O
35	all	_	_	O
36	cancer	_	_	O
37	patients	_	_	O
38	.	_	_	O

39	Exercise	_	_	O
40	has	_	_	O
41	been	_	_	O
42	found	_	_	O
43	to	_	_	O
44	effectively	_	_	O
45	decrease	_	_	O
46	fatigue	_	_	O
47	levels	_	_	O
48	and	_	_	O
49	improve	_	_	O
50	physical	_	_	O
51	functioning	_	_	O
52	in	_	_	O
53	cancer	_	_	O
54	patients	_	_	O
55	.	_	_	O

56	One	_	_	O
57	hundred	_	_	O
58	two	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	resected	_	_	O
62	PPC	_	_	O
63	consented	_	_	O
64	to	_	_	O
65	participate	_	_	O
66	in	_	_	O
67	this	_	_	O
68	study	_	_	O
69	and	_	_	O
70	were	_	_	O
71	randomized	_	_	O
72	to	_	_	O
73	either	_	_	O
74	an	_	_	O
75	intervention	_	_	O
76	group	_	_	O
77	(	_	_	O
78	IG	_	_	O
79	)	_	_	O
80	or	_	_	O
81	a	_	_	O
82	usual	_	_	O
83	care	_	_	O
84	group	_	_	O
85	(	_	_	O
86	UCG	_	_	O
87	)	_	_	O
88	.	_	_	O

89	Subjects	_	_	O
90	completed	_	_	O
91	visual	_	_	O
92	analog	_	_	O
93	scales	_	_	O
94	,	_	_	O
95	the	_	_	O
96	FACIT-Fatigue	_	_	O
97	Scale	_	_	O
98	and	_	_	O
99	the	_	_	O
100	Short	_	_	O
101	Form-36v2	_	_	O
102	after	_	_	O
103	surgery	_	_	O
104	and	_	_	O
105	again	_	_	O
106	3	_	_	O
107	to	_	_	O
108	6	_	_	O
109	months	_	_	O
110	after	_	_	O
111	hospital	_	_	O
112	discharge	_	_	O
113	.	_	_	O

114	Patients	_	_	O
115	in	_	_	O
116	the	_	_	O
117	IG	_	_	O
118	and	_	_	O
119	UCG	_	_	O
120	were	_	_	O
121	comparable	_	_	O
122	with	_	_	O
123	regard	_	_	O
124	to	_	_	O
125	demographics	_	_	O
126	,	_	_	O
127	comorbidities	_	_	O
128	,	_	_	O
129	cancer	_	_	O
130	type	_	_	O
131	and	_	_	O
132	staging	_	_	O
133	,	_	_	O
134	type	_	_	O
135	of	_	_	O
136	resection	_	_	O
137	,	_	_	O
138	preoperative	_	_	O
139	fatigue	_	_	O
140	and	_	_	O
141	pain	_	_	O
142	levels	_	_	O
143	,	_	_	O
144	adjuvant	_	_	O
145	therapy	_	_	O
146	,	_	_	O
147	and	_	_	O
148	baseline	_	_	O
149	walking	_	_	O
150	distance	_	_	O
151	.	_	_	O

152	Patients	_	_	B-Premise
153	in	_	_	I-Premise
154	the	_	_	I-Premise
155	IG	_	_	I-Premise
156	had	_	_	I-Premise
157	significantly	_	_	I-Premise
158	improved	_	_	I-Premise
159	scores	_	_	I-Premise
160	on	_	_	I-Premise
161	the	_	_	I-Premise
162	FACIT-Fatigue	_	_	I-Premise
163	Scale	_	_	I-Premise
164	at	_	_	I-Premise
165	study	_	_	I-Premise
166	completion	_	_	I-Premise
167	,	_	_	I-Premise
168	improved	_	_	I-Premise
169	fatigue	_	_	I-Premise
170	and	_	_	I-Premise
171	pain	_	_	I-Premise
172	scores	_	_	I-Premise
173	,	_	_	I-Premise
174	as	_	_	I-Premise
175	well	_	_	I-Premise
176	as	_	_	I-Premise
177	overall	_	_	I-Premise
178	physical	_	_	I-Premise
179	functioning	_	_	I-Premise
180	and	_	_	I-Premise
181	mental	_	_	I-Premise
182	health	_	_	I-Premise
183	composite	_	_	I-Premise
184	scores	_	_	I-Premise
185	.	_	_	I-Premise

186	At	_	_	B-Premise
187	study	_	_	I-Premise
188	completion	_	_	I-Premise
189	,	_	_	I-Premise
190	participants	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	IG	_	_	I-Premise
194	were	_	_	I-Premise
195	walking	_	_	I-Premise
196	twice	_	_	I-Premise
197	as	_	_	I-Premise
198	far	_	_	I-Premise
199	and	_	_	I-Premise
200	were	_	_	I-Premise
201	significantly	_	_	I-Premise
202	more	_	_	I-Premise
203	likely	_	_	I-Premise
204	to	_	_	I-Premise
205	have	_	_	I-Premise
206	continued	_	_	I-Premise
207	walking	_	_	I-Premise
208	or	_	_	I-Premise
209	another	_	_	I-Premise
210	form	_	_	I-Premise
211	of	_	_	I-Premise
212	exercise	_	_	I-Premise
213	as	_	_	I-Premise
214	compared	_	_	I-Premise
215	with	_	_	I-Premise
216	the	_	_	I-Premise
217	UCG	_	_	I-Premise
218	.	_	_	I-Premise

219	Using	_	_	O
220	hierarchical	_	_	O
221	cluster	_	_	O
222	analysis	_	_	O
223	,	_	_	O
224	3	_	_	O
225	mutually	_	_	O
226	exclusive	_	_	O
227	symptom	_	_	O
228	groupings	_	_	O
229	were	_	_	O
230	identified	_	_	O
231	in	_	_	O
232	the	_	_	O
233	cohort	_	_	O
234	.	_	_	O

235	Kaplan-Meier	_	_	B-Premise
236	survival	_	_	I-Premise
237	analysis	_	_	I-Premise
238	did	_	_	I-Premise
239	not	_	_	I-Premise
240	indicate	_	_	I-Premise
241	an	_	_	I-Premise
242	overall	_	_	I-Premise
243	survival	_	_	I-Premise
244	benefit	_	_	I-Premise
245	for	_	_	I-Premise
246	the	_	_	I-Premise
247	IG	_	_	I-Premise
248	.	_	_	I-Premise

249	This	_	_	B-Claim
250	is	_	_	I-Claim
251	the	_	_	I-Claim
252	first	_	_	I-Claim
253	prospective	_	_	I-Claim
254	,	_	_	I-Claim
255	randomized	_	_	I-Claim
256	controlled	_	_	I-Claim
257	trial	_	_	I-Claim
258	to	_	_	I-Claim
259	report	_	_	I-Claim
260	that	_	_	I-Claim
261	participation	_	_	I-Claim
262	in	_	_	I-Claim
263	a	_	_	I-Claim
264	home	_	_	I-Claim
265	walking	_	_	I-Claim
266	program	_	_	I-Claim
267	confers	_	_	I-Claim
268	a	_	_	I-Claim
269	significant	_	_	I-Claim
270	benefit	_	_	I-Claim
271	in	_	_	I-Claim
272	resected	_	_	I-Claim
273	PPC	_	_	I-Claim
274	patients	_	_	I-Claim
275	with	_	_	I-Claim
276	regard	_	_	I-Claim
277	to	_	_	I-Claim
278	fatigue	_	_	I-Claim
279	levels	_	_	I-Claim
280	,	_	_	I-Claim
281	physical	_	_	I-Claim
282	functioning	_	_	I-Claim
283	,	_	_	I-Claim
284	and	_	_	I-Claim
285	health-related	_	_	I-Claim
286	quality	_	_	I-Claim
287	of	_	_	I-Claim
288	life	_	_	I-Claim
289	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	of	_	_	O
5	mindfulness-based	_	_	O
6	stress	_	_	O
7	reduction	_	_	O
8	(	_	_	O
9	MBSR	_	_	O
10	)	_	_	O
11	for	_	_	O
12	mood	_	_	O
13	,	_	_	O
14	breast-	_	_	O
15	and	_	_	O
16	endocrine-specific	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	,	_	_	O
21	and	_	_	O
22	well-being	_	_	O
23	after	_	_	O
24	hospital	_	_	O
25	treatment	_	_	O
26	in	_	_	O
27	women	_	_	O
28	with	_	_	O
29	stage	_	_	O
30	0	_	_	O
31	to	_	_	O
32	III	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	.	_	_	O

36	A	_	_	O
37	randomized	_	_	O
38	,	_	_	O
39	wait-listed	_	_	O
40	,	_	_	O
41	controlled	_	_	O
42	trial	_	_	O
43	was	_	_	O
44	carried	_	_	O
45	out	_	_	O
46	in	_	_	O
47	229	_	_	O
48	women	_	_	O
49	after	_	_	O
50	surgery	_	_	O
51	,	_	_	O
52	chemotherapy	_	_	O
53	,	_	_	O
54	and	_	_	O
55	radiotherapy	_	_	O
56	for	_	_	O
57	breast	_	_	O
58	cancer	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	were	_	_	O
62	randomly	_	_	O
63	assigned	_	_	O
64	to	_	_	O
65	the	_	_	O
66	8-week	_	_	O
67	MBSR	_	_	O
68	program	_	_	O
69	or	_	_	O
70	standard	_	_	O
71	care	_	_	O
72	.	_	_	O

73	Profile	_	_	O
74	of	_	_	O
75	Mood	_	_	O
76	States	_	_	O
77	(	_	_	O
78	POMS	_	_	O
79	;	_	_	O
80	primary	_	_	O
81	outcome	_	_	O
82	)	_	_	O
83	,	_	_	O
84	Functional	_	_	O
85	Assessment	_	_	O
86	of	_	_	O
87	Cancer	_	_	O
88	Therapy-Breast	_	_	O
89	(	_	_	O
90	FACT-B	_	_	O
91	)	_	_	O
92	,	_	_	O
93	Functional	_	_	O
94	Assessment	_	_	O
95	of	_	_	O
96	Cancer	_	_	O
97	Therapy-Endocrine	_	_	O
98	Symptoms	_	_	O
99	(	_	_	O
100	FACT-ES	_	_	O
101	)	_	_	O
102	scales	_	_	O
103	and	_	_	O
104	the	_	_	O
105	WHO	_	_	O
106	five-item	_	_	O
107	well-being	_	_	O
108	questionnaire	_	_	O
109	(	_	_	O
110	WHO-5	_	_	O
111	)	_	_	O
112	evaluated	_	_	O
113	mood	_	_	O
114	,	_	_	O
115	quality	_	_	O
116	of	_	_	O
117	life	_	_	O
118	,	_	_	O
119	and	_	_	O
120	well-being	_	_	O
121	at	_	_	O
122	weeks	_	_	O
123	0	_	_	O
124	,	_	_	O
125	8	_	_	O
126	,	_	_	O
127	and	_	_	O
128	12	_	_	O
129	.	_	_	O

130	For	_	_	O
131	each	_	_	O
132	outcome	_	_	O
133	measure	_	_	O
134	,	_	_	O
135	a	_	_	O
136	repeated-measures	_	_	O
137	analysis	_	_	O
138	of	_	_	O
139	variance	_	_	O
140	model	_	_	O
141	,	_	_	O
142	which	_	_	O
143	incorporated	_	_	O
144	week	_	_	O
145	0	_	_	O
146	measurements	_	_	O
147	as	_	_	O
148	a	_	_	O
149	covariate	_	_	O
150	,	_	_	O
151	was	_	_	O
152	used	_	_	O
153	to	_	_	O
154	compare	_	_	O
155	treatment	_	_	O
156	groups	_	_	O
157	at	_	_	O
158	8	_	_	O
159	and	_	_	O
160	12	_	_	O
161	weeks	_	_	O
162	.	_	_	O

163	There	_	_	B-Premise
164	were	_	_	I-Premise
165	statistically	_	_	I-Premise
166	significant	_	_	I-Premise
167	improvements	_	_	I-Premise
168	in	_	_	I-Premise
169	outcome	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	experimental	_	_	I-Premise
173	group	_	_	I-Premise
174	compared	_	_	I-Premise
175	with	_	_	I-Premise
176	control	_	_	I-Premise
177	group	_	_	I-Premise
178	at	_	_	I-Premise
179	both	_	_	I-Premise
180	8	_	_	I-Premise
181	and	_	_	I-Premise
182	12	_	_	I-Premise
183	weeks	_	_	I-Premise
184	(	_	_	I-Premise
185	except	_	_	I-Premise
186	as	_	_	I-Premise
187	indicated	_	_	I-Premise
188	)	_	_	I-Premise
189	for	_	_	I-Premise
190	POMS	_	_	I-Premise
191	total	_	_	I-Premise
192	mood	_	_	I-Premise
193	disturbance	_	_	I-Premise
194	(	_	_	I-Premise
195	and	_	_	I-Premise
196	its	_	_	I-Premise
197	subscales	_	_	I-Premise
198	of	_	_	I-Premise
199	anxiety	_	_	I-Premise
200	,	_	_	I-Premise
201	depression	_	_	I-Premise
202	[	_	_	I-Premise
203	8	_	_	I-Premise
204	weeks	_	_	I-Premise
205	only	_	_	I-Premise
206	]	_	_	I-Premise
207	,	_	_	I-Premise
208	anger	_	_	I-Premise
209	[	_	_	I-Premise
210	12	_	_	I-Premise
211	weeks	_	_	I-Premise
212	only	_	_	I-Premise
213	]	_	_	I-Premise
214	,	_	_	I-Premise
215	vigor	_	_	I-Premise
216	,	_	_	I-Premise
217	fatigue	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	confusion	_	_	I-Premise
221	[	_	_	I-Premise
222	8	_	_	I-Premise
223	weeks	_	_	I-Premise
224	only	_	_	I-Premise
225	]	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	FACT-B	_	_	I-Premise
229	,	_	_	I-Premise
230	FACT-ES	_	_	I-Premise
231	,	_	_	I-Premise
232	(	_	_	I-Premise
233	and	_	_	I-Premise
234	Functional	_	_	I-Premise
235	Assessment	_	_	I-Premise
236	of	_	_	I-Premise
237	Cancer	_	_	I-Premise
238	Therapy	_	_	I-Premise
239	subscales	_	_	I-Premise
240	of	_	_	I-Premise
241	physical	_	_	I-Premise
242	,	_	_	I-Premise
243	social	_	_	I-Premise
244	[	_	_	I-Premise
245	8	_	_	I-Premise
246	weeks	_	_	I-Premise
247	only	_	_	I-Premise
248	]	_	_	I-Premise
249	,	_	_	I-Premise
250	emotional	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	functional	_	_	I-Premise
254	well-being	_	_	I-Premise
255	)	_	_	I-Premise
256	,	_	_	I-Premise
257	and	_	_	I-Premise
258	WHO-5	_	_	I-Premise
259	.	_	_	I-Premise

260	MSBR	_	_	B-Premise
261	improved	_	_	I-Premise
262	mood	_	_	I-Premise
263	,	_	_	I-Premise
264	breast-	_	_	I-Premise
265	and	_	_	I-Premise
266	endocrine-related	_	_	I-Premise
267	quality	_	_	I-Premise
268	of	_	_	I-Premise
269	life	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	well-being	_	_	I-Premise
273	more	_	_	I-Premise
274	effectively	_	_	I-Premise
275	than	_	_	I-Premise
276	standard	_	_	I-Premise
277	care	_	_	I-Premise
278	in	_	_	I-Premise
279	women	_	_	I-Premise
280	with	_	_	I-Premise
281	stage	_	_	I-Premise
282	0	_	_	I-Premise
283	to	_	_	I-Premise
284	III	_	_	I-Premise
285	breast	_	_	I-Premise
286	cancer	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	these	_	_	I-Premise
290	results	_	_	I-Premise
291	persisted	_	_	I-Premise
292	at	_	_	I-Premise
293	three	_	_	I-Premise
294	months	_	_	I-Premise
295	.	_	_	I-Premise

296	To	_	_	B-Claim
297	our	_	_	I-Claim
298	knowledge	_	_	I-Claim
299	,	_	_	I-Claim
300	this	_	_	I-Claim
301	study	_	_	I-Claim
302	provided	_	_	I-Claim
303	novel	_	_	I-Claim
304	evidence	_	_	I-Claim
305	that	_	_	I-Claim
306	MBSR	_	_	I-Claim
307	can	_	_	I-Claim
308	help	_	_	I-Claim
309	alleviate	_	_	I-Claim
310	long-term	_	_	I-Claim
311	emotional	_	_	I-Claim
312	and	_	_	I-Claim
313	physical	_	_	I-Claim
314	adverse	_	_	I-Claim
315	effects	_	_	I-Claim
316	of	_	_	I-Claim
317	medical	_	_	I-Claim
318	treatments	_	_	I-Claim
319	,	_	_	I-Claim
320	including	_	_	I-Claim
321	endocrine	_	_	I-Claim
322	treatments	_	_	I-Claim
323	.	_	_	I-Claim

324	MBSR	_	_	B-Claim
325	is	_	_	I-Claim
326	recommended	_	_	I-Claim
327	to	_	_	I-Claim
328	support	_	_	I-Claim
329	survivors	_	_	I-Claim
330	of	_	_	I-Claim
331	breast	_	_	I-Claim
332	cancer	_	_	I-Claim
333	.	_	_	I-Claim


0	Patients	_	_	O
1	with	_	_	O
2	lymphoma	_	_	O
3	experience	_	_	O
4	sleep	_	_	O
5	problems	_	_	O
6	that	_	_	O
7	may	_	_	O
8	be	_	_	O
9	managed	_	_	O
10	with	_	_	O
11	aerobic	_	_	O
12	exercise	_	_	O
13	but	_	_	O
14	no	_	_	O
15	previous	_	_	O
16	study	_	_	O
17	has	_	_	O
18	examined	_	_	O
19	this	_	_	O
20	issue	_	_	O
21	.	_	_	O

22	We	_	_	O
23	randomized	_	_	O
24	122	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	lymphoma	_	_	O
28	to	_	_	O
29	usual	_	_	O
30	care	_	_	O
31	(	_	_	O
32	n	_	_	O
33	=	_	_	O
34	62	_	_	O
35	)	_	_	O
36	or	_	_	O
37	12	_	_	O
38	weeks	_	_	O
39	of	_	_	O
40	supervised	_	_	O
41	aerobic	_	_	O
42	exercise	_	_	O
43	training	_	_	O
44	(	_	_	O
45	AET	_	_	O
46	;	_	_	O
47	n	_	_	O
48	=	_	_	O
49	60	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Our	_	_	O
53	primary	_	_	O
54	sleep	_	_	O
55	endpoint	_	_	O
56	was	_	_	O
57	global	_	_	O
58	sleep	_	_	O
59	quality	_	_	O
60	assessed	_	_	O
61	by	_	_	O
62	the	_	_	O
63	Pittsburgh	_	_	O
64	Sleep	_	_	O
65	Quality	_	_	O
66	Index	_	_	O
67	(	_	_	O
68	PSQI	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Secondary	_	_	O
72	endpoints	_	_	O
73	were	_	_	O
74	the	_	_	O
75	PSQI	_	_	O
76	component	_	_	O
77	scores	_	_	O
78	.	_	_	O

79	Planned	_	_	O
80	subgroup	_	_	O
81	analyses	_	_	O
82	were	_	_	O
83	also	_	_	O
84	conducted	_	_	O
85	.	_	_	O

86	Intention-to-treat	_	_	B-Premise
87	analyses	_	_	I-Premise
88	indicated	_	_	I-Premise
89	that	_	_	I-Premise
90	AET	_	_	I-Premise
91	resulted	_	_	I-Premise
92	in	_	_	I-Premise
93	a	_	_	I-Premise
94	nonsignificant	_	_	I-Premise
95	(	_	_	I-Premise
96	P	_	_	I-Premise
97	=	_	_	I-Premise
98	0.16	_	_	I-Premise
99	)	_	_	I-Premise
100	improvement	_	_	I-Premise
101	in	_	_	I-Premise
102	global	_	_	I-Premise
103	sleep	_	_	I-Premise
104	quality	_	_	I-Premise
105	compared	_	_	I-Premise
106	with	_	_	I-Premise
107	usual	_	_	I-Premise
108	care	_	_	I-Premise
109	[	_	_	I-Premise
110	mean	_	_	I-Premise
111	group	_	_	I-Premise
112	difference	_	_	I-Premise
113	=	_	_	I-Premise
114	-0.64	_	_	I-Premise
115	;	_	_	I-Premise
116	95	_	_	I-Premise
117	%	_	_	I-Premise
118	confidence	_	_	I-Premise
119	interval	_	_	I-Premise
120	(	_	_	I-Premise
121	CI	_	_	I-Premise
122	)	_	_	I-Premise
123	,	_	_	I-Premise
124	-1.56	_	_	I-Premise
125	to	_	_	I-Premise
126	+0.27	_	_	I-Premise
127	]	_	_	I-Premise
128	.	_	_	I-Premise

129	In	_	_	B-Premise
130	planned	_	_	I-Premise
131	subgroup	_	_	I-Premise
132	analyses	_	_	I-Premise
133	,	_	_	I-Premise
134	statistically	_	_	I-Premise
135	significant	_	_	I-Premise
136	or	_	_	I-Premise
137	borderline	_	_	I-Premise
138	significant	_	_	I-Premise
139	interactions	_	_	I-Premise
140	were	_	_	I-Premise
141	identified	_	_	I-Premise
142	for	_	_	I-Premise
143	type	_	_	I-Premise
144	of	_	_	I-Premise
145	lymphoma	_	_	I-Premise
146	(	_	_	I-Premise
147	P	_	_	I-Premise
148	(	_	_	I-Premise
149	interaction	_	_	I-Premise
150	)	_	_	I-Premise
151	=	_	_	I-Premise
152	0.006	_	_	I-Premise
153	)	_	_	I-Premise
154	,	_	_	I-Premise
155	current	_	_	I-Premise
156	treatment	_	_	I-Premise
157	status	_	_	I-Premise
158	(	_	_	I-Premise
159	P	_	_	I-Premise
160	(	_	_	I-Premise
161	interaction	_	_	I-Premise
162	)	_	_	I-Premise
163	=	_	_	I-Premise
164	0.036	_	_	I-Premise
165	)	_	_	I-Premise
166	,	_	_	I-Premise
167	time	_	_	I-Premise
168	since	_	_	I-Premise
169	diagnosis	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	(	_	_	I-Premise
173	interaction	_	_	I-Premise
174	)	_	_	I-Premise
175	=	_	_	I-Premise
176	0.010	_	_	I-Premise
177	)	_	_	I-Premise
178	,	_	_	I-Premise
179	body	_	_	I-Premise
180	mass	_	_	I-Premise
181	index	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	(	_	_	I-Premise
185	interaction	_	_	I-Premise
186	)	_	_	I-Premise
187	=	_	_	I-Premise
188	0.075	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	and	_	_	I-Premise
192	baseline	_	_	I-Premise
193	sleep	_	_	I-Premise
194	quality	_	_	I-Premise
195	(	_	_	I-Premise
196	P	_	_	I-Premise
197	(	_	_	I-Premise
198	interaction	_	_	I-Premise
199	)	_	_	I-Premise
200	=	_	_	I-Premise
201	0.041	_	_	I-Premise
202	)	_	_	I-Premise
203	.	_	_	I-Premise

204	Specifically	_	_	O
205	,	_	_	O
206	AET	_	_	B-Premise
207	improved	_	_	I-Premise
208	global	_	_	I-Premise
209	sleep	_	_	I-Premise
210	quality	_	_	I-Premise
211	in	_	_	I-Premise
212	patients	_	_	I-Premise
213	with	_	_	I-Premise
214	lymphoma	_	_	I-Premise
215	who	_	_	I-Premise
216	had	_	_	I-Premise
217	indolent	_	_	I-Premise
218	non-Hodgkin	_	_	I-Premise
219	lymphoma	_	_	I-Premise
220	(	_	_	I-Premise
221	P	_	_	I-Premise
222	=	_	_	I-Premise
223	0.001	_	_	I-Premise
224	)	_	_	I-Premise
225	,	_	_	I-Premise
226	were	_	_	I-Premise
227	receiving	_	_	I-Premise
228	chemotherapy	_	_	I-Premise
229	(	_	_	I-Premise
230	P	_	_	I-Premise
231	=	_	_	I-Premise
232	0.013	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	were	_	_	I-Premise
236	<	_	_	I-Premise
237	2	_	_	I-Premise
238	years	_	_	I-Premise
239	post-diagnosis	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	0.005	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	were	_	_	I-Premise
247	obese	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	=	_	_	I-Premise
251	0.025	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	and	_	_	I-Premise
255	were	_	_	I-Premise
256	poor	_	_	I-Premise
257	sleepers	_	_	I-Premise
258	at	_	_	I-Premise
259	baseline	_	_	I-Premise
260	(	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	0.007	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	AET	_	_	B-Claim
267	did	_	_	I-Claim
268	not	_	_	I-Claim
269	significantly	_	_	I-Claim
270	improve	_	_	I-Claim
271	sleep	_	_	I-Claim
272	quality	_	_	I-Claim
273	in	_	_	I-Claim
274	this	_	_	I-Claim
275	heterogeneous	_	_	I-Claim
276	sample	_	_	I-Claim
277	of	_	_	I-Claim
278	patients	_	_	I-Claim
279	with	_	_	I-Claim
280	lymphoma	_	_	I-Claim
281	;	_	_	I-Claim
282	however	_	_	B-Claim
283	,	_	_	I-Claim
284	clinically	_	_	I-Claim
285	identifiable	_	_	I-Claim
286	subgroups	_	_	I-Claim
287	appeared	_	_	I-Claim
288	to	_	_	I-Claim
289	benefit	_	_	I-Claim
290	.	_	_	I-Claim

291	Future	_	_	O
292	exercise	_	_	O
293	trials	_	_	O
294	targeting	_	_	O
295	these	_	_	O
296	responsive	_	_	O
297	subgroups	_	_	O
298	are	_	_	O
299	needed	_	_	O
300	to	_	_	O
301	confirm	_	_	O
302	these	_	_	O
303	findings	_	_	O
304	.	_	_	O

305	If	_	_	O
306	replicated	_	_	O
307	in	_	_	O
308	larger	_	_	O
309	and	_	_	O
310	more	_	_	O
311	focused	_	_	O
312	trials	_	_	O
313	,	_	_	O
314	aerobic	_	_	O
315	exercise	_	_	O
316	may	_	_	O
317	be	_	_	O
318	an	_	_	O
319	attractive	_	_	O
320	option	_	_	O
321	to	_	_	O
322	manage	_	_	O
323	sleep	_	_	O
324	dysfunction	_	_	O
325	in	_	_	O
326	patients	_	_	O
327	with	_	_	O
328	cancer	_	_	O
329	because	_	_	O
330	of	_	_	O
331	its	_	_	O
332	favorable	_	_	O
333	safety	_	_	O
334	profile	_	_	O
335	and	_	_	O
336	other	_	_	O
337	documented	_	_	O
338	health	_	_	O
339	benefits	_	_	O
340	.	_	_	O


0	Phase	_	_	O
1	III	_	_	O
2	EGF104900	_	_	O
3	data	_	_	O
4	demonstrated	_	_	O
5	that	_	_	O
6	lapatinib	_	_	O
7	plus	_	_	O
8	trastuzumab	_	_	O
9	significantly	_	_	O
10	improved	_	_	O
11	progression-free	_	_	O
12	survival	_	_	O
13	(	_	_	O
14	PFS	_	_	O
15	)	_	_	O
16	and	_	_	O
17	clinical	_	_	O
18	benefit	_	_	O
19	rate	_	_	O
20	versus	_	_	O
21	lapatinib	_	_	O
22	monotherapy	_	_	O
23	,	_	_	O
24	offering	_	_	O
25	a	_	_	O
26	chemotherapy-free	_	_	O
27	option	_	_	O
28	for	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	heavily	_	_	O
32	pretreated	_	_	O
33	human	_	_	O
34	epidermal	_	_	O
35	growth	_	_	O
36	factor	_	_	O
37	receptor	_	_	O
38	2	_	_	O
39	(	_	_	O
40	HER2	_	_	O
41	)	_	_	O
42	-positive	_	_	O
43	metastatic	_	_	O
44	breast	_	_	O
45	cancer	_	_	O
46	(	_	_	O
47	MBC	_	_	O
48	)	_	_	O
49	.	_	_	O

50	Final	_	_	O
51	planned	_	_	O
52	overall	_	_	O
53	survival	_	_	O
54	(	_	_	O
55	OS	_	_	O
56	)	_	_	O
57	analysis	_	_	O
58	from	_	_	O
59	EGF104900	_	_	O
60	is	_	_	O
61	reported	_	_	O
62	here	_	_	O
63	.	_	_	O

64	Patients	_	_	O
65	with	_	_	O
66	HER2-positive	_	_	O
67	MBC	_	_	O
68	whose	_	_	O
69	disease	_	_	O
70	progressed	_	_	O
71	during	_	_	O
72	prior	_	_	O
73	trastuzumab-based	_	_	O
74	therapies	_	_	O
75	were	_	_	O
76	randomly	_	_	O
77	assigned	_	_	O
78	to	_	_	O
79	receive	_	_	O
80	lapatinib	_	_	O
81	monotherapy	_	_	O
82	or	_	_	O
83	lapatinib	_	_	O
84	in	_	_	O
85	combination	_	_	O
86	with	_	_	O
87	trastuzumab	_	_	O
88	.	_	_	O

89	OS	_	_	O
90	and	_	_	O
91	updated	_	_	O
92	PFS	_	_	O
93	data	_	_	O
94	are	_	_	O
95	presented	_	_	O
96	using	_	_	O
97	Kaplan-Meier	_	_	O
98	curves	_	_	O
99	and	_	_	O
100	log-rank	_	_	O
101	tests	_	_	O
102	stratified	_	_	O
103	for	_	_	O
104	hormone	_	_	O
105	receptor	_	_	O
106	and	_	_	O
107	visceral	_	_	O
108	disease	_	_	O
109	status	_	_	O
110	.	_	_	O

111	Subgroup	_	_	O
112	analyses	_	_	O
113	were	_	_	O
114	conducted	_	_	O
115	to	_	_	O
116	identify	_	_	O
117	characteristics	_	_	O
118	of	_	_	O
119	patients	_	_	O
120	deriving	_	_	O
121	the	_	_	O
122	greatest	_	_	O
123	clinical	_	_	O
124	benefit	_	_	O
125	.	_	_	O

126	In	_	_	B-Premise
127	this	_	_	I-Premise
128	updated	_	_	I-Premise
129	final	_	_	I-Premise
130	analysis	_	_	I-Premise
131	of	_	_	I-Premise
132	all	_	_	I-Premise
133	patients	_	_	I-Premise
134	randomly	_	_	I-Premise
135	assigned	_	_	I-Premise
136	with	_	_	I-Premise
137	strata	_	_	I-Premise
138	(	_	_	I-Premise
139	n	_	_	I-Premise
140	=	_	_	I-Premise
141	291	_	_	I-Premise
142	)	_	_	I-Premise
143	,	_	_	I-Premise
144	lapatinib	_	_	I-Premise
145	plus	_	_	I-Premise
146	trastuzumab	_	_	I-Premise
147	continued	_	_	I-Premise
148	to	_	_	I-Premise
149	show	_	_	I-Premise
150	superiority	_	_	I-Premise
151	to	_	_	I-Premise
152	lapatinib	_	_	I-Premise
153	monotherapy	_	_	I-Premise
154	in	_	_	I-Premise
155	PFS	_	_	I-Premise
156	(	_	_	I-Premise
157	hazard	_	_	I-Premise
158	ratio	_	_	I-Premise
159	[	_	_	I-Premise
160	HR	_	_	I-Premise
161	]	_	_	I-Premise
162	,	_	_	I-Premise
163	0.74	_	_	I-Premise
164	;	_	_	I-Premise
165	95	_	_	I-Premise
166	%	_	_	I-Premise
167	CI	_	_	I-Premise
168	,	_	_	I-Premise
169	0.58	_	_	I-Premise
170	to	_	_	I-Premise
171	0.94	_	_	I-Premise
172	;	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.011	_	_	I-Premise
176	)	_	_	I-Premise
177	and	_	_	I-Premise
178	offered	_	_	I-Premise
179	significant	_	_	I-Premise
180	OS	_	_	I-Premise
181	benefit	_	_	I-Premise
182	(	_	_	I-Premise
183	HR	_	_	I-Premise
184	,	_	_	I-Premise
185	0.74	_	_	I-Premise
186	;	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	CI	_	_	I-Premise
190	,	_	_	I-Premise
191	0.57	_	_	I-Premise
192	to	_	_	I-Premise
193	0.97	_	_	I-Premise
194	;	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	.026	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Improvements	_	_	B-Premise
201	in	_	_	I-Premise
202	absolute	_	_	I-Premise
203	OS	_	_	I-Premise
204	rates	_	_	I-Premise
205	were	_	_	I-Premise
206	10	_	_	I-Premise
207	%	_	_	I-Premise
208	at	_	_	I-Premise
209	6	_	_	I-Premise
210	months	_	_	I-Premise
211	and	_	_	I-Premise
212	15	_	_	I-Premise
213	%	_	_	I-Premise
214	at	_	_	I-Premise
215	12	_	_	I-Premise
216	months	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	combination	_	_	I-Premise
220	arm	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	the	_	_	I-Premise
224	monotherapy	_	_	I-Premise
225	arm	_	_	I-Premise
226	.	_	_	I-Premise

227	Multiple	_	_	B-Premise
228	baseline	_	_	I-Premise
229	factors	_	_	I-Premise
230	,	_	_	I-Premise
231	including	_	_	I-Premise
232	Eastern	_	_	I-Premise
233	Cooperative	_	_	I-Premise
234	Oncology	_	_	I-Premise
235	Group	_	_	I-Premise
236	performance	_	_	I-Premise
237	status	_	_	I-Premise
238	of	_	_	I-Premise
239	0	_	_	I-Premise
240	,	_	_	I-Premise
241	nonvisceral	_	_	I-Premise
242	disease	_	_	I-Premise
243	,	_	_	I-Premise
244	<	_	_	I-Premise
245	three	_	_	I-Premise
246	metastatic	_	_	I-Premise
247	sites	_	_	I-Premise
248	,	_	_	I-Premise
249	and	_	_	I-Premise
250	less	_	_	I-Premise
251	time	_	_	I-Premise
252	from	_	_	I-Premise
253	initial	_	_	I-Premise
254	diagnosis	_	_	I-Premise
255	until	_	_	I-Premise
256	random	_	_	I-Premise
257	assignment	_	_	I-Premise
258	,	_	_	I-Premise
259	were	_	_	I-Premise
260	associated	_	_	I-Premise
261	with	_	_	I-Premise
262	improved	_	_	I-Premise
263	OS	_	_	I-Premise
264	.	_	_	I-Premise

265	Incidence	_	_	B-Premise
266	of	_	_	I-Premise
267	adverse	_	_	I-Premise
268	events	_	_	I-Premise
269	was	_	_	I-Premise
270	consistent	_	_	I-Premise
271	with	_	_	I-Premise
272	previously	_	_	I-Premise
273	reported	_	_	I-Premise
274	rates	_	_	I-Premise
275	.	_	_	I-Premise

276	These	_	_	B-Claim
277	data	_	_	I-Claim
278	demonstrated	_	_	I-Claim
279	a	_	_	I-Claim
280	significant	_	_	I-Claim
281	4.5-month	_	_	I-Claim
282	median	_	_	I-Claim
283	OS	_	_	I-Claim
284	advantage	_	_	I-Claim
285	with	_	_	I-Claim
286	the	_	_	I-Claim
287	lapatinib	_	_	I-Claim
288	and	_	_	I-Claim
289	trastuzumab	_	_	I-Claim
290	combination	_	_	I-Claim
291	and	_	_	I-Claim
292	support	_	_	I-Claim
293	dual	_	_	I-Claim
294	HER2	_	_	I-Claim
295	blockade	_	_	I-Claim
296	in	_	_	I-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	heavily	_	_	I-Claim
300	pretreated	_	_	I-Claim
301	HER2-positive	_	_	I-Claim
302	MBC	_	_	I-Claim
303	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	tested	_	_	O
3	hyperbaric	_	_	O
4	oxygen	_	_	O
5	(	_	_	O
6	HBO	_	_	O
7	)	_	_	O
8	as	_	_	O
9	an	_	_	O
10	adjunct	_	_	O
11	to	_	_	O
12	surgery	_	_	O
13	and	_	_	O
14	antibiotics	_	_	O
15	in	_	_	O
16	the	_	_	O
17	treatment	_	_	O
18	of	_	_	O
19	bisphosphonate-related	_	_	O
20	osteonecrosis	_	_	O
21	of	_	_	O
22	the	_	_	O
23	jaw	_	_	O
24	(	_	_	O
25	ONJ	_	_	O
26	)	_	_	O
27	and	_	_	O
28	evaluated	_	_	O
29	its	_	_	O
30	effects	_	_	O
31	on	_	_	O
32	gingival	_	_	O
33	healing	_	_	O
34	,	_	_	O
35	pain	_	_	O
36	,	_	_	O
37	and	_	_	O
38	quality	_	_	O
39	of	_	_	O
40	life	_	_	O
41	.	_	_	O

42	The	_	_	O
43	investigators	_	_	O
44	implemented	_	_	O
45	a	_	_	O
46	randomized	_	_	O
47	controlled	_	_	O
48	trial	_	_	O
49	and	_	_	O
50	enrolled	_	_	O
51	a	_	_	O
52	sample	_	_	O
53	composed	_	_	O
54	of	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	ONJ	_	_	O
58	,	_	_	O
59	where	_	_	O
60	the	_	_	O
61	predictor	_	_	O
62	variable	_	_	O
63	was	_	_	O
64	HBO	_	_	O
65	administered	_	_	O
66	at	_	_	O
67	2	_	_	O
68	atm	_	_	O
69	twice	_	_	O
70	a	_	_	O
71	day	_	_	O
72	for	_	_	O
73	40	_	_	O
74	treatments	_	_	O
75	as	_	_	O
76	an	_	_	O
77	adjunct	_	_	O
78	to	_	_	O
79	conventional	_	_	O
80	therapy	_	_	O
81	of	_	_	O
82	surgery	_	_	O
83	and	_	_	O
84	antibiotics	_	_	O
85	versus	_	_	O
86	conventional	_	_	O
87	therapy	_	_	O
88	alone	_	_	O
89	.	_	_	O

90	Over	_	_	O
91	the	_	_	O
92	next	_	_	O
93	24	_	_	O
94	months	_	_	O
95	,	_	_	O
96	oral	_	_	O
97	lesion	_	_	O
98	size	_	_	O
99	and	_	_	O
100	number	_	_	O
101	,	_	_	O
102	pain	_	_	O
103	,	_	_	O
104	and	_	_	O
105	quality	_	_	O
106	of	_	_	O
107	life	_	_	O
108	were	_	_	O
109	assessed	_	_	O
110	.	_	_	O

111	Forty-six	_	_	O
112	patients	_	_	O
113	(	_	_	O
114	mean	_	_	O
115	age	_	_	O
116	,	_	_	O
117	66	_	_	O
118	yrs	_	_	O
119	;	_	_	O
120	57	_	_	O
121	%	_	_	O
122	women	_	_	O
123	)	_	_	O
124	contributed	_	_	O
125	data	_	_	O
126	to	_	_	O
127	the	_	_	O
128	trial	_	_	O
129	.	_	_	O

130	There	_	_	O
131	were	_	_	O
132	no	_	_	O
133	statistically	_	_	O
134	significant	_	_	O
135	differences	_	_	O
136	in	_	_	O
137	the	_	_	O
138	distribution	_	_	O
139	of	_	_	O
140	variables	_	_	O
141	used	_	_	O
142	to	_	_	O
143	assess	_	_	O
144	randomization	_	_	O
145	success	_	_	O
146	between	_	_	O
147	the	_	_	O
148	HBO	_	_	O
149	and	_	_	O
150	standard	_	_	O
151	treatment	_	_	O
152	groups	_	_	O
153	.	_	_	O

154	Seventeen	_	_	B-Premise
155	of	_	_	I-Premise
156	25	_	_	I-Premise
157	HBO-treated	_	_	I-Premise
158	patients	_	_	I-Premise
159	(	_	_	I-Premise
160	68	_	_	I-Premise
161	%	_	_	I-Premise
162	)	_	_	I-Premise
163	improved	_	_	I-Premise
164	versus	_	_	I-Premise
165	8	_	_	I-Premise
166	of	_	_	I-Premise
167	21	_	_	I-Premise
168	controls	_	_	I-Premise
169	(	_	_	I-Premise
170	38.1	_	_	I-Premise
171	%	_	_	I-Premise
172	;	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.043	_	_	I-Premise
176	,	_	_	I-Premise
177		_	_	I-Premise
178	(	_	_	I-Premise
179	2	_	_	I-Premise
180	)	_	_	I-Premise
181	test	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	Mean	_	_	B-Premise
185	time	_	_	I-Premise
186	to	_	_	I-Premise
187	improvement	_	_	I-Premise
188	was	_	_	I-Premise
189	39.7	_	_	I-Premise
190	weeks	_	_	I-Premise
191	(	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	confidence	_	_	I-Premise
195	interval	_	_	I-Premise
196	[	_	_	I-Premise
197	CI	_	_	I-Premise
198	]	_	_	I-Premise
199	,	_	_	I-Premise
200	22.4	_	_	I-Premise
201	to	_	_	I-Premise
202	57.0	_	_	I-Premise
203	weeks	_	_	I-Premise
204	)	_	_	I-Premise
205	for	_	_	I-Premise
206	HBO-treated	_	_	I-Premise
207	patients	_	_	I-Premise
208	versus	_	_	I-Premise
209	67.9	_	_	I-Premise
210	weeks	_	_	I-Premise
211	(	_	_	I-Premise
212	95	_	_	I-Premise
213	CI	_	_	I-Premise
214	,	_	_	I-Premise
215	48.4	_	_	I-Premise
216	to	_	_	I-Premise
217	87.5	_	_	I-Premise
218	weeks	_	_	I-Premise
219	)	_	_	I-Premise
220	for	_	_	I-Premise
221	controls	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.03	_	_	I-Premise
226	,	_	_	I-Premise
227	log-rank	_	_	I-Premise
228	test	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	However	_	_	B-Premise
232	,	_	_	I-Premise
233	complete	_	_	I-Premise
234	gingival	_	_	I-Premise
235	healing	_	_	I-Premise
236	occurred	_	_	I-Premise
237	in	_	_	I-Premise
238	only	_	_	I-Premise
239	14	_	_	I-Premise
240	of	_	_	I-Premise
241	25	_	_	I-Premise
242	HBO-treated	_	_	I-Premise
243	patients	_	_	I-Premise
244	(	_	_	I-Premise
245	52	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	versus	_	_	I-Premise
249	7	_	_	I-Premise
250	of	_	_	I-Premise
251	21	_	_	I-Premise
252	controls	_	_	I-Premise
253	(	_	_	I-Premise
254	33.3	_	_	I-Premise
255	%	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=	_	_	I-Premise
259	.203	_	_	I-Premise
260	,	_	_	I-Premise
261		_	_	I-Premise
262	(	_	_	I-Premise
263	2	_	_	I-Premise
264	)	_	_	I-Premise
265	test	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	time	_	_	I-Premise
270	to	_	_	I-Premise
271	healing	_	_	I-Premise
272	was	_	_	I-Premise
273	59	_	_	I-Premise
274	weeks	_	_	I-Premise
275	(	_	_	I-Premise
276	95	_	_	I-Premise
277	%	_	_	I-Premise
278	CI	_	_	I-Premise
279	,	_	_	I-Premise
280	42.8	_	_	I-Premise
281	%	_	_	I-Premise
282	to	_	_	I-Premise
283	75.8	_	_	I-Premise
284	%	_	_	I-Premise
285	)	_	_	I-Premise
286	for	_	_	I-Premise
287	HBO-treated	_	_	I-Premise
288	patients	_	_	I-Premise
289	versus	_	_	I-Premise
290	70	_	_	I-Premise
291	weeks	_	_	I-Premise
292	(	_	_	I-Premise
293	95	_	_	I-Premise
294	CI	_	_	I-Premise
295	,	_	_	I-Premise
296	52.2	_	_	I-Premise
297	%	_	_	I-Premise
298	to	_	_	I-Premise
299	88.36	_	_	I-Premise
300	%	_	_	I-Premise
301	)	_	_	I-Premise
302	for	_	_	I-Premise
303	controls	_	_	I-Premise
304	(	_	_	I-Premise
305	P	_	_	I-Premise
306	=	_	_	I-Premise
307	.32	_	_	I-Premise
308	,	_	_	I-Premise
309	log-rank	_	_	I-Premise
310	test	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Pain	_	_	B-Premise
314	decreased	_	_	I-Premise
315	faster	_	_	I-Premise
316	for	_	_	I-Premise
317	HBO-treated	_	_	I-Premise
318	subjects	_	_	I-Premise
319	(	_	_	I-Premise
320	P	_	_	I-Premise
321	<	_	_	I-Premise
322	.01	_	_	I-Premise
323	,	_	_	I-Premise
324	linear	_	_	I-Premise
325	regression	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	Quality-of-life	_	_	B-Premise
329	scores	_	_	I-Premise
330	for	_	_	I-Premise
331	physical	_	_	I-Premise
332	health	_	_	I-Premise
333	(	_	_	I-Premise
334	P	_	_	I-Premise
335	=	_	_	I-Premise
336	.002	_	_	I-Premise
337	)	_	_	I-Premise
338	and	_	_	I-Premise
339	perceived	_	_	I-Premise
340	health	_	_	I-Premise
341	(	_	_	I-Premise
342	P	_	_	I-Premise
343	=	_	_	I-Premise
344	.043	_	_	I-Premise
345	)	_	_	I-Premise
346	decreased	_	_	I-Premise
347	at	_	_	I-Premise
348	6	_	_	I-Premise
349	months	_	_	I-Premise
350	for	_	_	I-Premise
351	control	_	_	I-Premise
352	group	_	_	I-Premise
353	but	_	_	I-Premise
354	for	_	_	I-Premise
355	not	_	_	I-Premise
356	the	_	_	I-Premise
357	HBO	_	_	I-Premise
358	group	_	_	I-Premise
359	.	_	_	I-Premise

360	ONJ	_	_	B-Claim
361	is	_	_	I-Claim
362	multifactorial	_	_	I-Claim
363	and	_	_	I-Claim
364	no	_	_	I-Claim
365	single	_	_	I-Claim
366	treatment	_	_	I-Claim
367	modality	_	_	I-Claim
368	is	_	_	I-Claim
369	likely	_	_	I-Claim
370	to	_	_	I-Claim
371	reverse	_	_	I-Claim
372	it	_	_	I-Claim
373	;	_	_	I-Claim
374	however	_	_	B-Claim
375	,	_	_	I-Claim
376	it	_	_	I-Claim
377	is	_	_	I-Claim
378	treatable	_	_	I-Claim
379	and	_	_	I-Claim
380	even	_	_	I-Claim
381	advanced	_	_	I-Claim
382	presentations	_	_	I-Claim
383	can	_	_	I-Claim
384	improve	_	_	I-Claim
385	with	_	_	I-Claim
386	intensive	_	_	I-Claim
387	multimodal	_	_	I-Claim
388	therapy	_	_	I-Claim
389	.	_	_	I-Claim

390	Clinically	_	_	B-Claim
391	,	_	_	I-Claim
392	HBO	_	_	I-Claim
393	appears	_	_	I-Claim
394	to	_	_	I-Claim
395	be	_	_	I-Claim
396	a	_	_	I-Claim
397	useful	_	_	I-Claim
398	adjunct	_	_	I-Claim
399	to	_	_	I-Claim
400	ONJ	_	_	I-Claim
401	treatment	_	_	I-Claim
402	,	_	_	I-Claim
403	particularly	_	_	I-Claim
404	for	_	_	I-Claim
405	more	_	_	I-Claim
406	severe	_	_	I-Claim
407	cases	_	_	I-Claim
408	,	_	_	I-Claim
409	although	_	_	I-Claim
410	this	_	_	I-Claim
411	study	_	_	I-Claim
412	was	_	_	I-Claim
413	underpowered	_	_	I-Claim
414	to	_	_	I-Claim
415	fully	_	_	I-Claim
416	support	_	_	I-Claim
417	this	_	_	I-Claim
418	claim	_	_	I-Claim
419	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	safety	_	_	O
5	and	_	_	O
6	efficacy	_	_	O
7	of	_	_	O
8	a	_	_	O
9	single	_	_	O
10	trabecular	_	_	O
11	micro-bypass	_	_	O
12	stent	_	_	O
13	with	_	_	O
14	concomitant	_	_	O
15	cataract	_	_	O
16	surgery	_	_	O
17	versus	_	_	O
18	cataract	_	_	O
19	surgery	_	_	O
20	alone	_	_	O
21	for	_	_	O
22	mild	_	_	O
23	to	_	_	O
24	moderate	_	_	O
25	open-angle	_	_	O
26	glaucoma	_	_	O
27	.	_	_	O

28	Twenty-nine	_	_	O
29	investigational	_	_	O
30	sites	_	_	O
31	,	_	_	O
32	United	_	_	O
33	States	_	_	O
34	.	_	_	O

35	Prospective	_	_	O
36	randomized	_	_	O
37	controlled	_	_	O
38	multicenter	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	.	_	_	O

42	Eyes	_	_	O
43	with	_	_	O
44	mild	_	_	O
45	to	_	_	O
46	moderate	_	_	O
47	glaucoma	_	_	O
48	with	_	_	O
49	an	_	_	O
50	unmedicated	_	_	O
51	intraocular	_	_	O
52	pressure	_	_	O
53	(	_	_	O
54	IOP	_	_	O
55	)	_	_	O
56	of	_	_	O
57	22	_	_	O
58	mm	_	_	O
59	Hg	_	_	O
60	or	_	_	O
61	higher	_	_	O
62	and	_	_	O
63	36	_	_	O
64	mm	_	_	O
65	Hg	_	_	O
66	or	_	_	O
67	lower	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	have	_	_	O
73	cataract	_	_	O
74	surgery	_	_	O
75	with	_	_	O
76	iStent	_	_	O
77	trabecular	_	_	O
78	micro-bypass	_	_	O
79	stent	_	_	O
80	implantation	_	_	O
81	(	_	_	O
82	stent	_	_	O
83	group	_	_	O
84	)	_	_	O
85	or	_	_	O
86	cataract	_	_	O
87	surgery	_	_	O
88	alone	_	_	O
89	(	_	_	O
90	control	_	_	O
91	group	_	_	O
92	)	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	followed	_	_	O
97	for	_	_	O
98	24	_	_	O
99	months	_	_	O
100	postoperatively	_	_	O
101	.	_	_	O

102	The	_	_	B-Premise
103	incidence	_	_	I-Premise
104	of	_	_	I-Premise
105	adverse	_	_	I-Premise
106	events	_	_	I-Premise
107	was	_	_	I-Premise
108	low	_	_	I-Premise
109	in	_	_	I-Premise
110	both	_	_	I-Premise
111	groups	_	_	I-Premise
112	through	_	_	I-Premise
113	24	_	_	I-Premise
114	months	_	_	I-Premise
115	of	_	_	I-Premise
116	follow-up	_	_	I-Premise
117	.	_	_	I-Premise

118	At	_	_	B-Premise
119	24	_	_	I-Premise
120	months	_	_	I-Premise
121	,	_	_	I-Premise
122	the	_	_	I-Premise
123	proportion	_	_	I-Premise
124	of	_	_	I-Premise
125	patients	_	_	I-Premise
126	with	_	_	I-Premise
127	an	_	_	I-Premise
128	IOP	_	_	I-Premise
129	of	_	_	I-Premise
130	21	_	_	I-Premise
131	mm	_	_	I-Premise
132	Hg	_	_	I-Premise
133	or	_	_	I-Premise
134	lower	_	_	I-Premise
135	without	_	_	I-Premise
136	ocular	_	_	I-Premise
137	hypotensive	_	_	I-Premise
138	medications	_	_	I-Premise
139	was	_	_	I-Premise
140	significantly	_	_	I-Premise
141	higher	_	_	I-Premise
142	in	_	_	I-Premise
143	the	_	_	I-Premise
144	stent	_	_	I-Premise
145	group	_	_	I-Premise
146	than	_	_	I-Premise
147	in	_	_	I-Premise
148	the	_	_	I-Premise
149	control	_	_	I-Premise
150	group	_	_	I-Premise
151	(	_	_	I-Premise
152	P=.036	_	_	I-Premise
153	)	_	_	I-Premise
154	.	_	_	I-Premise

155	Overall	_	_	O
156	,	_	_	O
157	the	_	_	B-Premise
158	mean	_	_	I-Premise
159	IOP	_	_	I-Premise
160	was	_	_	I-Premise
161	stable	_	_	I-Premise
162	between	_	_	I-Premise
163	12	_	_	I-Premise
164	months	_	_	I-Premise
165	and	_	_	I-Premise
166	24	_	_	I-Premise
167	months	_	_	I-Premise
168	(	_	_	I-Premise
169	17.0	_	_	I-Premise
170	mm	_	_	I-Premise
171	Hg	_	_	I-Premise
172		_	_	I-Premise
173	2.8	_	_	I-Premise
174	[	_	_	I-Premise
175	SD	_	_	I-Premise
176	]	_	_	I-Premise
177	and	_	_	I-Premise
178	17.1	_	_	I-Premise
179		_	_	I-Premise
180	2.9	_	_	I-Premise
181	mm	_	_	I-Premise
182	Hg	_	_	I-Premise
183	,	_	_	I-Premise
184	respectively	_	_	I-Premise
185	)	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	stent	_	_	I-Premise
189	group	_	_	I-Premise
190	but	_	_	I-Premise
191	increased	_	_	I-Premise
192	(	_	_	I-Premise
193	17.0	_	_	I-Premise
194		_	_	I-Premise
195	3.1	_	_	I-Premise
196	mm	_	_	I-Premise
197	Hg	_	_	I-Premise
198	to	_	_	I-Premise
199	17.8	_	_	I-Premise
200		_	_	I-Premise
201	3.3	_	_	I-Premise
202	mm	_	_	I-Premise
203	Hg	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	)	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	control	_	_	I-Premise
210	group	_	_	I-Premise
211	.	_	_	I-Premise

212	Ocular	_	_	B-Premise
213	hypotensive	_	_	I-Premise
214	medication	_	_	I-Premise
215	was	_	_	I-Premise
216	statistically	_	_	I-Premise
217	significantly	_	_	I-Premise
218	lower	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	stent	_	_	I-Premise
222	group	_	_	I-Premise
223	at	_	_	I-Premise
224	12	_	_	I-Premise
225	months	_	_	I-Premise
226	;	_	_	I-Premise
227	it	_	_	I-Premise
228	was	_	_	I-Premise
229	also	_	_	I-Premise
230	lower	_	_	I-Premise
231	at	_	_	I-Premise
232	24	_	_	I-Premise
233	months	_	_	I-Premise
234	,	_	_	I-Premise
235	although	_	_	I-Premise
236	the	_	_	I-Premise
237	difference	_	_	I-Premise
238	was	_	_	I-Premise
239	no	_	_	I-Premise
240	longer	_	_	I-Premise
241	statistically	_	_	I-Premise
242	significant	_	_	I-Premise
243	.	_	_	I-Premise

244	Patients	_	_	B-Claim
245	with	_	_	I-Claim
246	combined	_	_	I-Claim
247	single	_	_	I-Claim
248	trabecular	_	_	I-Claim
249	micro-bypass	_	_	I-Claim
250	stent	_	_	I-Claim
251	and	_	_	I-Claim
252	cataract	_	_	I-Claim
253	surgery	_	_	I-Claim
254	had	_	_	I-Claim
255	significantly	_	_	I-Claim
256	better	_	_	I-Claim
257	IOP	_	_	I-Claim
258	control	_	_	I-Claim
259	on	_	_	I-Claim
260	no	_	_	I-Claim
261	medication	_	_	I-Claim
262	through	_	_	I-Claim
263	24	_	_	I-Claim
264	months	_	_	I-Claim
265	than	_	_	I-Claim
266	patients	_	_	I-Claim
267	having	_	_	I-Claim
268	cataract	_	_	I-Claim
269	surgery	_	_	I-Claim
270	alone	_	_	I-Claim
271	.	_	_	I-Claim

272	Both	_	_	B-Claim
273	groups	_	_	I-Claim
274	had	_	_	I-Claim
275	a	_	_	I-Claim
276	similar	_	_	I-Claim
277	favorable	_	_	I-Claim
278	long-term	_	_	I-Claim
279	safety	_	_	I-Claim
280	profile	_	_	I-Claim
281	.	_	_	I-Claim


0	Nocturnal	_	_	O
1	administration	_	_	O
2	of	_	_	O
3	branched-chain	_	_	O
4	amino	_	_	O
5	acid	_	_	O
6	(	_	_	O
7	BCAA	_	_	O
8	)	_	_	O
9	granules	_	_	O
10	improves	_	_	O
11	serum	_	_	O
12	albumin	_	_	O
13	levels	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	cirrhosis	_	_	O
18	.	_	_	O

19	However	_	_	O
20	,	_	_	O
21	it	_	_	O
22	is	_	_	O
23	unclear	_	_	O
24	whether	_	_	O
25	or	_	_	O
26	not	_	_	O
27	this	_	_	O
28	administration	_	_	O
29	method	_	_	O
30	can	_	_	O
31	improve	_	_	O
32	the	_	_	O
33	patients	_	_	O
34	'	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	(	_	_	O
39	QOL	_	_	O
40	)	_	_	O
41	.	_	_	O

42	In	_	_	O
43	this	_	_	O
44	study	_	_	O
45	,	_	_	O
46	we	_	_	O
47	aimed	_	_	O
48	to	_	_	O
49	investigate	_	_	O
50	the	_	_	O
51	efficacy	_	_	O
52	of	_	_	O
53	BCAA	_	_	O
54	granules	_	_	O
55	,	_	_	O
56	given	_	_	O
57	nocturnally	_	_	O
58	,	_	_	O
59	in	_	_	O
60	improving	_	_	O
61	QOL	_	_	O
62	in	_	_	O
63	these	_	_	O
64	patients	_	_	O
65	.	_	_	O

66	We	_	_	O
67	performed	_	_	O
68	a	_	_	O
69	multicenter	_	_	O
70	,	_	_	O
71	randomized	_	_	O
72	controlled	_	_	O
73	trial	_	_	O
74	examining	_	_	O
75	the	_	_	O
76	comparative	_	_	O
77	effects	_	_	O
78	of	_	_	O
79	BCAA	_	_	O
80	granules	_	_	O
81	given	_	_	O
82	orally	_	_	O
83	for	_	_	O
84	3	_	_	O
85	months	_	_	O
86	with	_	_	O
87	daytime	_	_	O
88	or	_	_	O
89	nocturnal	_	_	O
90	administration	_	_	O
91	in	_	_	O
92	patients	_	_	O
93	with	_	_	O
94	compensated	_	_	O
95	cirrhosis	_	_	O
96	.	_	_	O

97	Health-related	_	_	O
98	QOL	_	_	O
99	was	_	_	O
100	measured	_	_	O
101	by	_	_	O
102	a	_	_	O
103	Japanese	_	_	O
104	version	_	_	O
105	of	_	_	O
106	the	_	_	O
107	questionnaire	_	_	O
108	on	_	_	O
109	subjective	_	_	O
110	and	_	_	O
111	objective	_	_	O
112	symptoms	_	_	O
113	,	_	_	O
114	and	_	_	O
115	the	_	_	O
116	Short	_	_	O
117	Form-8	_	_	O
118	(	_	_	O
119	SF-8	_	_	O
120	)	_	_	O
121	questionnaire	_	_	O
122	.	_	_	O

123	Twenty-one	_	_	O
124	patients	_	_	O
125	received	_	_	O
126	BCAA	_	_	O
127	granules	_	_	O
128	three	_	_	O
129	times	_	_	O
130	a	_	_	O
131	day	_	_	O
132	(	_	_	O
133	one	_	_	O
134	sachet	_	_	O
135	after	_	_	O
136	each	_	_	O
137	meal	_	_	O
138	:	_	_	O
139	the	_	_	O
140	daytime	_	_	O
141	group	_	_	O
142	)	_	_	O
143	,	_	_	O
144	and	_	_	O
145	16	_	_	O
146	patients	_	_	O
147	received	_	_	O
148	the	_	_	O
149	granules	_	_	O
150	twice	_	_	O
151	a	_	_	O
152	day	_	_	O
153	(	_	_	O
154	one	_	_	O
155	sachet	_	_	O
156	after	_	_	O
157	breakfast	_	_	O
158	,	_	_	O
159	and	_	_	O
160	two	_	_	O
161	sachets	_	_	O
162	before	_	_	O
163	bedtime	_	_	O
164	:	_	_	O
165	the	_	_	O
166	nocturnal	_	_	O
167	group	_	_	O
168	)	_	_	O
169	.	_	_	O

170	Baseline	_	_	O
171	characteristics	_	_	O
172	did	_	_	O
173	not	_	_	O
174	differ	_	_	O
175	between	_	_	O
176	the	_	_	O
177	groups	_	_	O
178	(	_	_	O
179	whole	_	_	O
180	cohort	_	_	O
181	:	_	_	O
182	Child-Pugh	_	_	O
183	grade	_	_	O
184	A/B	_	_	O
185	,	_	_	O
186	21/16	_	_	O
187	;	_	_	O
188	mean	_	_	O
189	age	_	_	O
190	,	_	_	O
191	68.2	_	_	O
192	years	_	_	O
193	)	_	_	O
194	.	_	_	O

195	There	_	_	B-Premise
196	was	_	_	I-Premise
197	no	_	_	I-Premise
198	significant	_	_	I-Premise
199	difference	_	_	I-Premise
200	in	_	_	I-Premise
201	any	_	_	I-Premise
202	of	_	_	I-Premise
203	the	_	_	I-Premise
204	subjects	_	_	I-Premise
205	revealed	_	_	I-Premise
206	by	_	_	I-Premise
207	the	_	_	I-Premise
208	questionnaire	_	_	I-Premise
209	regarding	_	_	I-Premise
210	subjective	_	_	I-Premise
211	or	_	_	I-Premise
212	objective	_	_	I-Premise
213	symptoms	_	_	I-Premise
214	,	_	_	I-Premise
215	or	_	_	I-Premise
216	by	_	_	I-Premise
217	the	_	_	I-Premise
218	SF-8	_	_	I-Premise
219	between	_	_	I-Premise
220	the	_	_	I-Premise
221	daytime	_	_	I-Premise
222	group	_	_	I-Premise
223	and	_	_	I-Premise
224	the	_	_	I-Premise
225	nocturnal	_	_	I-Premise
226	group	_	_	I-Premise
227	after	_	_	I-Premise
228	3	_	_	I-Premise
229	months	_	_	I-Premise
230	of	_	_	I-Premise
231	treatment	_	_	I-Premise
232	.	_	_	I-Premise

233	The	_	_	B-Premise
234	daytime	_	_	I-Premise
235	group	_	_	I-Premise
236	showed	_	_	I-Premise
237	a	_	_	I-Premise
238	significant	_	_	I-Premise
239	effect	_	_	I-Premise
240	on	_	_	I-Premise
241	general	_	_	I-Premise
242	health	_	_	I-Premise
243	,	_	_	I-Premise
244	vitality	_	_	I-Premise
245	,	_	_	I-Premise
246	social	_	_	I-Premise
247	functioning	_	_	I-Premise
248	,	_	_	I-Premise
249	mental	_	_	I-Premise
250	health	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	role	_	_	I-Premise
254	emotional	_	_	I-Premise
255	as	_	_	I-Premise
256	revealed	_	_	I-Premise
257	on	_	_	I-Premise
258	the	_	_	I-Premise
259	SF-8	_	_	I-Premise
260	.	_	_	I-Premise

261	Conversely	_	_	B-Premise
262	,	_	_	I-Premise
263	the	_	_	I-Premise
264	nocturnal	_	_	I-Premise
265	group	_	_	I-Premise
266	exhibited	_	_	I-Premise
267	a	_	_	I-Premise
268	significant	_	_	I-Premise
269	decrease	_	_	I-Premise
270	in	_	_	I-Premise
271	the	_	_	I-Premise
272	occurrence	_	_	I-Premise
273	of	_	_	I-Premise
274	muscle	_	_	I-Premise
275	cramps	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	legs	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	=	_	_	I-Premise
282	0.014	_	_	I-Premise
283	)	_	_	I-Premise
284	and	_	_	I-Premise
285	significantly	_	_	I-Premise
286	improved	_	_	I-Premise
287	Fisher	_	_	I-Premise
288	's	_	_	I-Premise
289	ratio	_	_	I-Premise
290	after	_	_	I-Premise
291	3	_	_	I-Premise
292	months	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	0.04	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Nocturnal	_	_	B-Claim
300	administration	_	_	I-Claim
301	of	_	_	I-Claim
302	BCAA	_	_	I-Claim
303	granules	_	_	I-Claim
304	in	_	_	I-Claim
305	patients	_	_	I-Claim
306	with	_	_	I-Claim
307	cirrhosis	_	_	I-Claim
308	reduced	_	_	I-Claim
309	the	_	_	I-Claim
310	occurrence	_	_	I-Claim
311	of	_	_	I-Claim
312	muscle	_	_	I-Claim
313	cramps	_	_	I-Claim
314	in	_	_	I-Claim
315	the	_	_	I-Claim
316	leg	_	_	I-Claim
317	but	_	_	I-Claim
318	did	_	_	I-Claim
319	not	_	_	I-Claim
320	improve	_	_	I-Claim
321	the	_	_	I-Claim
322	patients	_	_	I-Claim
323	'	_	_	I-Claim
324	QOL	_	_	I-Claim
325	.	_	_	I-Claim


0	Implant-based	_	_	O
1	reconstruction	_	_	O
2	is	_	_	O
3	performed	_	_	O
4	in	_	_	O
5	the	_	_	O
6	majority	_	_	O
7	of	_	_	O
8	women	_	_	O
9	offered	_	_	O
10	primary	_	_	O
11	reconstruction	_	_	O
12	for	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	.	_	_	O

16	Two	_	_	O
17	different	_	_	O
18	expander	_	_	O
19	implants	_	_	O
20	were	_	_	O
21	compared	_	_	O
22	prospectively	_	_	O
23	.	_	_	O

24	The	_	_	O
25	primary	_	_	O
26	endpoint	_	_	O
27	was	_	_	O
28	the	_	_	O
29	number	_	_	O
30	of	_	_	O
31	operations	_	_	O
32	needed	_	_	O
33	in	_	_	O
34	each	_	_	O
35	group	_	_	O
36	to	_	_	O
37	obtain	_	_	O
38	patient	_	_	O
39	satisfaction	_	_	O
40	.	_	_	O

41	Secondary	_	_	O
42	endpoints	_	_	O
43	were	_	_	O
44	evaluation	_	_	O
45	of	_	_	O
46	breast	_	_	O
47	volume	_	_	O
48	and	_	_	O
49	shape	_	_	O
50	and	_	_	O
51	aspects	_	_	O
52	of	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	.	_	_	O

57	Seventy	_	_	O
58	consecutive	_	_	O
59	breast	_	_	O
60	cancer	_	_	O
61	patients	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	either	_	_	O
66	a	_	_	O
67	one-stage	_	_	O
68	reconstruction	_	_	O
69	with	_	_	O
70	a	_	_	O
71	round	_	_	O
72	permanent	_	_	O
73	expander	_	_	O
74	implant	_	_	O
75	(	_	_	O
76	Becker	_	_	O
77	25	_	_	O
78	;	_	_	O
79	n=35	_	_	O
80	)	_	_	O
81	or	_	_	O
82	a	_	_	O
83	two-stage	_	_	O
84	reconstruction	_	_	O
85	with	_	_	O
86	a	_	_	O
87	crescent-shaped	_	_	O
88	expander	_	_	O
89	(	_	_	O
90	LV	_	_	O
91	133	_	_	O
92	;	_	_	O
93	n=35	_	_	O
94	)	_	_	O
95	,	_	_	O
96	later	_	_	O
97	replaced	_	_	O
98	by	_	_	O
99	a	_	_	O
100	form-stable	_	_	O
101	anatomical	_	_	O
102	implant	_	_	O
103	.	_	_	O

104	Thirty	_	_	O
105	patients	_	_	O
106	had	_	_	O
107	to	_	_	O
108	be	_	_	O
109	excluded	_	_	O
110	and	_	_	O
111	40	_	_	O
112	patients	_	_	O
113	,	_	_	O
114	20	_	_	O
115	in	_	_	O
116	each	_	_	O
117	group	_	_	O
118	,	_	_	O
119	were	_	_	O
120	evaluated	_	_	O
121	.	_	_	O

122	The	_	_	O
123	median	_	_	O
124	follow-up	_	_	O
125	for	_	_	O
126	both	_	_	O
127	groups	_	_	O
128	was	_	_	O
129	3.5	_	_	O
130	years	_	_	O
131	(	_	_	O
132	range	_	_	O
133	,	_	_	O
134	1.5	_	_	O
135	to	_	_	O
136	5	_	_	O
137	years	_	_	O
138	)	_	_	O
139	.	_	_	O

140	Plastic	_	_	O
141	cups	_	_	O
142	,	_	_	O
143	plastic	_	_	O
144	casts	_	_	O
145	,	_	_	O
146	and	_	_	O
147	two	_	_	O
148	-and	_	_	O
149	three-dimensional	_	_	O
150	scanning	_	_	O
151	techniques	_	_	O
152	were	_	_	O
153	used	_	_	O
154	for	_	_	O
155	objective	_	_	O
156	assessment	_	_	O
157	of	_	_	O
158	breast	_	_	O
159	volume	_	_	O
160	and	_	_	O
161	shape	_	_	O
162	.	_	_	O

163	The	_	_	O
164	aesthetic	_	_	O
165	outcome	_	_	O
166	was	_	_	O
167	evaluated	_	_	O
168	by	_	_	O
169	a	_	_	O
170	panel	_	_	O
171	of	_	_	O
172	experts	_	_	O
173	and	_	_	O
174	lay	_	_	O
175	people	_	_	O
176	,	_	_	O
177	and	_	_	O
178	by	_	_	O
179	the	_	_	O
180	patients	_	_	O
181	.	_	_	O

182	Quality	_	_	O
183	of	_	_	O
184	life	_	_	O
185	was	_	_	O
186	evaluated	_	_	O
187	with	_	_	O
188	a	_	_	O
189	validated	_	_	O
190	questionnaire	_	_	O
191	(	_	_	O
192	36-Item	_	_	O
193	Short	_	_	O
194	Form	_	_	O
195	Health	_	_	O
196	Survey	_	_	O
197	)	_	_	O
198	.	_	_	O

199	Of	_	_	B-Premise
200	the	_	_	I-Premise
201	patients	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	one-stage	_	_	I-Premise
205	group	_	_	I-Premise
206	,	_	_	I-Premise
207	70	_	_	I-Premise
208	percent	_	_	I-Premise
209	had	_	_	I-Premise
210	revision	_	_	I-Premise
211	surgery	_	_	I-Premise
212	,	_	_	I-Premise
213	mostly	_	_	I-Premise
214	because	_	_	I-Premise
215	of	_	_	I-Premise
216	upper	_	_	I-Premise
217	pole	_	_	I-Premise
218	fullness	_	_	I-Premise
219	and	_	_	I-Premise
220	poor	_	_	I-Premise
221	ptosis	_	_	I-Premise
222	.	_	_	I-Premise

223	These	_	_	O
224	findings	_	_	O
225	agreed	_	_	O
226	with	_	_	O
227	the	_	_	O
228	data	_	_	O
229	from	_	_	O
230	the	_	_	O
231	two-dimensional	_	_	O
232	scanning	_	_	O
233	and	_	_	O
234	from	_	_	O
235	the	_	_	O
236	expert	_	_	O
237	panel	_	_	O
238	and	_	_	O
239	the	_	_	O
240	patients	_	_	O
241	'	_	_	O
242	subjective	_	_	O
243	judgment	_	_	O
244	.	_	_	O

245	Quality	_	_	B-Premise
246	of	_	_	I-Premise
247	life	_	_	I-Premise
248	was	_	_	I-Premise
249	similar	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	two	_	_	I-Premise
253	groups	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Claim
256	permanent	_	_	I-Claim
257	expander	_	_	I-Claim
258	method	_	_	I-Claim
259	failed	_	_	I-Claim
260	significantly	_	_	I-Claim
261	as	_	_	I-Claim
262	a	_	_	I-Claim
263	one-stage	_	_	I-Claim
264	procedure	_	_	I-Claim
265	.	_	_	I-Claim

266	The	_	_	B-Claim
267	crescent	_	_	I-Claim
268	two-stage	_	_	I-Claim
269	method	_	_	I-Claim
270	gave	_	_	I-Claim
271	the	_	_	I-Claim
272	most	_	_	I-Claim
273	acceptable	_	_	I-Claim
274	results	_	_	I-Claim
275	both	_	_	I-Claim
276	objectively	_	_	I-Claim
277	and	_	_	I-Claim
278	subjectively	_	_	I-Claim
279	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	our	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	the	_	_	O
9	effect	_	_	O
10	of	_	_	O
11	cognitive	_	_	O
12	behavioral	_	_	O
13	therapy	_	_	O
14	(	_	_	O
15	CBT	_	_	O
16	)	_	_	O
17	,	_	_	O
18	physical	_	_	O
19	exercise	_	_	O
20	(	_	_	O
21	PE	_	_	O
22	)	_	_	O
23	,	_	_	O
24	and	_	_	O
25	of	_	_	O
26	these	_	_	O
27	two	_	_	O
28	interventions	_	_	O
29	combined	_	_	O
30	(	_	_	O
31	CBT/PE	_	_	O
32	)	_	_	O
33	on	_	_	O
34	menopausal	_	_	O
35	symptoms	_	_	O
36	(	_	_	O
37	primary	_	_	O
38	outcome	_	_	O
39	)	_	_	O
40	,	_	_	O
41	body	_	_	O
42	image	_	_	O
43	,	_	_	O
44	sexual	_	_	O
45	functioning	_	_	O
46	,	_	_	O
47	psychological	_	_	O
48	well-being	_	_	O
49	,	_	_	O
50	and	_	_	O
51	health-related	_	_	O
52	quality	_	_	O
53	of	_	_	O
54	life	_	_	O
55	(	_	_	O
56	secondary	_	_	O
57	outcomes	_	_	O
58	)	_	_	O
59	in	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	breast	_	_	O
63	cancer	_	_	O
64	experiencing	_	_	O
65	treatment-induced	_	_	O
66	menopause	_	_	O
67	.	_	_	O

68	Patients	_	_	O
69	with	_	_	O
70	breast	_	_	O
71	cancer	_	_	O
72	reporting	_	_	O
73	treatment-induced	_	_	O
74	menopausal	_	_	O
75	symptoms	_	_	O
76	(	_	_	O
77	N=422	_	_	O
78	)	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	CBT	_	_	O
84	(	_	_	O
85	n=109	_	_	O
86	)	_	_	O
87	,	_	_	O
88	PE	_	_	O
89	(	_	_	O
90	n=104	_	_	O
91	)	_	_	O
92	,	_	_	O
93	CBT/PE	_	_	O
94	(	_	_	O
95	n=106	_	_	O
96	)	_	_	O
97	,	_	_	O
98	or	_	_	O
99	to	_	_	O
100	a	_	_	O
101	waiting	_	_	O
102	list	_	_	O
103	control	_	_	O
104	group	_	_	O
105	(	_	_	O
106	n=103	_	_	O
107	)	_	_	O
108	.	_	_	O

109	Self-report	_	_	O
110	questionnaires	_	_	O
111	were	_	_	O
112	completed	_	_	O
113	at	_	_	O
114	baseline	_	_	O
115	,	_	_	O
116	12	_	_	O
117	weeks	_	_	O
118	,	_	_	O
119	and	_	_	O
120	6	_	_	O
121	months	_	_	O
122	.	_	_	O

123	Multilevel	_	_	O
124	procedures	_	_	O
125	were	_	_	O
126	used	_	_	O
127	to	_	_	O
128	compare	_	_	O
129	the	_	_	O
130	intervention	_	_	O
131	groups	_	_	O
132	with	_	_	O
133	the	_	_	O
134	control	_	_	O
135	group	_	_	O
136	over	_	_	O
137	time	_	_	O
138	.	_	_	O

139	Compared	_	_	B-Premise
140	with	_	_	I-Premise
141	the	_	_	I-Premise
142	control	_	_	I-Premise
143	group	_	_	I-Premise
144	,	_	_	I-Premise
145	the	_	_	I-Premise
146	intervention	_	_	I-Premise
147	groups	_	_	I-Premise
148	had	_	_	I-Premise
149	a	_	_	I-Premise
150	significant	_	_	I-Premise
151	decrease	_	_	I-Premise
152	in	_	_	I-Premise
153	levels	_	_	I-Premise
154	of	_	_	I-Premise
155	endocrine	_	_	I-Premise
156	symptoms	_	_	I-Premise
157	(	_	_	I-Premise
158	Functional	_	_	I-Premise
159	Assessment	_	_	I-Premise
160	of	_	_	I-Premise
161	Cancer	_	_	I-Premise
162	Therapy-Endocrine	_	_	I-Premise
163	Symptoms	_	_	I-Premise
164	;	_	_	I-Premise
165	P	_	_	I-Premise
166	<	_	_	I-Premise
167	.001	_	_	I-Premise
168	;	_	_	I-Premise
169	effect	_	_	I-Premise
170	size	_	_	I-Premise
171	,	_	_	I-Premise
172	0.31-0.52	_	_	I-Premise
173	)	_	_	I-Premise
174	and	_	_	I-Premise
175	urinary	_	_	I-Premise
176	symptoms	_	_	I-Premise
177	(	_	_	I-Premise
178	Bristol	_	_	I-Premise
179	Female	_	_	I-Premise
180	Lower	_	_	I-Premise
181	Urinary	_	_	I-Premise
182	Tract	_	_	I-Premise
183	Symptoms	_	_	I-Premise
184	Questionnaire	_	_	I-Premise
185	;	_	_	I-Premise
186	P=.002	_	_	I-Premise
187	;	_	_	I-Premise
188	effect	_	_	I-Premise
189	size	_	_	I-Premise
190	,	_	_	I-Premise
191	0.29-0.33	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	and	_	_	I-Premise
195	they	_	_	I-Premise
196	showed	_	_	I-Premise
197	an	_	_	I-Premise
198	improvement	_	_	I-Premise
199	in	_	_	I-Premise
200	physical	_	_	I-Premise
201	functioning	_	_	I-Premise
202	(	_	_	I-Premise
203	36-Item	_	_	I-Premise
204	Short	_	_	I-Premise
205	Form	_	_	I-Premise
206	Health	_	_	I-Premise
207	Survey	_	_	I-Premise
208	physical	_	_	I-Premise
209	functioning	_	_	I-Premise
210	subscale	_	_	I-Premise
211	;	_	_	I-Premise
212	P=.002	_	_	I-Premise
213	;	_	_	I-Premise
214	effect	_	_	I-Premise
215	size	_	_	I-Premise
216	,	_	_	I-Premise
217	0.37-0.46	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	The	_	_	B-Premise
221	groups	_	_	I-Premise
222	that	_	_	I-Premise
223	included	_	_	I-Premise
224	CBT	_	_	I-Premise
225	also	_	_	I-Premise
226	showed	_	_	I-Premise
227	a	_	_	I-Premise
228	significant	_	_	I-Premise
229	decrease	_	_	I-Premise
230	in	_	_	I-Premise
231	the	_	_	I-Premise
232	perceived	_	_	I-Premise
233	burden	_	_	I-Premise
234	of	_	_	I-Premise
235	hot	_	_	I-Premise
236	flashes	_	_	I-Premise
237	and	_	_	I-Premise
238	night	_	_	I-Premise
239	sweats	_	_	I-Premise
240	(	_	_	I-Premise
241	problem	_	_	I-Premise
242	rating	_	_	I-Premise
243	scale	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	Hot	_	_	I-Premise
247	Flush	_	_	I-Premise
248	Rating	_	_	I-Premise
249	Scale	_	_	I-Premise
250	;	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	.001	_	_	I-Premise
254	;	_	_	I-Premise
255	effect	_	_	I-Premise
256	size	_	_	I-Premise
257	,	_	_	I-Premise
258	0.39-0.56	_	_	I-Premise
259	)	_	_	I-Premise
260	and	_	_	I-Premise
261	an	_	_	I-Premise
262	increase	_	_	I-Premise
263	in	_	_	I-Premise
264	sexual	_	_	I-Premise
265	activity	_	_	I-Premise
266	(	_	_	I-Premise
267	Sexual	_	_	I-Premise
268	Activity	_	_	I-Premise
269	Questionnaire	_	_	I-Premise
270	habit	_	_	I-Premise
271	subscale	_	_	I-Premise
272	;	_	_	I-Premise
273	P=.027	_	_	I-Premise
274	;	_	_	I-Premise
275	effect	_	_	I-Premise
276	size	_	_	I-Premise
277	,	_	_	I-Premise
278	0.65	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	Most	_	_	O
282	of	_	_	O
283	these	_	_	O
284	effects	_	_	O
285	were	_	_	O
286	observed	_	_	O
287	at	_	_	O
288	both	_	_	O
289	the	_	_	O
290	12-week	_	_	O
291	and	_	_	O
292	6-month	_	_	O
293	follow-ups	_	_	O
294	.	_	_	O

295	CBT	_	_	B-Claim
296	and	_	_	I-Claim
297	PE	_	_	I-Claim
298	can	_	_	I-Claim
299	have	_	_	I-Claim
300	salutary	_	_	I-Claim
301	effects	_	_	I-Claim
302	on	_	_	I-Claim
303	endocrine	_	_	I-Claim
304	symptoms	_	_	I-Claim
305	and	_	_	I-Claim
306	,	_	_	I-Claim
307	to	_	_	I-Claim
308	a	_	_	I-Claim
309	lesser	_	_	I-Claim
310	degree	_	_	I-Claim
311	,	_	_	I-Claim
312	on	_	_	I-Claim
313	sexuality	_	_	I-Claim
314	and	_	_	I-Claim
315	physical	_	_	I-Claim
316	functioning	_	_	I-Claim
317	of	_	_	I-Claim
318	patients	_	_	I-Claim
319	with	_	_	I-Claim
320	breast	_	_	I-Claim
321	cancer	_	_	I-Claim
322	experiencing	_	_	I-Claim
323	treatment-induced	_	_	I-Claim
324	menopause	_	_	I-Claim
325	.	_	_	I-Claim

326	Future	_	_	B-Claim
327	work	_	_	I-Claim
328	is	_	_	I-Claim
329	needed	_	_	I-Claim
330	to	_	_	I-Claim
331	improve	_	_	I-Claim
332	the	_	_	I-Claim
333	design	_	_	I-Claim
334	and	_	_	I-Claim
335	the	_	_	I-Claim
336	planning	_	_	I-Claim
337	of	_	_	I-Claim
338	these	_	_	I-Claim
339	interventions	_	_	I-Claim
340	to	_	_	I-Claim
341	improve	_	_	I-Claim
342	program	_	_	I-Claim
343	adherence	_	_	I-Claim
344	.	_	_	I-Claim


0	Cancer	_	_	O
1	related	_	_	O
2	fatigue	_	_	O
3	(	_	_	O
4	CRF	_	_	O
5	)	_	_	O
6	is	_	_	O
7	a	_	_	O
8	common	_	_	O
9	problem	_	_	O
10	for	_	_	O
11	cancer	_	_	O
12	patients	_	_	O
13	across	_	_	O
14	diagnoses	_	_	O
15	during	_	_	O
16	chemotherapy	_	_	O
17	and	_	_	O
18	is	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	physical	_	_	O
22	inactivity	_	_	O
23	,	_	_	O
24	lower	_	_	O
25	functional	_	_	O
26	level	_	_	O
27	and	_	_	O
28	lack	_	_	O
29	of	_	_	O
30	energy	_	_	O
31	.	_	_	O

32	Few	_	_	O
33	RCT	_	_	O
34	exercise	_	_	O
35	intervention	_	_	O
36	studies	_	_	O
37	have	_	_	O
38	included	_	_	O
39	cancer	_	_	O
40	patients	_	_	O
41	undergoing	_	_	O
42	chemotherapy	_	_	O
43	.	_	_	O

44	The	_	_	O
45	objective	_	_	O
46	of	_	_	O
47	this	_	_	O
48	study	_	_	O
49	is	_	_	O
50	to	_	_	O
51	evaluate	_	_	O
52	whether	_	_	O
53	a	_	_	O
54	six-week	_	_	O
55	supervised	_	_	O
56	multimodal	_	_	O
57	exercise	_	_	O
58	intervention	_	_	O
59	,	_	_	O
60	adjunct	_	_	O
61	to	_	_	O
62	chemotherapy	_	_	O
63	and	_	_	O
64	standard	_	_	O
65	care	_	_	O
66	,	_	_	O
67	can	_	_	O
68	reduce	_	_	O
69	the	_	_	O
70	patient	_	_	O
71	's	_	_	O
72	CRF	_	_	O
73	level	_	_	O
74	.	_	_	O

75	Data	_	_	O
76	is	_	_	O
77	based	_	_	O
78	on	_	_	O
79	analyses	_	_	O
80	of	_	_	O
81	a	_	_	O
82	prospective	_	_	O
83	randomised	_	_	O
84	controlled	_	_	O
85	trial	_	_	O
86	'The	_	_	O
87	Body	_	_	O
88	Cancer	_	_	O
89	Trial	_	_	O
90	'	_	_	O
91	.	_	_	O

92	213	_	_	O
93	cancer	_	_	O
94	patients	_	_	O
95	with	_	_	O
96	different	_	_	O
97	diagnoses	_	_	O
98	were	_	_	O
99	randomised	_	_	O
100	into	_	_	O
101	an	_	_	O
102	intervention	_	_	O
103	group	_	_	O
104	or	_	_	O
105	wait-list	_	_	O
106	control	_	_	O
107	group	_	_	O
108	.	_	_	O

109	The	_	_	O
110	primary	_	_	O
111	outcome	_	_	O
112	,	_	_	O
113	Fatigue	_	_	O
114	score	_	_	O
115	(	_	_	O
116	CRF	_	_	O
117	)	_	_	O
118	,	_	_	O
119	was	_	_	O
120	evaluated	_	_	O
121	by	_	_	O
122	the	_	_	O
123	Functional	_	_	O
124	Assessment	_	_	O
125	of	_	_	O
126	Cancer	_	_	O
127	Therapy-Anaemia	_	_	O
128	Questionnaire	_	_	O
129	(	_	_	O
130	FACT-An-	_	_	O
131	)	_	_	O
132	(	_	_	O
133	FACT-G	_	_	O
134	score	_	_	O
135	&	_	_	O
136	FACT-An	_	_	O
137	Anemia	_	_	O
138	subscale	_	_	O
139	)	_	_	O
140	.	_	_	O

141	Supervised	_	_	O
142	exercise	_	_	O
143	,	_	_	O
144	comprising	_	_	O
145	high-intensity	_	_	O
146	cardiovascular	_	_	O
147	and	_	_	O
148	heavy	_	_	O
149	resistance	_	_	O
150	training	_	_	O
151	,	_	_	O
152	relaxation-	_	_	O
153	and	_	_	O
154	body	_	_	O
155	awareness	_	_	O
156	training	_	_	O
157	and	_	_	O
158	massage	_	_	O
159	,	_	_	O
160	9	_	_	O
161	h	_	_	O
162	weekly	_	_	O
163	for	_	_	O
164	6	_	_	O
165	weeks	_	_	O
166	.	_	_	O

167	CRF	_	_	B-Premise
168	was	_	_	I-Premise
169	significantly	_	_	I-Premise
170	reduced	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	intervention	_	_	I-Premise
174	group	_	_	I-Premise
175	,	_	_	I-Premise
176	corresponding	_	_	I-Premise
177	to	_	_	I-Premise
178	a	_	_	I-Premise
179	Fatigue	_	_	I-Premise
180	score	_	_	I-Premise
181	reduction	_	_	I-Premise
182	of	_	_	I-Premise
183	3.04	_	_	I-Premise
184	(	_	_	I-Premise
185	effect	_	_	I-Premise
186	size	_	_	I-Premise
187	of	_	_	I-Premise
188	0.44	_	_	I-Premise
189	,	_	_	I-Premise
190	95	_	_	I-Premise
191	%	_	_	I-Premise
192	CI	_	_	I-Premise
193	0.17-0.72	_	_	I-Premise
194	)	_	_	I-Premise
195	(	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	.002	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	the	_	_	I-Premise
202	FACT-An	_	_	I-Premise
203	score	_	_	I-Premise
204	by	_	_	I-Premise
205	5.40	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.015	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	the	_	_	I-Premise
213	FACT-An	_	_	I-Premise
214	Toi	_	_	I-Premise
215	score	_	_	I-Premise
216	by	_	_	I-Premise
217	5.22	_	_	I-Premise
218	(	_	_	I-Premise
219	P	_	_	I-Premise
220	=	_	_	I-Premise
221	.009	_	_	I-Premise
222	)	_	_	I-Premise
223	and	_	_	I-Premise
224	the	_	_	I-Premise
225	Anaemia-ANS	_	_	I-Premise
226	by	_	_	I-Premise
227	3.76	_	_	I-Premise
228	(	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	.002	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	There	_	_	B-Premise
235	was	_	_	I-Premise
236	no	_	_	I-Premise
237	statistically	_	_	I-Premise
238	significant	_	_	I-Premise
239	effect	_	_	I-Premise
240	on	_	_	I-Premise
241	the	_	_	I-Premise
242	General	_	_	I-Premise
243	Quality	_	_	I-Premise
244	of	_	_	I-Premise
245	Life	_	_	I-Premise
246	score	_	_	I-Premise
247	(	_	_	I-Premise
248	FACT-G	_	_	I-Premise
249	)	_	_	I-Premise
250	or	_	_	I-Premise
251	on	_	_	I-Premise
252	any	_	_	I-Premise
253	of	_	_	I-Premise
254	the	_	_	I-Premise
255	individual	_	_	I-Premise
256	wellbeing	_	_	I-Premise
257	scores	_	_	I-Premise
258	;	_	_	I-Premise
259	Physical	_	_	I-Premise
260	(	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.13	_	_	I-Premise
264	)	_	_	I-Premise
265	,	_	_	I-Premise
266	Emotional	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	.87	_	_	I-Premise
271	)	_	_	I-Premise
272	,	_	_	I-Premise
273	Social	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	=	_	_	I-Premise
277	.83	_	_	I-Premise
278	)	_	_	I-Premise
279	and	_	_	I-Premise
280	Functional	_	_	I-Premise
281	(	_	_	I-Premise
282	P	_	_	I-Premise
283	=	_	_	I-Premise
284	.26	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	In	_	_	B-Claim
288	summary	_	_	I-Claim
289	,	_	_	I-Claim
290	this	_	_	I-Claim
291	six-week	_	_	I-Claim
292	supervised	_	_	I-Claim
293	multimodal	_	_	I-Claim
294	exercise	_	_	I-Claim
295	intervention	_	_	I-Claim
296	can	_	_	I-Claim
297	lead	_	_	I-Claim
298	to	_	_	I-Claim
299	significant	_	_	I-Claim
300	reduction	_	_	I-Claim
301	in	_	_	I-Claim
302	self-reported	_	_	I-Claim
303	CRF	_	_	I-Claim
304	in	_	_	I-Claim
305	cancer	_	_	I-Claim
306	patients	_	_	I-Claim
307	undergoing	_	_	I-Claim
308	chemotherapy	_	_	I-Claim
309	.	_	_	I-Claim


0	Exercise	_	_	O
1	for	_	_	O
2	Health	_	_	O
3	was	_	_	O
4	a	_	_	O
5	randomized	_	_	O
6	,	_	_	O
7	controlled	_	_	O
8	trial	_	_	O
9	designed	_	_	O
10	to	_	_	O
11	evaluate	_	_	O
12	two	_	_	O
13	modes	_	_	O
14	of	_	_	O
15	delivering	_	_	O
16	(	_	_	O
17	face-to-face	_	_	O
18	[	_	_	O
19	FtF	_	_	O
20	]	_	_	O
21	and	_	_	O
22	over-the-telephone	_	_	O
23	[	_	_	O
24	Tel	_	_	O
25	]	_	_	O
26	)	_	_	O
27	an	_	_	O
28	8-month	_	_	O
29	translational	_	_	O
30	exercise	_	_	O
31	intervention	_	_	O
32	,	_	_	O
33	commencing	_	_	O
34	6-weeks	_	_	O
35	post-breast	_	_	O
36	cancer	_	_	O
37	surgery	_	_	O
38	(	_	_	O
39	PS	_	_	O
40	)	_	_	O
41	.	_	_	O

42	Outcomes	_	_	O
43	included	_	_	O
44	quality	_	_	O
45	of	_	_	O
46	life	_	_	O
47	(	_	_	O
48	QoL	_	_	O
49	)	_	_	O
50	,	_	_	O
51	function	_	_	O
52	(	_	_	O
53	fitness	_	_	O
54	and	_	_	O
55	upper	_	_	O
56	body	_	_	O
57	)	_	_	O
58	and	_	_	O
59	treatment-related	_	_	O
60	side	_	_	O
61	effects	_	_	O
62	(	_	_	O
63	fatigue	_	_	O
64	,	_	_	O
65	lymphoedema	_	_	O
66	,	_	_	O
67	body	_	_	O
68	mass	_	_	O
69	index	_	_	O
70	,	_	_	O
71	menopausal	_	_	O
72	symptoms	_	_	O
73	,	_	_	O
74	anxiety	_	_	O
75	,	_	_	O
76	depression	_	_	O
77	and	_	_	O
78	pain	_	_	O
79	)	_	_	O
80	.	_	_	O

81	Generalised	_	_	O
82	estimating	_	_	O
83	equation	_	_	O
84	modelling	_	_	O
85	determined	_	_	O
86	time	_	_	O
87	(	_	_	O
88	baseline	_	_	O
89	[	_	_	O
90	5	_	_	O
91	weeks	_	_	O
92	PS	_	_	O
93	]	_	_	O
94	,	_	_	O
95	mid-intervention	_	_	O
96	[	_	_	O
97	6	_	_	O
98	months	_	_	O
99	PS	_	_	O
100	]	_	_	O
101	,	_	_	O
102	post-intervention	_	_	O
103	[	_	_	O
104	12	_	_	O
105	months	_	_	O
106	PS	_	_	O
107	]	_	_	O
108	)	_	_	O
109	,	_	_	O
110	group	_	_	O
111	(	_	_	O
112	FtF	_	_	O
113	,	_	_	O
114	Tel	_	_	O
115	,	_	_	O
116	Usual	_	_	O
117	Care	_	_	O
118	[	_	_	O
119	UC	_	_	O
120	]	_	_	O
121	)	_	_	O
122	and	_	_	O
123	time-by-group	_	_	O
124	effects	_	_	O
125	.	_	_	O

126	194	_	_	O
127	women	_	_	O
128	representative	_	_	O
129	of	_	_	O
130	the	_	_	O
131	breast	_	_	O
132	cancer	_	_	O
133	population	_	_	O
134	were	_	_	O
135	randomised	_	_	O
136	to	_	_	O
137	the	_	_	O
138	FtF	_	_	O
139	(	_	_	O
140	n	_	_	O
141	=	_	_	O
142	67	_	_	O
143	)	_	_	O
144	,	_	_	O
145	Tel	_	_	O
146	(	_	_	O
147	n	_	_	O
148	=	_	_	O
149	67	_	_	O
150	)	_	_	O
151	and	_	_	O
152	UC	_	_	O
153	(	_	_	O
154	n	_	_	O
155	=	_	_	O
156	60	_	_	O
157	)	_	_	O
158	groups	_	_	O
159	.	_	_	O

160	There	_	_	B-Premise
161	were	_	_	I-Premise
162	significant	_	_	I-Premise
163	(	_	_	I-Premise
164	p	_	_	I-Premise
165	<	_	_	I-Premise
166	0.05	_	_	I-Premise
167	)	_	_	I-Premise
168	interaction	_	_	I-Premise
169	effects	_	_	I-Premise
170	on	_	_	I-Premise
171	QoL	_	_	I-Premise
172	,	_	_	I-Premise
173	fitness	_	_	I-Premise
174	and	_	_	I-Premise
175	fatigue	_	_	I-Premise
176	with	_	_	I-Premise
177	differences	_	_	I-Premise
178	being	_	_	I-Premise
179	observed	_	_	I-Premise
180	between	_	_	I-Premise
181	the	_	_	I-Premise
182	treatment	_	_	I-Premise
183	groups	_	_	I-Premise
184	and	_	_	I-Premise
185	the	_	_	I-Premise
186	UC	_	_	I-Premise
187	group	_	_	I-Premise
188	.	_	_	I-Premise

189	Trends	_	_	B-Premise
190	observed	_	_	I-Premise
191	for	_	_	I-Premise
192	the	_	_	I-Premise
193	treatment	_	_	I-Premise
194	groups	_	_	I-Premise
195	were	_	_	I-Premise
196	similar	_	_	I-Premise
197	.	_	_	I-Premise

198	The	_	_	B-Premise
199	treatment	_	_	I-Premise
200	groups	_	_	I-Premise
201	reported	_	_	I-Premise
202	improved	_	_	I-Premise
203	QoL	_	_	I-Premise
204	,	_	_	I-Premise
205	fitness	_	_	I-Premise
206	and	_	_	I-Premise
207	fatigue	_	_	I-Premise
208	over	_	_	I-Premise
209	time	_	_	I-Premise
210	and	_	_	I-Premise
211	changes	_	_	I-Premise
212	observed	_	_	I-Premise
213	between	_	_	I-Premise
214	baseline	_	_	I-Premise
215	and	_	_	I-Premise
216	post-intervention	_	_	I-Premise
217	were	_	_	I-Premise
218	clinically	_	_	I-Premise
219	relevant	_	_	I-Premise
220	.	_	_	I-Premise

221	In	_	_	B-Premise
222	contrast	_	_	I-Premise
223	,	_	_	I-Premise
224	the	_	_	I-Premise
225	UC	_	_	I-Premise
226	group	_	_	I-Premise
227	experienced	_	_	I-Premise
228	no	_	_	I-Premise
229	change	_	_	I-Premise
230	,	_	_	I-Premise
231	or	_	_	I-Premise
232	worsening	_	_	I-Premise
233	QoL	_	_	I-Premise
234	,	_	_	I-Premise
235	fitness	_	_	I-Premise
236	and	_	_	I-Premise
237	fatigue	_	_	I-Premise
238	,	_	_	I-Premise
239	mid-intervention	_	_	I-Premise
240	.	_	_	I-Premise

241	Although	_	_	B-Premise
242	improvements	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	UC	_	_	I-Premise
246	group	_	_	I-Premise
247	occurred	_	_	I-Premise
248	by	_	_	I-Premise
249	12-months	_	_	I-Premise
250	post-surgery	_	_	I-Premise
251	,	_	_	I-Premise
252	the	_	_	B-Premise
253	change	_	_	I-Premise
254	did	_	_	I-Premise
255	not	_	_	I-Premise
256	meet	_	_	I-Premise
257	the	_	_	I-Premise
258	clinically	_	_	I-Premise
259	relevant	_	_	I-Premise
260	threshold	_	_	I-Premise
261	.	_	_	I-Premise

262	There	_	_	B-Premise
263	were	_	_	I-Premise
264	no	_	_	I-Premise
265	differences	_	_	I-Premise
266	in	_	_	I-Premise
267	other	_	_	I-Premise
268	treatment-related	_	_	I-Premise
269	side	_	_	I-Premise
270	effects	_	_	I-Premise
271	between	_	_	I-Premise
272	groups	_	_	I-Premise
273	.	_	_	I-Premise

274	This	_	_	B-Claim
275	translational	_	_	I-Claim
276	intervention	_	_	I-Claim
277	trial	_	_	I-Claim
278	,	_	_	I-Claim
279	delivered	_	_	I-Claim
280	either	_	_	I-Claim
281	FtF	_	_	I-Claim
282	or	_	_	I-Claim
283	Tel	_	_	I-Claim
284	,	_	_	I-Claim
285	supports	_	_	I-Claim
286	exercise	_	_	I-Claim
287	as	_	_	I-Claim
288	a	_	_	I-Claim
289	form	_	_	I-Claim
290	of	_	_	I-Claim
291	adjuvant	_	_	I-Claim
292	breast	_	_	I-Claim
293	cancer	_	_	I-Claim
294	therapy	_	_	I-Claim
295	that	_	_	I-Claim
296	can	_	_	I-Claim
297	prevent	_	_	I-Claim
298	declines	_	_	I-Claim
299	in	_	_	I-Claim
300	fitness	_	_	I-Claim
301	and	_	_	I-Claim
302	function	_	_	I-Claim
303	during	_	_	I-Claim
304	treatment	_	_	I-Claim
305	and	_	_	I-Claim
306	optimise	_	_	I-Claim
307	recovery	_	_	I-Claim
308	post-treatment	_	_	I-Claim
309	.	_	_	I-Claim


0	Over	_	_	O
1	30	_	_	O
2	%	_	_	O
3	of	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	non-small	_	_	O
7	cell	_	_	O
8	lung	_	_	O
9	cancer	_	_	O
10	(	_	_	O
11	NSCLC	_	_	O
12	)	_	_	O
13	develop	_	_	O
14	brain	_	_	O
15	metastases	_	_	O
16	.	_	_	O

17	If	_	_	O
18	inoperable	_	_	O
19	,	_	_	O
20	optimal	_	_	O
21	supportive	_	_	O
22	care	_	_	O
23	(	_	_	O
24	OSC	_	_	O
25	)	_	_	O
26	,	_	_	O
27	including	_	_	O
28	steroids	_	_	O
29	,	_	_	O
30	and	_	_	O
31	whole	_	_	O
32	brain	_	_	O
33	radiotherapy	_	_	O
34	(	_	_	O
35	WBRT	_	_	O
36	)	_	_	O
37	are	_	_	O
38	generally	_	_	O
39	considered	_	_	O
40	to	_	_	O
41	be	_	_	O
42	standard	_	_	O
43	care	_	_	O
44	,	_	_	O
45	although	_	_	O
46	there	_	_	O
47	is	_	_	O
48	no	_	_	O
49	randomised	_	_	O
50	evidence	_	_	O
51	demonstrating	_	_	O
52	that	_	_	O
53	the	_	_	O
54	addition	_	_	O
55	of	_	_	O
56	WBRT	_	_	O
57	to	_	_	O
58	OSC	_	_	O
59	improves	_	_	O
60	survival	_	_	O
61	or	_	_	O
62	quality	_	_	O
63	of	_	_	O
64	life	_	_	O
65	.	_	_	O

66	QUARTZ	_	_	O
67	is	_	_	O
68	a	_	_	O
69	randomised	_	_	O
70	,	_	_	O
71	non-inferiority	_	_	O
72	,	_	_	O
73	phase	_	_	O
74	III	_	_	O
75	trial	_	_	O
76	comparing	_	_	O
77	OSC	_	_	O
78	+	_	_	O
79	WBRT	_	_	O
80	versus	_	_	O
81	OSC	_	_	O
82	in	_	_	O
83	patients	_	_	O
84	with	_	_	O
85	inoperable	_	_	O
86	brain	_	_	O
87	metastases	_	_	O
88	from	_	_	O
89	NSCLC	_	_	O
90	.	_	_	O

91	The	_	_	O
92	primary	_	_	O
93	outcome	_	_	O
94	measure	_	_	O
95	is	_	_	O
96	quality-adjusted	_	_	O
97	life	_	_	O
98	years	_	_	O
99	(	_	_	O
100	QALYs	_	_	O
101	)	_	_	O
102	.	_	_	O

103	QUARTZ	_	_	O
104	was	_	_	O
105	threatened	_	_	O
106	with	_	_	O
107	both	_	_	O
108	loss	_	_	O
109	of	_	_	O
110	funding	_	_	O
111	and	_	_	O
112	early	_	_	O
113	closure	_	_	O
114	due	_	_	O
115	to	_	_	O
116	poor	_	_	O
117	accrual	_	_	O
118	.	_	_	O

119	A	_	_	O
120	lack	_	_	O
121	of	_	_	O
122	preliminary	_	_	O
123	randomised	_	_	O
124	data	_	_	O
125	supporting	_	_	O
126	the	_	_	O
127	trial	_	_	O
128	's	_	_	O
129	hypotheses	_	_	O
130	was	_	_	O
131	thought	_	_	O
132	to	_	_	O
133	underlie	_	_	O
134	the	_	_	O
135	poor	_	_	O
136	accrual	_	_	O
137	,	_	_	O
138	so	_	_	O
139	,	_	_	O
140	with	_	_	O
141	no	_	_	O
142	knowledge	_	_	O
143	of	_	_	O
144	the	_	_	O
145	data	_	_	O
146	,	_	_	O
147	the	_	_	O
148	independent	_	_	O
149	trial	_	_	O
150	steering	_	_	O
151	committee	_	_	O
152	agreed	_	_	O
153	to	_	_	O
154	the	_	_	O
155	unusual	_	_	O
156	step	_	_	O
157	of	_	_	O
158	releasing	_	_	O
159	interim	_	_	O
160	data	_	_	O
161	.	_	_	O

162	Between	_	_	O
163	March	_	_	O
164	2007	_	_	O
165	and	_	_	O
166	April	_	_	O
167	2010	_	_	O
168	,	_	_	O
169	151	_	_	O
170	(	_	_	O
171	of	_	_	O
172	the	_	_	O
173	planned	_	_	O
174	534	_	_	O
175	)	_	_	O
176	patients	_	_	O
177	were	_	_	O
178	randomised	_	_	O
179	(	_	_	O
180	75	_	_	O
181	OSC	_	_	O
182	+	_	_	O
183	WBRT	_	_	O
184	,	_	_	O
185	76	_	_	O
186	OSC	_	_	O
187	)	_	_	O
188	.	_	_	O

189	Participants	_	_	O
190	'	_	_	O
191	baseline	_	_	O
192	demographics	_	_	O
193	included	_	_	O
194	median	_	_	O
195	age	_	_	O
196	67	_	_	O
197	years	_	_	O
198	(	_	_	O
199	interquartile	_	_	O
200	range	_	_	O
201	62-73	_	_	O
202	)	_	_	O
203	,	_	_	O
204	60	_	_	O
205	%	_	_	O
206	male	_	_	O
207	,	_	_	O
208	50	_	_	O
209	%	_	_	O
210	with	_	_	O
211	a	_	_	O
212	Karnofsky	_	_	O
213	performance	_	_	O
214	status	_	_	O
215	<	_	_	O
216	70	_	_	O
217	;	_	_	O
218	steroid	_	_	O
219	usage	_	_	O
220	was	_	_	O
221	similar	_	_	O
222	in	_	_	O
223	the	_	_	O
224	two	_	_	O
225	groups	_	_	O
226	;	_	_	O
227	64/75	_	_	O
228	(	_	_	O
229	85	_	_	O
230	%	_	_	O
231	)	_	_	O
232	received	_	_	O
233	WBRT	_	_	O
234	(	_	_	O
235	20	_	_	O
236	Gy	_	_	O
237	in	_	_	O
238	five	_	_	O
239	fractions	_	_	O
240	)	_	_	O
241	.	_	_	O

242	Median	_	_	B-Premise
243	survival	_	_	I-Premise
244	was	_	_	I-Premise
245	:	_	_	I-Premise
246	OSC	_	_	I-Premise
247	+	_	_	I-Premise
248	WBRT	_	_	I-Premise
249	49	_	_	I-Premise
250	days	_	_	I-Premise
251	(	_	_	I-Premise
252	95	_	_	I-Premise
253	%	_	_	I-Premise
254	confidence	_	_	I-Premise
255	interval	_	_	I-Premise
256	39-61	_	_	I-Premise
257	)	_	_	I-Premise
258	,	_	_	I-Premise
259	OSC	_	_	I-Premise
260	51	_	_	I-Premise
261	days	_	_	I-Premise
262	(	_	_	I-Premise
263	95	_	_	I-Premise
264	%	_	_	I-Premise
265	confidence	_	_	I-Premise
266	interval	_	_	I-Premise
267	27-57	_	_	I-Premise
268	)	_	_	I-Premise
269	-	_	_	I-Premise
270	hazard	_	_	I-Premise
271	ratio	_	_	I-Premise
272	1.11	_	_	I-Premise
273	(	_	_	I-Premise
274	95	_	_	I-Premise
275	%	_	_	I-Premise
276	confidence	_	_	I-Premise
277	interval	_	_	I-Premise
278	0.80-1.53	_	_	I-Premise
279	)	_	_	I-Premise
280	in	_	_	I-Premise
281	favour	_	_	I-Premise
282	of	_	_	I-Premise
283	WBRT	_	_	I-Premise
284	.	_	_	I-Premise

285	Quality	_	_	B-Premise
286	of	_	_	I-Premise
287	life	_	_	I-Premise
288	assessed	_	_	I-Premise
289	using	_	_	I-Premise
290	EQ-5D	_	_	I-Premise
291	showed	_	_	I-Premise
292	no	_	_	I-Premise
293	evidence	_	_	I-Premise
294	of	_	_	I-Premise
295	a	_	_	I-Premise
296	difference	_	_	I-Premise
297	.	_	_	I-Premise

298	The	_	_	B-Premise
299	estimated	_	_	I-Premise
300	mean	_	_	I-Premise
301	QALYs	_	_	I-Premise
302	was	_	_	I-Premise
303	:	_	_	I-Premise
304	OSC	_	_	I-Premise
305	+	_	_	I-Premise
306	WBRT	_	_	I-Premise
307	31	_	_	I-Premise
308	days	_	_	I-Premise
309	and	_	_	I-Premise
310	OSC	_	_	I-Premise
311	30	_	_	I-Premise
312	days	_	_	I-Premise
313	,	_	_	I-Premise
314	difference	_	_	I-Premise
315	-1	_	_	I-Premise
316	day	_	_	I-Premise
317	(	_	_	I-Premise
318	95	_	_	I-Premise
319	%	_	_	I-Premise
320	confidence	_	_	I-Premise
321	interval	_	_	I-Premise
322	-12.0	_	_	I-Premise
323	to	_	_	I-Premise
324	+13.2	_	_	I-Premise
325	days	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	These	_	_	B-Claim
329	interim	_	_	I-Claim
330	data	_	_	I-Claim
331	indicate	_	_	I-Claim
332	no	_	_	I-Claim
333	early	_	_	I-Claim
334	evidence	_	_	I-Claim
335	of	_	_	I-Claim
336	detriment	_	_	I-Claim
337	to	_	_	I-Claim
338	quality	_	_	I-Claim
339	of	_	_	I-Claim
340	life	_	_	I-Claim
341	,	_	_	I-Claim
342	overall	_	_	I-Claim
343	survival	_	_	I-Claim
344	or	_	_	I-Claim
345	QALYs	_	_	I-Claim
346	for	_	_	I-Claim
347	patients	_	_	I-Claim
348	allocated	_	_	I-Claim
349	to	_	_	I-Claim
350	OSC	_	_	I-Claim
351	alone	_	_	I-Claim
352	.	_	_	I-Claim

353	They	_	_	O
354	provide	_	_	O
355	key	_	_	O
356	information	_	_	O
357	for	_	_	O
358	discussing	_	_	O
359	the	_	_	O
360	trial	_	_	O
361	with	_	_	O
362	patients	_	_	O
363	and	_	_	O
364	strengthen	_	_	O
365	the	_	_	O
366	argument	_	_	O
367	for	_	_	O
368	continuing	_	_	O
369	QUARTZ	_	_	O
370	to	_	_	O
371	definitively	_	_	O
372	answer	_	_	O
373	this	_	_	O
374	important	_	_	O
375	clinical	_	_	O
376	question	_	_	O
377	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	effect	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	topical	_	_	O
14	brimonidine	_	_	O
15	to	_	_	O
16	that	_	_	O
17	of	_	_	O
18	timolol	_	_	O
19	,	_	_	O
20	and	_	_	O
21	to	_	_	O
22	study	_	_	O
23	the	_	_	O
24	additive	_	_	O
25	effect	_	_	O
26	of	_	_	O
27	topical	_	_	O
28	brimonidine	_	_	O
29	to	_	_	O
30	topical	_	_	O
31	prostaglandin	_	_	O
32	(	_	_	O
33	PG	_	_	O
34	)	_	_	O
35	analogues	_	_	O
36	in	_	_	O
37	475	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	either	_	_	O
41	ocular	_	_	O
42	hypertension	_	_	O
43	or	_	_	O
44	primary	_	_	O
45	open	_	_	O
46	angle	_	_	O
47	glaucoma	_	_	O
48	.	_	_	O

49	The	_	_	O
50	primary	_	_	O
51	endpoint	_	_	O
52	was	_	_	O
53	the	_	_	O
54	mean	_	_	O
55	IOP	_	_	O
56	change	_	_	O
57	from	_	_	O
58	the	_	_	O
59	baseline	_	_	O
60	at	_	_	O
61	0	_	_	O
62	and	_	_	O
63	2	_	_	O
64	hours	_	_	O
65	at	_	_	O
66	week	_	_	O
67	4	_	_	O
68	.	_	_	O

69	The	_	_	B-Premise
70	mean	_	_	I-Premise
71	changes	_	_	I-Premise
72	were	_	_	I-Premise
73	-4.7	_	_	I-Premise
74	+/-	_	_	I-Premise
75	2.1	_	_	I-Premise
76	(	_	_	I-Premise
77	S.	_	_	I-Premise
78	D.	_	_	I-Premise
79	)	_	_	I-Premise
80	in	_	_	I-Premise
81	the	_	_	I-Premise
82	timolol	_	_	I-Premise
83	and	_	_	I-Premise
84	-4.0	_	_	I-Premise
85	+/-	_	_	I-Premise
86	2.0	_	_	I-Premise
87	mmHg	_	_	I-Premise
88	in	_	_	I-Premise
89	the	_	_	I-Premise
90	brimonidine	_	_	I-Premise
91	group	_	_	I-Premise
92	(	_	_	I-Premise
93	p	_	_	I-Premise
94	=	_	_	I-Premise
95	0.0138	_	_	I-Premise
96	)	_	_	I-Premise
97	.	_	_	I-Premise

98	The	_	_	B-Premise
99	95	_	_	I-Premise
100	%	_	_	I-Premise
101	confidence	_	_	I-Premise
102	interval	_	_	I-Premise
103	of	_	_	I-Premise
104	the	_	_	I-Premise
105	inter-group	_	_	I-Premise
106	difference	_	_	I-Premise
107	was	_	_	I-Premise
108	greater	_	_	I-Premise
109	than	_	_	I-Premise
110	the	_	_	I-Premise
111	pre-determined	_	_	I-Premise
112	criterion	_	_	I-Premise
113	of	_	_	I-Premise
114	non-inferiority	_	_	I-Premise
115	of	_	_	I-Premise
116	brimonidine	_	_	I-Premise
117	to	_	_	I-Premise
118	timolol	_	_	I-Premise
119	.	_	_	I-Premise

120	When	_	_	B-Premise
121	added	_	_	I-Premise
122	to	_	_	I-Premise
123	PG	_	_	I-Premise
124	analogues	_	_	I-Premise
125	,	_	_	I-Premise
126	the	_	_	I-Premise
127	IOP-lowering	_	_	I-Premise
128	effect	_	_	I-Premise
129	of	_	_	I-Premise
130	brimonidine	_	_	I-Premise
131	(	_	_	I-Premise
132	-2.9	_	_	I-Premise
133	+/-	_	_	I-Premise
134	1.8	_	_	I-Premise
135	mmHg	_	_	I-Premise
136	)	_	_	I-Premise
137	was	_	_	I-Premise
138	greater	_	_	I-Premise
139	than	_	_	I-Premise
140	that	_	_	I-Premise
141	of	_	_	I-Premise
142	the	_	_	I-Premise
143	placebo	_	_	I-Premise
144	(	_	_	I-Premise
145	-2.1	_	_	I-Premise
146	+/-	_	_	I-Premise
147	1.8	_	_	I-Premise
148	mmHg	_	_	I-Premise
149	)	_	_	I-Premise
150	(	_	_	I-Premise
151	p	_	_	I-Premise
152	=	_	_	I-Premise
153	0.0010	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	No	_	_	O
157	appreciable	_	_	O
158	adverse	_	_	O
159	side	_	_	O
160	effects	_	_	O
161	were	_	_	O
162	encountered	_	_	O
163	.	_	_	O

164	Topical	_	_	B-Claim
165	brimonidine	_	_	I-Claim
166	showed	_	_	I-Claim
167	an	_	_	I-Claim
168	additive	_	_	I-Claim
169	IOP-lowering	_	_	I-Claim
170	effect	_	_	I-Claim
171	to	_	_	I-Claim
172	topical	_	_	I-Claim
173	PG	_	_	I-Claim
174	analogues	_	_	I-Claim
175	,	_	_	I-Claim
176	although	_	_	B-Claim
177	its	_	_	I-Claim
178	IOP-lowering	_	_	I-Claim
179	effect	_	_	I-Claim
180	was	_	_	I-Claim
181	inferior	_	_	I-Claim
182	to	_	_	I-Claim
183	topical	_	_	I-Claim
184	timolol	_	_	I-Claim
185	as	_	_	I-Claim
186	monotherapy	_	_	I-Claim
187	.	_	_	I-Claim


0	Quality	_	_	O
1	of	_	_	O
2	life	_	_	O
3	(	_	_	O
4	QoL	_	_	O
5	)	_	_	O
6	after	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	is	_	_	O
10	nowadays	_	_	O
11	a	_	_	O
12	major	_	_	O
13	challenge	_	_	O
14	.	_	_	O

15	Complementary	_	_	O
16	interventions	_	_	O
17	are	_	_	O
18	necessary	_	_	O
19	because	_	_	O
20	of	_	_	O
21	frequent	_	_	O
22	depression	_	_	O
23	symptoms	_	_	O
24	after	_	_	O
25	treatment	_	_	O
26	and	_	_	O
27	also	_	_	O
28	to	_	_	O
29	favour	_	_	O
30	return	_	_	O
31	to	_	_	O
32	activity	_	_	O
33	.	_	_	O

34	Besides	_	_	O
35	,	_	_	O
36	radio-chemotherapy	_	_	O
37	has	_	_	O
38	side-effects	_	_	O
39	like	_	_	O
40	weight	_	_	O
41	gain	_	_	O
42	and	_	_	O
43	fatigue	_	_	O
44	.	_	_	O

45	Several	_	_	O
46	strategies	_	_	O
47	including	_	_	O
48	group	_	_	O
49	behavioural-educational	_	_	O
50	interventions	_	_	O
51	,	_	_	O
52	physical	_	_	O
53	training	_	_	O
54	and/or	_	_	O
55	dietary	_	_	O
56	education	_	_	O
57	,	_	_	O
58	have	_	_	O
59	been	_	_	O
60	tested	_	_	O
61	to	_	_	O
62	answer	_	_	O
63	these	_	_	O
64	difficulties	_	_	O
65	with	_	_	O
66	moderate	_	_	O
67	success	_	_	O
68	in	_	_	O
69	the	_	_	O
70	long	_	_	O
71	run	_	_	O
72	.	_	_	O

73	Two	_	_	O
74	hundred	_	_	O
75	and	_	_	O
76	fifty-one	_	_	O
77	non-metastatic	_	_	O
78	patients	_	_	O
79	were	_	_	O
80	accrued	_	_	O
81	after	_	_	O
82	chemotherapy	_	_	O
83	in	_	_	O
84	a	_	_	O
85	prospective	_	_	O
86	randomised	_	_	O
87	multicenter	_	_	O
88	trial	_	_	O
89	between	_	_	O
90	2008	_	_	O
91	and	_	_	O
92	2010	_	_	O
93	,	_	_	O
94	testing	_	_	O
95	a	_	_	O
96	2-week	_	_	O
97	intervention	_	_	O
98	in	_	_	O
99	SPA	_	_	O
100	centres	_	_	O
101	.	_	_	O

102	Intervention	_	_	O
103	comprised	_	_	O
104	group	_	_	O
105	physical	_	_	O
106	training	_	_	O
107	,	_	_	O
108	dietary	_	_	O
109	education	_	_	O
110	and	_	_	O
111	physiotherapy	_	_	O
112	.	_	_	O

113	Selected	_	_	O
114	patients	_	_	O
115	were	_	_	O
116	in	_	_	O
117	complete	_	_	O
118	remission	_	_	O
119	.	_	_	O

120	QoL	_	_	O
121	was	_	_	O
122	evaluated	_	_	O
123	with	_	_	O
124	SF36	_	_	O
125	questionnaire	_	_	O
126	,	_	_	O
127	anxiety	_	_	O
128	and	_	_	O
129	depression	_	_	O
130	with	_	_	O
131	the	_	_	O
132	hospital	_	_	O
133	anxiety	_	_	O
134	and	_	_	O
135	depression	_	_	O
136	(	_	_	O
137	HAD	_	_	O
138	)	_	_	O
139	one	_	_	O
140	.	_	_	O

141	Anthropometric	_	_	O
142	measures	_	_	O
143	and	_	_	O
144	QoL	_	_	O
145	evaluations	_	_	O
146	were	_	_	O
147	obtained	_	_	O
148	before	_	_	O
149	randomisation	_	_	O
150	and	_	_	O
151	every	_	_	O
152	6	_	_	O
153	months	_	_	O
154	during	_	_	O
155	3	_	_	O
156	years	_	_	O
157	.	_	_	O

158	Two	_	_	O
159	hundred	_	_	O
160	and	_	_	O
161	twenty	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	evaluable	_	_	O
165	at	_	_	O
166	1	_	_	O
167	year	_	_	O
168	.	_	_	O

169	Intervention	_	_	B-Premise
170	increased	_	_	I-Premise
171	SF36	_	_	I-Premise
172	score	_	_	I-Premise
173	by	_	_	I-Premise
174	9.5	_	_	I-Premise
175	points	_	_	I-Premise
176	(	_	_	I-Premise
177	p=0.000006	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	4.6	_	_	I-Premise
181	(	_	_	I-Premise
182	p=0.032	_	_	I-Premise
183	)	_	_	I-Premise
184	and	_	_	I-Premise
185	6.2	_	_	I-Premise
186	(	_	_	I-Premise
187	p=0.028	_	_	I-Premise
188	)	_	_	I-Premise
189	respectively	_	_	I-Premise
190	at	_	_	I-Premise
191	6	_	_	I-Premise
192	,	_	_	I-Premise
193	12	_	_	I-Premise
194	and	_	_	I-Premise
195	24	_	_	I-Premise
196	months	_	_	I-Premise
197	.	_	_	I-Premise

198	Effect	_	_	B-Premise
199	size	_	_	I-Premise
200	(	_	_	I-Premise
201	ES	_	_	I-Premise
202	)	_	_	I-Premise
203	was	_	_	I-Premise
204	0.63	_	_	I-Premise
205	[	_	_	I-Premise
206	0.37	_	_	I-Premise
207	;	_	_	I-Premise
208	0.90	_	_	I-Premise
209	]	_	_	I-Premise
210	,	_	_	I-Premise
211	0.29	_	_	I-Premise
212	[	_	_	I-Premise
213	0.03	_	_	I-Premise
214	;	_	_	I-Premise
215	0.55	_	_	I-Premise
216	]	_	_	I-Premise
217	and	_	_	I-Premise
218	0.41	_	_	I-Premise
219	[	_	_	I-Premise
220	0.04	_	_	I-Premise
221	;	_	_	I-Premise
222	0.78	_	_	I-Premise
223	]	_	_	I-Premise
224	.	_	_	I-Premise

225	Anxiety	_	_	B-Premise
226	score	_	_	I-Premise
227	was	_	_	I-Premise
228	shortly	_	_	I-Premise
229	minored	_	_	I-Premise
230	by	_	_	I-Premise
231	intervention	_	_	I-Premise
232	(	_	_	I-Premise
233	6-month	_	_	I-Premise
234	ES=-0.24	_	_	I-Premise
235	[	_	_	I-Premise
236	-0.42	_	_	I-Premise
237	;	_	_	I-Premise
238	-0.05	_	_	I-Premise
239	]	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	depression	_	_	I-Premise
243	score	_	_	I-Premise
244	more	_	_	I-Premise
245	durably	_	_	I-Premise
246	:	_	_	I-Premise
247	ES=-0.45	_	_	I-Premise
248	[	_	_	I-Premise
249	-0.72	_	_	I-Premise
250	;	_	_	I-Premise
251	-0.18	_	_	I-Premise
252	]	_	_	I-Premise
253	,	_	_	I-Premise
254	-0.34	_	_	I-Premise
255	[	_	_	I-Premise
256	-061	_	_	I-Premise
257	;	_	_	I-Premise
258	-0.08	_	_	I-Premise
259	]	_	_	I-Premise
260	,	_	_	I-Premise
261	and	_	_	I-Premise
262	-0.26	_	_	I-Premise
263	[	_	_	I-Premise
264	-0.63	_	_	I-Premise
265	;	_	_	I-Premise
266	0.11	_	_	I-Premise
267	]	_	_	I-Premise
268	at	_	_	I-Premise
269	6	_	_	I-Premise
270	,	_	_	I-Premise
271	12	_	_	I-Premise
272	and	_	_	I-Premise
273	24	_	_	I-Premise
274	months	_	_	I-Premise
275	.	_	_	I-Premise

276	This	_	_	B-Claim
277	2-week	_	_	I-Claim
278	group	_	_	I-Claim
279	intervention	_	_	I-Claim
280	seemed	_	_	I-Claim
281	to	_	_	I-Claim
282	durably	_	_	I-Claim
283	influence	_	_	I-Claim
284	QoL	_	_	I-Claim
285	of	_	_	I-Claim
286	breast	_	_	I-Claim
287	cancer	_	_	I-Claim
288	patients	_	_	I-Claim
289	treated	_	_	I-Claim
290	by	_	_	I-Claim
291	chemotherapy	_	_	I-Claim
292	.	_	_	I-Claim

293	Differences	_	_	B-Claim
294	,	_	_	I-Claim
295	smaller	_	_	I-Claim
296	at	_	_	I-Claim
297	12	_	_	I-Claim
298	months	_	_	I-Claim
299	than	_	_	I-Claim
300	at	_	_	I-Claim
301	six	_	_	I-Claim
302	,	_	_	I-Claim
303	suggest	_	_	I-Claim
304	that	_	_	I-Claim
305	a	_	_	I-Claim
306	second	_	_	I-Claim
307	but	_	_	I-Claim
308	shorter	_	_	I-Claim
309	intervention	_	_	I-Claim
310	could	_	_	I-Claim
311	help	_	_	I-Claim
312	maintain	_	_	I-Claim
313	the	_	_	I-Claim
314	6-month	_	_	I-Claim
315	benefits	_	_	I-Claim
316	.	_	_	I-Claim


0	The	_	_	O
1	addition	_	_	O
2	of	_	_	O
3	mTOR	_	_	O
4	inhibitor	_	_	O
5	everolimus	_	_	O
6	(	_	_	O
7	EVE	_	_	O
8	)	_	_	O
9	to	_	_	O
10	exemestane	_	_	O
11	(	_	_	O
12	EXE	_	_	O
13	)	_	_	O
14	was	_	_	O
15	evaluated	_	_	O
16	in	_	_	O
17	an	_	_	O
18	international	_	_	O
19	,	_	_	O
20	phase	_	_	O
21	3	_	_	O
22	study	_	_	O
23	(	_	_	O
24	BOLERO-2	_	_	O
25	)	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	hormone-receptor-positive	_	_	O
30	(	_	_	O
31	HR	_	_	O
32	(	_	_	O
33	+	_	_	O
34	)	_	_	O
35	)	_	_	O
36	breast	_	_	O
37	cancer	_	_	O
38	refractory	_	_	O
39	to	_	_	O
40	letrozole	_	_	O
41	or	_	_	O
42	anastrozole	_	_	O
43	.	_	_	O

44	The	_	_	O
45	safety	_	_	O
46	and	_	_	O
47	efficacy	_	_	O
48	of	_	_	O
49	anticancer	_	_	O
50	treatments	_	_	O
51	may	_	_	O
52	be	_	_	O
53	influenced	_	_	O
54	by	_	_	O
55	ethnicity	_	_	O
56	(	_	_	O
57	Sekine	_	_	O
58	et	_	_	O
59	al	_	_	O
60	.	_	_	O

61	in	_	_	O
62	Br	_	_	O
63	J	_	_	O
64	Cancer	_	_	O
65	99:1757-62	_	_	O
66	,	_	_	O
67	2008	_	_	O
68	)	_	_	O
69	.	_	_	O

70	Safety	_	_	O
71	and	_	_	O
72	efficacy	_	_	O
73	results	_	_	O
74	from	_	_	O
75	Asian	_	_	O
76	versus	_	_	O
77	non-Asian	_	_	O
78	patients	_	_	O
79	in	_	_	O
80	BOLERO-2	_	_	O
81	are	_	_	O
82	reported	_	_	O
83	.	_	_	O

84	Patients	_	_	O
85	were	_	_	O
86	randomized	_	_	O
87	(	_	_	O
88	2:1	_	_	O
89	)	_	_	O
90	to	_	_	O
91	10	_	_	O
92	mg/day	_	_	O
93	EVE	_	_	O
94	+	_	_	O
95	EXE	_	_	O
96	or	_	_	O
97	placebo	_	_	O
98	(	_	_	O
99	PBO	_	_	O
100	)	_	_	O
101	+	_	_	O
102	EXE	_	_	O
103	.	_	_	O

104	Primary	_	_	O
105	endpoint	_	_	O
106	was	_	_	O
107	progression-free	_	_	O
108	survival	_	_	O
109	(	_	_	O
110	PFS	_	_	O
111	)	_	_	O
112	.	_	_	O

113	Secondary	_	_	O
114	endpoints	_	_	O
115	included	_	_	O
116	overall	_	_	O
117	survival	_	_	O
118	,	_	_	O
119	response	_	_	O
120	rate	_	_	O
121	,	_	_	O
122	clinical	_	_	O
123	benefit	_	_	O
124	rate	_	_	O
125	,	_	_	O
126	and	_	_	O
127	safety	_	_	O
128	.	_	_	O

129	Of	_	_	O
130	143	_	_	O
131	Asian	_	_	O
132	patients	_	_	O
133	,	_	_	O
134	98	_	_	O
135	received	_	_	O
136	EVE	_	_	O
137	+	_	_	O
138	EXE	_	_	O
139	and	_	_	O
140	45	_	_	O
141	received	_	_	O
142	PBO	_	_	O
143	+	_	_	O
144	EXE	_	_	O
145	.	_	_	O

146	Treatment	_	_	B-Premise
147	with	_	_	I-Premise
148	EVE	_	_	I-Premise
149	+	_	_	I-Premise
150	EXE	_	_	I-Premise
151	significantly	_	_	I-Premise
152	improved	_	_	I-Premise
153	median	_	_	I-Premise
154	PFS	_	_	I-Premise
155	versus	_	_	I-Premise
156	PBO	_	_	I-Premise
157	+	_	_	I-Premise
158	EXE	_	_	I-Premise
159	among	_	_	I-Premise
160	Asian	_	_	I-Premise
161	patients	_	_	I-Premise
162	by	_	_	I-Premise
163	38	_	_	I-Premise
164	%	_	_	I-Premise
165	(	_	_	I-Premise
166	HR	_	_	I-Premise
167	=	_	_	I-Premise
168	0.62	_	_	I-Premise
169	;	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	,	_	_	I-Premise
174	0.41-0.94	_	_	I-Premise
175	)	_	_	I-Premise
176	.	_	_	I-Premise

177	Median	_	_	B-Premise
178	PFS	_	_	I-Premise
179	was	_	_	I-Premise
180	also	_	_	I-Premise
181	improved	_	_	I-Premise
182	among	_	_	I-Premise
183	non-Asian	_	_	I-Premise
184	patients	_	_	I-Premise
185	by	_	_	I-Premise
186	59	_	_	I-Premise
187	%	_	_	I-Premise
188	(	_	_	I-Premise
189	HR	_	_	I-Premise
190	=	_	_	I-Premise
191	0.41	_	_	I-Premise
192	;	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	,	_	_	I-Premise
197	0.33-0.50	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Median	_	_	B-Premise
201	PFS	_	_	I-Premise
202	duration	_	_	I-Premise
203	among	_	_	I-Premise
204	EVE-treated	_	_	I-Premise
205	Asian	_	_	I-Premise
206	patients	_	_	I-Premise
207	was	_	_	I-Premise
208	8.48	_	_	I-Premise
209	versus	_	_	I-Premise
210	4.14	_	_	I-Premise
211	months	_	_	I-Premise
212	for	_	_	I-Premise
213	PBO	_	_	I-Premise
214	+	_	_	I-Premise
215	EXE	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	7.33	_	_	I-Premise
219	versus	_	_	I-Premise
220	2.83	_	_	I-Premise
221	months	_	_	I-Premise
222	,	_	_	I-Premise
223	respectively	_	_	I-Premise
224	,	_	_	I-Premise
225	in	_	_	I-Premise
226	non-Asian	_	_	I-Premise
227	patients	_	_	I-Premise
228	.	_	_	I-Premise

229	The	_	_	B-Premise
230	most	_	_	I-Premise
231	common	_	_	I-Premise
232	grade	_	_	I-Premise
233	3/4	_	_	I-Premise
234	adverse	_	_	I-Premise
235	events	_	_	I-Premise
236	(	_	_	I-Premise
237	stomatitis	_	_	I-Premise
238	,	_	_	I-Premise
239	anemia	_	_	I-Premise
240	,	_	_	I-Premise
241	elevated	_	_	I-Premise
242	liver	_	_	I-Premise
243	enzymes	_	_	I-Premise
244	,	_	_	I-Premise
245	hyperglycemia	_	_	I-Premise
246	,	_	_	I-Premise
247	and	_	_	I-Premise
248	dyspnea	_	_	I-Premise
249	)	_	_	I-Premise
250	occurred	_	_	I-Premise
251	at	_	_	I-Premise
252	similar	_	_	I-Premise
253	frequencies	_	_	I-Premise
254	in	_	_	I-Premise
255	Asian	_	_	I-Premise
256	and	_	_	I-Premise
257	non-Asian	_	_	I-Premise
258	patients	_	_	I-Premise
259	.	_	_	I-Premise

260	Grade	_	_	B-Premise
261	1/2	_	_	I-Premise
262	interstitial	_	_	I-Premise
263	lung	_	_	I-Premise
264	disease	_	_	I-Premise
265	occurred	_	_	I-Premise
266	more	_	_	I-Premise
267	frequently	_	_	I-Premise
268	in	_	_	I-Premise
269	Asian	_	_	I-Premise
270	patients	_	_	I-Premise
271	.	_	_	I-Premise

272	Quality	_	_	B-Premise
273	of	_	_	I-Premise
274	life	_	_	I-Premise
275	was	_	_	I-Premise
276	similar	_	_	I-Premise
277	between	_	_	I-Premise
278	treatment	_	_	I-Premise
279	arms	_	_	I-Premise
280	in	_	_	I-Premise
281	Asian	_	_	I-Premise
282	patients	_	_	I-Premise
283	.	_	_	I-Premise

284	Adding	_	_	B-Claim
285	EVE	_	_	I-Claim
286	to	_	_	I-Claim
287	EXE	_	_	I-Claim
288	provided	_	_	I-Claim
289	substantial	_	_	I-Claim
290	clinical	_	_	I-Claim
291	benefit	_	_	I-Claim
292	in	_	_	I-Claim
293	both	_	_	I-Claim
294	Asian	_	_	I-Claim
295	and	_	_	I-Claim
296	non-Asian	_	_	I-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	similar	_	_	I-Claim
300	safety	_	_	I-Claim
301	profiles	_	_	I-Claim
302	.	_	_	I-Claim

303	This	_	_	B-Claim
304	combination	_	_	I-Claim
305	represents	_	_	I-Claim
306	an	_	_	I-Claim
307	improvement	_	_	I-Claim
308	in	_	_	I-Claim
309	the	_	_	I-Claim
310	management	_	_	I-Claim
311	of	_	_	I-Claim
312	postmenopausal	_	_	I-Claim
313	women	_	_	I-Claim
314	with	_	_	I-Claim
315	HR	_	_	I-Claim
316	(	_	_	I-Claim
317	+	_	_	I-Claim
318	)	_	_	I-Claim
319	/HER2	_	_	I-Claim
320	(	_	_	I-Claim
321	-	_	_	I-Claim
322	)	_	_	I-Claim
323	advanced	_	_	I-Claim
324	breast	_	_	I-Claim
325	cancer	_	_	I-Claim
326	progressing	_	_	I-Claim
327	on	_	_	I-Claim
328	nonsteroidal	_	_	I-Claim
329	aromatase	_	_	I-Claim
330	inhibitors	_	_	I-Claim
331	,	_	_	I-Claim
332	regardless	_	_	I-Claim
333	of	_	_	I-Claim
334	ethnicity	_	_	I-Claim
335	.	_	_	I-Claim


0	Cancer	_	_	O
1	treatment	_	_	O
2	can	_	_	O
3	profoundly	_	_	O
4	impact	_	_	O
5	the	_	_	O
6	patient	_	_	O
7	's	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	.	_	_	O

15	It	_	_	O
16	has	_	_	O
17	been	_	_	O
18	well	_	_	O
19	documented	_	_	O
20	that	_	_	O
21	there	_	_	O
22	are	_	_	O
23	gender	_	_	O
24	differences	_	_	O
25	in	_	_	O
26	the	_	_	O
27	symptoms	_	_	O
28	associated	_	_	O
29	with	_	_	O
30	cancer	_	_	O
31	treatment	_	_	O
32	.	_	_	O

33	This	_	_	O
34	study	_	_	O
35	explores	_	_	O
36	the	_	_	O
37	impact	_	_	O
38	of	_	_	O
39	gender	_	_	O
40	on	_	_	O
41	QOL	_	_	O
42	for	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	newly	_	_	O
46	diagnosed	_	_	O
47	advanced	_	_	O
48	cancer	_	_	O
49	.	_	_	O

50	A	_	_	O
51	randomized	_	_	O
52	,	_	_	O
53	controlled	_	_	O
54	clinical	_	_	O
55	trial	_	_	O
56	in	_	_	O
57	patients	_	_	O
58	receiving	_	_	O
59	radiotherapy	_	_	O
60	for	_	_	O
61	advanced	_	_	O
62	cancer	_	_	O
63	demonstrated	_	_	O
64	maintenance	_	_	O
65	of	_	_	O
66	QOL	_	_	O
67	with	_	_	O
68	a	_	_	O
69	six	_	_	O
70	session	_	_	O
71	multidisciplinary	_	_	O
72	structured	_	_	O
73	intervention	_	_	O
74	compared	_	_	O
75	to	_	_	O
76	controls	_	_	O
77	.	_	_	O

78	This	_	_	O
79	current	_	_	O
80	study	_	_	O
81	reports	_	_	O
82	the	_	_	O
83	gender	_	_	O
84	differences	_	_	O
85	in	_	_	O
86	that	_	_	O
87	trial	_	_	O
88	.	_	_	O

89	Outcome	_	_	O
90	measures	_	_	O
91	included	_	_	O
92	the	_	_	O
93	functional	_	_	O
94	assessment	_	_	O
95	of	_	_	O
96	cancer	_	_	O
97	therapy-general	_	_	O
98	(	_	_	O
99	FACT-G	_	_	O
100	)	_	_	O
101	,	_	_	O
102	linear	_	_	O
103	analog	_	_	O
104	self-assessment	_	_	O
105	(	_	_	O
106	LASA	_	_	O
107	)	_	_	O
108	,	_	_	O
109	and	_	_	O
110	profile	_	_	O
111	of	_	_	O
112	mood	_	_	O
113	states	_	_	O
114	(	_	_	O
115	POMS	_	_	O
116	)	_	_	O
117	at	_	_	O
118	baseline	_	_	O
119	and	_	_	O
120	weeks	_	_	O
121	4	_	_	O
122	,	_	_	O
123	27	_	_	O
124	,	_	_	O
125	and	_	_	O
126	52	_	_	O
127	.	_	_	O

128	Kruskal-Wallis	_	_	O
129	was	_	_	O
130	used	_	_	O
131	to	_	_	O
132	compare	_	_	O
133	QOL	_	_	O
134	scores	_	_	O
135	.	_	_	O

136	One	_	_	O
137	hundred	_	_	O
138	thirty-one	_	_	O
139	patients	_	_	O
140	(	_	_	O
141	45	_	_	O
142	women	_	_	O
143	and	_	_	O
144	86	_	_	O
145	men	_	_	O
146	,	_	_	O
147	mean	_	_	O
148	age	_	_	O
149	58.7	_	_	O
150	)	_	_	O
151	participated	_	_	O
152	in	_	_	O
153	the	_	_	O
154	clinical	_	_	O
155	trial	_	_	O
156	.	_	_	O

157	At	_	_	B-Premise
158	week	_	_	I-Premise
159	4	_	_	I-Premise
160	postintervention	_	_	I-Premise
161	,	_	_	I-Premise
162	women	_	_	I-Premise
163	in	_	_	I-Premise
164	the	_	_	I-Premise
165	intervention	_	_	I-Premise
166	group	_	_	I-Premise
167	had	_	_	I-Premise
168	statistically	_	_	I-Premise
169	significant	_	_	I-Premise
170	improvement	_	_	I-Premise
171	in	_	_	I-Premise
172	their	_	_	I-Premise
173	FACT-G	_	_	I-Premise
174	score	_	_	I-Premise
175	,	_	_	I-Premise
176	FACT-G	_	_	I-Premise
177	physical	_	_	I-Premise
178	well-being	_	_	I-Premise
179	subscale	_	_	I-Premise
180	,	_	_	I-Premise
181	LASA	_	_	I-Premise
182	fatigue	_	_	I-Premise
183	,	_	_	I-Premise
184	POMS	_	_	I-Premise
185	total	_	_	I-Premise
186	score	_	_	I-Premise
187	,	_	_	I-Premise
188	POMS	_	_	I-Premise
189	fatigue-inertia	_	_	I-Premise
190	subscale	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	POMS	_	_	I-Premise
194	confusion-bewilderment	_	_	I-Premise
195	subscale	_	_	I-Premise
196	(	_	_	I-Premise
197	p	_	_	I-Premise
198	<	_	_	I-Premise
199	0.05	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Men	_	_	B-Premise
203	receiving	_	_	I-Premise
204	the	_	_	I-Premise
205	intervention	_	_	I-Premise
206	had	_	_	I-Premise
207	a	_	_	I-Premise
208	smaller	_	_	I-Premise
209	decrease	_	_	I-Premise
210	in	_	_	I-Premise
211	FACT-G	_	_	I-Premise
212	score	_	_	I-Premise
213	compared	_	_	I-Premise
214	to	_	_	I-Premise
215	controls	_	_	I-Premise
216	(	_	_	I-Premise
217	p	_	_	I-Premise
218	=	_	_	I-Premise
219	0.048	_	_	I-Premise
220	)	_	_	I-Premise
221	and	_	_	I-Premise
222	also	_	_	I-Premise
223	worsened	_	_	I-Premise
224	on	_	_	I-Premise
225	the	_	_	I-Premise
226	LASA	_	_	I-Premise
227	financial	_	_	I-Premise
228	(	_	_	I-Premise
229	p	_	_	I-Premise
230	=	_	_	I-Premise
231	0.02	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	At	_	_	B-Premise
235	week	_	_	I-Premise
236	27	_	_	I-Premise
237	,	_	_	I-Premise
238	the	_	_	I-Premise
239	only	_	_	I-Premise
240	gender	_	_	I-Premise
241	difference	_	_	I-Premise
242	was	_	_	I-Premise
243	that	_	_	I-Premise
244	intervention	_	_	I-Premise
245	group	_	_	I-Premise
246	men	_	_	I-Premise
247	had	_	_	I-Premise
248	more	_	_	I-Premise
249	POMS	_	_	I-Premise
250	anger-hostility	_	_	I-Premise
251	(	_	_	I-Premise
252	p	_	_	I-Premise
253	=	_	_	I-Premise
254	0.009	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	By	_	_	B-Premise
258	week	_	_	I-Premise
259	52	_	_	I-Premise
260	,	_	_	I-Premise
261	there	_	_	I-Premise
262	were	_	_	I-Premise
263	no	_	_	I-Premise
264	statistically	_	_	I-Premise
265	significant	_	_	I-Premise
266	gender	_	_	I-Premise
267	differences	_	_	I-Premise
268	in	_	_	I-Premise
269	any	_	_	I-Premise
270	of	_	_	I-Premise
271	the	_	_	I-Premise
272	QOL	_	_	I-Premise
273	measures	_	_	I-Premise
274	.	_	_	I-Premise

275	Gender-based	_	_	B-Claim
276	differences	_	_	I-Claim
277	appear	_	_	I-Claim
278	to	_	_	I-Claim
279	play	_	_	I-Claim
280	a	_	_	I-Claim
281	role	_	_	I-Claim
282	in	_	_	I-Claim
283	the	_	_	I-Claim
284	early	_	_	I-Claim
285	,	_	_	I-Claim
286	but	_	_	I-Claim
287	not	_	_	I-Claim
288	late	_	_	I-Claim
289	,	_	_	I-Claim
290	response	_	_	I-Claim
291	to	_	_	I-Claim
292	a	_	_	I-Claim
293	multidisciplinary	_	_	I-Claim
294	intervention	_	_	I-Claim
295	to	_	_	I-Claim
296	improve	_	_	I-Claim
297	QOL	_	_	I-Claim
298	for	_	_	I-Claim
299	patients	_	_	I-Claim
300	with	_	_	I-Claim
301	advanced	_	_	I-Claim
302	cancer	_	_	I-Claim
303	,	_	_	I-Claim
304	suggesting	_	_	O
305	that	_	_	O
306	early	_	_	B-Claim
307	interventions	_	_	I-Claim
308	can	_	_	I-Claim
309	be	_	_	I-Claim
310	tailored	_	_	I-Claim
311	for	_	_	I-Claim
312	each	_	_	I-Claim
313	gender	_	_	I-Claim
314	.	_	_	I-Claim


0	Although	_	_	O
1	chemotherapy-induced	_	_	O
2	cognitive	_	_	O
3	impairment	_	_	O
4	is	_	_	O
5	common	_	_	O
6	among	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	patients	_	_	O
10	,	_	_	O
11	evidence	_	_	O
12	for	_	_	O
13	effective	_	_	O
14	interventions	_	_	O
15	addressing	_	_	O
16	cognitive	_	_	O
17	deficits	_	_	O
18	is	_	_	O
19	limited	_	_	O
20	.	_	_	O

21	This	_	_	O
22	randomized	_	_	O
23	controlled	_	_	O
24	trial	_	_	O
25	examined	_	_	O
26	the	_	_	O
27	feasibility	_	_	O
28	and	_	_	O
29	preliminary	_	_	O
30	efficacy	_	_	O
31	of	_	_	O
32	a	_	_	O
33	Tibetan	_	_	O
34	Sound	_	_	O
35	Meditation	_	_	O
36	(	_	_	O
37	TSM	_	_	O
38	)	_	_	O
39	program	_	_	O
40	to	_	_	O
41	improve	_	_	O
42	cognitive	_	_	O
43	function	_	_	O
44	and	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	in	_	_	O
49	breast	_	_	O
50	cancer	_	_	O
51	patients	_	_	O
52	.	_	_	O

53	Forty-seven	_	_	O
54	breast	_	_	O
55	cancer	_	_	O
56	patients	_	_	O
57	(	_	_	O
58	mean	_	_	O
59	age	_	_	O
60	56.3	_	_	O
61	years	_	_	O
62	)	_	_	O
63	,	_	_	O
64	who	_	_	O
65	were	_	_	O
66	staged	_	_	O
67	I-III	_	_	O
68	at	_	_	O
69	diagnosis	_	_	O
70	,	_	_	O
71	6-60	_	_	O
72	months	_	_	O
73	post-chemotherapy	_	_	O
74	,	_	_	O
75	and	_	_	O
76	reported	_	_	O
77	cognitive	_	_	O
78	impairment	_	_	O
79	at	_	_	O
80	study	_	_	O
81	entry	_	_	O
82	were	_	_	O
83	recruited	_	_	O
84	.	_	_	O

85	Participants	_	_	O
86	were	_	_	O
87	randomized	_	_	O
88	to	_	_	O
89	either	_	_	O
90	two	_	_	O
91	weekly	_	_	O
92	TSM	_	_	O
93	sessions	_	_	O
94	for	_	_	O
95	6	_	_	O
96	weeks	_	_	O
97	or	_	_	O
98	a	_	_	O
99	wait	_	_	O
100	list	_	_	O
101	control	_	_	O
102	group	_	_	O
103	.	_	_	O

104	Neuropsychological	_	_	O
105	assessments	_	_	O
106	were	_	_	O
107	completed	_	_	O
108	at	_	_	O
109	baseline	_	_	O
110	and	_	_	O
111	1	_	_	O
112	month	_	_	O
113	post-treatment	_	_	O
114	.	_	_	O

115	Self-report	_	_	O
116	measures	_	_	O
117	of	_	_	O
118	cognitive	_	_	O
119	function	_	_	O
120	(	_	_	O
121	Functional	_	_	O
122	Assessment	_	_	O
123	of	_	_	O
124	Cancer	_	_	O
125	Therapy	_	_	O
126	(	_	_	O
127	FACT	_	_	O
128	)	_	_	O
129	-Cog	_	_	O
130	)	_	_	O
131	,	_	_	O
132	quality	_	_	O
133	of	_	_	O
134	life	_	_	O
135	(	_	_	O
136	SF-36	_	_	O
137	)	_	_	O
138	,	_	_	O
139	depressive	_	_	O
140	symptoms	_	_	O
141	(	_	_	O
142	Center	_	_	O
143	for	_	_	O
144	Epidemiologic	_	_	O
145	Studies	_	_	O
146	Depression	_	_	O
147	Scale	_	_	O
148	)	_	_	O
149	,	_	_	O
150	sleep	_	_	O
151	disturbance	_	_	O
152	(	_	_	O
153	Pittsburgh	_	_	O
154	Sleep	_	_	O
155	Quality	_	_	O
156	Index	_	_	O
157	)	_	_	O
158	,	_	_	O
159	fatigue	_	_	O
160	(	_	_	O
161	Brief	_	_	O
162	Fatigue	_	_	O
163	Inventory	_	_	O
164	)	_	_	O
165	,	_	_	O
166	and	_	_	O
167	spirituality	_	_	O
168	(	_	_	O
169	FACT-Sp	_	_	O
170	)	_	_	O
171	were	_	_	O
172	completed	_	_	O
173	at	_	_	O
174	baseline	_	_	O
175	,	_	_	O
176	the	_	_	O
177	end	_	_	O
178	of	_	_	O
179	treatment	_	_	O
180	,	_	_	O
181	and	_	_	O
182	1	_	_	O
183	month	_	_	O
184	later	_	_	O
185	.	_	_	O

186	Relative	_	_	B-Premise
187	to	_	_	I-Premise
188	the	_	_	I-Premise
189	control	_	_	I-Premise
190	group	_	_	I-Premise
191	,	_	_	I-Premise
192	women	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	TSM	_	_	I-Premise
196	group	_	_	I-Premise
197	performed	_	_	I-Premise
198	better	_	_	I-Premise
199	on	_	_	I-Premise
200	the	_	_	I-Premise
201	verbal	_	_	I-Premise
202	memory	_	_	I-Premise
203	test	_	_	I-Premise
204	(	_	_	I-Premise
205	Rey	_	_	I-Premise
206	Auditory	_	_	I-Premise
207	Verbal	_	_	I-Premise
208	Learning	_	_	I-Premise
209	Test	_	_	I-Premise
210	trial	_	_	I-Premise
211	1	_	_	I-Premise
212	)	_	_	I-Premise
213	(	_	_	I-Premise
214	p	_	_	I-Premise
215	=	_	_	I-Premise
216	0.06	_	_	I-Premise
217	)	_	_	I-Premise
218	and	_	_	I-Premise
219	the	_	_	I-Premise
220	short-term	_	_	I-Premise
221	memory	_	_	I-Premise
222	and	_	_	I-Premise
223	processing	_	_	I-Premise
224	speed	_	_	I-Premise
225	task	_	_	I-Premise
226	(	_	_	I-Premise
227	Digit	_	_	I-Premise
228	Symbol	_	_	I-Premise
229	)	_	_	I-Premise
230	(	_	_	I-Premise
231	p	_	_	I-Premise
232	=	_	_	I-Premise
233	0.09	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	reported	_	_	I-Premise
237	improved	_	_	I-Premise
238	cognitive	_	_	I-Premise
239	function	_	_	I-Premise
240	(	_	_	I-Premise
241	p	_	_	I-Premise
242	=	_	_	I-Premise
243	0.06	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	cognitive	_	_	I-Premise
247	abilities	_	_	I-Premise
248	(	_	_	I-Premise
249	p	_	_	I-Premise
250	=	_	_	I-Premise
251	0.08	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	mental	_	_	I-Premise
255	health	_	_	I-Premise
256	(	_	_	I-Premise
257	p	_	_	I-Premise
258	=	_	_	I-Premise
259	0.04	_	_	I-Premise
260	)	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	spirituality	_	_	I-Premise
264	(	_	_	I-Premise
265	p	_	_	I-Premise
266	=	_	_	I-Premise
267	0.05	_	_	I-Premise
268	)	_	_	I-Premise
269	at	_	_	I-Premise
270	the	_	_	I-Premise
271	end	_	_	I-Premise
272	of	_	_	I-Premise
273	treatment	_	_	I-Premise
274	but	_	_	I-Premise
275	not	_	_	I-Premise
276	1	_	_	I-Premise
277	month	_	_	I-Premise
278	later	_	_	I-Premise
279	.	_	_	I-Premise

280	This	_	_	B-Claim
281	randomized	_	_	I-Claim
282	controlled	_	_	I-Claim
283	trial	_	_	I-Claim
284	revealed	_	_	I-Claim
285	that	_	_	I-Claim
286	TSM	_	_	I-Claim
287	program	_	_	I-Claim
288	appears	_	_	I-Claim
289	to	_	_	I-Claim
290	be	_	_	I-Claim
291	a	_	_	I-Claim
292	feasible	_	_	I-Claim
293	and	_	_	I-Claim
294	acceptable	_	_	I-Claim
295	intervention	_	_	I-Claim
296	and	_	_	I-Claim
297	may	_	_	I-Claim
298	be	_	_	I-Claim
299	associated	_	_	I-Claim
300	with	_	_	I-Claim
301	short-term	_	_	I-Claim
302	improvements	_	_	I-Claim
303	in	_	_	I-Claim
304	objective	_	_	I-Claim
305	and	_	_	I-Claim
306	subjective	_	_	I-Claim
307	cognitive	_	_	I-Claim
308	function	_	_	I-Claim
309	as	_	_	I-Claim
310	well	_	_	I-Claim
311	as	_	_	I-Claim
312	mental	_	_	I-Claim
313	health	_	_	I-Claim
314	and	_	_	I-Claim
315	spirituality	_	_	I-Claim
316	in	_	_	I-Claim
317	breast	_	_	I-Claim
318	cancer	_	_	I-Claim
319	patients	_	_	I-Claim
320	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	impact	_	_	O
4	of	_	_	O
5	advanced	_	_	O
6	practice	_	_	O
7	nurse	_	_	O
8	(	_	_	O
9	APN	_	_	O
10	)	_	_	O
11	-administered	_	_	O
12	low-level	_	_	O
13	laser	_	_	O
14	therapy	_	_	O
15	(	_	_	O
16	LLLT	_	_	O
17	)	_	_	O
18	as	_	_	O
19	both	_	_	O
20	a	_	_	O
21	stand-alone	_	_	O
22	and	_	_	O
23	complementary	_	_	O
24	treatment	_	_	O
25	for	_	_	O
26	arm	_	_	O
27	volume	_	_	O
28	,	_	_	O
29	symptoms	_	_	O
30	,	_	_	O
31	and	_	_	O
32	quality	_	_	O
33	of	_	_	O
34	life	_	_	O
35	(	_	_	O
36	QOL	_	_	O
37	)	_	_	O
38	in	_	_	O
39	women	_	_	O
40	with	_	_	O
41	breast	_	_	O
42	cancer-related	_	_	O
43	lymphedema	_	_	O
44	.	_	_	O

45	A	_	_	O
46	three-group	_	_	O
47	,	_	_	O
48	pilot	_	_	O
49	,	_	_	O
50	randomized	_	_	O
51	clinical	_	_	O
52	trial	_	_	O
53	.	_	_	O

54	A	_	_	O
55	private	_	_	O
56	rehabilitation	_	_	O
57	practice	_	_	O
58	in	_	_	O
59	the	_	_	O
60	southeastern	_	_	O
61	United	_	_	O
62	States	_	_	O
63	.	_	_	O

64	46	_	_	O
65	breast	_	_	O
66	cancer	_	_	O
67	survivors	_	_	O
68	with	_	_	O
69	treatment-related	_	_	O
70	lymphedema	_	_	O
71	.	_	_	O

72	Patients	_	_	O
73	were	_	_	O
74	screened	_	_	O
75	for	_	_	O
76	eligibility	_	_	O
77	and	_	_	O
78	then	_	_	O
79	randomized	_	_	O
80	to	_	_	O
81	either	_	_	O
82	manual	_	_	O
83	lymphatic	_	_	O
84	drainage	_	_	O
85	(	_	_	O
86	MLD	_	_	O
87	)	_	_	O
88	for	_	_	O
89	40	_	_	O
90	minutes	_	_	O
91	,	_	_	O
92	LLLT	_	_	O
93	for	_	_	O
94	20	_	_	O
95	minutes	_	_	O
96	,	_	_	O
97	or	_	_	O
98	20	_	_	O
99	minutes	_	_	O
100	of	_	_	O
101	MLD	_	_	O
102	followed	_	_	O
103	by	_	_	O
104	20	_	_	O
105	minutes	_	_	O
106	of	_	_	O
107	LLLT	_	_	O
108	.	_	_	O

109	Compression	_	_	O
110	bandaging	_	_	O
111	was	_	_	O
112	applied	_	_	O
113	after	_	_	O
114	each	_	_	O
115	treatment	_	_	O
116	.	_	_	O

117	Data	_	_	O
118	were	_	_	O
119	collected	_	_	O
120	pretreatment	_	_	O
121	,	_	_	O
122	daily	_	_	O
123	,	_	_	O
124	weekly	_	_	O
125	,	_	_	O
126	and	_	_	O
127	at	_	_	O
128	the	_	_	O
129	end	_	_	O
130	of	_	_	O
131	treatment	_	_	O
132	.	_	_	O

133	Independent	_	_	O
134	variables	_	_	O
135	consisted	_	_	O
136	of	_	_	O
137	three	_	_	O
138	types	_	_	O
139	of	_	_	O
140	APN-administered	_	_	O
141	lymphedema	_	_	O
142	treatment	_	_	O
143	.	_	_	O

144	Outcome	_	_	O
145	variables	_	_	O
146	included	_	_	O
147	limb	_	_	O
148	volume	_	_	O
149	,	_	_	O
150	extracellular	_	_	O
151	fluid	_	_	O
152	,	_	_	O
153	psychological	_	_	O
154	and	_	_	O
155	physical	_	_	O
156	symptoms	_	_	O
157	,	_	_	O
158	and	_	_	O
159	QOL	_	_	O
160	.	_	_	O

161	No	_	_	B-Premise
162	statistically	_	_	I-Premise
163	significant	_	_	I-Premise
164	between-group	_	_	I-Premise
165	differences	_	_	I-Premise
166	were	_	_	I-Premise
167	found	_	_	I-Premise
168	in	_	_	I-Premise
169	volume	_	_	I-Premise
170	reduction	_	_	I-Premise
171	;	_	_	I-Premise
172	however	_	_	B-Premise
173	,	_	_	I-Premise
174	all	_	_	I-Premise
175	groups	_	_	I-Premise
176	had	_	_	I-Premise
177	clinically	_	_	I-Premise
178	and	_	_	I-Premise
179	statistically	_	_	I-Premise
180	significant	_	_	I-Premise
181	reduction	_	_	I-Premise
182	in	_	_	I-Premise
183	volume	_	_	I-Premise
184	.	_	_	I-Premise

185	No	_	_	B-Premise
186	group	_	_	I-Premise
187	differences	_	_	I-Premise
188	were	_	_	I-Premise
189	noted	_	_	I-Premise
190	in	_	_	I-Premise
191	psychological	_	_	I-Premise
192	and	_	_	I-Premise
193	physical	_	_	I-Premise
194	symptoms	_	_	I-Premise
195	or	_	_	I-Premise
196	QOL	_	_	I-Premise
197	;	_	_	I-Premise
198	however	_	_	B-Premise
199	,	_	_	I-Premise
200	treatment-related	_	_	I-Premise
201	improvements	_	_	I-Premise
202	were	_	_	I-Premise
203	noted	_	_	I-Premise
204	in	_	_	I-Premise
205	symptom	_	_	I-Premise
206	burden	_	_	I-Premise
207	within	_	_	I-Premise
208	all	_	_	I-Premise
209	groups	_	_	I-Premise
210	.	_	_	I-Premise

211	Skin	_	_	B-Premise
212	improvement	_	_	I-Premise
213	was	_	_	I-Premise
214	noted	_	_	I-Premise
215	in	_	_	I-Premise
216	each	_	_	I-Premise
217	group	_	_	I-Premise
218	that	_	_	I-Premise
219	received	_	_	I-Premise
220	LLLT	_	_	I-Premise
221	.	_	_	I-Premise

222	LLLT	_	_	B-Claim
223	with	_	_	I-Claim
224	bandaging	_	_	I-Claim
225	may	_	_	I-Claim
226	offer	_	_	I-Claim
227	a	_	_	I-Claim
228	time-saving	_	_	I-Claim
229	therapeutic	_	_	I-Claim
230	option	_	_	I-Claim
231	to	_	_	I-Claim
232	conventional	_	_	I-Claim
233	MLD	_	_	I-Claim
234	.	_	_	I-Claim

235	Alternatively	_	_	O
236	,	_	_	O
237	compression	_	_	B-Claim
238	bandaging	_	_	I-Claim
239	alone	_	_	I-Claim
240	could	_	_	I-Claim
241	account	_	_	I-Claim
242	for	_	_	I-Claim
243	the	_	_	I-Claim
244	demonstrated	_	_	I-Claim
245	volume	_	_	I-Claim
246	reduction	_	_	I-Claim
247	.	_	_	I-Claim

248	APNs	_	_	B-Claim
249	can	_	_	I-Claim
250	effectively	_	_	I-Claim
251	treat	_	_	I-Claim
252	lymphedema	_	_	I-Claim
253	.	_	_	I-Claim

254	APNs	_	_	O
255	in	_	_	O
256	private	_	_	O
257	healthcare	_	_	O
258	practices	_	_	O
259	can	_	_	O
260	serve	_	_	O
261	as	_	_	O
262	valuable	_	_	O
263	research	_	_	O
264	collaborators	_	_	O
265	.	_	_	O

266	Lasers	_	_	B-Claim
267	may	_	_	I-Claim
268	provide	_	_	I-Claim
269	effective	_	_	I-Claim
270	,	_	_	I-Claim
271	less	_	_	I-Claim
272	burdensome	_	_	I-Claim
273	treatment	_	_	I-Claim
274	for	_	_	I-Claim
275	lymphedema	_	_	I-Claim
276	.	_	_	I-Claim

277	APNs	_	_	B-Claim
278	with	_	_	I-Claim
279	lymphedema	_	_	I-Claim
280	certification	_	_	I-Claim
281	can	_	_	I-Claim
282	effectively	_	_	I-Claim
283	treat	_	_	I-Claim
284	this	_	_	I-Claim
285	patient	_	_	I-Claim
286	population	_	_	I-Claim
287	with	_	_	I-Claim
288	the	_	_	I-Claim
289	use	_	_	I-Claim
290	of	_	_	I-Claim
291	LLLT	_	_	I-Claim
292	.	_	_	I-Claim

293	In	_	_	O
294	addition	_	_	O
295	,	_	_	O
296	bioelectrical	_	_	B-Claim
297	impedance	_	_	I-Claim
298	and	_	_	I-Claim
299	tape	_	_	I-Claim
300	measurements	_	_	I-Claim
301	can	_	_	I-Claim
302	be	_	_	I-Claim
303	used	_	_	I-Claim
304	to	_	_	I-Claim
305	assess	_	_	I-Claim
306	lymphedema	_	_	I-Claim
307	.	_	_	I-Claim


0	Analgesia	_	_	B-Claim
1	and	_	_	I-Claim
2	early	_	_	I-Claim
3	quality	_	_	I-Claim
4	of	_	_	I-Claim
5	recovery	_	_	I-Claim
6	may	_	_	I-Claim
7	be	_	_	I-Claim
8	improved	_	_	I-Claim
9	by	_	_	I-Claim
10	epidural	_	_	I-Claim
11	analgesia	_	_	I-Claim
12	.	_	_	I-Claim

13	We	_	_	O
14	aimed	_	_	O
15	to	_	_	O
16	assess	_	_	O
17	the	_	_	O
18	effect	_	_	O
19	of	_	_	O
20	receiving	_	_	O
21	epidural	_	_	O
22	analgesia	_	_	O
23	on	_	_	O
24	surgical	_	_	O
25	adverse	_	_	O
26	events	_	_	O
27	and	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	after	_	_	O
32	laparotomy	_	_	O
33	for	_	_	O
34	endometrial	_	_	O
35	cancer	_	_	O
36	.	_	_	O

37	Patients	_	_	O
38	were	_	_	O
39	enrolled	_	_	O
40	in	_	_	O
41	an	_	_	O
42	international	_	_	O
43	,	_	_	O
44	multicentre	_	_	O
45	,	_	_	O
46	prospective	_	_	O
47	randomised	_	_	O
48	trial	_	_	O
49	of	_	_	O
50	outcomes	_	_	O
51	for	_	_	O
52	laparoscopic	_	_	O
53	versus	_	_	O
54	open	_	_	O
55	surgical	_	_	O
56	treatment	_	_	O
57	for	_	_	O
58	the	_	_	O
59	management	_	_	O
60	of	_	_	O
61	apparent	_	_	O
62	stage	_	_	O
63	I	_	_	O
64	endometrial	_	_	O
65	cancer	_	_	O
66	(	_	_	O
67	LACE	_	_	O
68	trial	_	_	O
69	)	_	_	O
70	.	_	_	O

71	The	_	_	O
72	current	_	_	O
73	analysis	_	_	O
74	focussed	_	_	O
75	on	_	_	O
76	patients	_	_	O
77	who	_	_	O
78	received	_	_	O
79	an	_	_	O
80	open	_	_	O
81	abdominal	_	_	O
82	hysterectomy	_	_	O
83	via	_	_	O
84	vertical	_	_	O
85	midline	_	_	O
86	incision	_	_	O
87	only	_	_	O
88	(	_	_	O
89	n=257	_	_	O
90	)	_	_	O
91	,	_	_	O
92	examining	_	_	O
93	outcomes	_	_	O
94	in	_	_	O
95	patients	_	_	O
96	who	_	_	O
97	did	_	_	O
98	(	_	_	O
99	n=108	_	_	O
100	)	_	_	O
101	and	_	_	O
102	did	_	_	O
103	not	_	_	O
104	(	_	_	O
105	n=149	_	_	O
106	)	_	_	O
107	receive	_	_	O
108	epidural	_	_	O
109	analgesia	_	_	O
110	.	_	_	O

111	Baseline	_	_	O
112	characteristics	_	_	O
113	were	_	_	O
114	comparable	_	_	O
115	between	_	_	O
116	patients	_	_	O
117	with	_	_	O
118	or	_	_	O
119	without	_	_	O
120	epidural	_	_	O
121	analgesia	_	_	O
122	.	_	_	O

123	More	_	_	B-Premise
124	patients	_	_	I-Premise
125	without	_	_	I-Premise
126	epidural	_	_	I-Premise
127	(	_	_	I-Premise
128	34	_	_	I-Premise
129	%	_	_	I-Premise
130	)	_	_	I-Premise
131	ceased	_	_	I-Premise
132	opioid	_	_	I-Premise
133	analgesia	_	_	I-Premise
134	3-5	_	_	I-Premise
135	days	_	_	I-Premise
136	after	_	_	I-Premise
137	surgery	_	_	I-Premise
138	compared	_	_	I-Premise
139	to	_	_	I-Premise
140	patients	_	_	I-Premise
141	who	_	_	I-Premise
142	had	_	_	I-Premise
143	an	_	_	I-Premise
144	epidural	_	_	I-Premise
145	(	_	_	I-Premise
146	7	_	_	I-Premise
147	%	_	_	I-Premise
148	;	_	_	I-Premise
149	p	_	_	I-Premise
150	<	_	_	I-Premise
151	0.01	_	_	I-Premise
152	)	_	_	I-Premise
153	.	_	_	I-Premise

154	Postoperative	_	_	B-Premise
155	complications	_	_	I-Premise
156	(	_	_	I-Premise
157	any	_	_	I-Premise
158	grade	_	_	I-Premise
159	)	_	_	I-Premise
160	occurred	_	_	I-Premise
161	in	_	_	I-Premise
162	86	_	_	I-Premise
163	%	_	_	I-Premise
164	of	_	_	I-Premise
165	patients	_	_	I-Premise
166	with	_	_	I-Premise
167	and	_	_	I-Premise
168	in	_	_	I-Premise
169	66	_	_	I-Premise
170	%	_	_	I-Premise
171	of	_	_	I-Premise
172	patients	_	_	I-Premise
173	without	_	_	I-Premise
174	an	_	_	I-Premise
175	epidural	_	_	I-Premise
176	(	_	_	I-Premise
177	p	_	_	I-Premise
178	<	_	_	I-Premise
179	0.01	_	_	I-Premise
180	)	_	_	I-Premise
181	but	_	_	O
182	there	_	_	B-Premise
183	was	_	_	I-Premise
184	no	_	_	I-Premise
185	difference	_	_	I-Premise
186	in	_	_	I-Premise
187	serious	_	_	I-Premise
188	adverse	_	_	I-Premise
189	events	_	_	I-Premise
190	(	_	_	I-Premise
191	p=0.19	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	Epidural	_	_	B-Premise
195	analgesia	_	_	I-Premise
196	was	_	_	I-Premise
197	associated	_	_	I-Premise
198	with	_	_	I-Premise
199	increased	_	_	I-Premise
200	length	_	_	I-Premise
201	of	_	_	I-Premise
202	stay	_	_	I-Premise
203	(	_	_	I-Premise
204	up	_	_	I-Premise
205	to	_	_	I-Premise
206	48	_	_	I-Premise
207	days	_	_	I-Premise
208	compared	_	_	I-Premise
209	to	_	_	I-Premise
210	up	_	_	I-Premise
211	to	_	_	I-Premise
212	34	_	_	I-Premise
213	days	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	non-epidural	_	_	I-Premise
217	group	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	There	_	_	B-Claim
221	was	_	_	I-Claim
222	no	_	_	I-Claim
223	difference	_	_	I-Claim
224	in	_	_	I-Claim
225	postoperative	_	_	I-Claim
226	quality	_	_	I-Claim
227	of	_	_	I-Claim
228	life	_	_	I-Claim
229	up	_	_	I-Claim
230	to	_	_	I-Claim
231	six	_	_	I-Claim
232	months	_	_	I-Claim
233	after	_	_	I-Claim
234	surgery	_	_	I-Claim
235	.	_	_	I-Claim

236	Epidural	_	_	B-Claim
237	analgesia	_	_	I-Claim
238	was	_	_	I-Claim
239	associated	_	_	I-Claim
240	with	_	_	I-Claim
241	an	_	_	I-Claim
242	increase	_	_	I-Claim
243	in	_	_	I-Claim
244	any	_	_	I-Claim
245	,	_	_	I-Claim
246	but	_	_	I-Claim
247	not	_	_	I-Claim
248	serious	_	_	I-Claim
249	,	_	_	I-Claim
250	postoperative	_	_	I-Claim
251	complications	_	_	I-Claim
252	and	_	_	I-Claim
253	length	_	_	I-Claim
254	of	_	_	I-Claim
255	stay	_	_	I-Claim
256	after	_	_	I-Claim
257	abdominal	_	_	I-Claim
258	hysterectomy	_	_	I-Claim
259	.	_	_	I-Claim

260	Randomised	_	_	B-Claim
261	controlled	_	_	I-Claim
262	trials	_	_	I-Claim
263	are	_	_	I-Claim
264	needed	_	_	I-Claim
265	to	_	_	I-Claim
266	examine	_	_	I-Claim
267	the	_	_	I-Claim
268	effect	_	_	I-Claim
269	of	_	_	I-Claim
270	epidural	_	_	I-Claim
271	analgesia	_	_	I-Claim
272	on	_	_	I-Claim
273	surgical	_	_	I-Claim
274	adverse	_	_	I-Claim
275	events	_	_	I-Claim
276	,	_	_	I-Claim
277	especially	_	_	O
278	as	_	_	O
279	the	_	_	B-Claim
280	present	_	_	I-Claim
281	data	_	_	I-Claim
282	do	_	_	I-Claim
283	not	_	_	I-Claim
284	support	_	_	I-Claim
285	a	_	_	I-Claim
286	quality	_	_	I-Claim
287	of	_	_	I-Claim
288	life	_	_	I-Claim
289	benefit	_	_	I-Claim
290	with	_	_	I-Claim
291	epidural	_	_	I-Claim
292	analgesia	_	_	I-Claim
293	.	_	_	I-Claim


0	Non-randomised	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	suggested	_	_	O
4	that	_	_	O
5	the	_	_	B-Claim
6	postoperative	_	_	I-Claim
7	complications	_	_	I-Claim
8	of	_	_	I-Claim
9	(	_	_	I-Claim
10	Campos	_	_	I-Claim
11	LS	_	_	I-Claim
12	,	_	_	I-Claim
13	Limberger	_	_	I-Claim
14	LF	_	_	I-Claim
15	,	_	_	I-Claim
16	Stein	_	_	I-Claim
17	AT	_	_	I-Claim
18	,	_	_	I-Claim
19	Kalil	_	_	I-Claim
20	AN	_	_	I-Claim
21	)	_	_	I-Claim
22	laparoscopic	_	_	I-Claim
23	radical	_	_	I-Claim
24	hysterectomy	_	_	I-Claim
25	are	_	_	I-Claim
26	similar	_	_	I-Claim
27	to	_	_	I-Claim
28	those	_	_	I-Claim
29	in	_	_	I-Claim
30	abdominal	_	_	I-Claim
31	radical	_	_	I-Claim
32	hysterectomy	_	_	I-Claim
33	.	_	_	I-Claim

34	However	_	_	O
35	,	_	_	O
36	no	_	_	O
37	study	_	_	O
38	evaluating	_	_	O
39	postoperative	_	_	O
40	pain	_	_	O
41	comparing	_	_	O
42	both	_	_	O
43	techniques	_	_	O
44	has	_	_	O
45	been	_	_	O
46	published	_	_	O
47	thus	_	_	O
48	far	_	_	O
49	.	_	_	O

50	Our	_	_	O
51	objective	_	_	O
52	was	_	_	O
53	to	_	_	O
54	compare	_	_	O
55	pain	_	_	O
56	intensity	_	_	O
57	and	_	_	O
58	other	_	_	O
59	perioperative	_	_	O
60	outcomes	_	_	O
61	between	_	_	O
62	laparoscopic	_	_	O
63	radical	_	_	O
64	hysterectomy	_	_	O
65	(	_	_	O
66	LRH	_	_	O
67	)	_	_	O
68	and	_	_	O
69	abdominal	_	_	O
70	radical	_	_	O
71	hysterectomy	_	_	O
72	(	_	_	O
73	ARH	_	_	O
74	)	_	_	O
75	in	_	_	O
76	early	_	_	O
77	cervical	_	_	O
78	cancer	_	_	O
79	.	_	_	O

80	This	_	_	O
81	single	_	_	O
82	centre	_	_	O
83	,	_	_	O
84	randomised	_	_	O
85	,	_	_	O
86	controlled	_	_	O
87	trial	_	_	O
88	enrolled	_	_	O
89	30	_	_	O
90	cervical	_	_	O
91	cancer	_	_	O
92	patients	_	_	O
93	who	_	_	O
94	were	_	_	O
95	clinically	_	_	O
96	staged	_	_	O
97	IA2	_	_	O
98	with	_	_	O
99	lymph	_	_	O
100	vascular	_	_	O
101	invasion	_	_	O
102	and	_	_	O
103	IB	_	_	O
104	according	_	_	O
105	to	_	_	O
106	the	_	_	O
107	FIGO	_	_	O
108	(	_	_	O
109	International	_	_	O
110	Federation	_	_	O
111	of	_	_	O
112	Gynaecology	_	_	O
113	and	_	_	O
114	Obstetrics	_	_	O
115	)	_	_	O
116	classification	_	_	O
117	,	_	_	O
118	and	_	_	O
119	underwent	_	_	O
120	LRH	_	_	O
121	or	_	_	O
122	ARH	_	_	O
123	between	_	_	O
124	late	_	_	O
125	1999	_	_	O
126	and	_	_	O
127	early	_	_	O
128	2004	_	_	O
129	.	_	_	O

130	Postoperative	_	_	O
131	pain	_	_	O
132	,	_	_	O
133	as	_	_	O
134	measured	_	_	O
135	by	_	_	O
136	a	_	_	O
137	10-point	_	_	O
138	numerical	_	_	O
139	rate	_	_	O
140	scale	_	_	O
141	,	_	_	O
142	was	_	_	O
143	considered	_	_	O
144	the	_	_	O
145	primary	_	_	O
146	endpoint	_	_	O
147	.	_	_	O

148	Postoperative	_	_	O
149	pain	_	_	O
150	was	_	_	O
151	assessed	_	_	O
152	every	_	_	O
153	six	_	_	O
154	hours	_	_	O
155	during	_	_	O
156	a	_	_	O
157	patient	_	_	O
158	's	_	_	O
159	usual	_	_	O
160	postoperative	_	_	O
161	care	_	_	O
162	.	_	_	O

163	Perioperative	_	_	O
164	outcomes	_	_	O
165	were	_	_	O
166	also	_	_	O
167	registered	_	_	O
168	.	_	_	O

169	Both	_	_	O
170	surgical	_	_	O
171	techniques	_	_	O
172	were	_	_	O
173	executed	_	_	O
174	by	_	_	O
175	the	_	_	O
176	same	_	_	O
177	surgical	_	_	O
178	team	_	_	O
179	.	_	_	O

180	Secondary	_	_	O
181	outcomes	_	_	O
182	included	_	_	O
183	intraoperative	_	_	O
184	and	_	_	O
185	other	_	_	O
186	postoperative	_	_	O
187	surgicopathological	_	_	O
188	factors	_	_	O
189	and	_	_	O
190	5-year	_	_	O
191	survival	_	_	O
192	rates	_	_	O
193	.	_	_	O

194	IA2	_	_	O
195	patients	_	_	O
196	with	_	_	O
197	lymphatic	_	_	O
198	vascular	_	_	O
199	space	_	_	O
200	invasion	_	_	O
201	and	_	_	O
202	IB	_	_	O
203	cervical	_	_	O
204	cancer	_	_	O
205	patients	_	_	O
206	were	_	_	O
207	randomised	_	_	O
208	to	_	_	O
209	either	_	_	O
210	the	_	_	O
211	LRH	_	_	O
212	group	_	_	O
213	(	_	_	O
214	16	_	_	O
215	patients	_	_	O
216	)	_	_	O
217	or	_	_	O
218	the	_	_	O
219	ARH	_	_	O
220	group	_	_	O
221	(	_	_	O
222	14	_	_	O
223	patients	_	_	O
224	)	_	_	O
225	.	_	_	O

226	Four	_	_	B-Premise
227	patients	_	_	I-Premise
228	(	_	_	I-Premise
229	25	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	LRH	_	_	I-Premise
235	group	_	_	I-Premise
236	and	_	_	I-Premise
237	5	_	_	I-Premise
238	patients	_	_	I-Premise
239	(	_	_	I-Premise
240	36	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	ARH	_	_	I-Premise
246	group	_	_	I-Premise
247	presented	_	_	I-Premise
248	with	_	_	I-Premise
249	transoperative	_	_	I-Premise
250	or	_	_	I-Premise
251	serious	_	_	I-Premise
252	postoperative	_	_	I-Premise
253	complications	_	_	I-Premise
254	.	_	_	I-Premise

255	All	_	_	B-Premise
256	of	_	_	I-Premise
257	the	_	_	I-Premise
258	transoperative	_	_	I-Premise
259	complications	_	_	I-Premise
260	occurred	_	_	I-Premise
261	in	_	_	I-Premise
262	the	_	_	I-Premise
263	LRH	_	_	I-Premise
264	group	_	_	I-Premise
265	.	_	_	I-Premise

266	The	_	_	B-Premise
267	relative	_	_	I-Premise
268	risk	_	_	I-Premise
269	of	_	_	I-Premise
270	presenting	_	_	I-Premise
271	with	_	_	I-Premise
272	complications	_	_	I-Premise
273	was	_	_	I-Premise
274	0.70	_	_	I-Premise
275	;	_	_	I-Premise
276	CI	_	_	I-Premise
277	95	_	_	I-Premise
278	%	_	_	I-Premise
279	(	_	_	I-Premise
280	0.23-2.11	_	_	I-Premise
281	)	_	_	I-Premise
282	;	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	0.694	_	_	I-Premise
286	.	_	_	I-Premise

287	LRH	_	_	B-Premise
288	group	_	_	I-Premise
289	mean	_	_	I-Premise
290	pain	_	_	I-Premise
291	score	_	_	I-Premise
292	was	_	_	I-Premise
293	significantly	_	_	I-Premise
294	lower	_	_	I-Premise
295	than	_	_	I-Premise
296	ARH	_	_	I-Premise
297	after	_	_	I-Premise
298	36	_	_	I-Premise
299	h	_	_	I-Premise
300	of	_	_	I-Premise
301	observation	_	_	I-Premise
302	(	_	_	I-Premise
303	P	_	_	I-Premise
304	=	_	_	I-Premise
305	0.044	_	_	I-Premise
306	;	_	_	I-Premise
307	mean	_	_	I-Premise
308	difference	_	_	I-Premise
309	score	_	_	I-Premise
310	:	_	_	I-Premise
311	1.42	_	_	I-Premise
312	;	_	_	I-Premise
313	95	_	_	I-Premise
314	%	_	_	I-Premise
315	CI	_	_	I-Premise
316	:	_	_	I-Premise
317	0.04-2.80	_	_	I-Premise
318	)	_	_	I-Premise
319	.	_	_	I-Premise

320	The	_	_	O
321	survival	_	_	O
322	results	_	_	O
323	will	_	_	O
324	be	_	_	O
325	published	_	_	O
326	elsewhere	_	_	O
327	.	_	_	O

328	LRH	_	_	B-Claim
329	provided	_	_	I-Claim
330	lower	_	_	I-Claim
331	pain	_	_	I-Claim
332	scores	_	_	I-Claim
333	after	_	_	I-Claim
334	36	_	_	I-Claim
335	h	_	_	I-Claim
336	of	_	_	I-Claim
337	observation	_	_	I-Claim
338	in	_	_	I-Claim
339	this	_	_	I-Claim
340	series	_	_	I-Claim
341	.	_	_	I-Claim

342	The	_	_	B-Claim
343	perioperative	_	_	I-Claim
344	and	_	_	I-Claim
345	serious	_	_	I-Claim
346	postoperative	_	_	I-Claim
347	complications	_	_	I-Claim
348	ratios	_	_	I-Claim
349	were	_	_	I-Claim
350	comparable	_	_	I-Claim
351	between	_	_	I-Claim
352	the	_	_	I-Claim
353	groups	_	_	I-Claim
354	.	_	_	I-Claim


0	Combination	_	_	O
1	therapy	_	_	O
2	has	_	_	O
3	been	_	_	O
4	recommended	_	_	O
5	for	_	_	O
6	the	_	_	O
7	treatment	_	_	O
8	of	_	_	O
9	patients	_	_	O
10	harboring	_	_	O
11	multiple	_	_	O
12	drug-resistant	_	_	O
13	hepatitis	_	_	O
14	B	_	_	O
15	virus	_	_	O
16	(	_	_	O
17	HBV	_	_	O
18	)	_	_	O
19	.	_	_	O

20	However	_	_	O
21	,	_	_	O
22	we	_	_	O
23	recently	_	_	O
24	demonstrated	_	_	O
25	that	_	_	O
26	monotherapy	_	_	O
27	with	_	_	O
28	tenofovir	_	_	O
29	disoproxil	_	_	O
30	fumarate	_	_	O
31	(	_	_	O
32	TDF	_	_	O
33	)	_	_	O
34	for	_	_	O
35	48	_	_	O
36	weeks	_	_	O
37	displayed	_	_	O
38	noninferior	_	_	O
39	efficacy	_	_	O
40	to	_	_	O
41	TDF	_	_	O
42	plus	_	_	O
43	entecavir	_	_	O
44	(	_	_	O
45	ETV	_	_	O
46	)	_	_	O
47	combination	_	_	O
48	therapy	_	_	O
49	in	_	_	O
50	patients	_	_	O
51	with	_	_	O
52	HBV	_	_	O
53	resistant	_	_	O
54	to	_	_	O
55	multiple	_	_	O
56	drugs	_	_	O
57	,	_	_	O
58	including	_	_	O
59	ETV	_	_	O
60	and	_	_	O
61	adefovir	_	_	O
62	.	_	_	O

63	Nonetheless	_	_	O
64	,	_	_	O
65	whether	_	_	O
66	prolonged	_	_	O
67	TDF	_	_	O
68	monotherapy	_	_	O
69	would	_	_	O
70	be	_	_	O
71	safe	_	_	O
72	and	_	_	O
73	increase	_	_	O
74	the	_	_	O
75	virologic	_	_	O
76	response	_	_	O
77	rate	_	_	O
78	in	_	_	O
79	these	_	_	O
80	patients	_	_	O
81	was	_	_	O
82	unclear	_	_	O
83	.	_	_	O

84	Among	_	_	O
85	192	_	_	O
86	patients	_	_	O
87	with	_	_	O
88	HBV-resistance	_	_	O
89	mutations	_	_	O
90	to	_	_	O
91	ETV	_	_	O
92	and/or	_	_	O
93	adefovir	_	_	O
94	,	_	_	O
95	who	_	_	O
96	were	_	_	O
97	randomized	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	TDF	_	_	O
101	monotherapy	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	95	_	_	O
106	)	_	_	O
107	or	_	_	O
108	TDF/ETV	_	_	O
109	combination	_	_	O
110	therapy	_	_	O
111	(	_	_	O
112	n	_	_	O
113	=	_	_	O
114	97	_	_	O
115	)	_	_	O
116	for	_	_	O
117	48	_	_	O
118	weeks	_	_	O
119	,	_	_	O
120	189	_	_	O
121	agreed	_	_	O
122	to	_	_	O
123	continue	_	_	O
124	TDF	_	_	O
125	monotherapy	_	_	O
126	(	_	_	O
127	TDF-TDF	_	_	O
128	group	_	_	O
129	)	_	_	O
130	or	_	_	O
131	to	_	_	O
132	switch	_	_	O
133	to	_	_	O
134	TDF	_	_	O
135	monotherapy	_	_	O
136	(	_	_	O
137	TDF/ETV-TDF	_	_	O
138	group	_	_	O
139	)	_	_	O
140	and	_	_	O
141	180	_	_	O
142	(	_	_	O
143	93.8	_	_	O
144	%	_	_	O
145	)	_	_	O
146	completed	_	_	O
147	the	_	_	O
148	144-week	_	_	O
149	study	_	_	O
150	.	_	_	O

151	Serum	_	_	B-Premise
152	HBV	_	_	I-Premise
153	DNA	_	_	I-Premise
154	<	_	_	I-Premise
155	15	_	_	I-Premise
156	IU/mL	_	_	I-Premise
157	at	_	_	I-Premise
158	week	_	_	I-Premise
159	48	_	_	I-Premise
160	,	_	_	I-Premise
161	the	_	_	I-Premise
162	primary	_	_	I-Premise
163	efficacy	_	_	I-Premise
164	endpoint	_	_	I-Premise
165	,	_	_	I-Premise
166	was	_	_	I-Premise
167	achieved	_	_	I-Premise
168	in	_	_	I-Premise
169	66.3	_	_	I-Premise
170	%	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	TDF-TDF	_	_	I-Premise
174	group	_	_	I-Premise
175	and	_	_	I-Premise
176	68.0	_	_	I-Premise
177	%	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	TDF/ETV-TDF	_	_	I-Premise
181	group	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	=	_	_	I-Premise
185	0.80	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	At	_	_	B-Premise
189	week	_	_	I-Premise
190	144	_	_	I-Premise
191	,	_	_	I-Premise
192	the	_	_	I-Premise
193	proportion	_	_	I-Premise
194	with	_	_	I-Premise
195	HBV	_	_	I-Premise
196	DNA	_	_	I-Premise
197	<	_	_	I-Premise
198	15	_	_	I-Premise
199	IU/mL	_	_	I-Premise
200	increased	_	_	I-Premise
201	to	_	_	I-Premise
202	74.5	_	_	I-Premise
203	%	_	_	I-Premise
204	,	_	_	I-Premise
205	which	_	_	I-Premise
206	was	_	_	I-Premise
207	significantly	_	_	I-Premise
208	higher	_	_	I-Premise
209	compared	_	_	I-Premise
210	with	_	_	I-Premise
211	that	_	_	I-Premise
212	at	_	_	I-Premise
213	week	_	_	I-Premise
214	48	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	0.03	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	without	_	_	I-Premise
222	a	_	_	I-Premise
223	significant	_	_	I-Premise
224	difference	_	_	I-Premise
225	between	_	_	I-Premise
226	groups	_	_	I-Premise
227	(	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	0.46	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	By	_	_	B-Premise
234	on-treatment	_	_	I-Premise
235	analysis	_	_	I-Premise
236	,	_	_	I-Premise
237	a	_	_	I-Premise
238	total	_	_	I-Premise
239	of	_	_	I-Premise
240	79.4	_	_	I-Premise
241	%	_	_	I-Premise
242	had	_	_	I-Premise
243	HBV	_	_	I-Premise
244	DNA	_	_	I-Premise
245	<	_	_	I-Premise
246	15	_	_	I-Premise
247	IU/mL	_	_	I-Premise
248	at	_	_	I-Premise
249	week	_	_	I-Premise
250	144	_	_	I-Premise
251	.	_	_	I-Premise

252	Transient	_	_	B-Premise
253	virologic	_	_	I-Premise
254	breakthrough	_	_	I-Premise
255	occurred	_	_	I-Premise
256	in	_	_	I-Premise
257	6	_	_	I-Premise
258	patients	_	_	I-Premise
259	,	_	_	I-Premise
260	which	_	_	I-Premise
261	was	_	_	I-Premise
262	due	_	_	I-Premise
263	to	_	_	I-Premise
264	poor	_	_	I-Premise
265	drug	_	_	I-Premise
266	adherence	_	_	I-Premise
267	.	_	_	I-Premise

268	At	_	_	B-Premise
269	week	_	_	I-Premise
270	144	_	_	I-Premise
271	,	_	_	I-Premise
272	19	_	_	I-Premise
273	patients	_	_	I-Premise
274	who	_	_	I-Premise
275	had	_	_	I-Premise
276	HBV	_	_	I-Premise
277	DNA	_	_	I-Premise
278	levels	_	_	I-Premise
279	>	_	_	I-Premise
280	60	_	_	I-Premise
281	IU/mL	_	_	I-Premise
282	qualified	_	_	I-Premise
283	for	_	_	I-Premise
284	genotypic	_	_	I-Premise
285	resistance	_	_	I-Premise
286	analysis	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	6	_	_	I-Premise
290	retained	_	_	I-Premise
291	some	_	_	I-Premise
292	of	_	_	I-Premise
293	their	_	_	I-Premise
294	baseline	_	_	I-Premise
295	resistance	_	_	I-Premise
296	mutations	_	_	I-Premise
297	of	_	_	I-Premise
298	HBV	_	_	I-Premise
299	.	_	_	I-Premise

300	No	_	_	B-Premise
301	patients	_	_	I-Premise
302	developed	_	_	I-Premise
303	additional	_	_	I-Premise
304	resistance	_	_	I-Premise
305	mutations	_	_	I-Premise
306	throughout	_	_	I-Premise
307	the	_	_	I-Premise
308	study	_	_	I-Premise
309	period	_	_	I-Premise
310	.	_	_	I-Premise

311	TDF	_	_	B-Claim
312	monotherapy	_	_	I-Claim
313	was	_	_	I-Claim
314	efficacious	_	_	I-Claim
315	and	_	_	I-Claim
316	safe	_	_	I-Claim
317	for	_	_	I-Claim
318	up	_	_	I-Claim
319	to	_	_	I-Claim
320	144	_	_	I-Claim
321	weeks	_	_	I-Claim
322	,	_	_	I-Claim
323	providing	_	_	I-Claim
324	an	_	_	I-Claim
325	increasing	_	_	I-Claim
326	rate	_	_	I-Claim
327	of	_	_	I-Claim
328	virologic	_	_	I-Claim
329	response	_	_	I-Claim
330	in	_	_	I-Claim
331	heavily	_	_	I-Claim
332	pretreated	_	_	I-Claim
333	patients	_	_	I-Claim
334	with	_	_	I-Claim
335	multidrug-resistant	_	_	I-Claim
336	HBV	_	_	I-Claim
337	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	additive	_	_	O
4	effects	_	_	O
5	and	_	_	O
6	safety	_	_	O
7	of	_	_	O
8	1	_	_	O
9	%	_	_	O
10	brinzolamide/0.5	_	_	O
11	%	_	_	O
12	timolol	_	_	O
13	fixed	_	_	O
14	combination	_	_	O
15	(	_	_	O
16	BTFC	_	_	O
17	)	_	_	O
18	versus	_	_	O
19	the	_	_	O
20	low-dose	_	_	O
21	regimen	_	_	O
22	of	_	_	O
23	1	_	_	O
24	%	_	_	O
25	dorzolamide/0.5	_	_	O
26	%	_	_	O
27	timolol	_	_	O
28	fixed	_	_	O
29	combination	_	_	O
30	(	_	_	O
31	DTFC	_	_	O
32	)	_	_	O
33	in	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	open-angle	_	_	O
37	glaucoma	_	_	O
38	and	_	_	O
39	ocular	_	_	O
40	hypertension	_	_	O
41	(	_	_	O
42	OAG/OH	_	_	O
43	)	_	_	O
44	following	_	_	O
45	treatment	_	_	O
46	with	_	_	O
47	prostaglandin	_	_	O
48	analogues	_	_	O
49	(	_	_	O
50	PGAs	_	_	O
51	)	_	_	O
52	.	_	_	O

53	A	_	_	O
54	prospective	_	_	O
55	,	_	_	O
56	randomized	_	_	O
57	,	_	_	O
58	double-masked	_	_	O
59	,	_	_	O
60	multicentre	_	_	O
61	,	_	_	O
62	parallel-group	_	_	O
63	and	_	_	O
64	active-controlled	_	_	O
65	study	_	_	O
66	included	_	_	O
67	201	_	_	O
68	Japanese	_	_	O
69	OAG/OH	_	_	O
70	patients	_	_	O
71	who	_	_	O
72	had	_	_	O
73	been	_	_	O
74	treated	_	_	O
75	with	_	_	O
76	PGA	_	_	O
77	.	_	_	O

78	Efficacy	_	_	O
79	was	_	_	O
80	assessed	_	_	O
81	as	_	_	O
82	the	_	_	O
83	change	_	_	O
84	in	_	_	O
85	intra-ocular	_	_	O
86	pressure	_	_	O
87	(	_	_	O
88	IOP	_	_	O
89	)	_	_	O
90	from	_	_	O
91	baseline	_	_	O
92	after	_	_	O
93	weeks	_	_	O
94	4	_	_	O
95	and	_	_	O
96	8	_	_	O
97	.	_	_	O

98	Safety	_	_	O
99	was	_	_	O
100	assessed	_	_	O
101	with	_	_	O
102	adverse	_	_	O
103	event	_	_	O
104	rates	_	_	O
105	,	_	_	O
106	ocular	_	_	O
107	discomfort	_	_	O
108	score	_	_	O
109	,	_	_	O
110	blur	_	_	O
111	scale	_	_	O
112	,	_	_	O
113	blood	_	_	O
114	pressure	_	_	O
115	and	_	_	O
116	heart	_	_	O
117	rates	_	_	O
118	,	_	_	O
119	best-corrected	_	_	O
120	visual	_	_	O
121	acuity	_	_	O
122	(	_	_	O
123	BCVA	_	_	O
124	)	_	_	O
125	and	_	_	O
126	slit	_	_	O
127	lamp	_	_	O
128	examinations	_	_	O
129	.	_	_	O

130	Intra-ocular	_	_	B-Premise
131	pressure	_	_	I-Premise
132	(	_	_	I-Premise
133	IOP	_	_	I-Premise
134	)	_	_	I-Premise
135	change	_	_	I-Premise
136	from	_	_	I-Premise
137	baseline	_	_	I-Premise
138	at	_	_	I-Premise
139	9	_	_	I-Premise
140	AM/11	_	_	I-Premise
141	AM	_	_	I-Premise
142	pooled	_	_	I-Premise
143	over	_	_	I-Premise
144	the	_	_	I-Premise
145	8	_	_	I-Premise
146	weeks	_	_	I-Premise
147	was	_	_	I-Premise
148	-3.3/-3.3	_	_	I-Premise
149	mmHg	_	_	I-Premise
150	in	_	_	I-Premise
151	the	_	_	I-Premise
152	BTFC	_	_	I-Premise
153	group	_	_	I-Premise
154	and	_	_	I-Premise
155	-2.9/-3.4	_	_	I-Premise
156	mmHg	_	_	I-Premise
157	in	_	_	I-Premise
158	the	_	_	I-Premise
159	DTFC	_	_	I-Premise
160	group	_	_	I-Premise
161	,	_	_	I-Premise
162	demonstrating	_	_	O
163	non-inferiority	_	_	O
164	of	_	_	O
165	BTFC	_	_	O
166	to	_	_	O
167	DTFC	_	_	O
168	.	_	_	O

169	Ocular	_	_	B-Premise
170	irritation	_	_	I-Premise
171	was	_	_	I-Premise
172	frequently	_	_	I-Premise
173	seen	_	_	I-Premise
174	in	_	_	I-Premise
175	DTFC	_	_	I-Premise
176	group	_	_	I-Premise
177	.	_	_	I-Premise

178	Although	_	_	O
179	blurred	_	_	B-Premise
180	vision	_	_	I-Premise
181	was	_	_	I-Premise
182	frequently	_	_	I-Premise
183	seen	_	_	I-Premise
184	in	_	_	I-Premise
185	BTFC	_	_	I-Premise
186	group	_	_	I-Premise
187	,	_	_	I-Premise
188	it	_	_	O
189	was	_	_	O
190	transient	_	_	O
191	and	_	_	O
192	blurring	_	_	O
193	became	_	_	O
194	the	_	_	O
195	equivalent	_	_	O
196	3	_	_	O
197	min	_	_	O
198	after	_	_	O
199	instillation	_	_	O
200	between	_	_	O
201	two	_	_	O
202	groups	_	_	O
203	.	_	_	O

204	No	_	_	B-Premise
205	noteworthy	_	_	I-Premise
206	issue	_	_	I-Premise
207	was	_	_	I-Premise
208	observed	_	_	I-Premise
209	in	_	_	I-Premise
210	other	_	_	I-Premise
211	safety	_	_	I-Premise
212	outcome	_	_	I-Premise
213	.	_	_	I-Premise

214	Non-inferiority	_	_	B-Claim
215	of	_	_	I-Claim
216	BTFC	_	_	I-Claim
217	to	_	_	I-Claim
218	DTFC	_	_	I-Claim
219	in	_	_	I-Claim
220	IOP	_	_	I-Claim
221	reduction	_	_	I-Claim
222	was	_	_	I-Claim
223	demonstrated	_	_	I-Claim
224	after	_	_	I-Claim
225	adding	_	_	I-Claim
226	onto	_	_	I-Claim
227	PGA	_	_	I-Claim
228	therapy	_	_	I-Claim
229	in	_	_	I-Claim
230	Japanese	_	_	I-Claim
231	OAG/OH	_	_	I-Claim
232	patients	_	_	I-Claim
233	.	_	_	I-Claim

234	Although	_	_	O
235	the	_	_	B-Claim
236	score	_	_	I-Claim
237	of	_	_	I-Claim
238	blurred	_	_	I-Claim
239	vision	_	_	I-Claim
240	was	_	_	I-Claim
241	transiently	_	_	I-Claim
242	higher	_	_	I-Claim
243	in	_	_	I-Claim
244	BTFC	_	_	I-Claim
245	than	_	_	I-Claim
246	DTFC	_	_	I-Claim
247	,	_	_	I-Claim
248	treatment	_	_	B-Claim
249	difference	_	_	I-Claim
250	decreased	_	_	I-Claim
251	and	_	_	I-Claim
252	disappeared	_	_	I-Claim
253	with	_	_	I-Claim
254	time	_	_	I-Claim
255	.	_	_	I-Claim

256	Thus	_	_	O
257	,	_	_	O
258	BTFC	_	_	B-Claim
259	can	_	_	I-Claim
260	be	_	_	I-Claim
261	considered	_	_	I-Claim
262	as	_	_	I-Claim
263	a	_	_	I-Claim
264	safe	_	_	I-Claim
265	and	_	_	I-Claim
266	effective	_	_	I-Claim
267	agent	_	_	I-Claim
268	for	_	_	I-Claim
269	glaucoma	_	_	I-Claim
270	treatment	_	_	I-Claim
271	.	_	_	I-Claim


0	To	_	_	O
1	prospectively	_	_	O
2	evaluate	_	_	O
3	visual	_	_	O
4	outcomes	_	_	O
5	and	_	_	O
6	complications	_	_	O
7	during	_	_	O
8	and	_	_	O
9	after	_	_	O
10	cataract	_	_	O
11	surgery	_	_	O
12	with	_	_	O
13	or	_	_	O
14	without	_	_	O
15	prophylactic	_	_	O
16	sclerostomy	_	_	O
17	in	_	_	O
18	nanophthalmic	_	_	O
19	eyes	_	_	O
20	with	_	_	O
21	visually	_	_	O
22	significant	_	_	O
23	cataract.Sixty	_	_	O
24	nanophthalmic	_	_	O
25	eyes	_	_	O
26	of	_	_	O
27	60	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	visually	_	_	O
31	significant	_	_	O
32	cataract	_	_	O
33	were	_	_	O
34	randomly	_	_	O
35	assigned	_	_	O
36	to	_	_	O
37	cataract	_	_	O
38	surgery	_	_	O
39	alone	_	_	O
40	(	_	_	O
41	control	_	_	O
42	group	_	_	O
43	,	_	_	O
44	n	_	_	O
45	=	_	_	O
46	31	_	_	O
47	)	_	_	O
48	or	_	_	O
49	cataract	_	_	O
50	surgery	_	_	O
51	with	_	_	O
52	concomitant	_	_	O
53	prophylactic	_	_	O
54	sclerostomy	_	_	O
55	(	_	_	O
56	sclerostomy	_	_	O
57	group	_	_	O
58	,	_	_	O
59	n	_	_	O
60	=	_	_	O
61	29	_	_	O
62	)	_	_	O
63	.	_	_	O

64	Surgery	_	_	O
65	was	_	_	O
66	performed	_	_	O
67	using	_	_	O
68	phacoemulsification	_	_	O
69	or	_	_	O
70	manual	_	_	O
71	small-incision	_	_	O
72	cataract	_	_	O
73	surgery	_	_	O
74	(	_	_	O
75	SICS	_	_	O
76	)	_	_	O
77	based	_	_	O
78	on	_	_	O
79	the	_	_	O
80	LOCS	_	_	O
81	III	_	_	O
82	grading	_	_	O
83	score	_	_	O
84	.	_	_	O

85	Group	_	_	O
86	differences	_	_	O
87	in	_	_	O
88	intraoperative	_	_	O
89	and	_	_	O
90	postoperative	_	_	O
91	complications	_	_	O
92	were	_	_	O
93	analyzed	_	_	O
94	and	_	_	O
95	risk	_	_	O
96	factors	_	_	O
97	assessed	_	_	O
98	.	_	_	O

99	Fewer	_	_	B-Premise
100	complications	_	_	I-Premise
101	were	_	_	I-Premise
102	noted	_	_	I-Premise
103	in	_	_	I-Premise
104	eyes	_	_	I-Premise
105	receiving	_	_	I-Premise
106	sclerostomy	_	_	I-Premise
107	(	_	_	I-Premise
108	5/29	_	_	I-Premise
109	,	_	_	I-Premise
110	17.2	_	_	I-Premise
111	%	_	_	I-Premise
112	)	_	_	I-Premise
113	as	_	_	I-Premise
114	compared	_	_	I-Premise
115	to	_	_	I-Premise
116	control	_	_	I-Premise
117	group	_	_	I-Premise
118	eyes	_	_	I-Premise
119	(	_	_	I-Premise
120	12/31	_	_	I-Premise
121	,	_	_	I-Premise
122	38.7	_	_	I-Premise
123	%	_	_	I-Premise
124	)	_	_	I-Premise
125	,	_	_	I-Premise
126	though	_	_	I-Premise
127	differences	_	_	I-Premise
128	were	_	_	I-Premise
129	marginally	_	_	I-Premise
130	significant	_	_	I-Premise
131	(	_	_	I-Premise
132	P	_	_	I-Premise
133	=	_	_	I-Premise
134	.065	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	Four	_	_	B-Premise
138	control	_	_	I-Premise
139	group	_	_	I-Premise
140	,	_	_	I-Premise
141	but	_	_	I-Premise
142	no	_	_	I-Premise
143	sclerostomy	_	_	I-Premise
144	group	_	_	I-Premise
145	,	_	_	I-Premise
146	eyes	_	_	I-Premise
147	developed	_	_	I-Premise
148	postoperative	_	_	I-Premise
149	uveal	_	_	I-Premise
150	effusions	_	_	I-Premise
151	(	_	_	I-Premise
152	P	_	_	I-Premise
153	=	_	_	I-Premise
154	.04	_	_	I-Premise
155	)	_	_	I-Premise
156	.	_	_	I-Premise

157	In	_	_	B-Premise
158	multivariable	_	_	I-Premise
159	models	_	_	I-Premise
160	,	_	_	I-Premise
161	sclerostomy	_	_	I-Premise
162	decreased	_	_	I-Premise
163	the	_	_	I-Premise
164	odds	_	_	I-Premise
165	of	_	_	I-Premise
166	an	_	_	I-Premise
167	intraoperative	_	_	I-Premise
168	or	_	_	I-Premise
169	postoperative	_	_	I-Premise
170	complication	_	_	I-Premise
171	by	_	_	I-Premise
172	80	_	_	I-Premise
173	%	_	_	I-Premise
174	(	_	_	I-Premise
175	odds	_	_	I-Premise
176	ratio	_	_	I-Premise
177	[	_	_	I-Premise
178	OR	_	_	I-Premise
179	]	_	_	I-Premise
180	=	_	_	I-Premise
181	0.2	_	_	I-Premise
182	,	_	_	I-Premise
183	95	_	_	I-Premise
184	%	_	_	I-Premise
185	confidence	_	_	I-Premise
186	interval	_	_	I-Premise
187	[	_	_	I-Premise
188	CI	_	_	I-Premise
189	]	_	_	I-Premise
190	=	_	_	I-Premise
191	0.04-0.92	_	_	I-Premise
192	,	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	.039	_	_	I-Premise
196	)	_	_	I-Premise
197	;	_	_	I-Premise
198	SICS	_	_	B-Premise
199	was	_	_	I-Premise
200	associated	_	_	I-Premise
201	with	_	_	I-Premise
202	a	_	_	I-Premise
203	significantly	_	_	I-Premise
204	higher	_	_	I-Premise
205	risk	_	_	I-Premise
206	of	_	_	I-Premise
207	complications	_	_	I-Premise
208	as	_	_	I-Premise
209	compared	_	_	I-Premise
210	to	_	_	I-Premise
211	phacoemulsification	_	_	I-Premise
212	(	_	_	I-Premise
213	OR	_	_	I-Premise
214	=	_	_	I-Premise
215	5.95	_	_	I-Premise
216	,	_	_	I-Premise
217	95	_	_	I-Premise
218	%	_	_	I-Premise
219	CI	_	_	I-Premise
220	=	_	_	I-Premise
221	1.49-23.73	_	_	I-Premise
222	,	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.012	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	while	_	_	I-Premise
229	high	_	_	I-Premise
230	preoperative	_	_	I-Premise
231	intraocular	_	_	I-Premise
232	pressure	_	_	I-Premise
233	(	_	_	I-Premise
234	OR	_	_	I-Premise
235	=	_	_	I-Premise
236	4.54	_	_	I-Premise
237	,	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	CI	_	_	I-Premise
241	=	_	_	I-Premise
242	0.99-20.9	_	_	I-Premise
243	,	_	_	I-Premise
244	P	_	_	I-Premise
245	=	_	_	I-Premise
246	.052	_	_	I-Premise
247	)	_	_	I-Premise
248	and	_	_	I-Premise
249	greater	_	_	I-Premise
250	lens	_	_	I-Premise
251	thickness	_	_	I-Premise
252	(	_	_	I-Premise
253	OR	_	_	I-Premise
254	=	_	_	I-Premise
255	3.38	_	_	I-Premise
256	,	_	_	I-Premise
257	95	_	_	I-Premise
258	%	_	_	I-Premise
259	CI	_	_	I-Premise
260	=	_	_	I-Premise
261	0.88-12.91	_	_	I-Premise
262	,	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	.075	_	_	I-Premise
266	)	_	_	I-Premise
267	demonstrated	_	_	I-Premise
268	a	_	_	I-Premise
269	marginally	_	_	I-Premise
270	significant	_	_	I-Premise
271	association	_	_	I-Premise
272	.	_	_	I-Premise

273	Cataract	_	_	B-Claim
274	surgery	_	_	I-Claim
275	in	_	_	I-Claim
276	eyes	_	_	I-Claim
277	with	_	_	I-Claim
278	nanophthalmos	_	_	I-Claim
279	is	_	_	I-Claim
280	associated	_	_	I-Claim
281	with	_	_	I-Claim
282	a	_	_	I-Claim
283	high	_	_	I-Claim
284	risk	_	_	I-Claim
285	for	_	_	I-Claim
286	vision-threatening	_	_	I-Claim
287	complications	_	_	I-Claim
288	.	_	_	I-Claim

289	Performing	_	_	B-Claim
290	a	_	_	I-Claim
291	simultaneous	_	_	I-Claim
292	prophylactic	_	_	I-Claim
293	sclerostomy	_	_	I-Claim
294	with	_	_	I-Claim
295	cataract	_	_	I-Claim
296	surgery	_	_	I-Claim
297	reduces	_	_	I-Claim
298	complication	_	_	I-Claim
299	rates	_	_	I-Claim
300	,	_	_	I-Claim
301	particularly	_	_	I-Claim
302	uveal	_	_	I-Claim
303	effusions	_	_	I-Claim
304	.	_	_	I-Claim

305	Cataract	_	_	B-Claim
306	surgery	_	_	I-Claim
307	at	_	_	I-Claim
308	earlier	_	_	I-Claim
309	stages	_	_	I-Claim
310	by	_	_	I-Claim
311	phacoemulsification	_	_	I-Claim
312	may	_	_	I-Claim
313	be	_	_	I-Claim
314	more	_	_	I-Claim
315	beneficial	_	_	I-Claim
316	than	_	_	I-Claim
317	undergoing	_	_	I-Claim
318	manual	_	_	I-Claim
319	SICS	_	_	I-Claim
320	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	effect	_	_	O
5	and	_	_	O
6	safety	_	_	O
7	of	_	_	O
8	long-acting	_	_	O
9	pegylated	_	_	O
10	interferon--2b	_	_	O
11	(	_	_	O
12	Peg-IFN--2b	_	_	O
13	)	_	_	O
14	(	_	_	O
15	Y	_	_	O
16	shape	_	_	O
17	,	_	_	O
18	40	_	_	O
19	kD	_	_	O
20	)	_	_	O
21	injection	_	_	O
22	(	_	_	O
23	180	_	_	O
24	g/week	_	_	O
25	)	_	_	O
26	in	_	_	O
27	the	_	_	O
28	treatment	_	_	O
29	of	_	_	O
30	HBeAg-positive	_	_	O
31	chronic	_	_	O
32	hepatitis	_	_	O
33	B	_	_	O
34	(	_	_	O
35	CHB	_	_	O
36	)	_	_	O
37	patients	_	_	O
38	,	_	_	O
39	with	_	_	O
40	standard-dose	_	_	O
41	Peg-IFN--2a	_	_	O
42	as	_	_	O
43	positive	_	_	O
44	control	_	_	O
45	.	_	_	O

46	This	_	_	O
47	study	_	_	O
48	was	_	_	O
49	a	_	_	O
50	multicenter	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	,	_	_	O
54	open-label	_	_	O
55	,	_	_	O
56	and	_	_	O
57	positive-controlled	_	_	O
58	phase	_	_	O
59	III	_	_	O
60	clinical	_	_	O
61	trial	_	_	O
62	.	_	_	O

63	Eligible	_	_	O
64	HBeAg-positive	_	_	O
65	CHB	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	screened	_	_	O
69	out	_	_	O
70	and	_	_	O
71	randomized	_	_	O
72	to	_	_	O
73	Peg-IFN--2b	_	_	O
74	(	_	_	O
75	Y	_	_	O
76	shape	_	_	O
77	,	_	_	O
78	40	_	_	O
79	kD	_	_	O
80	)	_	_	O
81	trial	_	_	O
82	group	_	_	O
83	and	_	_	O
84	Peg-IFN--2a	_	_	O
85	control	_	_	O
86	group	_	_	O
87	at	_	_	O
88	a	_	_	O
89	ratio	_	_	O
90	of	_	_	O
91	2:1	_	_	O
92	.	_	_	O

93	The	_	_	O
94	course	_	_	O
95	of	_	_	O
96	treatment	_	_	O
97	was	_	_	O
98	48	_	_	O
99	weeks	_	_	O
100	and	_	_	O
101	the	_	_	O
102	patients	_	_	O
103	were	_	_	O
104	followed	_	_	O
105	up	_	_	O
106	for	_	_	O
107	24	_	_	O
108	weeks	_	_	O
109	after	_	_	O
110	drug	_	_	O
111	withdrawal	_	_	O
112	.	_	_	O

113	Plasma	_	_	O
114	samples	_	_	O
115	were	_	_	O
116	collected	_	_	O
117	at	_	_	O
118	screening	_	_	O
119	,	_	_	O
120	baseline	_	_	O
121	,	_	_	O
122	and	_	_	O
123	12	_	_	O
124	,	_	_	O
125	24	_	_	O
126	,	_	_	O
127	36	_	_	O
128	,	_	_	O
129	48	_	_	O
130	,	_	_	O
131	60	_	_	O
132	,	_	_	O
133	and	_	_	O
134	72	_	_	O
135	weeks	_	_	O
136	for	_	_	O
137	centralized	_	_	O
138	detection	_	_	O
139	.	_	_	O

140	COBAS	_	_	O
141	Ampliprep/COBAS	_	_	O
142	TaqMan	_	_	O
143	HBV	_	_	O
144	Test	_	_	O
145	was	_	_	O
146	used	_	_	O
147	to	_	_	O
148	measure	_	_	O
149	HBV	_	_	O
150	DNA	_	_	O
151	level	_	_	O
152	by	_	_	O
153	quantitative	_	_	O
154	real-time	_	_	O
155	PCR	_	_	O
156	.	_	_	O

157	Electrochemiluminescence	_	_	O
158	immunoassay	_	_	O
159	with	_	_	O
160	Elecsys	_	_	O
161	kit	_	_	O
162	was	_	_	O
163	used	_	_	O
164	to	_	_	O
165	measure	_	_	O
166	HBV	_	_	O
167	markers	_	_	O
168	(	_	_	O
169	HBsAg	_	_	O
170	,	_	_	O
171	anti-HBs	_	_	O
172	,	_	_	O
173	HBeAg	_	_	O
174	,	_	_	O
175	anti-HBe	_	_	O
176	)	_	_	O
177	.	_	_	O

178	Adverse	_	_	O
179	events	_	_	O
180	were	_	_	O
181	recorded	_	_	O
182	in	_	_	O
183	detail	_	_	O
184	.	_	_	O

185	The	_	_	O
186	primary	_	_	O
187	outcome	_	_	O
188	measure	_	_	O
189	was	_	_	O
190	HBeAg	_	_	O
191	seroconversion	_	_	O
192	rate	_	_	O
193	after	_	_	O
194	the	_	_	O
195	24-week	_	_	O
196	follow-up	_	_	O
197	,	_	_	O
198	and	_	_	O
199	non-inferiority	_	_	O
200	was	_	_	O
201	also	_	_	O
202	tested	_	_	O
203	.	_	_	O

204	The	_	_	O
205	difference	_	_	O
206	in	_	_	O
207	HBeAg	_	_	O
208	seroconversion	_	_	O
209	rate	_	_	O
210	after	_	_	O
211	treatment	_	_	O
212	between	_	_	O
213	the	_	_	O
214	trial	_	_	O
215	group	_	_	O
216	and	_	_	O
217	the	_	_	O
218	control	_	_	O
219	group	_	_	O
220	and	_	_	O
221	two-sided	_	_	O
222	confidence	_	_	O
223	interval	_	_	O
224	(	_	_	O
225	CI	_	_	O
226	)	_	_	O
227	were	_	_	O
228	calculated	_	_	O
229	,	_	_	O
230	and	_	_	O
231	non-inferiority	_	_	O
232	was	_	_	O
233	demonstrated	_	_	O
234	if	_	_	O
235	the	_	_	O
236	lower	_	_	O
237	limit	_	_	O
238	of	_	_	O
239	95	_	_	O
240	%	_	_	O
241	CI	_	_	O
242	was	_	_	O
243	>	_	_	O
244	-10	_	_	O
245	%	_	_	O
246	.	_	_	O

247	The	_	_	O
248	t-test	_	_	O
249	,	_	_	O
250	chi-square	_	_	O
251	test	_	_	O
252	,	_	_	O
253	or	_	_	O
254	rank	_	_	O
255	sum	_	_	O
256	test	_	_	O
257	was	_	_	O
258	used	_	_	O
259	according	_	_	O
260	to	_	_	O
261	the	_	_	O
262	types	_	_	O
263	and	_	_	O
264	features	_	_	O
265	of	_	_	O
266	data	_	_	O
267	.	_	_	O

268	A	_	_	O
269	total	_	_	O
270	of	_	_	O
271	855	_	_	O
272	HBeAg-positive	_	_	O
273	CHB	_	_	O
274	patients	_	_	O
275	were	_	_	O
276	enrolled	_	_	O
277	and	_	_	O
278	820	_	_	O
279	of	_	_	O
280	them	_	_	O
281	received	_	_	O
282	treatment	_	_	O
283	(	_	_	O
284	538	_	_	O
285	in	_	_	O
286	the	_	_	O
287	trial	_	_	O
288	group	_	_	O
289	and	_	_	O
290	282	_	_	O
291	in	_	_	O
292	the	_	_	O
293	control	_	_	O
294	group	_	_	O
295	)	_	_	O
296	.	_	_	O

297	The	_	_	B-Premise
298	data	_	_	I-Premise
299	of	_	_	I-Premise
300	the	_	_	I-Premise
301	full	_	_	I-Premise
302	analysis	_	_	I-Premise
303	set	_	_	I-Premise
304	showed	_	_	I-Premise
305	that	_	_	I-Premise
306	HBeAg	_	_	I-Premise
307	seroconversion	_	_	I-Premise
308	rate	_	_	I-Premise
309	at	_	_	I-Premise
310	week	_	_	I-Premise
311	72	_	_	I-Premise
312	was	_	_	I-Premise
313	27.32	_	_	I-Premise
314	%	_	_	I-Premise
315	in	_	_	I-Premise
316	the	_	_	I-Premise
317	trial	_	_	I-Premise
318	group	_	_	I-Premise
319	and	_	_	I-Premise
320	22.70	_	_	I-Premise
321	%	_	_	I-Premise
322	in	_	_	I-Premise
323	the	_	_	I-Premise
324	control	_	_	I-Premise
325	group	_	_	I-Premise
326	with	_	_	I-Premise
327	a	_	_	I-Premise
328	rate	_	_	I-Premise
329	difference	_	_	I-Premise
330	of	_	_	I-Premise
331	4.63	_	_	I-Premise
332	%	_	_	I-Premise
333	(	_	_	I-Premise
334	95	_	_	I-Premise
335	%	_	_	I-Premise
336	CI	_	_	I-Premise
337	-1.54	_	_	I-Premise
338	%	_	_	I-Premise
339	to	_	_	I-Premise
340	10.80	_	_	I-Premise
341	%	_	_	I-Premise
342	,	_	_	I-Premise
343	P	_	_	I-Premise
344	=	_	_	I-Premise
345	0.1493	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	The	_	_	B-Premise
349	data	_	_	I-Premise
350	of	_	_	I-Premise
351	the	_	_	I-Premise
352	per-protocol	_	_	I-Premise
353	set	_	_	I-Premise
354	showed	_	_	I-Premise
355	that	_	_	I-Premise
356	HBeAg	_	_	I-Premise
357	seroconversion	_	_	I-Premise
358	rate	_	_	I-Premise
359	at	_	_	I-Premise
360	week	_	_	I-Premise
361	72	_	_	I-Premise
362	was	_	_	I-Premise
363	30.75	_	_	I-Premise
364	%	_	_	I-Premise
365	in	_	_	I-Premise
366	the	_	_	I-Premise
367	trial	_	_	I-Premise
368	group	_	_	I-Premise
369	and	_	_	I-Premise
370	27.14	_	_	I-Premise
371	%	_	_	I-Premise
372	in	_	_	I-Premise
373	the	_	_	I-Premise
374	control	_	_	I-Premise
375	group	_	_	I-Premise
376	with	_	_	I-Premise
377	a	_	_	I-Premise
378	rate	_	_	I-Premise
379	difference	_	_	I-Premise
380	of	_	_	I-Premise
381	3.61	_	_	I-Premise
382	%	_	_	I-Premise
383	(	_	_	I-Premise
384	95	_	_	I-Premise
385	%	_	_	I-Premise
386	CI	_	_	I-Premise
387	-3.87	_	_	I-Premise
388	%	_	_	I-Premise
389	to	_	_	I-Premise
390	11.09	_	_	I-Premise
391	%	_	_	I-Premise
392	,	_	_	I-Premise
393	P	_	_	I-Premise
394	=	_	_	I-Premise
395	0.3436	_	_	I-Premise
396	)	_	_	I-Premise
397	.	_	_	I-Premise

398	95	_	_	B-Premise
399	%	_	_	I-Premise
400	CI	_	_	I-Premise
401	met	_	_	I-Premise
402	the	_	_	I-Premise
403	non-inferiority	_	_	I-Premise
404	criteria	_	_	I-Premise
405	,	_	_	I-Premise
406	and	_	_	I-Premise
407	the	_	_	I-Premise
408	trial	_	_	I-Premise
409	group	_	_	I-Premise
410	was	_	_	I-Premise
411	non-inferior	_	_	I-Premise
412	to	_	_	I-Premise
413	the	_	_	I-Premise
414	control	_	_	I-Premise
415	group	_	_	I-Premise
416	.	_	_	I-Premise

417	The	_	_	B-Premise
418	two	_	_	I-Premise
419	groups	_	_	I-Premise
420	had	_	_	I-Premise
421	similar	_	_	I-Premise
422	incidence	_	_	I-Premise
423	rates	_	_	I-Premise
424	of	_	_	I-Premise
425	adverse	_	_	I-Premise
426	events	_	_	I-Premise
427	,	_	_	I-Premise
428	serious	_	_	I-Premise
429	adverse	_	_	I-Premise
430	events	_	_	I-Premise
431	,	_	_	I-Premise
432	and	_	_	I-Premise
433	common	_	_	I-Premise
434	adverse	_	_	I-Premise
435	events	_	_	I-Premise
436	.	_	_	I-Premise

437	In	_	_	B-Claim
438	Peg-IFN-	_	_	I-Claim
439	regimen	_	_	I-Claim
440	for	_	_	I-Claim
441	HBeAg-positive	_	_	I-Claim
442	CHB	_	_	I-Claim
443	patients	_	_	I-Claim
444	,	_	_	I-Claim
445	the	_	_	I-Claim
446	new	_	_	I-Claim
447	drug	_	_	I-Claim
448	Peg-IFN--2b	_	_	I-Claim
449	(	_	_	I-Claim
450	Y	_	_	I-Claim
451	shape	_	_	I-Claim
452	,	_	_	I-Claim
453	40	_	_	I-Claim
454	kD	_	_	I-Claim
455	)	_	_	I-Claim
456	has	_	_	I-Claim
457	comparable	_	_	I-Claim
458	effect	_	_	I-Claim
459	and	_	_	I-Claim
460	safety	_	_	I-Claim
461	to	_	_	I-Claim
462	the	_	_	I-Claim
463	control	_	_	I-Claim
464	drug	_	_	I-Claim
465	Peg-IFN--2a	_	_	I-Claim
466	.	_	_	I-Claim


0	Uncontrolled	_	_	O
1	hypertension	_	_	O
2	is	_	_	O
3	a	_	_	O
4	major	_	_	O
5	problem	_	_	O
6	among	_	_	O
7	non-Hispanic	_	_	O
8	black	_	_	O
9	men	_	_	O
10	,	_	_	O
11	who	_	_	O
12	are	_	_	O
13	underrepresented	_	_	O
14	in	_	_	O
15	pharmacist	_	_	O
16	intervention	_	_	O
17	trials	_	_	O
18	in	_	_	O
19	traditional	_	_	O
20	health	_	_	O
21	care	_	_	O
22	settings	_	_	O
23	.	_	_	O

24	We	_	_	O
25	enrolled	_	_	O
26	a	_	_	O
27	cohort	_	_	O
28	of	_	_	O
29	319	_	_	O
30	black	_	_	O
31	male	_	_	O
32	patrons	_	_	O
33	with	_	_	O
34	systolic	_	_	O
35	blood	_	_	O
36	pressure	_	_	O
37	of	_	_	O
38	140	_	_	O
39	mm	_	_	O
40	Hg	_	_	O
41	or	_	_	O
42	more	_	_	O
43	from	_	_	O
44	52	_	_	O
45	black-owned	_	_	O
46	barbershops	_	_	O
47	(	_	_	O
48	nontraditional	_	_	O
49	health	_	_	O
50	care	_	_	O
51	setting	_	_	O
52	)	_	_	O
53	in	_	_	O
54	a	_	_	O
55	cluster-randomized	_	_	O
56	trial	_	_	O
57	in	_	_	O
58	which	_	_	O
59	barbershops	_	_	O
60	were	_	_	O
61	assigned	_	_	O
62	to	_	_	O
63	a	_	_	O
64	pharmacist-led	_	_	O
65	intervention	_	_	O
66	(	_	_	O
67	in	_	_	O
68	which	_	_	O
69	barbers	_	_	O
70	encouraged	_	_	O
71	meetings	_	_	O
72	in	_	_	O
73	barbershops	_	_	O
74	with	_	_	O
75	specialty-trained	_	_	O
76	pharmacists	_	_	O
77	who	_	_	O
78	prescribed	_	_	O
79	drug	_	_	O
80	therapy	_	_	O
81	under	_	_	O
82	a	_	_	O
83	collaborative	_	_	O
84	practice	_	_	O
85	agreement	_	_	O
86	with	_	_	O
87	the	_	_	O
88	participants	_	_	O
89		_	_	O
90	doctors	_	_	O
91	)	_	_	O
92	or	_	_	O
93	to	_	_	O
94	an	_	_	O
95	active	_	_	O
96	control	_	_	O
97	approach	_	_	O
98	(	_	_	O
99	in	_	_	O
100	which	_	_	O
101	barbers	_	_	O
102	encouraged	_	_	O
103	lifestyle	_	_	O
104	modification	_	_	O
105	and	_	_	O
106	doctor	_	_	O
107	appointments	_	_	O
108	)	_	_	O
109	.	_	_	O

110	The	_	_	O
111	primary	_	_	O
112	outcome	_	_	O
113	was	_	_	O
114	reduction	_	_	O
115	in	_	_	O
116	systolic	_	_	O
117	blood	_	_	O
118	pressure	_	_	O
119	at	_	_	O
120	6	_	_	O
121	months	_	_	O
122	.	_	_	O

123	At	_	_	O
124	baseline	_	_	O
125	,	_	_	O
126	the	_	_	O
127	mean	_	_	O
128	systolic	_	_	O
129	blood	_	_	O
130	pressure	_	_	O
131	was	_	_	O
132	152.8	_	_	O
133	mm	_	_	O
134	Hg	_	_	O
135	in	_	_	O
136	the	_	_	O
137	intervention	_	_	O
138	group	_	_	O
139	and	_	_	O
140	154.6	_	_	O
141	mm	_	_	O
142	Hg	_	_	O
143	in	_	_	O
144	the	_	_	O
145	control	_	_	O
146	group	_	_	O
147	.	_	_	O

148	At	_	_	B-Premise
149	6	_	_	I-Premise
150	months	_	_	I-Premise
151	,	_	_	I-Premise
152	the	_	_	I-Premise
153	mean	_	_	I-Premise
154	systolic	_	_	I-Premise
155	blood	_	_	I-Premise
156	pressure	_	_	I-Premise
157	fell	_	_	I-Premise
158	by	_	_	I-Premise
159	27.0	_	_	I-Premise
160	mm	_	_	I-Premise
161	Hg	_	_	I-Premise
162	(	_	_	I-Premise
163	to	_	_	I-Premise
164	125.8	_	_	I-Premise
165	mm	_	_	I-Premise
166	Hg	_	_	I-Premise
167	)	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	intervention	_	_	I-Premise
171	group	_	_	I-Premise
172	and	_	_	I-Premise
173	by	_	_	I-Premise
174	9.3	_	_	I-Premise
175	mm	_	_	I-Premise
176	Hg	_	_	I-Premise
177	(	_	_	I-Premise
178	to	_	_	I-Premise
179	145.4	_	_	I-Premise
180	mm	_	_	I-Premise
181	Hg	_	_	I-Premise
182	)	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	control	_	_	I-Premise
186	group	_	_	I-Premise
187	;	_	_	I-Premise
188	the	_	_	I-Premise
189	mean	_	_	I-Premise
190	reduction	_	_	I-Premise
191	was	_	_	I-Premise
192	21.6	_	_	I-Premise
193	mm	_	_	I-Premise
194	Hg	_	_	I-Premise
195	greater	_	_	I-Premise
196	with	_	_	I-Premise
197	the	_	_	I-Premise
198	intervention	_	_	I-Premise
199	(	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	confidence	_	_	I-Premise
203	interval	_	_	I-Premise
204	,	_	_	I-Premise
205	14.7	_	_	I-Premise
206	to	_	_	I-Premise
207	28.4	_	_	I-Premise
208	;	_	_	I-Premise
209	P	_	_	I-Premise
210	<	_	_	I-Premise
211	0.001	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	A	_	_	B-Premise
215	blood-pressure	_	_	I-Premise
216	level	_	_	I-Premise
217	of	_	_	I-Premise
218	less	_	_	I-Premise
219	than	_	_	I-Premise
220	130/80	_	_	I-Premise
221	mm	_	_	I-Premise
222	Hg	_	_	I-Premise
223	was	_	_	I-Premise
224	achieved	_	_	I-Premise
225	among	_	_	I-Premise
226	63.6	_	_	I-Premise
227	%	_	_	I-Premise
228	of	_	_	I-Premise
229	the	_	_	I-Premise
230	participants	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	intervention	_	_	I-Premise
234	group	_	_	I-Premise
235	versus	_	_	I-Premise
236	11.7	_	_	I-Premise
237	%	_	_	I-Premise
238	of	_	_	I-Premise
239	the	_	_	I-Premise
240	participants	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	control	_	_	I-Premise
244	group	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	0.001	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	In	_	_	B-Premise
252	the	_	_	I-Premise
253	intervention	_	_	I-Premise
254	group	_	_	I-Premise
255	,	_	_	I-Premise
256	the	_	_	I-Premise
257	rate	_	_	I-Premise
258	of	_	_	I-Premise
259	cohort	_	_	I-Premise
260	retention	_	_	I-Premise
261	was	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	there	_	_	I-Premise
267	were	_	_	I-Premise
268	few	_	_	I-Premise
269	adverse	_	_	I-Premise
270	events	_	_	I-Premise
271	(	_	_	I-Premise
272	three	_	_	I-Premise
273	cases	_	_	I-Premise
274	of	_	_	I-Premise
275	acute	_	_	I-Premise
276	kidney	_	_	I-Premise
277	injury	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Among	_	_	B-Claim
281	black	_	_	I-Claim
282	male	_	_	I-Claim
283	barbershop	_	_	I-Claim
284	patrons	_	_	I-Claim
285	with	_	_	I-Claim
286	uncontrolled	_	_	I-Claim
287	hypertension	_	_	I-Claim
288	,	_	_	I-Claim
289	health	_	_	I-Claim
290	promotion	_	_	I-Claim
291	by	_	_	I-Claim
292	barbers	_	_	I-Claim
293	resulted	_	_	I-Claim
294	in	_	_	I-Claim
295	larger	_	_	I-Claim
296	blood-pressure	_	_	I-Claim
297	reduction	_	_	I-Claim
298	when	_	_	I-Claim
299	coupled	_	_	I-Claim
300	with	_	_	I-Claim
301	medication	_	_	I-Claim
302	management	_	_	I-Claim
303	in	_	_	I-Claim
304	barbershops	_	_	I-Claim
305	by	_	_	I-Claim
306	specialty-trained	_	_	I-Claim
307	pharmacists	_	_	I-Claim
308	.	_	_	I-Claim


0	Low	_	_	B-Claim
1	serum	_	_	I-Claim
2	vitamin	_	_	I-Claim
3	D	_	_	I-Claim
4	has	_	_	I-Claim
5	been	_	_	I-Claim
6	associated	_	_	I-Claim
7	with	_	_	I-Claim
8	metabolic	_	_	I-Claim
9	syndrome	_	_	I-Claim
10	and	_	_	I-Claim
11	Non-alcoholic	_	_	I-Claim
12	fatty	_	_	I-Claim
13	liver	_	_	I-Claim
14	disease	_	_	I-Claim
15	(	_	_	I-Claim
16	NAFLD	_	_	I-Claim
17	)	_	_	I-Claim
18	.	_	_	I-Claim

19	This	_	_	O
20	study	_	_	O
21	aimed	_	_	O
22	to	_	_	O
23	investigate	_	_	O
24	the	_	_	O
25	impact	_	_	O
26	of	_	_	O
27	vitamin	_	_	O
28	D	_	_	O
29	supplementation	_	_	O
30	in	_	_	O
31	treatment	_	_	O
32	of	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	NAFLD	_	_	O
36	.	_	_	O

37	In	_	_	O
38	a	_	_	O
39	double	_	_	O
40	blind	_	_	O
41	,	_	_	O
42	randomized	_	_	O
43	,	_	_	O
44	placebo	_	_	O
45	controlled	_	_	O
46	trial	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	NAFLD	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	one	_	_	O
55	weekly	_	_	O
56	pearl	_	_	O
57	of	_	_	O
58	placebo	_	_	O
59	,	_	_	O
60	50,000	_	_	O
61	U	_	_	O
62	vitamin	_	_	O
63	D3	_	_	O
64	(	_	_	O
65	cholecalciferol	_	_	O
66	)	_	_	O
67	pearl	_	_	O
68	per	_	_	O
69	week	_	_	O
70	and	_	_	O
71	0.25	_	_	O
72	mg	_	_	O
73	calcitriol	_	_	O
74	(	_	_	O
75	1,25	_	_	O
76	dihydroxycholecalciferol	_	_	O
77	)	_	_	O
78	pearl	_	_	O
79	per	_	_	O
80	day	_	_	O
81	for	_	_	O
82	3	_	_	O
83	months	_	_	O
84	.	_	_	O

85	106	_	_	O
86	NAFLD	_	_	O
87	patients	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	to	_	_	O
91	receive	_	_	O
92	calcitriol	_	_	O
93	,	_	_	O
94	vitamin	_	_	O
95	D3	_	_	O
96	and	_	_	O
97	placebo	_	_	O
98	pearls	_	_	O
99	for	_	_	O
100	12	_	_	O
101	weeks	_	_	O
102	and	_	_	O
103	data	_	_	O
104	for	_	_	O
105	91	_	_	O
106	patients	_	_	O
107	were	_	_	O
108	analyzed	_	_	O
109	.	_	_	O

110	After	_	_	B-Premise
111	12	_	_	I-Premise
112	weeks	_	_	I-Premise
113	of	_	_	I-Premise
114	treatment	_	_	I-Premise
115	,	_	_	I-Premise
116	serum	_	_	I-Premise
117	alkaline	_	_	I-Premise
118	phosphatase	_	_	I-Premise
119	levels	_	_	I-Premise
120	was	_	_	I-Premise
121	significantly	_	_	I-Premise
122	decreased	_	_	I-Premise
123	from	_	_	I-Premise
124	baseline	_	_	I-Premise
125	levels	_	_	I-Premise
126	in	_	_	I-Premise
127	vitamin	_	_	I-Premise
128	D	_	_	I-Premise
129	and	_	_	I-Premise
130	calcitriol	_	_	I-Premise
131	treated	_	_	I-Premise
132	groups	_	_	I-Premise
133	(	_	_	I-Premise
134	P	_	_	I-Premise
135	<	_	_	I-Premise
136	0.05	_	_	I-Premise
137	)	_	_	I-Premise
138	.	_	_	I-Premise

139	Serum	_	_	B-Premise
140	and	_	_	I-Premise
141	gamma	_	_	I-Premise
142	glutamyl	_	_	I-Premise
143	transferase	_	_	I-Premise
144	(	_	_	I-Premise
145	GGT	_	_	I-Premise
146	)	_	_	I-Premise
147	level	_	_	I-Premise
148	was	_	_	I-Premise
149	also	_	_	I-Premise
150	significantly	_	_	I-Premise
151	decreased	_	_	I-Premise
152	compared	_	_	I-Premise
153	to	_	_	I-Premise
154	the	_	_	I-Premise
155	baseline	_	_	I-Premise
156	levels	_	_	I-Premise
157	after	_	_	I-Premise
158	12	_	_	I-Premise
159	weeks	_	_	I-Premise
160	of	_	_	I-Premise
161	treatment	_	_	I-Premise
162	with	_	_	I-Premise
163	vitamin	_	_	I-Premise
164	D.	_	_	I-Premise
165	There	_	_	B-Premise
166	was	_	_	I-Premise
167	no	_	_	I-Premise
168	statistically	_	_	I-Premise
169	significant	_	_	I-Premise
170	difference	_	_	I-Premise
171	between	_	_	I-Premise
172	placebo	_	_	I-Premise
173	,	_	_	I-Premise
174	calcitriol	_	_	I-Premise
175	,	_	_	I-Premise
176	vitamin	_	_	I-Premise
177	D	_	_	I-Premise
178	groups	_	_	I-Premise
179	in	_	_	I-Premise
180	terms	_	_	I-Premise
181	of	_	_	I-Premise
182	serum	_	_	I-Premise
183	aminotransferase	_	_	I-Premise
184	,	_	_	I-Premise
185	alkaline	_	_	I-Premise
186	phosphatase	_	_	I-Premise
187	,	_	_	I-Premise
188	serum	_	_	I-Premise
189	GGT	_	_	I-Premise
190	and	_	_	I-Premise
191	lipid	_	_	I-Premise
192	profile	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	>	_	_	I-Premise
196	0.05	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	While	_	_	O
200	significant	_	_	B-Claim
201	reduction	_	_	I-Claim
202	of	_	_	I-Claim
203	serum	_	_	I-Claim
204	alkaline	_	_	I-Claim
205	phosphatase	_	_	I-Claim
206	and	_	_	I-Claim
207	GGT	_	_	I-Claim
208	were	_	_	I-Claim
209	seen	_	_	I-Claim
210	with	_	_	I-Claim
211	vitamin	_	_	I-Claim
212	D	_	_	I-Claim
213	and	_	_	I-Claim
214	calcitriol	_	_	I-Claim
215	supplementation	_	_	I-Claim
216	from	_	_	I-Claim
217	baseline	_	_	I-Claim
218	levels	_	_	I-Claim
219	,	_	_	I-Claim
220	no	_	_	B-Claim
221	beneficial	_	_	I-Claim
222	effects	_	_	I-Claim
223	was	_	_	I-Claim
224	seen	_	_	I-Claim
225	when	_	_	I-Claim
226	comparing	_	_	I-Claim
227	vitamin	_	_	I-Claim
228	D	_	_	I-Claim
229	,	_	_	I-Claim
230	calcitriol	_	_	I-Claim
231	and	_	_	I-Claim
232	placebo	_	_	I-Claim
233	groups	_	_	I-Claim
234	at	_	_	I-Claim
235	the	_	_	I-Claim
236	end	_	_	I-Claim
237	of	_	_	I-Claim
238	trial	_	_	I-Claim
239	.	_	_	I-Claim


0	To	_	_	O
1	estimate	_	_	O
2	the	_	_	O
3	real-world	_	_	O
4	effects	_	_	O
5	of	_	_	O
6	offering	_	_	O
7	a	_	_	O
8	group-based	_	_	O
9	lifestyle	_	_	O
10	intervention	_	_	O
11	(	_	_	O
12	GLI	_	_	O
13	)	_	_	O
14	to	_	_	O
15	adults	_	_	O
16	with	_	_	O
17	diabetes	_	_	O
18	.	_	_	O

19	This	_	_	O
20	randomized	_	_	O
21	encouragement	_	_	O
22	trial	_	_	O
23	included	_	_	O
24	adult	_	_	O
25	primary	_	_	O
26	care	_	_	O
27	patients	_	_	O
28	in	_	_	O
29	metropolitan	_	_	O
30	Chicago	_	_	O
31	with	_	_	O
32	type	_	_	O
33	2	_	_	O
34	diabetes	_	_	O
35	and	_	_	O
36	body	_	_	O
37	mass	_	_	O
38	index	_	_	O
39	24	_	_	O
40	kg/m2	_	_	O
41	.	_	_	O

42	Participants	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	to	_	_	O
46	standard	_	_	O
47	care	_	_	O
48	(	_	_	O
49	brief	_	_	O
50	dietary	_	_	O
51	and	_	_	O
52	lifestyle	_	_	O
53	counseling	_	_	O
54	)	_	_	O
55	or	_	_	O
56	standard	_	_	O
57	care	_	_	O
58	plus	_	_	O
59	being	_	_	O
60	encouraged	_	_	O
61	,	_	_	O
62	but	_	_	O
63	not	_	_	O
64	required	_	_	O
65	,	_	_	O
66	to	_	_	O
67	participate	_	_	O
68	in	_	_	O
69	a	_	_	O
70	free-of-charge	_	_	O
71	GLI	_	_	O
72	offered	_	_	O
73	by	_	_	O
74	the	_	_	O
75	YMCA	_	_	O
76	.	_	_	O

77	The	_	_	O
78	GLI	_	_	O
79	was	_	_	O
80	a	_	_	O
81	group-based	_	_	O
82	adaptation	_	_	O
83	of	_	_	O
84	the	_	_	O
85	Look	_	_	O
86	AHEAD	_	_	O
87	lifestyle	_	_	O
88	intervention	_	_	O
89	.	_	_	O

90	Of	_	_	O
91	331	_	_	O
92	participants	_	_	O
93	,	_	_	O
94	167	_	_	O
95	were	_	_	O
96	randomized	_	_	O
97	to	_	_	O
98	standard	_	_	O
99	care	_	_	O
100	and	_	_	O
101	164	_	_	O
102	to	_	_	O
103	the	_	_	O
104	GLI	_	_	O
105	encouragement	_	_	O
106	arm	_	_	O
107	.	_	_	O

108	About	_	_	O
109	one	_	_	O
110	third	_	_	O
111	of	_	_	O
112	participants	_	_	O
113	were	_	_	O
114	non-Hispanic	_	_	O
115	White	_	_	O
116	(	_	_	O
117	34.4	_	_	O
118	%	_	_	O
119	)	_	_	O
120	.	_	_	O

121	In	_	_	O
122	the	_	_	O
123	GLI	_	_	O
124	arm	_	_	O
125	,	_	_	O
126	75	_	_	O
127	(	_	_	O
128	45.7	_	_	O
129	%	_	_	O
130	)	_	_	O
131	attended	_	_	O
132	1	_	_	O
133	GLI	_	_	O
134	visits	_	_	O
135	.	_	_	O

136	In	_	_	B-Premise
137	the	_	_	I-Premise
138	primary	_	_	I-Premise
139	intention-to-treat	_	_	I-Premise
140	analysis	_	_	I-Premise
141	,	_	_	I-Premise
142	the	_	_	I-Premise
143	effect	_	_	I-Premise
144	of	_	_	I-Premise
145	GLI	_	_	I-Premise
146	encouragement	_	_	I-Premise
147	was	_	_	I-Premise
148	0.95	_	_	I-Premise
149	%	_	_	I-Premise
150	weight	_	_	I-Premise
151	loss	_	_	I-Premise
152	at	_	_	I-Premise
153	six	_	_	I-Premise
154	months	_	_	I-Premise
155	(	_	_	I-Premise
156	95	_	_	I-Premise
157	%	_	_	I-Premise
158	confidence	_	_	I-Premise
159	interval	_	_	I-Premise
160	[	_	_	I-Premise
161	CI	_	_	I-Premise
162	]	_	_	I-Premise
163	,	_	_	I-Premise
164	0.13-1.77	_	_	I-Premise
165	%	_	_	I-Premise
166	;	_	_	I-Premise
167	P	_	_	I-Premise
168	=	_	_	I-Premise
169	0.02	_	_	I-Premise
170	)	_	_	I-Premise
171	,	_	_	I-Premise
172	and	_	_	I-Premise
173	1.20	_	_	I-Premise
174	%	_	_	I-Premise
175	weight	_	_	I-Premise
176	loss	_	_	I-Premise
177	at	_	_	I-Premise
178	12	_	_	I-Premise
179	months	_	_	I-Premise
180	(	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	,	_	_	I-Premise
185	0.05-2.36	_	_	I-Premise
186	%	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	0.04	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	At	_	_	B-Premise
194	12	_	_	I-Premise
195	months	_	_	I-Premise
196	,	_	_	I-Premise
197	there	_	_	I-Premise
198	was	_	_	I-Premise
199	a	_	_	I-Premise
200	0.30	_	_	I-Premise
201	%	_	_	I-Premise
202	(	_	_	I-Premise
203	3.3	_	_	I-Premise
204	mmol/mol	_	_	I-Premise
205	)	_	_	I-Premise
206	reduction	_	_	I-Premise
207	in	_	_	I-Premise
208	hemoglobin	_	_	I-Premise
209	A1c	_	_	I-Premise
210	,	_	_	I-Premise
211	but	_	_	B-Premise
212	this	_	_	I-Premise
213	result	_	_	I-Premise
214	did	_	_	I-Premise
215	not	_	_	I-Premise
216	achieve	_	_	I-Premise
217	statistical	_	_	I-Premise
218	significance	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	0.054	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	In	_	_	B-Premise
226	instrumental	_	_	I-Premise
227	variable	_	_	I-Premise
228	analysis	_	_	I-Premise
229	estimating	_	_	I-Premise
230	effects	_	_	I-Premise
231	among	_	_	I-Premise
232	the	_	_	I-Premise
233	subgroup	_	_	I-Premise
234	of	_	_	I-Premise
235	participants	_	_	I-Premise
236	who	_	_	I-Premise
237	attended	_	_	I-Premise
238	any	_	_	I-Premise
239	GLI	_	_	I-Premise
240	visits	_	_	I-Premise
241	,	_	_	I-Premise
242	the	_	_	I-Premise
243	effect	_	_	I-Premise
244	of	_	_	I-Premise
245	GLI	_	_	I-Premise
246	attendance	_	_	I-Premise
247	was	_	_	I-Premise
248	2.30	_	_	I-Premise
249	%	_	_	I-Premise
250	weight	_	_	I-Premise
251	loss	_	_	I-Premise
252	at	_	_	I-Premise
253	six	_	_	I-Premise
254	months	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.30-4.30	_	_	I-Premise
261	%	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	0.02	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	2.07	_	_	I-Premise
270	%	_	_	I-Premise
271	weight	_	_	I-Premise
272	loss	_	_	I-Premise
273	at	_	_	I-Premise
274	12	_	_	I-Premise
275	months	_	_	I-Premise
276	(	_	_	I-Premise
277	95	_	_	I-Premise
278	%	_	_	I-Premise
279	CI	_	_	I-Premise
280	,	_	_	I-Premise
281	0.25-3.88	_	_	I-Premise
282	%	_	_	I-Premise
283	;	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	0.02	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	We	_	_	O
290	detected	_	_	O
291	no	_	_	O
292	significant	_	_	O
293	blood	_	_	O
294	pressure	_	_	O
295	or	_	_	O
296	cholesterol	_	_	O
297	effects	_	_	O
298	.	_	_	O

299	Among	_	_	B-Claim
300	adults	_	_	I-Claim
301	with	_	_	I-Claim
302	type	_	_	I-Claim
303	2	_	_	I-Claim
304	diabetes	_	_	I-Claim
305	,	_	_	I-Claim
306	a	_	_	I-Claim
307	group-based	_	_	I-Claim
308	lifestyle	_	_	I-Claim
309	intervention	_	_	I-Claim
310	in	_	_	I-Claim
311	a	_	_	I-Claim
312	community-based	_	_	I-Claim
313	setting	_	_	I-Claim
314	achieved	_	_	I-Claim
315	modest	_	_	I-Claim
316	weight	_	_	I-Claim
317	loss	_	_	I-Claim
318	at	_	_	I-Claim
319	6	_	_	I-Claim
320	and	_	_	I-Claim
321	12	_	_	I-Claim
322	months	_	_	I-Claim
323	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	continuous	_	_	O
6	glucose	_	_	O
7	monitoring	_	_	O
8	(	_	_	O
9	CGM	_	_	O
10	)	_	_	O
11	on	_	_	O
12	nocturnal	_	_	O
13	and	_	_	O
14	daytime	_	_	O
15	hypoglycemia	_	_	O
16	in	_	_	O
17	persons	_	_	O
18	with	_	_	O
19	type	_	_	O
20	1	_	_	O
21	diabetes	_	_	O
22	treated	_	_	O
23	with	_	_	O
24	multiple	_	_	O
25	daily	_	_	O
26	insulin	_	_	O
27	injections	_	_	O
28	(	_	_	O
29	MDI	_	_	O
30	)	_	_	O
31	;	_	_	O
32	we	_	_	O
33	also	_	_	O
34	evaluated	_	_	O
35	factors	_	_	O
36	related	_	_	O
37	to	_	_	O
38	differences	_	_	O
39	in	_	_	O
40	hypoglycemia	_	_	O
41	confidence	_	_	O
42	in	_	_	O
43	this	_	_	O
44	population	_	_	O
45	.	_	_	O

46	Evaluations	_	_	O
47	were	_	_	O
48	performed	_	_	O
49	from	_	_	O
50	the	_	_	O
51	GOLD	_	_	O
52	randomized	_	_	O
53	trial	_	_	O
54	,	_	_	O
55	an	_	_	O
56	open-label	_	_	O
57	multicenter	_	_	O
58	crossover	_	_	O
59	randomized	_	_	O
60	clinical	_	_	O
61	trial	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	161	_	_	O
66	)	_	_	O
67	over	_	_	O
68	69	_	_	O
69	weeks	_	_	O
70	comparing	_	_	O
71	CGM	_	_	O
72	to	_	_	O
73	self-measurement	_	_	O
74	of	_	_	O
75	blood	_	_	O
76	glucose	_	_	O
77	(	_	_	O
78	SMBG	_	_	O
79	)	_	_	O
80	in	_	_	O
81	persons	_	_	O
82	with	_	_	O
83	type	_	_	O
84	1	_	_	O
85	diabetes	_	_	O
86	treated	_	_	O
87	with	_	_	O
88	MDI	_	_	O
89	.	_	_	O

90	Masked	_	_	O
91	CGM	_	_	O
92	and	_	_	O
93	the	_	_	O
94	hypoglycemia	_	_	O
95	confidence	_	_	O
96	questionnaire	_	_	O
97	were	_	_	O
98	used	_	_	O
99	for	_	_	O
100	evaluations	_	_	O
101	.	_	_	O

102	Time	_	_	B-Premise
103	with	_	_	I-Premise
104	nocturnal	_	_	I-Premise
105	hypoglycemia	_	_	I-Premise
106	,	_	_	I-Premise
107	glucose	_	_	I-Premise
108	levels	_	_	I-Premise
109	<	_	_	I-Premise
110	70	_	_	I-Premise
111	mg/dL	_	_	I-Premise
112	was	_	_	I-Premise
113	reduced	_	_	I-Premise
114	by	_	_	I-Premise
115	48	_	_	I-Premise
116	%	_	_	I-Premise
117	(	_	_	I-Premise
118	10.2	_	_	I-Premise
119	vs.	_	_	I-Premise
120	19.6	_	_	I-Premise
121	min	_	_	I-Premise
122	each	_	_	I-Premise
123	night	_	_	I-Premise
124	,	_	_	I-Premise
125	P	_	_	I-Premise
126	<	_	_	I-Premise
127	0.001	_	_	I-Premise
128	)	_	_	I-Premise
129	and	_	_	I-Premise
130	glucose	_	_	I-Premise
131	levels	_	_	I-Premise
132	<	_	_	I-Premise
133	54	_	_	I-Premise
134	mg/dL	_	_	I-Premise
135	by	_	_	I-Premise
136	65	_	_	I-Premise
137	%	_	_	I-Premise
138	.	_	_	I-Premise

139	(	_	_	I-Premise
140	3.1	_	_	I-Premise
141	vs.	_	_	I-Premise
142	8.9	_	_	I-Premise
143	min	_	_	I-Premise
144	,	_	_	I-Premise
145	P	_	_	I-Premise
146	<	_	_	I-Premise
147	0.001	_	_	I-Premise
148	)	_	_	I-Premise
149	.	_	_	I-Premise

150	For	_	_	B-Premise
151	the	_	_	I-Premise
152	corresponding	_	_	I-Premise
153	glucose	_	_	I-Premise
154	cutoffs	_	_	I-Premise
155	,	_	_	I-Premise
156	daytime	_	_	I-Premise
157	hypoglycemia	_	_	I-Premise
158	was	_	_	I-Premise
159	reduced	_	_	I-Premise
160	by	_	_	I-Premise
161	40	_	_	I-Premise
162	%	_	_	I-Premise
163	(	_	_	I-Premise
164	29	_	_	I-Premise
165	vs.	_	_	I-Premise
166	49	_	_	I-Premise
167	min	_	_	I-Premise
168	,	_	_	I-Premise
169	P	_	_	I-Premise
170	<	_	_	I-Premise
171	0.001	_	_	I-Premise
172	)	_	_	I-Premise
173	and	_	_	I-Premise
174	54	_	_	I-Premise
175	%	_	_	I-Premise
176	(	_	_	I-Premise
177	8	_	_	I-Premise
178	vs.	_	_	I-Premise
179	18	_	_	I-Premise
180	min.	_	_	I-Premise
181	,	_	_	I-Premise
182	P	_	_	I-Premise
183	<	_	_	I-Premise
184	0.001	_	_	I-Premise
185	)	_	_	I-Premise
186	,	_	_	I-Premise
187	respectively	_	_	I-Premise
188	.	_	_	I-Premise

189	Compared	_	_	B-Premise
190	with	_	_	I-Premise
191	SMBG	_	_	I-Premise
192	,	_	_	I-Premise
193	CGM	_	_	I-Premise
194	use	_	_	I-Premise
195	improved	_	_	I-Premise
196	hypoglycemia-related	_	_	I-Premise
197	confidence	_	_	I-Premise
198	in	_	_	I-Premise
199	social	_	_	I-Premise
200	situations	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	0.016	_	_	I-Premise
205	)	_	_	I-Premise
206	and	_	_	I-Premise
207	confidence	_	_	I-Premise
208	in	_	_	I-Premise
209	more	_	_	I-Premise
210	broadly	_	_	I-Premise
211	avoiding	_	_	I-Premise
212	serious	_	_	I-Premise
213	problems	_	_	I-Premise
214	due	_	_	I-Premise
215	to	_	_	I-Premise
216	hypoglycemia	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	0.0020	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	Persons	_	_	B-Premise
224	also	_	_	I-Premise
225	reported	_	_	I-Premise
226	greater	_	_	I-Premise
227	confidence	_	_	I-Premise
228	in	_	_	I-Premise
229	detecting	_	_	I-Premise
230	and	_	_	I-Premise
231	responding	_	_	I-Premise
232	to	_	_	I-Premise
233	decreasing	_	_	I-Premise
234	blood	_	_	I-Premise
235	glucose	_	_	I-Premise
236	levels	_	_	I-Premise
237	(	_	_	I-Premise
238	thereby	_	_	I-Premise
239	avoiding	_	_	I-Premise
240	hypoglycemia	_	_	I-Premise
241	)	_	_	I-Premise
242	during	_	_	I-Premise
243	CGM	_	_	I-Premise
244	use	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	0.0033	_	_	I-Premise
249	)	_	_	I-Premise
250	and	_	_	O
251	indicated	_	_	B-Premise
252	greater	_	_	I-Premise
253	conviction	_	_	I-Premise
254	that	_	_	I-Premise
255	they	_	_	I-Premise
256	could	_	_	I-Premise
257	more	_	_	I-Premise
258	freely	_	_	I-Premise
259	live	_	_	I-Premise
260	their	_	_	I-Premise
261	lives	_	_	I-Premise
262	despite	_	_	I-Premise
263	the	_	_	I-Premise
264	risk	_	_	I-Premise
265	of	_	_	I-Premise
266	hypoglycemia	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	0.022	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	CGM	_	_	B-Claim
274	reduced	_	_	I-Claim
275	time	_	_	I-Claim
276	in	_	_	I-Claim
277	both	_	_	I-Claim
278	nocturnal	_	_	I-Claim
279	and	_	_	I-Claim
280	daytime	_	_	I-Claim
281	hypoglycemia	_	_	I-Claim
282	in	_	_	I-Claim
283	persons	_	_	I-Claim
284	with	_	_	I-Claim
285	type	_	_	I-Claim
286	1	_	_	I-Claim
287	diabetes	_	_	I-Claim
288	treated	_	_	I-Claim
289	with	_	_	I-Claim
290	MDI	_	_	I-Claim
291	and	_	_	I-Claim
292	improved	_	_	I-Claim
293	hypoglycemia-related	_	_	I-Claim
294	confidence	_	_	I-Claim
295	,	_	_	I-Claim
296	especially	_	_	I-Claim
297	in	_	_	I-Claim
298	social	_	_	I-Claim
299	situations	_	_	I-Claim
300	,	_	_	I-Claim
301	thus	_	_	I-Claim
302	contributing	_	_	I-Claim
303	to	_	_	I-Claim
304	greater	_	_	I-Claim
305	well-being	_	_	I-Claim
306	and	_	_	I-Claim
307	quality	_	_	I-Claim
308	of	_	_	I-Claim
309	life	_	_	I-Claim
310	.	_	_	I-Claim


0	Treatment-related	_	_	B-Claim
1	quality	_	_	I-Claim
2	of	_	_	I-Claim
3	life	_	_	I-Claim
4	(	_	_	I-Claim
5	QOL	_	_	I-Claim
6	)	_	_	I-Claim
7	is	_	_	I-Claim
8	an	_	_	I-Claim
9	important	_	_	I-Claim
10	aspect	_	_	I-Claim
11	of	_	_	I-Claim
12	diabetes	_	_	I-Claim
13	management	_	_	I-Claim
14	.	_	_	I-Claim

15	However	_	_	O
16	,	_	_	O
17	no	_	_	O
18	studies	_	_	O
19	have	_	_	O
20	compared	_	_	O
21	the	_	_	O
22	influence	_	_	O
23	of	_	_	O
24	dipeptidyl	_	_	O
25	peptidase-4	_	_	O
26	inhibitors	_	_	O
27	versus	_	_	O
28	alpha-glucosidase	_	_	O
29	inhibitors	_	_	O
30	on	_	_	O
31	treatment-related	_	_	O
32	QOL	_	_	O
33	.	_	_	O

34	This	_	_	O
35	prespecified	_	_	O
36	sub-analysis	_	_	O
37	of	_	_	O
38	the	_	_	O
39	Linagliptin	_	_	O
40	Study	_	_	O
41	of	_	_	O
42	Effects	_	_	O
43	on	_	_	O
44	Postprandial	_	_	O
45	blood	_	_	O
46	glucose	_	_	O
47	(	_	_	O
48	L-STEP	_	_	O
49	)	_	_	O
50	compared	_	_	O
51	the	_	_	O
52	effects	_	_	O
53	of	_	_	O
54	linagliptin	_	_	O
55	(	_	_	O
56	5	_	_	O
57	mg	_	_	O
58	once	_	_	O
59	daily	_	_	O
60	)	_	_	O
61	and	_	_	O
62	voglibose	_	_	O
63	(	_	_	O
64	0.2	_	_	O
65	mg/meal	_	_	O
66	thrice	_	_	O
67	daily	_	_	O
68	)	_	_	O
69	on	_	_	O
70	treatment-related	_	_	O
71	QOL	_	_	O
72	in	_	_	O
73	Japanese	_	_	O
74	patients	_	_	O
75	with	_	_	O
76	type	_	_	O
77	2	_	_	O
78	diabetes	_	_	O
79	(	_	_	O
80	T2DM	_	_	O
81	)	_	_	O
82	inadequately	_	_	O
83	controlled	_	_	O
84	with	_	_	O
85	diet	_	_	O
86	and	_	_	O
87	exercise	_	_	O
88	therapy	_	_	O
89	.	_	_	O

90	Among	_	_	O
91	366	_	_	O
92	subjects	_	_	O
93	in	_	_	O
94	the	_	_	O
95	original	_	_	O
96	study	_	_	O
97	,	_	_	O
98	182	_	_	O
99	in	_	_	O
100	the	_	_	O
101	linagliptin	_	_	O
102	group	_	_	O
103	and	_	_	O
104	173	_	_	O
105	in	_	_	O
106	the	_	_	O
107	voglibose	_	_	O
108	group	_	_	O
109	were	_	_	O
110	included	_	_	O
111	in	_	_	O
112	this	_	_	O
113	analysis	_	_	O
114	.	_	_	O

115	The	_	_	O
116	outcome	_	_	O
117	of	_	_	O
118	this	_	_	O
119	study	_	_	O
120	was	_	_	O
121	change	_	_	O
122	in	_	_	O
123	QOL	_	_	O
124	as	_	_	O
125	assessed	_	_	O
126	by	_	_	O
127	the	_	_	O
128	Diabetes	_	_	O
129	Therapy-Related	_	_	O
130	Quality	_	_	O
131	of	_	_	O
132	Life	_	_	O
133	17	_	_	O
134	(	_	_	O
135	DTR-QOL17	_	_	O
136	)	_	_	O
137	questionnaire	_	_	O
138	from	_	_	O
139	baseline	_	_	O
140	to	_	_	O
141	week	_	_	O
142	12	_	_	O
143	.	_	_	O

144	Compared	_	_	B-Premise
145	with	_	_	I-Premise
146	baseline	_	_	I-Premise
147	data	_	_	I-Premise
148	,	_	_	I-Premise
149	total	_	_	I-Premise
150	DTR-QOL17	_	_	I-Premise
151	scores	_	_	I-Premise
152	were	_	_	I-Premise
153	significantly	_	_	I-Premise
154	higher	_	_	I-Premise
155	after	_	_	I-Premise
156	12	_	_	I-Premise
157	weeks	_	_	I-Premise
158	of	_	_	I-Premise
159	linagliptin	_	_	I-Premise
160	and	_	_	I-Premise
161	voglibose	_	_	I-Premise
162	treatment	_	_	I-Premise
163	.	_	_	I-Premise

164	The	_	_	B-Premise
165	change	_	_	I-Premise
166	in	_	_	I-Premise
167	the	_	_	I-Premise
168	total	_	_	I-Premise
169	DTR-QOL17	_	_	I-Premise
170	score	_	_	I-Premise
171	and	_	_	I-Premise
172	the	_	_	I-Premise
173	score	_	_	I-Premise
174	of	_	_	I-Premise
175	one	_	_	I-Premise
176	domain	_	_	I-Premise
177	,	_	_	I-Premise
178	burden	_	_	I-Premise
179	on	_	_	I-Premise
180	social	_	_	I-Premise
181	activities	_	_	I-Premise
182	and	_	_	I-Premise
183	daily	_	_	I-Premise
184	activities	_	_	I-Premise
185	,	_	_	I-Premise
186	was	_	_	I-Premise
187	significantly	_	_	I-Premise
188	greater	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	linagliptin	_	_	I-Premise
192	group	_	_	I-Premise
193	than	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	voglibose	_	_	I-Premise
197	group	_	_	I-Premise
198	.	_	_	I-Premise

199	In	_	_	B-Premise
200	addition	_	_	I-Premise
201	,	_	_	I-Premise
202	only	_	_	I-Premise
203	linagliptin	_	_	I-Premise
204	treatment	_	_	I-Premise
205	was	_	_	I-Premise
206	identified	_	_	I-Premise
207	as	_	_	I-Premise
208	a	_	_	I-Premise
209	factor	_	_	I-Premise
210	associated	_	_	I-Premise
211	with	_	_	I-Premise
212	an	_	_	I-Premise
213	increased	_	_	I-Premise
214	total	_	_	I-Premise
215	DTR-QOL17	_	_	I-Premise
216	score	_	_	I-Premise
217	.	_	_	I-Premise

218	Linagliptin	_	_	B-Claim
219	is	_	_	I-Claim
220	superior	_	_	I-Claim
221	to	_	_	I-Claim
222	voglibose	_	_	I-Claim
223	in	_	_	I-Claim
224	terms	_	_	I-Claim
225	of	_	_	I-Claim
226	improving	_	_	I-Claim
227	treatment-related	_	_	I-Claim
228	QOL	_	_	I-Claim
229	in	_	_	I-Claim
230	Japanese	_	_	I-Claim
231	patients	_	_	I-Claim
232	with	_	_	I-Claim
233	T2DM	_	_	I-Claim
234	.	_	_	I-Claim


0	A	_	_	O
1	single-item	_	_	O
2	linear	_	_	O
3	analogue	_	_	O
4	self-assessment	_	_	O
5	scale	_	_	O
6	for	_	_	O
7	mood	_	_	O
8	was	_	_	O
9	compared	_	_	O
10	with	_	_	O
11	a	_	_	O
12	28-item	_	_	O
13	adjective	_	_	O
14	checklist	_	_	O
15	for	_	_	O
16	emotional	_	_	O
17	well-being	_	_	O
18	.	_	_	O

19	To	_	_	O
20	confirm	_	_	O
21	its	_	_	O
22	concurrent	_	_	O
23	validity	_	_	O
24	and	_	_	O
25	responsiveness	_	_	O
26	to	_	_	O
27	treatment	_	_	O
28	and	_	_	O
29	recurrence	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	,	_	_	O
36	emotional	_	_	O
37	well-being	_	_	O
38	was	_	_	O
39	assessed	_	_	O
40	every	_	_	O
41	3	_	_	O
42	months	_	_	O
43	for	_	_	O
44	2	_	_	O
45	years	_	_	O
46	and	_	_	O
47	at	_	_	O
48	1	_	_	O
49	and	_	_	O
50	6	_	_	O
51	months	_	_	O
52	after	_	_	O
53	recurrence	_	_	O
54	in	_	_	O
55	1,169	_	_	O
56	patients	_	_	O
57	who	_	_	O
58	were	_	_	O
59	premenopausal	_	_	O
60	and	_	_	O
61	960	_	_	O
62	patients	_	_	O
63	who	_	_	O
64	were	_	_	O
65	postmenopausal	_	_	O
66	.	_	_	O

67	These	_	_	O
68	patients	_	_	O
69	were	_	_	O
70	enrolled	_	_	O
71	in	_	_	O
72	two	_	_	O
73	International	_	_	O
74	Breast	_	_	O
75	Cancer	_	_	O
76	Study	_	_	O
77	Group	_	_	O
78	randomized	_	_	O
79	clinical	_	_	O
80	trials	_	_	O
81	in	_	_	O
82	operable	_	_	O
83	breast	_	_	O
84	cancer	_	_	O
85	conducted	_	_	O
86	from	_	_	O
87	1986	_	_	O
88	to	_	_	O
89	1993	_	_	O
90	.	_	_	O

91	To	_	_	O
92	assess	_	_	O
93	concurrent	_	_	O
94	validity	_	_	O
95	,	_	_	O
96	Pearson	_	_	O
97	's	_	_	O
98	correlation	_	_	O
99	between	_	_	O
100	the	_	_	O
101	linear	_	_	O
102	analogue	_	_	O
103	self-assessment	_	_	O
104	scale	_	_	O
105	and	_	_	O
106	the	_	_	O
107	adjective	_	_	O
108	checklist	_	_	O
109	were	_	_	O
110	calculated	_	_	O
111	for	_	_	O
112	each	_	_	O
113	time-point	_	_	O
114	within	_	_	O
115	each	_	_	O
116	treatment	_	_	O
117	group	_	_	O
118	and	_	_	O
119	for	_	_	O
120	the	_	_	O
121	two	_	_	O
122	assessments	_	_	O
123	after	_	_	O
124	recurrence	_	_	O
125	.	_	_	O

126	Responsiveness	_	_	O
127	to	_	_	O
128	treatment	_	_	O
129	and	_	_	O
130	recurrence	_	_	O
131	were	_	_	O
132	analyzed	_	_	O
133	using	_	_	O
134	paired	_	_	O
135	t	_	_	O
136	tests	_	_	O
137	and	_	_	O
138	the	_	_	O
139	squared	_	_	O
140	ratio	_	_	O
141	of	_	_	O
142	these	_	_	O
143	t	_	_	O
144	tests	_	_	O
145	,	_	_	O
146	an	_	_	O
147	estimate	_	_	O
148	of	_	_	O
149	relative	_	_	O
150	efficiency	_	_	O
151	.	_	_	O

152	Concurrent	_	_	O
153	validity	_	_	O
154	of	_	_	O
155	the	_	_	O
156	mood	_	_	O
157	linear	_	_	O
158	analogue	_	_	O
159	self-assessment	_	_	O
160	was	_	_	O
161	consistently	_	_	O
162	confirmed	_	_	O
163	across	_	_	O
164	four	_	_	O
165	language	_	_	O
166	groups	_	_	O
167	.	_	_	O

168	Both	_	_	B-Claim
169	measures	_	_	I-Claim
170	were	_	_	I-Claim
171	responsive	_	_	I-Claim
172	;	_	_	I-Claim
173	out	_	_	B-Premise
174	of	_	_	I-Premise
175	24	_	_	I-Premise
176	changes	_	_	I-Premise
177	over	_	_	I-Premise
178	time	_	_	I-Premise
179	,	_	_	I-Premise
180	19	_	_	I-Premise
181	were	_	_	I-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	expected	_	_	I-Premise
185	direction	_	_	I-Premise
186	for	_	_	I-Premise
187	the	_	_	I-Premise
188	linear	_	_	I-Premise
189	analogue	_	_	I-Premise
190	self-assessment	_	_	I-Premise
191	scale	_	_	I-Premise
192	(	_	_	I-Premise
193	p	_	_	I-Premise
194	<	_	_	I-Premise
195	or	_	_	I-Premise
196	=	_	_	I-Premise
197	0.05	_	_	I-Premise
198	for	_	_	I-Premise
199	9	_	_	I-Premise
200	of	_	_	I-Premise
201	19	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	17	_	_	I-Premise
205	for	_	_	I-Premise
206	the	_	_	I-Premise
207	adjective	_	_	I-Premise
208	checklist	_	_	I-Premise
209	(	_	_	I-Premise
210	p	_	_	I-Premise
211	<	_	_	I-Premise
212	or	_	_	I-Premise
213	=	_	_	I-Premise
214	0.05	_	_	I-Premise
215	for	_	_	I-Premise
216	10	_	_	I-Premise
217	of	_	_	I-Premise
218	17	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	The	_	_	B-Premise
222	linear	_	_	I-Premise
223	analogue	_	_	I-Premise
224	self-assessment	_	_	I-Premise
225	scale	_	_	I-Premise
226	was	_	_	I-Premise
227	less	_	_	I-Premise
228	but	_	_	I-Premise
229	significantly	_	_	I-Premise
230	efficient	_	_	I-Premise
231	for	_	_	I-Premise
232	detection	_	_	I-Premise
233	of	_	_	I-Premise
234	treatment	_	_	I-Premise
235	effects	_	_	I-Premise
236	,	_	_	I-Premise
237	with	_	_	I-Premise
238	relative	_	_	I-Premise
239	efficiency	_	_	I-Premise
240	estimates	_	_	I-Premise
241	ranging	_	_	I-Premise
242	from	_	_	I-Premise
243	0.16	_	_	I-Premise
244	to	_	_	I-Premise
245	2.45	_	_	I-Premise
246	and	_	_	I-Premise
247	a	_	_	I-Premise
248	median	_	_	I-Premise
249	of	_	_	I-Premise
250	0.66	_	_	I-Premise
251	among	_	_	I-Premise
252	the	_	_	I-Premise
253	comparisons	_	_	I-Premise
254	with	_	_	I-Premise
255	relatively	_	_	I-Premise
256	stable	_	_	I-Premise
257	estimates	_	_	I-Premise
258	(	_	_	I-Premise
259	/t/	_	_	I-Premise
260	>	_	_	I-Premise
261	or	_	_	I-Premise
262	=	_	_	I-Premise
263	1.0	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	I-Premise
266	more	_	_	I-Premise
267	efficient	_	_	I-Premise
268	for	_	_	I-Premise
269	recurrence	_	_	I-Premise
270	than	_	_	I-Premise
271	the	_	_	I-Premise
272	adjective	_	_	I-Premise
273	checklist	_	_	I-Premise
274	.	_	_	I-Premise

275	The	_	_	B-Claim
276	mood	_	_	I-Claim
277	linear	_	_	I-Claim
278	analogue	_	_	I-Claim
279	self-assessment	_	_	I-Claim
280	scale	_	_	I-Claim
281	is	_	_	I-Claim
282	a	_	_	I-Claim
283	valid	_	_	I-Claim
284	indicator	_	_	I-Claim
285	of	_	_	I-Claim
286	emotional	_	_	I-Claim
287	well-being	_	_	I-Claim
288	in	_	_	I-Claim
289	patients	_	_	I-Claim
290	with	_	_	I-Claim
291	breast	_	_	I-Claim
292	cancer	_	_	I-Claim
293	in	_	_	I-Claim
294	large	_	_	I-Claim
295	multicenter	_	_	I-Claim
296	,	_	_	I-Claim
297	multicultural	_	_	I-Claim
298	trials	_	_	I-Claim
299	in	_	_	I-Claim
300	which	_	_	I-Claim
301	comprehensive	_	_	I-Claim
302	scales	_	_	I-Claim
303	are	_	_	I-Claim
304	less	_	_	I-Claim
305	feasible	_	_	I-Claim
306	.	_	_	I-Claim

307	This	_	_	B-Claim
308	investigation	_	_	I-Claim
309	supports	_	_	I-Claim
310	the	_	_	I-Claim
311	clinical	_	_	I-Claim
312	relevance	_	_	I-Claim
313	of	_	_	I-Claim
314	linear	_	_	I-Claim
315	analogue	_	_	I-Claim
316	self-assessment	_	_	I-Claim
317	scales	_	_	I-Claim
318	as	_	_	I-Claim
319	indicators	_	_	I-Claim
320	of	_	_	I-Claim
321	components	_	_	I-Claim
322	of	_	_	I-Claim
323	quality	_	_	I-Claim
324	of	_	_	I-Claim
325	life	_	_	I-Claim
326	in	_	_	I-Claim
327	cancer	_	_	I-Claim
328	clinical	_	_	I-Claim
329	trials	_	_	I-Claim
330	.	_	_	I-Claim


0	Combined	_	_	B-Claim
1	radiation	_	_	I-Claim
2	therapy	_	_	I-Claim
3	and	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	after	_	_	I-Claim
6	surgery	_	_	I-Claim
7	,	_	_	I-Claim
8	compared	_	_	I-Claim
9	with	_	_	I-Claim
10	postsurgical	_	_	I-Claim
11	radiation	_	_	I-Claim
12	therapy	_	_	I-Claim
13	alone	_	_	I-Claim
14	,	_	_	I-Claim
15	has	_	_	I-Claim
16	been	_	_	I-Claim
17	shown	_	_	I-Claim
18	to	_	_	I-Claim
19	improve	_	_	I-Claim
20	disease-free	_	_	I-Claim
21	survival	_	_	I-Claim
22	and	_	_	I-Claim
23	overall	_	_	I-Claim
24	survival	_	_	I-Claim
25	significantly	_	_	I-Claim
26	among	_	_	I-Claim
27	patients	_	_	I-Claim
28	with	_	_	I-Claim
29	poor-prognosis	_	_	I-Claim
30	(	_	_	I-Claim
31	i.e.	_	_	I-Claim
32	,	_	_	I-Claim
33	advanced	_	_	I-Claim
34	stage	_	_	I-Claim
35	disease	_	_	I-Claim
36	or	_	_	I-Claim
37	metastasis	_	_	I-Claim
38	to	_	_	I-Claim
39	regional	_	_	I-Claim
40	lymph	_	_	I-Claim
41	nodes	_	_	I-Claim
42	)	_	_	I-Claim
43	resectable	_	_	I-Claim
44	rectal	_	_	I-Claim
45	cancer	_	_	I-Claim
46	.	_	_	I-Claim

47	However	_	_	B-Claim
48	,	_	_	I-Claim
49	the	_	_	I-Claim
50	combined	_	_	I-Claim
51	therapy	_	_	I-Claim
52	is	_	_	I-Claim
53	associated	_	_	I-Claim
54	with	_	_	I-Claim
55	more	_	_	I-Claim
56	toxic	_	_	I-Claim
57	effects	_	_	I-Claim
58	,	_	_	I-Claim
59	raising	_	_	I-Claim
60	the	_	_	I-Claim
61	question	_	_	I-Claim
62	of	_	_	I-Claim
63	whether	_	_	I-Claim
64	the	_	_	I-Claim
65	benefits	_	_	I-Claim
66	of	_	_	I-Claim
67	the	_	_	I-Claim
68	treatment	_	_	I-Claim
69	justify	_	_	I-Claim
70	its	_	_	I-Claim
71	quality-of-life	_	_	I-Claim
72	costs	_	_	I-Claim
73	for	_	_	I-Claim
74	the	_	_	I-Claim
75	individual	_	_	I-Claim
76	patient	_	_	I-Claim
77	.	_	_	I-Claim

78	To	_	_	O
79	assess	_	_	O
80	the	_	_	O
81	trade-offs	_	_	O
82	between	_	_	O
83	improved	_	_	O
84	survival	_	_	O
85	and	_	_	O
86	increased	_	_	O
87	treatment	_	_	O
88	toxicity	_	_	O
89	,	_	_	O
90	we	_	_	O
91	reanalyzed	_	_	O
92	data	_	_	O
93	from	_	_	O
94	a	_	_	O
95	randomized	_	_	O
96	clinical	_	_	O
97	trial	_	_	O
98	that	_	_	O
99	compared	_	_	O
100	the	_	_	O
101	efficacy	_	_	O
102	of	_	_	O
103	combined	_	_	O
104	adjuvant	_	_	O
105	chemotherapy	_	_	O
106	and	_	_	O
107	radiation	_	_	O
108	therapy	_	_	O
109	with	_	_	O
110	adjuvant	_	_	O
111	radiation	_	_	O
112	therapy	_	_	O
113	alone	_	_	O
114	in	_	_	O
115	the	_	_	O
116	treatment	_	_	O
117	of	_	_	O
118	patients	_	_	O
119	with	_	_	O
120	poor-prognosis	_	_	O
121	resectable	_	_	O
122	rectal	_	_	O
123	cancer	_	_	O
124	.	_	_	O

125	The	_	_	O
126	data	_	_	O
127	were	_	_	O
128	from	_	_	O
129	a	_	_	O
130	North	_	_	O
131	Central	_	_	O
132	Cancer	_	_	O
133	Treatment	_	_	O
134	Group	_	_	O
135	trial	_	_	O
136	in	_	_	O
137	which	_	_	O
138	204	_	_	O
139	patients	_	_	O
140	with	_	_	O
141	poor-prognosis	_	_	O
142	rectal	_	_	O
143	cancer	_	_	O
144	were	_	_	O
145	randomly	_	_	O
146	assigned	_	_	O
147	to	_	_	O
148	receive	_	_	O
149	either	_	_	O
150	postoperative	_	_	O
151	radiation	_	_	O
152	therapy	_	_	O
153	alone	_	_	O
154	or	_	_	O
155	radiation	_	_	O
156	therapy	_	_	O
157	plus	_	_	O
158	fluorouracil-based	_	_	O
159	chemotherapy	_	_	O
160	.	_	_	O

161	A	_	_	O
162	quality-adjusted	_	_	O
163	time	_	_	O
164	without	_	_	O
165	symptoms	_	_	O
166	or	_	_	O
167	toxicity	_	_	O
168	(	_	_	O
169	Q-TWiST	_	_	O
170	)	_	_	O
171	analysis	_	_	O
172	was	_	_	O
173	used	_	_	O
174	to	_	_	O
175	account	_	_	O
176	for	_	_	O
177	freedom	_	_	O
178	from	_	_	O
179	symptomatic	_	_	O
180	disease	_	_	O
181	and	_	_	O
182	from	_	_	O
183	early	_	_	O
184	and	_	_	O
185	late	_	_	O
186	side	_	_	O
187	effects	_	_	O
188	of	_	_	O
189	treatment	_	_	O
190	.	_	_	O

191	All	_	_	O
192	reported	_	_	O
193	P	_	_	O
194	values	_	_	O
195	are	_	_	O
196	two-sided	_	_	O
197	.	_	_	O

198	As	_	_	B-Premise
199	reported	_	_	I-Premise
200	previously	_	_	I-Premise
201	,	_	_	I-Premise
202	the	_	_	I-Premise
203	combined	_	_	I-Premise
204	therapy	_	_	I-Premise
205	reduced	_	_	I-Premise
206	the	_	_	I-Premise
207	risk	_	_	I-Premise
208	of	_	_	I-Premise
209	relapse	_	_	I-Premise
210	by	_	_	I-Premise
211	34	_	_	I-Premise
212	%	_	_	I-Premise
213	(	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	confidence	_	_	I-Premise
217	interval	_	_	I-Premise
218	[	_	_	I-Premise
219	CI	_	_	I-Premise
220	]	_	_	I-Premise
221	=	_	_	I-Premise
222	12	_	_	I-Premise
223	%	_	_	I-Premise
224	-50	_	_	I-Premise
225	%	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.0016	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	reduced	_	_	I-Premise
233	the	_	_	I-Premise
234	overall	_	_	I-Premise
235	death	_	_	I-Premise
236	rate	_	_	I-Premise
237	by	_	_	I-Premise
238	29	_	_	I-Premise
239	%	_	_	I-Premise
240	(	_	_	I-Premise
241	95	_	_	I-Premise
242	%	_	_	I-Premise
243	CI	_	_	I-Premise
244	=	_	_	I-Premise
245	7	_	_	I-Premise
246	%	_	_	I-Premise
247	-45	_	_	I-Premise
248	%	_	_	I-Premise
249	;	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	.025	_	_	I-Premise
253	)	_	_	I-Premise
254	in	_	_	I-Premise
255	comparison	_	_	I-Premise
256	with	_	_	I-Premise
257	adjuvant	_	_	I-Premise
258	radiation	_	_	I-Premise
259	therapy	_	_	I-Premise
260	alone	_	_	I-Premise
261	.	_	_	I-Premise

262	In	_	_	B-Premise
263	the	_	_	I-Premise
264	5	_	_	I-Premise
265	years	_	_	I-Premise
266	following	_	_	I-Premise
267	assignment	_	_	I-Premise
268	to	_	_	I-Premise
269	treatment	_	_	I-Premise
270	,	_	_	I-Premise
271	patients	_	_	I-Premise
272	who	_	_	I-Premise
273	received	_	_	I-Premise
274	the	_	_	I-Premise
275	combined	_	_	I-Premise
276	therapy	_	_	I-Premise
277	had	_	_	I-Premise
278	more	_	_	I-Premise
279	time	_	_	I-Premise
280	with	_	_	I-Premise
281	toxicity	_	_	I-Premise
282	(	_	_	I-Premise
283	3.1	_	_	I-Premise
284	months	_	_	I-Premise
285	;	_	_	I-Premise
286	95	_	_	I-Premise
287	%	_	_	I-Premise
288	CI	_	_	I-Premise
289	=	_	_	I-Premise
290	2.0-4.1	_	_	I-Premise
291	months	_	_	I-Premise
292	)	_	_	I-Premise
293	,	_	_	I-Premise
294	shorter	_	_	I-Premise
295	survival	_	_	I-Premise
296	after	_	_	I-Premise
297	relapse	_	_	I-Premise
298	(	_	_	I-Premise
299	3.6	_	_	I-Premise
300	months	_	_	I-Premise
301	less	_	_	I-Premise
302	;	_	_	I-Premise
303	95	_	_	I-Premise
304	%	_	_	I-Premise
305	CI	_	_	I-Premise
306	=	_	_	I-Premise
307	0.9-6.3	_	_	I-Premise
308	months	_	_	I-Premise
309	less	_	_	I-Premise
310	)	_	_	I-Premise
311	,	_	_	I-Premise
312	and	_	_	I-Premise
313	more	_	_	I-Premise
314	TWiST	_	_	I-Premise
315	(	_	_	I-Premise
316	6.1	_	_	I-Premise
317	months	_	_	I-Premise
318	;	_	_	I-Premise
319	95	_	_	I-Premise
320	%	_	_	I-Premise
321	CI	_	_	I-Premise
322	=	_	_	I-Premise
323	0.2-12.0	_	_	I-Premise
324	months	_	_	I-Premise
325	)	_	_	I-Premise
326	than	_	_	I-Premise
327	patients	_	_	I-Premise
328	who	_	_	I-Premise
329	received	_	_	I-Premise
330	adjuvant	_	_	I-Premise
331	radiation	_	_	I-Premise
332	therapy	_	_	I-Premise
333	alone	_	_	I-Premise
334	.	_	_	I-Premise

335	Despite	_	_	B-Claim
336	an	_	_	I-Claim
337	increase	_	_	I-Claim
338	in	_	_	I-Claim
339	the	_	_	I-Claim
340	amount	_	_	I-Claim
341	of	_	_	I-Claim
342	time	_	_	I-Claim
343	that	_	_	I-Claim
344	individuals	_	_	I-Claim
345	spent	_	_	I-Claim
346	with	_	_	I-Claim
347	early	_	_	I-Claim
348	and	_	_	I-Claim
349	late	_	_	I-Claim
350	toxic	_	_	I-Claim
351	effects	_	_	I-Claim
352	,	_	_	I-Claim
353	the	_	_	I-Claim
354	Q-TWiST	_	_	I-Claim
355	analysis	_	_	I-Claim
356	indicated	_	_	I-Claim
357	that	_	_	I-Claim
358	the	_	_	I-Claim
359	combined	_	_	I-Claim
360	therapy	_	_	I-Claim
361	conferred	_	_	I-Claim
362	significantly	_	_	I-Claim
363	greater	_	_	I-Claim
364	benefit	_	_	I-Claim
365	for	_	_	I-Claim
366	a	_	_	I-Claim
367	wide	_	_	I-Claim
368	range	_	_	I-Claim
369	of	_	_	I-Claim
370	patient	_	_	I-Claim
371	preferences	_	_	I-Claim
372	about	_	_	I-Claim
373	living	_	_	I-Claim
374	with	_	_	I-Claim
375	the	_	_	I-Claim
376	toxicity	_	_	I-Claim
377	of	_	_	I-Claim
378	treatment	_	_	I-Claim
379	or	_	_	I-Claim
380	the	_	_	I-Claim
381	symptoms	_	_	I-Claim
382	of	_	_	I-Claim
383	overt	_	_	I-Claim
384	disease	_	_	I-Claim
385	.	_	_	I-Claim

386	Use	_	_	B-Claim
387	of	_	_	I-Claim
388	combined	_	_	I-Claim
389	chemotherapy	_	_	I-Claim
390	and	_	_	I-Claim
391	radiation	_	_	I-Claim
392	therapy	_	_	I-Claim
393	as	_	_	I-Claim
394	an	_	_	I-Claim
395	adjuvant	_	_	I-Claim
396	to	_	_	I-Claim
397	surgery	_	_	I-Claim
398	for	_	_	I-Claim
399	patients	_	_	I-Claim
400	with	_	_	I-Claim
401	poor-prognosis	_	_	I-Claim
402	resectable	_	_	I-Claim
403	rectal	_	_	I-Claim
404	cancer	_	_	I-Claim
405	is	_	_	I-Claim
406	justified	_	_	I-Claim
407	,	_	_	I-Claim
408	since	_	_	B-Premise
409	the	_	_	I-Premise
410	improved	_	_	I-Premise
411	outcome	_	_	I-Premise
412	in	_	_	I-Premise
413	terms	_	_	I-Premise
414	of	_	_	I-Premise
415	delayed	_	_	I-Premise
416	recurrence	_	_	I-Premise
417	and	_	_	I-Premise
418	increased	_	_	I-Premise
419	survival	_	_	I-Premise
420	balances	_	_	I-Premise
421	the	_	_	I-Premise
422	time	_	_	I-Premise
423	spent	_	_	I-Premise
424	with	_	_	I-Premise
425	early	_	_	I-Premise
426	and	_	_	I-Premise
427	late	_	_	I-Premise
428	toxic	_	_	I-Premise
429	effects	_	_	I-Premise
430	.	_	_	I-Premise

431	The	_	_	B-Claim
432	Q-TWiST	_	_	I-Claim
433	method	_	_	I-Claim
434	is	_	_	I-Claim
435	an	_	_	I-Claim
436	excellent	_	_	I-Claim
437	way	_	_	I-Claim
438	to	_	_	I-Claim
439	compare	_	_	I-Claim
440	treatment	_	_	I-Claim
441	outcomes	_	_	I-Claim
442	that	_	_	I-Claim
443	include	_	_	I-Claim
444	quality-of-life	_	_	I-Claim
445	considerations	_	_	I-Claim
446	.	_	_	I-Claim


0	Latanoprost	_	_	O
1	is	_	_	O
2	a	_	_	O
3	PGF2	_	_	O
4	alpha	_	_	O
5	analogue	_	_	O
6	which	_	_	O
7	reduces	_	_	O
8	the	_	_	O
9	intraocular	_	_	O
10	pressure	_	_	O
11	(	_	_	O
12	IOP	_	_	O
13	)	_	_	O
14	by	_	_	O
15	increasing	_	_	O
16	the	_	_	O
17	uveoscleral	_	_	O
18	outflow	_	_	O
19	.	_	_	O

20	The	_	_	O
21	objective	_	_	O
22	of	_	_	O
23	this	_	_	O
24	study	_	_	O
25	was	_	_	O
26	to	_	_	O
27	investigate	_	_	O
28	the	_	_	O
29	effect	_	_	O
30	of	_	_	O
31	two	_	_	O
32	different	_	_	O
33	regimens	_	_	O
34	of	_	_	O
35	latanoprost	_	_	O
36	on	_	_	O
37	the	_	_	O
38	diurnal	_	_	O
39	IOP	_	_	O
40	and	_	_	O
41	also	_	_	O
42	the	_	_	O
43	effect	_	_	O
44	of	_	_	O
45	latanoprost	_	_	O
46	on	_	_	O
47	the	_	_	O
48	blood-aqueous	_	_	O
49	barrier	_	_	O
50	measured	_	_	O
51	with	_	_	O
52	a	_	_	O
53	laser	_	_	O
54	flare	_	_	O
55	cell	_	_	O
56	meter	_	_	O
57	(	_	_	O
58	Kowa	_	_	O
59	FM-500	_	_	O
60	)	_	_	O
61	.	_	_	O

62	Moreover	_	_	O
63	,	_	_	O
64	the	_	_	O
65	safety	_	_	O
66	aspects	_	_	O
67	of	_	_	O
68	the	_	_	O
69	two	_	_	O
70	regimens	_	_	O
71	regarding	_	_	O
72	hyperemia	_	_	O
73	were	_	_	O
74	studied	_	_	O
75	.	_	_	O

76	A	_	_	O
77	double-masked	_	_	O
78	,	_	_	O
79	randomized	_	_	O
80	study	_	_	O
81	was	_	_	O
82	performed	_	_	O
83	in	_	_	O
84	30	_	_	O
85	patients	_	_	O
86	(	_	_	O
87	9	_	_	O
88	males	_	_	O
89	,	_	_	O
90	21	_	_	O
91	females	_	_	O
92	;	_	_	O
93	mean	_	_	O
94	age	_	_	O
95	61.9	_	_	O
96	years	_	_	O
97	)	_	_	O
98	with	_	_	O
99	primary	_	_	O
100	open-angle	_	_	O
101	glaucoma	_	_	O
102	or	_	_	O
103	pseudoexfoliation	_	_	O
104	glaucoma	_	_	O
105	.	_	_	O

106	Twenty	_	_	O
107	patients	_	_	O
108	were	_	_	O
109	treated	_	_	O
110	with	_	_	O
111	latanoprost	_	_	O
112	0.0015	_	_	O
113	%	_	_	O
114	twice	_	_	O
115	daily	_	_	O
116	or	_	_	O
117	0.005	_	_	O
118	%	_	_	O
119	once	_	_	O
120	daily	_	_	O
121	for	_	_	O
122	3	_	_	O
123	weeks	_	_	O
124	in	_	_	O
125	a	_	_	O
126	cross-over	_	_	O
127	design	_	_	O
128	.	_	_	O

129	Ten	_	_	O
130	patients	_	_	O
131	received	_	_	O
132	timolol	_	_	O
133	0.5	_	_	O
134	%	_	_	O
135	twice	_	_	O
136	daily	_	_	O
137	as	_	_	O
138	control	_	_	O
139	.	_	_	O

140	Latanoprost	_	_	B-Premise
141	0.005	_	_	I-Premise
142	%	_	_	I-Premise
143	once	_	_	I-Premise
144	daily	_	_	I-Premise
145	reduced	_	_	I-Premise
146	IOP	_	_	I-Premise
147	(	_	_	I-Premise
148	+/-	_	_	I-Premise
149	SEM	_	_	I-Premise
150	)	_	_	I-Premise
151	more	_	_	I-Premise
152	effectively	_	_	I-Premise
153	than	_	_	I-Premise
154	latanoprost	_	_	I-Premise
155	0.0015	_	_	I-Premise
156	%	_	_	I-Premise
157	twice	_	_	I-Premise
158	daily	_	_	I-Premise
159	(	_	_	I-Premise
160	9.8	_	_	I-Premise
161	+/-	_	_	I-Premise
162	0.9	_	_	I-Premise
163	mm	_	_	I-Premise
164	Hg	_	_	I-Premise
165	and	_	_	I-Premise
166	6.7	_	_	I-Premise
167	+/-	_	_	I-Premise
168	0.9	_	_	I-Premise
169	mm	_	_	I-Premise
170	Hg	_	_	I-Premise
171	,	_	_	I-Premise
172	respectively	_	_	I-Premise
173	)	_	_	I-Premise
174	.	_	_	I-Premise

175	There	_	_	B-Premise
176	was	_	_	I-Premise
177	a	_	_	I-Premise
178	statistically	_	_	I-Premise
179	significant	_	_	I-Premise
180	increase	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	aqueous	_	_	I-Premise
184	humour	_	_	I-Premise
185	protein	_	_	I-Premise
186	concentration	_	_	I-Premise
187	within	_	_	I-Premise
188	the	_	_	I-Premise
189	timolol	_	_	I-Premise
190	group	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0.004	_	_	I-Premise
195	)	_	_	I-Premise
196	,	_	_	I-Premise
197	but	_	_	I-Premise
198	not	_	_	I-Premise
199	within	_	_	I-Premise
200	the	_	_	I-Premise
201	latanoprost	_	_	I-Premise
202	group	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.97	_	_	I-Premise
207	)	_	_	I-Premise
208	.	_	_	I-Premise

209	There	_	_	B-Premise
210	was	_	_	I-Premise
211	no	_	_	I-Premise
212	statistically	_	_	I-Premise
213	significant	_	_	I-Premise
214	difference	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	change	_	_	I-Premise
218	in	_	_	I-Premise
219	aqueous	_	_	I-Premise
220	humour	_	_	I-Premise
221	protein	_	_	I-Premise
222	concentration	_	_	I-Premise
223	from	_	_	I-Premise
224	baseline	_	_	I-Premise
225	between	_	_	I-Premise
226	latanoprost	_	_	I-Premise
227	and	_	_	I-Premise
228	timolol	_	_	I-Premise
229	groups	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	0.08	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	No	_	_	B-Premise
237	statistically	_	_	I-Premise
238	significant	_	_	I-Premise
239	difference	_	_	I-Premise
240	in	_	_	I-Premise
241	conjunctival	_	_	I-Premise
242	hyperemia	_	_	I-Premise
243	between	_	_	I-Premise
244	the	_	_	I-Premise
245	two	_	_	I-Premise
246	latanoprost	_	_	I-Premise
247	regimens	_	_	I-Premise
248	was	_	_	I-Premise
249	found	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	0.37	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Latanoprost	_	_	B-Premise
257	0.005	_	_	I-Premise
258	%	_	_	I-Premise
259	once	_	_	I-Premise
260	daily	_	_	I-Premise
261	reduced	_	_	I-Premise
262	IOP	_	_	I-Premise
263	more	_	_	I-Premise
264	effectively	_	_	I-Premise
265	than	_	_	I-Premise
266	latanoprost	_	_	I-Premise
267	0.0015	_	_	I-Premise
268	%	_	_	I-Premise
269	twice	_	_	I-Premise
270	daily	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	<	_	_	I-Premise
274	0.001	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	Latanoprost	_	_	B-Claim
278	had	_	_	I-Claim
279	no	_	_	I-Claim
280	statistically	_	_	I-Claim
281	or	_	_	I-Claim
282	clinically	_	_	I-Claim
283	significant	_	_	I-Claim
284	effect	_	_	I-Claim
285	on	_	_	I-Claim
286	the	_	_	I-Claim
287	blood-aqueous	_	_	I-Claim
288	barrier	_	_	I-Claim
289	.	_	_	I-Claim

290	There	_	_	B-Claim
291	was	_	_	I-Claim
292	no	_	_	I-Claim
293	difference	_	_	I-Claim
294	in	_	_	I-Claim
295	hyperemia	_	_	I-Claim
296	between	_	_	I-Claim
297	the	_	_	I-Claim
298	two	_	_	I-Claim
299	regimens	_	_	I-Claim
300	.	_	_	I-Claim

301	Both	_	_	B-Claim
302	concentrations	_	_	I-Claim
303	of	_	_	I-Claim
304	latanoprost	_	_	I-Claim
305	reduced	_	_	I-Claim
306	IOP	_	_	I-Claim
307	at	_	_	I-Claim
308	least	_	_	I-Claim
309	as	_	_	I-Claim
310	well	_	_	I-Claim
311	as	_	_	I-Claim
312	timolol	_	_	I-Claim
313	0.5	_	_	I-Claim
314	%	_	_	I-Claim
315	eye	_	_	I-Claim
316	drops	_	_	I-Claim
317	.	_	_	I-Claim


0	Although	_	_	O
1	many	_	_	O
2	drug	_	_	O
3	combination	_	_	O
4	therapies	_	_	O
5	have	_	_	O
6	been	_	_	O
7	proposed	_	_	O
8	,	_	_	O
9	there	_	_	B-Claim
10	is	_	_	I-Claim
11	no	_	_	I-Claim
12	standard	_	_	I-Claim
13	therapy	_	_	I-Claim
14	for	_	_	I-Claim
15	patients	_	_	I-Claim
16	with	_	_	I-Claim
17	advanced	_	_	I-Claim
18	gastric	_	_	I-Claim
19	carcinoma	_	_	I-Claim
20	.	_	_	I-Claim

21	The	_	_	B-Claim
22	superiority	_	_	I-Claim
23	of	_	_	I-Claim
24	combination	_	_	I-Claim
25	therapy	_	_	I-Claim
26	over	_	_	I-Claim
27	monochemotherapy	_	_	I-Claim
28	has	_	_	I-Claim
29	not	_	_	I-Claim
30	been	_	_	I-Claim
31	demonstrated	_	_	I-Claim
32	convincingly	_	_	I-Claim
33	.	_	_	I-Claim

34	To	_	_	O
35	explore	_	_	O
36	the	_	_	O
37	role	_	_	O
38	of	_	_	O
39	monochemotherapy	_	_	O
40	,	_	_	O
41	the	_	_	O
42	authors	_	_	O
43	evaluated	_	_	O
44	5-fluorouracil	_	_	O
45	(	_	_	O
46	5-FU	_	_	O
47	)	_	_	O
48	,	_	_	O
49	modulated	_	_	O
50	by	_	_	O
51	6S-leucovorin	_	_	O
52	(	_	_	O
53	6S-LV	_	_	O
54	)	_	_	O
55	and	_	_	O
56	a	_	_	O
57	cisplatin-containing	_	_	O
58	regimen	_	_	O
59	,	_	_	O
60	which	_	_	O
61	was	_	_	O
62	comprised	_	_	O
63	of	_	_	O
64	epirubicin	_	_	O
65	,	_	_	O
66	etoposide	_	_	O
67	,	_	_	O
68	and	_	_	O
69	cisplatin	_	_	O
70	with	_	_	O
71	the	_	_	O
72	addition	_	_	O
73	of	_	_	O
74	the	_	_	O
75	reversal	_	_	O
76	agent	_	_	O
77	lonidamine	_	_	O
78	(	_	_	O
79	EEP-L	_	_	O
80	)	_	_	O
81	.	_	_	O

82	After	_	_	O
83	stratification	_	_	O
84	according	_	_	O
85	to	_	_	O
86	performance	_	_	O
87	status	_	_	O
88	(	_	_	O
89	PS	_	_	O
90	)	_	_	O
91	and	_	_	O
92	resection	_	_	O
93	of	_	_	O
94	the	_	_	O
95	primary	_	_	O
96	tumor	_	_	O
97	,	_	_	O
98	72	_	_	O
99	patients	_	_	O
100	with	_	_	O
101	advanced	_	_	O
102	gastric	_	_	O
103	carcinoma	_	_	O
104	were	_	_	O
105	randomized	_	_	O
106	to	_	_	O
107	2	_	_	O
108	parallel	_	_	O
109	Phase	_	_	O
110	II	_	_	O
111	trials	_	_	O
112	with	_	_	O
113	5-FU/6S-LV	_	_	O
114	and	_	_	O
115	EEP-L	_	_	O
116	,	_	_	O
117	respectively	_	_	O
118	.	_	_	O

119	Thirty-six	_	_	O
120	patients	_	_	O
121	in	_	_	O
122	Study	_	_	O
123	A	_	_	O
124	received	_	_	O
125	bolus	_	_	O
126	6S-LV	_	_	O
127	,	_	_	O
128	100	_	_	O
129	mg/m2	_	_	O
130	,	_	_	O
131	followed	_	_	O
132	by	_	_	O
133	bolus	_	_	O
134	5-FU	_	_	O
135	,	_	_	O
136	370	_	_	O
137	mg/m2	_	_	O
138	,	_	_	O
139	on	_	_	O
140	Days	_	_	O
141	1-5	_	_	O
142	and	_	_	O
143	36	_	_	O
144	others	_	_	O
145	in	_	_	O
146	Study	_	_	O
147	B	_	_	O
148	received	_	_	O
149	epirubicin	_	_	O
150	,	_	_	O
151	30	_	_	O
152	mg/m2	_	_	O
153	,	_	_	O
154	on	_	_	O
155	Days	_	_	O
156	1	_	_	O
157	and	_	_	O
158	5	_	_	O
159	;	_	_	O
160	etoposide	_	_	O
161	,	_	_	O
162	100	_	_	O
163	mg/m2	_	_	O
164	,	_	_	O
165	on	_	_	O
166	Days	_	_	O
167	1	_	_	O
168	,	_	_	O
169	3	_	_	O
170	,	_	_	O
171	and	_	_	O
172	5	_	_	O
173	;	_	_	O
174	cisplatin	_	_	O
175	,	_	_	O
176	30	_	_	O
177	mg/m2	_	_	O
178	,	_	_	O
179	on	_	_	O
180	Days	_	_	O
181	2	_	_	O
182	and	_	_	O
183	4	_	_	O
184	;	_	_	O
185	and	_	_	O
186	lonidamine	_	_	O
187	,	_	_	O
188	150	_	_	O
189	mg/day	_	_	O
190	.	_	_	O

191	There	_	_	O
192	were	_	_	O
193	6	_	_	O
194	partial	_	_	O
195	responses	_	_	O
196	(	_	_	O
197	18.2	_	_	O
198	%	_	_	O
199	)	_	_	O
200	(	_	_	O
201	95	_	_	O
202	%	_	_	O
203	confidence	_	_	O
204	interval	_	_	O
205	[	_	_	O
206	CI	_	_	O
207	]	_	_	O
208	+/-	_	_	O
209	13.2	_	_	O
210	)	_	_	O
211	in	_	_	O
212	Study	_	_	O
213	A	_	_	O
214	and	_	_	O
215	7	_	_	O
216	partial	_	_	O
217	responses	_	_	O
218	(	_	_	O
219	21.9	_	_	O
220	%	_	_	O
221	)	_	_	O
222	(	_	_	O
223	95	_	_	O
224	%	_	_	O
225	CI	_	_	O
226	+/-	_	_	O
227	14.3	_	_	O
228	)	_	_	O
229	in	_	_	O
230	Study	_	_	O
231	B	_	_	O
232	.	_	_	O

233	Partial	_	_	O
234	responses	_	_	O
235	were	_	_	O
236	more	_	_	O
237	frequent	_	_	O
238	in	_	_	O
239	patients	_	_	O
240	with	_	_	O
241	resected	_	_	O
242	tumors	_	_	O
243	or	_	_	O
244	with	_	_	O
245	an	_	_	O
246	Eastern	_	_	O
247	Cooperative	_	_	O
248	Oncology	_	_	O
249	Group	_	_	O
250	PS	_	_	O
251	of	_	_	O
252	0-1	_	_	O
253	.	_	_	O

254	The	_	_	B-Premise
255	median	_	_	I-Premise
256	duration	_	_	I-Premise
257	of	_	_	I-Premise
258	response	_	_	I-Premise
259	was	_	_	I-Premise
260	8.8	_	_	I-Premise
261	and	_	_	I-Premise
262	8.3	_	_	I-Premise
263	months	_	_	I-Premise
264	,	_	_	I-Premise
265	respectively	_	_	I-Premise
266	,	_	_	I-Premise
267	in	_	_	I-Premise
268	Study	_	_	I-Premise
269	A	_	_	I-Premise
270	and	_	_	I-Premise
271	Study	_	_	I-Premise
272	B	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	B-Premise
275	median	_	_	I-Premise
276	survival	_	_	I-Premise
277	reached	_	_	I-Premise
278	8	_	_	I-Premise
279	months	_	_	I-Premise
280	in	_	_	I-Premise
281	Study	_	_	I-Premise
282	A	_	_	I-Premise
283	and	_	_	I-Premise
284	9	_	_	I-Premise
285	months	_	_	I-Premise
286	in	_	_	I-Premise
287	Study	_	_	I-Premise
288	B	_	_	I-Premise
289	.	_	_	I-Premise

290	In	_	_	B-Premise
291	the	_	_	I-Premise
292	whole	_	_	I-Premise
293	population	_	_	I-Premise
294	of	_	_	I-Premise
295	patients	_	_	I-Premise
296	survival	_	_	I-Premise
297	was	_	_	I-Premise
298	significantly	_	_	I-Premise
299	higher	_	_	I-Premise
300	in	_	_	I-Premise
301	patients	_	_	I-Premise
302	with	_	_	I-Premise
303	a	_	_	I-Premise
304	PS	_	_	I-Premise
305	of	_	_	I-Premise
306	0-1	_	_	I-Premise
307	(	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	0.05	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Patients	_	_	B-Premise
314	with	_	_	I-Premise
315	a	_	_	I-Premise
316	PS	_	_	I-Premise
317	of	_	_	I-Premise
318	0-1	_	_	I-Premise
319	and	_	_	I-Premise
320	a	_	_	I-Premise
321	resected	_	_	I-Premise
322	tumor	_	_	I-Premise
323	had	_	_	I-Premise
324	the	_	_	I-Premise
325	significantly	_	_	I-Premise
326	longest	_	_	I-Premise
327	survival	_	_	I-Premise
328	both	_	_	I-Premise
329	in	_	_	I-Premise
330	EEP-L	_	_	I-Premise
331	treated	_	_	I-Premise
332	patients	_	_	I-Premise
333	and	_	_	I-Premise
334	in	_	_	I-Premise
335	all	_	_	I-Premise
336	evaluable	_	_	I-Premise
337	patients	_	_	I-Premise
338	in	_	_	I-Premise
339	the	_	_	I-Premise
340	two	_	_	I-Premise
341	studies	_	_	I-Premise
342	.	_	_	I-Premise

343	The	_	_	B-Premise
344	most	_	_	I-Premise
345	frequent	_	_	I-Premise
346	World	_	_	I-Premise
347	Health	_	_	I-Premise
348	Organization	_	_	I-Premise
349	Grade	_	_	I-Premise
350	3-4	_	_	I-Premise
351	toxic	_	_	I-Premise
352	effects	_	_	I-Premise
353	were	_	_	I-Premise
354	gastrointestinal	_	_	I-Premise
355	in	_	_	I-Premise
356	Study	_	_	I-Premise
357	A	_	_	I-Premise
358	and	_	_	I-Premise
359	hematologic	_	_	I-Premise
360	in	_	_	I-Premise
361	Study	_	_	I-Premise
362	B	_	_	I-Premise
363	.	_	_	I-Premise

364	No	_	_	B-Premise
365	treatment-related	_	_	I-Premise
366	death	_	_	I-Premise
367	was	_	_	I-Premise
368	observed	_	_	I-Premise
369	.	_	_	I-Premise

370	The	_	_	B-Claim
371	efficacy	_	_	I-Claim
372	of	_	_	I-Claim
373	5-FU	_	_	I-Claim
374	,	_	_	I-Claim
375	modulated	_	_	I-Claim
376	with	_	_	I-Claim
377	6S-LV	_	_	I-Claim
378	,	_	_	I-Claim
379	is	_	_	I-Claim
380	moderate	_	_	I-Claim
381	in	_	_	I-Claim
382	patients	_	_	I-Claim
383	with	_	_	I-Claim
384	advanced	_	_	I-Claim
385	gastric	_	_	I-Claim
386	carcinoma	_	_	I-Claim
387	,	_	_	I-Claim
388	similar	_	_	I-Claim
389	to	_	_	I-Claim
390	cisplatin-containing	_	_	I-Claim
391	regimens	_	_	I-Claim
392	.	_	_	I-Claim

393	PS	_	_	B-Claim
394	and	_	_	I-Claim
395	other	_	_	I-Claim
396	prognostic	_	_	I-Claim
397	factors	_	_	I-Claim
398	could	_	_	I-Claim
399	influence	_	_	I-Claim
400	the	_	_	I-Claim
401	response	_	_	I-Claim
402	rate	_	_	I-Claim
403	,	_	_	I-Claim
404	which	_	_	I-Claim
405	does	_	_	I-Claim
406	not	_	_	I-Claim
407	appear	_	_	I-Claim
408	to	_	_	I-Claim
409	be	_	_	I-Claim
410	a	_	_	I-Claim
411	reliable	_	_	I-Claim
412	parameter	_	_	I-Claim
413	for	_	_	I-Claim
414	evaluating	_	_	I-Claim
415	the	_	_	I-Claim
416	outcome	_	_	I-Claim
417	of	_	_	I-Claim
418	chemotherapy	_	_	I-Claim
419	trials	_	_	I-Claim
420	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	two	_	_	O
3	cisplatin	_	_	O
4	based	_	_	O
5	chemotherapy	_	_	O
6	schedules	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	advanced	_	_	O
11	non-small-cell	_	_	O
12	lung	_	_	O
13	cancer	_	_	O
14	(	_	_	O
15	NSCLC	_	_	O
16	)	_	_	O
17	.	_	_	O

18	A	_	_	O
19	total	_	_	O
20	of	_	_	O
21	332	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	advanced	_	_	O
25	NSCLC	_	_	O
26	were	_	_	O
27	randomized	_	_	O
28	to	_	_	O
29	receive	_	_	O
30	cisplatin	_	_	O
31	80	_	_	O
32	mg/m2	_	_	O
33	on	_	_	O
34	day	_	_	O
35	1	_	_	O
36	either	_	_	O
37	in	_	_	O
38	combination	_	_	O
39	with	_	_	O
40	teniposide	_	_	O
41	100	_	_	O
42	mg/m2	_	_	O
43	on	_	_	O
44	days	_	_	O
45	1	_	_	O
46	,	_	_	O
47	3	_	_	O
48	,	_	_	O
49	and	_	_	O
50	5	_	_	O
51	(	_	_	O
52	arm	_	_	O
53	A	_	_	O
54	)	_	_	O
55	or	_	_	O
56	paclitaxel	_	_	O
57	175	_	_	O
58	mg/m2	_	_	O
59	by	_	_	O
60	3-hour	_	_	O
61	infusion	_	_	O
62	on	_	_	O
63	day	_	_	O
64	1	_	_	O
65	(	_	_	O
66	arm	_	_	O
67	B	_	_	O
68	)	_	_	O
69	;	_	_	O
70	cycles	_	_	O
71	were	_	_	O
72	repeated	_	_	O
73	every	_	_	O
74	3	_	_	O
75	weeks	_	_	O
76	.	_	_	O

77	Fifteen	_	_	O
78	patients	_	_	O
79	were	_	_	O
80	ineligible	_	_	O
81	;	_	_	O
82	patient	_	_	O
83	characteristics	_	_	O
84	were	_	_	O
85	well	_	_	O
86	balanced	_	_	O
87	between	_	_	O
88	the	_	_	O
89	two	_	_	O
90	arms	_	_	O
91	:	_	_	O
92	71	_	_	O
93	%	_	_	O
94	were	_	_	O
95	male	_	_	O
96	,	_	_	O
97	71	_	_	O
98	%	_	_	O
99	had	_	_	O
100	less	_	_	O
101	than	_	_	O
102	5	_	_	O
103	%	_	_	O
104	weight	_	_	O
105	loss	_	_	O
106	,	_	_	O
107	89	_	_	O
108	%	_	_	O
109	had	_	_	O
110	a	_	_	O
111	World	_	_	O
112	Health	_	_	O
113	Organization	_	_	O
114	(	_	_	O
115	WHO	_	_	O
116	)	_	_	O
117	performance	_	_	O
118	status	_	_	O
119	of	_	_	O
120	0	_	_	O
121	to	_	_	O
122	1	_	_	O
123	,	_	_	O
124	51	_	_	O
125	%	_	_	O
126	had	_	_	O
127	adenocarcinoma	_	_	O
128	,	_	_	O
129	and	_	_	O
130	61	_	_	O
131	%	_	_	O
132	had	_	_	O
133	stage	_	_	O
134	IV	_	_	O
135	disease	_	_	O
136	.	_	_	O

137	Hematologic	_	_	B-Premise
138	toxicity	_	_	I-Premise
139	was	_	_	I-Premise
140	significantly	_	_	I-Premise
141	more	_	_	I-Premise
142	severe	_	_	I-Premise
143	in	_	_	I-Premise
144	arm	_	_	I-Premise
145	A	_	_	I-Premise
146	(	_	_	I-Premise
147	leukopenia	_	_	I-Premise
148	,	_	_	I-Premise
149	neutropenia	_	_	I-Premise
150	,	_	_	I-Premise
151	and	_	_	I-Premise
152	thrombocytopenia	_	_	I-Premise
153	grade	_	_	I-Premise
154	3	_	_	I-Premise
155	or	_	_	I-Premise
156	4	_	_	I-Premise
157	:	_	_	I-Premise
158	66	_	_	I-Premise
159	%	_	_	I-Premise
160	v	_	_	I-Premise
161	19	_	_	I-Premise
162	%	_	_	I-Premise
163	,	_	_	I-Premise
164	83	_	_	I-Premise
165	%	_	_	I-Premise
166	v	_	_	I-Premise
167	55	_	_	I-Premise
168	%	_	_	I-Premise
169	,	_	_	I-Premise
170	36	_	_	I-Premise
171	%	_	_	I-Premise
172	v	_	_	I-Premise
173	2	_	_	I-Premise
174	%	_	_	I-Premise
175	in	_	_	I-Premise
176	arms	_	_	I-Premise
177	A	_	_	I-Premise
178	and	_	_	I-Premise
179	B	_	_	I-Premise
180	,	_	_	I-Premise
181	respectively	_	_	I-Premise
182	)	_	_	I-Premise
183	,	_	_	I-Premise
184	which	_	_	I-Premise
185	resulted	_	_	I-Premise
186	in	_	_	I-Premise
187	more	_	_	I-Premise
188	febrile	_	_	I-Premise
189	neutropenia	_	_	I-Premise
190	(	_	_	I-Premise
191	27	_	_	I-Premise
192	%	_	_	I-Premise
193	v	_	_	I-Premise
194	3	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	arms	_	_	I-Premise
198	A	_	_	I-Premise
199	and	_	_	I-Premise
200	B	_	_	I-Premise
201	,	_	_	I-Premise
202	respectively	_	_	I-Premise
203	)	_	_	I-Premise
204	,	_	_	I-Premise
205	dose	_	_	I-Premise
206	reductions	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	treatment	_	_	I-Premise
210	delays	_	_	I-Premise
211	.	_	_	I-Premise

212	There	_	_	B-Premise
213	were	_	_	I-Premise
214	a	_	_	I-Premise
215	total	_	_	I-Premise
216	of	_	_	I-Premise
217	nine	_	_	I-Premise
218	toxic	_	_	I-Premise
219	deaths	_	_	I-Premise
220	,	_	_	I-Premise
221	six	_	_	I-Premise
222	due	_	_	I-Premise
223	to	_	_	I-Premise
224	neutropenic	_	_	I-Premise
225	sepsis	_	_	I-Premise
226	:	_	_	I-Premise
227	five	_	_	I-Premise
228	in	_	_	I-Premise
229	arm	_	_	I-Premise
230	A	_	_	I-Premise
231	and	_	_	I-Premise
232	one	_	_	I-Premise
233	in	_	_	I-Premise
234	arm	_	_	I-Premise
235	B	_	_	I-Premise
236	.	_	_	I-Premise

237	In	_	_	B-Premise
238	contrast	_	_	I-Premise
239	,	_	_	I-Premise
240	arthralgia/myalgia	_	_	I-Premise
241	(	_	_	I-Premise
242	grade	_	_	I-Premise
243	2	_	_	I-Premise
244	or	_	_	I-Premise
245	3	_	_	I-Premise
246	,	_	_	I-Premise
247	4	_	_	I-Premise
248	%	_	_	I-Premise
249	v	_	_	I-Premise
250	17	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	peripheral	_	_	I-Premise
255	neurotoxicity	_	_	I-Premise
256	(	_	_	I-Premise
257	grade	_	_	I-Premise
258	2	_	_	I-Premise
259	or	_	_	I-Premise
260	3	_	_	I-Premise
261	,	_	_	I-Premise
262	6	_	_	I-Premise
263	%	_	_	I-Premise
264	v	_	_	I-Premise
265	29	_	_	I-Premise
266	%	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	and	_	_	I-Premise
270	hypersensitivity	_	_	I-Premise
271	reactions	_	_	I-Premise
272	(	_	_	I-Premise
273	1	_	_	I-Premise
274	%	_	_	I-Premise
275	v	_	_	I-Premise
276	7	_	_	I-Premise
277	%	_	_	I-Premise
278	,	_	_	I-Premise
279	all	_	_	I-Premise
280	grades	_	_	I-Premise
281	)	_	_	I-Premise
282	were	_	_	I-Premise
283	significantly	_	_	I-Premise
284	more	_	_	I-Premise
285	frequent	_	_	I-Premise
286	in	_	_	I-Premise
287	arm	_	_	I-Premise
288	B	_	_	I-Premise
289	.	_	_	I-Premise

290	The	_	_	B-Claim
291	frequency	_	_	I-Claim
292	and	_	_	I-Claim
293	severity	_	_	I-Claim
294	of	_	_	I-Claim
295	other	_	_	I-Claim
296	toxicities	_	_	I-Claim
297	were	_	_	I-Claim
298	comparable	_	_	I-Claim
299	between	_	_	I-Claim
300	the	_	_	I-Claim
301	two	_	_	I-Claim
302	arms	_	_	I-Claim
303	.	_	_	I-Claim

304	Responses	_	_	B-Premise
305	were	_	_	I-Premise
306	one	_	_	I-Premise
307	complete	_	_	I-Premise
308	and	_	_	I-Premise
309	44	_	_	I-Premise
310	partial	_	_	I-Premise
311	on	_	_	I-Premise
312	arm	_	_	I-Premise
313	A	_	_	I-Premise
314	(	_	_	I-Premise
315	28	_	_	I-Premise
316	%	_	_	I-Premise
317	)	_	_	I-Premise
318	and	_	_	I-Premise
319	two	_	_	I-Premise
320	complete	_	_	I-Premise
321	and	_	_	I-Premise
322	61	_	_	I-Premise
323	partial	_	_	I-Premise
324	(	_	_	I-Premise
325	41	_	_	I-Premise
326	%	_	_	I-Premise
327	)	_	_	I-Premise
328	on	_	_	I-Premise
329	arm	_	_	I-Premise
330	B	_	_	I-Premise
331	(	_	_	I-Premise
332	P	_	_	I-Premise
333	=	_	_	I-Premise
334	.018	_	_	I-Premise
335	)	_	_	I-Premise
336	.	_	_	I-Premise

337	There	_	_	B-Premise
338	was	_	_	I-Premise
339	no	_	_	I-Premise
340	significant	_	_	I-Premise
341	difference	_	_	I-Premise
342	in	_	_	I-Premise
343	survival	_	_	I-Premise
344	,	_	_	I-Premise
345	with	_	_	I-Premise
346	median	_	_	I-Premise
347	and	_	_	I-Premise
348	1-year	_	_	I-Premise
349	survivals	_	_	I-Premise
350	9.9	_	_	I-Premise
351	versus	_	_	I-Premise
352	9.7	_	_	I-Premise
353	months	_	_	I-Premise
354	and	_	_	I-Premise
355	41	_	_	I-Premise
356	%	_	_	I-Premise
357	versus	_	_	I-Premise
358	43	_	_	I-Premise
359	%	_	_	I-Premise
360	,	_	_	I-Premise
361	respectively	_	_	I-Premise
362	in	_	_	I-Premise
363	arm	_	_	I-Premise
364	A	_	_	I-Premise
365	and	_	_	I-Premise
366	B.	_	_	I-Premise
367	Progression-free	_	_	B-Premise
368	survival	_	_	I-Premise
369	was	_	_	I-Premise
370	4.9	_	_	I-Premise
371	and	_	_	I-Premise
372	5.4	_	_	I-Premise
373	months	_	_	I-Premise
374	in	_	_	I-Premise
375	arm	_	_	I-Premise
376	A	_	_	I-Premise
377	and	_	_	I-Premise
378	B	_	_	I-Premise
379	,	_	_	I-Premise
380	respectively	_	_	I-Premise
381	.	_	_	I-Premise

382	Selected	_	_	O
383	centers	_	_	O
384	participated	_	_	O
385	in	_	_	O
386	a	_	_	O
387	quality-of-life	_	_	O
388	(	_	_	O
389	QoL	_	_	O
390	)	_	_	O
391	assessment	_	_	O
392	,	_	_	O
393	which	_	_	O
394	was	_	_	O
395	performed	_	_	O
396	by	_	_	O
397	the	_	_	O
398	European	_	_	O
399	Organization	_	_	O
400	for	_	_	O
401	Research	_	_	O
402	and	_	_	O
403	Treatment	_	_	O
404	of	_	_	O
405	Cancer	_	_	O
406	(	_	_	O
407	EORTC	_	_	O
408	)	_	_	O
409	QLQ-C30	_	_	O
410	and	_	_	O
411	LC-13	_	_	O
412	administered	_	_	O
413	at	_	_	O
414	baseline	_	_	O
415	and	_	_	O
416	every	_	_	O
417	6	_	_	O
418	weeks	_	_	O
419	thereafter	_	_	O
420	.	_	_	O

421	Arm	_	_	B-Premise
422	B	_	_	I-Premise
423	achieved	_	_	I-Premise
424	a	_	_	I-Premise
425	better	_	_	I-Premise
426	score	_	_	I-Premise
427	at	_	_	I-Premise
428	week	_	_	I-Premise
429	6	_	_	I-Premise
430	for	_	_	I-Premise
431	emotional	_	_	I-Premise
432	,	_	_	I-Premise
433	cognitive	_	_	I-Premise
434	and	_	_	I-Premise
435	social	_	_	I-Premise
436	functioning	_	_	I-Premise
437	,	_	_	I-Premise
438	global	_	_	I-Premise
439	health	_	_	I-Premise
440	status	_	_	I-Premise
441	,	_	_	I-Premise
442	fatigue	_	_	I-Premise
443	,	_	_	I-Premise
444	and	_	_	I-Premise
445	appetite	_	_	I-Premise
446	loss	_	_	I-Premise
447	,	_	_	I-Premise
448	which	_	_	I-Premise
449	was	_	_	I-Premise
450	lost	_	_	I-Premise
451	at	_	_	I-Premise
452	12	_	_	I-Premise
453	weeks	_	_	I-Premise
454	.	_	_	I-Premise

455	In	_	_	B-Claim
456	conclusion	_	_	I-Claim
457	,	_	_	I-Claim
458	arm	_	_	I-Claim
459	B	_	_	I-Claim
460	appears	_	_	I-Claim
461	superior	_	_	I-Claim
462	to	_	_	I-Claim
463	arm	_	_	I-Claim
464	A	_	_	I-Claim
465	with	_	_	I-Claim
466	regard	_	_	I-Claim
467	to	_	_	I-Claim
468	response	_	_	I-Claim
469	rate	_	_	I-Claim
470	,	_	_	I-Claim
471	side	_	_	I-Claim
472	effects	_	_	I-Claim
473	,	_	_	I-Claim
474	and	_	_	I-Claim
475	QoL	_	_	I-Claim
476	.	_	_	I-Claim

477	Although	_	_	B-Claim
478	survival	_	_	I-Claim
479	was	_	_	I-Claim
480	not	_	_	I-Claim
481	improved	_	_	I-Claim
482	,	_	_	I-Claim
483	arm	_	_	B-Claim
484	B	_	_	I-Claim
485	offers	_	_	I-Claim
486	a	_	_	I-Claim
487	better	_	_	I-Claim
488	palliation	_	_	I-Claim
489	for	_	_	I-Claim
490	advanced	_	_	I-Claim
491	NSCLC	_	_	I-Claim
492	patients	_	_	I-Claim
493	than	_	_	I-Claim
494	arm	_	_	I-Claim
495	A	_	_	I-Claim
496	.	_	_	I-Claim


0	The	_	_	O
1	finding	_	_	O
2	of	_	_	O
3	a	_	_	O
4	decrease	_	_	O
5	in	_	_	O
6	contralateral	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	incidence	_	_	O
10	following	_	_	O
11	tamoxifen	_	_	O
12	administration	_	_	O
13	for	_	_	O
14	adjuvant	_	_	O
15	therapy	_	_	O
16	led	_	_	O
17	to	_	_	O
18	the	_	_	O
19	concept	_	_	O
20	that	_	_	O
21	the	_	_	O
22	drug	_	_	O
23	might	_	_	O
24	play	_	_	O
25	a	_	_	O
26	role	_	_	O
27	in	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	prevention	_	_	O
31	.	_	_	O

32	To	_	_	O
33	test	_	_	O
34	this	_	_	O
35	hypothesis	_	_	O
36	,	_	_	O
37	the	_	_	O
38	National	_	_	O
39	Surgical	_	_	O
40	Adjuvant	_	_	O
41	Breast	_	_	O
42	and	_	_	O
43	Bowel	_	_	O
44	Project	_	_	O
45	initiated	_	_	O
46	the	_	_	O
47	Breast	_	_	O
48	Cancer	_	_	O
49	Prevention	_	_	O
50	Trial	_	_	O
51	(	_	_	O
52	P-1	_	_	O
53	)	_	_	O
54	in	_	_	O
55	1992	_	_	O
56	.	_	_	O

57	Women	_	_	O
58	(	_	_	O
59	N=13388	_	_	O
60	)	_	_	O
61	at	_	_	O
62	increased	_	_	O
63	risk	_	_	O
64	for	_	_	O
65	breast	_	_	O
66	cancer	_	_	O
67	because	_	_	O
68	they	_	_	O
69	1	_	_	O
70	)	_	_	O
71	were	_	_	O
72	60	_	_	O
73	years	_	_	O
74	of	_	_	O
75	age	_	_	O
76	or	_	_	O
77	older	_	_	O
78	,	_	_	O
79	2	_	_	O
80	)	_	_	O
81	were	_	_	O
82	35-59	_	_	O
83	years	_	_	O
84	of	_	_	O
85	age	_	_	O
86	with	_	_	O
87	a	_	_	O
88	5-year	_	_	O
89	predicted	_	_	O
90	risk	_	_	O
91	for	_	_	O
92	breast	_	_	O
93	cancer	_	_	O
94	of	_	_	O
95	at	_	_	O
96	least	_	_	O
97	1.66	_	_	O
98	%	_	_	O
99	,	_	_	O
100	or	_	_	O
101	3	_	_	O
102	)	_	_	O
103	had	_	_	O
104	a	_	_	O
105	history	_	_	O
106	of	_	_	O
107	lobular	_	_	O
108	carcinoma	_	_	O
109	in	_	_	O
110	situ	_	_	O
111	were	_	_	O
112	randomly	_	_	O
113	assigned	_	_	O
114	to	_	_	O
115	receive	_	_	O
116	placebo	_	_	O
117	(	_	_	O
118	n=6707	_	_	O
119	)	_	_	O
120	or	_	_	O
121	20	_	_	O
122	mg/day	_	_	O
123	tamoxifen	_	_	O
124	(	_	_	O
125	n=6681	_	_	O
126	)	_	_	O
127	for	_	_	O
128	5	_	_	O
129	years	_	_	O
130	.	_	_	O

131	Gail	_	_	O
132	's	_	_	O
133	algorithm	_	_	O
134	,	_	_	O
135	based	_	_	O
136	on	_	_	O
137	a	_	_	O
138	multivariate	_	_	O
139	logistic	_	_	O
140	regression	_	_	O
141	model	_	_	O
142	using	_	_	O
143	combinations	_	_	O
144	of	_	_	O
145	risk	_	_	O
146	factors	_	_	O
147	,	_	_	O
148	was	_	_	O
149	used	_	_	O
150	to	_	_	O
151	estimate	_	_	O
152	the	_	_	O
153	probability	_	_	O
154	(	_	_	O
155	risk	_	_	O
156	)	_	_	O
157	of	_	_	O
158	occurrence	_	_	O
159	of	_	_	O
160	breast	_	_	O
161	cancer	_	_	O
162	over	_	_	O
163	time	_	_	O
164	.	_	_	O

165	Tamoxifen	_	_	B-Premise
166	reduced	_	_	I-Premise
167	the	_	_	I-Premise
168	risk	_	_	I-Premise
169	of	_	_	I-Premise
170	invasive	_	_	I-Premise
171	breast	_	_	I-Premise
172	cancer	_	_	I-Premise
173	by	_	_	I-Premise
174	49	_	_	I-Premise
175	%	_	_	I-Premise
176	(	_	_	I-Premise
177	two-sided	_	_	I-Premise
178	P	_	_	I-Premise
179	<	_	_	I-Premise
180	.00001	_	_	I-Premise
181	)	_	_	I-Premise
182	,	_	_	I-Premise
183	with	_	_	I-Premise
184	cumulative	_	_	I-Premise
185	incidence	_	_	I-Premise
186	through	_	_	I-Premise
187	69	_	_	I-Premise
188	months	_	_	I-Premise
189	of	_	_	I-Premise
190	follow-up	_	_	I-Premise
191	of	_	_	I-Premise
192	43.4	_	_	I-Premise
193	versus	_	_	I-Premise
194	22.0	_	_	I-Premise
195	per	_	_	I-Premise
196	1000	_	_	I-Premise
197	women	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	placebo	_	_	I-Premise
201	and	_	_	I-Premise
202	tamoxifen	_	_	I-Premise
203	groups	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	.	_	_	I-Premise

207	The	_	_	O
208	decreased	_	_	O
209	risk	_	_	O
210	occurred	_	_	O
211	in	_	_	O
212	women	_	_	O
213	aged	_	_	O
214	49	_	_	O
215	years	_	_	O
216	or	_	_	O
217	younger	_	_	O
218	(	_	_	O
219	44	_	_	O
220	%	_	_	O
221	)	_	_	O
222	,	_	_	O
223	50-59	_	_	O
224	years	_	_	O
225	(	_	_	O
226	51	_	_	O
227	%	_	_	O
228	)	_	_	O
229	,	_	_	O
230	and	_	_	O
231	60	_	_	O
232	years	_	_	O
233	or	_	_	O
234	older	_	_	O
235	(	_	_	O
236	55	_	_	O
237	%	_	_	O
238	)	_	_	O
239	;	_	_	O
240	risk	_	_	B-Premise
241	was	_	_	I-Premise
242	also	_	_	I-Premise
243	reduced	_	_	I-Premise
244	in	_	_	I-Premise
245	women	_	_	I-Premise
246	with	_	_	I-Premise
247	a	_	_	I-Premise
248	history	_	_	I-Premise
249	of	_	_	I-Premise
250	lobular	_	_	I-Premise
251	carcinoma	_	_	I-Premise
252	in	_	_	I-Premise
253	situ	_	_	I-Premise
254	(	_	_	I-Premise
255	56	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	or	_	_	I-Premise
259	atypical	_	_	I-Premise
260	hyperplasia	_	_	I-Premise
261	(	_	_	I-Premise
262	86	_	_	I-Premise
263	%	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	I-Premise
266	in	_	_	I-Premise
267	those	_	_	I-Premise
268	with	_	_	I-Premise
269	any	_	_	I-Premise
270	category	_	_	I-Premise
271	of	_	_	I-Premise
272	predicted	_	_	I-Premise
273	5-year	_	_	I-Premise
274	risk	_	_	I-Premise
275	.	_	_	I-Premise

276	Tamoxifen	_	_	B-Premise
277	reduced	_	_	I-Premise
278	the	_	_	I-Premise
279	risk	_	_	I-Premise
280	of	_	_	I-Premise
281	noninvasive	_	_	I-Premise
282	breast	_	_	I-Premise
283	cancer	_	_	I-Premise
284	by	_	_	I-Premise
285	50	_	_	I-Premise
286	%	_	_	I-Premise
287	(	_	_	I-Premise
288	two-sided	_	_	I-Premise
289	P	_	_	I-Premise
290	<	_	_	I-Premise
291	.002	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	Tamoxifen	_	_	B-Premise
295	reduced	_	_	I-Premise
296	the	_	_	I-Premise
297	occurrence	_	_	I-Premise
298	of	_	_	I-Premise
299	estrogen	_	_	I-Premise
300	receptor-positive	_	_	I-Premise
301	tumors	_	_	I-Premise
302	by	_	_	I-Premise
303	69	_	_	I-Premise
304	%	_	_	I-Premise
305	,	_	_	I-Premise
306	but	_	_	I-Premise
307	no	_	_	I-Premise
308	difference	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	occurrence	_	_	I-Premise
312	of	_	_	I-Premise
313	estrogen	_	_	I-Premise
314	receptor-negative	_	_	I-Premise
315	tumors	_	_	I-Premise
316	was	_	_	I-Premise
317	seen	_	_	I-Premise
318	.	_	_	I-Premise

319	Tamoxifen	_	_	B-Premise
320	administration	_	_	I-Premise
321	did	_	_	I-Premise
322	not	_	_	I-Premise
323	alter	_	_	I-Premise
324	the	_	_	I-Premise
325	average	_	_	I-Premise
326	annual	_	_	I-Premise
327	rate	_	_	I-Premise
328	of	_	_	I-Premise
329	ischemic	_	_	I-Premise
330	heart	_	_	I-Premise
331	disease	_	_	I-Premise
332	;	_	_	I-Premise
333	however	_	_	I-Premise
334	,	_	_	I-Premise
335	a	_	_	I-Premise
336	reduction	_	_	I-Premise
337	in	_	_	I-Premise
338	hip	_	_	I-Premise
339	,	_	_	I-Premise
340	radius	_	_	I-Premise
341	(	_	_	I-Premise
342	Colles	_	_	I-Premise
343	'	_	_	I-Premise
344	)	_	_	I-Premise
345	,	_	_	I-Premise
346	and	_	_	I-Premise
347	spine	_	_	I-Premise
348	fractures	_	_	I-Premise
349	was	_	_	I-Premise
350	observed	_	_	I-Premise
351	.	_	_	I-Premise

352	The	_	_	B-Premise
353	rate	_	_	I-Premise
354	of	_	_	I-Premise
355	endometrial	_	_	I-Premise
356	cancer	_	_	I-Premise
357	was	_	_	I-Premise
358	increased	_	_	I-Premise
359	in	_	_	I-Premise
360	the	_	_	I-Premise
361	tamoxifen	_	_	I-Premise
362	group	_	_	I-Premise
363	(	_	_	I-Premise
364	risk	_	_	I-Premise
365	ratio	_	_	I-Premise
366	=	_	_	I-Premise
367	2.53	_	_	I-Premise
368	;	_	_	I-Premise
369	95	_	_	I-Premise
370	%	_	_	I-Premise
371	confidence	_	_	I-Premise
372	interval	_	_	I-Premise
373	=	_	_	I-Premise
374	1.35-4.97	_	_	I-Premise
375	)	_	_	I-Premise
376	;	_	_	I-Premise
377	this	_	_	I-Premise
378	increased	_	_	I-Premise
379	risk	_	_	I-Premise
380	occurred	_	_	I-Premise
381	predominantly	_	_	I-Premise
382	in	_	_	I-Premise
383	women	_	_	I-Premise
384	aged	_	_	I-Premise
385	50	_	_	I-Premise
386	years	_	_	I-Premise
387	or	_	_	I-Premise
388	older	_	_	I-Premise
389	.	_	_	I-Premise

390	All	_	_	O
391	endometrial	_	_	O
392	cancers	_	_	O
393	in	_	_	O
394	the	_	_	O
395	tamoxifen	_	_	O
396	group	_	_	O
397	were	_	_	O
398	stage	_	_	O
399	I	_	_	O
400	(	_	_	O
401	localized	_	_	O
402	disease	_	_	O
403	)	_	_	O
404	;	_	_	O
405	no	_	_	B-Premise
406	endometrial	_	_	I-Premise
407	cancer	_	_	I-Premise
408	deaths	_	_	I-Premise
409	have	_	_	I-Premise
410	occurred	_	_	I-Premise
411	in	_	_	I-Premise
412	this	_	_	I-Premise
413	group	_	_	I-Premise
414	.	_	_	I-Premise

415	No	_	_	B-Premise
416	liver	_	_	I-Premise
417	cancers	_	_	I-Premise
418	or	_	_	I-Premise
419	increase	_	_	I-Premise
420	in	_	_	I-Premise
421	colon	_	_	I-Premise
422	,	_	_	I-Premise
423	rectal	_	_	I-Premise
424	,	_	_	I-Premise
425	ovarian	_	_	I-Premise
426	,	_	_	I-Premise
427	or	_	_	I-Premise
428	other	_	_	I-Premise
429	tumors	_	_	I-Premise
430	was	_	_	I-Premise
431	observed	_	_	I-Premise
432	in	_	_	I-Premise
433	the	_	_	I-Premise
434	tamoxifen	_	_	I-Premise
435	group	_	_	I-Premise
436	.	_	_	I-Premise

437	The	_	_	B-Premise
438	rates	_	_	I-Premise
439	of	_	_	I-Premise
440	stroke	_	_	I-Premise
441	,	_	_	I-Premise
442	pulmonary	_	_	I-Premise
443	embolism	_	_	I-Premise
444	,	_	_	I-Premise
445	and	_	_	I-Premise
446	deep-vein	_	_	I-Premise
447	thrombosis	_	_	I-Premise
448	were	_	_	I-Premise
449	elevated	_	_	I-Premise
450	in	_	_	I-Premise
451	the	_	_	I-Premise
452	tamoxifen	_	_	I-Premise
453	group	_	_	I-Premise
454	;	_	_	I-Premise
455	these	_	_	I-Premise
456	events	_	_	I-Premise
457	occurred	_	_	I-Premise
458	more	_	_	I-Premise
459	frequently	_	_	I-Premise
460	in	_	_	I-Premise
461	women	_	_	I-Premise
462	aged	_	_	I-Premise
463	50	_	_	I-Premise
464	years	_	_	I-Premise
465	or	_	_	I-Premise
466	older	_	_	I-Premise
467	.	_	_	I-Premise

468	Tamoxifen	_	_	B-Claim
469	decreases	_	_	I-Claim
470	the	_	_	I-Claim
471	incidence	_	_	I-Claim
472	of	_	_	I-Claim
473	invasive	_	_	I-Claim
474	and	_	_	I-Claim
475	noninvasive	_	_	I-Claim
476	breast	_	_	I-Claim
477	cancer	_	_	I-Claim
478	.	_	_	I-Claim

479	Despite	_	_	B-Claim
480	side	_	_	I-Claim
481	effects	_	_	I-Claim
482	resulting	_	_	I-Claim
483	from	_	_	I-Claim
484	administration	_	_	I-Claim
485	of	_	_	I-Claim
486	tamoxifen	_	_	I-Claim
487	,	_	_	I-Claim
488	its	_	_	I-Claim
489	use	_	_	I-Claim
490	as	_	_	I-Claim
491	a	_	_	I-Claim
492	breast	_	_	I-Claim
493	cancer	_	_	I-Claim
494	preventive	_	_	I-Claim
495	agent	_	_	I-Claim
496	is	_	_	I-Claim
497	appropriate	_	_	I-Claim
498	in	_	_	I-Claim
499	many	_	_	I-Claim
500	women	_	_	I-Claim
501	at	_	_	I-Claim
502	increased	_	_	I-Claim
503	risk	_	_	I-Claim
504	for	_	_	I-Claim
505	the	_	_	I-Claim
506	disease	_	_	I-Claim
507	.	_	_	I-Claim

